{
  "responseHeader":{
    "status":0,
    "QTime":12,
    "params":{
      "q":"(Background: \"non-small cell carcinoma\"^4 OR NSCLC OR Doc_title: \"non-small cell carcinoma\"^4 OR NSCLC) AND (Background: MET^4 OR \"HGFR\" OR \"AUTS9\" OR \"RCCP2\" OR \"c-Met\" OR \"DFNB97\" OR Doc_title: MET OR \"HGFR\" OR \"AUTS9\" OR \"RCCP2\" OR \"c-Met\" OR \"DFNB97\")"}},
  "response":{"numFound":487,"start":0,"docs":[
      {
        "Meeting_name":" Treatments of NSCLC-PDX with c-MET gene amplification by c-MET inhibitors lead to rapid development of drug resistance.",
        "Background":"['Drug resistance is one of important factors limiting effect of most cancer therapies. Understanding mechanisms causing resistance can facilitate overcoming resistance. c-MET gene activation, via either activating mutations or gene amplification, is an oncogenic driver for some non-small cell lung cancers (NSCLC) in patients as well as in patient derived xenograft (PDX) (1). c-MET gene activation is also one of the two most dominant TKI-resistance seen among the patients treated with EGFR-TKI (tyrosine kinase inhibitors) (1, 2). Therefore, c-MET inhibitor could become an important treatment option for NSCLC patients whose c-MET is either de nova activated or activated during TKI treatment (1). We recently demonstrated that Crizotinib (PF2341066), an approved drug against NSCLC with ALK-fusion and a known c-MET inhibitor, can effectively treat NSCLC with c-MET gene amplification, including those resistant to EGFR-TKIs (1), in PDXs. Specifically, we described two models LU1901 and LU2503  both with amplified gene, accompanied with over-expression, of c-MET, and both sensitive to Crizotinib (complete regression in LU2503, while near-complete regression in LU1901) (1), confirming the c-MET activation as dominant oncogenic driver for these two tumors.In the present study, interestingly, the treated LU1901 tumors subsequently re-emerge and re-grow even in the presence of continuous treatment. In particular, the re-growed LU1901 become completely resistant to Crizotinib (we call LU1901R), even after it was re-engrafted. Pharmacodynamic analysis revealed that the LU1901R tumor has similar level of phosphorylation (or activation) of c-MET as the parental LU1901. Crizotinib treatment caused nearly-similar inhibition of c-MET in both LU1901 and LU1901R, as well as the downstream signaling, including pMEK and pAKT by Crizotinib in both LU1901 and LU1901R tumors along with c-MET inhibition. All these suggest that the threshold of c-MET activation for prompting tumor growth/survival is significantly lower in LU1901R than LU1901. We are currently characterizing the LU1901R in order to identify the mechanisms of resistance, and attempt to find approach to overcome them.In summary, we have successfully developed c-MET inhibitor resistant models that may reflect resistance emergence in the clinics. These models could be particularly useful in investigating clinical resistant mechanisms and evaluating new therapy that can overcome resistance.']",
        "Doc_id":"AACR_2013-5630",
        "Doc_title":" Treatments of NSCLC-PDX with c-MET gene amplification by c-MET inhibitors lead to rapid development of drug resistance.",
        "_version_":1606189007804301313},
      {
        "Meeting_name":" A novel c-Met targeting antibody drug conjugate for NSCLC",
        "Background":"['c-Met, the proto-oncogene transmembrane receptor tyrosine kinase, is involved in cell proliferation, survival, motility, and invasion in normal and tumor cells. It is widely expressed and associated with poor prognosis in breast, lung, liver, kidney and brain cancers. Hepatocyte growth factor (HGF) is the only known ligand of c-Met, also found in many tumors and cancers where activity is driven by the c-Met receptor. c-Met is accepted as an attractive anti-cancer target, but the development of cancer therapy targeting c-Met receptor or kinase remain very challenging. Clinical development of c-Met/HGF targeting antibodies has shown initial evidence of clinical efficacy but failed in phase III. Small molecule inhibitors often suffer from selectivity issues. Antibody drug conjugates (ADCs) which combine an antibody with highly potent cytotoxic agents, becomes an attractive approach against c-Met overexpressing cancers such NSCLC. We have identified an anti-c-Met antibody STI-0602 and generated ADCs from a panel of cytotoxic agents such as microtubulin inhibitor and DNA damaging agents. ADCs retained the binding to c-Met receptor and showed potent cell killing in a variety of c-Met-positive cell lines. ADCs also showed in vivo efficacy in a panel of c-Met-positive human NSCLC xenograft models like A549, H292, EBC-1, HCC827 and H1993, which suggest a potential therapy for c-Met overexpressing lung cancer and other cancers.']",
        "Doc_id":"AACR_2016-3897",
        "Doc_title":" A novel c-Met targeting antibody drug conjugate for NSCLC",
        "_version_":1606189039149383680},
      {
        "Meeting_name":" C-MET overexpression as a resistance biomarker to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.",
        "Background":"['Background', ' Multiple mechanisms of C-MET activation have been reported in non-small cell lung cancer (NSCLC) including amplification and mutation. C-MET protein overexpression also occurs in 25%-75% of NSCLC and is associated with poor prognosis of NSCLC. This study aimed to evaluate whether C-MET protein expression is associated with the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in EGFR-mutant NSCLC. Methods', ' We retrospectively analyzed 1199 consecutive NSCLC patients, who were tested for C-MET expression by immunohistochemistry (IHC) between Nov 2013 and Sep 2015. The staining intensity within tumor tissue was graded on a scale of 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). C-MET positivity was defined as C-MET expression with strong staining intensity (grade 3+) in more than 50% of tumor cells. Among 262 patients with EGFR exon 19 deletions or exon 21 L858R mutation, 83 EGFR-mutant patients received EGFR-TKI as a first line therapy. Results', ' In total of 1199 tumors, the frequency of each tumor with C-MET grade 0 to grade 3+ was 10.8%, 41.0%, 32.5%, and 15.7%, respectively. C-MET expression was significantly stronger in the tumors with adenocarcinoma than those with squamous cell carcinoma (P< 0.001). In the tumors with adenocarcinoma, EGFR-mutant tumors showed stronger expression of C-MET than EGFR-wild type tumors (P< 0.001) but no difference in C-MET expression by mutation types was observed (P= 0.248). In the first-line EGFR-TKI treatment group, there was no significant difference in response rate to EGFR-TKI between the patients with C-MET positivity (n = 7) and those with C-MET negativity (n = 76) (71% vs. 88%, P= 0.231). However, the median progression-free survival (PFS) to EGFR-TKI was significantly shorter in the C-MET positive group compared with the C-MET negative group (4.3 months vs. 11.9 months, P= 0.015). Conclusions', ' C-MET overexpression was associated with shorter PFS to EGFR-TKI in the patients with EGFR-mutant NSCLC. C-MET overexpression might be as a biomarker to resistance to EGFR-TKI therapy in this population.']",
        "Doc_id":"ASCO_171477-176",
        "Doc_title":" C-MET overexpression as a resistance biomarker to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.",
        "_version_":1606189011917864960},
      {
        "Meeting_name":" c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer",
        "Background":"['c-Met is a member of the receptor tyrosine kinase family and is the receptor for hepatocyte growth factor (HGF). c-Met is involved in many mechanisms of cancer proliferation and metastasis. Inappropriate activation of c-Met can be induced by ligand-independent mechanisms such as gene amplification, specific genetic mutations, and transcriptional up-regulation, or by ligand-dependent autocrine or paracrine mechanisms. Lung cancer is the leading cause of cancer death worldwide. Despite the successful development of EGFR- or EML4-ALK-targetd therapies, treatment options remain limited for patients with advanced lung cancer, making the identification of new therapeutic targets essential. c-Met expression was reported in 41-72% non-small cell lung cancer (NSCLC), amplification of c-Met occurs in 5-10 % of patients, and c-Met mutations have been detected in 8-13% of patients. We have developed a bi-valent c-Met antibody LY2875358 (LA480), which blocks ligand-dependent and ligand-independent c-Met activations. It is currently in clinical development. Here, we have demonstrated that LY2875358 alone or in combination with standard-of-care (SOC) affected cell proliferation, migration and signal transduction in NSCLC cells with c-Met gene amplification, mutations and overexpression. In vitro, LY2875358 induces wild type and mutant c-Met internalization and degradation. In vivo, LY2875358 alone shows a marked antitumor activity in Met amplification NSCLC xenograft models. The combination of LY2875358 with SOC chemotherapeutics treatments has better efficacy than either treatment alone, both in vitro and in vivo.']",
        "Doc_id":"AACR_2012-2734",
        "Doc_title":" c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer",
        "_version_":1606188978884575232},
      {
        "Meeting_name":" Elevated expression of Fn14 in non-small cell lung cancer correlates with c-MET and promotes tumor cell invasion and metastasis.",
        "Background":"['Tumor invasiveness and therapeutic resistance strongly contribute to the low (<10%) five-year survival rate for advanced stage lung cancer; thus, identification of novel interventions targeting metastasis and therapeutic resistance is a necessity. Hepatocyte growth factor receptor (c-Met) and fibroblast growth factor-inducible 14 (Fn14) are two cell surface receptors known to be associated with lung cancer invasiveness and cell survival. Our lab recently demonstrated that Fn14 was over-expressed in non-small cell lung cancer (NSCLC), correlated with activated epidermal growth factor receptor, and that expression of Fn14 modulated NSCLC cell invasiveness and metastasis. We hypothesize that elevated Fn14 expression can be maintained by c-Met activation, and that blockade of Fn14 can suppress NSCLC invasiveness driven by c-Met. Here we demonstrate that Fn14 protein expression significantly correlated with c-Met expression in primary NSCLC patient tumors. Fn14 and c-Met were more highly expressed in metastatic tumors compared to patient-matched primary NSCLC tumors, suggesting a role in the metastatic phenotype. To further elucidate the relationship between Fn14 and c-Met in NSCLC invasiveness, we employed two cell lines derived from a primary tumor (H2073) and metastatic lymph node (H1993) of the same patient. H1993 cells (c-Met receptor amplification) expressed significantly elevated protein levels of Fn14 compared to H2073 (low c-Met), which were significantly diminished in H1993 cells upon c-Met inhibition through SU11274 treatment. Moreover, exposure of H2073 cells to HGF induced the protein expression of Fn14. The elevated expression of Fn14 through HGF stimulation (H2073) or c-Met receptor amplification (H1993) was attenuated by pretreatment of the cells with U0126, a potent MEK inhibitor, suggesting that c-Met-induced Fn14 expression may depend on MAPK signaling. To further elucidate the effect of Fn14 on global c-Met-induced expression, genome-wide expression analysis was employed to determine genes both over-expressed in H1993 compared to H2073 and subsequently suppressed in Fn14 depleted H1993 cells. RALGPS2, a gene over-expressed in lung tumors that induces of c-fos and OPRL1, a gene elevated in metastatic melanoma, were elevated in the metastatic cell line and subsequently suppressed with Fn14 depletion. In addition, shRNA-mediated depletion of Fn14 in H1993 cells attenuated cell migration and invasion by 45% and 40%, respectively. This work demonstrates that c-Met and Fn14 may play a critical role in NSCLC metastasis, and suggests that targeting Fn14 may impact c-Met-driven NSCLC invasiveness. Successful targeting of NSCLC invasiveness would have significant clinical impact on a disease that is deadly in its advanced stages.']",
        "Doc_id":"AACR_2013-3785",
        "Doc_title":" Elevated expression of Fn14 in non-small cell lung cancer correlates with c-MET and promotes tumor cell invasion and metastasis.",
        "_version_":1606189039942107136},
      {
        "Meeting_name":" Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer.",
        "Background":"['Background', ' Activation of c-MET lead to a wide range of biological activities. MET has recently been identified as a novel promising target in NSCLC, some c-MET inhibitors have been developed. The primary aim of this study was to evaluate the c-MET amplification status in advanced NSCLC and compare the consistency of c-MET amplification analyses in metastatic lymph nodes and tumor tissue.Methods', ' Real-time fluorescent quantitative polymerase chain reaction was used to test the tumor tissues in 368 patients of NSCLCs and 178 paired metastatic lymph nodes samples and compared the amplifications consistency inmetastatic lymph nodesand tissue samples, and analyzed the correlation between c-MET gene amplification and clinical characteristics of patients. Another 5 cases of normal lung tissue were taken as negative control.Results', ' The c-MET gene amplification rate was 8.97%(33/368) in tumor tissues . Of the178 paired cases, c-MET gene amplification was positive in 7.95%(15/178) cancerous tissuesand18.54%(33/178) in metastatic lymph nodes; Of these patients,13 were positive in the two kinds of samples. 20 cases in the paired group were detected positive c-MET in metastatic lymph nodes but was negative in cancerous tissues; 2 cases in the paired group were detected positive c-MET gene amplification in cancerous tissues but was negative in metastatic lymph nodes,there were statistically significant differences between the two samples (2= 45.536, P < 0.001). c-MET gene amplification was detected more in metastatic lymph nodes than the primary cancerous tissue. Consistency was evaluated by consistency test(Kappa = 0.482, P < 0.001).When lymph nodes were used as surrogate samples of primary cancerous tissues, sensitivity was86.67%, the specificity was 87.69%.Conclusions', ' More c-MET gene amplification positive were detected in metastatic lymph nodes compare with the primary cancerous tissue. c-MET gene amplification detected in lymph node metastases could screen more patients suitable for TKI therapy. Lymph node Metastasis can predict the c-MET gene amplification of primary tumor, and guide the clinical use of gene targeted drugs.']",
        "Doc_id":"ASCO_186389-199",
        "Doc_title":" Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer.",
        "_version_":1606188975031058432},
      {
        "Meeting_name":" Analysis of c-Met gene amplification in Japanese patients with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  Several studies have reported that increased gene copy number (GCN) of c-Met is associated with poor prognosis and resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI). A recent phase II study of mostly Caucasian subjects showed that addition of a c-Met receptor TKI to EGFR-TKI prolonged progression-free survival in NSCLC. It is unclear whether c-Met gene status differs between Caucasians and Asians. Thus, c-Met GCN was evaluated in Japanese patients with advanced NSCLC to determine whether c-Met could be a therapeutic target in Asian patients. EGFR mutation and GCNs of EGFR and Her2 were also analyzed.  Methods', '  Tumor samples suitable for gene amplification and mutation analysis were collected from 40 patients with institutional review board approval. Fluorescence in situ hybridization was used to assess c-Met, EGFR, and Her2 GCNs. DNA was extracted from tumor tissue after micro dissection. PCR and direct sequencing of exons 18, 19, and 21 of the EGFR gene were also performed.  Results', '    Of the 40 patients, 10 (25%) were female, 12 (40.0%) were light or never-smokers, and 34 (85%) had adenocarcinoma. The median age was 63 (range 41-81) years, and 36 patients (90.0%) had a good PS (0-1). The median GCNs of c-Met, EGFR, and Her2 were 1.1 (range 0.3-1.7), 1.1 (range 0.9-7.0), and 1.2 (range 0.9-3.5). No patients had more than 4 c-Met copies. Overall survival was not significantly different between patients with more than 1.1 copies of c-Met and those with less than 1.0 copy of c-Met. GCNs of c-Met, EGFR, and Her2 were not associated with any patients characteristics. The c-Met GCN was significantly correlated with Her2 GCN (r=0.401), but not EGFR mutation status or EGFR gene amplification. Thirteen patients were treated with EGFR-TKI; the response rate was higher in patients with EGFR mutations (7/11 vs. 0/2). The mean c-Met GCN was not correlated with EGFR-TKI response (1.08 vs. 1.07). The mean EGFR and Her2 GCNs were higher in EGFR-TKI responders than non-responders (2.91 vs. 1.05, p=0.03; 1.46 vs. 1.12, p=0.053).  Conclusions', '  The c-Met GCN of Japanese NSCLC patients was obviously smaller than in the previous study of Caucasians. There might be ethnic difference in c-Met gene amplification such as EGFR mutation.']",
        "Doc_id":"ASCO_81331-102",
        "Doc_title":" Analysis of c-Met gene amplification in Japanese patients with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188993724022784},
      {
        "Meeting_name":" An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study",
        "Background":"['Background', ' A phase 2, randomized study of erlotinib administered with or without tivantinib, a selective c-MET inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC) showed a significant overall survival benefit associated with the combination of tivantinib and erlotinib in patients with nonsquamous cell histology (adjusted HR = 0.58; 95% CI, 0.34-0.99; P = 0.04). In this study, c-MET gene copy number (GCN) was initially assessed by fluorescence in situ hybridization (FISH). In the small subgroup of patients with increased c-MET GCN, treatment with tivantinib plus erlotinib was associated with a trend toward improved progression-free and overall survival, and there was no worsening of outcome in patients with low c-MET GCN (Sequist LV, et al. J Clin Oncol. 2011). Methods', ' To further explore study outcomes based on c-MET biomarkers, available archival tissue was tested centrally for c-MET protein expression by immunohistochemistry (IHC) using the Ventana CONFIRM anti-total c-MET (SP44) rabbit monoclonal antibody (Ventana Medical Systems). Fifty of 167 patients had evaluable tumor samples for IHC evaluation. Staining intensity was scored on a scale of 0, 1+, 2+, 3+. Samples that scored  2+ in  50% of tumor were considered c-MET positive (+). Result', ' Among 50 evaluable patients, 27 (54%) of tumors were c-MET+. Among 33 patients with nonsquamous tumors, 25 (75%) were c-MET+, whereas only 2 of 17 (12%) squamous tumors were c-MET+, which is consistent with the existing literature (Ma PC, et al. Cancer Res. 2005). Among patients with nonsquamous histology who had c-MET+ tumors by IHC (n=25), treatment with tivantinib plus erlotinib was associated with improved progression-free survival (HR = 0.58; P = 0.28) and overall survival (HR = 0.46; P = 0.21) compared with erlotinib plus placebo. Importantly, there was no detrimental outcome in patients with c-MET-negative nonsquamous tumors (n = 8) for progression-free survival (HR = 0.36; P = 0.29) or overall survival (HR = 0.58; P = 0.55). Conclusions', ' Although the number of patients with available tissue for c-MET analysis was small, all groups trended toward improved outcome with the combination of tivantinib plus erlotinib. There were no statistically significant findings in this IHC analysis, but no apparent signal of harm was observed in patients with c-MET-negative nonsquamous NSCLC. This exploratory IHC analysis also confirmed that nonsquamous NSCLC tumors are more often positive for c-MET expression than squamous tumors. Two ongoing, randomized, phase 3 trials (MARQUEE and ATTENTION) are enrolling only nonsquamous NSCLC patients, which should enrich the population de facto with c-MET+ patients.']",
        "Doc_id":"AACR_2012-1729",
        "Doc_title":" An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study",
        "_version_":1606189015095050240},
      {
        "Meeting_name":" Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC",
        "Background":"['Background', ' Patients (pts) with NSCLC that is initially responsive to EGFR tyrosine kinase inhibitors (EGFR TKI) typically develop resistance, often associated with aberrant c-Met activity. Dual inhibition of EGFR and c-Met is therefore a rational option to treat c-Met+ EGFR TKI-resistant NSCLC. Tepotinib is a highly selective c-Met inhibitor with good tolerability and promising activity against solid tumors. We report final data from a phase Ib trial of tepotinib + gefitinib in pts with c-Met+/EGFR-mutant NSCLC conducted in Asia. Methods', ' Eligible pts were adults with locally advanced/metastatic NSCLC and ECOG PS 01. Tumors had to express EGFR with an activating mutation be resistant to EGFR TKI therapy and be c-Met+ by IHC. Pts received tepotinib 300 or 500 mg QD combined with gefitinib 250 mg QD (T300G250 or T500G250). The primary objective was to determine the recommended phase II dose (RP2D) of tepotinib in combination with gefitinib; secondary objectives included pharmacokinetics (PK), safety, and antitumor activity. Results', ' 18 pts were enrolled (median age 65 [4178]; 8 male); 6 received T300G250, 12 T500G250. No dose-limiting toxicities were observed, and tepotinib 500 mg QD was confirmed as the RP2D. 17 pts experienced treatment-related treatment-emergent adverse events (TRTEAEs), mostly grade 2 and most commonly diarrhea (12), rash (8), and amylase increase (6). Grade 3 TRTEAEs were increased amylase (n = 4), increased lipase (3), neutropenia (1), and hyperglycemia (1). The best overall response was partial response in 6 pts; 4/7 pts with IHC 3+ tumors responded (all treated with T500G250) vs 2/11 with IHC 2+ tumors. Response durations of pts with PR were 4.212.5 months. 4/18 pts (IHC 2+, n = 3) had stable disease. 8 pts experienced progression free survival > 5 months, 3 pts > 10 months. PK were as expected from previous studies. Conclusions', ' Tepotinib in combination with gefitinib was well tolerated. The RP2D of tepotinib for use in combination with gefitinib in NSCLC is 500 mg QD. T500G250 showed signs of activity against c-Met+ tumors. A phase II trial is randomizing 156 pts with c-Met+/T790M tumors who have failed first-line EFGR TKI 2', '1 to tepotinib + gefitinib or pemetrexed + cisplatin/carboplatin. Clinical trial information', ' NCT02864992']",
        "Doc_id":"ASCO_186597-199",
        "Doc_title":" Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC",
        "_version_":1606188970823122944},
      {
        "Meeting_name":" Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC",
        "Background":"['c-Met and EGFR are therapeutic targets in NSCLC with a direct role in tumor progression. Highly specific TKIs against c-Met, have limited efficacy individually, and resistance to c-Met TKIs could be due to activation/mutations in EGFR, or c-Met amplification/mutations which could lead to increased expression and constitutive phosphorylation of c-Met. In recent clinical trials, simultaneous treatment with tyrosine kinase inhibitors (TKIs) against c-Met/EGFR has improved patient prognosis, however, their efficacy has been limited due to the development of resistance to TKIs. To establish the mechanism of TKI resistance in NSCLC, two cell lines (H2170 and H358) were made resistant to c-Met and EGFR TKIs (15-30 fold increase in IC50 of SU11274 and 8-10 fold increase in IC50 of Erlotinib) by exposing the cells to progressively increasing concentrations of both drugs simultaneously. In H2170 cell lines, a 4-fold downregulation p-cMet 1003 (c-cbl binding site) and a 5-fold increase in p-c-Met 1234/1235 (autophosphorylation site) was observed. Additionally, several proteins in signaling pathways (mTOR and Wnt) linked to EGFR and c-Met, were also found to be differentially modulated in H2170 and H358 resistant lines', ' active -catenin (1.5-2.5 fold increase), p-mTOR (2-4 fold increase), and phospho-pS6kinase (2-20 fold increase). Interestingly, few differences were observed in p-ERK or p-AKT, which are EGFR/c-Met downstream signaling proteins, indicating that other pathways such as mTOR and Wnt may cause TKI resistance. To confirm the role of mTOR and Wnt pathways in resistance and to break their resistance, parental and resistant cell lines were treated with the mTOR inhibitor everolimus and the Wnt inhibitor XAV 939 in addition to c-Met and EGFR TKIs. An MTT viability assay showed resistant cell lines to be 2-4 fold more susceptible in comparison to parental cells with the addition of everolimus to TKI combination treatment. In response to the Wnt inhibitor XAV 939, parental cell lines showed no significant increase in sensitivity while resistant lines showed a 2.5-3 fold decrease in viability when compared to c-Met and EGFR TKI combination treatment. Our results suggest novel mechanisms of resistance to c-Met TKI which are mediated by increased c-Met stability, resulting in increases in Wnt expression/mTOR activation. The decreased phosphorylation of c-Met 1003 may lead to decreased binding/activity of Cbl and/or deficient ubiquitination of c-Met. This may result in increased stabilization of c-Met as evidenced by the increased phosphorylation of c-Met 1234/1235 and the subsequent activation of PI3K/Akt/mTOR and Wnt pathways which has been shown. These studies suggest a new treatment modality since inhibitors of Wnt pathway or agents targeting -catenin have not entered clinical testing. These results suggest that Wnt/ mTOR inhibitors combined with c-Met/EGFR TKIs may be a novel combination therapy for lung cancer.']",
        "Doc_id":"AACR_2012-1890",
        "Doc_title":" Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC",
        "_version_":1606188990986190848},
      {
        "Meeting_name":" Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models",
        "Background":"['In clinical practice, acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) causes EGFR TKI treatment failure. Several resistance mechanisms have been identified; EGFR T790M mutation and aberrant activation of c-Met through c-Met gene amplification and/or HGF upregulation are the two most common mechanisms. We have previously shown that combining the highly selective c-Met inhibitor tepotinib with 1st or 2nd-generation EGFR TKIs overcomes gefitinib resistance caused only by c-MET amplification. Third-generation EGFR TKIs such as rociletinib have been developed specifically to overcome T790M-mediated resistance to EGFR TKIs. We hypothesized that combining a 3rd-generation EGFR TKI with tepotinib could overcome resistance to a 1st or 2nd-generation EGFR TKI (e.g. gefitinib) regardless of the mechanism of resistance.We assessed the efficacy of tepotinib and a Merck-synthesized version of rociletinib (MSR) as monotherapy or in combination in a NSCLC cell line xenograft model (HCC827-GR-T790M) with an EGFR del 19 mutation, c-Met amplification, and exogenous T790M expression, and in a patient-derived xenograft model (DFCI081) with an EGFR del 19 mutation and c-Met amplification, but not a T790M mutation.Single-agent tepotinib, erlotinib, and afatinib did not show antitumor activity in HCC827-GR-T790M xenografts and tumors progressed on treatment (median tumor volume [TV] changes >73%). The combinations of tepotinib + erlotinib and tepotinib + afatinib delayed tumor regrowth more than single-agent therapy, but were no more effective than single-agent MSR. In contrast, the combination of tepotinib + MSR had strong antitumor activity in this model with double resistance due to c-Met amplification and exogenous T790M expression, resulting in complete tumor regression (median TV change -97%).In the patient-derived xenograft model DFCI081, tumors progressed under single-agent therapy with the EGFR TKIs erlotinib, afatinib, and MSR, as expected given that this cell line expresses c-Met. In contrast, tepotinib induced complete tumor regression as monotherapy and when combined with each of the EGFR TKIs (median TV change -100%). Complete regression was maintained until the end of the 60-day observation period after treatment termination.These findings are compatible with the hypothesis that combining tepotinib with a 3rd-generation EGFR TKI to overcome double resistance to 1st and 2nd-generation TKIs mediated by T790M and c-Met in NSCLC is more effective than using either agent alone. Furthermore, whereas EGFR TKIs were not effective in tumor models showing c-Met amplification and EGFR del 19 mutation but not T790M mutation, ie resistance is c-Met mediated, tepotinib monotherapy induced complete tumor regression.']",
        "Doc_id":"AACR_2016-4663",
        "Doc_title":" Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models",
        "_version_":1606189035727880192},
      {
        "Meeting_name":" Co-inhibition of ALK and EGFR and/or c-MET on cell growth and response to radiation in ALK-positive NSCLC cells",
        "Background":"['ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor) and c-MET are molecular drivers for a subset of non-small cell lung cancers (NSCLC). Approximately 4-7% of NSCLCs carry the EML4-ALK chromosomal rearrangement. We identified overexpression of EGFR and c-MET in EML4-ALK-positive NSCLC cell lines H3122 and H2228. ALK, EGFR, and c-MET may function cooperatively to modulate tumor growth, stress response, and survival in EML4-ALK-positive cells and co-inhibition may favorably impact tumor control. We therefore investigated the effects of co-inhibition of ALK and EGFR or c-MET on cell survival and response to radiation in EML4-ALK-positive NSCLC cells.Compared with ALK-negative cell lines (H226, A549 and H520), the ALK-positive cell lines (H3122, H2228) were highly sensitive to the ALK inhibitors crizotinb, ceritinib and alectinib, although with differing sensitivity to radiation. Crizotinib, ceritinib and alectinib sensitized H3122 and H2228 to radiation, as evaluated by clonogenic assay. However, knockdown of ALK by siRNA in H3122 and H2228, or overexpression of EML4-ALK in NIH-3T3 cells, had only moderate effects on radiosensitivity. Simultaneous knockdown of ALK and MET, or ALK and EGFR, increased radiosensitivity as assessed by clonogenic survival in H3122 and H2228 cells, while also increasing inhibitory effects on cell growth and proliferation. These results were confirmed in cells treated with the combination of ceritinib and su11274 (c-MET inhibitor) or with ceritinib and erlotinib (EGFR inhibitor). We further assessed the impact of drug alone or in combination with radiation on cell cycle, cell survival and DNA damage repair pathways. To further evaluate ALK function in the cellular response to radiation in NSCLC, we are developing EML4-ALK stable expression cell lines. Evaluation of drug-radiation interactions in xenograft model systems are also under consideration.These data indicate that co-inhibition of ALK and EGFR or c-MET can enhance growth inhibitory effects in ALK-positive cells and augment radiosensitivity in-vitro, suggesting the potential value for ALK inhibitors combined with EGFR/c-MET-targeting for therapeutic benefit in ALK-positive NSCLC patients with or without radiation.']",
        "Doc_id":"AACR_2015-3309",
        "Doc_title":" Co-inhibition of ALK and EGFR and/or c-MET on cell growth and response to radiation in ALK-positive NSCLC cells",
        "_version_":1606189022398382080},
      {
        "Meeting_name":" Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.",
        "Background":"['Background', ' PF-02341066 (PF) is a selective, ATP-competitive, small molecule oral inhibitor of the c-Met/HGFR and ALK receptor tyrosine kinases that has not previously been tested in humans. A Phase 1 dose-escalation trial evaluating PF as an oral single agent was conducted to investigate safety, PK and PD in patients (pts) with advanced cancer (excluding leukemias). Methods', ' PF was administered under fasting conditions QD or BID on a continuous schedule to pts in successive dose-escalating cohorts at doses ranging from 50 mg QD to 300 mg BID. Pts with advanced cancer were enrolled in the study. Results', ' Thirty-seven pts were enrolled into the dose escalation part of the study. Tumor types included colorectal, pancreatic, sarcoma, ALCL and NSCLC. The MTD was 250 mg BID. Three DLTs were observed', ' grade 3 increase in ALT (1 pt at 200 mg QD) and grade 3 fatigue (2 pts at 300 mg BID). The most common AEs were nausea, emesis, fatigue and diarrhea. Nausea and emesis were independent of dose or duration of treatment. Mean AUC (30-57% CV) and Cmax (36-69% CV) increased proportionally with dose from 100 mg QD to 300 mg BID. The median terminal half-life was 46 hours. A 2- to 4-fold increase in the oral midazolam (MDZ) AUC was observed following 28-days of PF dosing at 100 mg QD (n = 3) and 300 mg BID (n = 2), respectively, suggesting PF to be an inhibitor of CYP3A. Ten pts have entered an enriched RP2D cohort of pts with tumors harboring c-Met amplification/gene mutation or ALK fusion genes. There has been 1 confirmed PR in a sarcoma pt with ALK rearrangement (inflammatory myofibroblastic tumor). Among 10 NSCLC pts whose tumors harbor EML4-ALK rearrangement, 1 pt has had a PR, 2 pts have achieved unconfirmed PR and 4 pts have had SD (3 have experienced reduction in tumor burden by ~20% in measurable lesions and 1 has been treated for 28 weeks). Conclusions', ' The MTD of PF is 250 mg BID. The major AEs were fatigue or GI-related, and all AEs were manageable and reversible. There was no evidence of non-linear PK at PF doses >100 QD. Treatment with PF-02341066 resulted in promising clinical activity against tumors carrying activating ALK gene rearrangements. Further study of PF in pts with ALK-dependent tumors is warranted.']",
        "Doc_id":"ASCO_30947-65",
        "Doc_title":" Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.",
        "_version_":1606189020801400832},
      {
        "Meeting_name":" Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes.",
        "Background":"['Background', '  The common driver genes in non-small-cell lung cancer (NSCLC) include EGFR, ALK and KRAS. We investigate the frequency of MET overexpression coexisting with oncogenic drivers and response to tyrosine kinase inhibitors (TKIs).   Methods', ' We screened 806 consecutive NSCLC patients for the presence of MET overexpression by immunohistochemistry (IHC), in which  50% tumor cells with moderate to high intensity staining were defined as MET positive. MET amplification and ALK rearrangements were detected by fluorescence in situ hybridization (FISH), and FISH positive was defined as gene focal amplification or high polysomy (at least 15% cells with  5 copy numbers). Meanwhile, KRAS and EGFRmutations were tested by DNA sequencing or Scorpion amplification refractory mutation system (ARMS).  Results', ' The frequency of MET overexpression was 31.9% (257/806) in NSCLC. Among c-MET positive patients, the frequency of EGFR mutation was 38.1% (98/257) and that of ALK rearrangement was 8.7% (22/257). Response rate (RR) of EGFR-TKIs was 22.2% (8/36) in advanced NSCLC patients with concomitant EGFR mutation and c-MET overexpression, and 56.8% (21/37) in those with only EGFR mutation, P= 0.033. However, there was no significant difference in RR between the patients with concomitant ALK rearrangement and c-MET overexpression and those with only ALK rearrangement, 61.5% (8/13) vs. 75.0% (6/8), P= 0.656. Among 2 cases with concomitant MET amplification and EGFR mutations, one responded to gefitinib, but the other had stable disease. Dramatic response was observed in one with concomitant MET amplification and KRAS mutations.  Conclusions', ' Advanced NSCLC patients with concomitant EGFR mutation and MET overexpression have significantly low RR with EGFR-TKIs, indicating that MET overexpression  potentially causes intrinsic resistance to EGFR-TKIs. Similar response was observed in ALK positive patients with or without c-MET overexpression treated with crizotinib.']",
        "Doc_id":"ASCO_150866-156",
        "Doc_title":" Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes.",
        "_version_":1606188974882160640},
      {
        "Meeting_name":" Mechanism of EGFR and c-Met TKI resistance and role of co-expression of EGFR and c-Met in non-small cell lung cancer patients",
        "Background":"['Current EGFR/c-Met tyrosine kinase inhibitor (TKI) combination therapies are shown to be susceptible to acquired resistance in the majority of NSCLC patients. To understand how cells develop EGFR/c-Met TKI resistance, we use three model NSCLC cell lines', ' H2170, H358 and H1975. H2170 and H358 cell lines express high levels of EGFR and c-Met and are EGFR wild-type. These cell lines were made resistant to the EGFR TKI erlotinib, the c-Met TKI SU11274 and a combination of both by exposure to increasing concentrations of these TKIs. The H1975 cell line is positive for two EGFR TKD mutations (T790M and L858R) which confer resistance to erlotinib.Studies have shown that EGFR/c-Met TKI resistant cells may use alternative signaling pathways to activate downstream transcription/translation proteins previously activated by EGFR and c-Met signaling. The Wnt/-catenin and mTOR pathways are demonstrated to have significant roles in cell survival, resistance and tumorigenesis in NSCLC. Several EGFR/c-Met-linked proteins in these two signaling pathways were differentially modulated in H2170 and H358 resistant lines. The Wnt signaling transducer -catenin plays a role in cellular proliferation and death and its deregulation is implicated in lung cancer. Protein kinase GSK-3 also plays an important role in lung cancer and its inhibition by Wnt results in mTOR activation. It is encoded by two genes, GSK-3 and GSK-3. GATA-6 is a transcriptional activator of Wnt and is also implicated in several cancers. Active -catenin was found to be 2 to 4-fold upreglated in H2170 SU11274-resistant (SR) cells and 2 to 20-fold upreglated in H2170 erlotinib-resistant (ER) cells, in the presence and absence of TKIs and growth factor ligands, when compared to nave H2170 cells. GATA-6 was found to be 1.5 to 4-fold upreglated in H2170 SR cells and 2 to 3-fold upreglated in H2170 ER cells. Conversely, p-GSK-3 and p-GSK-3 were found to be 1.2 to 4.8-fold and 1.5 to 10.7-fold downreglated in H2170 SR cells, respectively. These results indicate increased activation of the Wnt/-catenin and mTOR pathways in TKI resistant cells.We are currently studying the expression of these proteins further in the H1975 cell line.To translate our studies to patients, we are investigating the role of EGFR/c-Met synergism in NSCLC by conducting a retrospective biomarker analysis using IHC on 100 tissue samples from patients with stage 3 and 4 squamous cell and adenocarcinoma. Preliminary results indicate that EGFR and c-Met receptors are co-expressed in lung cancer tissues and we are acquiring data to determine how co-localization and synergism affects patient prognosis. Further studies are being conducted on proteins in the Wnt and mTOR signaling pathways, such as p70S6Kinase, mTOR, -Catenin and Axin-2, and their involvement in patient prognosis and resistance. This study may provide clinicians with novel targets for improving treatment options for future NSCLC patients.']",
        "Doc_id":"AACR_2014-1838",
        "Doc_title":" Mechanism of EGFR and c-Met TKI resistance and role of co-expression of EGFR and c-Met in non-small cell lung cancer patients",
        "_version_":1606189018750386176},
      {
        "Meeting_name":" c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors",
        "Background":"['c-Met amplification and acquisition of a second T790M mutation are key mechanisms accounting for majority of resistant cases to first generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs; i.e., erlotinib). The third generation EGFR-TKIs (e.g., AZD9291), which selectively and irreversibly inhibit EGFR activating and T790M mutants while sparing wild-type EGFR, represent very promising therapeutic options for NSCLC patients who have become resistant to 1st generation EGFR-TKIs due to T790M mutation. However, eventual resistance to the 3rd generation EGFR-TKIs has already been described in the clinic, resulting in disease progression. Therefore, there is a great challenge and urgent need to understand how this resistance occurs and to develop effective strategies to delay or overcome the resistance. We show that c-Met amplification and hyperactivation is an universal mechanism to both 1st and 3rd generation EGFR-TKIs since both erlotinib- and AZD9291-resistant HCC827 cell lines possessed elevated levels of c-Met (due to gene amplification) and p-c-Met and were cross-resistant to AZD9291 or erlotinib. Both chemical and genetic inhibition of c-Met overcame the resistance of these cell lines to AZD9291 including enhancement of apoptosis or G1 cell cycle arrest. Consistently the combination of AZD9291 and c-Met inhibition effectively inhibited the growth of both erlotinib- and AZD9291-resistant HCC827 xenografts in nude mice. Hence, we suggest that inhibition of c-Met is also an effective strategy to overcome resistance of EGFR-mutated NSCLCs with c-Met amplification or hyperactivation to AZD9291, providing the rationale for clinical development of this novel combination strategy. (SSR, TKO and SYS are Georgia Research Alliance Distinguished Cancer Scientists)']",
        "Doc_id":"AACR_2016-2105",
        "Doc_title":" c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors",
        "_version_":1606188991675105280},
      {
        "Meeting_name":" Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' The c-Met receptor is overexpressed in ~50% of pts with NSCLC. ABBV-399 is a first-in-class ADC composed of ABT-700, an antic-Met antibody, conjugated to monomethyl auristatin E (a microtubule inhibitor). Preclinical data demonstrate that ABBV-399 can deliver a potent cytotoxin directly to c-Met+ tumor cells. Methods', ' ABBV-399 was administered at doses ranging from 2.4 to 3.0 mg/kg (dose expansion and combination cohorts at 2.7 mg/kg) once every 21 days to 29 pts with advanced c-Met+ (immunohistochemistry [IHC] H-score 150) NSCLC both as monotherapy (ABBV-399/monoT; 16 pts) and in combination with oral erlotinib 150 mg daily (ABBV-399/ERL; 13 pts) (NCT02099058). c-Met overexpression was assessed by IHC utilizing the SP44 antibody (Ventana; Tucson, AZ, USA). Results', ' As of January 9, 2017, 16 pts with c-Met+ NSCLC received 1 dose of ABBV-399/monoT. Monotherapy treatment-related adverse events (TRAEs) occurring in 10% of pts (all dose levels and all grades) were fatigue (43.8%), nausea (37.5%), neuropathy (25.0%), vomiting (18.8%), and anemia, constipation, and diarrhea (12.5% each). Three of 16 (19%) ABBV-399treated c-Met+ NSCLC pts had a confirmed partial response (PR) with duration of response (DOR) 3, 4.5, and 10+ months. At week 12, 6 of 16 pts (37.5%) had disease control. TRAEs in ABBV-399/ERL occurring in 10% of pts (all grades) were neuropathy (30.8%), and acneiform rash, diarrhea, fatigue, nausea, and dry skin (15.4% each). Four of 13 (31%) evaluable ABBV-399/ERLtreated c-Met+ pts had a PR (3 confirmed, 1 unconfirmed) with DOR 1+, 2.7, 5.3+, and 11+ months. Three of the 4 pts with PR had EGFR-mutated tumor and recently progressed on TKI. At week 12, 8 of 13 pts (61.5%) had disease control. There were no treatment-related deaths as monotherapy or in combination with erlotinib. Responses were seen in both squamous and non-squamous histology. Conclusions', ' ABBV-399 is well tolerated at 2.7 mg/kg once every 21 days and has demonstrated antitumor activity in pts with c-Met+ NSCLC both as monotherapy and in combination with erlotinib. Updated efficacy/safety data and MET gene status will be presented. Clinical trial information', ' NCT02099058']",
        "Doc_id":"ASCO_183940-199",
        "Doc_title":" Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).",
        "_version_":1606188984458805248},
      {
        "Meeting_name":" Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.",
        "Background":"['Background', ' The c-Met receptor is overexpressed in multiple tumors. ABBV-399 is a first-in-class antibody-drug conjugate (ADC) comprised of the anti-c-Met antibody, ABT-700, and monomethyl auristatin E. Although prior efforts at targeting c-Met overexpression have met with limited clinical success, an ADC directed against c-Met represents a unique strategy to deliver a potent cytotoxin directly to c-Met+ tumor cells. Methods', ' In a 3+3 dose escalation design, ABBV-399 was administered at doses ranging from 0.15 to 3.3 mg/kg once every 21 days to pts with metastatic solid tumors (NCT02099058). The recommended single-agent phase 2 dose (RPTD) of ABBV-399 was then studied in a dose-expansion cohort in pts with c-Met+ (immunohistochemistry (IHC) 2+) non-small cell lung cancer (NSCLC). c-Met overexpression was assessed by an IHC assay utilizing the SP44 antibody (Ventana). Results', ' As of January 4, 2016, 45 pts received at least 1 dose of ABBV-399. Dose-proportional increases of area under the curve (AUC) for ABBV-399 and total antibody were observed after single dose administration. Half-lives for ABBV-399 and total antibody were approximately 2-4 days. Dose-limiting toxicity (DLT) of febrile neutropenia occurred in 1 pt at 3 mg/kg and 1 pt (with septic shock) at 3.3 mg/kg. The RPTD of 2.7 mg/kg was chosen based primarily on safety and tolerability. There were no toxic deaths. Treatment-related adverse events occurring in 10% of pts (including all dose levels and all grades) were fatigue (20%), nausea (17.8%), neuropathy (13.3%), decreased appetite (13.3%), hypoalbuminemia (11.1%), and vomiting (11%). 3/10 evaluable c-Met+ NSCLC pts had a partial response; the duration of response ranged from 1+ to 5 months. There were no responses among 9 pts with c-Met negative tumors. Conclusions', ' ABBV-399 is well tolerated at the RPTD of 2.7 mg/kg and has demonstrated promising anti-tumor activity in pts with cMet+ NSCLC. The study will continue to assess the anti-tumor activity and safety of ABBV-399 in c-Met+ pts both as monotherapy and in combination with standard of care. Clinical trial information', ' NCT02099058']",
        "Doc_id":"ASCO_164513-176",
        "Doc_title":" Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.",
        "_version_":1606189031092125696},
      {
        "Meeting_name":" Prognostic significance of miR-34a and its inverse correlation with c-MET and CDK6 in lung adenocarcinoma",
        "Background":"['Background', ' The microRNA(miR)s affect all aspects of cellular physiology including proliferation, apoptosis, development, aging, and metabolism. miR-34a has tumor suppressive role in various human cancers including non-small cell lung cancer (NSCLC). Recently, various targets of miR-34a including c-MET and G1-phase regulators have been reported in NSCLC cell lines. The aim of this study is to determine whether miR-34a is correlated with c-MET and G1 phase regulators such as cyclin dependent kinase (CDK) 4, CDK6 and cyclin D (CCND)1 in human NSCLC and assess the correlation between miR-34a and clinicopathologic characteristics and recurrence free survival (RFS).Material and Methods', ' In fresh frozen, paired tumor/normal adjacent tissue samples from 58 NSCLC patients underwent curative resection, expressions of miR-34a and c-MET, CDK4/6, and CCND1 were investigated by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis.Results', ' There was inverse correlation between miR-34a and c-MET (R = -0.316; P = 0.003) and CDK6 (R = -0.4582; P = 0.004), however, neither CDK4 (P = 0.556) nor CCND1 (P = 0.143). Of 14 patients with low miR-34a, the patients showing high expression of c-MET protein were 12 (85.7%), whereas, in 5 patients with high miR-34a, high expression of c-MET protein was observed in 3 (60.0%). The expression level of miR-34a was significantly lower in the patients with squamous cell histology (P < 0.001) and lymphatic invasion (P = 0.001). The patients expressing high level of miR-34a were significantly associated with a longer RFS (55.6 months; 95% CI, 47.83-63.36 vs 21.6 months; 95% CI, 17.42-25.82, P = 0.020, respectively) for adenocarcinoma subtype. We could not detect any correlation between the c-MET and RFS (P = 0.666), however, adenocarcinoma patients exhibiting low c-MET mRNA and high miR-34a expression had a significantly longer RFS (54.4 months; 95% CI, 44.59-64.20 vs 18.7 months; 95% CI, 8.93-28.42, P = 0.042). Likewise, although CDK6 expression was not associated with RFS (P = 0.601), the adenocarcinomas having low CDK6 mRNA and high miR-34a expression tended to be longer RFS (55.1 months; 95% CI, 46.40-67.73 vs 27.8 months; 95% CI, 23.04-32.56, P = 0.059). In univariate Cox regression analysis, the relative risk (RR) for recurrence for adenocarcinoma patients with low miR-34a expression was 8.1 (95% CI, 1.01-65.58; P = 0.049) as well as with TNM stage, LN involvement, and the presence of lymphatic invasion of 13.6 (95% CI, 2.93-62.64; P = 0.001), 4.2 (95% CI, 1.05-16.76; P = 0.043) and 7.1 (95% CI, 1.46-34.00; P = 0.015), respectively. In multivariate analysis, miR-34a retained its prognostic independency for RFS (RR, 11.5; 95% CI, 1.31-100.68; P = 0.027).Conclusions', ' We demonstrated the inverse correlation between miR-34a and c-MET and CDK6 in human NSCLC and their prognostic significance for RFS especially in lung adenocarcinoma.']",
        "Doc_id":"AACR_2015-3131",
        "Doc_title":" Prognostic significance of miR-34a and its inverse correlation with c-MET and CDK6 in lung adenocarcinoma",
        "_version_":1606189022728683520},
      {
        "Meeting_name":" Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC",
        "Background":"['Background', ' Patients (pts) with NSCLC treated with EGFR inhibitors (EGFRi) ultimately develop resistance, often through c-Met activation. Dual EGFR and c-Met inhibition is therefore a rational option to treat c-Met+, EGFRi-resistant NSCLC. Tepotinib is a highly selective c-Met inhibitor with good tolerability and promising efficacy against solid tumors. This phase Ib trial examined tepotinib plus gefitinib in Asian pts with c-Met+/EGFR-mutant NSCLC. Methods', ' Asian adults were eligible if they had locally advanced/metastatic NSCLC, ECOG PS 0-1, EGFR mutation confirmed by Therascreen EGFR RGQ PCR (Qiagen), and c-Met positivity as determined by IHC using CONFIRM anti-c-Met mAb (SP44; Ventana/Roche). A 3+3 design was used with expansion at the RP2D. Pts received tepotinib 300 or 500 mg/day combined with gefitinib 250 mg/day (T300G250 or T500G250). The primary objective was to determine the RP2D of tepotinib in combination with gefitinib; secondary objectives included pharmacokinetics (PK), safety, and antitumor activity. Results', ' 18 pts were enrolled (median age 65 [4178], male 8). Pts had received a median of 2 (18) prior regimens including an EGFR inhibitor. 6 received T300G250, 12 T500G250. No dose-limiting toxicities were observed, and tepotinib 500 mg/day was confirmed as the RP2D. T500G250 was associated with treatment-related grade  3 increased amylase (n = 2), increased lipase (2), neutropenia (1), and hyperglycemia (1). No evidence of cumulative toxicity was noted. The best overall response was partial response in 5/18 pts, 4 with IHC 3+ tumors, all treated with T500G250; 4/18 pts (IHC 2+, n = 3) had stable disease. PK were as expected based on historical comparisons. Conclusions', ' Tepotinib was well tolerated in combination with gefitinib; the RP2D of tepotinib for use in combination with gefitinib in NSCLC is 500 mg/kg/day. Data suggest an increased likelihood of response for IHC 3+ tumors and prolonged disease stabilization for IHC 2+ tumors. A phase II trial is randomizing 136 pts with T790M/c-Met+ tumors who have failed first-line gefitinib to tepotinib + gefitinib or cisplatin/pemetrexed. Clinical trial information', ' NCT01982955']",
        "Doc_id":"ASCO_165384-176",
        "Doc_title":" Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC",
        "_version_":1606189015196762112},
      {
        "Meeting_name":" PDX from the nave NSCLC patients containing activating EGFR mutations are resistant to erlotinib but sensitive to c-met inhibitor",
        "Background":"['NSCLC is a common cancer with the highest mortality and few effective treatment options, except for the patients with EGFR (Erlotinib, Iressa) and ALK (Crizotinib) activating mutations. Recent studies indicated that some patients with the activating EGFR mutations but without pre-exposure to EGFR tyrosine kinase inhibitors (TKIs) are resistant to TKIs. The proposed mechanisms (1) include', ' T790M gatekeeper mutation preventing accessing the kinase activation site, Kras mutation, pTEN loss (2), or c-met amplification (3) that activates ERBB3 signaling (4). Patient Derived Xenograft (PDX) models have been suggested to more closely represent patient tumors (5, 6). We established several PDXs, including HuPrime LU858, LU859, LU357, LU387, LU1901 and LU2503, using tumor tissues from individual NSCLC patients. LU858/859 contain the classic activating EGFR mutation, L858R; LU1868 contain L858R/T790M double mutations; LU357/LUF387 contain the common exon 20 insertion (2319-2320 AACCCCCAC); and LU1901/2503 have wild type EGFR. To our surprise, the two models with single L858R mutation, just like the model with double mutations, respond to the erlotinib poorly, as seen in some of clinic cases (1). Since they do not have T790M and Kras mutation, we examined them for c-met status, finding that their c-met gene are significantly amplified with also increased c-met/HGF expression as measured by at mRNA and protein levels (IHC), consistent with those seen in clinic (3). Furthermore, LU357 is sensitive to erlotinib while LU387 is not, corresponding to no c-met amplification in LU357 but significant amplification in LU387. All these suggest that the observed erlotinib resistance in these models could potentially be attributed to c-met signaling activation via c-met/HGF autocrine. To this end, we treated LU858, LU859 and LU2503 (also with c-met amplification) with c-met inhibitor, Crizotinib. Indeed, Crizotinib caused significant tumor response as expected in all these models. In particular, the combination treatment of LU858 and LU859 with erlotinib caused complete tumor regression by overcoming the resistance, suggesting a new potential effective treatment option. The results using PDX models can potentially help to design a prospective human study to demonstrate improved efficacy by the combination treatment via patient stratification to include the nave NSCLC patient subjects with c-met amplification/EGFR mutation. 1. A. F. Gazdar, Oncogene 28 Suppl 1, S24, 2009 2. M. L. Sos et al., Cancer Res 69, 3256, 2009 3. T. Kubo et al., Int J Cancer 124, 1778, 2009 4. A. B. Turke et al., Cancer Cell 17, 77, 2010. 5. L. Ding et al., Nature 464, 999, 2010 6. E. Marangoni et al., Clin Cancer Res 13, 3989, 2007']",
        "Doc_id":"AACR_2012-2344",
        "Doc_title":" PDX from the nave NSCLC patients containing activating EGFR mutations are resistant to erlotinib but sensitive to c-met inhibitor",
        "_version_":1606189016571445249},
      {
        "Meeting_name":" Overexpression of ABC transporters through HGF/c-MET activation results in anti-cancer drug resistance in SCLC",
        "Background":"['Upregulation of hepatocyte growth factor (HGF)/c-MET pathway causes drug resistance to anti-cancer agents such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in non-small lung cancer (NSCLC) with EGFR mutation and cytotoxic agents in small cell lung cancer (SCLC), but the roles and mechanisms of c-MET in drug-resistant cancer cells are not clarified. We studied to reveal the role of c-MET overexpression in the resistant lung cancer cell lines and to demonstrate whether MET-inhibition could restore drug sensitivity in anti-cancer drug resistant cell lines via ABC transporters down-regulation. In this study we used the 7-ethyl-10-hydroxycamptothesin (SN-38)-resistant cell line (PC-6/SN-38) that was derived from the human SCLC cell line PC-6. We compared the expression levels of the purposed genes by quantitative real-time PCR (qRT-PCR) and western blotting (WB). MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay was used to measure cell viability of the resistant cells compared with the parental cells. Inhibition of c-MET activation was performed by c-MET inhibitors, PHA665752 and Crizotinib or small interfering RNA against c-MET. We found MET inhibitors (4 or 8M) reduced cell growth and restored drug sensitivity (2M) of resistant cells, PC-6/SN38, compared to parental cells. To reveal the mechanisms of c-MET in drug resistance we examined ATP-binding cassette (ABC) transporters expression in PC-6/SN-38 compared to the parental cells by qRT-PCR, and found the mRNA level of ABCG2, which effluxes SN-38 as substrate, in PC-6/SN-38 cells was extremely increased and another ABC transporters that do not efflux SN-38 were not. Recently we reported PC-6/SN-38 cells had c-MET overexpression, and c-MET inhibition in resistant cells such PC-6/SN-38 resulted in restoration drug resistance. Based on this report we examined c-MET inhibition by c-MET inhibitor and small interfering RNA against c-MET in PC-6/SN38, and qRT-PCR and WB were performed to investigate alteration of ABCG2 expression, and found both two c-MET inhibition reduced ABCG2 expression. In addition, to demonstrate c-MET upregulation in resistant cells is addicted to the ligand HGF, PC-6 cells were incubated with HGF treated for 3 weeks and made PC-6/HGF, then continued to incubate with HGF and SN-38 was added two times in a week. Although c-MET expression is equal in PC-6 and PC-6/HGF, after SN-38 treatment c-MET was overexpressed. Furthermore, serum HGF level in SCLC patients correlated with clinical course. We demonstrated upregulation of ABC transporters via HGF/c-MET signaling activation might be one of the mechanisms of acquired resistance to cytotoxic anticancer agents in lung cancer cells. Decreased ABC transporters expression through inhibition of c-MET activation might overcome drug resistance to cytotoxic agents.']",
        "Doc_id":"AACR_2016-5045",
        "Doc_title":" Overexpression of ABC transporters through HGF/c-MET activation results in anti-cancer drug resistance in SCLC",
        "_version_":1606189038825373696},
      {
        "Meeting_name":" Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification.",
        "Background":"['It is well recognized that non-small cell lung carcinoma (NSCLC) patients with activating EGFR mutations will develop drug resistance after receiving EGFR-tyrosine kinase inhibitors (EGFR-TKI). About 20% of those patients with TKI resistance were identified to harbor Met gene amplification. The aim of this study includes two aspects', ' a) generating an acquired c-Met amplified EGFR-TKI resistant tumor line in preclinical setting, and b) exploring combination effect of c-met inhibitor volitinib and EGFR inhibitor gefitinib on the new tumor line. Volitinib is a novel, highly potent and selective c-Met inhibitor, currently being evaluated in the phase I clinical trial.HCC827(exon 19 del E746-A750), a human NSCLC cell line, was treated with increasing concentrations of EGFR inhibitor for about 6 months and gradually produced the resistance to EGFR-TKIs, such as gefitinib and erlotinib. One of the subclones, HCC827C4R was isolated and was confirmed to carry Met gene amplification in comparison to parent cell line HCC827. It was not sensitive to volitinib treatment in cell survival assay due to dual activation of EGFR and c-Met pathways. The results from signal pathway study demonstrated that in HCC827C4R cells, volitinib or gefitinib alone only inhibited the phosphorylation of c-Met or EGFR, respectively, but had no effect on the activation of downstream molecules such as Akt and ERK which drive tumor cell proliferation and other cell functions. In contrast, combination of volitinib and gefitinib significantly inhibited phosphorylation of EGFR, c-Met, Akt and ERK in HCC827C4R, and consequently led to a synergistic effect on inhibiting tumor cell growth in vitro. These results were further confirmed in HCC827C4R xenograft model in vivo at clinically relevant doses. Combination of volitinib and gefitinib induced significant tumor regression and displayed synergistic effect compared to treatment by either gefitinib or volitinib alone. Consistent with in vitro results, combination group strongly inhibited the downstream Akt and ERK phosphorylation. In addition, combination treatment was well tolerant and no significant drug-drug exposure interaction was observed. These data indicated that both c-Met and EGFR could contribute to activating downstream signaling pathway and control HCC827C4R cell growth. Blocking either pathway may not be strong enough to stop tumor growth.In conclusion, a cell line with activating EGFR mutation and c-Met gene amplification was generated with resistance to gefitinib and insensitivity to volitinib. The combination treatment with volitinib and an EGFR inhibitor gefitinib was highly effective in vitro and in vivo, suggesting that such combination could provide a safe and effective treatment in clinics for this particular patient population.']",
        "Doc_id":"AACR_2013-971",
        "Doc_title":" Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification.",
        "_version_":1606188981689516032},
      {
        "Meeting_name":" Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened HGF signaling in the airways.",
        "Background":"['The hepatocyte growth factor (HGF)/c-Met signaling pathway is often dysregulated in lung cancer. We previously showed that HGF activation of c-Met in non-small cell lung cancer (NSCLC) cells led to a significant induction of cyclooxygenase-2 (COX-2) followed by secretion of PGE2. PGE2 caused secretion of TGF by NSCLC cells, followed by both phosphorylation of EGFR and later, delayed phosphorylation of c-Met that does not require HGF. Secretion of PGE2 also appears to boost c-Met pathway signaling downstream via cross-activation by EGFR, in a reinforcing loop that is independent of HGF. We hypothesized that targeting of both c-Met and COX-2 might lead to enhanced anti-tumor effects by blocking both upstream and downstream pro-tumor events. Maximum effects on cell proliferation, invasion and EMT markers were observed in vitro in NSCLC cell lines with combination celecoxib and crizotinib treatment. We next tested whether targeting c-Met with the tyrosine kinase inhibitor crizotinib combined with celecoxib to target COX-2 would result in enhanced anti-tumor effects in an animal model with heightened HGF/c-Met pathway signaling in the airways. Mice transgenic for airway expression of human HGF were treated with the tobacco carcinogen, 4-(methylnitroso-amino)-1-(3-pyridyl)-1-butanone, from weeks 1-4. Crizotinib (40mg/kg), celecoxib (50mg/kg), combined crizotinib and celecoxib or placebo control was administered by oral gavage daily from week 3 until week 15, at which time lung tumors were evaluated. A highly significant decrease in the number of lung tumors per animal was observed with crizotinib treatment (mean 3.6, range 2-6), celecoxib treatment (mean 4.3, range 3-6) and combination treatment (mean 1.5, range 0-3) compared to placebo control (mean 9.9, range 6-13; P<0.001, Poisson regression). The number of tumors in the combination treatment group was also significantly lower than either single agent treatment (P<0.001). There was also a significant decrease in mean tumor size with crizotinib (mean 0.20mm2), celecoxib (mean 0.22mm2) and combination (mean 0.15mm2) compared to placebo (mean 0.38mm2, P<0.001, mixed effects modeling). Three biomarkers (COX-2, PGE2, and P-MAPK) were optimally down-modulated by combination treatment, compared to single treatment. Additionally, E-cadherin expression was up-regulated while the E-cadherin repressor, snail, was down-regulated with dual treatment. In a pulmonary environment with heightened HGF/c-Met pathway activity, dual inhibition of the c-Met and COX-2 pathways may enhance anti-tumor effects by targeting reinforcing up- and downstream signaling. Such a combination has potential clinical benefit for lung cancer patients with dysregulated c-Met/COX-2 pathways. Supported by R01 CA79882 and P50 CA090440.']",
        "Doc_id":"AACR_2013-2026",
        "Doc_title":" Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened HGF signaling in the airways.",
        "_version_":1606188996012015616},
      {
        "Meeting_name":" Expression profiles of EGFR, c-Met, and mTOR/Wnt alternative signaling pathway proteins in non-small cell lung cancer",
        "Background":"[\"Lung cancer is projected to be the number one cause of cancer mortality in the United States in 2014. Therapies such as tyrosine kinase inhibitors (TKIs) have been developed to treat non-small cell lung cancer (NSCLC), which accounts for 80-85% of all lung cancer cases. EGFR is a protein that is often targeted by these TKIs and several EGFR-TKIs have been approved for clinical use. However, NSCLC tumors almost inevitably acquire resistance to EGFR-TKIs, limiting drug efficacy. Previous studies have suggested that co-localization of c-MET and EGFR may be one possible modality of acquired resistance. Additionally, upregulation of alternative signaling pathways such as Wnt or mTOR have been shown to be associated with poor prognosis and have been described as potential mechanisms of resistance. Thus, this study examined these signaling pathways and the status of EGFR/c-Met co-expression in 42 patients with stage I-IV NSCLC. Tumor tissue from biopsy or resection was obtained with patient consent and IRB approval and was subsequently processed, sectioned, and mounted on microscope slides. Total and active forms of EGFR, c-Met, mTOR, S6K, -Catenin, and Axin2 were detected using a singleplex or multiplexed immunohistochemistry staining procedure, and stains were graded by an independent pathologist using a validated scoring system. 65.9% of patients exhibited co-expression of EGFR and c-Met (n = 27) while 51.2% showed co-activation of the two markers (n = 21). Additionally, we observed EGFR/c-Met co-expression to have a statistically significant positive correlation with mTOR expression with a Spearman's rho of 0.411 (p = 0.033), suggesting EGFR/c-Met co-expression may play a role in tumorigenesis possibly via regulation of the mTOR pathway. This notion is further supported by our finding that expression of pS6K, a downstream mTOR pathway protein, showed a strong positive correlation with EGFR expression with a Spearman's rho of 0.504 (p = 0.001). In contrast, Wnt pathway protein active -Catenin exhibits a negative correlation with EGFR expression while Axin2, a negative regulator of active -Catenin, showed a positive correlation. Our findings indicate an inverse relationship between the two signaling pathways in NSCLC with increasing mTOR activation correlating with Wnt downregulation. Furthermore, EGFR expression may be associated with this relationship. Thus, we conclude that EGFR/c-Met co-expression as well as activation of the mTOR pathway may be involved in enhanced pathogenesis of NSCLC and possibly acquired resistance to EGFR-TKI therapy.\"]",
        "Doc_id":"AACR_2015-743",
        "Doc_title":" Expression profiles of EGFR, c-Met, and mTOR/Wnt alternative signaling pathway proteins in non-small cell lung cancer",
        "_version_":1606189016533696512},
      {
        "Meeting_name":" The c-Met inhibitors EMD 1214063 and EMD 1204831 are effective in combination with EGFR and VEGF inhibitors in NSCLC models",
        "Background":"['c-Met is a receptor tyrosine kinase that has hepatocyte growth factor as its ligand. Evidence from biochemical and human genetic studies indicate that c-Met is one of the most frequently activated tyrosine kinases in human cancer. Dysregulated c-Met signaling can result in the development of tumors highly dependent on c-Met. Furthermore, enhanced c-Met signaling is likely involved in conferring resistance to epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors. The orally available EMD 1214063 and EMD 1204831 inhibit c-Met activity in a potent and highly selective fashion, and are currently being evaluated in cancer patients. Here we report the activity of these compounds in combination with inhibitors of EGFR and VEGF in various tumor xenograft models. EMD 1214063 was tested alone and in combination with EGFR inhibitors (erlotinib and cetuximab) in xenografts of erlotinib-resistant tumor cells, namely the lung cancer H1975 and the NCI-H441 non-small-cell lung cancer (NSCLC) cell lines. The H1975 cell line expresses moderate amounts of c-Met, and EMD 1214063 was inactive as a single agent (treatment group/control group [T/C] 78%; tumor growth delay [TGD] 2 days). Cetuximab was active with a T/C of 13% inducing a TGD of 21 days. The combination of EMD 1214063 and cetuximab was active with a T/C of 1% and a TGD of 42 days. The NCI-H441 cell line is characterized by constitutive c-Met overexpression and is sensitive to c-Met inhibitors in vivo. EMD 1214063 (100 mg/kg) was active inducing a T/C of 20%, while erlotinib alone (30 mg/kg) was not efficacious. However, the combination of EMD 1214063 with erlotinib enhanced tumor growth inhibition, induced partial tumor regression in 2/9 mice, and delayed tumor re-growth. These data are compatible with the hypothesis that cMet pathway activation confers resistance to EGFR inhibitors. We additionally investigated the combination of either EMD 1214063 or EMD 1204831 with VEGF inhibitors in NSCLC models. In NCI-H441 xenografts, EMD 1204831 produced a modest T/C (66%) at the suboptimal dose of 25 mg/kg/bid, similarly to aflibercept at 40 mg/kg (T/C 55%). In contrast, the combination of both compounds yielded a T/C of 1% with partial responses in 2/10 mice. In the EBC-1 model, treatment with EMD 1214063 (10 mg/kg) or with the antiVEGF antibody B20-4.1 (20 mg/kg) as single agents resulted in a T/C of 21% (with partial regression in 1/10 mice) and 19%, respectively. In contrast, the combination of EMD 1214063 and B20-4.1 exhibited enhanced anti-tumor activity with a T/C of 72% and partial regressions in 10/10 mice. These data support the hypothesis that EMD 1214063 or EMD 1204831 may be effective in NSCLC patients in combination with VEGF-targeting agents. In conclusion, our findings provide a rationale to evaluate the efficacy of the combination of EMD 1214063 or EMD 1204831 with EGFR and VEGF inhibitors in NSCLC patients.']",
        "Doc_id":"AACR_2012-1787",
        "Doc_title":" The c-Met inhibitors EMD 1214063 and EMD 1204831 are effective in combination with EGFR and VEGF inhibitors in NSCLC models",
        "_version_":1606188983351508992},
      {
        "Meeting_name":" Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by Marsdenia tenacissima extract.",
        "Background":"['Apart from EGFR T790M mutation, the bypass activation of c-Met and Axl kinase also can lead to the resistance to tyrosine kinase inhibitors (TKIs) in NSCLC. Axl and c-Met share same downstream pathways with EGFR, thus combined treatments of EGFR inhibitors with Axl or Met inhibitor are promising to overcome acquired resistance of TKIs.']",
        "Doc_id":"AACR_2017-1199",
        "Doc_title":" Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by Marsdenia tenacissima extract.",
        "_version_":1606188990234361857},
      {
        "Meeting_name":" Correlation of expression of EGFR, cMET and mTOR signaling pathway proteins with each other and their impact on prognosis in non-small cell lung cancer patients",
        "Background":"['NSCLC tumors acquire resistance to EGFR-TKIs, and studies have suggested that co-localization of c-MET and EGFR may be a modality of acquired resistance. Upregulation of alternative signaling pathways such as Wnt or mTOR have been shown to be associated with poor prognosis and are a potential mechanism of resistance. This study aims at examining these signaling pathways and EGFR/c-MET co-expression in 100 patients with stage I-IV NSCLC. We have data on 50 patients, and are working on the remaining samples. Tumor tissue from biopsies or resections have been obtained with IRB approval, processed, sectioned, and mounted on microscope slides. Total and active forms of EGFR, c-MET, mTOR, S6K, beta-catenin, and Axin2 were detected using singleplex or multiplex IHC staining procedures, and stains were graded by an independent pathologist using a validated scoring system. We selected Stage IV NSCLC (n = 32) patients to correlate EGFR/c-MET expression with overall survival, and analyzed them for months to mortality based on high or low EGFR expression. Patients with high EGFR expression (n = 16) showed lower overall survival compared to those with low EGFR expression (n = 16). Expression of c-MET is linked to decreased survival in Stage IV NSCLC patients (n = 4). Patients with EGFR/c-MET co-localization (n = 19) showed decreased overall survival compared to patients without EGFR/c-MET co-localization (n = 9). Elevated mTOR and p-mTOR are associated with worse prognosis in Stage IV NSCLC patients. Patients categorized with either low mTOR expression (n = 10) or high mTOR expression (n = 19) showed increased mortality with high mTOR expression (5.9 months) compared to patients with low mTOR expression (13.5 months). A similar trend was seen in patients with either low (n = 4, 7.5 months) or high (n = 24, 15.9 months) p-mTOR expression. Patients with low beta-catenin expression (n = 4) showed improved survival in comparison to patients with high beta-catenin expression (n = 18), 9.4 months vs 6.3 months, respectively. To determine correlations in expression of these proteins we found that EGFR/c-MET co-expression is inversely correlated with active beta-catenin and directly correlated with a negative regulator of beta-catenin, Axin-2 suggesting EGFR/c-MET co-expression is associated with a downregulation of Wnt activity. In contrast, elevated EGFR/c-MET co-expression and co-activation is statistically significantly correlated with elevated mTOR-S6K expression and activation suggesting EGFR/c-MET co-expression is associated with an upregulation of the mTOR pathway activity. Elevated mTOR pathway activation at the time of diagnosis is statistically significantly associated with poor prognosis in patients with stage IV NSCLC. These preliminary results suggest that mTOR inhibition therapy in addition to EGFR/c-MET inhibition therapies may be beneficial in this population.']",
        "Doc_id":"AACR_2016-4755",
        "Doc_title":" Correlation of expression of EGFR, cMET and mTOR signaling pathway proteins with each other and their impact on prognosis in non-small cell lung cancer patients",
        "_version_":1606189011196444672},
      {
        "Meeting_name":" Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.",
        "Background":"['Combination therapy of c-Met/EGFR TKIs against c-Met/EGFR, while initially effective, has been shown to be susceptible to acquired resistance. To establish a mechanism of TKI resistance, the NSCLC model cell lines H2170 and H358 were made resistant to the c-Met/EGFR TKIs SU11274, erlotinib, or a combination by exposing the cells to progressively increasing concentrations of inhibitors. Phospho-Met (Tyr1003) was found to be downregulated 4- and 1.5- fold in H2170 and H358 cells, respectively. Phospho-EGFR was found to be upregulated in H2170 cells and downregulated in H358 cells. Interestingly, no significant differences were observed in c-Met/EGFR downstream signaling proteins, indicating that alternative signaling pathways such as the canonical Wnt pathway may confer TKI resistance. To determine differences in Wnt signaling between parental and resistant cell lines, immunoblotting was performed. In the H2170 erlotinib resistant (H2170-ER) cell line, a 5- and 6-fold increase in phospho-LRP5/6 as well as a 2- and 3-fold increase in total-LRP5/6 was observed in the presence or absence of erlotinib, respectively. Furthermore, H2170-ER cells exhibited a 3- and 16-fold increase in NKD2 as well as a 2.5- and 6-fold increase in Wnt3A in the presence or absence of EGF, respectively. A 2- to 2.5-fold increase was also observed in DVL2/3 in the absence of EGF. However, the Wnt pathway did not seem to have a significant role in H358 cells. Since EGFR and Wnt signaling are known to exhibit crosstalk, activation of the Wnt pathway may stimulate activation of EGFR causing resistance. This is suggested as upregulation of proteins involved in the Wnt pathway was seen only in the H2170 cell line. These results were confirmed by treating H2170 cells with the Wnt inhibitor XAV939. MTT analysis indicated that parental cells showed no significant response to XAV939, however, resistant cell lines showed a 2-fold decrease in viability when compared to a c-Met/EGFR TKI combination treatment. We propose a new treatment modality with Wnt inhibitors which have not yet entered clinical testing.To identify new targets for NSCLC, stable isotope labeling by heavy/light amino acids in cell culture (SILAC) coupled with mass spectroscopy was used. Analysis revealed more than 200 proteins modulated greater than 1.5-fold, six of which have significant potential to influence cell growth and survival based on their biological roles in NSCLC. These proteins include total--catenin, TPR, syntenin, HMGB2, TOM34 and AIF. We are currently using tandem mass tagging (TMT) to further investigate additional modulated proteins. Proteins of interest identified by this method include TPD52, erbB2, MESDC2, PIN1, PEA15 and NRAS. Proteins confirmed to be upregulated/activated in resistant cell lines will be further investigated as targets which induce drug resistance in NSCLC.Citation Format', ' Ryan Jacobs, Jason Fong, David Moravec, Greg Botting, Ryan Bomgarden, John Rogers, Rosa Viner, Michael Blank, Neelu Puri. Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 5653. doi', '10.1158/1538-7445.AM2013-5653']",
        "Doc_id":"AACR_2013-5653",
        "Doc_title":" Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.",
        "_version_":1606188971417665536},
      {
        "Meeting_name":" Activity of MSC2156119J in non-small cell lung cancer models with activating EGFR mutation",
        "Background":"['The therapeutic success of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) is hampered in a subset of patients by the development of drug resistance through the EGFR T790M gate keeper mutation. Recent investigations suggest that aberrant activation of the c-Met receptor through c-Met amplification and/or HGF upregulation may be an additional mechanism for acquired resistance. Combination of an EGFR TKI with a c-Met inhibitor could, therefore, delay and/or prevent the emergence of c-Met-driven resistance.The aim of our study was to evaluate the efficacy of MSC2156119J, a highly selective small molecule c-Met inhibitor, as monotherapy or in combination with EGFR TKIs (erlotinib, gefitinib and afatinib) in human xenograft models transplanted with two different primary NSCLC explants, LU342 and LU0858. While both tumors express the activated EGFR mutant form, LU342 expresses low levels of c-Met, while LU0858 expresses high levels of c-Met and carries an amplified c-Met locus.Single-agent MSC2156119J was inactive against the low c-Met-expressing LU342 explant and tumors progressed on treatment (median tumor volume [TV] change >73%). Erlotinib treatment resulted in tumor regression, with median TV change of -93% and tumor growth delay (TGD) of 56 days. The combination of MSC2156119J and erlotinib was more active, delaying tumor regrowth by 73 days compared to erlotinib monotherapy. Administration of afatinib at 5mg/kg was highly active in this model, inducing complete tumor regression (median TV change -100%), similar to the combination of afatinib and MSC2156119J.In contrast, the LU0858 explant, which carries an amplified c-Met locus, was sensitive to MSC2156119J at a dose of 100mg/kg 5 days on and 2 days off (5 on/2 off), inducing tumor stasis with a median TV change of 19% and TGD of 34 days. While gefitinib and afatinib alone at doses of 150mg/kg 5 on/2 off and 5mg/kg 5 on/2 off, respectively, were inactive (median TV changes >73%), in combination with MSC2156119J tumor growth inhibition was enhanced, resulting in tumor regression (median TV changes of -64% and -85%, respectively). In comparison, tumors treated with platinum-based doublet chemotherapy (cisplatin 5mg/kg QW/pemetrexed 200mg/kg QW) progressed, with TGD of 16 days. When MSC2156119J was combined with cisplatin/pemetrexed, antitumor activity was not significantly enhanced compared to single-agent MSC2156119J (median TV change -32%, TGD 30 days).Together, these findings are compatible with the hypothesis that inhibition of the c-Met pathway prevents and/or delays the emergence of c-Met-driven resistance in EGFR-mutant NSCLC. Furthermore, the enhancement of antitumor activity in the low c-Met-expressing LU342 model when MSC2156119J was combined with erlotinib suggests that the combination of an EGFR TKI + MSC2156119J may also be active in tumors with low levels of c-Met expression.']",
        "Doc_id":"AACR_2015-2591",
        "Doc_title":" Activity of MSC2156119J in non-small cell lung cancer models with activating EGFR mutation",
        "_version_":1606189036728221696},
      {
        "Meeting_name":" A prospective observational study evaluating c-MET expression and EGFR gene mutation correlation with erlotinib response in second line treatment for advanced/metastatic non-small cell lung cancer patients.",
        "Background":"['Background', ' The c-MET is associated with tumor progression and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study was to evaluate the prevalence and predictive role of c-MET and EGFR mutation in non-small cell lung cancer (NSCLC).']",
        "Doc_id":"AACR_2017-2773",
        "Doc_title":" A prospective observational study evaluating c-MET expression and EGFR gene mutation correlation with erlotinib response in second line treatment for advanced/metastatic non-small cell lung cancer patients.",
        "_version_":1606189019005190144},
      {
        "Meeting_name":" Phase II study of erlotinib plus tivantinib in patients with EGFR-mutationpositive NSCLC who failed in immediately previous EGFR-TKI therapy.",
        "Background":"['Background', '  Although driver mutations in EGFR gene are often associated with initial dramatic response to EGFR-TKI, those patients inevitably develop acquired resistance. It is suggested that dual inhibition of EGFR and c-Met may overcome or delay emergence of this resistance. Therefore, we conducted a multicenter, open-label, single arm Phase II combining erlotinib and a c-Met inhibitor tivantinib, in EGFR-mutated NSCLC patients with EGFR-TKI resistance. Methods', '  NSCLC patients who developed progressive disease during their immediately previous treatment with either erlotinib or gefitinib were enrolled. Fresh tumor biopsy was mandatory prior to starting the combination. All patients received daily oral erlotinib and tivantinib, until discontinuation criteria were met. Tumor response was evaluated by the independent radiological committee. The biopsy specimens were used for a comprehensive biomarker analysis, such as IHC assay of c-Met and HGF, and for multiplex mutation analysis (LungCarta Panel) of lung cancer associate genes including KRAS, c-MET, PTEN, EGFR and TP53. Plasma concentration of soluble c-Met and 8 angiogenic cytokines were also determined by ELISA and Luminex assay, respectively. Results', '  Forty-five patients were treated. The Table below shows objective response rate (ORR) and progression free survival (PFS) in the overall population, and in a subpopulation defined by c-Met expression or resistance mutations in EGFR (i.e. T790M or Exon 20 ins). Most of AEs were similar to the previous trials. Conclusions', '  In patients with EGFR-mutated NSCLC with EGFR-TKI resistance, erlotinib/tivantinib combination therapy may be beneficial to those with high c-Met expression or in those without resistance mutations in EGFR. The more detailed multivariate analyses regarding biomarkers will also be reported.   Clinical trial information', ' NCT01580735.']",
        "Doc_id":"ASCO_128630-144",
        "Doc_title":" Phase II study of erlotinib plus tivantinib in patients with EGFR-mutationpositive NSCLC who failed in immediately previous EGFR-TKI therapy.",
        "_version_":1606189030620266496},
      {
        "Meeting_name":" Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.",
        "Background":"['Background', ' Approximately 3-4% of lung adenocarcinomas express a truncated form of c-Met (c-Metex14) due to mutation-induced exon 14 skipping. c-Metex14 accumulates on the cell surface and is constitutively active with the ability to drive NSCLC. Data suggest that lung adenocarcinomas harboring c-METex14 are sensitive to c-Met kinase inhibitors. The highly selective c-Met inhibitor tepotinib is well tolerated and active at an oral dose of 500 mg QD. This single-arm phase II trial (NCT02864992) is investigating the efficacy and safety of tepotinib in patients (pts) with advanced lung adenocarcinoma harboring METex14. Methods', ' Adults with stage IIIB/IV lung adenocarcinoma who have failed 1 or 2 lines of systemic therapy, including a platinum doublet-containing regimen, are eligible. Tumors must harbor mutations that are known to cause exon 14 skipping, confirmed by a central laboratory, but not activating EGFR mutations or ALK rearrangements. Pts receive tepotinib 500 mg QD until disease progression, intolerable toxicity, or withdrawal from treatment for other reasons. The primary endpoint is objective response rate. Secondary endpoints include progression-free and overall survival, safety, pharmacokinetics, and quality of life. Recruitment of 60 patients in Europe, USA, and Japan is planned. Results', ' Four pts (age 6477 years; 3 stage IV, 1 stage IIIB, all Caucasian males) have been enrolled. All had received two prior chemotherapy regimens including a platinum doublet. Pts have currently completed 15 cycles of tepotinib therapy. The majority of adverse events observed to date have been grade 1/2 in severity; grade 3 disease-related dyspnea, pulmonary embolism, and pleural effusion were observed in one patient and grade 3 tepotinib-related elevated serum amylase in another. Of the 3 pts with post-baseline tumor evaluations, two have had an unconfirmed partial response and the third (with only one post-baseline assessment) stable disease. Conclusions', ' These initial data suggest that the efficacy of tepotinib 500 mg QD is comparable to that of less selective c-Met inhibitors in pts with c-METex14 NSCLC (ORR > 40%). Tepotinib is also well tolerated. Recruitment to the trial is ongoing. Clinical trial information', ' NCT02864992']",
        "Doc_id":"ASCO_183977-199",
        "Doc_title":" Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.",
        "_version_":1606189015437934592},
      {
        "Meeting_name":" Impact of different MET alterations on the efficacy of crizotinib in non-small-cell lung cancer.",
        "Background":"['Background', ' We reported MET overexpression could be as a biomarker for de novo MET activated non-small cell lung cancer (NSCLC) last year, and the rs13223756 SNP variation (-648A > G) might be a candidate for primary resistance. The relationship between the efficacy of MET-TKIs and MET status, such as amplification and overexpression, has not been well established. Methods', ' Advanced NSCLC patients with de novo MET expression were detected by immunohistochemistry (IHC) and Sanger sequence for SNP . H-score  60 were defined as c-Met positive. Gene copy numbers were detected by FISH ( By Cappuzzo scoring system & MET/CEP7 ratio).  5 copies were positive or MET/CEP7 ratio  1.8 was defined as MET amplification with low  1.8-  2.2, Intermediate > 2.2- < 5 and High  5.The statuses of EGFR, ALK, KRAS and ROS1 were also tested. Results', ' From January 2013 to December 2015, 32 eligible patients with MET IHC overexpression received crizotinib treatment (4 females, median age 59 years), with 25 evaluable for response. EGFR, ALK, KRAS and ROS1 were negative for all patients. Sixteen of them (64%,16/25) achieved partial response (PR), 1(4%,1/25) was stable disease (SD) and 8(32%,8/25) were progressive disease (PD). All responders had high c-Met IHC status. Ten of 13 (77%) FISHpositive patients had PR. Exon 14 splicing mutation was observed in 2 patients (1 with PR and 1 with PD). The significant difference occurred in the ORR (objective response rate) between FISH-positive and FISH-negative (83.3% vs. 30% respectively; P = 0.032).The incidence of SNP was not different in patients with AG or GG when compared with those with AA genotype (47.8%. vs. 52.2% respectively; P= 0.4), and there was no significant difference in ORR (70%vs. 33.3% respectively; P = 0.27). Adverse events of grade 3 QT prolongation have been found in 1 patient. For one death with interstitial lung disease, causality to crizotinib was not ruled out. The other common drug-related AEs were grade1/2. Conclusions', ' MET amplification could be a remarkable biomarker for de novo MET overexpressed NSCLC. The combination of IHC and FISH predicted the efficacy of crizotinib more precisely. The SNP Q648 variant in the MET gene is not a significant predictor for primary resistance.']",
        "Doc_id":"ASCO_169179-176",
        "Doc_title":" Impact of different MET alterations on the efficacy of crizotinib in non-small-cell lung cancer.",
        "_version_":1606189001234972672},
      {
        "Meeting_name":" Tumoral MET/HGF expression and MET gene amplification in patients with ALK 2p23 fusion driven lung cancer.",
        "Background":"['Background', '  MET receptor and its ligand HGF are both promising targets in non-small cell lung cancer (NSCLC) therapy. Crizotinib, a recently approved ALK inhibitor for NSCLC harboring oncogenic ALK 2p23 fusion (ALK+), was initially developed as a bona fide MET inhibitor. The role of MET/HGF pathway in ALK+ NSCLC is still unknown.  Methods', '  The study included 73 NSCLC patients tested for ALK rearrangements at Cleveland Clinic (2000-2012), including 21 ALK+ and 52 ALK-. Immunohistochemistry (IHC) on FFPE tumor tissue was performed for c-MET using a monoclonal CONFIRM antibody (SP44, Ventana) with Ventana Benchmark XT automated immunostainer and for HGF using a polyclonal antibody (R&D) following a manual protocol. IHC scoring was interpreted on a 4-tier  system (0, 1+, 2+, 3+). MET gene amplification by MET/Chromosome 7 dual probe in-situ hybridiazation (DISH) (Ventana) was also performed. Statistical analysis was performed using Fisher exact test in JMP.   Results', '  Of the tested tumors, 61 were adenocarcinoma (21 ALK+ and 40 ALK-), 6 squamous cell, 4 large cell and 2 NSCLC-NOS. None received any MET inhibitor prior to tissue collection. MET expression by IHC score 0-3 was', ' 35%, 33%, 15% and 17% in ALK-, and 5%, 37%, 42% and 16% in ALK+ tumor group, respectively. HGF IHC score 0-3 was 34%, 55%, 11% and 0% in ALK-, and 0%, 63%, 32% and 5% in ALK+ tumor group, respectively. The percentages of high MET or HGF expression (2+ or 3+) were higher in ALK+ group compared to ALK- (58% vs 32%, p=0.06, and 37% vs 11%, p=0.03). The correlation coefficient between MET and HGF expression was 0.48. MET gene amplification by DISH was detected in 15% (7/47) ALK- tumors but 0% (0/15) ALK+ tumors (difference not statistically significant, p=0.18). The correlation coefficient between MET IHC and MET gene amplification was 0.33.  Conclusions', '  MET and HGF expression is commonly seen in NSCLC, with more frequent high expression levels in ALK+ than ALK- tumors. Using a newly developed DISH method, we show that MET gene amplification tend to be less frequent in ALK+ tumor. A prospective study with larger sample size is warranted to further define the role of MET/HGF as biomarkers in the biology of NSCLC with ALK rearrangements and their targeted therapy.']",
        "Doc_id":"ASCO_116773-132",
        "Doc_title":" Tumoral MET/HGF expression and MET gene amplification in patients with ALK 2p23 fusion driven lung cancer.",
        "_version_":1606189000419180544},
      {
        "Meeting_name":" A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.",
        "Background":"['Background', ' INCB028060 is a potent and selective inhibitor of c-MET receptor tyrosine kinase (RTK). This first-in-human study aims to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of INCB028060. Methods', ' In a standard 3+3 escalation, patients (pts) age =18 years with advanced solid tumors are treated with INCB028060 orally once (QD) or twice daily on a continuous 28-day schedule. C-MET inhibition is evaluated by adding c-MET overexpressing SNU-5 human gastric cancer cells to pts whole blood and then analyzing for inhibition of phospho-c-MET by ELISA. Results', ' At this time 17 pts have been treated across dose levels of 10, 20, 50, and 70 mg/once daily. Median age is 63 years, median ECOG PS is 0, and the most common tumor types are colorectal (4), NSCLC (3), and prostate/HCC/cholangiocarcinoma (2 each). One pt with breast cancer and diffuse liver metastases treated at 50 mg QD developed grade 3 AST elevation on C1D22, having had grade 2 AST at baseline; the AST continued to rise once treatment was discontinued. The MTD has not been reached and no other grade 3/4 adverse events (AEs) noted. CTC grade 1-2 AEs considered possibly treatment-related have included mild tremor, fatigue, nausea, diarrhea, indigestion, headache, and agitation. The Cmax and AUC values of INCB028060 have been dose-proportional, with a mean half-life of 6.8 hours. For the 70 mg QD cohort, INCB028060 mean plasma concentrations exceeded IC90 for 17 h of the day. At the 70 mg dose level on day 15, the oral CL was 35.2 (+/- 11.5) L/h and renal clearance was negligible. Dose-dependent reductions in phospho-c-MET levels have been detected on day 15 (pre-dose) by whole blood-based PD analysis, with mean inhibition of 41.3%, 45.7%, 67.5% and 69% at 10, 20, 50 and 70 mg/day, respectively. Conclusions', ' Thus far, toxicity has been manageable with INCB028060. The PK profile is favorable and supports exploration of a BID schedule. Dose-dependent decreases in phospho-c-MET are promising.']",
        "Doc_id":"ASCO_82236-102",
        "Doc_title":" A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.",
        "_version_":1606188993873969152},
      {
        "Meeting_name":" Profiling c-Met and EGFR kinase inhibitor resistance pathways in non-small lung cancer cells",
        "Background":"['Tyrosine kinase inhibitors (TKIs) against c-MET and EGFR have positive therapeutic effects in a subset of Non-Small Cell Lung Cancer (NSCLC) patients; however, their clinical efficacies are limited due to the development of TKI resistance. To determine mechanisms of TKI resistance, two NSCLC model cell lines H2170 and H358 were made resistant to the c-Met/EGFR TKIs SU11274, erlotinib or a combination of both by exposing the cells to progressively increasing concentrations of inhibitor. Initial characterization of these cell lines using phospho-specific antibodies showed that phospho-c-Met was found to be downregulated 4- and 1.5- fold in SU11274-resistant (SR) H2170 and SR H358 cells, respectively. Phospho-EGFR was found to be constitutively autophosphorylated (upregulated 19-fold) in erlotinib-resistant (ER) H2170 cells, but downregulated 6-fold in ER H358 cells. Interestingly, c-Met/EGFR downstream signaling proteins p-mTOR, p-p70S6K and p-ERK were found to be 2-4-fold upregulated, 2-fold upregulated and 2-5-fold upregulated, respectively, in ER H2170 and H358 cells. Phospho-p70S6K was also found to be upregulated 20-fold in SR H2170 cells. These results indicate that alternative signaling pathways may confer TKI resistance in these cell lines. To identify which signaling pathways may be responsible for TKI resistance, H358 parental and resistant cell lines were analyzed by mass spectrometry (MS). Differences in protein expression in cell lines treated with and without EGF and/or erlotinib were measured using higher multiplexing Thermo Scientific Tandem Mass Tag (TMT) reagents. More than 1500 protein groups were identified and quantified using a Thermo Scientific Orbitrap Fusion platform with HCD-MS2 and MS3 fragmentation methods. Protein expression in ER H358 cells showed a marked increase in expression of DNA replication proteins, transcription factors, apoptosis inhibitors and some Ras-associated signal transduction pathways. To further investigate the mechanism of TKI resistance, phospho-peptide enrichment was also used in combination with TMT quantitation to profile changes in protein phosphorylation state. Overall, the combination of phospho-peptide enrichment coupled with higher multiplexing TMT and high resolution MS analysis enabled deeper global profiling of TKI resistance signaling pathways compared to previous studies without enrichment.']",
        "Doc_id":"AACR_2014-1608",
        "Doc_title":" Profiling c-Met and EGFR kinase inhibitor resistance pathways in non-small lung cancer cells",
        "_version_":1606189023909380096},
      {
        "Meeting_name":" Association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type NSCLC patients treated with rilotumumab and erlotinib.",
        "Background":"['Background', ' We previously reported a 59% disease control rate among EGFR wild-type (WT) patients in a phase II trial of the combination of rilotumumab (an HGF neutralizing antibody) and erlotinib (an EGFR tyrosine kinase inhibitor) in patients with metastatic previously treated NSCLC. There was 1 partial response (PR) and 16 patients with stable disease (SD) among 29 confirmed EGFR WT cases. There were two confirmed EGFR mutant cases (1 PR, 1 SD). Baseline plasma was collected from 35 patients enrolled in the study to identify potential biomarkers of treatment response. Methods', ' We examined 10 circulating biomarkers associated with the EGFR and c-Met pathways for association with clinical benefit among 35 trial participants for whom blood was successfully processed (31 EGFR WT, 1 EGFR mutant). Biomarkers measured included 4 EGFR ligands', ' amphiregulin (AREG), heparin-binding EGF (HB-EGF), TGF, and neuregulin-1 (NRG1). We also measured plasma levels of soluble c-Met, HGF, VEGF, IL6 and IL8. Results', ' Baseline levels of four proteins (AREG, IL6, NRG1, and TGF) showed significant associations with progression-free survival, with false discovery rate < 10% High NRG1 was protective and associated with longer PFS (HR = 0.41, 95% CI = .19-.87), while high AREG (HR = 2.14, CI = 1.48-3.08) and TGF (HR = 1.77, CI = 1.01-3.11) were associated with more rapid progression. Conclusions', ' NRG1 is a ligand for HER3, an EGFR family member that often dimerizes with EGFR/HER1, and also can be activated by c-Met. HER3 may serve as a mediator of more prolonged signaling from both EGFR and c-Met. NSCLC tumors that show elevated HER3 pathway signaling may be more dependent on EGFR-c-Met cross talk and/or more dependent on HER3 to propagate c-Met signaling.']",
        "Doc_id":"ASCO_170795-176",
        "Doc_title":" Association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type NSCLC patients treated with rilotumumab and erlotinib.",
        "_version_":1606189038170013697},
      {
        "Meeting_name":" The prognostic significance of circulating angiogenesis biomarkers in stage I NSCLC.",
        "Background":"['Background', '  Dysregulation of angiogenesis has been shown to be intimately associated with tumorigenesis and metastatic progression in multiple carcinomas. The objective of this study was to establish the value of circulating angiogenesis biomarker to identify cases of stage I NSCLC at high risk for disease recurrence. We hypothesize differences in angiogenesis biomarker levels will associate strongly with lung cancer progression and may have prognostic value.  Methods', '  We enrolled a total of 147 patients stage I NSCLC in which there was 39 cases of disease recurrence. Histology for these cases were predominately adenocarcinoma (71.2%), followed by squamous cell carcinoma (17.8%) and NSCLC other (11%). Serum from these patients were evaluated for 37 biomarkers associated with angiogenesis were assayed on the Luminex platform including', ' EGF, Angiopoietin-2, G-CSF, BMP-9, Endoglin, Endothelin-1, Leptin, FGF-1, FGF-2, Follistatin, IL-8, HGF, HB-EGF, PLGF, VEGF-A, VEGF-C, VEGF-D, angiostatin, sAXL, sc-KIT, sEGFR, sHer2, sHer3, E-selectin, HGFR/c-Met, Tenascin C, PDGF-AB/BB, sIL-6R, sTie-2, Thrombospondin, sNeutrophilin-1, suPAR, sVEGFR1, sVEGFR2, sVEGFR3, PECAM-1, osteopontin. Biomarkers levels were analyzed using COX regression or log-rank test for progression-free survival (PFS) or overall survival (OS).  Results', '    In our cohort of 147 cases of stage I NSCLC we found 4 biomarkers with significant log-rank p-values (p<0.05) for PFS, including sEGFR, IL-8, sc-KIT, FGF-1. For OS we identified 9 biomarkers with strongly significant a log-rank p-values (p<0.01), including endothelin-1, sHGFR/cMET, VEGF-C, IL-8, angiopoietin-2, sVEGFR-3, PECAM-1, and sc-KIT. Further, an additional 13 angiogenesis biomarkers were found to have log-rank p-values that were significant (p<0.05).  Conclusions', '    We discovered a series of circulating biomarkers of angiogenesis that were significantly associated with prognosis in stage I NSCLC. These angiogenesis biomarkers may provide ideal targets for the establishment of a validated model for predicting lung cancer progression and may have implications for the adjuvant treatment of stage I lung cancer.']",
        "Doc_id":"ASCO_153605-156",
        "Doc_title":" The prognostic significance of circulating angiogenesis biomarkers in stage I NSCLC.",
        "_version_":1606188979616481281},
      {
        "Meeting_name":" Overcoming acquired EGFRi resistance in NSCLC with targeted beam irradiation in combination with targeted agents",
        "Background":"['BACKGROUND', ' Non-small cell lung cancer (NSCLC) patients undergo primary, adjuvant or neoadjuvant radiotherapy treatment with image-guided radiotherapy (IGRT) being widely used to provide more accurate treatment plans and reduced side effects.Patients who have activating mutations in the epidermal growth factor receptor (EGFR) gene are treated with EGFR tyrosine kinase inhibitors (EGFRi). However, resistance to EGFRi occurs in the majority of patients with the main clinical drivers being secondary gatekeeper mutations (T790M) or amplification of genes such as c-MET and Her2.The small animal radiation research platform (SARRP), which allows the treatment of rodent models of cancer more accurately with planned protocols similar to those utilised in the clinic, was used in combination with EGFRi, to assess the efficacy of combination treatment strategies of irradiation (IR) in EGFRi resistant NSCLC xenografts.METHODS', ' Resistance to EGFRi in the NSCLC cell line HCC827, which harbours an activating EGFR mutation, was generated through repeated exposure to Gefitinib or Erlotinib. Resistant models were characterised for further mutations in the EGFR gene by direct sequencing and for c-MET, Axl and Her2 over-expression/genomic amplification by quantitative PCR.EGFRi resistant or parental HCC827 cells were implanted subcutaneously into nude mice, xenograft growth was monitored by calliper measurements and treatment initiated when the mean tumour volume reached 200mm3. An image guided IR dose of 3Gy/mouse/day (30Gy total) was targeted directly to the xenografts whilst sparing the surrounding normal tissue. Mice were treated with IR either alone or in combination with Erlotinib or Crizotinib; response to treatment was evaluated by tumour volume measurement.RESULTS', ' EGFR-TKI resistant HCC827 cell lines were generated following successive cycles of treatment. Amplification of c-MET was identified in a number of clones, but no Her2 amplification or gatekeeper mutations; therefore Crizotinib, a c-MET inhibitor, was selected for evaluation in these models.When assessed in vivo, treatment of parental HCC827 xenografts with targeted IR or Erlotinib treatment resulted in tumour regression. However, in the c-MET driven resistant model, both the IR and Erlotinib response was significantly attenuated, resulting in tumour re-growth. Combination testing with Crizotinib restored the efficacy of both IR and Erlotinib to nave treatment levels confirming the role of c-MET in resistance.CONCLUSIONS', ' Resistance to EGFRi and IR in a HCC827 model is driven by c-MET amplification. Treatment with Crizotinib restored sensitivity to both EGFRi and IR demonstrating that pre-clinical models of resistance are invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent/overcome resistance to EGFRi.']",
        "Doc_id":"AACR_2015-765",
        "Doc_title":" Overcoming acquired EGFRi resistance in NSCLC with targeted beam irradiation in combination with targeted agents",
        "_version_":1606188970613407744},
      {
        "Meeting_name":" Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.",
        "Background":"['Background', ' Activation of MET oncogene as the result of amplification or activation MET exon 14 mutations represents an emerging molecular target for non-small cell lung cancer (NSCLC) treatment. MET exon 14 mutations account for 1.0% in Chinese NSCLC patients. However, few data have been reported on the coexisting of MET exon 14 mutations and EGFR mutations in NSCLC. Moreover, the clinicopathological characteristics and targeted therapy of these MET/EGFR-coexisting patients remain elusive. Methods', ' Next-generation sequencing was performed on the DNA of 969 patients and Sanger sequencing was conducted on cDNA of 621 patients for MET exon 14 mutations in NSCLCs. EGFR mutations were determined by direct DNA sequencing. Results', ' Fifteen patients harbored positive MET exon 14 mutations. Frequency of concomitant EGFR and MET exon 14 mutations was 0.2%(3/1590). 3 patients with concomitant MET exon 14 mutation and EGFR activating mutation were all female, never smokers and adenocarcinoma. Their stagings were stageB (n = 1) and stage (n = 2). The stage B patient harboring concomitant MET exon 14 skipping and EGFR L858R mutation did not relapse 2 years after operation. The other two stage  patients received first-line gefitinib. Case one harbored concomitant MET exon 14 point mutations (IVS13-36G > A) and EGFR exon 19 deletion, and showed resistance to gefitinib with progression free survival(PFS) of 2 weeks and overall survival(OS) of 1 month. Case two had concomitant MET exon 14 point mutations (IVS13-36G > A) and EGFR L858R mutation. Meanwhile, she also had both METamplification and c-Met overexpression at the baseline. She showed partial response (PR) to gefitinib with 3.8 months PFS. Then she was enrolled in a clinical trial (NCT02374645) to receive volitinib plus gefitinib on December 20, 2016. Initial response was good PR on January 24, 2017. Only grade 1 rash was observed. Conclusions', ' Coexisting MET exon 14/EGFR mutation is an uncommon molecular event in NSCLC patients. Such coexisted patients might show relative resistance to EGFR inhibitor. However, combination of MET and EGFR inhibitors will be potentially a good strategy to overcome such a relative resistance for MET exon 14/EGFR co-mutant patients.']",
        "Doc_id":"ASCO_187940-199",
        "Doc_title":" Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.",
        "_version_":1606189004358680577},
      {
        "Meeting_name":" MET expression in circulating tumor cells (CTCs) isolated on the ISET platform correlates with MET expression in matched tumor tissue in advanced NSCLC patients",
        "Background":"['Background', ' Overexpression of the MET receptor tyrosine kinase is frequent in lung cancers and is associated with poor prognosis. Recent clinical studies of MET targeted therapies have used immunohistochemistry (IHC) in tissue biopsies to evaluate MET protein expression. Due to the difficulty in obtaining adequate tissue in diseases such as NSCLC, we investigated the utility of circulating tumor cells (CTCs) as a non-invasive method to evaluate MET status in NSCLC patients. We compared two platforms for CTC capture, CellSearch and ISET, and assessed MET expression in CTCs vs. matched bronchial biopsies in patients with advanced-stage III/IV lung adenocarcinomaDesign', ' CTC capture and MET expression in CTCs was evaluated in 358 MET positive NSCLC patients (Phase III OAM4971 trial) using the CellSearch platform. CTC capture and MET expression was evaluated in a cohort of 80 CTC-positive NSCLC patients using the ISET platform (filtration). MET was detected in CellSearch-captured CTCs by immunofluorescence using the 15A5 mouse monoclonal antibody (Genentech), and in ISET-captured CTCs and FFPE tissue sections by immunohistochemistry using the SP44 c-MET antibody from Ventana Medical Systems, Tucson, USA. Both reagents performed equally on the CellSearch platform.Results', ' CTCs were detected in 108 of 358 (30%) patients evaluated on CellSearch, with CTC enumeration ranging from 0 to 193 CTCs/7.5 ml blood, and median 0 CTCs/7.5ml blood. Although OAM4971 patients were selected for positive MET expression in tissue, we failed to detect MET expression in most CTCs isolated by CellSearch, with 75% patients showing CTC H-score < 15. On the ISET platform, CTCs enumeration ranged from 2 to 268 CTCs/ml, with median 65 CTCs/ml. Clusters of CTCs were observed in 93% of patients, exhibiting between 1 to 23-clusters/ml blood. The MET assay on CTCs was positive in 54 of 75 (72%) patients, and the MET assay on tissue was positive in 46 of 75 (62%) patients using the onartuzumab IHC scoring algorithm*, with MET status in CTCs concordant with status in patient-matched tumor tissue.Conclusion', ' Based on our data, CTCs enumeration and MET status on CTCs from NSCLC patients captured and evaluated on the ISET system were more successful than on the CellSearch platform. On ISET, MET status in CTCs correlated strongly with MET status in tumor tissue biopsies, illustrating the potential for using CTCs as a non-invasive, real-time biopsy to determine MET status of patients entering clinical trials. We are now expanding the CTC analysis on ISET to other biomarkers with relevance for lung therapeutics.* Koeppen H et al. Clin Cancer Res. 2014 Sep 1;20(17)', '4488-98']",
        "Doc_id":"AACR_2015-1580",
        "Doc_title":" MET expression in circulating tumor cells (CTCs) isolated on the ISET platform correlates with MET expression in matched tumor tissue in advanced NSCLC patients",
        "_version_":1606189023315886080},
      {
        "Meeting_name":" Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.",
        "Background":"['Background', ' Met is associated with a poor outcome in many cancers, including NSCLC. Met activation is a mechanism of resistance to EGFR inhibition, supporting dual inhibition of Met/EGFR. MetMAb is a monovalent monoclonal antibody that specifically binds the Met receptor. Methods', ' OAM4558g is a global randomized, double-blind phase II study comparing MetMAb plus erlotinib (ME) to placebo plus erlotinib (PE) in 2nd/3rd line NSCLC. Tissue collection was mandatory to assess c-Met IHC expression levels (Met Dx). Co-primary endpoints were PFS in the Met Dx+ and ITT populations. Safety and OS were additional endpoints. Following the initial unblinding, Met Dx- patients (pts) were removed from ME. Results', ' 128 NSCLC pts were equally randomized to receive ME or PE. 95% of tissue was evaluable for c-Met IHC, 88% for EGFR and KRAS mutations (mut), and 75% for MET FISH. Baseline characteristics were well balanced. 54% of pts had Met Dx+ NSCLC, which was associated with a worse outcome (OS HR 2.52, PE cohort). A total of 99 PFS and 70 OS events have occurred, median follow up is 9.9mos. In the Met Dx+ group, ME resulted in a statistically and clinically significant improvement in both PFS and OS. An OS benefit from ME was observed in MET FISH+ NSCLC as well as in FISH-/IHC+; removing pts with EGFR mut did not alter results. Selective benefit of ME was not observed in other subgroups. E-related toxicities were comparable between treatment arms. Conclusions', ' Met Dx+ NSCLC represented more than half the population and was associated with a worse outcome. The addition of M to E in these pts significantly improved PFS and OS, resulting in a near 3-fold reduction in the risk of death. This benefit was not exclusive to EGFR mut or MET FISH+ and was observed in FISH-/IHC+ pts suggesting IHC is a more sensitive predictor of benefit from MetMAb.']",
        "Doc_id":"ASCO_82156-102",
        "Doc_title":" Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.",
        "_version_":1606189015649746944},
      {
        "Meeting_name":" Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '   Mechanisms of acquired resistance to erlotinib (E) in NSCLC include aberrant activation of alternative receptor tyrosine kinases and/or their downstream signal transduction cascades (e.g, c-Met and AKT), indicating a need for strategies to detect such resistance mechanisms and agents to overcome them. The effects of MK2206, a selective AKT inhibitor, on E activity in NSCLC cell lines with diverse oncogenic mutation profiles and a range of E sensitivity were investigated. We hypothesized that inhibition of AKT signaling would augment E activity and reverse resistance.  Methods', '   Four cell lines were evaluated', ' HCC827 (EGFR-mutant, E-hypersensitive), H1666 (EGFR-wild type, E-sensitive), H358 (EGFR-wild type, E-sensitive) and A549 (EGFR-wild type, E-resistant). Treatment effects were assessed by MTT assay, colony formation, flow cytometry and immunoblotting for signaling and apoptosis.  Results', '   The combination of MK2206 and E showed significantly enhanced growth inhibition compared to single-agent treatment in all lines tested, including E-resistant cells. Addition of the c-Met ligand, HGF, blocked anti-proliferative and cytotoxic effects of E. Treatment with MK-2206 restored E sensitivity in cells rendered resistant by HGF. In comparison, c-Met inhibition (using PHA665752) effectively overcame HGF-mediated resistance, but was ineffective as a single agent or in combination with E. In E-resistant A549 cells, the addition of MK2206 significantly reduced colony formation compared to the single agents.  Conclusions', '  MK2206 enhanced E activity in both E-sensitive and E-resistant NSCLC cell lines, and re-sensitized cells rendered resistant through c-Met activation by HGF. This paradigm is currently being tested in an ongoing NCI-sponsored phase II trial of MK-2206 in combination with E in patients with advanced NSCLC (stratified by EGFR mutational status) who have previously benefited from E-based therapy.']",
        "Doc_id":"ASCO_80944-102",
        "Doc_title":" Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC).",
        "_version_":1606189008738582528},
      {
        "Meeting_name":" A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.",
        "Background":"['Background', '  Dysregulation of the tyrosine kinase receptor c-Met, is associated with tumorigenesis, metastasis and progression via hepatocyte growth factor (HGF)-dependent or-independent mechanisms.  Methods', '  ARGX-111, a monoclonal IgG1 SIMPLE Antibody glyco-engineered for enhanced ADCC properties (POTELLIGENT), is currently being investigated in a Phase 1 clinical trial (accelerated titration design) in patients with advanced solid tumors (NCT 02055066).  Results', '    As of January 2015, 16 patients (median age', ' 59 years; prior chemotherapy/targeted therapies/biological therapies', ' 81%/44%/31%;) with tumors staining positive (> 50% of tumor cells) for c-Met by immunohistochemistry have been treated at 4 dose levels (0.3, 1, 3, and 10 mg/kg IV q3 weeks; n = 2, 2, 9, and 3, respectively) and received a total of 41 cycles (median = 2; range 1-9). Patients with different histologies were enrolled (5 upper GI, 3 RCC, 2 pancreas, 2 NSCLC, 2 cervix and 2 others). The most common drug-related adverse events (AE) were', ' infusion-related reaction (IRR) (56%), fatigue (38%) and diarrhea (25%). Drug-related Grade 3 AEs (IRRs) were observed in 2 patients. The MTD was 3 mg/kg IV q3 weeks. Pharmacokinetics were dose-linear, with a half-life of 3-4 days. Serum HGF levels remained stable during treatment. Ex vivoADCC and depletion of circulating c-Met+ cells were observed in all patients and NK cell counts remained stable during treatment across all dose levels.  One patient with metastatic, c-Met amplified gastric cancer refractory to platinum and taxane-based chemotherapy regimens, was treated at 0.3 mg/kg (escalated to 1.0 mg/kg) and maintained stable disease by RECIST for 6 months, associated with mixed metabolic response on PET scan, and a more than 50% reduction in CTCs.  Conclusions', '    Recruitment of the safety expansion cohort is ongoing.  Full results will be presented at the meeting.   Clinical trial information', ' NCT 02055066.Dose0.3 mg/kg1 mg/kg3 mg/kg10 mg/kgCmax(mean) (g/ml)5.611.443.4113.2ADANoNoNoNoHGF levelsStableStableStableNDADCCYesYesYesYesNK-cell countStableStableStableStable']",
        "Doc_id":"ASCO_151360-156",
        "Doc_title":" A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.",
        "_version_":1606189011832930304},
      {
        "Meeting_name":" Tumoral MET expression and plasma HGF level in patients with ALK 2p23 fusion driven lung cancer.",
        "Background":"['Background. MET is the tyrosine kinase receptor for the ligand hepatocyte growth factor (HGF). MET kinase has been identified as a novel promising target in non-small cell lung lung cancer (NSCLC). Crizotinib, a recently FDA-approved ALK inhibitor for NSCLC harboring ALK 2p23 fusion (ALK+), was initially developed as a MET inhibitor. MET expression level is a potential biomarker for response to MET inhibitors. The role of MET/HGF pathway in ALK+ NSCLC is unknown.Methods. A cohort of 51 NSCLC patients tested for ALK fusion at Cleveland Clinic (2000 to 2012), including 15 ALK(+) and 36 ALK(-) subjects, were included in the study. Immunohistochemistry (IHC) stain against MET was performed using a monoclonal CONFIRM anti-Total c-MET antibody (SP44, Ventana). Staining was performed on a Ventana Benchmark XT automated immunostainer (Ventana Medical Systems). A four-tier (0, 1+, 2+, 3+) scoring system and H-score (the sum of each intensity score x %) were used. Thirteen ALK(+) patients treated on crizotinib therapy were prospectively followed and a total of 32 blood plasma samples were collected (1) prior to crizotinib initiation, (2) during responding period and (3) at disease progression, for HGF level measurement using HGF ELISA kit (R&D). Statistical analysis was performed using Fisher exact test and Wilcoxon rank sum test in JMP.Results. Of the 51 tumor tested for MET IHC, 39 were adenocarcinoma (15 ALK+ and 24 ALK-), 6 squamous cell, 4 large cell carcinoma and 2 other NSCLC. None received any MET inhibitor when tissue was collected. The percentage of negative MET IHC (score 0 or 1+ in 50% tumor cells) was not statistically significant between ALK(+) and ALK(-) groups (40% vs 30%, p=0.5). The plasma HGF levels in ALK(+) patients varies from undetectable to 14000pg/ml. The median (25th-75th quantiles) level in patients prior to crizotinib therapy (n=5), during responding period (CR/PR/SD, n=12) and at disease progression (n=5) were 2137(767-12100)pg/ml, 1629(785-3430)pg/ml and 4064(1108-7308)pg/ml. The plasma HGF level showed a trend of decreasing during clinical response to crizotinib and elevation upon disease progression, albeit not reaching statistical significance in this small study cohort (p>0.05).Conclusions. MET expression is commonly seen in NSCLC, and no significant difference were observed between fusion ALK(+) and ALK(-) NSCLC. The baseline plasma HGF concentration varied significantly among ALK(+) NSCLC patients, but showed a trend correlating with therapeutic response and resistant progression, to crizotinib therapy. Prospective study with larger cohorts is warranted to further evaluate the role of MET/HGF as biomarker in ALK targeted therapy.']",
        "Doc_id":"AACR_2013-2374",
        "Doc_title":" Tumoral MET expression and plasma HGF level in patients with ALK 2p23 fusion driven lung cancer.",
        "_version_":1606189029753094144},
      {
        "Meeting_name":" Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.",
        "Background":"['Background', ' MetMAb (M) is a monovalent monoclonal antibody that blocks HGF-induced Met signaling. A Phase II double-blinded, randomized trial of MetMAb+erlotinib (M+E) or placebo+erlotinib (P+E) in 2nd- and /3rd- line NSCLC was recently completed. The M+E arm demonstrated both PFS and OS advantages in the c-Met IHC expression positive 2+ /3+ (Met Dx+) patients only. Methods', ' Adverse events (AEs) were assessed for MetMAb related toxicities. In addition to AEs, tumor growth rate and onset of new lesions were evaluated to understand their potential contribution to the clinical outcomes. Results', ' In the M+E arm, median cycles of M were higher in Met Dx+ vs. Met Dx- pts (4 vs. 2) as were median E doses (61 vs. 42 respectively). Overall pattern of AEs were similar in the two treatment arms, with the exception of peripheral edema which was higher on M+E; regardless of c-Met expression levels. Time to onset of any Grade 3 AE in M+E treated patients was also similar across groups.  In the Met Dx- group, Grade 3 AEs on M+E were higher than on P+E (56% vs. 35%), but the rate was similar to that observed for Met Dx+ pts on M+E (57%) or P+E (53%). AEs leading to death were highest in Met Dx- pts on M+E (n=5), whereas the number of AEs leading to treatment discontinuation was highest in Met Dx+ pts on M+E (n=6)', ' no consistent patterns were observed for either. The rate of tumor growth was not significantly different between treatment arms or Met sub groups. 55% of Met Dx+ pts progressed with new lesions vs 43% of Met Dx- (P+E), but the addition of M had no effect on this rate. The power to detect a difference is limited by the number of subjects in the study, ie., 65 with Met Dx+  (35 on M+E and 30 on P+E) and 56 with Met Dx- (27 on M+E and 29 on P+E). Conclusions', ' The combination of M+E did not substantially alter the safety profile of erlotinib and differences in AEs do not clearly explain the PFS and OS outcomes observed in Met Dx subgroups on M+E. Furthermore, the addition of M to E in Met Dx- patients did not appear to alter tumor growth rates or patterns of disease progression.']",
        "Doc_id":"ASCO_77987-102",
        "Doc_title":" Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.",
        "_version_":1606188994066907136},
      {
        "Meeting_name":" Targeting Met signaling to overcome human cancer cell resistance to radiation.",
        "Background":"['Purpose', ' Targeting signaling pathways that are implicated in cancer cell resistance to therapy are being investigated to improve therapy outcome. One of the receptor tyrosine kinases, c-Met (Met) is frequently overexpressed in many cancer types including non small cell lung cancers (NSCLCs) and head and neck squamous cell carcinomas (HNSCCs) and is associated with resistance to radiation. EMD1214063 is a small molecule inhibitor that suppresses the kinase activity of Met. The current study investigated the potential of EMD1214063 (provided by EMD Serono Merck Inc) in enhancing cancer cell sensitivity to radiation.Materials and Methods', ' Three NSCLC lines (A549, H460 and H1993) and three HNSCC lines (FaDu, HN-5 and UMSCC-1) with different levels of Met protein were used for the study. The effects of EMD1214063 on Met expression, cell viability, migration and cell radiosensitivity were assessed. Various scheduling effect on the magnitude of increased cell radiosensitivity was evaluated. 53BP1 foci formation was assayed for DNA repair kinetics. In vivo tumor growth delay assays on two NSCLCs and two HNSCCs generated in mice were performed to test the efficacy of EMD1214063 on tumor growth and tumor response to radiation.Results', ' NSCLC lines expressed higher levels of Met than HNSCC lines. EMD1214063 reduced survival of NSCLC lines markedly and had a minimal effect on HNSCC lines in vitro. Western blots showed three major Met protein bands with molecular weights of about 145 kDa, 60 kDa and 45 kDa. Radiation increased the expression levels of the 145 kDa and 60 kDa fragments of Met in a dose dependent manner. EMD1214063 suppressed the radiation-induced expression of Met and prolonged the presence of 53BP1 foci. It potently enhanced the radiosensitivity of A549, H1993, HN-5 and FaDu but not that of H460 and UMSCC-1. The enhancement factors at the survival fraction of 0.5 ranged from 1.11 to 2.24, with H1993 being the most responsive cell line. In vivo data showed lack of single agent activity of EMD1214063 on the growth of tumor xenografts tested (A549, H460 and FaDu). However, it showed a schedule dependent effect in enhancing A549 tumor xenograft response to radiation', ' a marked enhancement was observed only when EMD1214063 was given concurrently with fractionated doses of radiation. In vivo studies on other tumor types are ongoing.Conclusions', ' This study demonstrated that EMD1214063 reduced viability and migration of NSCLC cells and it selectively enhanced radiosensitivity of cells that express higher levels of basal or induced Met and the underlying mechanism may be inhibition of DNA repair. In vivo study data showed EMD1214063 induced a schedule dependent enhancement of tumor response to radiation in a NSCLC line. These data warrant further in vivo investigations aiming at taking best regimens to the clinic testing.This study is being supported by EMD Serono Merck via an independent medical grant.']",
        "Doc_id":"AACR_2013-4435",
        "Doc_title":" Targeting Met signaling to overcome human cancer cell resistance to radiation.",
        "_version_":1606189034540892160},
      {
        "Meeting_name":" Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors.",
        "Background":"['Background', '   Amplifications and activating mutations in the c-MET proto-oncogene are known oncogenic drivers that have proven responsive to targeted therapy. Alterations affecting the splice sites of MET exon 14 have been identified, which cause exon skipping, MET activation, and predict sensitivity to MET inhibitors in vitro. We undertook comprehensive genomic profiling (CGP) of a large series of advanced cancers to identify MET exon 14 alterations. Methods', '   DNA was typically extracted from 40 microns of FFPE sections from 34,735 cases examined between April 2012 and January 2015. CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of > 500x. All classes of genomic alterations (GA) were evaluated. Results', '   CGP of 34,735 patients identified 200 cases harboring METex14 alterations. The alterations had diverse sequence composition, with > 100 distinct sequence variants represented. The 200 patients had a median age of 68.2 years (range 15-83), with 86 males and 114 females. The cases were comprised of lung carcinoma (173), carcinomas of unknown primary (14), brain glioma (6),  and one each of adrenal cortical carcinoma, hepatocellular carcinoma,  melanoma, Merkel cell carcinoma renal cell carcinoma, rhabdomyosarcoma, sarcoma NOS, and synovial sarcoma. The majority were stage IV. Identification of this alteration via CGP in routine clinical care has led to treatment with MET inhibitors such as crizotinib, and to durable partial responses or better exceeding 3 months in histiocytic sarcoma (1), sarcomatoid lung carcinoma (1), and nsclc (1+). Multiple patients (5+) have initiated treatment on either crizotinib or MET inhibitors in clinical development, and additional outcome data will be reported. Conclusions', '   MET exon 14 alterations define a hereto unrecognized population of advanced cancers. Early reports of patients demonstrate cases harboring such alterations are responsive to multiple small molecule MET inhibitors. This finding expands the population of advanced cancer patients who can derive benefit from MET-targeted therapies.']",
        "Doc_id":"ASCO_153522-156",
        "Doc_title":" Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors.",
        "_version_":1606188991125651456},
      {
        "Meeting_name":" High ALK gene copy number as a predictor of response to crizotinib in non-small cell lung cancer cell lines",
        "Background":"['Introduction', ' The anaplastic lymphoma kinase (ALK) gene translocation is a rare event, described in approximately 4-6% of lung adenocarcinoma. ALK translocation is a robust predictive factor for ALK inhibitors sensitivity. However, increased ALK gene copy number seems to be a frequent event, described in 13-17% of Non-small cell lung cancer (NSCLC). The goal of this study was to explore the predictive value of ALK High copy number for 2 ALK inhibitors, crizotinib and TAE684 in NSCLC cell lines. Methods', ' 27 NSCLC cell lines were screened for ALK copy number by FISH after cytospin. ALK high copy number (HCN) was defined as the presence of  5 copies of ALK. FISH with CEP2 was performed to determine the plody status in cell lines with HCN. As crizotinib is a dual c-MET and ALK inhibitor, FISH c-MET was performed in selected cell lines for in vitro studies. C-MET scoring was based on Cappuzzo criteria. In vitro sensitivity was evaluated through WST1 assays and clonogenic tests. Kelly, an ALK mutated neuroblastic cell line, was added as a positive control. Cells were seeded in triplicates in 96-well plates 18h before the treatment with TAE 684 or crizotinib with concentrations varying from 50 to 4000nM and 100 to 10000nM respectively. The half maximal inhibitory concentration of the two drugs (IC50) was estimated after 72h of treatment with 4 and 5 parameters logistic regression models. In clonogenic tests, crizotinib was tested with three schedules of concentrations', ' low dose (50nM), intermediate (200nM) and high (1000nM). Results', ' Among NSCLC cell lines, 6 (22%) displayed more than 5 copies of ALK, 19 (70%) presented a gain of 3 or 4 ALK copy number, only one cell line exhibited normal ALK copies and one harbored EML4-ALK translocation. FISH with CEP2 revealed a polysomy of chromosome 2 in cases with ALK HCN. C-MET amplification was observed in only three cell lines. Based on ALK FISH status, 9 NSCLC cell lines were selected to undergo in vitro assays, 6 exhibiting ALK HCN (H2030, H661, A427, H3255, BEN, H1299) and 3 exhibiting low ALK copy number (LCN) (H1975, H1651, H1650). Kelly and A549 cell lines were added as sensitive and resistant controls respectively. In ALK HCN cell lines, two (H661 and A427) were as sensitive as Kelly for crizotinib through clonogenic and WST1 assays. In addition, ALK HCN cell lines exhibited lower IC50 for anti-ALK drugs than cell lines with ALK LCN (median IC50 with crizotinib values', ' 1750nM [300-2800nM] in ALK HCN cell lines versus 4500nM [800-8000nM] in ALK LCN cell lines, p=0.35). The trend of crizotinib activity was not due to c-MET inhibition. Conclusion', ' The in vitro assays suggest that ALK HCN may be a predictive marker for sensitivity to crizotinib. The predictive value of ALK HCN would be investigated in in vivo models.']",
        "Doc_id":"AACR_2012-1715",
        "Doc_title":" High ALK gene copy number as a predictor of response to crizotinib in non-small cell lung cancer cell lines",
        "_version_":1606189007276867585},
      {
        "Meeting_name":" Exploratory biomarker analyses from OAM4558g",
        "Background":"['Background', ' MetMAb, a monovalent anti-cMet receptor antibody, inhibits HGF-mediated activation of c-Met. The Phase II study testing MetMAb in combination with erlotinib in patients with advanced NSCLC (n=128) demonstrated an OS benefit in Met Diagnostic (Dx)+ patients (n=65, defined as 50% of tumor cells staining 2+ or 3+ intensity for c-Met by IHC; HR=0.37, p=0.002). Methods', ' Exploratory tumor biomarkers related to c-Met and/or EGFR signaling were measured by FISH, qRT-PCR or various mutation detection techniques from archival tumor tissue specimens. Plasma HGF levels were measured by ELISA. Analyses with outcome were carried out independent of Met Dx status. Results', ' Baseline characteristics of patients with evaluable tumor or plasma specimens were generally comparable. MET gene copy number was evaluated in 96 specimens with a median mean copy number of 3.44 copies/cell (range 1.625.0) and true gene amplification was detected in 8%. Analysis of different copy number cutoffs revealed a non-significant trend toward improved OS when MET FISH-positivity was defined as 5 copies/cell (HR=0.47, p=0.19), but not at lower thresholds 4 copies (HR=0.89, p=0.82). An OS HR of 1.37 (95% CI', ' 0.43-4.36) was observed in 23 patients with both MET and EGFR FISH copy number gains (high polysomy or amplification). EGFR mutations were detected in 12% (13/112) of evaluable specimens; mutations were detected in 6 of 7 patients with objective responses. KRAS mutations were detected in 23% (26/112) of evaluable specimens and status did not affect OS for patients on MetMAb. High expression levels (median) of MET, HGF, EGFR, AREG or EREG mRNA did not independently predict an OS benefit. However, in the patient population for whom qRT-PCR data was available (n=67), the OS benefit in Met Dx+ patients was not as apparent (HR=0.69, p=0.48). A trend in improved OS on MetMAb was additionally observed in patients with low (<median) baseline plasma HGF levels (HR=0.46, p=0.11). Conclusions', ' The data continues to support c-Met IHC as a sensitive and independent predictor of OS benefit from MetMAb. Continued investigation of biomarkers is warranted in future clinical studies.']",
        "Doc_id":"ASCO_83948-102",
        "Doc_title":" Exploratory biomarker analyses from OAM4558g",
        "_version_":1606189036918013952},
      {
        "Meeting_name":" MET exon 14 mutation may not be a potential predictive biomarker in Chinese patients.",
        "Background":"['Background', ' Recent studies have come to the conclusion that MET exon 14 mutation would define an unique subtype of NSCLC and optimize the genotype-directed therapies. Here we report our different results about the detection of MET exon 14 mutation in Chinese patients. Methods', ' In total, 1101 patients with lung adenocarcinoma has been screened for MET exon 14 mutation. Both NGS and sanger sequencing was used. Moreover IHC and FISH was also performed on the specimens of MET exon 14 mutational patients. Results', ' 826 of them were detected by NGS and 275 by sanger sequencing. A total of 10 patients have been identified with MET exon 14 mutations which accounted for only 0.91% of lung adenocarcinoma, much less than the western patients data of 3%. Then 6 of MET exon 14 mutational patients have been performed with IHC and FISH. All the detailed data has been presented in Table 1. Furthermore among 2 patients received crizotinib, only 1 patient combined with MET amplification experienced a partial response and PFS has been 9 months. However whether sensitivity to crizotinib in this patient was conferred by the MET exon 14 mutation or by MET amplification is still unclear. For the other one, the disease has progressed in only 1.0 month. Conclusions', 'MET exon skipping mutation rate is lower and may not a good predictive biomarker for c-MET inhibitor in Chinese lung adenocarcinoma patients. Clinical characteristics of patients with lung cancers harboring MET exon 14 mutation.GenderAgesmokingHistologyTNMstagec-METIHCc-METFISHCrizotinibClinicalbenefitBestresponsePFS(month)P 1M6060ADCIVNegativeNegative(ratio1', '1)NoNAP 2F410ADCINegativeNegative(ratio1', '1)NoNAP 3M490ADCINegativeNegative(ratio1', '1)NoNAP 4M4520ADCIV100%++Negative(ratio1', '1)YesNoPD1.0P 5M760ADCIV80%++copies>5YesYesPR9.0P 6F500ADCIV70%+++30%++Negative(ratio1', '1)NoNA']",
        "Doc_id":"ASCO_166918-176",
        "Doc_title":" MET exon 14 mutation may not be a potential predictive biomarker in Chinese patients.",
        "_version_":1606189033855123456},
      {
        "Meeting_name":" A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .",
        "Background":"['Background', ' ARQ 197 (A) is a selective, oral, nonATP-competitive, small-molecule inhibitor of the c-MET receptor tyrosine kinase, which is implicated in tumor cell migration, invasion, proliferation, and metastasis. The EGFR tyrosine kinase inhibitor (TKI), erlotinib (E) is approved for the treatment of advanced or metastatic NSCLC after failure of   1 prior chemotherapy regimen. Resistance to EGFR TKI in EGFR mutation-positive NSCLC is associated with amplification of c-MET. A + EGFR TKI showed greater preclinical antitumor activity than either drug alone. A randomized, placebo-controlled, phase II study in previously-treated metastatic NSCLC patients (pts) showed that E + A prolongs progression free survival, overall survival (OS), and delays the onset of new metastases compared to E alone in pts with non-squamous NSCLC (J Clin Oncol 28', '18s, 2010 (suppl; abstr LBA7502). Methods', ' A follow-up phase III trial has been initiated. Eligible patients must have locally advanced unresectable or metastatic non-squamous NSCLC previously treated with 1 or 2 lines of systemic anticancer therapy, of which one must be platinum-doublet therapy; pts must be EGFR TKI nave; have ECOG performance status  1, adequate organ function; measurable disease by RECIST, and archival tumor tissue available for histology, EGFR, KRAS, and c-MET testing. Pts treated with only adjuvant therapy are eligible if progression occurred < 6 months after completion of treatment. Pts with clinically unstable CNS metastases are excluded. 988 pts are planned to be stratified by the number of prior therapies, gender, smoking history, EGFR and KRAS mutation status. Pts are randomized 1', '1 to receive E+A or E + placebo until progression, unacceptable toxicity or other discontinuation criterion is met. This study is powered to detect a significant improvement in median OS in the E+A arm over E alone. Radiographic efficacy assessments will occur every 8 weeks. Pts discontinued from study treatment will be followed for survival. The study is sponsored by Daiichi Sankyo Inc. in collaboration with ArQule, Inc.']",
        "Doc_id":"ASCO_82220-102",
        "Doc_title":" A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .",
        "_version_":1606188973963608064},
      {
        "Meeting_name":" Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib.",
        "Background":"['Background', ' ARQ197 (A) is a selective, non-ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation. Phase I data for ARQ 197 monotherapy is previously reported. Recent evidence suggests c-Met promotes resistance to EGFR-inhibition by driving ERBB3 (HER3)-dependent PI3K activation. Dual EGFR-Met inhibition is now proposed as a strategy for overcoming resistance to EGFR-inhibition. Methods', ' Patients (pts) were enrolled in a sequential-cohort dose-escalation trial seeking to define safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of A in combination with 150 mg daily oral erlotinib (E). Oral A was administered at escalating doses of 120, 240, and 360 mg bid. Intra-patient dose escalation was allowed in the absence of dose-limiting toxicity (DLT) through 1 cycle of therapy (21 days). Results', ' 25 pts (10 F/15 M; mean 60.5 yrs) received EA combination with starting A dose of 120 (8 pts), 240 (4 pts), and 360 (13 pts) mg bid. PK data reveal linear kinetics through 360 bid and no evidence of drug-drug interaction. Adverse events (AEs) considered related to combination therapy were reported in 13 (52%) of pts incl.sinus bradycardia (5 pts), fatigue (5 pts), rash (4 pts), itching (3 pts), and diarrhea (3 pts). 2 pts experienced related serious AEs incl. neutropenia (360 bid) and sinus bradycardia (240 bid). 1 death occurring on-study was considered unrelated to study drug. 9/10 evaluable pts demonstrated disease stabilization (SD) as their best RECIST response (5.9-27.1+ wks). Tumor regressions (2.3%-19.4%) were observed in 4/10 evaluable pts. Of note, 3/3 evaluable pts with NSCLC achieved SD for durations (14-32 wks) exceeding median PFS in BR.21 (9.7 wks). Conclusions', ' Continuous therapy with EA combination appears well tolerated and without drug-drug interaction. While no formal MTD was identified, a phase 2 combination dose (R2PD) of 360 mg bid A + 150 mg daily E is recommended. This RP2D is currently being investigated in an ongoing randomized trial comparing EA to E monotherapy in 2nd/3rd line NSCLC.']",
        "Doc_id":"ASCO_31504-65",
        "Doc_title":" Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib.",
        "_version_":1606189013521137664},
      {
        "Meeting_name":" Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models.",
        "Background":"['The development of therapies targeting tumor angiogenesis, tumor driver gene alterations and tumor immune evasion has made tremendous advancement in improving overall survival. However, efficacy may be limited and resistance often develops rapidly when targeting a single axis of tumorigenesis. Therefore, it is worthwhile to explore rational combination of therapies based on tumor-specific features. Fruquintinib is a potent and selective oral VEGFR inhibitor currently in Phase III clinical trials for non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). We report here the evaluation of anti-tumor effect of fruquintinib in preclinical animal tumor models in combination with therapies targeting tumor driver gene alterations such as EGFR and c-MET or with immune checkpoints. In NSCLC xenograft models with EGFR activation such as activating mutations, gene amplification or protein overexpression, fruquintinib plus an EGFR tyrosine kinase inhibitor such as gefitinib or theliatinib (HMPL-309) was found to be more efficacious than either monotherapy. For instance, in PC-9 subcutaneous tumor model carrying EGFR exon 19 deletion, single agent treatment with fruquintinib at 2 mg/kg and gefitinib at 5 mg/kg produced the tumor growth inhibition (TGI) of 58% and 63%, respectively, while the combination treatment resulted in a TGI of 100% and tumor regression was observed in 11 of 16 mice treated with combinational therapy. In multiple xenograft models derived from lung cancer or renal cell cancer with c-MET activation (amplification or over-expression), addition of fruquintinib to a c-MET inhibitor savolitinib (AZD6094, HMPL-504) also improved the tumor growth inhibition substantially. At the end of the efficacy studies, CD31 and phosphorylation of EGFR, c-MET, AKT and ERK were analyzed with immunohistochemistry and western blotting method in tumor tissues. The results suggested that the enhanced anti-tumor effect in combination therapy could be attributed to the simultaneous blockade of cell signaling in tumor cells (EGFR or c-MET) and VEGFR suppression in the tumor microenvironment. Up-regulation of the immune inhibitory checkpoints induced by VEGF is one of the important mechanisms for tumor cells to escape immune surveillance. In a syngeneic murine tumor model, co-administration of fruquintinib and anti-PD-L1 antibody was found to provide improved anti-tumor effect compared to fruquintinib or anti-PD-L1 single agent alone. Studies to understand the mechanism responsible for the combination effect are under way. All combinations with fruquintinib described above were well tolerated. The efficacy observed in these models suggested that simultaneous blockade of tumor angiogenesis and tumor cell signaling or immune evasion may be a promising approach in improving treatment outcomes.']",
        "Doc_id":"AACR_2017-2089",
        "Doc_title":" Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models.",
        "_version_":1606189006101413888},
      {
        "Meeting_name":" Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.",
        "Background":"['Background', '    Ficlatuzumab is a humanized anti-HGF IgG1 MAb that inhibits activation of the c-Met receptor by neutralizing its only known natural ligand, HGF. HGF/c-Met pathway activation has been implicated in EGFR TKI resistance in NSCLC.  In an ongoing phase Ib trial, the combination of ficlatuzumab + G was found to be well tolerated up to the maximum tested dose of 20 mg/kg of ficlatuzumab and 250 mg of G, and demonstrated clinical activity in pts with NSCLC.  Methods', '    It is a multi-center, open-label, 2-arm, randomized study comparing  ficlatuzumab +  G versus G alone in clinically selected Asian pts with previously untreated lung adenocarcinoma (never- or former-light smokers) who have a high likelihood of harboring activating EGFR mutations.  Stratification is by ECOG performance status (0-1 vs. 2), smoking status (nonsmoker vs. light ex-smoker) and gender.  Pts will be treated in continuous 28-day cycles, during which all pts will receive G daily (250 mg/day PO), and pts randomized to ficlatuzumab + G will also receive ficlatuzumab (20 mg/kg IV) on Days 1 and 15 of each cycle.  Pts who progress after achieving initial disease control (CR, PR, or SD for 12 weeks or longer) in the G alone arm may cross over to the combination arm.   The primary objective is to compare the Objective Response Rate (ORR) between the arms.  Secondary objectives are to evaluate the safety and tolerability of ficlatuzumab +  G, response duration, Progression-Free Survival (PFS), and Overall Survival (OS), to investigate the relationship between the anti-tumor activity of ficlatuzumab + G and molecular markers such as activating EGFR mutations, cMet and EGFR gene copy numbers (FISH positivity), HGF, c-Met and p-Met expression, HGF serum levels, and to assess whether acquired resistance to G can be overcome with the addition of ficlatuzumab in pts who progressed after initial demonstration of disease control (CR, PR, or SD for 12 weeks or longer) in the G alone arm.  Estimated sample size is 170 pts.']",
        "Doc_id":"ASCO_80323-102",
        "Doc_title":" Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.",
        "_version_":1606188987022573568},
      {
        "Meeting_name":" Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.",
        "Background":"['Activation of c-MET through hepatocyte growth factor (HGF) increases tumorigenesis, induces resistance, and is associated with poor prognosis in various solid tumors. We previously reported that lung cancer cell lines had increased expression of c-MET due to gene amplification-induced cytotoxic drug resistance, and that resistant cells paracrine HGF and promote its resistance. However, the clinical significance of sHGF in patients with advanced or recurrent NSCLC, especially in patients treated with cytotoxic chemotherapy, is yet to be identified. Here, we present sHGF may be useful to predict tumor response and PFS in patients with advanced NSCLC. A total of 81 patients with 101 treatment regimens were investigated; 53 patients received first-line therapy and 48 patients received second-line therapy during the observation period. sHGF levels were evaluated using ELISA at 4 time-points', ' at pre-treatment, at response-evaluation (1-2 months after treatment initiation), at the best tumor response, and at the disease progression. As a control biomarker, serum carcinoembryonic antigen (CEA) was also evaluated. sHGF at response-evaluation in patients with progressive disease was higher compared with that of disease controls in both first-line and second-line treatment (median value (MV)', ' under the limited of detection (LOD) vs. 0.40; P=0.0086 and MV', ' under the LOD vs. 0.41; P=0.0035, respectively). Positive-sHGF at response-evaluation predicts poor progression-free survival (PFS) compared with negative-sHGF in both first-line (median, 153.5 vs. 288.0; P=0.047) and second-line treatment (87.0 vs. 219.5; P=0.014). Lung adenocarcinoma subgroup analysis showed that in patients receiving second cytotoxic chemotherapy, there were no significant differences in PFS or HR between patients with low-CEA compared with those with high-CEA, but positive-sHGF at pre-treatment or at response-evaluation predicts poor PFS (35 vs. 132; P=0.0045, 50 vs. 215; P=0.0047, respectively). Simple and repeatable markers for activation of the HGF/c-MET pathway would provide rationale for future research investigating the merit of sHGF as a potential clinical biomarker to indicate administration of MET inhibitors.']",
        "Doc_id":"AACR_2017-5736",
        "Doc_title":" Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.",
        "_version_":1606189038216151040},
      {
        "Meeting_name":" Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein",
        "Background":"['Background and purpose', ' Besides targeting the well-known oncogenic c-Met, crizotinib is the first oral tyrosine kinase inhibitor (TKI) inhibiting anaplastic lymphoma kinase (ALK) in clinical trials for the treatment of non-small cell lung cancer (NSCLC). In this study, we investigated the potential multidrug resistance (MDR) reversal by crizotinib in vitro and in vivo. Experimental approach', ' MTT methods were used in vitro and the xenografts in nude mice were used in vivo to investigate crizotinib reversal of MDR. To understand the mechanisms for MDR reversal, the alterations of intracellular doxorubicin(Dox) or rhodamine 123 accumulation, Dox effluxion, ABCB1 expression level, ATPase activity of ABCB1, and crizotinib-induced c-Met, Akt and Erk1/2 phosphorylation were examined. Key results', ' Crizotinib significantly enhanced the cytotoxicity of ABCB1 substrate chemotherapeutic agents in MDR cells, with no effect found on sensitive cells in vitro and in vivo. In addition, crizotinib significantly increased the intracellular accumulation of rhodamine 123 and doxorubicin and inhibited the drug efflux in ABCB1-overexpressing MDR cells. Further studies showed that crizotinib enhanced the ATPase activity of ABCB1 in concentration-dependent manner. However, the expressions of ABCB1 were not affected and the reversal activity of crizotinib was not related to the phosphorylation of c-Met, Akt or Erk1/2. Importantly, crizotinib significantly enhanced the effect of paclitaxel against the KBv200 cell xenografts in nude mice. Conclusions and implications', ' Crizotinib was found to reverse ABCB1-mediated MDR by inhibiting ABCB1 transport function without involvement of ABCB1 expression or blockade of the Akt or Erk1/2 pathways. These findings is useful for combination chemotherapy of crizotinib with conventional chemotherapeutic drugs.']",
        "Doc_id":"AACR_2012-773",
        "Doc_title":" Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein",
        "_version_":1606189040165453824},
      {
        "Meeting_name":" Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E).",
        "Background":"['Background', \" Pts who respond to the EGFR- tyrosine kinase inhibitors (TKI's) frequently have activating mutations in the kinase domain of EGFR or EGFR overexpression. EGFR activating mutations correlate with adenocarcinoma histology, non-smoking history, female gender, and Asian ethnicity. The presence of EGFR kinase domain mutations is predictive of response but, the relationship is not always concordant. Furthermore, mutations may not predict survival benefit with TKI therapy and other factors are likely involved. It has also been determined that EGFR and met can crosstalk, and serve as potential mechanism of resistance in NSCLC. Most data collected to date on response and overall survival with EGFR-TKI's have been in the Caucasian or Asian community. Hence we collected data specific to the AA pt as they tend to have worse outcomes stage for stage. The purpose of this study is to report the response rate, overall survival, progression free survival (PFS) and clinical characteristics of AA pts with NSCLC treated with an EGFR-TKI. We will correlate these data with EGFR mutation and c-Met expression/mutations/amplifications for markers of NSCLC. Methods\", ' We have listed patients with NSCLC receiving E therapy over the past 5 years. We then retrospectively collected demographic data (age, race, sex, and tobacco history), tumor histology, response rates, survival data and duration of response from AA pts treated with E as single agent. The response to E was correlated with outcome. Results', ' Data from 44 AA pts (27 women, 17 men) on erlotinib were reviewed. Mean age was 67.1 years (range 48-89 yrs), tobacco use (37 positive, 3 negative, and 4 not recorded). Histology included NSCLC not specified-14, squamous cell- 16, adenocarcinoma-11, large cell-1 and 2 not available. Overall response rate of 13.6% (6-PR, 16-SD, 18-progessive disease, and 4 patients lost to follow up). The PFS was 4.0 months; 95% CI', ' (2.5-6.6 mos) and overall survival 8.6 mos; 95% CI', ' (7.2-30.9 mos). EGFR mutations and c-Met analysis will be provided by ASCO meeting in May 2009. Conclusions', \" AA survival and response rates appear similar to previous data seen with all NSCLC patients receiving treatment with EGFR-TKI's. More data and relationship to biomarkers is needed in this population.\"]",
        "Doc_id":"ASCO_35549-65",
        "Doc_title":" Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E).",
        "_version_":1606189009766187008},
      {
        "Meeting_name":" Development of a highly specific Met antibody for screening Met overexpression in NSCLC",
        "Background":"['Approximately 5%-22% of non-small cell lung cancer (NSCLC) patients with secondary resistance to EGFR TKIs had evidence of amplification of the Met oncogene. This dysregulation of Met signaling was implicated in the proliferation and eventual metastasis of NSCLC, and therefore represents an attractive target for anticancer drug development.Currently, there are a number of clinical trials for Met targeted small molecule and monoclonal antibody therapies. Immunohistochemistry (IHC) analysis of the Met protein will be very important for these Met targeted therapies and requires a highly specific antibody to prevent false positives. To develop a highly specific monoclonal antibody against Met for IHC analysis in NSCLC, we generated 97 monoclonal antibodies. IHC evaluation showed that 8 of the antibodies had suitable performance in Met positive NSCLC patient tissues. The 8 Met monoclonal antibodies were further tested on a high density protein microarray chip containing 17,000 human proteins. The microarray analysis showed that clone 3G5 was highly specific as evidenced with it only reacting with Met on the microarray. This new 3G5 Met monoclonal antibody will be a promising candidate as a diagnostic reagent for detecting Met protein in NSCLC with minimal false positives.']",
        "Doc_id":"AACR_2015-561",
        "Doc_title":" Development of a highly specific Met antibody for screening Met overexpression in NSCLC",
        "_version_":1606189036249022464},
      {
        "Meeting_name":" Brain metastases (mets) in lung cancer patients (pts)",
        "Background":"['Background', ' Brain mets in lung cancer pts are associated with morbidity and can limit therapeutic options. We conducted an analysis of the Detroit SEER data to describe the occurrence of brain mets in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) pts, the demographics, the temporal trends in brain mets, the risk of brain mets in pts with non-metastatic lung cancer at diagnosis and the survival of pts with brain mets. Methods', ' Caucasian (C) or African-American (AA) lung cancer pts diagnosed between 1973-2007 in the Detroit SEER registry were included. Median survival and 95% confidence intervals (CI) were generated by histology and brain mets status. Cox Proportional Hazards models were generated by histology to compare survival between those with and without brain mets. Results', ' 75,564 pts were identified; 62,860 (83%) had NSCLC. The proportion of NSCLC pts and SCLC pts with brain mets were 16.4% and 25.1%, respectively. Brain mets occurred significantly more in females with NSCLC (17.7% vs. 15.7%) but not among SCLC pts. Brain mets occurred significantly more in AA pts (18.9% v. 15.6%- NSCLC; 27.6% v. 24.5%- SCLC; p < 0.0001) and pts  60 yrs (24.5% vs. 13%- NSCLC, 31.4% vs. 22.4%-SCLC, p < 0.0001). The proportion of brain mets for NSCLC and SCLC pts in 1973-84 was 16% and 20.5%, and in 1997-2007 was 16.1% and 24.8%, respectively. The hazard ratio for death among metastatic NSCLC pts with brain mets was significantly greater at 1.13 than in pts without brain mets (1.1-1.16) but for metastatic SCLC it was 0.87 (0.83- 0.92). Among pts with nonmetastatic lung cancer at diagnosis, 9% of NSCLC and 19% of SCLC pts developed brain mets. In these pts, brain mets occurred significantly more among females and patients  60 yrs. The hazard ratio for death among non-metastatic NSCLC pts who developed brain mets was 1.44 (1.38-1.51) and among SCLC pts was 1.05 (0.96-1.14). Conclusions', ' The proportion of NSCLC and SCLC pts with brain mets is 16.4 and 25.1%. Brain mets occurred significantly more in females with NSCLC, AA and younger pts. The hazard ratio for death among NSCLC pts with brain mets is significantly greater than in patients without brain mets but not so in SCLC pts.']",
        "Doc_id":"ASCO_41741-74",
        "Doc_title":" Brain metastases (mets) in lung cancer patients (pts)",
        "_version_":1606188994518843393},
      {
        "Meeting_name":" The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines",
        "Background":"['Lung cancer is the leading cause of cancer related death in the world. Platinum-based combination regimen or molecular target drugs, such as EGFR tyrosine kinase inhibitors (EGFR-TKIs) and ALK inhibitors are used for first line chemotherapy of NSCLC. Somatic mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified in NSCLC and those mutations confer sensitivity to the EGFR-TKIs such as gefitinib. Unfortunately, it is well known that the almost cases are developed to drug resistance after chemotherapy. Several EGFR-TKI resistant mechanisms have been reported, including gatekeeper mutation (T790M), c-MET amplification and ErbB3 activation. Re-biopsy is generally required for determine the resistance mechanism and second line chemotherapy. However, re-biopsy is invasive test for cancer patients. Recently, microRNAs (miRNAs) are paid attention as biomarkers for cancer diagnosis and sensitivity to chemotherapy in various cancers. In the previous study, we revealed that the miRNA biosynthesis pathway is critical for maintain the cisplatin resistant phenotype. Further, it was reported that EGFR modulated microRNA maturation through the phosphorylation of AGO2. Protein phosphorylation is one of most important post transcriptional modification mechanisms and miRNA is also associated with fine tuning of mRNA expression. Thus, we focused on the relationship between miRNA expression and kinase signaling in gefitinib resistance. In this study, we performed characterization of gefitinib resistant cell lines, PC-9/MET200 and PC-9/MET1000 established from NSCLC cell line, PC-9, which were confirmed to have a c-MET amplification using miRNA microarray and quantitative PCR. Furthermore, we analyzed miRNA activity and kinase signaling using a luciferase reporter assay system, siRNA, RTK/phosphokinase protein array and kinase inhibitors. We revealed that miR-205 was significantly elevated in both gefitinib resistant cell lines. By the computational analysis using miRNA target prediction database, we found that ErbB3 was a target of miR-205. However, ErbB3 expression levels were rather up-regulated and highly phosphorylated in both resistant cell lines compared with a parental cell line. Under ErbB3 knockdown condition, miR-205 expression levels were slightly down regulated. Furthermore, under c-MET knockdown or Foretinib treatment condition, miR-205 activity were down regulated and ErbB3 dephosphorylated in resistant cell lines. This down-regulation of miR-205 appears to be mediated by inhibition of kinase signals. Moreover, we found that some kinase inhibitors suppressed miR-205 activity in gefitinib resistant cell lines. In conclusion, our results suggest that alterations of kinase signals are more effective for miR-205 regulation than protein expression of target molecule itself, such as ErbB3.']",
        "Doc_id":"AACR_2016-1893",
        "Doc_title":" The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines",
        "_version_":1606188984686346240},
      {
        "Meeting_name":" A MET x MET bispecific antibody that induces receptor degradation potently inhibits the growth of MET-addicted tumor xenografts.",
        "Background":"['Aberrant regulation of MET receptor tyrosine kinase signaling is associated with development and progression of various human tumors. Elevated MET signaling during tumorigenesis results from MET amplification, mutation or up-regulation of the ligand, HGF. MET amplification is thought to be a key driver of oncogenesis in non-small cell lung cancers (NSCLC) and oesophagogastric malignancies. In addition, mutations resulting in exon 14 deletion of MET have been described as oncogenic drivers in a subset of NSCLC. Both preclinical and recent clinical results indicate that tumors harboring these genetic alterations respond to MET inhibitors, validating MET as a cancer driver.']",
        "Doc_id":"AACR_2017-34",
        "Doc_title":" A MET x MET bispecific antibody that induces receptor degradation potently inhibits the growth of MET-addicted tumor xenografts.",
        "_version_":1606189038331494400},
      {
        "Meeting_name":" Mechanism of TKI resistance and role of epithelial mesenchymal transition in NSCLC",
        "Background":"['Current EGFR/c-Met tyrosine kinase inhibitor (TKI) combination therapies are shown to be susceptible to acquired resistance in the majority of NSCLC patients. To understand how cells develop EGFR/c-Met TKI resistance, we used three model NSCLC cell lines', ' H2170, H3255 and H1975. H2170 cell line express high levels of EGFR and c-Met and are EGFR wild-type. The H3255 cell line is positive for an EGFR TKD mutation, L858R, and is sensitive to initial TKI treatment. The H1975 cell line is positive for two EGFR TKD mutations, T790M and L858R, which confer resistance to erlotinib.Previous studies in our lab have shown that activation of alternative signaling pathways lead to the development of TKI resistance. In the wild type TKI resistant cells, H2170 erlotinib resistant (ER) and H2170 SU11274 resistant(SR), we observed activation of Wnt and mTOR pathway along with increased accumulation of -catenin in the nucleus. However, in H1975 cells with mutated EGFR (L858R and T790M), we observed activation of only mTOR pathway. -catenin is associated with Epithelial-Mesenchymal Transition (EMT), during which cells lose tight junction proteins such E-Cadherin and gain expression of transcriptional proteins such as -catenin and ZEB1, which may lead to aberrant activation of Wnt signaling pathway and increased motility and invasion. Activation of mTOR pathway leads to increased expression of p70S6K and 4E-BP1 which are key translational regulators.We found increased accumulation of active -catenin in the nucleus by 1.9-2.5 folds and 2.9-3.1 folds in H2170 ER and SR cells, respectively, compared to H2170 parental cells. In H2170 ER cells we observed modulations in key EMT-related proteins, N-Cadherin (2-3.3 fold) and Claudin-1 (2.5-14 fold) were upregulated and Snail was downregulated 1.7-2.5 fold in the presence and absence of erlotinib and EGF, when compared to H2170 parental cells. Similarly in H2170 SR cells we observed upregulation of N-Cadherin (1.3-2.3 fold) and Zeb-1 (1.2-1.4 fold) and downregulation of ZO-1 (1.4-1.9 fold) and E-Cadherin (1.5-2.0 fold) in the presence and absence of HGF and SU11274 when compared to H2170 parental cells. Morphological changes indicative of EMT were detected using immunostaining with Vimentin and E-Cadherin antibodies, which displayed increased Vimentin filaments (2-fold) and loss of E-Cadherin (5-10 fold) in H2170 ER cells when compared to H2170 parental cells. In H1975 cells we observed that proteins related to mTOR signaling pathway such as p-mTOR, p-GSK3-, p-4EBP1 and p-p70S6K were upregulated 2.5 fold, 4-5 fold, 2.2-2.4 fold, and 4.4-10.4 fold, respectively, when compared to H3255 cells in the presence of erlotinib. Based on these results, we treated H1975 cells with combination of EGFR and mTOR inhibitors. We observed that 1 M everolimus with 2.5 M erlotinib synergistically inhibited cell growth by 53%. These studies may provide clinicians with novel targets for improving treatment options for future NSCLC patients.']",
        "Doc_id":"AACR_2015-337",
        "Doc_title":" Mechanism of TKI resistance and role of epithelial mesenchymal transition in NSCLC",
        "_version_":1606189035733123072},
      {
        "Meeting_name":" Results from ARQ 197-209",
        "Background":"['Background', ' Orally administered ARQ197 is a selective, non-ATP competitive inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and proliferation. Dual EGFR-MET inhibition is a promising strategy for overcoming MET-mediated resistance to EGFR inhibitors. A prior phase I trial demonstrated the safety of ARQ197 plus erlotinib and suggested activity in patients (pts) with advanced NSCLC. Methods', ' This is a global, randomized, placebo-controlled, double-blind trial comparing erlotinib plus ARQ197 (E+A) versus erlotinib plus placebo (E+P). Archival tissue was collected for all pts for k-RAS, EGFR, and MET analyses. The primary endpoint was PFS; secondary endpoints included safety, ORR, OS, and subgroup analyses. Results', ' 167 pts were randomized to E+A (84 pts) or E+P (83 pts). Mean age was 63 yrs and baseline characteristics were well balanced for sex (39%/41% F); race (93%/96% white) and smoking history (20%/22% never smoker). Imbalances were seen among treatment arms in NSCLC histology (54%/64% adeno) and predictive molecular genotypes', ' EGFR mutations (7%/13%) and k-RAS mutations (12%/6%). Final PFS was prolonged with E+A (median = 16.1 wks) vs E+P (9.7 wks) among ITT pts (HR 0.81 [95% CI 0.57, 1.15]; p=0.23). Planned multivariable Cox regression model adjusting for prognostic factors (including histology, genotype) yielded PFS HR 0.68 (95% CI 0.47, 0.98; p<0.05). PFS improvement was particularly prominent among pts with nonsquamous histology, EGFR wild-type status, and k-RAS mutations. Preliminary safety analysis revealed no major differences between arms with AEs (10% of pts; all grades) including rash (64%/52%); diarrhea (48%/53%); fatigue (33%/37%); nausea (26%/26%); and anemia (14%/13%). OS, ORR, and final safety data will be analyzed at study conclusion. Conclusions', ' Combined with erlotinib in the treatment of second/third-line EGFR-inhibitor nave NSCLC, ARQ-197 is well-tolerated and prolongs PFS. Particular benefit is observed among pts with non-squamous histology, k-RAS mutations, and EGFR wild-type status.']",
        "Doc_id":"ASCO_51587-74",
        "Doc_title":" Results from ARQ 197-209",
        "_version_":1606189028339613696},
      {
        "Meeting_name":" A c-met inhibitor in the treatment of metastatic non small cell lung cancer with c-met amplification.",
        "Background":"['Background', ' Amplification of the mesenchymal-epithelial transition factor (MET) gene plays a vital role in non-small cell lung cancer (NSCLC). The anti-MET therapeutic strategies are still unclear in epidermal growth factor receptor (EGFR) mutant patients and EGFR-naive patients. Aims of our study are to discuss role of MET amplification in Chinese NSCLC patients, and evaluate the antitumor activity of crizotinib (MET inhibitor) in Chinese NSCLC patients with MET gene amplification. Methods', ' From Jun 2015 to Jan 2016, we detected 11 metastatic NSCLC patients with MET amplification by fluorescence in situ hybridization (FISH). MET amplification was defined as gene focal amplification or high polysomy (at least 15% cells with  5 copy numbers). Patients with MET de novo amplification received crizotinib, patients with concomitant MET acquired amplification and EGFR mutation received combined therapy of EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib, icotinib)and crizotinib. All enrolled subjects received tumor measurement according to RECIST1.1 Results', ' The frequency of MET de novo amplification was 54.5%(6/11), and that of concomitant MET acquired amplification and EGFR mutation was 45.5%(5/11) respectively. 4 of 6 patients with MET de novo amplification received crizotinib, 2 patients had partial response (PR), 1 patient had stable disease (SD), 1 patient died due to heart disease. Response rate (RR) of crizotinib was 50%(2/4). Encouraging response was observed in one case ,a CT scan performed 31 days after starting crizotinib revealed 42.2% decrease , until now, a 7-month CT revealed 60.0% decrease in tumor measurement. 3 of 5 patients with concomitant MET acquired amplification and EGFR mutation received the combined therapy of EGFR-TKIs and crizotinib. 1 patient achieved PR, 2 patients had SD. RR of combined therapy was 33.3%(1/3). Dramatic response was observed in one case with combined therapy, a 2-month CT revealed 31.0% decrease in tumor measurement. Conclusions', ' According to our study, patients with MET amplification benefited from crizotinib, and RR was inspiring. Patients with concomitant MET acquired amplification and EGFR mutation need combined targeted therapy.']",
        "Doc_id":"ASCO_163044-176",
        "Doc_title":" A c-met inhibitor in the treatment of metastatic non small cell lung cancer with c-met amplification.",
        "_version_":1606189022124703744},
      {
        "Meeting_name":" In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) patients that have activating mutations in the epidermal growth factor receptor (EGFR) gene are treated with EGFR tyrosine kinase inhibitors (TKIs) e.g. Erlotinib (Tarceva) and Gefitinib (Iressa). Most NSCLC patients with activating EGFR mutations will respond to EGFR-TKIs; however, in about 50% of these cases a secondary mutation in EGFR (T790M) subsequently occurs which results in resistance to treatment. Other mechanisms of clinical resistance can also occur such as amplification of c-MET kinase, Her-2 and EMT conversion; however, additional routes of resistance are poorly defined. Using a novel NSCLC patient-derived xenograft (PDX) model, driven by the L858R EGFR mutation, we set out to recapitulate the reported clinical routes of resistance to EGFR inhibitors and to evaluate if additional mechanism could also be identified.Methods', ' LU6422 is a Caucasian NSCLC adenocarcinoma PDX model with an activating EGFR mutation (L858R) which is maintained subcutaneously in vivo admixed with a human stromal cell component. HCC827 is NSCLC adenocarcinoma cell line with an activating EGFR mutation (exon 19 del E746-A750).Resistant models of LU6422 and HCC827 were generated in vivo and in vitro (respectively) through repeated dosing or exposure to EGFR-TKIs. Resistant tumour material was characterised for further mutations in the EGFR gene by direct sequencing and for c-MET, Axl and Her2 over-expression and genomic amplification by quantitative PCR. Combination efficacy treatment (in vitro and in vivo) was carried out to verify documented resistance mechanisms.Results', ' Nave LU6422 and HCC827 tissue exhibited exquisite sensitivity to EGFR-TKIs (100% reduction in pre-treatment tumour volume, p<0.0001). Following successive cycles of EGFR-TKI treatment several resistant subtypes were generated, cloned and characterized. Combination treatment of resistant HCC827 variants restored efficacy to nave treatment levels.Conclusions', ' EGFR-TKI resistant subtypes were generated in vivo and in vitro from a proprietary patient-derived xenograft model (LU6422) and the HCC827 cell line and were characterised for their resistance mechanisms.Pre-clinical modes of acquired resistance will be invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent or overcome resistance to EGFR-TKIs.']",
        "Doc_id":"AACR_2014-4875",
        "Doc_title":" In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations",
        "_version_":1606189006496727041},
      {
        "Meeting_name":" Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR",
        "Background":"['Background', '  A randomized phase II study suggested that adding a c-Met inhibitor tivantinib (T) to an EGFR-TKI erlotinib (E) may prolong PFS in non-squamous NSCLC patients (pts) with 1-2 prior chemotherapy. Furthermore, the subset analysis suggested that survival benefit was more prominent in pts with wild-type EGFR (WT-EGFR) than in those with EGFR mutation. Therefore we conducted the phase III ATTENTION trial to compare overall survival (OS) between T+E vs. placebo (P)+E, in Asian pts with pretreated NSCLC with WT-EGFR.  Methods', '  Four-hundred-and sixty Asian (Japan, Korea, and Taiwan) pts who had been treated with 1-2 chemotherapy for non-squamous NSCLC with WT-EGFR were planned to be randomized between T+E and P+E. The doses of T were 360mg BID and 240mg BID, for CYP2C19 extensive metabolizers (EM) and poor metabolizers (PM), respectively, whereas that of E was 150 mg QD for both EM and PM. The primary endpoint was OS, and secondary endpoints included PFS, ORR, and safety. Exploratory analysis tested biomarkers including c-Met expression and KRAS mutation.  Results', '  New enrollment was stopped when 307 pts had been randomized, following the Safety Review Committees recommendation based on an observed imbalance in interstitial lung disease (ILD) between the groups. Accordingly,153 and 154 pts were treated with T+E and P+E, respectively. Patient backgrounds including CYP2C19 genotype were well balanced. Results are summarized below. Typical Gr.3 adverse events in T+E were anemia (13.2 %), neutropenia (10.5 %), and leukopenia (6.6 %). Fourteen pts (including 3 deaths) and 6 pts (0 deaths) developed ILD in T+E and P+E, respectively.  Conclusions', '  Although this trial lacked a statistical power due to the prematurely termination owing to toxicity concern, our results indicated some sign for benefit for adding T to E in this population. OS was numerically prolonged but this did not reach statistical significance. Exploratory biomarker analysis may identify subsets in which benefit and risk from this treatment is well balanced.  Clinical trial information', ' NCT01377376.']",
        "Doc_id":"ASCO_128631-144",
        "Doc_title":" Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR",
        "_version_":1606189030940082176},
      {
        "Meeting_name":" Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Dramatic responses to MET inhibitors have been reported in patients with NSCLC harboring activating mutations that cause MET exon 14 (METdel14) skipping. We conducted a multicenter retrospective analysis of pts with METdel14 NSCLC to determine if treatment with MET inhibitors impacts survival. Methods', ' We collected clinicopathologic data on pts with METdel14 NSCLC. Event-time distributions were estimated using Kaplan-Meier and compared with the log-rank test. Multivariable Cox models were fitted to estimate hazard ratios. Results', ' Of the 148 pts with METdel14 mutant NSCLC, the median age was 72 (range 43-88); 57% were women, and 41% were never smokers. The most common histologies were adenocarcinoma (77%) and pulmonary sarcomatoid carcinoma (14%). Overlap with oncogenic driver mutations in other genes was rare. At the time of diagnosis, 70% of pts had stage I-III disease, and 30% had stage IV disease. Of the 34 pts with metastastic disease who never received a MET inhibitor, the median overall survival (mOS) was 8.1 months. In this cohort, cancers that also had concurrent MET amplification had a trend toward worse survival compared to cancers without MET amplification (5.2 months vs 10.5 months, P = 0.06). Of the 27 pts with metastatic disease who received at least one MET inhibitor (including crizotinib, glesatinib, capmatinib, and ABBV-399), the mOS was 24.6 months. A model adjusting for receipt of a MET inhibitor as first- or second-line therapy as a time-dependent covariate demonstrated that treatment with a MET inhibitor was associated with a significant prolongation in survival (HR 0.11, 95% CI 0.01-0.92, P = 0.04). Among 22 patients treated with crizotinib, the median progression-free survival (PFS) was 7.36 months. Conclusions', ' Forpts with METdel14 NSCLC, treatment with a MET inhibitor is associated with an improvement in overall survival. The prognosis of pts who never received treatment with a MET inhibitor appears to be poor, particularly among METdel14 cancers with concurrent MET amplification.']",
        "Doc_id":"ASCO_194689-199",
        "Doc_title":" Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).",
        "_version_":1606189026857975808},
      {
        "Meeting_name":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "Background":"['MET amplification has been implicated in signaling pathways that promote cell proliferation, invasion, and survival. It has been identified as an oncogenic driver in various malignancies and is currently being investigated as a potential therapeutic target. To date, MET exon 14 skipping by sequencing and MET amplification by FISH have been found to have potential clinical utility in predicting those patients who may derive benefit from MET-targeted therapy. However, little research has been conducted on alternative technologies to FISH such as CISH, which does not require a dark room and can be interpreted by a board-certified pathologist. The purpose of this study is to report our experience with MET amplification across solid tumors using CISH.A retrospective analysis was done on 26,619 specimens analyzed for MET amplification by CISH at a CLIA-certified lab (Caris Life Sciences). The validated CISH assay, previously validated against a FISH assay, utilized a gene copy number > 5 to assess amplification. Concordance and correlative studies were done in MET-amplified, non-small cell lung cancer (NSCLC) specimens analyzed using a cMET IHC (SP44, 2+ or 3+ staining intensity in 50% or more tumor cell membrane) analyzing protein expression. Correlative studies involving co-existing aberrations, including PD-L1 (SP142, any intensity in at least 50% of tumor cells), in this MET-amplified, NSCLC cohort were also performed.MET amplification utilizing CISH was 0.7% (188/26,619) overall. MET-amplified solid tumors included carcinomas such as NSCLC (3.1%, 87/2767), gastric adenocarcinoma (3.8%, 11/293), esophageal and esophagogastric junction adenocarcinoma (3.3%, 11/338), and endometrial carcinoma (0.4%, 9/2020) along with non-carcinomas, including glioblastoma multiforme (1.0%, 5/510), uterine sarcoma (1.3%, 5/400), melanoma (0.4%, 2/538), and rare tumors such as placental-site trophoblastic tumor (100%, 1/1) and prostatic neuroendocrine tumor (100%, 1/1). A sub-analysis of MET-amplified, NSCLC specimens demonstrated co-occurring protein overexpression in 92.6% (75/81) of cases. These same MET-amplified, NSCLC specimens were found to have EGFR pathogenic/presumed pathogenic mutations (19.7%, 15/76), ALK rearrangements (2.5%, 2/80), and PD-L1 overexpression (27.5%, 14/51). ROS1 rearrangements were not detected in this NSCLC cohort (0%, 0/76).Our data suggest MET amplification detection utilizing CISH is a viable option for identifying MET-driven cancers. The presence of MET across various solid tumors contrasts with biomarkers like HER2, which are exclusive to carcinomas. A sub-analysis of our NSCLC population shows MET-amplified tumors contains a similar molecular distribution to the general NSCLC population. Future studies should incorporate MET CISH in clinical trials utilizing MET-targeted agents to determine its potential as a predictive test for evaluating who may derive the most benefit.']",
        "Doc_id":"AACR_2016-396",
        "Doc_title":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "_version_":1606188983115579392},
      {
        "Meeting_name":" Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '  Cabozantinib (C) is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2 & RET. MET is involved in tumor differentiation & VEGFR2 is a mediator of angiogenesis. Erlotinib (E) is FDA approved for the treatment of NSCLC.  Methods', '  The primary objective of this randomized phase II study was to compare progression-free survival (PFS) of patients (pts) treated with E vs. C, & E vs E+C; each comparison had 91% power to detect a PFS hazard ratio (HR) of 0.5 with a 1-sided 0.10-level test stratified on prior number of therapies & ECOG PS.  Secondary objectives included overall survival (OS), RECIST 1.1 response & CTCAE v4 toxicity. Pts were selected with previously treated (1-2 regimens) metastatic non-squamous EGFR wt NSCLC. Submission of archival tissue for central MET IHC testing was required. Oral daily dosing was', ' E-150 mg; C-60 mg; E+C-150 mg E, 40 mg C. Imaging was performed every 8 weeks. Pts optionally crossed over to E+C following progression on E or C.  Results', '  One hundred and twenty-five pts were enrolled, of which 115 were eligible and treated (E, n = 39; C, n = 39; E+C, n = 37). Pt characteristics were balanced between arms except for lower rate of brain mets history on E (p = 0.02). Median follow up is 8.5 m. Compared with E (median 1.9 m), PFS was significantly improved on C (3.9 m, HR 0.33, p = 0.0002, 80% CI 0.22-0.49) and E+C (4.1 m, HR 0.31, p = 0.0002, 80% CI 0.21-0.46). Similarly, compared with E (median 4.0 m), OS was significantly improved on C (HR 0.52, p = 0.02) and E+C arm HR 0.50, p = 0.02). Grade 3-4 treatment-related hypertension & mucositis were higher on C and grade 3-4 diarrhea was higher on E+C. Overall worst grade toxicities were also significantly higher on C and E+C. MET IHC results were available on 88 patients from the primary analysis & 85% were positive (1-3+ membrane or cytoplasm staining with MET4 antibody). There was no correlation between MET status and PFS.  Conclusions', '   C & C+E significantly improved PFS over E alone in pts with EGFR wt NSCLC. Cabozantinib-based regimens are promising for further investigation in this patient population. Funded by ECOG-ACRIN and NCI Contract No. HHSN261200800001E. Clinical trial information', ' NCT01708954']",
        "Doc_id":"ASCO_145500-156",
        "Doc_title":" Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC)",
        "_version_":1606189038988951552},
      {
        "Meeting_name":" Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors.",
        "Background":"['Background', '   Golvatinib is a highly potent, small molecule ATP-competitive inhibitor of the c-Met receptor tyrosine kinase and multiple members of the Eph receptor family as well as c-Kit and Ron, based on isolated kinase assays. Golvatinib showed antiproliferative activity in human cancer xenograft models, warranting further investigation in the clinical setting.  Methods', '   Japanese patients (pts) with advanced solid tumors that had progressed after approved therapy received oral golvatinib at escalating doses of 50 to 100, 200 and 300 mg administered twice daily (BID) in conventional 3 pt cohorts. The primary objective was to determine the MTD of golvatinib when administered continually BID. The secondary objectives were to evaluate the safety, PK, PD biomarkers, and efficacy.  Results', '   16pts were enrolled (8 M, 8 F; med age 59 years; ECOG 0-1). Tumor types were colorectal (5), gastric (4) and others (7). One DLT (Gr 3 ALT increase) and 1 equivalent DLT (Gr 2 vomiting, nausea and anorexia) appeared in 2 pts in the 300 mg BID cohort and the dose escalation was terminated. The MTD was determined to be 200 mg BID. Frequently observed adverse drug reactions were proteinuria [50.0% (8/16)], ALT increased [43.8% (7/16)], AST increased, nausea, vomiting [37.5% (6/16)], and blood alkaline phosphatase increased, decreased appetite, diarrhea, leukopenia [31.3% (5/16)], which were all mild to moderate in severity with  Gr 2. No related severe adverse event was observed. Responses included 4 stable diseases (84-113 days) in 3 pts with gastric cancer and 1 patient with NSCLC, 11 progressive diseases, and 1 non evaluable. The golvatinib plasma concentration after first-dose reached Cmax at a median time of 2 to 4 hours, and declined bi-exponentially with a t of approximately 40 hours. Cmax and AUC0-inf increased with dose. Analysis of blood PD biomarker showed a significant increase in soluble c-Met levels after golvatinib treatment.  Conclusions', '   The MTD of golvatinib was achieved at 200 mg BID. Golvatinib was well tolerated with manageable toxicities at dose levels up to and including the MTD. 4 of 16 pts showed stable disease after golvatinib treatment.']",
        "Doc_id":"ASCO_95142-114",
        "Doc_title":" Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors.",
        "_version_":1606189039003631616},
      {
        "Meeting_name":" Preclinical evaluation of anti-MET antibodies for immunohistochemical staining.",
        "Background":"['Background', '  The monovalent anti-MET antibody onartuzumab in combination with erlotinib showed clinical benefit in a phase II trial in advanced non-small cell lung cancer (NSCLC); this benefit was limited to MET-positive tumors as determined by immunohistochemistry (IHC) using the CONFIRM anti-total MET rabbit monoclonal antibody (Ventana). The trial results demonstrate the importance of a reliable IHC assay to distinguish MET-positive from MET-negative cancers. Therefore, it is important to gain a pre-clinical understanding of available antibodies that may warrant further investigation. The aim of this study was to evaluate nine anti-MET antibodies for sensitivity and specificity using various standard staining conditions.  Methods', '  All antibodies were evaluated on eight formalin-fixed paraffin-embedded (FFPE) cell lines with known RNA and protein (ELISA) MET expression levels. Antibodies with adequate sensitivity and specificity were then analyzed on a NSCLC tissue microarray (TMA) and on whole sections of NSCLC and gastric adenocarcinoma (GAC) of known MET status. The antibody evaluation included four autostainers (Ventana Benchmark XT, Leica BOND-III, Dako Autostainer Plus and Dako Omnis), 14 antigen retrieval (AR) methods and 7 detection methods.  Results', '  The SP44 and D1C2 antibodies showed staining on cell lines, NSCLC TMA, and large sections of NSCLC and GAC of adequate sensitivity and specificity when used under the following conditions', ' (1) Ventana Benchmark XT with CC1 standard and CC1 extended AR, (2) Leica BOND-III with ER2 AR, (3)DAKO Autostainer with EnVision FLEX Target High pH AR. All other antibodies and AR/detection methodologies showed inferior staining characteristics due to insufficient sensitivity and/or specificity.  Conclusions', '  SP44 and D1C2 showed staining performance similar in sensitivity and specificity to the CONFIRM anti-Total MET antibody. Additional validation on larger cohorts of clinically annotated tissues is required prior to any clinical application.   MET antibodies.']",
        "Doc_id":"ASCO_133275-144",
        "Doc_title":" Preclinical evaluation of anti-MET antibodies for immunohistochemical staining.",
        "_version_":1606188972594167808},
      {
        "Meeting_name":" MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression.",
        "Background":"['Background', ' Activating alterations of the mesenchymal epithelial transition (MET) oncogene in NSCLC are potentially actionable with targeted MET inhibitors. MET exon 14 skipping mutations have been described in 3% of patients (p) in NSCLC,.Fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) are currently used for detecting MET amplification and overexpression, respectively, but are not useful to detect MET splicing variants. On the other hand, the reverse transcription-polymerase chain reaction (RT-PCR) technique has the potential to detect this actionable alteration.']",
        "Doc_id":"AACR_2017-2723",
        "Doc_title":" MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression.",
        "_version_":1606188984504942592},
      {
        "Meeting_name":" Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC",
        "Background":"['MET is a transmembrane tyrosine kinase receptor that is deregulated (gene amplification, mutation and over-expression) across multiple cancer types. Signaling through MET is normally activated through interactions with its specific ligand, hepatocyte growth factor (HGF). Aberrant MET/HGF activation can stimulate tumor growth, promote angiogenesis, induce metastasis and may contribute to resistance mechanisms in several tumor types. Several non-selective MET inhibitors have entered clinical development; results have been mixed based on potency, selectivity, and/or patient selection. Volitinib is a potent (IC50 4 nM) and selective (>650 fold selectivity over 265 kinases), small molecule inhibitor of MET. Recent evaluation of Volitinib across a panel of cancer cell lines demonstrated selectivity for MET-driven disease, with MET amplified cell lines being most sensitive (IC50s of 1nM) and also suggesting limited off target activity. Volitinib resistant cell lines with MET amplification were identified and used to better understand the relationship of concurrent mutations with response. In addition to cancer cell line selectivity, we are analyzing preclinical models of NSCLC (non small cell lung cancer) that are representative of key patient segments, namely MET amplification and over expression. In newly diagnosed NSCLC adenocarcinomas, focal MET amplification events represent 3% of the population while over expression of MET (without gene amplification) is observed in the majority of patients. In preclinical models, focal Met amplification in EBC-1 and NCI-H1993 caused significant tumor growth inhibition, confirming sensitivity to Volitinib. Given the prevalence of over expression in NSCLC, however, we sought to build a platform of evidence for the therapeutic use of Volitinib in preclinical models lacking amplification of the MET gene. Using a patient-derived xenograft model (PDX) of EGFR WT, KRAS WT and metastatic NSCLC disease (HLXF-036LN), we demonstrate that Volitinib induces tumor regression as monotherapy and has added therapeutic benefit when used in combination with taxotere. In addition, we show robust efficacy effects for additional preclinical models, LG0567, LG0645 and Calu-3, for either Volitinib alone or in combination with taxotere. In parallel pharmacodynamic studies, we demonstrate that Volitinib inhibits p-MET and downstream signaling in each model. Together, using an integrated platform of molecular characterization and MET FISH and IHC scores, corresponding antitumor responses to Volitinib are being evaluated for several patient segments. We are using these studies to inform the design of patient selection criteria for upcoming clinical trials in NSCLC.']",
        "Doc_id":"AACR_2014-3114",
        "Doc_title":" Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC",
        "_version_":1606188990625480704},
      {
        "Meeting_name":" Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.",
        "Background":"['Background', ' The common driver genes in non-small-cell lung cancer (NSCLC) include EGFR, ALK, KRAS and so on. MET amplification coexisting with EGFR mutation is recognized as intrinsic resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs). We investigate the frequency of MET overexpression coexisting with EGFRmutation, response to EGFR TKIs and survival in advanced NSCLC patients with such co-alterations. Methods', ' From Jan 1st 2014 to Dec 31st 2015, we screened 149 consecutive NSCLC patients for the presence of MET overexpression concomitant EGFR mutation. MET overexpression was detected by immunohistochemistry (IHC), in which  50% tumor cells with moderate to high intensity staining were defined as MET positive. MET amplification was detected by fluorescence in situ hybridization (FISH), and FISH positive was defined as gene focal amplification or high polysomy (at least 15% cells with  5 copy numbers). Meanwhile, EGFRmutations were tested by DNA sequencing or Scorpion amplification refractory mutation system (ARMS). Results', ' The frequency of concomitant MET overexpression and EGFR mutation was 38.9% (58/149) in advanced NSCLC. However, the frequency of MET amplification was 13.6% (6/44). The frequency of primary resistance to EGFR TKIs was 24.1% (14/58) in EGFR/MET-coexisted patients and 14.2% (13/91) in those with only EGFR mutations, P= 0.13. Response rate (RR) of EGFR-TKIs was 48.3% (28/58), and 71.4% (65/91) in these two arms respectively, P= 0.004. Median PFS was 10.7 vs 11.2 months, Hazard ratio (HR) = 1.05, 95% CI 0.69~1.60, P = 0.82. Primary resistance to EGFR TKIs were found in 2 cases with concomitant MET amplification and EGFRmutations, but they responded to combination of EGFR and MET inhibitors. Conclusions', ' Advanced NSCLC patients with concomitant EGFR mutation and MET overexpression have relatively low RR with EGFR-TKIs, indicating that MET overexpression potentially causes primary resistance to EGFR-TKIs which might be overcome by combination of EGFR and MET inhibitors.']",
        "Doc_id":"ASCO_169259-176",
        "Doc_title":" Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.",
        "_version_":1606188990170398721},
      {
        "Meeting_name":" Strengthening anti-cancer effects on non-small cell lung carcinoma by dual blockage of MET and EGFR in a context-dependent manner.",
        "Background":"['Non-small cell lung carcinoma (NSCLC) accounts for more than 80% of lung cancer, the leading cause of death among all cancer casualties. The MET receptor tyrosine kinase (RTK) is often co-expressed with EGFR in the NSCLC cells, and is an important alternative resistant mechanism for escaping EGFR-targeted therapy. To assess the benefit of dual blockage of MET and EGFR for NSCLC therapy, we investigated the activities of these two RTK pathways in several NSCLC cell lines carrying distinct cellular contexts, and determined their responses to SGX523 and erlotinib, the small molecule kinase inhibitors of MET and EGFR, respectively. Here, we showed that MET can cross-activate EGFR in MET-amplified or overexpressing cells via hetero-receptor dimerization, and the MET-dependent phosphorylation of EGFR can be abolished by SGX523 but not by erlotinib. More importantly, combined inhibition of MET and EGFR in vitro results in a maximal suppression of downstream ERK and AKT activation and of cell proliferation when their ligands (HGF and EGF) are present. Furthermore, we demonstrated that SGX523 and erlotinib combination strengthens anti-cancer activity in vivo in a cellular context-dependent manner. The combination led to regression of MET-amplified H1993 tumors by enhancing suppression of proliferation and inducing apoptosis, whereas significantly reduced MET-non-amplified H1373 tumor growths by suppression of proliferation without inducing apoptosis. Although SGX523 alone was sufficient to achieve near complete regression of MET-addicted EBC-1 tumors, its combination with erlotinib strongly inhibited viability of a population of SGX523-insensitive cells emerging from SGX523-treated EBC-1 tumor relapse. Our data suggest that dual blockage of MET and EGFR can enhance anti-cancer effects on NSCLC in a context-dependent manner, and provide a strong rationale and mechanisms for combining MET and EGFR inhibitors for NSCLC therapy.']",
        "Doc_id":"AACR_2013-2167",
        "Doc_title":" Strengthening anti-cancer effects on non-small cell lung carcinoma by dual blockage of MET and EGFR in a context-dependent manner.",
        "_version_":1606189032845344768},
      {
        "Meeting_name":" Efficacy of MET inhibitors in NSCLC with CBL alterations",
        "Background":"['Purpose/Objective(s)', ' Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and adaptor molecule that is important in cancer. It belongs in the family with CBL-B and CBL-3. Our previous studies detected CBL mutations, loss of heterozygosity, and low protein expression in non-small cell lung cancer (NSCLC). We also determined the genetic variations of CBL, their relationship to receptor tyrosine kinases (RTK) such as EGFR and MET, and their functionality in NSCLC. However, ubiquitination of EGFR showed no difference between CBL wild type (WT) and mutants (Mts). Therefore, we undertook to investigate whether MET is a potential target of CBL and better therapeutic strategy.Materials/ Methods', ' CBL alterations were determined in NSCLC patients with next generation sequencing. Immunoprecipitation was performed to detect the ubiquitination of MET by CBL WT and Mts. MET inhibitor SU11274 was utilized to compare cell viability of CBL WT cells with viability of CBL Mt cells. Cell motility after SU11274 treatment was examined by wound healing assay. Soft agar assay was performed to investigate colony formation of shRNA knockdown (sh-CBL) cells and SU11274 treatment. PamGene Chip analysis was used to detect and predict the RTK phosphorylation difference between CBL WT and Mt/sh-CBL cells. In vivo mouse study was performed to examine tumor growth and metastasis of sh-CBL cells.Results', ' CBL had 6% (8/135) mutation rate in NSCLC patient population. When CBL and MET protein expression levels were analyzed by immunoblot, CBL WT cells had lower MET protein expression than CBL Mt cells. The ubiquitination of MET was decreased in cells that transiently expressed CBL Mt relative to CBL WT cells. In addition, CBL Mt cells were more sensitive to MET inhibitor SU11274 than CBL WT cells. Wound healing assay demonstrated sh-CBL cells had an increase in cell motility and more sensitive with SU11274 migration inhibition. Furthermore, soft agar assay showed an increase in colony number and size of sh-CBL cells compared to control cells. After treatment with SU11274, sh-CBL cells showed inhibition in colony formation. In vivo study showed sh-CBL cells had lower tumor growth but more metastasis than control cells. PamGene results predicted an effective cell signaling pathway involving MET, paxillin, EPHA2, and VEGFR..Conclusions', ' Ubiquitination assay result suggested MET is one of direct targets of CBL. The cell viability and motility results demonstrated that CBL mutants and sh-CBL cells are more sensitive than CBL WT cells to MET inhibitor SU11274, suggesting they have higher MET protein expression. Moreover, the PamGene results indicated that MET is involved in CBL cell signaling pathway. Thus, CBL gene status could be a potential indication for lung cancer therapy utilizing MET and other inhibitors.']",
        "Doc_id":"AACR_2015-4361",
        "Doc_title":" Efficacy of MET inhibitors in NSCLC with CBL alterations",
        "_version_":1606188987502821376},
      {
        "Meeting_name":" Inhibition of ABCB1 overcomes cancer stem cell-like properties and acquired resistance to MET inhibitor in non-small cell lung cancer",
        "Background":"['Non-small cell lung cancer (NSCLC) patients with EGFR mutations have shown a dramatic response to EGFR inhibitors (EGFR-TKI). EGFR T790M mutation and MET amplification have been recognized as mechanisms of acquired resistance to EGFR-TKI. Recently, MET inhibitors have been used in NSCLC patients for clinical trials. In this study, we tried to identify the mechanisms of acquired resistant to MET inhibitor. We analyzed the antitumor effects of two MET inhibitors; PHA-665752 and crizotinib, in 10 NSCLC cell lines. EBC1 cells with MET amplification were only sensitive cells to both of MET inhibitors. We have established PHA-665752 resistant cells; namely EBC1-R cells. EBC1-R cells showed high expression levels of ATP-binding Cassette Sub-family B Member 1 (ABCB1) as wells as phosphorylation MET (p-MET). EBC1-R cells grew as cell sphere that exhibited cancer stem cell-like (CSC) properties and epithelial mesenchymal transition (EMT) feature. Two miRNAs, miR-374a and miR-138 which targeted ABCB1, were decreased in EBC1-R cells. ABCB1 inhibitor elacridar could suppress sphere numbers and EMT phenomenon and restore to the resistance to PHA-665752 in EBC1-R cells. Our study demonstrated that ABCB1 overexpression associated with CSC properties and EMT may be critical for acquire resistance for MET inhibitor. ABCB1 inhibition might be a novel therapeutic strategy for resistance to MET inhibitor in NSCLC cells.']",
        "Doc_id":"AACR_2015-756",
        "Doc_title":" Inhibition of ABCB1 overcomes cancer stem cell-like properties and acquired resistance to MET inhibitor in non-small cell lung cancer",
        "_version_":1606189004980486144},
      {
        "Meeting_name":" Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).",
        "Background":"['Background', ' CNS mets occur in 20%40% of pts with adv NSCLC and are associated with poor overall survival (OS; median 7 mo). We evaluated nivo in this subgroup by', ' 1) pooling nivo-treated pts with adv NSCLC and pretreated (pretx) stable CNS mets at baseline (BL) across CheckMate 063 (phase [ph] II), 017 (ph III), and 057 (ph III); and 2) comparing OS with nivo vs docetaxel (doc) in pts with stable BL CNS mets in CheckMate 017 and 057. Methods', ' 1) Nivo-treated pts with adv NSCLC and pretx BL CNS mets from CheckMate 063 (n = 3), 017 (n = 9), and 057 (n = 34) were pooled to assess BL characteristics, safety, and CNS progression. 2) OS was analyzed in pts with pretx BL CNS mets and squamous (SQ; CheckMate 017) or non-SQ (NSQ; CheckMate 057) NSCLC treated with nivo 3 mg/kg Q2W vs doc 75 mg/m2 Q3W. Results', ' Of 46 nivo-assigned pts with pretx CNS mets, 74% had prior CNS-site radiotherapy and 85% had  2 extra-CNS sites of mets. Median follow-up was 8.4 mo (range', ' 0.3, 23.4); median treatment duration (n = 45; 1 pt not treated) was 2.3 mo (range', ' 0.03, 23.3). Any grade (gr) treatment-related (TR) adverse events (AEs) occurred in 67% of pts; gr 34 TRAEs occurred in 7%, with no TR deaths. CNS TRAEs occurred in 5 pts (11%) and were all gr 12 (paresthesia, n = 2; dizziness, somnolence, and tremor, n = 1 each). At time of overall disease progression (PD) or last tumor assessment, 33% of pts had no evidence of CNS progression (stable/decreased CNS lesions) and 52% had unequivocal progression in the CNS (15% had no post-BL CNS assessment). In pts with pretx CNS mets from CheckMate 017, median OS (events, n; HR) with nivo (n = 9) vs doc (n = 8) was 4.99 mo vs 3.86 mo (6 vs 8; not determined); in CheckMate 057, median OS with nivo (n = 34) vs doc (n = 34) was 7.61 mo vs 7.33 mo (30 vs 27; 1.04, 95% CI', ' 0.62, 1.76). Conclusions', ' Nivo was well-tolerated in pts with adv NSCLC and pretx CNS mets, with generally low-grade toxicities. One-third of pts had no evidence of CNS progression at time of PD/last assessment. In pts with SQ and NSQ NSCLC with pretx CNS mets, median OS was similar with nivo vs doc. Additional results (including OS and CNS progression rates in pts with/without pretx CNS mets and safety/efficacy of nivo in pts with untreated BL CNS mets from CheckMate 012) will be presented. Clinical trial information', ' NCT01721759; NCT01642004; NCT01673867']",
        "Doc_id":"ASCO_166920-176",
        "Doc_title":" Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).",
        "_version_":1606188988399353856},
      {
        "Meeting_name":" A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance",
        "Background":"['The epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition factor (MET) are receptor tyrosine kinases that each plays a key role in cancer signaling.Co-expression and activation of MET and EGFR are found in a number of tumor types, including non-small cell lung, colorectal, gastric, and head and neck cancers (Nanjo et al. 2013). Blocking one receptor tends to up-regulate the other, leading to resistance to single-agent treatment (Engelman et al. 2007). Amplification of MET and/or high levels of HGF expression has been observed in non-small cell lung cancer (NSCLC) patients with intrinsic or acquired resistance to tyrosine kinase inhibitors of EGFR (Engelman et al. 2007; Yano et al. 2011). Conversely, MET-amplified lung cancer cells exposed to MET-inhibiting agents for a prolonged period develop resistance via the EGFR pathway (McDermott et al. 2010). The crosstalk between the MET and EGFR pathways suggests that dual inhibition of these targets may lead to improved outcomes for patients with MET- and EGFR-positive cancers, and that simultaneous inhibition may overcome or delay resistance compared to the blockade of just a single pathway. LY3164530 is an engineered mAb-scFv bispecific antibody that consists of an immunoglobulin G4 (IgG4) antibody to MET and a single-chain variable fragment (scFv) to EGFR fused to the N-terminus of each heavy chain (HC). LY3164530 binds to extracellular domains of MET and EGFR with high affinity and inhibits signaling via both MET and EGFR receptors by blocking ligand binding and internalizing and degrading both receptors. In tumor cells, it binds and co-immunoprecipitates both receptors. LY3164530 has increased avidity binding to MET in cells expressing higher level of EGFR. This increased avidity binding leads to better neutralization of HGF compared to parental MET antibody in these cells. Surprisingly, LY3164530 has superior activity in internalizing/degrading EGFR (wild type and mutant forms) in vitro and in vivo relative to the combination of LY2875358 (i.e., emibetuzumab) and cetuximab in cells expressing high MET and EGFR. In addition, LY3164530 has superior activity in overcoming HGF-mediated resistance to erlotinib, gefitinib, lapatinib, or vemurafenib as compared to the combination of individual monoclonal antibodies targeting these receptors in cell-based assays. In vivo, administration of LY3164530 results in dose-dependent antitumor activity in multiple cell line-derived NSCLC and gastric xenografts. The antitumor activity of LY3164530 is equivalent, and in some cases superior to the combination of emibetuzumab and cetuximab in NSCLC and gastric tumor models. The Phase 1 study with LY3164530 is on-going (NCT02221882).']",
        "Doc_id":"AACR_2016-873",
        "Doc_title":" A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance",
        "_version_":1606188991185420288},
      {
        "Meeting_name":" Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.",
        "Background":"['Background', '     Ficlatuzumab is a humanized anti-HGF IgG1 MAb that inhibits activation of the c-Met receptor by neutralizing its only known natural ligand, HGF. HGF/c-Met pathway activation has been implicated in EGFR TKI resistance in NSCLC.  In a phase I trial in pts with solid tumors, ficlatuzumab was well tolerated up to the maximum tested dose of 20 mg/kg both as a single agent and in combination with erlotinib (150 mg/day).  Methods', '     Two dose levels of ficlatuzumab (10 and 20 mg/kg) in combination with 250 mg G were evaluated for safety, tolerability, and recommended phase II dose (RP2D).  Enrolled pts were Asians with unresectable NSCLC, performance status (PS) 2, and adequate organ function. Ficlatuzumab was given IV every 2 weeks and G was given PO once daily in 28 day cycles.  RP2D was defined as the highest dose at which  1 of 6 pts experienced a dose-limiting toxicity (DLT) during Cycle 1.  At RP2D, 6 additional pts were enrolled.  Pts were evaluated every 4 weeks for response using RECIST 1.1.  Results', '     15 pts enrolled', ' 5M/10F; median age 60 yrs, range 46-76 yrs; ECOG PS 0 (4 pts) or 1 (11 pts); median number of prior therapies was 3, range 1-5. Ten pts were EGFR TKI pretreated, 5 pts were EGFR TKI nave.  Three pts received ficlatuzumab 10 mg/kg and G 250 mg; 12 pts received ficlatuzumab 20 mg/kg and G 250 mg.  No DLTs were observed in the dose-escalation cohorts. Most frequent treatment-emergent adverse events (AEs)', ' dermatitis acneiform (53%), cough (40%), decreased appetite (33%), diarrhea (33%), paronychia (33%), edema (27%), drug hypersensitivity (27%), and fatigue (27%).  Grade 3/4 related AEs', '  diffuse alveolar damage, paronychia, edema, and rash.  RP2D is ficlatuzumab 20 mg/kg IV every 2 weeks with G 250 mg PO daily. Among 12 pts in the 20 mg/kg cohort', ' 5 pts had PR (all in EGFR TKI nave), 4 had SD, and 3 had PD. Median duration of treatment', ' 12 weeks (range 3.6-40).  Conclusions', '    The combination of ficlatuzumab and G was well tolerated and demonstrated clinical activity in pts with NSCLC.  A phase II open-label, randomized, first line trial is ongoing in Asian pts with lung adenocarcinoma (never- or former light-smokers) comparing ficlatuzumab + G vs G alone.']",
        "Doc_id":"ASCO_74960-102",
        "Doc_title":" Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.",
        "_version_":1606188990875041793},
      {
        "Meeting_name":" A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.",
        "Background":"['Background', ' MET signaling represents one mechanism of resistance to EGFR inhibition in EGFR mutant (mt) NSCLC. Emibetuzumab (LY2875358, LY) is a humanized IgG4 monoclonal bivalent MET antibody (mAb) blocking ligand dependent and independent HGF/MET signaling. This study tested whether acquired resistance to erlotinib (E) in MET Dx+ NSCLC pts enriched for EGFRmt can be overcome by LY+E or LY. Methods', ' Stage IV NSCLC pts with acquired resistance to E, ECOG PS  2, and MET Dx+ (  10% of cells  2+ by DAKO IHC) tumor sample (archival or fresh) were enrolled in this open-label phase 2 study (NCT01900652). Pts received LY 750mg IV Q2W with or without E 150 mg QD on a 28-day cycle after a maximum E washout period of  28 days. The primary objective was to evaluate the overall response rate (ORR) in both arms relative to historical control (10%), with a co-primary objective of ORR in pts with MET Dx-high (  60% of cells  2+) in the mandatory post E progression biopsy. Additional objectives included DCR, PFS, safety, PK, and exploratory biomarker analysis. Results', ' 111 MET Dx+ pts were randomized at a 3', '1 ratio to receive LY+E or LY. Median number of prior therapies was 2, 69% of pts had ECOG PS 1, 77% known activating EGFRmt, and 27% known T790M+. The ORR in pts with MET Dx+ NSCLC based on post E progression biopsies (n = 89) was 3.0% for LY+E (95% CI', ' 0.4, 10.5) and 4.3% for LY (95% CI', ' 0.1, 21.9). In MET Dx-high pts (n = 74), ORR was 3.8% for LY+E and 4.8% for LY. DCR and PFS were higher for LY+E (50%/3.3mo) than for LY (26%/1.6mo). No unexpected safety signals emerged. Related AEs in  15% of pts were reported for LY+E only and included fatigue, diarrhea, nausea, dermatitis acneiform, and edema. PK exposure of LY and E were comparable to historical data and no emergence of anti-LY antibody was detected. Exploratory biomarker analysis showed clinical PRs in pts with and without EGFRmt or MET amplification. Conclusions', ' Acquired resistance to E in MET Dx+ or MET Dx high pts was not reversed by LY+E or LY. LY was well tolerated and a subset of pts in both arms obtained clinical benefit. Further studies are warranted to identify pts benefiting most from emibetuzumab Clinical trial information', ' NCT01900652']",
        "Doc_id":"ASCO_164953-176",
        "Doc_title":" A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.",
        "_version_":1606189020094660608},
      {
        "Meeting_name":" MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.",
        "Background":"['Background', '  MET amplification is recognized as one of common molecular mechanisms of acquired resistance (AR) to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in advanced non-small-cell lung cancer (NSCLC). The aim of the present study is to investigate the frequency of MET overexpression, the correlated clinicopathologic features and the possible treatments in NSCLC with AR. Methods', '  Advanced NSCLC patients with AR to EGFR TKIs were detected for MET overexpression by immunohistochemistry (IHC). 50% tumor cells with moderate to high intensity staining were defined as MET positive.  MET positive patients were recommended to participate a clinical trial if eligible or receive other molecularly targeted therapies. The statuses of EGFR, ALK, KRAS and ROS1 were also tested.  Results', '  From January 2013 to January 2014, 58 advanced NSCLC patients with AR to gefitinib or erlotinib were enrolled prospectively. The frequencies of MET overexpression was 32.8% (19/58), MET overexpression+T790M 6.9% (4/58), T790M 29.3% (17/58), small cell lung cancer or squamous cell transformation 3.4% (2/58), KRAS mutation 1.7% (1/58), ROS1 fusion 1.7% (1/58) and unknown mechanism 24.1% (14/58),  respectively. No significant differencies were found in terms of clinicopathologic features (age, gender, smoking, performance status, histology, clinical stage, EGFR mutation types, and lines of EGFR TKIs), response rate of EGFR TKIs (69.6% versus 74.3%, p=0.694) and median progression-free survival (10.6 versus 13.0 months, p=0.569 ) for EGFR TKIs between MET positive and negative patients. Five of MET positive patients received gefitinib plus crizotinib (3 cases; 2 of them attaining partial response [PR] and 1 waiting for assessment of response), crizotinib (one case waiting for assessment) and axitinib (one case achieving PR) treatment, and all got prominently clinical benefit.  Conclusions', '  MET overexpression is one of common molecular mechanisms of AR to EGFR TKIs and has no correlated clinicopathologic features in NSCLC, but might serve as a promising therapeutic target when gefitinib plus crizotinib or other targeted therapy is provided.']",
        "Doc_id":"ASCO_131452-144",
        "Doc_title":" MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.",
        "_version_":1606189023207882752},
      {
        "Meeting_name":" Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models",
        "Background":"['MET splice site mutations that result in the deletion of exon 14 (METex14del) are implicated as oncogenic drivers in a subset of non-small cell lung cancer (NSCLC). MET exon 14 contains the Y1003 CBL ubiquitin ligase regulatory binding site that normally mediates CBL-dependent MET degradation and signal attenuation. Deletion of this exon results in sustained activation of MET and its downstream signaling pathways. The diverse splice site mutations leading to exon 14 skipping comprise a unique and unprecedented class of RTK activating mutations and the molecular mechanism by which these genetic alterations transform cancer cells is not fully understood. One major challenge in understanding the utility of MET inhibition of the METex14del class has been the lack of available pre-clinical models.In the present study, we generated and characterized multiple METex14del-driven cancer models to study the mechanism of MET-dependent cellular transformation as well as the response to MGCD265, a small molecule inhibitor of MET and AXL. METex14del models were identified via mining patient-derived xenograft (PDX) databases or were engineered using genome editing techniques to generate isogenic pairs of METex14del and WT cell lines.The METex14del cell lines formed increased size and number of colonies in anchorage independent growth assays compared to their WT counterparts. The transformation of METex14del cells was associated with an increase in durable HGF-dependent activation of MET and downstream signaling pathways potentially due to dysregulated MET processing and signaling attenuation. MGCD265 was shown to effectively inhibit this growth and MET-dependent signal transduction in a concentration-dependent manner. When evaluated in the amplified METex14del-driven gastric xenograft model Hs746T, significant tumor regression was observed following MGCD265 treatment. In addition, MGCD265 demonstrated substantial regression of large established tumors, in two novel NSCLC METex14del-positive PDX models.Together, these data confirm METex14del mutations are bona fide oncogenic drivers and sensitive to targeted therapeutics. Moreover, the models described in this study represent a relevant pre-clinical platform to further study receptor hyper-activation and drug action that is clinically actionable. Identification, development, and understanding of METex14del models will likely help further guide precision medicine strategies to treat NSCLC patients harboring these mutations.']",
        "Doc_id":"AACR_2016-2642",
        "Doc_title":" Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models",
        "_version_":1606189018136969216},
      {
        "Meeting_name":" MET exon 14 splice site mutation, protein expression, and amplification in pulmonary sarcomatoid carcinoma",
        "Background":"['Background', ' MET exon 14 splice site mutation (MET exon 14) was identified as a potential driver mutation in non-small cell lung cancer (NSCLC). Previously, several small sample size studies have revealed a higher frequency in pulmonary sarcomatoid carcinoma (PSC) than other types of NSCLC. In order to reveal the accurate frequency of MET gene alterations in Chinese PSCs, we comprehensively studied the frequency and the relationship among MET exon 14, protein expression and amplification in a large cohort of PSCs. Methods', ' MET exon 14, protein expression and amplification were detected in 148 surgically resected PSC samples from multiple medical centers by using Sanger sequencing, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. Results', ' MET exon 14 was identified in 9 (6.1%) of 148 cases. Six were pleomorphic carcinoma, two were spindle cell carcinoma and one was carcinosarcoma. MET exon 14 was more common in pleomorphic carcinoma compared with other subtypes of PSCs (p = 0.01, X2 test) and have an obvious tendency to occur in elder patients. MET protein overexpression was detected in 16.2% (24/148) of PSCs, and was found significantly associated with MET exon 14 (p = 0.045). MET FISH positive was detected in 15.5% (23/148), and 6 (4.1%) of them were confirmed as gene amplifications. MET FISH positivity (P < 0.001, X2 test) and amplification (P < 0.001, X2 test) were significantly associated with the IHC positive. No significant relationship between MET exon 14 and amplification was found. Conclusions', ' Chinese PSC has high incidence of METexon 14 and amplication. MET inhibition may benefit this specific subgroup of patients.']",
        "Doc_id":"ASCO_194473-199",
        "Doc_title":" MET exon 14 splice site mutation, protein expression, and amplification in pulmonary sarcomatoid carcinoma",
        "_version_":1606188995252846592},
      {
        "Meeting_name":" Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations.",
        "Background":"['Non-small cell lung cancer (NSCLC) carrying sensitizing epidermal growth factor receptor (EGFR) mutations can initially benefit from erlotinib (EGFR inhibitor) treatment. However, patients invariably develop resistance through secondary EGFR mutations, c-MET amplification, epithelial-mesenchymal transition (EMT), small cell lung cancer transformation, PIK3CA mutation and other unknown mechanisms. Here we examined whether Cripto1, which has been shown to induce EMT, could cause erlotinib resistance. We show that innate erlotinib-resistant lung adenocarcinomas carrying sensitizing EGFR mutations exhibit higher level of Cripto1 expression than their erlotinib sensitive counterparts. Ectopic expression of Cripto1 rendered erlotinib-sensitive lung adenocarcinoma cells resistant to erlotinib both in vitro and in a xenograft model. Moreover, Cripto1 activated Zeb1/EMT signaling pathway in EGFR-TKI resistant cells. High Cripto1 expression correlated with poor prognosis of NSCLC patients. Our study provides a novel Cripto1-dependent mechanism of EGFR-TKI resistance that may pave the way for the development of therapies to overcome EGFR-TKI resistance in lung cancer patients.']",
        "Doc_id":"AACR_2013-4468",
        "Doc_title":" Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations.",
        "_version_":1606189020594831360},
      {
        "Meeting_name":" LY2875358, a bivalent MET antibody with anti-tumor activity through blocking HGF as well as inducing degradation of MET, differentiates from a one-armed 5D5 MET antibody.",
        "Background":"['MET is involved in many mechanisms of cancer proliferation and metastasis. Inappropriate activation of MET can be induced by HGF-independent mechanisms such as gene amplification, specific genetic mutations, and transcriptional up-regulation, or by HGF-dependent autocrine or paracrine mechanisms. LY2875358 is a novel humanized bivalent MET antibody currently in phase I clinical testing (trial NCT01287546). LY2875358 has high neutralization and internalization activities against MET for inhibiting HGF-dependent and HGF-independent MET pathway activation and tumor growth. In HGF-dependent MET activation, LY2875358 blocks HGF binding to MET, HGF-induced MET phosphorylation and tumor growth both in cell culture and in mouse xenograft models, resembling activities of a humanized one-armed 5D5 MET antibody (monovalent antibody similar to Onartuzumab). In tumors with HGF-independent MET activation through MET gene amplification, LY2875358 induces internalization and degradation of MET, which results in decreased pMET and total MET, inhibition of cell proliferation and tumor growth in MKN45 and SNU5 gastric tumor lines and EBC-1 and H1993 NSCLC tumor lines. Moreover, LY2875358 enhances antitumor activity in combination with cisplatin or 5-FU in vitro and in vivo in MET amplified tumor cells. However, under the same ligand-independent conditions, the one-armed 5D5 antibody did not have anti-tumor activities. When HGF is added to tumor cells with high MET gene amplification, LY2875358 decreases cell proliferation, while the one-armed 5D5 antibody does not. In contrast to other bivalent MET antibodies, LY2875358 has no or otherwise negligible agonist activity and does not stimulate biological activities such as cell proliferation, scattering, invasion, tubulogenesis, apoptosis protection or angiogenesis in various HGF responsive cells. These findings indicate that LY2875358 has a different mechanism of action from the humanized one-armed 5D5 MET antibody. LY2875358 may be a promising therapy for treatment of patients whose tumors are driven by HGF-dependent and HGF-independent MET activation.']",
        "Doc_id":"AACR_2013-5465",
        "Doc_title":" LY2875358, a bivalent MET antibody with anti-tumor activity through blocking HGF as well as inducing degradation of MET, differentiates from a one-armed 5D5 MET antibody.",
        "_version_":1606189011211124736},
      {
        "Meeting_name":" A novel HGF-MET paracrine signaling pathway promotes growth and resistance to chemotherapy in lung cancer",
        "Background":"['Lung cancer is a leading cause of deaths from cancer among men and women worldwide with an estimated 1.5 million deaths each year. Available molecularly targeted therapies benefit a limited number of patients and even in these patients acquired resistance is a major impediment to effective therapeutic response. To address the need for additional therapeutic targets, we used a unique approach to identify and target tumor-stroma paracrine crosstalk pathways in non-small cell lung cancer (NSCLC).To explore paracrine crosstalk in NSCLC, we analyzed transcriptomes of specific stromal and epithelial compartments that were sorted from Kras driven mouse model of NSCLC. Transcriptome analysis and computational modeling of multi-cellular network identified potential tumor-stroma crosstalk signaling pathways. We have selected the hepatocyte growth factor (HGF)-MET tyrosine kinase receptor signaling pathway because both HGF and MET are associated with poor survival in many cancer types including lung cancer. Notably, we identified reprogrammed intratumoral macrophages as unique source of HGF, while the expression of MET receptor was confined to tumor epithelial compartment. Importantly, we have observed elevated HGF in chemoresistant tumors both in mouse and human. Previous studies have implicated MET receptor amplification or mutations as the main mechanism of acquired resistance to EGFR TKIs, but little is known about the contribution of HGF ligand-dependent activation of MET signaling in NSCLC growth and resistance to chemotherapeutic regimens that are widely used. We have used a combination of culture experiments and in vivo genetic approaches to show that macrophage-derived HGF interacts with the MET receptor on tumor epithelial cells in a paracrine fashion, to activate downstream signaling pathways that promote tumor progression and mediate resistance to standard chemotherapies. Our investigations on this relatively unexplored HGF-MET paracrine interaction as a key mechanism of resistance to standard-of-care chemotherapeutic regimens-and not just EGFR targeted therapies-have the potential to benefit the NSCLC population as whole rather than a small subset of patients.']",
        "Doc_id":"AACR_2014-1159",
        "Doc_title":" A novel HGF-MET paracrine signaling pathway promotes growth and resistance to chemotherapy in lung cancer",
        "_version_":1606189031380484096},
      {
        "Meeting_name":" Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    c Met expression is common in NSCLC tumors and has been implicated in the development of resistance to EGFR inhibitors. CRIZ is an ALK and MET/HGF receptor tyrosine kinase inhibitor (TKI). In pre-clinical studies, combining CRIZ with an EGFR inhibitor enhanced anti-tumor activity in NSCLC cell lines that were either sensitive or resistant to EGFR inhibition. The phase I portion of a phase I/II study (A8081002; NCT00965731) investigated the combination of E (EGFR TKI) and CRIZ in pts with advanced NSCLC.    Methods', '    Pts had advanced NSCLC, 1 or 2 prior chemotherapy regimens, and no previous MET-directed therapy. Endpoints included maximum tolerated dose (MTD) determination, safety, and pharmacokinetics (PK). Pts received CRIZ 150 or 200 mg BID combined with E 100 mg QD (150/100 and 200/100, respectively).  Results', '    Twenty-five pts have been treated to date. Median duration of combination therapy in 150/100 (n=18) was 6.6 weeks (0.125.3); for 200/100 (n=7) was 6.9 weeks (3.064.7). Five pts had dose-limiting toxicities (grade [G] 2 and unable to receive at least 80% of the planned dose or G3), all of which resolved', ' 3 pts at 150/100, G2 vomiting, G2 esophagitis and dysphagia, G3 diarrhea and dehydration; and at 200/100, G3 dry eye (1 pt) and G3 esophagitis (1 pt). Most pts (92%) experienced treatment-related adverse events (TRAEs), mainly of G1 or 2 severity. Common TRAEs were diarrhea (72%), rash (56%) and fatigue (44%). Six pts discontinued therapy due to TRAEs (150/100', ' G3 diarrhea, G3 dehydration, and G2 rash in 1 pt, G2 asthenia, G2 vomiting, G2 esophagitis, n=1 each; 200/100', ' G3 dry eyes, G1 esophagitis, n=1 each). One partial response (200/100; duration 61 weeks) and 9 stable diseases (n=7 150/100, n=2 200/100; duration 754 weeks) were observed overall. Co-administration of both doses of CRIZ with E increased E AUC by 1.8 fold, while CRIZ PK parameters appeared to be unaffected. Plasma exposure to E 100 mg QD with CRIZ was comparable to that of 150 mg QD from historical data.  Conclusions', '    E plus CRIZ at the MTD was well tolerated, with no unexpected AEs, and showed signs of activity in a pre-treated population. E 100 mg QD plus CRIZ 150 mg BID was defined as MTD.']",
        "Doc_id":"ASCO_96412-114",
        "Doc_title":" Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606189038199373824},
      {
        "Meeting_name":" S49076, a MET, AXL, FGFR inhibitor, potentiates radiation therapy in subcutaneous and orthotopic models of lung cancer",
        "Background":"['S49076 is an oral ATP-competitive inhibitor of the receptor tyrosine kinases MET, AXL, and FGFR1-3 currently in phase I/II clinical development in patients with advanced solid tumors. Here, we investigated the effect of S49076 on both MET- and non-MET- dependent cell lines alone and in association with ionizing radiation (IR) both in vitro and in vivo. We performed proliferation and clonogenic survival assays using the low MET-expressing H460 and A549 non-small-cell lung cancer (NSCLC) cell lines, the high MET-expressing H441 NSCLC cell line and the MET-dependent GTL16 gastric cancer cell line. Activity against the MET receptor and Aurora B kinase was assessed by analyzing the phosphorylation status of MET Tyr1234/1235 and Histone H3 Ser10 residues. Pharmacologic and RNA interference approaches against Aurora B and MET were used to determine the molecular mechanism of the cell response to S49076.S49076 inhibited MET activity in the nanomolar range (1 - 100 nM). At higher, but still clinically-relevant concentrations (0.5 - 1 M), S49076 was also found to inhibit Aurora B kinase activity in all cell lines tested. In non MET-dependent cell lines, the antiproliferative and anti-clonogenic effects of the drug correlated with its activity against Aurora B, whereas in the MET-dependent cell line, these effects could be attributed to direct inhibition of the MET receptor. When treatment with S49076 was combined with IR, an enhancement of IR effects was observed in all cell lines tested in vitro. In vivo, a significant growth delay of subcutaneous tumors was observed at 50 mg/kg bid oral S49076 in non-MET dependent models and at 3 mg/kg bid oral S49076 in the GTL16 MET-dependent model. For non MET-dependent models, immunohistochemistry revealed that treatment with S49076 reduced Histone H3 phosphorylation on Ser10. This is consistent with the finding that S49076 concentrations above 1 M were attained in the tumors, as determined by LC-MS/MS analysis. In all tumors tested, S49076 treatment significantly delayed tumor growth when combined to a fractionated IR (4 fractions of 2.5 Gy) compared to IR alone. An orthotopic model of lung cancer using luciferase-expressing H460 NSCLC cells was also used to evaluate the combination of S49076 (50mg/kg bid) and locally fractionated thoracic IR (4*2.5 Gy). In this model, the median survival after cell implantation was 22 days for control mice, 29.5 and 29 days for S49076 treated and irradiated mice respectively and 41 days for mice receiving the combined treatment (p<0.002 for combined treatment versus the irradiated arm or the S49076 treated arm).Our findings indicate that S49076 improves the efficacy of radiotherapy in both MET- and non-MET- dependent cell, supporting the use of combined treatment with S49076 and radiation in clinical trials without patient selection.']",
        "Doc_id":"AACR_2015-2568",
        "Doc_title":" S49076, a MET, AXL, FGFR inhibitor, potentiates radiation therapy in subcutaneous and orthotopic models of lung cancer",
        "_version_":1606188979403620353},
      {
        "Meeting_name":" Molecular profiling of pulmonary pleomorphic carcinoma",
        "Background":"['Background', ' Pulmonary pleomorphic carcinoma (PPC) is rare malignant tumor composed of carcinomatous and sarcomatous cell components which characterized by a more aggressive outcome than other histological subtype of non-small cell lung cancer (NSCLC). Various attempts to establish the clinical features of PPCs have been largely limited by small sample size. Thus, it will be important to further delineate the molecular characteristics of this disease entity to better understand the exact nature of this tumor type. Methods', ' We retrospectively examined the tumor specimen of 61 patients who underwent surgical resection of the lung in Samsung Medical Center from July 1995 to June 2009. Mutational or gene amplification status of epidermal growth factor receptor (EGFR), K-RAS (rat sarcoma virus), c-kit, FGFR (fibroblast growth factor receptor), c-MET (mesenchymal-epithelial trasition factor) was examined with genomic DNA sequencing, real-time PCR and/or fluorescence in situ hybridization(FISH). Overall survival impact was examined. Results', \" Out of 61 patients with pleomorphic carcinoma, it was revealed that 13 (21.3%) patients possessed EGFR tyrosine kinase domain deletion mutations in exon 19, point mutations in exon 20,21, 6 (9.8%) with K-ras point mutations in exon 2 and 3 (4.9%) c-kit point mutations in exon 9. High frequency gene copy number of c-met was found in 11 (18.0%) patients including one amplification by FISH and that of FGFR in 7 (11.5%) patients. A subset of patients demonstrated concurrent existence of multiple mutations, including one with EGFR and K-ras mutation simultaneously. No significant relationships were found between the occurrence and type of mutations and patients' survival or any other clincopathological variables. Conclusions\", ' We describe mutational analysis of a large set of PPC samples. Given the diverse repertoire of mutational profiles observed from PPC samples, clinical trials based on accurate cancer-genotyping should be considered as a legitimate treatment scheme for this rare disease entity in the future.']",
        "Doc_id":"ASCO_52061-74",
        "Doc_title":" Molecular profiling of pulmonary pleomorphic carcinoma",
        "_version_":1606188977224679424},
      {
        "Meeting_name":" Mechanisms of resistance to type I and type II MET inhibitors in non-small cell lung cancer.",
        "Background":"['Background', ' MET targeted therapies are clinically effective in MET amplified and MET exon 14 deletion mutant non-small cell lung cancers (NSCLC). At least 8 MET tyrosine kinase inhibitors (TKIs), including both type I and II, have been developed and are under clinical evaluation. We recently described a resistance mechanism in a patient with a unique MET secondary mutation, D1228V, refractory to all type I but sensitive to type II MET TKIs (Bahcall et al. Cancer Discovery 2016). We examined whether the sensitivity and resistance of other MET secondary mutations were similarly dependent on the mode of inhibitor binding, and sought to determine the optimal sequence of MET inhibitor use, so as to achieve the longest combined latency before the emergence of resistance.']",
        "Doc_id":"AACR_2017-4100",
        "Doc_title":" Mechanisms of resistance to type I and type II MET inhibitors in non-small cell lung cancer.",
        "_version_":1606188971547688960},
      {
        "Meeting_name":" An anti-MET IgG2 monoclonal antibody degrades both wild-type and exon 14 mutant MET receptor tyrosine kinase through a novel exon 14-independent mechanism and inhibits tumor growth",
        "Background":"['MET gene amplification and exon 14 mutations have been reported and implicated as oncogenic drivers in several types of cancer representing approximately 5-7% of NSCLC, 4-10% of gastric cancer, and 5-10% of colon cancers. Preclinical research and clinical data derived from patients with tumors containing MET gene amplification and exon 14 mutations showed significant growth inhibition and meaningful clinical benefit after treatment with MET-targeting tyrosine kinase inhibitors (TKIs), supporting the hypothesis that MET gene amplification and exon 14 mutations are actionable biomarkers. We have identified several anti-MET monoclonal antibodies that block MET-dependent signaling and tumor growth through', ' (1) binding to the Sema/PSI domain, (2) preventing HGF interaction with MET and (3) inducing receptor ubiqutination and degradation. One of the anti-MET antibodies, KTN0073, induces potent degradation of oncogenic exon 14 mutant MET, which has been reported to propagate prolonged MET signaling due to a defect in receptor degradation. Our data suggest that KTN0073 engages a pathway different from HGF-induced receptor degradation and protease-mediated shedding, which is independent of the 47 amino acids that are encoded by exon 14 in the intracellular juxtamembrane region and only partially inhibited by the TKI crizotinib. In summary, we report the use of an anti-MET monoclonal antibody to elucidate an exon 14-independent mechanism of MET degradation that could provide a novel way to design anti-MET therapeutics to inhibit growth of human tumors that are driven by HGF, MET amplification and exon 14 mutations. Based on this work, KTN0073-IgG2 anti-MET antibody has been humanized for further preclinical development to explore its potential as a therapeutic for the treatment of human MET expressing cancers.']",
        "Doc_id":"AACR_2016-3835",
        "Doc_title":" An anti-MET IgG2 monoclonal antibody degrades both wild-type and exon 14 mutant MET receptor tyrosine kinase through a novel exon 14-independent mechanism and inhibits tumor growth",
        "_version_":1606189031918403584},
      {
        "Meeting_name":" Co-amplification of MET and PIK3CA in NSCLC and data on a PDX mouse model.",
        "Background":"['Background', ' Amplification of the mesenchymal-epithelial transition (MET) proto-oncogene or phosphatidylinositol3-kinase (PI3K) is common in non-small-cell lung cancer (NSCLC) and represents a potential therapeutic target. NSCLC with coexisting driver mutations or amplifications is a cause of great concern. Methods', ' From 2013 until now, fluorescence in situ hybridization was used to screen for MET amplified NSCLC patients.The amplification of the MET was defined as centromere 7 ratio  2.0 and the criterion of Cappuzzi. The amplification of the PIK3CA was copy numbers  4.0. We established the patient-derived exnograft (PDX) mouse model from a dual MET/PIK3CA-amplified patient. Preclinical efficacy of single versus dual inhibition was evaluated in vivo. Six groups were allocated to receive the treatment of vehicle control, bozitinib,crizotinib, taselisib (PI3K inhibitor), bozitinib+taselisib, or crizotinib+taselisib, respectively. Results', ' Totally, 568 (568/2321, 24.47%) patients harbored positive MET amplification and 6 (6/568,1%) were comfirmed with dual MET/PI3K amplification. The two stage patients received MET inhibitor treatment.One trial (NCT02896231) patient was treated with bozitinib and achieved confirmed PR, but with 3 months PFS and 5 months OS. The best response was PR and PFS was 5.6 months for the other one receiving the study drug capmatinib (NCT02276027). In the PDX mouse model experiment, we found three single-anget inhibitors monotherapy to be active but only transiently effective in controlling the growth of PDX. The PDX models showed more sensitivity to taselisib among the three single-anget groups. In contrast, the combination of the two inhibitors caused a stronger and long-lasting growth inhibition in PDX models. The addition of taselisib to bozitinib or crizotinib monotherapy provided obvious enhanced activity. Regretfully, two mice died because of the toxicities in the crizotinib+taselisib group. Conclusions', ' Patients with dual MET/PIK3CA amplification represent a rare molecular subtype of NSCLC and have a relatively short duration of response to MET inhibitors.The combination of MET/PI3K inhibitors is synergistic preclinically.']",
        "Doc_id":"ASCO_188529-199",
        "Doc_title":" Co-amplification of MET and PIK3CA in NSCLC and data on a PDX mouse model.",
        "_version_":1606189019031404545},
      {
        "Meeting_name":" Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib",
        "Background":"['Alterations in the MET oncogene occurs across a broad range of tumor indications. Amplification or mutations in MET lead to increased activity of downstream pathways including PI3K and MAPK, eventually resulting in tumor formation. Several small molecule inhibitors are currently in clinical trials, including the selective inhibitor Savolitinib (HMP-504, Volitinib, AZD6094), which shows single digit nanomolar activity in MET-amplified cell lines. Newly emerging data suggest mutations in MET causing complete skipping of Exon 14 occur in approximately 4% of non-small cell lung cancer (NSCLC), and are more rare in other indications [1, 2]. MET exon 14 skipping mutations were shown to be mutually exclusive from EGFRm, ALK and KRAS and can occur in the context of MET gene amplification [3]. Exon 14 harbors the CBL binding site (Y1003), which is critical for receptor degradation after binding of its ligand, HGF, and suppression of downstream signaling events. Clinical trial results with less potent, pan RTK inhibitors Crizotinib (31nM GI50 vs 3nM for Savolitinib) and Cabozantinib show promising early results, but fall short in long term responses. Therefore, better therapies targeting MET are needed. Human cell line models with Exon 14 deletions are rare. Therefore, we used engineered cell lines to test the effect of Savolitinib on these mutations. To do this, we expressed MET-Y1003F mutants in NIH-3T3 and HEK293T cells. We found that Savolitinib potently inhibited phospho-MET in both models expressing this mutant (100% phospho-MET inhibition). In addition, we tested whether or not Savolitinib could inhibit HGF-dependent signaling and growth of a NSCLC cell line, NCI-H596. In the presence of FBS (10%), Savolitinib had no effect on the growth rate of these cells, however was highly efficient at blocking HGF-dependent growth in the absence of FBS. To test the effect of this mutation in the background of amplification, we also tested the gastric cancer cell line Hs746T, which harbors exon 14 skipping in addition to MET amplification. Savolitinib was highly efficacious at blocking the growth of this cell line. Future studies are aimed at looking at the in vivo effect of Savolitinib targeting exon 14 mutants. These data provide a platform of evidence for using Savolitinib to target exon 14 mutant MET in patients.1.Paik, P.K., et al., Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov, 2015. 5(8)', ' p. 842-9.2.Frampton, G.M., et al., Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov, 2015. 5(8)', ' p. 850-9.3.Cancer Genome Atlas Research, N., Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014. 511(7511)', ' p. 543-50.']",
        "Doc_id":"AACR_2016-1150",
        "Doc_title":" Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib",
        "_version_":1606188984073977856},
      {
        "Meeting_name":" Regulation of colon cancer metastasis by sprouty-2",
        "Background":"['Introduction', ' We earlier established that sprouty-2 is overexpressed in human colon cancer and up-regulates c-met and thereby increases the growth phenotype and metastatic potential of colon cancer cells (Oncogene, 29', ' 5241-53, 2010). To our knowledge, this was the first study to demonstrate the tumor oncogene phenotype of sprouty-2 in colon cancer metastasis. On the contrary, cancer protective role of sprouty-2 was noted in breast, liver and prostate cancers. However, a recent report on non-small cell lung cancer (NSCLC) discovered that silencing of sprouty-2 reduced c-met expression and thus confirmed our findings in colorectal cancer (PNAS, 110', ' 8573-78, 2013). We further extended our studies to demonstrate that this pathway modulates gastrointestinal specific microRNAs (miRNAs) and regulates various oncogenes and tumor suppressor genes in colon cancer cells. Methods', ' RNA from control and shRNA sprouty-2 transfected cells were labeled with Hy5 and Hy3 respectively and hybridized to miRCURY LNA arrays. Unsupervised miRNA clustering was carried out and a heat map prepared with Java TreeView. MicroRNA targets were identified by Real-time PCR, western blotting and 3UTR luciferase assays. Migratory phenotype of colon cancer cells was confirmed by cell migration and invasion assays in trans-well chambers. Cancer cells were transfected by miRNA mimics to assess the expression levels of target genes. Human colon cancer tissue microarrays were utilized to assess the expression of miRNA target genes. Human tumor sections were evaluated by immunofluorescence and immunohistochemical staining. Results', ' Sprouty-2 shRNA transfected stable cell lines demonstrated upregulation of tumor suppressive miRNAs and down-regulation of oncogenic miRNAs. Overexpression of gastrointestinal specific miRNA mimics inhibits colon cancer cells proliferation and metastasis. On the contrary, overexpression of miRNA inhibitor in colon cancer cells promotes proliferation and colonization. Studies further indicated that miRNA down-regulates expression of CDK7, RB1, AKT, FASL, IGF1R, EGFR and N-cadherin and up-regulates expression of P21 and E-cadherin. MiRNA regulated genes were responsible for cell cycle arrest, enhanced apoptosis and decreased metastasis. AKT was upregulated whereas E-cadherin was downregulated at the invasive fronts in human colon tumors. Conclusion', ' Sprouty-2/miRNA expression levels could be used to risk-stratify patients for CRC recurrence and sprouty-2 axis regulation may lead to the development of therapeutics in colon and lung cancer.']",
        "Doc_id":"AACR_2014-1466",
        "Doc_title":" Regulation of colon cancer metastasis by sprouty-2",
        "_version_":1606189006807105536},
      {
        "Meeting_name":" Characteristics of HIV+ lung cancer cases in a large clinical population",
        "Background":"['Background', '  Lung cancer (LCa) accounts for ~30% of cancer deaths and 10% of non-HIV-related deaths among HIV(+)s. Compared to those in the general population, even after accounting for smoking, HIV(+)s have a 2.55-fold higher risk of LCa, and are diagnosed younger. The National Lung Screening Trial (NLST) demonstrated survival improvements with low dose CT (LD-CT) screening in persons at high lung cancer risk (age 55-74 with 30 pack-years [pys] of smoking). We examined the age and smoking histories of HIV+ LCa patients to determine who would have met NLST screening eligibility.  Methods', '  The Cancer Registry (42,967 cancer cases) and the HIV Integrated Clinical Database (14,927 HIV+s) at Montefiore Medical Center  Einstein (Bronx, NY) were linked to identify HIV+ cancer cases between 2000-2012. Chart review was performed for those with LCa.  Results', '  Of the 935 invasive cancers in HIV+s, 90 (9.6%) were LCa (62% men, 38% women). Histology was 11% small cell, 20% squamous and 37% adenocarcinoma, 2% large cell, and remaining 30% were classified as non-small cell carcinomas. Median age at LCa diagnosis was 54 years ([y]; range', ' 2472), with 2% <35y, 52% 35-54y, 46% 55y. 4% were never smokers, and 3% had <15pys, 24% 15-29pys, 68% 30pys. Overall, 66 cases (73%) did not meet NLST age or smoking criteria. Most cases (85%) had been followed for HIV care. The median CD4+ was 238 cells/L, and median HIV viral load was 81 copies/mL. LCa was stage I in 8%, stage II in 11%, stage III in 23%, and stage IV in 58%. All stage I/II cases underwent surgical resection.  Conclusions', '  Most HIV+ LCa cases failed to meet NLST criteria for LD-CT screening due to age <55y or pys <30. If LD-CT is to be utilized in this high-risk population, age and smoking thresholds may need to be lowered. Notably, 19% of tumors were diagnosed at stage I/II without routine screening, reinforcing the potential to identify LCa at a treatable stage in HIV(+) persons.']",
        "Doc_id":"ASCO_129397-144",
        "Doc_title":" Characteristics of HIV+ lung cancer cases in a large clinical population",
        "_version_":1606188976329195521},
      {
        "Meeting_name":" AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models",
        "Background":"['Signaling through the MET receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), promotes cell proliferation, survival, and invasion. Activation of MET signaling is a relatively common hallmark of a diverse range of human cancer types, and as a result, inhibition of MET signaling represents an attractive therapeutic opportunity for the treatment of cancer. In this study, we describe the characterization of AMG 337, a potent and highly selective small molecule ATP-competitive MET kinase inhibitor that demonstrates robust activity in MET-dependent cancer models.In enzymatic assays, AMG 337 inhibited MET kinase activity with an IC50 of < 5nM nM. AMG 337 demonstrated exquisite selectivity for MET when profiled against a diverse panel of over 400 protein and lipid kinases in a competitive binding assay. In cellular assays, AMG 337 inhibited HGF-dependent MET phosphorylation with an IC50 of < 10 nM. To identify predictive genomic markers of response, AMG 337 was profiled in cell viability assays using a diverse panel of over 200 cancer cell lines. Treatment with AMG 337 only affected the viability of two gastric cancer cell lines (SNU-5 and Hs746T), both of which harbor amplification of the MET gene. The AMG 337 IC50 in the two sensitive cell lines was < 50 nM, and > 10 M in all other tested cell lines.Further studies in an expanded panel of additional cancer cell lines derived from gastric, NSCLC, and esophageal cancer confirmed that the in-vitro anti-proliferative activity of AMG 337 correlated with amplification of MET. In those cell lines, treatment with AMG 337 inhibited downstream PI3K and MAPK signaling pathways, which translated into growth arrest as evidenced by an accumulation of cells in the G1 phase of the cell cycle, a concomitant reduction in DNA synthesis, and the induction of apoptosis.In vivo, oral administration of AMG 337 resulted in robust dose-dependent anti-tumor efficacy in MET amplified gastric cancer xenograft models, with inhibition of tumor growth consistent with the pharmacodynamic modulation of MET signaling.In conclusion, these findings illustrate the potential clinical utility of AMG 337 as a therapeutic agent for the treatment of tumors with evidence of dysregulated MET signaling, including MET amplification. A phase 1 clinical study is currently evaluating the safety, tolerability and pharmacokinectics of AMG 337 in patients with solid tumors.']",
        "Doc_id":"AACR_2014-728",
        "Doc_title":" AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models",
        "_version_":1606188977023352832},
      {
        "Meeting_name":" Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC.",
        "Background":"['BACKGROUND', ' Foretinib (FORE) and cabozantinib (CABO) are two MET/VEGFR inhibitors with similar chemical structures. CABO is FDA-approved for medullary thyroid and renal cancer; in addition, it is in clinical trials for treatment of non-small cell lung cancer (NSCLC). Through an unbiased viability screen we have observed potent cellular activity of FORE, but not CABO, in several NSCLC cell lines. We have previously shown that most NSCLC cell lines are insensitive to MET or VEGFR inhibition, suggesting off-target activity of FORE in these cells. The aim of this project is to identify the mechanism of action of FORE in NSCLC and design an optimized combination therapy.']",
        "Doc_id":"AACR_2017-221",
        "Doc_title":" Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC.",
        "_version_":1606189027641262080},
      {
        "Meeting_name":" Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC",
        "Background":"['Background', '  Despite high response rates to EGFR tyrosine kinase inhibitors (TKIs), most patients (pts) with EGFR-mut NSCLC ultimately relapse.  Dysregulation of the MET pathway is implicated as a therapeutically tractable resistance mechanism, occurring in 1520% of cases. INC280 is a highly selective, oral MET inhibitor with preclinical activity in EGFR-mut/MET-activated NSCLC when combined with EGFR TKIs.  Methods', '  This Ph Ib/II, open-label, dose-escalation study of INC280 plus gef was performed in pts (age 18 yrs, ECOG PS 2) with EGFR-mut NSCLC who progressed after prior EGFR TKI, and have confirmed MET dysregulation (amplification [FISH 5 CN] or overexpression [IHC 2/3+]). The primary objective (Ph Ib) was to determine the MTD/recommended Ph II dose (RP2D) of INC280 plus gef; secondary objectives were safety, efficacy, pharmacodynamics and PK. An adaptive Bayesian logistic regression model with overdose control guided dose escalation to establish the MTD.  Results', '  As of December 2, 2013, 41 pts were enrolled in the ongoing Ph Ib part of the study (59% female, median age 58 years). Pts were treated with INC280 at 7 dose cohorts of 100800 mg QD and 200600 mg BID, in combination with gef 250 mg QD. Dose-limiting toxicities (DLTs) occurred in 2 pts', ' dizziness (800 mg QD) and dyspnea (600 mg BID). The most frequent drug-related AEs (any grade [Gr]) were nausea (27 %), vomiting, diarrhea, and rash (all 22%). The most common drug-related Gr 3/4 AEs were increased lipase (7 %), and increased amylase (5%). For one death, causality to INC280 was not ruled out. INC280 exposure increased with dose from 100800 mg QD and 200400 mg BID; preliminary data show no PK interactions with gef. Partial responses were seen in 6/41 (15%) evaluable pts; 5 confirmed, 1 unconfirmed, including 3/7 pts (43%) on 400 mg BID; 5/6 responders had EGFR TKIs as a last treatment prior to study entry. All responders had high MET status.  Conclusions', '  Oral INC280 in combination with gef is well tolerated; the RP2D has not yet been defined. Preliminary clinical activity supports further evaluation of INC280 combined with gef in MET-positive NSCLC resistant to EGFR TKIs. Clinical trial identifier', ' NCT01610336. Clinical trial information', ' NCT01610336.']",
        "Doc_id":"ASCO_128396-144",
        "Doc_title":" Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC",
        "_version_":1606188969974824960},
      {
        "Meeting_name":" Use of an EGFR mutation signature to estimate prognosis in EGFR wild-type lung adenocarcinomas and identify metastasis associated in colon cancer 1 (MACC1) as a regulator of MET.",
        "Background":"['Background', ' Non-small cell lung cancers (NSCLC) bearing EGFR activating mutations are typically sensitive to EGFR tyrosine kinase inhibitors (TKIs) and have increased MET levels through multiple mechanisms. We developed an EGFR mutation gene expression signature to identify genes associated with the EGFR-dependent phenotype. Methods', ' Gene expression and EGFR status were measured in 95 adenocarcinomas (training set), two sets of lung adenocarcinomas (N=102 and 82) and 53 NSCLC cell lines (testing sets). A proteomic profiling, generated by reverse phase protein array technology in 74 NSCLC cell lines, using 170 antibodies, was analyzed. MACC1 and MET immunostaining, of a tissue-microarray including 287 NSCLC, was studied. MACC1 knockdown experiments were conducted. Results', ' We identified a set of 45 genes significantly associated with EGFR status in the training set. The gene-set was used to compute a signature which was shown to be predictive of EGFR status in 3 testing sets. Pathway analysis of the genes showed that EGFR-mutations was marked by increased endocytosis and decreased mitosis genes. The signature was correlated with drug sensitivity to EGFR TKI in vitro, and significantly associated with survival in early stage adenocarcinomas, even in the subgroup with EGFR wild-type tumors. Our current study identified MACC1 as the most significantly up-regulated gene in EGFR mutant. MACC1 and MET expression levels, in vitro and in vivo, were highly correlated both at the mRNA and protein levels. A correlation heatmap of the proteomic profiling showed a strong correlation of MACC1 with MET, downstream signal transducers (STATs), markers of the epithelial phenotype (a classical feature of EGFR mutant tumors), and RAB25 (a member of the RAS superfamily of small GTPases that are involved in endocytosis). Finally, we showed that MACC1 knockdown in vitro reduced MET levels. Conclusions', ' A gene expression signature associated with EGFR-dependent phenotype was developed. The signature was shown to be prognostic regardless of EGFR status. The results also suggest MACC1 to be a regulator of MET in NSCLC.']",
        "Doc_id":"ASCO_61032-101",
        "Doc_title":" Use of an EGFR mutation signature to estimate prognosis in EGFR wild-type lung adenocarcinomas and identify metastasis associated in colon cancer 1 (MACC1) as a regulator of MET.",
        "_version_":1606189016137334784},
      {
        "Meeting_name":" MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib",
        "Background":"['Background', ' MGCD265 targets wild type Met, as well as clinically relevant Met mutants, VEGFR-1,-2 and -3, Ron and Tie-2. MGCD265 combinability with erlotinib is being evaluated in patients (pts) with advanced malignancies. Combining Met and EGFR inhibitors has recently been shown to be synergistic and can overcome resistance to either Met or EGFR inhibitors. Methods', ' Eligible pts in the initial cohort received MGCD265 at 96 mg/m2 once daily (QD) and erlotinib at 100 mg QD. Subsequent cohorts received full dose erlotinib (150 mg QD) with incremental doses of MGCD265, initially on a QD schedule and thereafter twice daily (BID) during a 21-day cycle. The primary objective was to determine the safety profile. Secondary objectives include anti-tumor activity, pharmacodynamics (PD) and pharmacokinetics (PK). Results', ' Pt characteristics (n=33)', ' gender', ' 23 M/10 F; median age', ' 57 (range 39-76) years; ECOG 0/1', ' 18/15.  Dose limiting toxicities include', ' diarrhea (1/8 pts at MGCD265 96 mg/m2 QD + erlotinib 100 mg); rash (1/9 pts at MGCD265 144 mg/m2 QD + erlotinib 150 mg) and fatigue (1/9 pts at MGCD265 144 mg/m2 QD + erlotinib 150 mg). The BID regimen of MGCD265 has been introduced at 72 mg/m2.  One pt with NSCLC experienced a partial response (after 2 cycles of treatment and continuing) and one pt with gastric cancer had resolution of ascites and a decrease in gastric wall thickness (cycle 15 and continuing). Molecular profiling of the archived tumor biopsy from this latter pt showed high levels of Met and phospho-Met protein expression in the absence of MET and EGFR gene amplification or detectable mutations.  Prolonged disease stabilization was observed in another pt with gastric cancer (8 cycles and continuing). Ten other pts completed 4-10 cycles. To date, a decrease in HGF plasma levels was observed in Cycle 1 Day 8. Preliminary PK data with MGCD265 in QD dosing indicated no drug-drug interaction and MGCD265 steady state plasma concentrations were multiples above the IC50 for Met and VEGFR2. Conclusions', ' Clinical data to date indicate that MGCD265 can be combined with full dose erlotinib with early signs of clinical activity.  This combination merits additional testing in NSCLC and gastric cancer.']",
        "Doc_id":"ASCO_82274-102",
        "Doc_title":" MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib",
        "_version_":1606188984386453504},
      {
        "Meeting_name":" Identification of inhibitors of TWIST1 as a treatment for lung cancer",
        "Background":"['Although a large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations, little progress has been made in the treatment of patients with the most frequently observed driver mutation, mutant KRAS. Acquired resistance to therapy targeting other driver mutations (EGFR mutant and ALK translocation positive tumors) is all but inevitable. We recently demonstrated that Twist1, a basic helix-loop-helix transcription factor, cooperates with mutant Kras to induce lung adenocarcinoma in mouse models, and that inhibition of Twist1 in murine models and human lung cancer cell lines led to oncogene-induced senescence (OIS) and in some cases, apoptosis. We have also found that TWIST1 is essential for tumor maintenance in human NSCLCs characterized by oncogenic drivers including KRAS mutation, EGFR mutation and c-MET amplification. As TWIST1 is not typically expressed post-natally, therapies directed against TWIST1 may present a more specific and perhaps less toxic therapy. Targeting the TWIST1 pathway represents an exciting and novel therapeutic strategy which may have a significant clinical impact.We employed a combined bioinformatics-chemical approach to identify pharmacologic inhibitors of TWIST1. We used gene expression profiles from several KRAS mutant human NSCLC cell lines following shRNA-mediated TWIST1 knockdown to perform connectivity map (CMAP) analysis. We found that several of our highly ranked compounds had significant growth inhibitory effects in NSCLC cell lines. Furthermore, several of our candidate agents produced dose-dependent inhibition of TWIST1-induced dissemination in a novel 3D organoid dissemination assay. Interestingly, a family of related harmala alkaloids including harmine ranked highly on the CMAP analysis. We found that harmine could not only inhibit growth in several oncogene driver defined NSCLC cell lines through the induction of apoptosis but could also decrease TWIST1 levels through a post-transcriptional mechanism. The growth inhibitory effects of the harmala alkaloids correlated with the ability to degrade TWIST1. Additionally, independent of our CMAP analysis, we identified another compound, salinomycin, which appears to modulate cancer cell growth and resulted in a decrease in TWIST1 levels through a post-transcriptional mechanism as well. Interestingly, salinomycin treatment induced a mesenchymal-epithelial transition (MET) in NSCLC which could be partially blocked in TWIST1 overexpressing NSCLC cell lines. We are currently examining the in vivo efficacy of these agents. In conclusion, we have identified several compounds that inhibit TWIST1 dependent dissemination and in some cases can lead to TWIST1 degradation. Since TWIST1 is essential for not only KRAS mutant NSCLC but more broadly for oncogene driven NSCLC, these studies could lead to the development of a novel class of inhibitors which could have a significant clinical impact.']",
        "Doc_id":"AACR_2014-4771",
        "Doc_title":" Identification of inhibitors of TWIST1 as a treatment for lung cancer",
        "_version_":1606189038123876352},
      {
        "Meeting_name":" High copy number of the MET gene predicts resistance to EGFR-TKI in non-small cell lung cancer patients.",
        "Background":"['Background Non-small cell lung cancer (NSCLC) patients with EGFR gene mutations have shown a dramatic responses to EGFR tyrosine kinase inhibitor (EGFR-TKI). However, it is recognized that, clinically, drug resistance eventually emerges and this limits the mean duration of response. Although mechanisms of acquired resistance to EGFR-TKI, such as T790M secondary mutation and MET amplification, have recently been described, other mechanisms of resistant to EGFR-TKI should be identified to broaden the therapeutic strategy for NSCLC in patients with EGFR gene mutations. Patients and Methods We evaluated 26 lung tumor samples from NSCLC patients who had received EGFR-TKI treatment from 2009 to 2011 at Nippon Medical School Hospital. Status of copy numbers and amplification of the MET gene were examined by fluorescence in situ hybridization (FISH) and estimated by high throughout automated image analysis. Results High copy number (>4 copies/cell) was observed in 6 patients (27%) and amplification (MET/CEP7 2.0) was seen in 0 of 26 NSCLC patients. MET gene copy number status was not correlated with EGFR gene mutation, gender, histology, or smoking history. In 2 of the 6 cases with high copy number, high copy numbers were found at both the pre- and post-treatment stages. Among the 6 patients with high copy number, 5 patients achieved partial response (PR) and one patient showed stable disease (SD) with EGFR-TKI therapy. However, the 6 patients with high copy number had statistically significantly shorter progression-free survival (PFS) than the 20 patients with low copy numbers. (p=0.048, log-rank test). The median PFS of patients with High copy number and low copy numbers was 9.5 months and 24.4 months, respectively. Conclusion Detection of high copy number of the MET gene by FISH may be useful for predicting response to EGFR-TKI. The correlation between MET gene copy number and response to EGFR-TKI should be further evaluated using larger sample sizes.']",
        "Doc_id":"AACR_2012-5548",
        "Doc_title":" High copy number of the MET gene predicts resistance to EGFR-TKI in non-small cell lung cancer patients.",
        "_version_":1606189017026527232},
      {
        "Meeting_name":" Are the gene expression profiles of Hispanic patients with lung cancer living in the US different from Hispanics living abroad?",
        "Background":"['Background', ' The frequency of epidermal growth factor receptor mutations (EGFR) in lung cancer tumors in Latin-America (LATAM) is higher than the US. We believe that the frequency of EGFR and other molecular markers (MM) in Hispanic (H) patients (pts) living in the US does not follow that pattern and its similar between H and non-Hispanic Whites (NHW). Methods', ' To identify EGFR and other MM (ALK, RET, ROS-1, KRAS, c-Met and BRAF), next generation sequencing (NGS) and FISH were done in tumors of pts with NSCLC at Memorial Cancer Institute and Lynn Cancer Center in Florida. All MM were not available for all pts. Pts were divided by ethnicity. Chi-square and Fishers Exact tests were used to assess associations between GEP and ethnicity. All summary statistics on time-to-event variables were calculated according to the Kaplan-Meier method and were compared by means of the log-rank test. Adjusted hazard ratios and 95% confidence intervals were reported based on the results of a multivariate Cox regression model for overall survival. Results', ' MM were requested for 492 pts and tumor samples were sufficient in 436 (88%). Of these pts', ' 25% were H, 61% women, 34% non-smokers and 93% had adenocarcinomas. EGFR were seen in 22% of the tumors [76 % in exons 19&21 and 13% in exons 18&20]. There was an increase in exon 19 in H vs. NHW (82% vs. 45% of good EGFRs) (p < 0.05). ALK 5%, RET 4%, ROS-1 8%, c-MET 31%, KRAS 30%, and BRAF 5%. There was no significant association between H vs. NHW with any MM. There were no differences in survival between H and NHW as well as differences in survival between H and NHW for any MM. Conclusions', ' The incidence of MM in H living in the US is lower than the one reported in LATAM and its similar to the NHW. There are no differences between H and NHW leaving in the US in the frequencies of MM presentations and survival. In our pts, EGFR exon 19 is more common in H than NHW. EGFR&ROS-1 frequency in NHW is higher than the US average. Molecular MarkerFrequency% in HISpts% in NHWpts# Tumors testedEGFR22%25%21%380ALK5%4.6%5.2%339ROS-18%3%9%180KRAS30%27%31%258c-MET31%27%32%165BRAF5%9.5%3.5%156RET4%0%6%122']",
        "Doc_id":"ASCO_163918-176",
        "Doc_title":" Are the gene expression profiles of Hispanic patients with lung cancer living in the US different from Hispanics living abroad?",
        "_version_":1606188975584706561},
      {
        "Meeting_name":" Met heterogeneity evaluation by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in nonsquamous non-small cell lung cancer (nsNSCLC).",
        "Background":"['Background', '  Molecular selection of patients who may benefit from Met inhibitors is being based on immunohistochemistry (IHC) with no consensus in the field. We sought to evaluate the association between MET gene copy number (GCN) and protein expression in NSCLC samples. Moreover, we wanted to analyze the heterogeneity within the same tumor specimen and its implications in Met evaluation.  Methods', '  First, surgical cases from patients with nsNSCLC were included in a tissue microarray (TMA) representing 2 distinct morphologic areas of the tumor (2 consecutive sections). Second, biopsies from newly diagnosed patients were analyzed. Met expression was assessed by IHC (Ventana) using H-scores and MetMAb criteria and MET GCN by FISH (MET and CEP7 probes from Vysis). Association between GCN and protein expression and their correlation with clinico-pathologic and molecular information (KRAS, EGFR) was investigated. Additionally, heterogeneity of METGCN and protein expression within different tumor cores and within consecutive sections was assessed.  Results', '  One hundred and twenty-seven samples (120 patients) were analyzed. Ninety percent were adenocarcinomas, 35% grade 3, 19% KRAS and 11% EGFR mutant.  Median age was 66 years, 70% males, and 53% current smokers. Median Met H-score was 140 and according to MetMAb criteria, 48% were Met high. High Met expression was associated with advanced stage (p=0.001). No association was observed with KRAS/EGFR mutations. MET amplification was observed in 8 cases (6.3%). No association was observed between MET GCN and protein expression. Met IHC score was high (H-score 400) in amplified cases with MET/CEP7 ratio >2, but not in those with MET GCN>5.  For Met IHC, intraclass correlation coefficient (ICC) was 0.8 between consecutive tumor sections and 0.4 between different tumor cores. For METFISH, ICC was 0.5 and 0.7, respectively. For amplified cases, 4 out of 12 cores were negative by FISH.  Conclusions', '  The definition of Met positivity in the clinical setting is challenging, due to tumor heterogeneity. Met IHC does not accurately identify Met driven tumors. More precise criteria are needed for defining Met dependence.']",
        "Doc_id":"ASCO_131121-144",
        "Doc_title":" Met heterogeneity evaluation by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in nonsquamous non-small cell lung cancer (nsNSCLC).",
        "_version_":1606188999691468800},
      {
        "Meeting_name":" Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib.",
        "Background":"['Background', '  Progression-free survival (PFS) in EGFR-mutant NSCLC p treated with erlotinib is unpredictable at the individual level. The initial presence of double mutations (EGFR L858R or del 19 plus T790M) is associated with shorter PFS. We hypothesized that the site of mets and/or prior chemotherapy could also influence outcome in these p with double EGFR mutations.  Methods', '  The T790M mutation was assessed in 129 advanced NSCLC p by TaqMan assay in the presence of a peptide-nucleic acid designed to inhibit the amplification of the wild-type allele.  Results', '  De novo T790M mutations were identified in 35% (45 of 129) of EGFR-mutant p before receiving erlotinib. PFS was 12 months (m) for p with double mutations and 18 for p with only L858R or del 19 (P=0.02). The T790M mutation was detected more frequently in p with bone mets (35.6% vs 16.7%; P=0.03). No effect on PFS or MS was observed in p with the T790M mutation according to bone, lung, liver or pleura mets. However, when p with T790M were divided according to the presence of brain mets, PFS was 1 m for 4 p with brain mets vs 13 m for 41 p without brain mets (P=0.002), and MS was 6 m for p with brain mets vs 36 m for those without (P=0.009). Overall, in the multivariate analysis, the presence of the double mutation did not affect the risk of shorter MS (HR, 1.3; P=0.49), but p who had received prior chemotherapy had significantly longer MS (HR, 0.48; P=0.02).  Conclusions', '  The initial double EGFR mutation (EGFR L858R or del 19 plus T790M) is a marker for poor prognosis in p with brain mets. In addition, initial chemotherapy can play a role in the management of NSCLC p with the double EGFR mutation.']",
        "Doc_id":"ASCO_76629-102",
        "Doc_title":" Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib.",
        "_version_":1606188980395573248},
      {
        "Meeting_name":" Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma",
        "Background":"['MET, which is located in 7q31, is a receptor tyrosine kinase for hepatocyte growth factor. Overexpression of MET has been reported in various malignancies and is associated with cell proliferation, inhibition of apoptosis, and metastasis. MET amplification has been reported to contribute to acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer(NSCLC), being observed among 5-10% of those patients. Therefore, MET gene alterations could be both prognostic and predictive. To evaluate MET gene copy number, fluorescence in situ hybridization (FISH), real-time PCR, and comparative genomic hybridization (CGH) have been used. The results of real-time PCR do not directly reflect cancer cells. CGH is not suitable for the evaluation of a large number of specimens due to cost. Therefore, FISH is the most practical method for evaluation of MET gene copy number. However, the frequency of positive cases varies due to a lack of standardized criteria. We evaluated MET gene copy number in lung adenocarcinoma and its association with clinicopathological characteristics. FISH was applied to evaluate high MET gene copy number and true amplification in 138 lung adenocarcinoma patients using two criteria', ' the Cappuzzo scoring system and PathVysion. MET positive cases according to the Cappuzzo scoring system evidenced both aneuploidy and true amplification, whereas PathVysion revealed only amplification. Proportion of MET FISH positive cases was 15% and 4% determined by the Cappuzzo system and PathVysion, respectively. PathVysion demonstrated higher frequencies of MET FISH positives among men and smokers and evidenced no MET FISH positives in patients with bronchioloalveolar carcinoma, which is recognized as pure lepidic growth without invasion of stroma, blood vessels, or pleura. Prognosis was significantly associated with MET FISH positive only as defined by the PathVysion system (gene amplification), not by the Cappuzzo system. However, progression-free survival time of patients with both EGFR mutations and MET FISH positive defined by the Cappuzzo scoring system was significantly shorter than with EGFR mutations alone. These results suggest that MET FISH is a potential prognostic factor and co-existence of EGFR mutation and MET FISH positive status evidences poorer prognosis compared to EGFR mutation alone, which is consistent with the results of in vitro experiments.']",
        "Doc_id":"AACR_2012-1737",
        "Doc_title":" Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma",
        "_version_":1606189009146478593},
      {
        "Meeting_name":" In vivo acquired resistance to an emibetuzumab analogue in MET-amplified gastric xenografts can be overcome by a MET-targeting antibody mixture or PIK3CA/AKT/mTOR inhibition.",
        "Background":"['Aberrant over-activation of MET receptor tyrosine kinase is involved in driving malignancies such as gastric and non-small cell lung cancer (NSCLC), and in the development of resistance to EGFR-targeting therapeutics. This has led to the development of several MET-targeting agents in the form of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), many of which are in clinical development. However, resistance to MET-targeted agents is an emerging problem. This study aims to understand mechanisms underlying resistance development to an analogue of emibetuzumab, a mAb targeting MET. Upon long term in vivo treatment, emibetuzumab-resistant tumors and cell lines were generated, isolated, and characterized to investigate their acquired resistance mechanisms. Extensive reverse phase protein array and network analysis were used to characterize the proteomic profiles of three resistant cell lines, revealing three distinct resistance profiles, one involving activation of the PI3Kinase/AKT/mTOR pathway. We further show, how these resistance mechanisms can be overcome by treatment with other targeting therapeutics both in vitro and in vivo. Two of the models demonstrated in vivo sensitivity to Sym015, a novel mixture of two mAbs targeting non-overlapping epitopes of MET, partly due to ADCC, indicating that Sym015 can overcome acquired resistance to emibetuzumab. The third model demonstrated a marked increase in PI3Kinase/AKT/mTOR pathway activation. This activation translated into induced cancer cell and tumor growth, which could be inhibited by agents targeting PI3Kinase, AKT, or mTOR. This study thus points to treatment of patients with acquired resistance to single targeting MET mAbs with PI3Kinase/AKT/mTOR-targeting agents or a MET-targeting antibody mixture such as Sym015.']",
        "Doc_id":"AACR_2017-3158",
        "Doc_title":" In vivo acquired resistance to an emibetuzumab analogue in MET-amplified gastric xenografts can be overcome by a MET-targeting antibody mixture or PIK3CA/AKT/mTOR inhibition.",
        "_version_":1606189033380118528},
      {
        "Meeting_name":" A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib.",
        "Background":"['Background', ' MET expression is a mechanism of resistance to EGFR inhibition in EGFRmt NSCLC and correlated with poor prognosis. Emi (LY2875358) is a humanized IgG4 monoclonal bivalent MET antibody that blocks ligand dependent and independent HGF/MET signaling. This Phase 2 study compared the clinical activity of Emi + E versus single agent E in 1st line EGFRmt metastatic NSCLC. Methods', ' Stage IV, EGFRmt NSCLC pts with disease control following an 8-week lead-in E (150 mg PO QD) treatment were randomized 1', '1 to receive Emi (750 mg IV Q2W) + E or E alone. Pts were stratified by ECOG PS, ethnicity, MET expression status, and response at the end of the lead-in. The primary endpoint was PFS from randomization. Additional endpoints included safety, OS, PK, and exploratory analysis of MET-expressing populations. Results', ' Out of181 pts enrolled, 141 pts were randomized (Emi+E', ' 71; E', ' 70). In the ITT population, median PFS for EMI+E was 9.3 months (m) compared with 9.5 m for E (HR = 0.89', ' 90% CI 0.64-1.23; p = 0.534). Exploratory analysis of MET-high expressing pts (MET 3+ expression in 90% of tumor cells; n = 24 pts) showed a 15.3 m improvement in PFS (EMI+E', ' 20.7 m; E', ' 5.4 m [HR', ' 0.39; 90% CI', ' 0.17-0.91]). No difference in PFS was observed in the complementary population (HR', ' 1.1 [90% CI', ' 0.7-1.7]). Similar frequencies of related AEs were reported for both treatment arms. Drug-related TEAEs that were more frequent ( > 10%) for Emi+E were peripheral edema and fatigue (all grade 1 or 2). Emi serum concentrations were consistent with previously obtained PK results, and no apparent exposure-response was observed. Median OS in the ITT population was not achieved (NA) for either arm. In MET-high expressing pts, median OS was 20.6 m for E (90% CI', ' 8.87, NA) whereas it was not achieved for Emi+E (90% CI', ' NA, NA). Conclusions', ' No statistically significant difference in PFS was noted in the ITT population.Exploratory analysis confirmed that high MET expression is a negative prognostic marker for pts treated with E and indicated that these pts may receive clinically meaningful benefit from Emi+E. Clinical trial information', ' NCT01897480']",
        "Doc_id":"ASCO_191468-199",
        "Doc_title":" A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib.",
        "_version_":1606189029744705536},
      {
        "Meeting_name":" Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Survival with EGFR/ALK+ve NSCLC can be prolonged with tyrosine kinase inhibitors (TKIs), but brain metastases (mets) are common. TKIs may control brain mets poorly, and radiation may have neurocognitive toxicity. Deteriorating performance status (PS) due to brain mets may affect the number of lines of treatment. We aimed to evaluate the impact of brain mets on lines of systemic therapy and overall survival (OS). Methods', ' This retrospective analysis included patients with EGFR/ALK+ve NSCLC treated at Princess Margaret Cancer Centre from 1998-2015. 2 groups were analyzed', ' those with brain mets at diagnosis of stage IV disease or on 1st line therapy, and those without brain mets. OS was calculated from date of metastatic disease using Kaplan-Meier method, and differences between groups were tested with the log-rank test. Results', ' 291 patients were included', ' 141 with and 150 without brain mets. Summary results are shown in the Table. 106/141 had brain mets at diagnosis of stage IV NSCLC. There were more patients with relapsed early stage NSCLC in the no brain mets group (29% vs 19%), and more smokers in the brain mets group (18% vs 7%). 1st treatment for brain mets included WBRT (84), SRS (32) and TKI alone (24). 1st line systemic therapy was TKI in 83% of brain mets group and 61% of no brain mets group. Median OS was longer in the no brain mets group', ' 4 vs 2.1 years, HR 1.55, p=0.013. There was no observed difference in number of treatment lines', ' median 1 in both groups, p=0.53. Conclusions', ' Patients with brain mets from EGFR/ALK+ve NSCLC have inferior OS, despite TKIs and similar exposure to systemic therapy. Further focus on this group is necessary to improve outcomes. No Brain metsN=150Brain metsN=141PAgeMedian(Range)61.9(27.6-82.9)59.8(29.2-86.3)0.35Female98(65%)96(68%)0.71Smoking HistoryNo139(93%)115(82%)0.005Yes11(7%)26(18%)EthnicityAsian72(48%)63(45%)0.85Caucasian55(37%)56(40%)Other23(15%)22(15%)ECOG PS0-1141(94%)133(94%)0.722-39(6%)8(6%)Stage IV at First Dx106(71%)114(81%)0.056MutationALK21(14%)14(10%)0.37EGFR129(86%)127(90%)Lines of treatmentMedian(range)1(0-9)1(0-4)0.53Median SurvivalYears4.02.10.011HR1.55 (95%CI 1.1-2.2)']",
        "Doc_id":"ASCO_163258-176",
        "Doc_title":" Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).",
        "_version_":1606189003900452864},
      {
        "Meeting_name":" Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers",
        "Background":"['Background', ' Epidermal growth factor receptor (EGFR) is a transmembrane protein consisting of an extracellular ligand-binding domain, and its activation leads to a multitude of effects including cell proliferation, cell differentiation, angiogenesis, metastasis, and antiapoptosis. EGFR can be a partner of heterodimer of other EGFR family such as HER2 and HER3. EGFR is often overexpressed in non-small cell lung cancer (NSCLC). Anti-EGFR agents including EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have considered to be effective for NSCLC when drug sensitive EGFR mutation is present. However, inherent and acquired resistances are major problems of EGFR targeting therapies. In this study, we knock-downed EGFR using small interfering RNAs (siRNAs) in NSCLC cell lines to examine the significance of targeting EGFR for NSCLC therapy. Materials and methods', ' We treated 14 NSCLC cell lines including nine EGFR mutant and five EGFR wild-type cell lines by geftinib or siRNAs for EGFR knock-down (siR-EGFR). Three cell line, PC-9-GR-N1, RPC-9, and HCC827-Met, were experimentally established as acquired resistant cells to gefitinib. The anti-tumor effect was determined by MTS or colony formation assay. The protein expression was evaluated using Western blotting. Results', ' All cell lines showed the expression of EGFR protein and siR-EGFR treatment down-regulated EGFR protein in all 14 cell lines. siR-EGFR suppressed cell viability in 7 of 9 EGFR mutant cells ranged from 8.0% to 73%. PC-9-GR-N1 and RPC-9 also showed inhibition. NCI-H1670 and HCC827-Met harboured EGFR mutation but were not inhibited. Of note, PTEN was deleted in NCI-H1670 and c-MET was amplified in HCC827-Met. Cell viability of all EGFR wild-type cells was not inhibited except NCI-H411. Conclusion', ' Our results indicated that EGFR can be the therapeutic target of NSCLC with EGFR activation. By contrast, targeting EGFR is not appropriate strategy for tumor of which EGFR is not activated even though EGFR is expressed.']",
        "Doc_id":"AACR_2012-7",
        "Doc_title":" Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers",
        "_version_":1606189004761333760},
      {
        "Meeting_name":" In vivo acquired resistance to the mutant EGFR inhibitor Rociletinib (CO-1686) is associated with activation of the c-MET pathway",
        "Background":"['Rociletinib is a novel, oral, targeted irreversible inhibitor of the cancer-causing mutant forms of EGFR currently being studied for the treatment of NSCLC. Rociletinib was designed to spare wild-type EGFR signaling. Heavily-pretreated T790M+ patients treated with rociletinib at 500 or 625mg BID demonstrated a 67% objective response rate (n = 56, Soria et al., ENA 2014). Despite these promising data, acquired resistance to rociletinib monotherapy is anticipated. To assess the in vivo mechanisms of acquired resistance to rociletinib, mice bearing PC-9 (EGFR del19) human NSCLC tumors were chronically dosed with erlotinib (50 mg/kg QD) or rociletinib (150 mg/kg BID). Rociletinib treated mice had an increased time to tumor progression as compared to erlotinib treated mice. Resistance, as defined by tumors reaching >300mm3, was observed in all (n = 10) erlotinib treated mice between days 42-61. Alternatively, resistance to rociletinib was only observed in 3/10 mice after 126 days of dosing. Emergence of the EGFR T790M resistance mutation was detected in all tumors resistant to erlotinib. Erlotinib resistant tumors (n = 7) were crossed over to rociletinib monotherapy on day 60 of the study at a mean tumor volume of 500mm3. Rociletinib treatment generated durable tumor regressions in both crossover and monotherapy treated mice, however continued dosing of rociletinib ultimately allowed for the collection of four resistant tumors. Rociletinib resistant tumors were analyzed using the SuraSeq 500 NGS panel, and all harbored copy number gains (n = 12-15) in MET and corresponding MET pathway activation as shown by RTK arrays and Western blotting. Combining rociletinib with the MET inhibitor crizotinib caused regression of the MET amplified rociletinib-resistant tumors. In separate experiments, the addition of 50 ng/ml exogenous HGF was sufficient to render several mutant EGFR cell lines immediately resistant to rociletinib, and this effect could be overcome with the combination of rociletinib and crizotinib. Finally, the combination of rociletinib and crizotinib also demonstrated potent activity in a patient derived L858R EGFR xenograft model with MET amplification (14 copies). Taken together, these data show that (1) in a PC-9 front-line model of mutant EGFR lung cancer, rociletinib has a longer time-to-resistance than erlotinib; and (2) MET/HGF pathway activation is a likely driver of acquired resistance to rociletinib in patients with mutant EGFR lung cancer, and can potentially be successfully prevented and/or treated with a combination of rociletinib plus a MET tyrosine kinase inhibitor.']",
        "Doc_id":"AACR_2015-3595",
        "Doc_title":" In vivo acquired resistance to the mutant EGFR inhibitor Rociletinib (CO-1686) is associated with activation of the c-MET pathway",
        "_version_":1606189001692151808},
      {
        "Meeting_name":" Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.",
        "Background":"['Background', ' MGCD265 targets wild type Met, as well as clinically relevant Met mutants, VEGFR-1,-2 and -3, Ron and Tie-2. MGCD265 combinability with docetaxel has been evaluated in patients (pts) with advanced malignancies. Methods', ' In the first portion of this phase I/II study, the primary objective was to determine the safety profile of the combination including the MTD and the dose liming toxicities (DLTs). Secondary objectives include anti-tumor activity, pharmacodynamics (PD) and pharmacokinetics (PK). Incremental MGCD265 dose increases of 50% occurred in cohorts of 3-4 pts in the absence of a DLT. If a DLT was observed during the first cycle of treatment, a minimum of 6 safety evaluable pts were enrolled at that dose level.  Daily (QD) and twice daily (BID) dosing of MGCD265 were evaluated. Docetaxel was administered intravenously on Day 1 of each 21-day cycle. Results', ' Pt characteristics (n=23)', ' gender', ' 13 M/10 F; median age', ' 69 (range 52-78) years; ECOG 0/1', ' 12/11.  The MTD was determined to be MGCD265 72 mg/m2 BID + docetaxel 75 mg/m2.  The observed DLTs were grade 3 diarrhea (n=1), grade 3 fatigue (n=1) and grade 3 lipase elevation (n=2).  Grade 2 and above treatment-related adverse events in  3 pts include anorexia, diarrhea, fatigue and neutropenia.  Eight pts with NSCLC have been recruited', ' 2 pts experienced a partial response (one pt for ~ 8 cycles and one pt after 2 cycles and continuing) and 3 pts experienced prolonged disease stabilization (12, 14 and 18 cycles).  Four of these 5 pts had previous taxane therapy for their NSCLC.   The available archived tumor biopsy from 3 of these pts showed Met and phospho-Met protein expression. At Cycle 1 Day 8, a decrease in plasma levels of HGF and an increase in plasma levels of VEGF were noted.  Preliminary PK data with MGCD265 in QD dosing indicated no drug-drug interaction and MGCD265 steady state plasma concentrations were multiples above the IC50 for Met and VEGFR2. Conclusions', ' MGCD265 can be safely combined with docetaxel with early signs of clinical activity. The MTD was determined to be MGCD265 72 mg/m2 BID + docetaxel 75 mg/m2.  This combination merits additional testing in second-line NSCLC patients.']",
        "Doc_id":"ASCO_81647-102",
        "Doc_title":" Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.",
        "_version_":1606188997555519488},
      {
        "Meeting_name":" Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.",
        "Background":"['Background', ' Specific EGFR tyrosine Kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. Somatic activating mutations of EGFR gene and some clinical and pathological features have been associated with tumor response and favourable clinical outcome with these agents. However, tumor that initially respond to EGFR-TKIs almost inevitably become resistant later. We present a comprehensive analysis of MET, EGFR, KRAS and PIK3CA mutations in advanced NSCLC patients treated with TKIs, with the aim of clarifying the relative contribution of these molecular alterations to resistance. Methods', ' Genomic DNA was isolated from paraffin-embedded tumor specimens, amplified for MET (exons 14, 15), EGFR (exons 18, 19, 20 and 21), PIK3CA (exons 9, 20) KRAS (exons 2, 3) by nested PCR and sequenced in both sense and antisense directions. Among all the mutations evaluated, only TKIs no-sensitive mutations were used for time to progression (TTP) and overall survival (OS) analysis. Results', ' Median age was 60.2 yrs (range 25.6-84), M/F', ' 91/75; adeno/bac/other', ' 102/17/47; never/former/current/unknown smokers', \"61/47/46/12. One hundred sixty-six patients (pts) have been treated with TKIs. MET, sensitive EGFR (exons 19 and 21), no-sensitive EGFR (exons 18 and 20), KRAS and PIK3CA mutations were detected in 3.8%, 19.4%, 3.0%, 6.8% and in 4.1% of pts, respectively. Patients with TKIs no-sensitive mutations showed a progression (96%, p = 0.0018). Median TTP of pts with TKIs no-sensitive mutations was 2.23 months vs 6.63 months (p < 0.0001) of other group. At univariate analysis of OS TKIs no-sensitive mutations were associated with worse prognosis (16.1 months vs 30.2 months, p = 0.02). Cox's multivariate analysis including histology and stage showed that TKIs no-sensitive mutations were independent factors to predict poor OS (p = 0.02). Conclusions\", ' When TKIs no-sensitive MET, KRAS, PIK3CA and EGFR mutations are concomitant, up to 96% of NSCLC patients unlikely to respond to anti-EGFR therapies, can be identified. Comprehensive molecular dissection of EGFR signalling pathways should be considered to select advanced NSCLC patients for TKIs therapies.']",
        "Doc_id":"ASCO_49871-74",
        "Doc_title":" Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.",
        "_version_":1606188988722315265},
      {
        "Meeting_name":" First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.",
        "Background":"['Background', '  Activation of the hepatocyte growth factor (HGF)/MET receptor pathway promotes tumor growth, invasion and dissemination. LY is a humanized IgG4 monoclonal bivalent antibody against MET which inhibits ligand dependent- and ligand independent activation of MET. Based on preclinical results, we examined LY alone in patients with advanced solid tumors and LY+E in advanced NSCLC patients.   Methods', '  LY monotherapy was administered 20-2,000 mg Q2W IV to 23 patients with advanced solid tumors.  Combination therapy with 700-2,000 mg Q2W IV of LY and E (150 mg QD) was completed in 14 patients with advanced NSCLC.  The primary objective was to determine a recommended phase II dose (RPTD) for LY and LY+E. Secondary objectives included assessment of toxicity, PK, PD (including MET extracelluar domain and HGF), and antitumor activity.   Results', '  LY and LY+E were well tolerated. No dose-limiting toxicities, serious adverse events, or  Grade 3 adverse events (AEs) possibly related to LY have been observed.  The most frequent (5% of patients) AEs possibly related to LY2875358 monotherapy were nausea (8.7 %), vomiting (8.7%), and diarrhea (8.7%). The most frequent (10% of patient) grade 1 or 2 adverse event possibly related to LY2875358 in patients treated with LY+E were fatigue (21.4%) and anorexia (14.3%). Durable PR according to RECIST were observed for LY (n=1) and LY+E (n=2 out of 13 evaluable patients; both PR patients positive for MET protein expression).  Conclusions', '  LY appears to be safe when administered as single agent and in combination with E up to 2,000 mg Q2W IV. The RPTD of LY is 750 mg Q2W IV for monotherapy and in combination with E based on PK/PD data. Clinical trial information', ' NTC 01287546.']",
        "Doc_id":"ASCO_115545-132",
        "Doc_title":" First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.",
        "_version_":1606188994633138176},
      {
        "Meeting_name":" Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations.",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (EGFRmu) responds favorably to the EGFR tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib. However, 25-30% of patients with EGFRmu show intrinsic resistance, and the responders invariably acquire resistance to EGFR-TKIs. Here, we examined the role of hepatocyte growth factor (HGF), a specific ligand of MET, in gefitinib resistance of NSCLC with EGFRmu. Methods', ' NSCLC cells, PC-9 and HCC827, with EGFRmu, but not T790M second mutation in EGFR or MET amplification, were used in this study. Sensitivity to gefitinib was determined by MTT assay. Phosphorylation of MET, EGFR, ERBB3, and the PI3K/Akt pathway were examined by Western blotting. HGF expression in 20 tumors from 16 NSCLC patients with EGFRmu who were treated with gefitinib was determined by immunohistochemistry. Results', ' HGF induced resistance to gefitinib by restoring Akt phosphorylation independently of ErbB3. Specific down-regulation of MET, but not ErbB3, reversed gefitinib resistance and Akt phosphorylation induced by HGF. Importantly, high levels of immunoreactivity for HGF were detected in cancer cells of 3 of 3 intrinsic resistant tumors and in one of 2 tumors with acquired resistance without T790M second mutation or MET amplification. Conclusions', ' The findings indicate that HGF-mediated MET activation is a novel mechanism of intrinsic and acquired gefitinib-resistance in NSCLC with EGFRmu. Therefore, inhibition of HGF-MET signaling may be considerable strategy for more successful treatment with EGFR-TKIs.']",
        "Doc_id":"ASCO_32524-65",
        "Doc_title":" Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations.",
        "_version_":1606189040741122048},
      {
        "Meeting_name":" Amethyst NSCLC trial",
        "Background":"['Background', ' MGCD265 is an oral, potent, small molecule RTK inhibitor of MET and Axl, which are important for mediating signals for cell growth, survival, and migration. MET mutations and/or gene amplification have been reported in approximately 7% of NSCLC and function as oncogenic drivers that promote cancer development and progression. MET splice site mutations that result in the deletion of exon 14 (METex14del) represent a novel class of genetic alterations that have been implicated as oncogenic drivers in a subset of NSCLC. METex14del contains the Y1003 CBL ubiquitin ligase regulatory binding site that mediates CBL-dependent MET degradation and signal attenuation. Deletion of this region results in sustained activation of MET and its downstream signaling pathways. MGCD265 has demonstrated anti-tumor efficacy with robust tumor regression in xenograft models of METex14del and MET amplification. Additionally, confirmed partial responses have been observed in pts with MET-altered NSCLC treated with MGCD265 in the Phase 1 setting. Methods', ' This global Phase 2 trial is enrolling pts with NSCLC characterized by activating genetic MET alterations in tumor tissue or blood and who have received at least one prior platinum-containing regimen for advanced disease. Pts will be enrolled to one of four study arms based on the type of MET dysregulation', ' 1) mutations in tissue, 2) amplification in tissue, 3) mutations in blood, and 4) amplification in blood. The primary endpoint is Objective Response Rate (ORR) in accordance with RECIST 1.1; a Bayesian Predictive Probability Design is applied independently to each treatment arm. Secondary objectives are safety and tolerability, response duration, survival, correlations between tissue and blood testing, and PK/PD. Pts are treated with MGCD265 in 21-day cycles until RECIST-defined progression or unacceptable toxicity. The study is open for enrollment and recruitment is ongoing. Clinical trial information', ' NCT02544633']",
        "Doc_id":"ASCO_170636-176",
        "Doc_title":" Amethyst NSCLC trial",
        "_version_":1606189034214785024},
      {
        "Meeting_name":" A NSCLC PDX with EML4-ALK fusion mutation responds to crizotinib.",
        "Background":"['Non-small cell lung cancer (NSCLC) has the highest mortality among all malignances while with limited treatment options. Among the most significant treatment advancement in recent years are the introduction of target therapies of EGFR-TKIs (Erlotinib and Gefitinib) for adenocarcinoma with EGFR activating mutations, and Crizotinib for NSCLC with ALK activation (EML4-ALK fusion)1. ALK activation are associated with a subset of NSCLC patients (35%).Crizotinib is considered not a particularly potent ALK inhibitor, with IC50 at range of tens of nanomoles. It may not be an ideal agent for treating NSCLC with activating ALK. Therefore, a new ALK inhibitor with better potency and specificity could be of particularly medical importance. Currently, the industry is actively searching for such new agents. A relevant experimental model could also greatly facilitate evaluating and validating these new drug candidates.Patient derived xenografts (PDX) (including NSCLC PDX) mirror patients histopathology and genetic profiles2, thus known as patient avatar. It has improved predictive power as preclinical cancer models, and enables discovery of predictive biomarkers for targeted therapeutics. We have established a large collection of NSCLC PDX models (NSCLC-HuPrime) by engrafting nave patient tumor tissues into immune-compromised mice2.Among these models, we have identified one model, LU1656, of NSCL carcinosarcoma histology and with EML4-ALK fusion mutation. This mutation apparently causes over-expression of ALK as measured at mRNA level. This model has wild-type KRAS, c-MET and EGFR genes. Treatment of LU1656 with Crizotinib caused significant but not complete tumor response, suggesting ALK activation is one of the oncogenic drivers of this model. In addition, LU1656 also responded to Cetuximab, but respond poorly to Erlotinib. It would be interesting to examine the combination of these treatments. This model is, to our knowledge, the first reported PDX model with EML4-ALK fusion mutation. We believe that LU1656 would be a useful model to evaluate investigational ALK inhibitors, and new combination treatment regimens of Crizotinib and standard of care chemotherapies.']",
        "Doc_id":"AACR_2013-337",
        "Doc_title":" A NSCLC PDX with EML4-ALK fusion mutation responds to crizotinib.",
        "_version_":1606188999613874176},
      {
        "Meeting_name":" Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.",
        "Background":"['Background', ' Therapeutics used to treat patients with NSCLC include cytotoxic agents such as taxanes, and targeted agents such as EGFR inhibitors. Although these treatments provide some clinical benefit, there is a need for improved therapies in advanced NSCLC. MGCD265 targets Met, VEGFR1/2/3, Tie-2 and Ron. Met is overexpressed and phosphorylated in NSCLC, and Met activation is identified as a molecular mechanism through which tumors evade specific inhibition of EGFR. In support of the clinical development of MGCD265, the studies described here provide a rationale for combining MGCD265 with a taxane or an EGFR inhibitor. Methods', ' The in vivo anti-tumor activity of MGCD265 (10 or 20mg/kg orally, daily) in combination with either docetaxel (5 or 10mg/kg, iv weekly), paclitaxel (30mg/kg iv, on days 0, 1, 13, 14),or an EGFR inhibitor, erlotinib (25 or 50 mg/kg orally, daily), was analyzed in multiple xenograft models including NSCLC models. The anti-angiogenic activity of MGCD265 with docetaxel was evaluated by immunohistochemistry following CD31 labeling of tumor sections from treated animals. Results', ' We demonstrate that the combination of MGCD265 with docetaxel or paclitaxel achieves greater anti-tumor responses than treating with either agent alone and this occurs in the absence of overt toxicity. The combination of MGCD265 with docetaxel also results in greater reduction of tumor vasculature. Good anti-tumor activity in the absence of overt toxicity is also demonstrated when MGCD265 is combined with erlotinib in NSCLC xenografts including a model that expresses an EGFR mutant resistant to erlotinib (T790M). PK analyses demonstrate that the combination of MGCD265 with either docetaxel, paclitaxel or erlotinib does not result in drug-drug interactions. Conclusions', ' The combination of MGCD265 with either a taxane or erlotinib results in improved antitumor activities when compared to treatments with either agent alone. In addition, these combinations are well tolerated and do not show drug-drug interactions. These preclinical studies support the clinical development of MGCD265 in combination with docetaxel or erlotinib in patients with NSCLC.']",
        "Doc_id":"ASCO_44232-74",
        "Doc_title":" Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.",
        "_version_":1606189003003920384},
      {
        "Meeting_name":" P53 is potential predictive biomarker for combination therapy of epidermal growth factor receptor (EGFR) and MET inhibitors in non-small cell lung cancer (NSCLC) with wild-type EGFR",
        "Background":"['Receptor tyrosine kinase (RTK) systems, such as hepatocyte growth factor (HGF) and its receptor MET and epidermal growth factor (EGF) and its receptor EGFR, are known to be expressed in non-small cell lung cancer (NSCLC) and play an important role in the progression of NSCLC. Recent research shows that co-inhibition of MET and EGFR signaling results in more robust antitumor activity, relative to either alone, although the mechanisms of this synergism are not clear. P53, a tumor suppressor gene, is a potent regulator of apoptosis which is induced by DNA damage. The dysregulation of p53 protein is related to both oncogenesis and drug resistance. The purpose of this study was to investigate the mechanisms of synergistic antitumor effects of an EGFR inhibitor (gefitinib) and two different MET inhibitors (SU11274 and tivantinib [ARQ 197]) and to potentially define the role of P53 function as a predictive biomarker for the observed synergy. P53 wild-type (A549 and H460) cells and P53 null-type (H358 and H1299) cells without met gene amplification or EGFR mutation were used. Combined gefitinib and SU11274 or tivantinib induced profound growth inhibitory effects and apoptosis in cell lines harboring wild-type P53, but not in cells harboring null P53. SU11274 or tivantinib appeared to abrogate the P53/Mdm2 interaction, concomitantly reducing P53-ubiquitination followed by protein stabilization. Treatment with gefitinib resulted in the translocation of P53 from cytosol to nucleus. In P53 wild-type cells, the combination treatment of SU11274 or ARQ197 with gefitinib induced more robust apoptosis than single agent treatment, presumably through up-regulation of p53 target genes (FAS, Bax and PUMA). Furthermore, inhibition of P53 expression in A549 cells using siRNA significantly reduced apoptosis and downregulated mRNA and protein expression of FAS, PUMA and Bax upon combined treatment with gefitinib and SU11274. Overexpression of wild-type P53 in H1299 cells enhanced growth inhibition and apoptosis by combined gefitinib and SU11274 treatment through up-regulation of FAS, PUMA and Bax and restoration of caspase activation. In an A549 xenograft model, the combination of gefitinib and SU11274 (or tivantinib) effectively shrunk tumor volume and also induced apoptosis more effectively than either treatment alone. In conclusion, P53 plays an essential role in determining synergistic efficacy of combination therapy with pharmacological EGFR and MET inhibition in NSCLC with wild type EGFR. The validation of the predictive value of P53 mutation is warranted in appropriate ongoing clinical trials of combination therapy in advanced NSCLC patients with wild-type EGFR.']",
        "Doc_id":"AACR_2012-2476",
        "Doc_title":" P53 is potential predictive biomarker for combination therapy of epidermal growth factor receptor (EGFR) and MET inhibitors in non-small cell lung cancer (NSCLC) with wild-type EGFR",
        "_version_":1606189040351051776},
      {
        "Meeting_name":" Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR.",
        "Background":"['Background', ' Aberrant activity of the MET, FGFR1 and AXL receptors has been associated with the development of resistance to first, second and third generation EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC) patients.']",
        "Doc_id":"AACR_2017-3077",
        "Doc_title":" Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR.",
        "_version_":1606189005223755776},
      {
        "Meeting_name":" Interim analysis of CALGB 150607",
        "Background":"['Background', ' MET is a receptor tyrosine kinase that has been shown to be dysregulated in a number of malignancies, including non-small cell lung cancer (NSCLC). In patients with NSCLC, alterations in MET, and its ligand, HGF, have been associated with higher pathological stage and worse outcome in a number of smaller studies. The primary objective of this study is to determine the correlation between MET expression with stage and overall survival in adenocarcinoma (AC) patients in a large series of patients. The secondary objectives are 1) to determine the correlation with MET mutations, epithelial mesenchymal transition (EMT), EGFR mutations and expression, KRAS mutations, and P53 mutations and expression with respect to survival; and 2) to determine the impact of MET amplification on prognosis. Methods', ' MET, EGFR exons 18-21, P53 exons 4-10, and KRAS exon 2 were sequenced using standard PCR and sequencing techniques. Standard immunohistochemistry (IHC) techniques were used to evaluate total MET, phosphorhylated (p)MET (Y1003 and Y1230/34/35), P53, HGF, EGFR and E-cadherin expression. Quantitative PCR was used to determine MET gene copy number. A total of 280 patients will be included in this study, and an interim analysis will be presented here. Results', ' Immunohistochemical data is available for 20 patients. High expression of total MET was seen in 95% of patients, high Y1003 MET expression was seen in 80% of patients, high Y1230/34/35 MET expression was seen in 55% of patients. Six out of 40 patients have been found to carry a mutation in the MET gene; three of these represent novel mutations in the semaphorin and juxtamembrane domains that have not been previously reported in the literature. MET amplification data will be forthcoming. Conclusions', ' Both MET and pMET are highly expressed in resected lung adenocarcinoma specimens. Novel MET mutations have been identified in key domains. Updated results and correlation with overall survival will be presented.']",
        "Doc_id":"ASCO_53966-74",
        "Doc_title":" Interim analysis of CALGB 150607",
        "_version_":1606189035748851713},
      {
        "Meeting_name":" Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.",
        "Background":"['Background', ' ARQ 197 is a selective, non-ATP competitive inhibitor of c-MET, the exclusive receptor tyrosine kinase for hepatocyte growth factor. Preclinical data suggest combinability of ARQ 197 with gemcitabine. This study aims to evaluate the safety, pharmacokinetics (PK), biomarkers, and preliminary efficacy of the combination in pts with advanced solid tumors. Methods', ' Multicenter, phase Ib 3+3 dose escalation trial. Oral ARQ 197 is administered at doses of 120-360mg bid across different schedules (continuous vs. continuous with 1 week [wk] break every 2 or 3 wks) in combination with fixed gemcitabine dosing and frequency (1000mg/m2/weekly 3 every 4 wks). Results', ' 25 metastatic pts (F', 'M = 13', '12; ECOG 0', '1 = 12', '13; mean age 61, range 44-75 yrs) with mean number of prior systemic treatments = 3.7 (1-9) were treated. No dose-limiting toxicities were observed. Adverse events (AEs) considered at least possibly drug-related were reported in 14 (56%) pts. Most commonly observed (>10%) AEs include neutropenia (10; 40%), thrombocytopenia (6; 24%), anemia (5; 20%), fatigue (4; 16%), leukopenia, nausea, and anorexia (2; 10%). One pt experienced a drug-related serious AE (anemia grade 4). One nonrelated death secondary to hemorrhage occurred on study. Of 16 evaluable pts, 4 pts obtained confirmed partial response by RECIST (ovarian, breast, uterine, NSCLC) and tumor marker decrease (38-83% reduction); 9 pts achieved stable disease (mean duration 15.5, range 8-28+ wks); 4 of these 9 pts had prior progression on gemcitabine (cholangio, ovarian, pancreatic), of whom 3 have now tumor marker decrease (33-80% reduction). PK analysis (patients dosed at 360 mg bid) show a day 1 mean Cmax of 1176  882 ng/mL and AUC(0-12) of 9146  8752 hr*ng/mL. Additional data will be available for presentation. Conclusions', ' To date, orally administered ARQ 197 in combination with gemcitabine appears well tolerated and without clinically apparent drug-drug interaction or significant exacerbation of known gemcitabine toxicity. Further efficacy is being explored in expanded cohorts for specific tumor types.']",
        "Doc_id":"ASCO_54099-74",
        "Doc_title":" Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.",
        "_version_":1606189002729193473},
      {
        "Meeting_name":" Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy.",
        "Background":"['Background', ' Bevacizumab (B) + carboplatin/paclitaxel received FDA approval in 10/06 for improving survival in first-line treatment of advanced NSCLC patients (pts). In the past, pts with brain mets had been excluded from trials of B due to concerns about the possibility of CNS hemorrhage. We report on the safety of B therapy in combination with E in a subset of pts with treated brain mets who enrolled in the BETA lung study for NSCLC. Methods', ' Pts in the subset had recurrent advanced stage NSCLC. Their disease at enrollment included brain mets previously treated with whole brain radiation therapy. Neurosurgery and stereotactic radiosurgery were permissible in addition to WBRT. Patients with an ongoing requirement for dexamethasone treatment and those who had previously been treated with anti-angiogenesis or epidermal growth factor receptor-targeted therapy were not eligible. Pts were treated with E+B or E+P. E dosing was at 150 mg daily; B/P dosing was 15mg/kg intravenous every (q) 3 weeks. Responses were evaluated q 6 wks until wk 24 and every 12 wks thereafter. Treatment continued until disease progression. Results', ' 68 pts with brain metastases were enrolled between June 2005 and April 2008. 37 pts received E+B and 31, E +P, with median treatment durations of 2.6 and 2.7 months respectively. No CNS hemorrhages or Gr 3+ bleeding events were reported among these pts. 3 Gr 3-4 nervous system adverse events (AE) were reported in each arm. One convulsion, one case of memory impairment and one case of toxic encephalopathy was reported in the E+P arm and a case of ataxia, headache, and cerebral ischemia were reported in the E+B arm. Conclusions', ' 37 pts with previously treated brain mets were treated with E+B in the BETA study. No CNS hemorrhages were reported in this subset and no new safety signals identified. The treatment duration for subjects with metastasis was equivalent in the E+B and E+ P arms. These data suggest an acceptable safety profile for the subset of patients with brain mets treated with B in the BETA lung study.']",
        "Doc_id":"ASCO_30808-65",
        "Doc_title":" Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy.",
        "_version_":1606189026019115008},
      {
        "Meeting_name":" Changes in molecular profile following platinum chemotherapy in NSCLC.",
        "Background":"['Background', '  Platinum-based combination is the standard 1st-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKI) have shown striking treatment efficacy in in patients with specific molecular profiles. This study investigated whether the genomic profiles of NSCLC differ before and after platinum-based chemotherapy, a still pending question.  Patients and Methods', '  Specimens from 50 stage IIIAN2, IIIB and IV NSCLC patients with diagnostic (therapy-nave) and post-chemotherapy (paclitaxel, docetaxel or gemcitabine+cisplatin)/chemo-radiotherapy were screened by fluorescence in situ hybridization (FISH) for ALK fusions and copy number gain (CNG) of EGFR and MET . Complete results were obtained in pre- and post-treatment specimens for 45 patients. A positive marker was defined as follows', ' EGFR CNG', ' 4 copies in  40% cells; MET CNG', ' mean 5 copies/cell; ALK', ' rearrangement in >15% of the cells.   Results', '  In diagnostic specimens, incidence of EGFR CNG (55%) was substantially higher than MET CNG (14%) or ALK+ (10%). All MET+ were also EGFR+ and all ALK+ were negative for EGFR and MET CNG. There was a significant association between EGFR CNG and female gender (p=0.001); no association was found between these biomarkers and age, smoking status, histology and stage. For ALK, there was no difference between diagnostic and post-treatment profiles in terms of presence or number of cells carrying the rearrangement (p=0.87). For EGFR and MET, no significant differences in mean copy number were detected (p=0.26 and p=0.87, respectively). However, 8 patients (18%) were classified in discordant EGFR copy number categories, 5 (10%) of which were likely due to real biological differences since similar discordance was also detected for MET.  Conclusions', '  Platinum chemotherapy does not seem to impact occurrence of ALK gene fusions in NSCLC. Conversely, a relevant change in the copy number profile of EGFR and MET was detected in at least 10% of NSCLC, when diagnostic and resection specimens were compared. These results demonstrate variability of chemotherapy impact in molecular pathways and support that molecular testing be performed in specimens collected just prior to selecting patients for targeted therapy.']",
        "Doc_id":"ASCO_78358-102",
        "Doc_title":" Changes in molecular profile following platinum chemotherapy in NSCLC.",
        "_version_":1606188988401451008},
      {
        "Meeting_name":" The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.",
        "Background":"['Background', ' Central nervous system (CNS) metastases (mets) occur in 30% of patients with advanced non-small cell lung cancer (NSCLC) and are associated with poor overall survival (OS). Although nivolumab, a programmed death-1 immune checkpoint inhibitor antibody, has demonstrated a longer survival benefit compared with docetaxel in previously treated NSCLC patients (CheckMate 017 and 057; N Engl J Med, 2015), patients with symptomatic or untreated CNS mets were excluded in these trials. In CheckMate 012 Arm M, 2 of 12 patients (16.7%) with untreated CNS mets showed intracranial responses, but the effect of nivolumab treatment for CNS mets was not fully investigated. Methods', ' To investigate the effect and safety of nivolumab for CNS mets in NSCLC patients, we retrospectively analyzed 48 patients with NSCLC who were treated with nivolumab from February 2016 to December 2016 at Okayama University Hospital. Results', ' Twenty-nine patients (60%) had no CNS lesions (group A) and 19 patients (40%) had brain mets (BM) (group B). In group B, 15 patients (79%) received radiotherapy (RT) for BM, including 5 patients who received RT just before nivolumab treatment. The responses of extra-CNS lesions to nivolumab are shown in the table. The PFS was longer in group A than in group B (p=0.14). In group B, the PFS of patients who received prior RT tended to be longer than in those without RT (p=0.42); OS was not reached in either group. In group B, the effects of nivolumab treatment for CNS mets were evaluated in 12 patients', ' SD occurred in 3 patients (25%), PD in 4 patients (33%), and NE in 5 patients (42%). All 4 patients with PD in the CNS lesion also showed PD in the extra-CNS lesion. In group A, no patients showed progression only in the CNS lesion. Conclusions', ' In this retrospective study, there were no patients treated only with nivolumab who showed a response to CNS mets. RT prior to nivolumab might be more effective, so future investigations should involve additional cases and prospective studies. Overall responsePFS (day)PR (%)SD (%)PD (%)NE (%)Without CNS mets (Group A) (n = 29)5 (17)10 (35)13 (45)1 (3)111With CNS mets (Group B) (n = 19)2 (11)2 (11)10 (53)5 (26)56With RT (n = 15)2 (13)1 (7)7 (47)5 (33)56Without RT (n = 4)0 (0)1 (25)3 (75)0 (0)32']",
        "Doc_id":"ASCO_192009-199",
        "Doc_title":" The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.",
        "_version_":1606188972591022080},
      {
        "Meeting_name":" Biomarker discovery through bioinformatic analysis of genomic profiles of PDX models with different responses to cancer therapies",
        "Background":"['Patient derived xenograft (PDX) tumor models have been proved to recapitulate the complexity and heterogeneity of their corresponding human tumors by phenotypic and genomic characterization, and thus become to be widely used in recent years in preclinical setting to facilitate drug discovery, translational studies and clinical trials support. Results from increasing number of preclinical studies, especially mouse trials, with PDX models in the past several years, have also demonstrated close correlation between drug response profiles with PDX models and clinical outcomes.GenenDesign has established over 800 PDX tumor models and derived around 100 resistance models to drugs of interest. Genomic profiling data of PDX models are acquired at hot-spot mutation, gene expression, gene copy number and RNA/Exome sequence levels. Through our in-house efforts, PDX models of different tumor types were tested with related SOCs and clinical candidates in biomarker-driven multi-drug multi-arm clinical trial settings. So far, more than 1200 data sets have been generated, including responses to targeted inhibitors against HER2, EGFR, FGFRs, c-Met/ALK, cell cycle regulators, Ras/Raf pathway, PI3K/Akt pathway, epigenetic targets, as well as chemotherapy drugs.In this study, we use bioinformatic tools to compare the genomic profiles of NSCLC PDX models based on their response profiles to multiple chemotherapy drugs. Biomarker signatures associated with SOC treatment sensitivity or resistance are revealed from bioinformatic analysis and being tested with both new NSCLC PDX models and clinical cohorts.The combination of genomic profiles and drug response information to multiple chemo/targeted therapies of over 800 PDX models at GenenDesign would help biomarker discovery for companion diagnosis to meet the increasing needs for precision medicine.']",
        "Doc_id":"AACR_2015-3222",
        "Doc_title":" Biomarker discovery through bioinformatic analysis of genomic profiles of PDX models with different responses to cancer therapies",
        "_version_":1606188988957196288},
      {
        "Meeting_name":" Changing the paradigm for treating drug resistance in NSCLC",
        "Background":"['Aberrant receptor tyrosine kinase (RTK) signaling is a well-documented driver of disease onset and progression across myriad cancer types, where the MET RTK contributes to tumor progression, maintenance and resistance to targeted therapies. Here we explore the therapeutic potential of AZD6094, a highly potent and selective MET inhibitor, in EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC). Although many EGFRm NSCLC patients receiving first-line EGFR Tyrosine Kinase Inhibitors (TKI) benefit from therapy initially, the majority of patients will acquire resistance in 9-14 months1,2. Of this patient population, 10-15% of patients with emerging resistance to early generation EGFRm-TKI will have MET amplification3. Using xenograft models (HCC827) of resistance to erlotinib or gefitinib, both first-generation EGFRm-TKI, we assessed the efficacy of AZD6094 in models with varying copy number gain for MET. We demonstrate that the combination of AZD6094 with gefitinib, or AZD9291, an irreversible, selective (EGFRm/T790M) EGFR TKI, results in tumor growth inhibition (TGI) of >100% in 3 models (HCC827-ER1, PCS030 clone 1 and 2)4, suggesting that the combination is necessary and sufficient to address acquired resistance due to MET gene amplification. Moreover, we explore efficacy of AZD6094 in models representative of resistance to first-line treatment with EGFRm-TKIs, harboring MET amplification and T790M EGFR mutations. In NCI-H820 xenografts (EGFRm/T790M/MET), we demonstrate for the first time that combining MET and EGFRm/T790M TKIs (AZD6094 with AZD9291) induces tumor regressions (TGI% >100%, 94% regressions) and the loss of palpable tumors in 5/7 animals as compared to AZD9291 (TGI 48%) or AZD6094 treatment alone (TGI >100%). Pharmacodynamic analysis of tumor lysates demonstrated potent and durable inhibition of pMET in all AZD6094 treatment groups. Due to the clinical importance of understanding acquired resistance to targeted TKIs, we then generated a model of resistance to AZD6094 in MET-amplified NSCLC NCI-H1993 cells and analyzed several resistant clones (H1993R). Interestingly, MET phosphorylation remains strongly inhibited in AZD6094-treated H1993R cells, while EGFR protein expression is upregulated and leads to co-dependency between both pathways. Enhanced expression and phosphorylation of EGFR, as well as AKT, MEK and ERK activation were commonly observed in H1993R cells. Taken together, our data support the potential of AZD6094 as a novel combination therapy for MET-driven NSCLC in the context of EGFRm TKI resistance, and highlight the clinical relevance of EGFR and MET signaling in the context of emerging TKI resistance mechanisms and coordinated pathways.1. Mok et al. N Engl J Med 2009;361', '947-957.2. Rosell et al. Lancet Oncol 2012;13', '239-246.3. Engelman et al. Science 2007;316', '1039-1043.4. Models from Precos Ltd']",
        "Doc_id":"AACR_2015-761",
        "Doc_title":" Changing the paradigm for treating drug resistance in NSCLC",
        "_version_":1606189028751704064},
      {
        "Meeting_name":" Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy",
        "Background":"['Background', ' New approaches to drug development in both the laboratory and clinic will be required to achieve the goal of personalized and molecular-based cancer therapy. Here we describe an integrated research platform (iGXT) engaging unique resources at The Jackson Laboratory (JAX-WEST), the NCI Center for Advanced Preclinical Research (CAPR) and the UC Davis Cancer Center. Non-small cell lung cancer (NSCLC) was selected for pilot studies employing this strategy due to molecular targets of interest, such as epidermal growth factor receptor (EGFR), heterogeneity in NSCLC tumor biology and the complexity of cancer signaling pathways. Methods', ' In pilot studies, EGFR-directed drugs of interest (example AKT inhibitor MK2206) are studied at NCI CAPR in genetically engineered mice (GEMs) bearing tumors with defined EGFR-related characteristics while NSCLC patients (pts) and JAX Nod Scid Gamma (NSG) mice with patient-derived xenografts (PDXs) from those pts are concurrently treated in a co-clinical trial paradigm, taking advantage of superior properties of the NSG mouse for propagating PDXs. Results in NSG models and pt trials are assessed by genome-wide technologies, integrated with data from CAPR, and extrapolated back to individual pts. Results', ' Tumor specimens from over 180 cancer pts have been xenotransplanted into NSG mice (~50 from NSCLC). Pilot studies at CAPR in GEMs with EGFR mutant (Tet-op-EGFR L858R +/- T790M) tumors demonstrate efficacy of MK2206 +/- erlotinib, and with the pan-EGFR inhibitor BIBW2992. Complementary in vitro studies at UCD confirm the ability of MK2206 to overcome c-MET-related resistance to erlotinib. An erlotinib-MK2206 clinical trial is ongoing. Demographics of host pts, histopatholgic features and molecular profiles will be presented. Conclusions', ' This pilot project supports the feasibility of systematically integrating data derived from iGXT models in order to optimize drug development and treatment strategies. Findings from this platform are likely to advance understanding of differences in intra-patient tumor biology and hasten the transition to personalized cancer therapy.']",
        "Doc_id":"ASCO_77141-102",
        "Doc_title":" Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy",
        "_version_":1606189025879654400},
      {
        "Meeting_name":" TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer",
        "Background":"['A large fraction of non-small cell lung cancers (NSCLC) have mutant KRAS, which is associated with poor response to current cytotoxic therapy and a poor prognosis. Although the KRAS signaling pathway has been well characterized, no current therapies target this critical oncogene. Several studies have demonstrated that bypass of senescence in Kras-mediated adenocarcinoma mouse models is essential for tumorigenesis. Therefore, activation of senescence in KRAS mutant NSCLC may be an effective therapeutic strategy. We recently demonstrated that the basic helix loop helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to activation of Kras-induced senescence and tumor stasis. In the current study, we examine the role of TWIST1 in KRAS mutant human NSCLC. Silencing of TWIST1 in multiple KRAS mutant NSCLC cell lines resulted in dramatic growth inhibition and either reactivation of oncogene-induced senescence or in some cases, apoptosis. Similar effects were also observed in four KRAS wild type lines, including cell lines with key driver mutations including a cell line with an activating EGFR mutation and a cell line with c-Met amplification. Gene set enrichment analysis of NSCLC cell lines after silencing of TWIST1 revealed a striking cell cycle arrest gene signature. Growth inhibition by silencing of TWIST1 was independent of p53 or Rb/p16 mutational status. Furthermore, activation of oncogene-induced senescence by TWIST1 silencing did not require previously defined mediators of senescence, p21 and p27, nor could this phenotype be rescued by overexpression of SKP2. To extend these observations in vivo, TWIST1 was silenced in both KRAS mutant and wildtype cell lines and these cells were implanted in NOD-SCID mice to assess tumor formation. Interestingly, silencing of TWIST1 in xenograft models preferentially inhibited KRAS mutant tumor formation suggesting that TWIST1 plays a critical in mediating KRAS tumorigenesis. Finally, inducible silencing of TWIST1 resulted in significant growth inhibition of established xenograft KRAS mutant tumors. Together these findings suggest TWIST1 is essential for the establishment and maintenance of KRAS mutant NSCLC tumors and silencing of TWIST1 in KRAS mutant NSCLC represents a novel and promising therapeutic strategy.']",
        "Doc_id":"AACR_2012-2954",
        "Doc_title":" TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer",
        "_version_":1606188994505211904},
      {
        "Meeting_name":" Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.",
        "Background":"['Background', '  Aberrations in the MET receptor tyrosine kinase pathway occur in various human malignancies (via MET amplification, mutation, or overexpression) driving cell proliferation, survival and metastasis. INC280 is a highly selective, oral small molecule MET inhibitor with preclinical activity in human tumor models. This dose escalation study evaluated INC280 in patients (pts) with MET dependent advanced solid tumors.  Methods', '  In this Phase (Ph) I study, the primary objective was to determine the MTD or recommended Ph II dose (RP2D), safety and tolerability of INC280; secondary objectives included preliminary antitumor activity and PK. Eligible pts (aged 18 years, ECOG PS 2) had tumors that were refractory to current therapy or for which no effective therapy exists, and confirmed MET dysregulation (by FISH or IHC). An adaptive Bayesian logistic regression model guided dose escalation in establishing the MTD/RP2D.  Results', '  As of December 2, 2013, 33 pts were enrolled in the dose-escalation part of the study (79% male, median age 57 years, 61% PS 0). The most common tumors were hepatocellular carcinoma (HCC; 45%) and colon cancer (21%). Pts were treated in 6 dose cohorts of 100600 mg BID. DLTs occurred at 200 mg BID, 250 mg BID and 450 mg BID (1 pt each). DLTs were Gr 3 fatigue (2 pts), and Gr 3 serum bilirubin increased. The most frequent drug-related AEs (any grade [Gr]) were decreased appetite (33%), nausea (30%), vomiting (27%), and fatigue (27%). The most common drug-related Gr 3/4 AEs were fatigue (9%), and decreased appetite (6%). INC280 plasma concentration generally increased with dose; mean steady state AUClast and Cmax following 600 mg BID were 6630 ng/mL and 29800 ng*h/mL, respectively, with a median Tmaxof 1.9 h and a mean apparent terminal half-life 3.1 h. Stable disease was reported in 8/33 (24%) heavily pretreated pts. Paired biopsy data showed near-complete phospho-MET shutdown in a colorectal cancer pt at 450 mg BID.  Conclusions', '  Oral INC280 BID is well tolerated, and the RP2D is 600 mg BID. Dose expansion is ongoing in pts with NSCLC, HCC, and other tumors. These results suggest INC280 should be further evaluated, and Ph II studies in various solid tumors are ongoing. Clinical trial information', ' NCT01324479.']",
        "Doc_id":"ASCO_128427-144",
        "Doc_title":" Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.",
        "_version_":1606189036757581824},
      {
        "Meeting_name":" Cross-resistance to 1st, 2nd, and 3rd generation EGFR tyrosine kinase inhibitors in vitro is characterized by MET amplification and PTEN loss",
        "Background":"['Reversible EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib offer significant clinical benefit to patients with EGFR mutation positive non-small cell lung cancer (NSCLC) compared to chemotherapy alone, but high rates of resistance especially at EGFR T790M (50-60% of resistant cases) underscore the need for better targeted treatments for NSCLC patients. Third generation irreversible TKIsAZD9291 and CO-1686were developed for efficacy in the T790M setting. However, resistance to the new class of EGFR TKIs is inevitable, prompting us to investigate the relationship between erlotinib and AZD9291 resistance mechanisms and explore novel ones. NSCLC cell lines harboring activating EGFR mutations with (NCI-H1975) or without T790M (HCC4006, HCC827, and PC-9) were exposed to erlotinib, dacomitnib, or AZD9291 at IC 75 or greater for three months to generate resistance. We observed cross-resistance to other EGFR TKIs in nearly all resistant lines, suggesting that T790M was not the main driver of resistance in the erlotinib-treated lines and that a common mechanism might account for resistance in each cell line set. An epithelial to mesenchymal transition (EMT) was observed and a corresponding increase in vimentin staining was seen in resistant lines, consistent with cross-resistance. Previous studies showed that MET amplification caused erlotinib resistance in HCC827; our data suggest MET amplification also accounted for the AZD9291 and dacomitnib resistance in HCC827. In AZD9291-resistant HCC4006 and H1975 lines, PTEN levels were substantially reduced compared to the parental line, with a corresponding increase in PIK3 pathway markers. Whole exome sequencing data support homozygous deletion of PTEN loss as a mechanism of acquired resistance to AZD9291 in NCI-H1975. The PTEN null line NCI-H1650 was found to be resistant to all three TKIs without long-term drug exposure, implicating PTEN loss as a mechanism of de novo resistance. An analysis of EGFR mutation status, PTEN status, MET expression, and the kinetics of acquired resistance will be presented and clinical implications will be discussed.']",
        "Doc_id":"AACR_2015-3602",
        "Doc_title":" Cross-resistance to 1st, 2nd, and 3rd generation EGFR tyrosine kinase inhibitors in vitro is characterized by MET amplification and PTEN loss",
        "_version_":1606189041248632832},
      {
        "Meeting_name":" Effect of metabolic syndrome and its components on survival in patients with early-stage  non-small cell lung cancer.",
        "Background":"['Background', '  Epidemiologic studies suggest that MetS increases the risk of lung cancer, yet its effect on cancer mortality remains controversial. We analyzed the effect of MetS/its various components on cancer mortality in large, national cohort of patients with early stage NSCLC, controlling for patient/tumor characteristics and treatment.  Methods', '  Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, we identified 11,190 patients aged 66 and older with stage I-II NSCLC diagnosed between 1999-2004. Patient/tumor characteristics were obtained from the SEER dataset; data on MetS/its components and cancer treatment was ascertained from Medicare claims. Relationships between the various patient/tumor characteristics and survival were analyzed using chi square tests and logistic regression. Survival in patients with/without MetS/its components was compared using multivariate Cox models.  Results', '  A significant proportion of patients had MetS (19.0%), diabetes (26.6%), hypertension (74.0%) and dyslipidemia (55.7%). Patients with MetS were more likely to be younger, non-white, less educated, and have greater comorbidity (all P<0.001). There was no association between tumor stage, histology, or grade and metabolic syndrome. MetS had no apparent effect on survival. When the effect of its individual components was analyzed, however, diabetes and hypertension were found to be independently associated with worse outcomes (adjusted hazard ratios [aHR] 1.18 [95% confidence internal {CI} 1.11-1.25] and 1.15 [95% CI 1.09-1.22], respectively) after adjusting for other patient/tumor/treatment factors. In contrast, dyslipidemia was associated with significantly improved survival on both univariate (5-year survival', ' 41% v 29%, P<0.001) and multivariate analyses (aHR 0.82 [95% CI 0.78-0.86]).  Conclusions', '  Diabetes and hypertension have independent adverse effects on survival in patients with early stage NSCLC, whereas dyslipidemia appears to have a protective effect. Trials are needed to determine if use of metformin (in diabetic patients) and/or statins in the adjuvant setting improves long term outcomes in this patient population.']",
        "Doc_id":"ASCO_84939-102",
        "Doc_title":" Effect of metabolic syndrome and its components on survival in patients with early-stage  non-small cell lung cancer.",
        "_version_":1606189036045598721},
      {
        "Meeting_name":" Targeted DNA- and RNA-based next-generation sequencing for identifying MET exon 14 alterations in pulmonary sarcomatoid carcinoma.",
        "Background":"['Background', 'Highly diverse somatic splice site alteration at MET exon 14 (METex14) result in exon skipping, which is supposed to be a therapeutic target in NSCLC. Here we report detection of METex14 alterations using targeted DNA- and RNA-based Next-Generation Sequencing (NGS) in pulmonary sarcomatoid carcinoma (PSC) with a high frequency of METex14 skipping. Methods', ' Tumor specimens were collected from 100 Chinese PSC patients. DNA and RNA were subject to targeted NGS, allowing the detection of somatic splice site alterations and intragenic METex14 skipping respectively. Then, somatic mutations that lead to METex14 skipping were recognized. Meanwhile, cross-platform performance comparison for detecting MET exon 14 skipping was achieved. Moreover, Sanger sequencing was also performed on the METex14-positive specimens. Results', ' So far, we have detected genetic aberrations in 34 FFPE samples. For RNA-based NGS, METex14 skipping was identified in 8 (23.5%) of 34 patient cases. The population frequency was accordant to the reported percent of 22% (PMID', ' 26215952). And 5 (62.5%) of 8 METex14-positive patients were detected somatic splice site mutations by DNA-based NGS, including 4 cases with known point mutations at the 3 splice region and one case with a novel deletion (chr7', ' 116412027- 116412042) at MET exon14 region, which is newly discovered. No somatic mutation was found at the splice junctions of METex14 in the remaining 3 samples using DNA-based NGS. Conclusions', ' Mutational events of MET leading to exon 14 skipping are frequent occurred in Chinese PSC patients. Our study also suggests that RNA-based NGS could identify more METex14 skipping, and thus provide more accurate results than DNA-based NGS.']",
        "Doc_id":"ASCO_194784-199",
        "Doc_title":" Targeted DNA- and RNA-based next-generation sequencing for identifying MET exon 14 alterations in pulmonary sarcomatoid carcinoma.",
        "_version_":1606188979208585216},
      {
        "Meeting_name":" Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models",
        "Background":"['Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor of ALK, ROS1 and c-MET that is approved in over 70 countries for the treatment of ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). Crizotinib achieved robust objective response rates of approximately 60% in ALK+ NSCLC and significantly improved progression free survival compared to chemotherapy. The emergence of secondary mutations within the ALK kinase domain or the activation of compensatory signaling pathways in crizotinib and other ALKi refractory tumors prompted searches for next generation of ALKi active against resistance mutations as single agents or in combination with other treatments. Such effort led to our recent discovery of PF-06463922, an ALK/ROS1 inhibitor with greatly improved ALK potency, brain penetration, and broad spectrum activity against all known clinical ALKi-resistant mutations. PF-06463922 is being tested in a Phase I clinical trial in both ALK+ and ROS1 fusion positive NSCLC in treatment naive or ALKi relapsed patients.In our current preclinical study, we explored rational combination strategies to further improve the efficacy of PF-06463922 in ALKi resistant cells or tumors. Our results show that compared to PF-06463922 alone, the combination of this compound with PI3K pathway inhibitors, such as PF-05212384 (PI3K/mTOR), GDC0941 (pan-PI3K) or GDC0032 (beta-sparing) leads to more robust anti-proliferative activity in vitro and greater duration of efficacy in vivo in the ALKi resistant models. These PI3K pathway inhibitors also partially overcome EGF or HGF ligand-induced resistance to PF-06463922. Interestingly, in addition to AKT signaling, both compounds inhibit ERK signaling as well, which may be essential for their enhancement of PF-06463922 cell activity or tumor efficacy in combination settings. Studies are ongoing to identify optimal partners for PF-06463922 combination using isoform selective PI3Ki, AKTi and mTORi. We are also exploring the breadth of efficacy of this combination in overcoming resistance to crizotinib, PF-06463922 or other ALKi. The findings provide important evidence that will help define the clinical development path for PF-06463922. This research effort may ultimately lead to more effective approaches to treat ALKi refractory patients in the clinic.']",
        "Doc_id":"AACR_2015-764",
        "Doc_title":" Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models",
        "_version_":1606188976416227329},
      {
        "Meeting_name":" Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Up to 60% of patients (pts) with NSCLC harboring an activating EGFR mutation (mut) and treated with a 1st generation EGFR TKI develop a secondary gatekeeper T790M mut. EGF816 is an irreversible EGFR TKI that is highly potent against activating mut (L858R, ex19del) and T790M mut, while sparing wild-type EGFR. As previously reported, in a Phase I dose escalation study, the overall response rate to EGF816 in pts with advanced EGFR T790M mut NSCLC was 47% and the disease control rate was 87%. However, pts ultimately develop disease progression. Tumor biopsies were obtained from pts who had progressed on EGF816 to identify mechanisms of resistance. Methods', ' Pts with NSCLC with locally or centrally confirmed T790M status were enrolled in this multicenter, dose escalation study to determine the safety, tolerability and antitumor activity of EGF816 (NCT02108964). EGF816 was administered at 7 dose levels ranging from of 75-350 mg QD. Following disease progression, a tumor sample was obtained and was analyzed by the Foundation Medicine next-generation sequencing (NGS) T7 panel, which interrogates 395 cancer-related genes for base substitutions, insertion-deletions, and copy number changes, as well as introns of 31 genes involved in rearrangements. Results', ' Tumor samples taken following disease progression on EGF816 were analyzed from 9 pts. Of the 8 pts whose tumors were T790M+ at baseline, this was detected in only 3 pts post-EGF816 progression samples. One patient developed an EGFR C797S mut and concurrent deletion in mTOR. Other identified alterations include BRAF fusions (n = 2) and c-MET amplification (n = 1). Only one patient was found to have concurrent TP53 mutation and RB1 truncating mutation. Individual patient response data, including duration of response, will be presented along with detailed genomic parameters. Conclusions', ' NGS analysis of tumors that developed resistance to EGF816 revealed multiple potential mechanisms of resistance. These data are hypothesis-generating and could lead to rational combination studies with EGF816 to improve the depth and/or duration of response to EGF816. Clinical trial information', ' NCT02108964']",
        "Doc_id":"ASCO_190250-199",
        "Doc_title":" Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188985636356096},
      {
        "Meeting_name":" A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.",
        "Background":"['Background', ' The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene can be detected in subsets of NSCLC, especially never-smoking patients with adenocarcinoma, and appears to be mutually exclusive of EGFR mutation. PF-1066, a potent and selective c-MET/ALK inhibitor, yields high response rates in ALK-positive patients, as detected by labor-intensive fluorescent in situ hybridization (FISH) methodology. Existing RT-PCR assays for these gene variants are designed to amplify large cDNA fragments (> 450 bases), while formalin-fixed paraffin-embedded (FFPE) specimens yield mostly RNA fragments of < 150 bases. Thus, our goal was to design a robust RT-PCR assay for EML4-ALK fusion gene transcripts suitable for use with commonly available FFPE tissues of limited size. Methods', \" Synthetic fragments representing the nine EML4-ALK fusion genes variants 1, 2, 3a, 3b, 4, 5a, 5b, 6 and 7 were generated by recursive PCR technology. The approach consisted of amplifying over-lapping fragments containing the fusion variant sequences with outside 5' and 3' primers. Primer probes were designed to detect specific EML4-ALK fusion gene fragments with a maximum amplicon of 170 bases by RT-PCR. Results\", ' Functional RT-PCR assay were developed for each specific EML4-ALK variant, meeting criteria specified above for optimal clinical testing. Assays detecting multiple fusion variants without distinguishing specific variants were also designed. All nine known EML4-ALK variants can be detected using 6 RT-PCR assays. Screening of NSCLC cDNAs from the Response Genetics database is underway (molecular and clinical correlations to be presented). Conclusions', ' We developed RT-PCR assays capable of detecting EML4-ALK fusion gene variants from FFPE tissues. Two assays were successfully established', ' one that can detect and identify each individual variant, and one capable of detecting the presence of any variant as a single assay. We expect this methodology to provide a useful tool for large-scale screening of NSCLC or other FFPE tissues for the EML4-ALK fusion gene.']",
        "Doc_id":"ASCO_51744-74",
        "Doc_title":" A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.",
        "_version_":1606188996468146176},
      {
        "Meeting_name":" An examination of crizotinib activity in human tumor primary culture micro-spheroids isolated from patients with advanced non-small cell lung cancer.",
        "Background":"['Background', '  The amino-pyridine, Crizotinib (Criz) (PF02341066, Xalkori), active against c-MET is an inhibitor of anaplastic lymphoma kinase (ALK). Identification of ALK-gene rearrangement in NSCLC led to clinical trials & FDA approval. Recognition of ROS-1 mutations as Criz targets provided additional therapy options.  ALK mutations found in NSCLC also occur in lymphoma, neuro & myofibroblastic tumors but may participate in the oncogenesis of other tumors.    Methods', '  We used ex vivo analysis of programmed cell death (EVA/PCD) (Nagourney, R. Curr Treat. Op Oncol, 2006) to examine Criz activity in human tumor 1culture micro-spheroids, from 60 surgical specimens, with a focus on NSCLC. Using metabolic (ATP-content; mitochondrial) & morphologic (membrane integrity) endpoints, dose response curves were interpolated to LC50 values for comparison of activity by patient & tumor type. Patients were screened for ALK & ROS-1 by FISH.  Results', '  ALK (+) tumors reveal lower LC50s (3.4 uM) vs. ROS-1 (+) (11.5 uM), despite clinical responses in both groups. A Criz-responding patient, at 2nd biopsy for progression, reverted to Criz-resistance but developed collateral sensitivity to cytotoxics that provided durable response. Despite FISH (-), a 39 y/o nonsmoker male, revealed exquisite sensitivity to Criz by repeat EVA/PCD. At our insistence, FISH conducted at a 2nd reference lab correctly identified ALK(+) qualifying for Criz, to which he responded, now at year 2. Using low LC50 as a phenotypicmarker of Criz responsiveness, we identified activity in an extremely rare pediatric sarcoma patient. When, secondarily screened, patient found ALK (+), followed by rapid objective response to Criz.  Conclusions', '  Primary culture analyses provide insights into Criz activity including ALK (+) vs. ROS-1(+), individual patient response profiles, and the identification of Criz candidates, who might otherwise not be screened for sensitizing mutations. By capturing human tumors in their native state EVA/PCD offers opportunities to study Criz for unrecognized targets and analyze novel strategies including synergy & sequence dependence, less readily examined with genomic platforms.']",
        "Doc_id":"ASCO_117562-132",
        "Doc_title":" An examination of crizotinib activity in human tumor primary culture micro-spheroids isolated from patients with advanced non-small cell lung cancer.",
        "_version_":1606188998712098817},
      {
        "Meeting_name":" Guideline adherence rates and costs of chemotherapy treatment for NSCLC patients treated in U.S. community oncology practices.",
        "Background":"['Background', ' Adherence to national treatment guidelines (TG) is a key step to improving the quality and outcomes of cancer treatment in the U.S. This study examined guideline adherence rates and cost of chemotherapy treatment for NSCLC patients treated in the adjuvant (Adj) and first-line metastatic (Met) settings in U.S. community oncology practices. Methods', ' Using a large U.S. medical oncology clinical database derived from web-based drug dispensing technology, adult patients (Pat) with NSCLC treated with Adj and Met chemotherapy were identified from 7/1/09-06/30/10. Regimens (Reg) utilized were compared to national guideline recommendations. Costs based on Medicare (MC) reimbursement were compared. Results', ' A total of 811 Adj and 2,761 Met regs were administered by 333 practices across 41 states.  Median patient age was 68 and 67 yrs in the Adj and Met groups respectively. National guidelines recommend 26 and 67 regs (TG-Reg) for Adj or Met treatment, respectively. The rate of guideline adherence was significantly higher in the Met group than the Adj group. Carboplatin (Carbo)-containing regs were administered (Adm) significantly more than Cisplatin (Cis)-containing regs in both groups.  Reg costs based on MC national reimbursement rates (including antineoplastic and supportive care drugs, CPT and some lab codes) for the top 5 regs in the Adj and Met settings varied. A standard course of therapy in the Adj group ranged from $2,803 [Carbo(AUC5)D1-Eto(100)D1-3 q21d] to $7,362 [Carbo(AUC2)D1,8,15-Pac(75)D1,8,15 q28d]. Reg costs in the Met group ranged from $3,297 [Carbo(6)D1-Pac(200)D1 q21d] to $29,322 [Carbo(AUC6)D1-Pac(200)D1-Bev(15)D1 q21d] based on 3 months of therapy. Conclusions', ' The rate of guideline adherence was significantly higher in the Met group than in the Adj group. Carbo-containing regs were administered more than Cis-containing regs.  There were a large number of unique regimens administered in the Met group. Costs for the top 5 regs vary considerably.']",
        "Doc_id":"ASCO_84314-102",
        "Doc_title":" Guideline adherence rates and costs of chemotherapy treatment for NSCLC patients treated in U.S. community oncology practices.",
        "_version_":1606189014112534529},
      {
        "Meeting_name":" Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC",
        "Background":"['Background', '  A placebo-controlled, phase II trial of erlotinib + onartuzumab, a humanized monovalent antibody to the MET receptor, demonstrated a benefit in progression-free survival (PFS) when compared with erlotinib in patients with MET-positive NSCLC (JCO 2013;31;4105). The aim of the METLung trial was to confirm the efficacy and safety of onartuzumab + erlotinib in MET-positive NSCLC.  Methods', '  This prospective, randomized, double-blind, placebo-controlled trial enrolled patients with previously treated MET-positive stage IIIb/IV NSCLC. MET diagnostic status was determined by an immunohistochemistry (IHC) assay using the CONFIRM anti-total MET SP44 monoclonal antibody (Ventana). Eligibility criteria included', ' ECOG PS 01, 12 prior lines of chemotherapy, and normal organ function. Stratification factors', ' EGFR mutation status (activating mutation vs negative; cobas EGFR assay), MET IHC (2+ vs 3+), number of prior treatments (1 vs 2), and histology (squamous vs non-squamous). Patients were randomized (1', '1) to receive erlotinib 150mg PO daily + placebo or onartuzumab 15mg/kg IV every 21 days. Tumor assessments occurred every 6 weeks. The primary endpoint was overall survival (OS). The sample size (n=490) was based on the assumption that adding onartuzumab to erlotinib would improve OS by 41% with 90% power (one-sided alpha 0.025). An interim analysis was planned when 67% (244 events) of the final events were reached.  Results', ' 499 patients were enrolled between Jan 2012 and Aug 2013. An independent data review committee recommended to stop the trial for futility, as the addition of onartuzumab to erlotinib did not improve OS (HR 1.27, p=0.068; median OS 6.8 mos vs 9.1 mos), PFS (HR 0.99, p=0.92; median PFS 2.7 mos vs 2.6 mos), or overall response rate (8.4% vs 9.6%; p=0.63). The most frequent adverse events that were higher in the combination arm were peripheral edema, hypoalbuminemia, back pain, dyspnea, nausea, acneiform dermatitis, and rash.   Conclusions', ' The phase III study did not confirm the efficacy results observed in the phase II study.  Exploratory analyses based on molecular subgroups are pending. Clinical trial information', ' NCT01456325.']",
        "Doc_id":"ASCO_128045-144",
        "Doc_title":" Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC",
        "_version_":1606188988095266816},
      {
        "Meeting_name":" The endocannabinoid system inhibits non-small cell lung cancer tumorigenesis by modulating the EGF/EGFR pathway",
        "Background":"['Non-small cell lung cancer (NSCLC) is a leading form of cancer with limited treatment regimens and is a major cause of cancer related mortality in the United States. The endocannabinoid system composed of two cannabinoid receptors- CB1 and CB2, their endogenous ligands and the enzymes for their metabolism has been implicated in several pathophysiological conditions. They have been extensively studied in various cancers as inhibitors of tumor cell growth by modulating key cell survival pathways. Anandamide (AEA), a well characterized neurotransmitter is an endogenous cannabinoid and agonist for the cannabinoid receptor CB1. One way to enhance the effect of endocannabinoid signaling is to inhibit the enzyme fatty acid amide hydrolase (FAAH), which metabolizes AEA by using the selective FAAH inhibitor URB597. To understand the physiological role of the endocannabinoid system, the NSCLC cell lines A549 and H460 were treated with either Met-F-AEA, URB597 or in combination and subjected to further analysis. Cells which were incubated in combination with Met-F-AEA and URB597 showed reduced proliferative and chemotactic activities in vitro when compared to AEA alone, which were confirmed by reduced MMP2 secretion and stress fiber formation. Also, we have shown that the combination treatment modulates activation of epidermal growth factor receptor (EGFR) and its downstream targets. In response to EGFR pathway activation, cells treated with Met-F-AEA in combination with URB597 underwent GO/G1 cell cycle arrest, ultimately leading to apoptosis via activation of caspase-9 and PARP. Furthermore, these results were validated in vivo in a xenograft nude mouse model system. Mouse xenografts treated with both Met-F-AEA and URB597 underwent reduction in tumor growth when compared to Met-F-AEA or URB597 alone. In summary, our results presented here show that Met-F-AEA in combination with URB597 inhibits the EGFR pathway, resulting in cell cycle arrest and apoptosis. Our findings suggest a novel perspective for the antitumorigenic activity of the endocannabinoid Met-F-AEA when used in combination with URB597 in NSCLC.']",
        "Doc_id":"AACR_2014-3324",
        "Doc_title":" The endocannabinoid system inhibits non-small cell lung cancer tumorigenesis by modulating the EGF/EGFR pathway",
        "_version_":1606188991347949568},
      {
        "Meeting_name":" Peroxisome proliferator-activated receptor  (PPAR) reveals a critical role in promoting the TGF-induced EMT and metastasis of non-small cell lung cancer cell (H460)",
        "Background":"['Although transforming growth factor  (TGF) is anti-cancer identified, it was also known to promote tumor malignancy by enhancing the growth, epithelial to mesenchymal transition (EMT), tissue invasion and metastasis in a variety of cancer cells, including non-small cell lung cancers (NSCLCs). The aim of this study was to know the contribution of peroxisome proliferator-activated receptor  (PPAR) to TGF-promoted EMT and metastasis in NSCLCs. The degree of EMT, cell scattering, migration and invasion, and protein expression of PPAR were first analyzed and compared between H460 and CH27 cells with or without TGF treatment (both are NSCLC cell lines). Chemical or shRNA blocking assay was also utilized to further confirm the importance of PPAR in promoting TGF-induced tumor metastasis. Finally, signaling pathway(s) responsible for TGF/PPAR-mediated metastasis was evaluated. The results demonstrated that TGF can effectively triggered the EMT, cell scattering, migration and invasion in H460 cell, but only a slight EMT was seen in TGF-treated CH27 cell. Meanwhile, PPAR expression was induced by TGF in H460 cells but remained unchanged in CH27 cell. This indicated that PPAR may involve in TGF-mediated metastasis. Co-treatment of TGF with GW9662 (a specific PPAR inhibitor) significantly blocked TGF-promoted metastasis of H460 cell indicating the presence of PPAR was indeed critical for TGF-attributed tumor metastasis. TGF appeared to act through P38 signaling pathway to trigger the expression of PPAR and the subsequent activation of epidermal growth factor receptor (EGFR)/c-mesenchymal-epithelial transition factor (c-MET) signaling pathway and the reduction of E-cadherin that eventually led to the EMT and metastasis of H460 cell. Additionally, TGF also act through P38 to trigger the expression of -catenin which could bind to and up-regulate the expression of PPAR. Blocking of -catenin activity, however, did not interfere with the metastasis indicating -catenin may not play a direct role in promoting the metastasis of H460 cell. Nevertheless, we can not preclude the possibility that -catenin may still act through PPAR to regulate the metastasis of H460 cell, indirectly. In summary, TGF-induced EMT and metastasis in H460 cell was PPAR-dependent and GW9662 revealed a therapeutical value in the control of NSCLCs (H460).']",
        "Doc_id":"AACR_2012-3028",
        "Doc_title":" Peroxisome proliferator-activated receptor  (PPAR) reveals a critical role in promoting the TGF-induced EMT and metastasis of non-small cell lung cancer cell (H460)",
        "_version_":1606189010966806528},
      {
        "Meeting_name":" Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.",
        "Background":"['Background', '    Amplification of cMET has been described as mechanism underlying resistance to EGFR-targeted therapy in EGFR-mutated NSCLC. Nevertheless, few is known about cMET amplification beside the EGFR-resistance setting. This study was performed in order to characterize patients with low-level, intermediate-level and high-level cMET amplification focusing on frequency, co-occuring driver mutations and clinical outcome.  Methods', '    Within a regional molecular screening network cMET amplification status was analyzed by fluorescence in-situ hybridization (FISH) in 588 patients with NSCLC regardless of histology. Next-generation parallel sequencing (NGS) using 102 amplicons and 14 genes was performed in all analyzed samples. Clinical parameters (age, sex, UICC tumor stage, smoking status and medical and therapeutical history) of all patients were assessed.  Results', '    171 patients (29.1%) with cMET amplification were identified, whereof 17 (9.9%) had high-level amplification. cMET amplifications co-occured in 98 patients (57.3%) with a large spectrum of other driver mutations (EGFR, KRAS, HER2, STK11, NRAS, BRAF) or amplifications (FGFR1) in both adenocarcinoma (60.2%) and squamous cell carcinoma (21.1%). 9 patients of the high-level-amplified patients did not have an additional driver mutation, while the remaining 8 patients had mutations within EGFR, KRAS, PIK3CA, BRAF and STK11. cMET amplification was associated with a history of smoking and detected in all UICC tumor stages.  Conclusions', '    Our data suggest a high prevalence of cMET amplification in NSCLC patients with many oncogenic driver mutations. Most patients with an additional mutations had KRAS mutations. These data show that screening for MET-amplified patients in order to identify patients for  MET-targeted treatment should not be performed on the basis of sequencing results.']",
        "Doc_id":"ASCO_149488-156",
        "Doc_title":" Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.",
        "_version_":1606189021305765889},
      {
        "Meeting_name":" Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer",
        "Background":"['Background', ' Alterations of crizotinib (crz) molecular targets ALK, MET, ROS1 are found in a wide range of adult and pediatric (ped) cancers. Crz is approved for the treatment of adult patients (pts) with ALK+ advanced NSCLC but not developed and licenced in Europe for children. To avoid off-label use and allow for a nationwide safe access to crz for pts with ALK, MET or ROS1+ tumor, the French National Cancer Institute (INCa) launched the AcS program, funding both access to tumor molecular diagnosis and an exploratory multi tumor phase II trial. We report the results of 11 ped cases out of 159 pts. Methods', ' Molecular diagnosis was performed in 28 regional INCa molecular genetic centers by break-apart FISH assays or sequencing. Rearrangements identified through pangenomic tumor profiling were eligible as well. Pts with ROS1, ALK or MET+ in treatment failure received crz 280 mg/m2 BID (except Anaplastic Large Cell Lymphoma [ALCL] pts who received crz 165 mg/m2BID) in capsules or oral solution. Responses were assessed every-8 weeks using RECIST v1.1. Results', ' From Aug. 2013 to Aug. 2015, 107 ped tumors were analyzed. Altered targets were found in 18 tumors (see table). 11 pts were enrolled, median age 9 yrs (range 316), 64% boys. 7 pts were still on treatment at the cut-off date, 2 for >12 months; 4 have stopped crz (2 PD, 1 doctors decision, 1 patients decision). Among the 8 evaluable pts (3 assessments pending), best responses were 1 CR (ALCL ALK trans), 3 PR (ALCL ALK trans, IMT ROS1 trans, meningioma ROS1 trans), 1 SD (mesothelioma ALK trans), and 3 PD (2 Nb ALK mut, glioma MET trans). Crz was well tolerated with 4 grade 3 AEs (QTc prolongation, nausea, loss of appetite, anemia). Mainly AEs were grade 1, were elevated transaminases (60% of pts), vomiting (50%), visual disorders (40%), fatigue (40%). Conclusions', ' Alterations of all crz targets were found in ped tumors and children can benefit from crz therapy. Clinical trial information', ' NCT02034981Neuroblastoma(Nb)N=49RhabdomyosarcomaN=10Inflammatory Myofibroblastic Tumor (IMT) N=3Malignant Glioma N=14Other cancersN=29Miscellaneous with pangenomic profiling N=2ALK Mutated5ALK Amplified (Amp)(>6 copies)20ALK Translocated (Trans)1*013ROS1 Trans11MET Amp(>6 copies)111MET Trans1*', ' + ALK mutated.']",
        "Doc_id":"ASCO_168844-176",
        "Doc_title":" Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer",
        "_version_":1606189035604148224},
      {
        "Meeting_name":" Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.",
        "Background":"['Background', ' We have observed a 70% response rate (RR) in NSCLC p with EGFR mutations treated with erlotinib. Primary resistance to erlotinib could result from the absence of an EGFR-organized network. Crosstalk and transactivation between other receptor tyrosine kinases, such as EGFR, IGF-1R and MET, is recognized as a mechanism of growth in several tumors. Mutant EGFR could activate the IL-6/gp130 pathway. Overexpression of AXL has been observed in NSCLC and in GIST imatinib-resistant tumors. Methods', ' The expression of MET, IGF-1R, IL-6/gp130 and AXL was examined by QPCR in the original pretreatment tumor biopsies of 98 NSCLC p with EGFR mutations. Expression levels by terciles were correlated with outcome to erlotinib. Results', ' There was a good correlation between the expression of IL-6/gp130 and AXL (r = 0.33; p = 0.001). No differences were observed in expression of the four genes according to gender, smoking history, type of EGFR mutation, or other clinical characteristics. The highest tercile of AXL expression was associated with a higher incidence of lung metastases (87.5%; p = 0.02). No other association between any of the genes and metastatic sites (including brain and bone) was observed. Overall RR was 70%, progression-free survival (PFS) was 14 months (m), and median survival (MS) was 27 m. No differences in RR, PFS or MS were observed according to the expression of any of the four genes. Conclusions', ' The coactivation of other receptor tyrosine kinases seems not to affect the initial outcome to erlotinib in NSCLC p with EGFR mutations. The association of high levels of AXL with lung metastases should be further examined, since AXL expression has been correlated with metastasis to the lung in a breast cancer model. The addition of AXL inhibition could be a novel treatment approach for enhancing the effect of erlotinib in p with EGFR mutations.']",
        "Doc_id":"ASCO_42827-74",
        "Doc_title":" Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.",
        "_version_":1606188981039398912},
      {
        "Meeting_name":" Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies.",
        "Background":"['Background', ' Alectinib showed robust efficacy and safety in two phase II studies (NP28673 [NCT01801111] and NP28761 [NCT01871805]) of patients (pts) with previously treated ALK+ NSCLC. A pooled analysis of these studies also showed highly consistent efficacy of alectinib in the central nervous system (CNS) (Gadgeel et al, WCLC 2015). This exploratory analysis used these pooled data to evaluate the cumulative incidence rate (CIR) of CNS and non-CNS progression for pts with and without CNS metastases (mets) at baseline (BL). Methods', ' All pts (n = 225) were  18 years with confirmed ALK+ NSCLC, which had progressed after prior crizotinib. They received 600 mg oral alectinib twice daily. All patients had BL imaging to detect CNS mets, with further prospective imaging as per the protocols. In this analysis, response was determined by RECIST v1.1, and progression (PD) categorized as CNS or non-CNS. CIR was calculated using competing risks methodology. Results', ' BL characteristics were similar in pts with (n = 136) or without (n = 89) BL CNS mets. Median follow-up was 12.8 months. CIRs at 6, 12 and 18 months are shown in the Table. In the BL CNS mets group, pts with prior radiation (RT; n = 95) had a slightly more rapid rate of CNS PD (39.7% [29.649.8] at 12 months) than those with no prior RT (n = 41; 20.1% [7.632.6] at 12 months) (p < 0.05), perhaps due to, for e.g., greater disease burden. Conclusions', ' These pooled phase II study data suggest that alectinib is effective in pts with BL CNS mets, regardless of prior RT. Based on the low incidence of CNS PD in pts without CNS mets at BL, alectinib may also have a potential preventative effect in these pts. The ongoing phase III ALEX study will assess rate of CNS relapse in pts receiving first-line alectinib vs crizotinib. Clinical trial information', ' NCT01801111 and NCT01871805MonthsCIR (%) CNS PDNo BL CNS mets vsBL CNS metsCIR (%) Non-CNS PDNo BL CNS mets vsBL CNS metsCIR (%) DeathNo BL CNS mets vsBL CNS mets65.8 (0.910.8) vs24.0 (16.831.3)28.9 (19.438.5) vs18.8 (12.125.4)5.7 (0.810.5) vs5.2 (1.59.0)127.0 (1.612.4) vs33.7 (25.641.9)36.2 (26.046.4) vs26.9 (19.334.6)9.3 (3.215.4) vs6.0 (2.010.1)189.0 (2.515.5) vs42.3 (32.352.4)61.2 (45.077.5) vs35.2 (20.150.3)9.3 (3.215.4) vs6.0 (2.010.1)']",
        "Doc_id":"ASCO_169608-176",
        "Doc_title":" Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies.",
        "_version_":1606189004013699073},
      {
        "Meeting_name":" Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' BV (Avastin) prolongs progression-free (PFS) and overall survival (OS) in advanced NSCLC. ARIES, a prospective OCS evaluating BV in a real world setting, includes pts underrepresented in randomized controlled trials (RCTs), i.e., pts 70y, with poor performance status (PS), or with CNS metastases (mets). Preliminary COs (effectiveness and safety) in ARIES subpopulations are presented. Methods', ' Pts with locally advanced nonsquamous NSCLC on first-line chemotherapy (CT) and BV enrolled. No prespecified treatments, doses or assessments. Data are collected electronically at baseline (BL) and quarterly (QU), including BV-targeted adverse events (AEs) and serious AEs (SAEs). Descriptive safety analyses were conducted for all pts and for subgroups. Median (med) PFS and OS are Kaplan-Meier estimates. Results', ' ARIES enrolled 1,970 NSCLC pts. Med follow-up at the 09/2009 data cut was 9.6 mo; 98% have 1 QU follow-up. Med PFS is 6.7 mo and OS is 13.6 mo for the entire cohort and were similar across subgroups except pts with PS2. The most common 1st-line CT is carboplatin/paclitaxel (CP). Pts 70y and pts with PS2 or CNS mets at BL generally used more nonplatin-containing CT and pemetrexed. AE rates across subgroups were similar to the overall cohort except for increased arterial thromboembolic events (ATE) in pts 70y and with PS2. No CNS bleeding events occurred in pts with CNS mets at BL. Conclusions', ' The COs (safety/effectiveness) of BV in pts 70y, or with PS2 or CNS mets are consistent with the known BV efficacy and safety profile. Pts with PS2 received less CP and had worse COs but not more AEs/SAEs. Pts 70y had COs similar to the overall cohort despite less doublet CT, suggesting that advanced age, poor PS, or CNS mets should not necessarily exclude pts from receiving BV therapy. All NSCLC pts (n = 1,970)Age 70(n = 650)PS 2(n = 182)CNS Mets(n = 150) Med PFS (mo)6.76.85.86.0 Med OS (mo)13.612.68.111.7 CP 1st-line CT, n (%)1,215 (62)382 (59)107 (59)82 (55) Severe pulmonary hemorrhage (PH), n (%)15 (0.8)2 (0.3)2 (1)Gr 3-5 bleeding excluding PH, n (%)52 (3)20 (3)7 (4)ATEs, n (%)35 (2)20 (3)6 (3)Gr 3-5 CNS bleed, n (%)2 (0.1)01 (0.5)0']",
        "Doc_id":"ASCO_49397-74",
        "Doc_title":" Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC)",
        "_version_":1606188981229191169},
      {
        "Meeting_name":" CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC",
        "Background":"['Background', ' CNS metastases (mets) are common in pts with advanced NSCLC. Preclinical studies have shown CNS penetration of osimertinib, and clinical data from a pooled analysis of 2 Phase II trials (AURA extension', ' NCT01802632, AURA2', ' NCT02094261) showed activity in the CNS. We report the first evidence of osimertinib efficacy in CNS mets from a randomized Phase III study (AURA3; NCT02151981) in pts with T790M-positive advanced NSCLC who have progressed on or after prior EGFR-TKI therapy. Methods', ' Pts were randomized 2', '1 to osimertinib 80 mg once daily or platinum-based doublet chemotherapy every 3 wks for up to 6 cycles; maintenance pemetrexed was allowed. Pts with stable, asymptomatic CNS mets were eligible for enrolment. A prespecified subgroup analysis was conducted in pts with CNS mets present on baseline brain scan, as assessed by blinded independent central neuroradiology review (BICR), to define CNS objective response rate (ORR), duration of response (DoR) and progression-free survival (PFS) by RECIST v1.1. The CNS full analysis set (cFAS) included pts with 1 measurable and/or non-measurable CNS mets present on baseline brain scan by BICR; the CNS evaluable for response set (cEFR) included only pts with 1 measurable CNS mets. Results', ' As of 15 April 2016, 116/419 (28%) pts were included in the cFAS. In the cEFR (n = 46), CNS ORR was 70% (21/30; 95% CI 51, 85) with osimertinib and 31% (5/16; 95% CI 11, 59) with chemotherapy (OR, 5.13; 95% CI 1.44, 20.64; p = 0.015). In the cFAS, CNS ORR was 40% (30/75; 95% CI 29, 52) with osimertinib and 17% (7/41; 95% CI 7, 32) with chemotherapy (OR, 3.24; 95% CI 1.33, 8.81; p = 0.014). In the cEFR and cFAS, median CNS DoR was 8.9 months (m) (95% CI 4.3, NC and 4.3, NC) for osimertinib and 5.7 m (95% CI NC, NC and 4.4, 5.7; respectively) for chemotherapy. Median CNS PFS in the cFAS was significantly longer with osimertinib than with chemotherapy (11.7 vs 5.6 m; HR 0.32; 95% CI 0.15, 0.69; p = 0.004). Conclusions', ' Consistent with the overall response to osimertinib reported in pts with T790M-positive advanced NSCLC, osimertinib was superior to chemotherapy in the treatment of pts with CNS mets; CNS response rate was higher, responses were more durable and CNS PFS was longer. Clinical trial information', ' NCT02151981']",
        "Doc_id":"ASCO_185658-199",
        "Doc_title":" CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC",
        "_version_":1606189039909601281},
      {
        "Meeting_name":" Integrating molecular profiling into cancer treatment decision making",
        "Background":"['Background', '  Molecular profiling of both common and rare cancer types provides for the identification of actionable targets for chemotherapy with many unexpected associations.  Methods', '  Caris Life Sciences database of >35,000 profiled cancers was reviewed for well-established driver gene mutations and copy number alterations, and protein expression patterns that are relevant for selection of targeted therapy.  Based on the published literature, these tumor characteristics were then associated with potential benefit or no benefit to the specific therapeutic agents.  All relevant published studies were evaluated using the USPSTF grading scheme for study design and validity. Assay methodologies included sequencing (Sanger, pyrosequencing), PCR, FISH, CISH, and immunohistochemistry.  Results', '  All common malignancies (10 most common cancer types in men and women) and 10 rare cancer types were well represented (minimum of 100 cases in each individual cancer type). Well established driver mutations and protein expression in common cancers were all identified with expected frequencies (e.g. HER2 amplification in breast, PIK3CA mutations in ER+ breast cancer, EGFR mutations in NSCLC, etc.). Importantly, unexpected new and potentially actionable targets were identified in common (e.g., 6.7% HER2 amplification in NSCLC, 1.6% KRAS mutation in prostatic adenocarcinoma) and rare cancers (e.g., 8.3% ALK alteration in soft tissue sarcomas, 10.5% c-MET and 26.4% EGFR gene amplification in melanomas, 16.3% KRAS mutation in cholangiocarcinomas, 10% AR expression in STS), as well in cancers of unknown primary site (approximately 4% of all tested cases).  Conclusions', '  This review of the large referral cancer profiling database provided an unparalleled insight in the distribution of common and rare genetic and protein alterations with direct and potential treatment implications. Numerous targets were discovered that had a potential to be treated by the conventional chemotherapy as well as targeted therapy not usually considered for the cancer type. Comparison between an individual patient tumor profile and database for the matched cancer type provides additional level of support for targeted treatment choices.']",
        "Doc_id":"ASCO_110052-132",
        "Doc_title":" Integrating molecular profiling into cancer treatment decision making",
        "_version_":1606189019414134784},
      {
        "Meeting_name":" Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer.",
        "Background":"['Background', '  Cetuximab, a monoclonal antibody targeting the epidermal growth factor (EGFR) is active in patients with NSCLC. Gate keeper mutations in EGFR, such as T790M and activation of alternative driven pathways such as Met amplification are known mechanisms of acquired resistance to EGFR TKI. Here we evaluated the effects of the class I histone deacetylase inhibitors (HDACi), entinostat with cetuximab or EGFR TKIs in NSCLC cell lines with 3 potential mechanisms of intrinsic and acquired EGFR inhibitor resistance', ' RAS mutation according to E-cadherin expression, T790M EGFR mutation, and amplified MET.  Methods', '  In vivo efficacy of entinostat alone or in combination with cetuximab or gefitinib was tested in athymic nude mice bearing RAS mutant, E-cadherin positive (A549) and E-cadherin negative (NCI-H460) NSCLC xenograft tumors.  NSCLC cell lines were treated with various dilutions of cetuximab, entinostat or erlotinib. The NCI-H1975 and NCI-H1993 cell lines harboring the EGFR-L858R/T790M mutation and MET amplification, respectively, were treated with the combination of entinostat and erlotinib. Cell growth was analyzed by the MTT assay. Expression of e-cadherin was evaluated using affymetix microarrays.  Results', '  When entinostat (E; 5mg/kg) was combined with cetuximab (C; 25mg/kg) in nude mice bearing the E-cadherin positive A549 xenograft, tumor growth inhibition was higher than each drug alone in (C', ' 65%; E', ' 70%; E+C', ' 88%; p=0.001) or what is detected in the E-cadherin negative H460 xenografts (C', ' 3%, E', ' 64%, E+C', ' 75%). Synergistic effects were detected when entinostat was combined with erlotinib in the NCI-H1975 or NCI-H1993 cell lines (combination index, CI<1).  Conclusions', '  Entinostat enhances the effect of Cetuximab in vivo in Ras mutant, E-cadherin positive NSCLC cell lines, or erlotinib in cell lines harboring the EGFR mutation T790M or amplified MET. The combination of entinostat and EGFR inhibitors could provide the rational for developing clinical trials in patients with NSCLC with tumors resistant to EGFR inhibitors.']",
        "Doc_id":"ASCO_98995-114",
        "Doc_title":" Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer.",
        "_version_":1606188998396477440},
      {
        "Meeting_name":" Contribution of miR-205 in gefitinib-resistant lung cancer cell lines",
        "Background":"['Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib is effective therapies for patients with advanced non-small cell lung cancer (NSCLC). Treatment with gefitinib frequently induces drug resistance in NSCLC. Two mechanisms of acquired resistance have been validated in patients. Secondly mutations in EGFR itself, EGFR T790M and amplification of the MET oncogene are observed in resistance case. However, it remains unclear how MET over expression contributes to TKI resistant NSCLC. Recently, micro RNA (miRNA) expression is noted and analyzed because the concern of these molecules in cancer pathogenesis and drug resistance has been elucidated. Circulating tumor cell (CTC) and miRNA are focused as sensitive and non-invasive biomarkers for cancer diagnosis. In this study, we aimed at the miRNA in the gefitinib-resistant cell lines, and evaluated the miRNAs being associated with resistance of gefitinib. We established gefitinib resistant cell lines, in which MET is amplified, PC-9/MET and PC-9/MET-1K by a stepwise escalation of gefitinib concentrations in vitro. Microarray and real time PCR analysis indicated that miR-205 is significantly elevated in both resistant cell lines, and ErbB3 was a significant target. We examine further to reveal that relation between miR-205 and EGFR family, such as ErbB2 and ErbB3. Our results suggest that miR-205 may function as a gefitinib resistance in NSCLC.']",
        "Doc_id":"AACR_2014-1840",
        "Doc_title":" Contribution of miR-205 in gefitinib-resistant lung cancer cell lines",
        "_version_":1606189003431739393},
      {
        "Meeting_name":" Combination of crizotinib and radiation in the treatment of ALK-positive and cetuximab-resistant lung cancer",
        "Background":"['Approximately 4% of patients with non-small cell lung carcinoma (NSCLC) carry the EML4-ALK chromosomal rearrangement. Crizotinib, a c-MET and ALK inhibitor, has shown significant therapeutic benefit as a single agent with FDA approval for the treatment of patients with ALK-positive NSCLC. Since radiation commonly plays a key role in lung cancer treatment, we sought to evaluate the potential of crizotinib as a radiation sensitizer and the role of ALK in cellular radiation sensitivity. We examined the effect of crizotinib in combination with radiation on ALK signaling, cell proliferation, cell cycle distribution and radiosensitivity in ALK-positive NSCLC cell lines H3122 and H2228 in vitro. We also examined the in-vivo effects of crizotinib in combination with radiation in H3122 and H2228 xenograft models.Crizotinib blocked phosphorylation of ALK and its downstream effectors and inhibited cell proliferation in a dose-dependent manner. The combination of crizotinib and radiation resulted in increased inhibition of cell growth. Although cells were sensitized to radiation by crizotinib, molecular knockdown of ALK by siRNA had only modest impact on cell radiosensitivity. Cell cycle analysis by flow cytometry showed that ALK-siRNA induced G1 arrest. Interestingly, low dose crizotinib induced G1 arrest, while doses above 2M induced G2 arrest. Combination treatment induced arrest in G1 and G2 phases and decreased the cell population in S-phase. Moreover, in xenograft tumor models, we observed combined treatment to produce additive tumor growth inhibition over that observed with either drug or radiation alone.We further examined the capacity of crizotinib overcome cetuximab resistance in our established in vitro resistance models. Compared with parental cells, cetuximab-resistant cells showed cross-resistance to radiation. Crizotinib inhibited the growth of cetuximab-resistant cells and resensitized cells to radiation. Compared with single-agent treatment, the combination of crizotinib and erlotinib resulted in increased growth inhibition and further re-sensitization to radiation.These data suggest that crizotinib in combination with radiation can enhance the inhibitory effect on ALK-positive tumor cell growth in vitro and in-vivo and also suggest the potential value of using crizotinib in combination with other EGFR-targeting therapeutics. Ultimately however, the potential value of crizotinib as a radiation sensitizer requires systematic clinical investigation.']",
        "Doc_id":"AACR_2014-856",
        "Doc_title":" Combination of crizotinib and radiation in the treatment of ALK-positive and cetuximab-resistant lung cancer",
        "_version_":1606188982432956416},
      {
        "Meeting_name":" Integrative study of dysregulated genes in translocated ALK-positive non-small cell lung cancer and personalized targeted therapy resistance.",
        "Background":"['Background', ' Recent studies revealed that ALK (anaplastic lymphoma kinase) 2p23 translocation, most commonly fused with echinoderm microtubule-associated protein-like 4 (EML4), is a novel driver oncogene in about 5% of non-small cell lung cancer (NSCLC). ALK 2p23 fusion (ALK+) can be diagnosed by dual color break-part ALK FISH assay to inform personalized targeted therapy using the ALK inhibitor crizotinib. However, the underlying mechanisms of ALK oncogenic signaling and more importantly ALK inhibitor crizotinib resistance are not well understood.Materials and Methods', ' To understand the mechanism of oncogenic ALK signaling, an ALK+ NSCLC microarray dataset was retrieved from NCBI-GEO data repository (GSE31210) and analyzed using data-mining bioinformatics approaches. This dataset includes the gene expression profiles of 11 ALK+ NSCLC and 20 normal lung tissue samples. Statistical analysis was carried out to identify altered genes in ALK+ NSCLC and Ingenuity Pathway Analysis (IPA) software was deployed to uncover their network interactions. To study the resistance mechanism of the ALK+ H3122 human NSCLC cell line against the specific ALK inhibitor TAE684, real-time polymerase chain reaction (qRT-PCR), cell viability assay and immunoblotting were performed using standard techniques.Results', ' We identified a set of 1,656 genes that were significantly altered in ALK+ NSCLC, consisting of 662 upregulated and 994 downregulated. The principal component analysis (PCA) based on the top 51 of these dysregulated genes evidently separated ALK+ and normal lung tissue samples, implicating that these genes could represent potential genomic signature of ALK+ NSCLC. The IPA analysis revealed 35 canonical pathways linked to ALK signaling, including beta-adrenergic and angiopoietin signaling pathways. The results of qRT-PCR, cell viability assay and immunoblotting showed that in translocated ALK+ H3122 human NSCLC cell line, HGF (hepatocyte growth factor) overexpression could activate ALK downstream signaling via activation of MET receptor kinase pathway, thus potentially bypassing the oncogenic ALK signaling under ALK inhibitor TAE684 treatment. Hence, alternative direct activation of ALK downstream signaling molecules via MET/HGF axis activation may potentially contribute to ALK inhibitor drug resistance.Conclusion', ' Using bioinformatics data-mining, we have identified dysregulated genes and pathways in ALK+ NSCLC, many of which are novel biomarkers not previously reported. We also verified the relevance and potential key role of MET/HGF signaling axis in ALK inhibitor resistance. Taken together, our results highlighted the cross-talk between ALK and MET signaling in NSCLC and shed new insights into possible pitfalls of potential specific ALK targeting inhibitor drugs.']",
        "Doc_id":"AACR_2013-4466",
        "Doc_title":" Integrative study of dysregulated genes in translocated ALK-positive non-small cell lung cancer and personalized targeted therapy resistance.",
        "_version_":1606188970243260416},
      {
        "Meeting_name":" DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.",
        "Background":"['Background', '  DAB2IP loss promotes primary tumor growth by activating Ras and drives metastasis through NFkB, serving as a signaling scaffold to coordinately regulate these pathways. DAB2IP is frequently methylated in lung cancer, and methylation in the m2a region is a key regulatory factor for DAB2IP expression in prostate cancer. We examined DAB2IP methylation in cell lines and in serum from erlotinib-treated NSCLC p with EGFR mutations.    Methods', '  In human lung, breast and colorectal cancer cell lines, we analyzed DAB2IP promoter methylation in regions m2a and m2b by methylation-specific PCR (MSP) and bisulfite genomic sequencing. In circulating serum DNA from 152 erlotinib-treated NSCLC p with EGFR mutations, we analyzed methylation in the m2a and m2b promoter regions of DAB2IP by MSP. Methylation status was correlated with clinical outcome.  Results', '  Methylation was detected in the m2a region of 42 (27.63%) p, and in the m2b region in 51 (33.55%) p. There were no major differences in clinical characteristics (age, gender, smoking history, EGFR mutation type, metastatic sites) between p with methylation in the m2a region and p with methylation in the m2b region. Overall progression-free survival (PFS) was 15 months (m), and median survival (MS) 28 m for all 152 p. For the 41 p with bone metastases (mets), PFS was 14 m for 30 p without methylation in the m2a region vs 8 m for 11 p with methylation in the m2a region (P=0.01), and MS was 23 m vs 10 m, respectively (P=0.19). For the 57 p with distant mets but no lung mets, PFS was 18 m for 36 p without methylation in the m2a region vs 10 m for 21 p with methylation in the m2a region (P=0.01), and MS was 24 m vs 16 m, respectively (P=0.03). No differences in either PFS or MS were observed according to the methylation status of the m2b region.        Conclusions', '  Methylation in the m2a region of DAB2IP in serum DNA correlates with PFS and MS to erlotinib in NSCLC p with EGFR mutations with non-lung mets. Surveillance of DAB2IP methylation status in circulating DNA could be a useful tool to predict outcome to erlotinib in EGFR-mutated NSCLC p with non-lung mets.']",
        "Doc_id":"ASCO_77205-102",
        "Doc_title":" DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.",
        "_version_":1606189013770698752},
      {
        "Meeting_name":" IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors",
        "Background":"['EGFR is one of the oncogenic drivers in non-small-cell lung adenocarcinoma (NSCLC AC). EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib, show remarkable single agent activity in NSCLC AC with EGFR mutations. However, a majority of the tumors develop resistance within twelve months. T790M secondary EGFR mutation and activation of alternative signaling pathways, such as MET, are the two most common resistance mechanisms.To address this clinical challenge, we developed IMGN289, an EGFR antibody-drug conjugate consisting of the novel J2898A antibody (Ab), which selectively binds to and inhibits EGFR-driven tumor cell growth, conjugated to the maytansinoid DM1, a potent anti-microtubule agent, via the SMCC thioether linker. IMGN289 showed significantly enhanced cytotoxic activity, relative to cetuximab or unconjugated J2898A, against tumor cell line models that are dependent on EGFR signaling (Chittenden et al., AACR 2013). To evaluate the ability of IMGN289 to overcome mechanisms of EGFR TKI resistance, IMGN289 activity was tested in erlotinib-resistant EGFR-mutant cell lines which overexpressed MET (HCC827-ER) or carry the T790M EGFR mutation (HCC827-EPR) (Suda et al., Clin Cancer Res 2010). Despite variable levels of EGFR expression in these cell lines, (193,000, 32,500 and 422,000 antigens per cell in HCC827, HCC827-ER and HCC827-EPR, respectively), IMGN289 showed comparable cytotoxic activities against these cell lines in vitro. In addition to MET overexpression, the MET pathway can also be activated by HGF, the MET ligand. While addition of HGF made the HCC827 cell line resistant to EGFR TKIs (Yano et al., Cancer Res 2008) and decreased growth inhibition by cetuximab, IMGN289 activity was unaffected. Additionally, we generated an erlotinib-resistant HCC827-ER-E4 cell line by exposing the EGFR-mutant HCC827 cells to increasing concentrations of erlotinib for 6 months, followed by subcloning. The HCC827-ER-E4 cell line expressed mesenchymal markers and acquired a mesenchymal phenotype. It expressed lower levels of EGFR, HER3 and MET compared to the parental cell line and showed no loss of PTEN. In the presence of erlotinib, HCC827-ER-E4 cells retained high levels of pAKT and pERK, suggesting that activation of alternative signaling pathways may be responsible for the erlotinib resistance. In vitro cytotoxic assays showed that IMGN289 was equally cytotoxic to the parental and the HCC827-ER-E4 cell line.In conclusion, IMGN289 demonstrated EGFR-targeted cytotoxicity against NSCLC cell lines that harbor some of the most common mechanisms of resistance to EGFR TKIs. IMGN289 represents a promising novel candidate for treatment of EGFR-expressing NSCLC AC that has acquired resistance to EGFR TKIs.']",
        "Doc_id":"AACR_2014-4513",
        "Doc_title":" IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors",
        "_version_":1606188991830294528},
      {
        "Meeting_name":" Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).",
        "Background":"['Background', '    Tivantinib, an oral MET inhibitor, showed activity in patients (pts) MET-High at immunohistochemistry (IHC) in randomized, placebo controlled studies in HCC, NSCLC, CRC, and prostate cancer. ARQ 197-215 was a RCT of tivantinib in second-line HCC. The study randomized 107 pts 2', '1 to tivantinib capsules or placebo, reached the primary endpoint of time to progression in the intent-to-treat population and the pre-specified secondary efficacy endpoints, including OS, in MET-High pts. Tumor MET was also found to be a strong independent prognostic factor. This analysis aims to study prognostic and predictive value of tumor and circulating biomarkers. Methods', '    Circulating MET, HGF, and AFP were centrally analyzed by ELISA and median values were used as cut-offs to determine High or Low status except for AFP, where the 75thpercentile was also used. Tumor MET was centrally analyzed and considered High if staining was >2+ in >50% of cells at IHC.  Results', '    Circulating MET was prognostic (N=102; OS', ' 4.6 vs 8.9 months in High vs Low, HR=0.61, p=0.023) and trended towards predicting tivantinibs activity. MET was also a pharmacodynamic marker', ' pts on tivantinib with a MET reduction over time survived longer; MET was reduced in pts stable on tivantinib but not on placebo. Circulating HGF was prognostic (N=102; OS', ' 5.0 vs 9.0 months in High vs Low, HR=0.6, p=0.02) and changes over time correlated with outcome. AFP by the 75thpercentile was prognostic (N=104; OS', ' 3.0 vs 7.9 months in High vs Low, HR=0.36, p<0.0001). Median IHC score (H-Score) was 175 for tumor MET-High, 40 for MET-Low pts (N=77). MET was highly expressed in 40% of biopsies taken before and in 82% of biopsies taken after sorafenib. A significant interaction between tivantinib and tumor MET in terms of OS was observed (p=0.039). No biomarker except for tumor MET was predictive of response to tivantinib.  Conclusions', '    A clear prognostic value was found for circulating MET, HGF, and AFP by the 75th percentile. Tumor MET was highly prognostic and predictive. IHC results on over 900 tumor samples analyzed in the ongoing METIV-HCC phase 3 study will also be presented. Clinical trial information', ' NCT00988741']",
        "Doc_id":"ASCO_159801-173",
        "Doc_title":" Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).",
        "_version_":1606188982303981568},
      {
        "Meeting_name":" Phase I study of polyphenon E (P) in addition to erlotinib (E) in advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    E is an oral tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). Polyphenon E is a green tea extract containing mainly epigallocatechin gallate (EGCG) which inhibits c-met and vascular endothelial growth factor (VEGF) signaling.  In vitro studies and in vivo tumor models have demonstrated synergism from EGCG when to added E . This phase I study evaluated safety and tolerability of P and E in patients (pts) with advanced NSCLC. Methods', ' Pts with stage IV NSCLC who had progressed after first or second line chemotherapy were included in the study. Pts were enrolled in cohorts of 3 with increasing dose of P (200mg, 400mg and 800mg PO once daily). E was given at 150mg/day continuously in 28 day cycles. End points were safety, tolerability and maximum tolerated dose (MTD) of P in combination with E.    Results', '    Between April 2008 and Nov 2010 a total of 11 pts were enrolled.  Two pts were not included in the final analysis as they discontinued therapy due to progression or worsening of performance status prior to completing the required minimum of 4 weeks of treatment. Median age was 64.6 years (range 57-75). All pts were male and all were current or former smokers. Seven patients had squamous cell histology and two had adenocarcinoma. There were no serious adverse events. Four pts developed acneiform rash (2  grade 2 and 2  grade 1). One patient developed herpes zoster deemed  unrelated to treatment. One patient in the 400mg cohort developed grade 2 transaminitis which resolved after temporarily holding E and P.  MTD of P in combination with E was not reached.  Nine patients were assessed for tumor response, 6 patients had stable disease and 3 had progression of disease. The median progression-free survival for the entire group was 3 months.  Conclusions', '    The combination of P and E was well-tolerated with no dose limiting toxicity observed at the maximum planned dose of P of 800mg. Preliminary efficacy data suggest a progression-free survival that is modestly better than that reported with E alone. This is the first reported trial evaluating the addition of P to E in NSCLC. Larger prospective studies are required to better define the role of this combination as second-line therapy in advanced NSCLC.']",
        "Doc_id":"ASCO_82412-102",
        "Doc_title":" Phase I study of polyphenon E (P) in addition to erlotinib (E) in advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188999280427008},
      {
        "Meeting_name":" Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells",
        "Background":"['Insulin-like growth factor (IGF) signaling is thought to have a role in the cancer progression and survival, and many carcinomas are known to overexpress IGF-1 receptor (IGF1R). Furthermore, it was clarified that IGF1R signaling contributes to EGFR-TKI resistance in NSCLC. IGF1R is thought to be a therapeutic target for cancer chemotherapy. Previously, we screened the combination effect of afatinib and various anticancer drugs on a panel of NSCLC cell lines including gefitinib-resistant and afatinib-resistant PC-9 cells which we established. As the result, the combination of afatinib and small molecule IGF1R-TKIs (BMS754807, NVP-ADW742) has shown the most cytotoxicity on wide variety cancer cells. However, these IGF1R-TKIs have cross-reactivity to insulin receptor and, as a result, are known to cause hyperglycemia. Moreover, a phase III trial of the combination chemotherapy between erlotinib and IGF1R specific antibody, figitumumab, in advanced nonadenocarcinoma NSCLC patients (ADVIGO 1018)was closed early because of futility and an increased incidence of serious adverse events.BI836845 is a humanized IGF ligand-neutralizing antibody which is neutralizing both IGF-1 and IGF-2. The proliferation of several cell lines was reported to be potently inhibited by BI 836845 with lower than 100 g/ml EC50 values. This antibody is thought to be a substitute approach to inhibit IGF1R signaling pathway other than previous IGF1R-TKIs. We evaluated the combination effect of afatinib and BI836845 on the same NSCLC panel by MTS assay. BI836845 had only a limited cytotoxicity by itself. The combination of afatinib and BI836845 had additive or synergistic cytotoxicity on most of the NSCLC cell lines including EGFR-TKIs-resistant cells except the cells overexpressing c-Met or expressing K-ras mutation. This combination significantly inhibited both EGFR and IGF1R autophosphorylation and their downstream signaling, especially Akt/mTOR pathway, as compared with each singular usage. These combination effects were attenuated when BI836845 combined with erlotinib. Since BI836845 cross-react to rodent IGFs, we examined pharmacological activity of this combination using SCID mice xenograft mode. The mice bearing tumor were given 6 mg/kg afatinib (5 times/week, p.o.) and 200 mg/kg BI836845 (1 time/week, i.p.) for 8 weeks. This combination synergistically inhibited afatinib-resistant tumor (PC-9Afa1, PC-9Afa2) and gefitinib-resistant tumor (PC-9ZD, expressed T790M mutant EGFR). This BI836845 administration completely inhibited IGFs activity in the mice serum without alteration of blood sugar level and insulin concentration. Though growth rate of the treated mice was slightly reduced, body weight loss and other serious adverse events were not observed.From these observations, this combination chemotherapy is thought to be a potential therapeutic strategy for NSCLC.']",
        "Doc_id":"AACR_2016-1208",
        "Doc_title":" Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells",
        "_version_":1606188982234775552},
      {
        "Meeting_name":" The molecular characters of acquired resistant non-small cell lung cancer cells to afatinib",
        "Background":"['[Background] The non-small cell lung carcinomas (NSCLCs) with activating epidermal growth factor receptor (EGFR) gene mutation show significant response to EGFR-tyrosine kinase inhibitors (TKIs). However, almost all of them acquire resistance to EGFR-TKIs due to various mechanisms, such as T790M mutation or MET amplification. Afatinib is an irreversible TKI for EGFR and HER2 and known to be effective to the EGFR T790M variant. However, a half of the patient responded afatinib acquire resistance by 12 months in clinical use. Thus, to unravel the mechanisms of the resistances and to overcome them are still important issues of EGFR-TKI treatment. In this study, we established various kinds of afatinib resistant cell lines with changing drug exposing condition as we previously reported (Shien K. et al Cancer Res. 2013). We also investigated these cell lines to understand mechanisms of afatinib resistances in NSCLC.[Materials and Methods] Afatinib resistant cell lines were established using four NSCLC cell lines with activating EGFR mutations by exposing afatinib with different procedures, escalation from 1 nM, escalation from 10 nM, intermittent 2 M and continuous 2 M procedures. These cell lines were investigated about previously reported resistant related features, T790M mutation, MET amplification, and epithelial to mesenchymal transition (EMT). ALDH1A1 and ABCB1 expression, which were putative stem cell markers, were also investigated. Proliferative inhibitions with various drugs were evaluated using MTS assay.[Results] There were no T790M mutations in all afatinib resistant cell lines. HCC827 sublines exposed afatinib with escalation from 1 nM and intermittent 2 M, and HCC4011 sublines showed MET amplification. HCC827 sublines exposed afatinib with escalation from 10 nM and continuous 2 M, and HCC4006 sublines showed EMT features. Furthermore, ALDH1A1 and ABCB1 expression were up-regulated in HCC827 afatinib resistant sublines with EMT features. Next, we examined the effect of afatinib or crizotinib for the afatinib resistant cell line with MET amplification. We found that combination therapy with afatinib and crizotinib was effective to the MET amplified cell. The combination exposure was continued to establish a resistant subline (HCC827-ACR) to combination therapy. The HCC827-ACR was also showed EMT features and up-regulation of stem cell markers.[Conclusions] As in the cases of reversible EGFR-TKI, MET amplification, EMT, and stem cell-like features were emerged in afatinib resistant cells. To develop strategies to resistant cells with stem cell-like property may be critical part to overcome EGFR-TKI resistance.']",
        "Doc_id":"AACR_2014-1834",
        "Doc_title":" The molecular characters of acquired resistant non-small cell lung cancer cells to afatinib",
        "_version_":1606189014498410497},
      {
        "Meeting_name":" A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' MET and VEGF play important roles in the pathobiology of NSCLC, and are associated with resistance to E. XL184 is an oral, potent inhibitor of MET, VEGFR2, and RET, with antitumor activity in combination with E in NSCLC xenografts with acquired E resistance. Thus, XL184 + E may be effective in pts with acquired E resistance. Methods', ' Adults with previously treated advanced NSCLC received daily doses of XL184 + E in a 3 + 3 design using combination doses across 5 cohorts in 2 parallel arms (A and B). Objectives include safety, pharmacokinetics (PK), pharmacodynamics, and maximum tolerated dose (MTD) determination. RECIST response is assessed every 8 weeks. Pts with at least 2 post-baseline tumor assessments or pts who discontinued early for PD or AE were assessable for response. Results', ' 54 NSCLC pts have been enrolled in phase Ib, the majority had prior E. The dose levels were', ' arm B (75 mg XL184 + 150 mg E and 50 mg XL184 + 150 mg E (MTD) and arm A (75 mg XL184 + 100 mg E; 125 mg XL184 + 100 mg E; and 125 mg XL184 + 50 mg E). MTD determination of arm A is ongoing. Across all dose levels, 12 pts experienced at least 1 DLT', ' diarrhea, elevated AST, palmar-plantar erythrodysesthesia, mucositis, hypertension, hypokalemia, elevated lipase, and fatigue. Of 34 pts in safety database, most frequent frade 3/4 AEs were diarrhea (26%), fatigue (15%), dyspnea (12%), and hypoxia (9%). Preliminary PK analysis does not show evidence of DDI. Genotyping plasma tumor DNA from 28 pts revealed EGFR T790M mutations in 7 pts (25%). FISH analysis of circulating tumor cells from 7 pts revealed MET copy number gain in 2 pts (28%). Six of 36 pts assessable for response including at least 3 pts with prior E therapy had  30% reduction in tumor measurements on at least 1 post-baseline scan, including 3 with a cPR (1 with MET amplification). Prolonged SD  4 months has been observed in some pts including one pt for 9+ months and one pt with EGFR T790M. Conclusions', ' The overall safety and tolerability profile of XL184 + E appears acceptable without evidence of a XL184/E DDI. Encouraging clinical activity of XL184 + E was observed in a largely E pretreated population, including pts with EGFR T790M and MET amplification.']",
        "Doc_id":"ASCO_49381-74",
        "Doc_title":" A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).",
        "_version_":1606189018093977600},
      {
        "Meeting_name":" ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).",
        "Background":"['Background', ' Transforming rearrangements of the ALK gene have been reported in a subset of NSCLC, commonly fusing the ALK kinase domain with EML4 promoter but rarer fusion partners (TFG and KIF5B) have also been described. ALK is a valid clinical target based on phase I clinical data with dual ALK/MET inhibitor. We investigated the cytogenetic patterns of ALK rearrangements using FISH and the molecular and clinical characteristics associated with ALK+ in an unselected NSCLC population. Methods', ' Cohort included 447 NSCLC with previous EGFR and MET copy number gain (CNG) available; median age at diagnosis = 66 years, 83% male, 52% former and 35% current smokers; 52% of tumors were adenocarcinoma/BAC, stage I to IV was 37%, 22%, 27%, and 14%, respectively. Dual color FISH analyses were performed with ALK break-apart probe (Abbott Molecular) and 3 novel fusion probe sets specific for EML4-ALK, KIF5B-ALK and TFG-ALK. Results', \" Using the break apart probe, 12 patients (2.68%) were identified as ALK+. Multiple different cytogenetic patterns were observed, but virtually all carried the EML4-ALK fusion when specific probe sets were used. Using logistic regression analyses, higher odds were verified for ALK+ among males vs. females (p = 0.03), never vs. ever smokers (p = 0.005), adenocarcinoma vs. other histologies (p = 0.0013), and younger vs. older age (p = 0.08). No association was found between ALK+ and clinical stage, EGFR or MET CNG. There was no association between survival and ALK+ after adjusting for patient's gender, smoking history, histology and age (HR = 0.70; 95% CI 0.0256, 1.913, p = 0.48). Conclusions\", ' In this large study of unselected Caucasian NSCLC patients, ALK+ was associated with male gender, never smoking status and adenocarcinoma histology suggesting these factors could be used to enrich ALK screened populations. The specific FISH probe sets identified EML4- ALK in different FISH patterns observed with the ALK rearrangement probe. ALK+ is distinct from EGFR and MET CNG, suggesting independent molecular mechanisms. ALK+ showed no significant prognostic impact, the observed favorable effect was unstable most likely due to the low number of ALK+.']",
        "Doc_id":"ASCO_50876-74",
        "Doc_title":" ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).",
        "_version_":1606188975708438528},
      {
        "Meeting_name":" A survey of thousands of tumor exomes and transcriptomes to expand clinical opportunities for crizotinib.",
        "Background":"['Background', '  Cancer driver events occur as a result of chromosomal rearrangements. There are several examples where targeted inhibition of the resulting fusion produces dramatic clinical response. For example, the EML4-ALK fusion in non-small cell lung cancer (NSCLC). Other ALK fusions have been described in NSCLC and other diseases including the NPM-ALK fusion in anaplastic large cell lymphoma (ALCL). The efficacy of crizotinib and other ALK inhibitors are being investigated in these diseases. ALK is also subject to activation via mutation and sensitivity to crizotinib is reported in ALK mutation positive neuroblastoma. Finally, crizotinib has activity not only against ALK, but also against ROS1, MST1R and MET. ROS1 fusions have been found in NSCLC and glioblastoma, and MET amplification events in gastric adenocarcinoma identify additional settings that may benefit from crizotinib treatment.   Methods', '  To further understand the full therapeutic potential of Crizotinib, we undertook a genomic survey of ALK, ROS1, MET and MST1R across 1,000s of patients from the The Cancer Genome Atlas (TCGA) and Oncomine.  Results', '  We confirmed the presence of EML4-ALK fusions in both lung and colorectal cancer (CRC), and also identified a novel ALK fusion in CRC. ALK hotspot mutations and focal amplifications were confined to neuroblastoma, as previously described. Our survey of ROS1 identified rare novel fusions in NSCLC and glioblastoma, and high-level amplifications in liposarcoma (2%) and rarely in breast cancer (0.2%). No fusions were identified for MET, however high-level amplifications were observed in 1-5% of papillary renal cell carcinoma, the intestinal subtype of gastric adenocarcinoma, oliogodendroglioma, glioblastoma and lung adenocarcinoma. Hotspot mutations were frequently observed in squamous head and neck (11%), and more rarely in hepatocellular carcinoma, small cell lung and ovarian cancers.   Conclusions', '   These results leverage all available genomic profiling data to provide a broadened scope of therapeutic opportunity for inhibitors like crizotinib. With the growing availability of next-generation sequencing, such surveys can support hypothesis-driven development of targeted therapies.']",
        "Doc_id":"ASCO_117415-132",
        "Doc_title":" A survey of thousands of tumor exomes and transcriptomes to expand clinical opportunities for crizotinib.",
        "_version_":1606188991182274560},
      {
        "Meeting_name":" Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Several immunotherapy approaches are currently under investigation in patients (pts) with human malignancies, including NSCLC, although clinically objective responses are observed only in a minority of cases. Tumoral expression of nitrotyrosines (NT), a marker of peroxynitrite activity in tissues, has been shown to suppress antitumor immune response in prostate cancer by negatively affecting tumor-infiltrating lymphocytes (TILs), and has emerged as a poor prognostic factor in breast cancer and melanomas, leading to the development of inhibitors of key enzymes involved in NT formation (inducible nitric oxide synthase [iNOS] and arginase [ARG] isoforms). The present study aimed to investigate the prognostic impact of NT expression in a formerly published cohort of unselected surgically resected NSCLC pts. Methods', ' NT expression was assessed by immunohistochemistry (IHC) in TMA sections including 447 surgically resected NSCLCs with known MET gene copy number status by FISH. All cases were assessed in triplicate. IHC results were scored from 0 to 3+ according to staining intensity. Results', ' NT IHC was successfully performed in 442 pts with the following results (n/%)', ' 0 (17/3.9), 1+ (230/52.0), 2+ (173/39.1), 3+ (22/5.0). Pts were grouped as NT+ (2-3+) and NT- (0-1+). No significant association was observed between NT status and clinicopathological characteristics, including sex, smoking status, stage, histology and grade, although female patients tested more frequently negative than positive (64% vs 36%). Interestingly, MET FISH+ pts had a higher probability of having an NT+ score (p=0.044), when compared with MET FISH- subjects. Overall survival was significantly longer in NT+ vs NT- pts, with a 5-year survival of 51.0 vs 38.1 months (p=0.025, log rank test). Multivariable analysis corrected for stage and MET gene status, previously reported as significant prognostic factors in this cohort, confirmed that NT+ pts had a lower risk of death when compared with the NT- group (HR 0.72, p=0.021, Cox model). Conclusions', ' NT are frequently overexpressed in NSCLC and represent an independent favourable prognostic factor in surgically resected pts. Assessment of TILs, iNOS and ARG in this cohort is ongoing.']",
        "Doc_id":"ASCO_84435-102",
        "Doc_title":" Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC).",
        "_version_":1606188994833416192},
      {
        "Meeting_name":" Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' The EGFR-TKIs erlotinib and gefitinib produce dramatic regressions of tumor in ~ 70% of NSCLC patients with activating mutations in the EGFR-TK domain. After a median time to progression of ~1 year, most pts have progressive disease. We undertook this study to search for mechanisms of \"acquired resistance\" to EGFR-TKIs, to determine the spectrum and frequency of secondary EGFR mutations which arose, and to determine the feasibility of rebiopsy in this setting. Methods', \" All pts had metastatic or recurrent NSCLC and prior treatment with EGFR-TKI and progressive disease while on EGFR-TKI. Pts must also have had an activating EGFR mutation OR radiographic response (RECIST or WHO) to EGFR-TKI OR significant and durable improvement in cancer-related symptoms as judged by patient's physician. Core biopsies were performed and studied for EGFR mutation (exons 18-21 including PCR-based test for T790M) and MET amplification. Results\", ' From 8/04-12/08 98 pts were consented for rebiopsy and 85 underwent the procedure. Demographics Female/Male=59/39; median age 62 (range 28-88); smoking', ' never=59, former/current=39. Primary EGFR mutation was exon 19 del-39; exon 21 L858R-11, other/WT-28, pending-7. Median time on EGFR-TKI before biopsy was 12 months (7-28 months). Secondary EGFR mutations', ' T790M-33, other-2, none detected-31, indeterminate-10, pending-9. MET amplification in 2/16 studied to date. Conclusions', ' 1) Rebiopsy of patients with NSCLC and acquired resistance to EGFR TKIs is feasible and well-received by pts. 2) Knowledge of EGFR genotype including EGFR T790M and MET status can inform clinical trials of targeted therapies in this population 3) More complete annotation of MET status and exploratory analyses of profiles of specimens by metastatic sites and prior EGFR-TKI versus chemo and EGFR-TKI is ongoing. Supported by the Doris Duke Foundation, the LaBrecque Foundation, Steps for Breath, NIH, and an anonymous donor.']",
        "Doc_id":"ASCO_34544-65",
        "Doc_title":" Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC).",
        "_version_":1606188970459267072},
      {
        "Meeting_name":" Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.",
        "Background":"['Background', ' Savolitinib (AZD6094, volitinib, HMPL-504) is a potent & selective small molecule MET inhibitor. In preclinical models the combination of savolitinib & gefitnib was more effective than either compound alone (DCruz et al, 2014; Zhou et al, 2013). EGFR TKI failure is frequently attributable to MET amplification. Methods', ' The intent of the study is to test that NSCLC pts who progressed on previous EGFR-TKI treatment, can receive treatment with gefitinib & savolitinib & potentially demonstrate an improved clinical response. This study (NCT02374645) has 2 phases', ' safety run-in phase (n~12) & expansion phase (n~20). Eligibility requires advanced EGFRm+ NSCLC, measurable disease, adequate PS (0-1) & organ function, progression on any prior EGFR-TKI. MET status is not required for the safety run-in but MET amplification by tumor biopsy confirmation is mandatory in the expansion phase. Data from the safety run-in phase presented here are unvalidated & preliminary. Results', ' As of 17 January 2016, 13pts have completed the DLT assessment with fixed dose of gefintinib 250 mg QD in combination with savolitinib at 600 mg QD (n = 6) & 800 mg QD (n = 7). No DLT in the 600mg QD cohort & a potential DLT of G3 febrile neutropenia in the 800 mg QD cohort. 11pts are evaluable for response & 12pts are evaluable for safety analysis at the data cut off. Drug-related (either gefitinib or savolitinib) adverse events most common across both dose levels were nausea (40% - G1), blood bilirubin increased (30% - G1/2), vomiting (30% - G1). Two confirmed partial responses (pts METamp neg) were reported at 12wks so far with this combination, at 18wks 1pt had PD & 1pt is ongoing. Exposure & PK parameters for gefitinib & savolitinib lie within range& align well with historical data. Conclusions', ' The toxicity & PK profile of savolitinib makes rational combination with gefitinib feasible in EGFRm+ NSCLC pts who failed EGFR TKI. The expansion phase in pts with MET amplification will evaluate anti-tumour activity. Reference', ' DCruz, C et al Cancer Res 2014;74(19 Suppl)', 'Abstract nr 3114. Zhou, F et al Cancer Res 2013;73(8 Suppl)', 'Abstract nr 971 Clinical trial information', ' NCT02374645']",
        "Doc_id":"ASCO_165713-176",
        "Doc_title":" Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.",
        "_version_":1606189023818153984},
      {
        "Meeting_name":" First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.",
        "Background":"['Background', ' LDK378 is a novel, potent and selective small molecule anaplastic lymphoma kinase (ALK) inhibitor (IC50 0.00015 M), that does not inhibit c-MET (IC50 3.2 M). Tumor regression has been observed in ALK-driven NSCLC xenografts. A first-in-human, Phase I study is being conducted to determine the MTD and safety profile in patients (pts) with tumors with ALK rearrangement, amplification or mutation. Other objectives were safety, PK and antitumor activity in pts with ALK-driven NSCLC, both nave to ALK inhibitors and relapsed following previous ALK inhibitor treatment, and other ALK-positive cancers. Methods', ' Adult pts with advanced malignancies harboring a genetic alteration in ALK who progressed on standard therapy or for whom there was no effective therapy, were given once daily oral LDK378 on a continuous 21-day schedule. Dose escalation, starting at 50 mg/day, was guided by a Bayesian logistic regression model (BLRM) to determine the MTD. Results', ' At a January 5th 2012 cutoff,31 pts (primary site', ' lung 26 pts; breast 3 pts; other 2 pts; median age 52 years; 87% ECOG PS 0/1) were enrolled and received LDK378 at doses of 50750 mg/day. Two dose limiting toxicities, Grade (Gr) 3 alanine aminotransferase elevation (1 pt), and Gr 3 hypophosphatemia (1 pt) occurred in 8 pts at a 400 mg dose level. BLRM allowed dose escalation, and there were no DLTs in 4 pts at 500 mg. Median duration of treatment with LDK378 was 7 weeks (range <122+). At the cutoff date, 13 (42%) pts discontinued treatment', ' 1 (3%) due to adverse events (AEs), and 12 (39%) due to disease progression; 18 (58%) pts were still on treatment. The most frequent AEs (all Gr) were nausea (45%), vomiting (36%), and diarrhea (29%). The most frequent Gr 3/4 AEs were diarrhea and dyspnea (2 pts [7%] each). At doses 400 mg steady state exposures exceeded efficacious exposures in xenograft models. Of 16 pts with available response data (RECIST, per investigator) there were 4/6 responses in crizotinib (CRZ)-treated pts, and 2/10 responses in CRZ-nave pts, of whom 7 were treated below 400 mg. All responses were in NSCLC. Conclusions', ' Daily oral LDK378 is well tolerated up to 500 mg/day, and escalation continues at 750 mg/day. Preliminary responses have been seen in both CRZ-nave and CRZ-relapsed pts.']",
        "Doc_id":"ASCO_95081-114",
        "Doc_title":" First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.",
        "_version_":1606188980897841152},
      {
        "Meeting_name":" LY2801653",
        "Background":"['Under normal conditions MET receptor activation, internalization, and degradation is a highly controlled process regulated by the binding of its ligand, HGF. In many cancers however, MET becomes highly dysregulated, and MET overexpression, with or without gene amplification, is associated with a poorer prognosis. Aberrant activation of MET can also occur through mutation, or increased autocrine or paracrine HGF production. MET activation leads to increased oncogenic activities including cell migration, proliferation, invasion, survival, tumor neovascularization and decreased apoptosis. Several inhibitors of MET, including type I and type II kinase inhibitors, are currently being investigated in clinical trials. LY2801653 is a type II MET kinase inhibitor being investigated in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037). In addition to MET, LY2801653 also inhibits ROS1 kinase, and the serine/threonine kinases MKNK1/2, with cell-based IC50 of 23nM and 7nM respectively. ROS1 is an orphan receptor that can be constitutively activated as a fusion protein either by genomic microdeletion or translocation. ROS1 fusion proteins are found in glioblastoma, NSCLC and cholangiocarcinoma. MKNK1/2 are kinases downstream of ERK and p38 and are capable of regulating translation through the direct phosphorylation of eIF4E. Increased MKNK1/2-dependent phosphorylation of the translation factor eIF4E is observed in head and neck squamous cell carcinoma and is correlated with a poor prognosis. This study evaluated the relative inhibitory effects of LY2801653, Crizotinib, XL184, XL880, and PF4217903 in a variety of cell lines against MET, ROS1, MKNK1/2, ERK, and other downstream molecules. In HCC78, a ROS1-fusion protein bearing cell line, and in NIH3T3 cells stably transfected with the FIG-ROS(s) fusion, LY2801653, XL184 and XL880 were more potent inhibitors of ROS1 compared with Crizotinib. Moreover, LY2801653 and Crizotinib were both efficacious in NIH3T3 FIG-ROS(s) xenografts, although LY2801653 was more potent in reducing p-ROS1 in these tumors than Crizotinib. In NCI-H2122 and Hs746T cells (mutated MET), A2780 cells (MET-negative), KP-4 cells (MET autocrine), H441 cells (HGF-independent; MET positive), HCT116 (mutated KRAS), and the cholangiocarcinoma cell lines EGI-1 and TFK-1, LY2801653 demonstrated more potent inhibitory activity against MKNK1/2 versus treatment with XL184 and XL880, while Crizotinib had no observed inhibitory activity against MKNK1/2. LY2801653 also showed inhibitory activity against MKNK1/2 in MET-amplified MKN45 cells. These findings suggests there may be clinical merits to testing LY2801653 in tumor types associated with increased MKNK1/2 activity or ROS1 fusion proteins alone, or in conjunction with aberrant MET activity, such as colorectal carcinoma, head and neck squamous cell carcinoma, and cholangiocarcinoma.']",
        "Doc_id":"AACR_2013-3042",
        "Doc_title":" LY2801653",
        "_version_":1606188998554812416},
      {
        "Meeting_name":" Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel.",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with broad spectrum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using the Next Generation Sequencing (NGS) technology, has become a key tool for NSCLC patients treatment decision and clinical management. Methods', ' The performance of a custom 23 gene multiplex amplification hot spot panel, based on Ion AmpliSeq Technology, was evaluated for the analysis of tumor DNA extracted from FFPE (Formalin Fixed Parraffin Embedded) tissue. Furthermore the Ion AmpliSeq RNA Fusion Lung Cancer Research Panel was used for fusion RNA transcript analysis. Tumors mutation spectrum was determined in a cohort of 502 patients with NSCLC using the aforementioned targeted gene panels. Results', ' The panel used for tumor DNA analysis in this study exhibit high rates (100%) of sensitivity, specificity and reproducibility at a mutation frequency of 3%. At least one DNA mutation was detected in 374 patients (74.5%) and an RNA fusion was identified in 16 patients, (3.2%). In total, alterations in a cancer driver gene were identified (including point mutations, gene rearrangements and MET amplifications) in 77.6% of the tumors tested. Among the NSCLC patients, 13.5% (68/502) presented a mutation in a gene with approved targeted therapy (EGFR, ALK ROS1) and 9.4% had an alteration in a gene related to emerging targeted therapies according the NCCN guidelines. These alterations include ERBB2, BRAF and MET mutations, MET amplification and RET rearrangements. The remaining 51.6% of the patients had a mutation in a gene that could be related to an off label therapy or give them access to a clinical trial. Conclusions', ' Thus the NGS panel validated is a reliable approach of clinical applicability for tumor molecular profile detection in NSCLC patients.']",
        "Doc_id":"ASCO_189381-199",
        "Doc_title":" Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel.",
        "_version_":1606188989988995072},
      {
        "Meeting_name":" Epithelial mesenchymal transition and its role in TKI resistant NSCLC cell lines",
        "Background":"['NSCLC cells acquire resistance to EGFR and c-Met TKIs after prolonged use. Our studies indicate that resistance maybe due to upregulation of alternative signaling pathways such as Wnt and mTOR. We have found that activation of Wnt/-Catenin is also associated with EMT which results in loss of cell adhesion properties and gain of motility and invasiveness. To understand the mechanism of TKI resistance in NSCLC cells with wild type EGFR, we have developed and used H2170-P (parental) cells and the TKI resistant H2170-ER (erlotinib resistant) and H2170-SR (SU11274 resistant) cells. We aim to study EMT and determine if inhibition of -Catenin, a key regulator of transcription by siRNA or inhibition of ZEB-1 a transcriptional repressor of cell adhesion proteins by inducing mir-200a will help overcome the TKI resistance in NSCLC cells.Using immunoblotting, we observed modulations in key EMT-related proteins in H2170-ER cells which showed upregulation of ZEB-1, N-cadherin, active beta-catenin, Vimentin, PRMT1 and ZO1 by 1.8, 2.4, 2, 1.8, 2.6 and 2 fold, respectively, and downregulation of E-cadherin (1.8 fold) as compared to H2170-P cells. Similar results were observed for H2170-SR cells. These results were verified using qPCR where we show that -catenin (3.4-3.2 fold) and N-cadherin (2-1.9 fold) have increased gene expression while E-cadherin (1.7-2.4 fold) has a decreased gene expression in TKI resistant H2170-ER and SR cells when compared to H2170-P cells. miR-200a induction in H2170-ER cells showed significant downregulation of ZEB-1 (3 fold) at 72 hr and an upregulation of E-cadherin (2 fold) when compared to the mock transfected cells. Morphological changes indicative of EMT were detected using immunofluorescence with Vimentin and E-Cadherin antibodies, which displayed upregulation of Vimentin filaments (2 fold) and downregulation of E-Cadherin (3 fold) in H2170-ER and H2170-SR cells when compared to H2170-P cells. We then conducted experiments where we suppressed ZEB-1 by inducing miR-200a in TKI resistant cells. The immunoblotting results suggested recovery of E-Cadherin, and downregulation of ZEB-1 and N-Cadherin in TKI resistant cells. We also observed increased sensitivity towards erlotinib and SU11274 by 20-25%. Additionally, we observed decrease in levels of -Catenin and upon siRNA knockdown of -Catenin, suppression of levels of ZEB-1. This indicates a direct correlation between nuclear accumulation of -Catenin and occurrence of EMT in TKI resistant cells by increase in expression of ZEB-1.Our results indicate that increased activation of Wnt/-Catenin pathway in the TKI resistant NSCLC cells is due to the EMT. In NSCLC patients, L858R and T790M mutations are associated with TKI resistance which could be responsible for inducing EMT. We are further studying cell lines with EGFR mutations to determine their role in induction of EMT this may provide clinicians with novel targets to overcome TKI resistance in NSCLC patients.']",
        "Doc_id":"AACR_2016-1599",
        "Doc_title":" Epithelial mesenchymal transition and its role in TKI resistant NSCLC cell lines",
        "_version_":1606189008706076672},
      {
        "Meeting_name":" Tumor biomarker evaluation of 6,785 patients for combination treatment strategies in NSCLC.",
        "Background":"['Background', '  Non-small cell lung cancer (NSCLC) exhibits activation of multiple tumor pathways.  Presence of multiple aberrations may account for drug resistance as well as strategies for combination therapies. We examined concurrent aberrations of biomarkers in NSCLC to present an overview of potential patient cohorts who may benefit from such combinations.   Methods', '  6,785 NSCLC cases were evaluated.  Specific testing was performed and included a multiplatform approach', ' sequencing (Sanger, NGS), protein expression (IHC) and gene amplification (CISH/FISH).   Results', '  The EGFR mutation (MT) rate in this population was 12.7% (135/1059), of which 57% (55/96) overexpressed EGFR (IHC) and 61% (169/277) had EGFR gene amplification (FISH).  This demonstrates the dependence on the EGFR pathway and potential importance of dual inhibition with cetuximab and EGFR TKIs.  66% (63/96) and 7% (6/90) of EGFR MT patients were MET high (IHC) and amplified (CISH), respectively, suggesting potential benefit from dual targeting of EGFR and MET.  Interestingly, TP53 mutations were observed in 54% (70/129) of EGFR MT which has important implications for resistance to EGFR TKIs and possible cross-resistance to radiotherapy.  ALK translocations were observed in 101 of 3611 (2.8%) patients, among which 19% (7/36), 3% (1/29) and 2% (1/48) carried concurrent EGFR, MET and HER2 amplification (ISH), respectively, suggesting the potential for combining crizotinib with agents such as cetuximab, onartuzumab or trastuzumab.  A BRAF mutation was observed in 3.3% (34/1061), among which EGFR and MET expression was high by IHC (both have been implicated in resistance to BRAFi in other tumor types) in 58% (15/26) and 48% (12/25), respectively, indicating benefit from combination of newly approved dabrafenib with cetuximab or onartuzumab.   Conclusions', '  This is one of the largest analyses in the United States of biomarkers in NSCLC.Our study shows the non-exclusive activation of multiple pathways.  These results also show the importance of multiplatform testing as both protein, gene copy number and genetic alterations were detected.']",
        "Doc_id":"ASCO_133696-144",
        "Doc_title":" Tumor biomarker evaluation of 6,785 patients for combination treatment strategies in NSCLC.",
        "_version_":1606189008883286017},
      {
        "Meeting_name":" A randomized phase II study of paclitaxel (P) and carboplatin (C)  bevacizumab (B)  dulanermin (D) in non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' D is a pro-apoptotic agonist of death receptors 4 and 5. A randomized, open-label, 5-arm, phase II study evaluated the efficacy and safety of PC  B  D in patients (pts) with advanced NSCLC. Methods', ' Planned sample size = 200 (40/arm). Eligible pts', ' chemonave, advanced NSCLC, ECOG PS 0-1. A brain scan was mandatory. Pts received P (200 mg/m2) + C (AUC = 6 mg/mL min). Pts with squamous NSCLC and/or CNS metastases (met) received PC (Arm 1) vs. PC + D (8 mg/kg for 5 days; Arm 2). Pts with non-squamous NSCLC and no CNS met received PC + B (15 mg/kg; Arm 3) vs. PCB + D (8 mg/kg for 5 days; Arm 4) vs. PCB + D (20 mg/kg for 2 days; Arm 5). Pts received PC  B  D  6 cycles Q3W, then continued B and/or D until disease progression. Primary endpoint', ' objective response rate (ORR; central assessment of complete and partial responses by modified RECIST). Results', ' 213 pts were randomized (41, 42, 44, 43, 43 to arms 1-5); all were eligible; 41, 39, 42, 40, 41 received  1 dose of study drug. Median age was 60 (range 23-79) years, 63% were men, 42% were ECOG PS 0. As of 10/09, 194 pts (dosed; 96%) had discontinued treatment; median follow-up = 49 (range 0-91) wks. See Table for efficacy and safety. The most common serious adverse events (SAE) were pneumonia and pulmonary embolism (each = 4%). Conclusions', ' PC  D  B was well tolerated. In this study, the addition of D did not appear to improve efficacy compared with the standard treatment arms. Squamous NSCLC and/or CNS met Nonsquamous NSCLC and no CNS met 1', ' PC2', ' PC + D2 vs. 13', ' PCB4', ' PCB + D5', ' PCB + D4 vs. 35 vs. 3 ORR16 (39%)16 (38%)OR = 1.04(0.39, 2.76),p = 122 (50%)17 (40%)17 (40%)OR = 1.53 (0.6, 3.91), p = 0.39OR = 1.53(0.6-3.91),p = 0.39 PFS events;KMmedian(95% CI),mo85%; 6.1(5.4-7.4)76%; 5.5(4.7-6.7)HR = 0.89(0.54, 1.46), p = 0.6568%; 7.3(5.6, 8.5)63%; 8.6(6, 12.6)63%; 9.5(6.8, 13.7)HR = 0.83 (0.49, 1.40), p = 0.48HR = 0.88 (0.52, 1.48), p = 0.62 OS events;KMmedian (95%CI),mo61%; 10.1 (8.2, NE)60%; 9.8 (5.9, 16.4)HR = 1.14 (0.66, 1.99) p = 0.6452%; 15.1 (9, NE)51%; 13.9 (11.4, 18.3)56%; 14.3 (10, 16.1)HR = 1.03 (0.57, 1.86) p = 0.92HR = 1.04 (0.59, 1.85) p = 0.89 AE37 (90%)36 (92%)41 (98%)40 (100%)39 (95%)Grade  3 AE17 (41%)30 (77%)29 (69%)23 (58%)30 (73%)SAE11 (27%)22 (56%)19 (45%)18 (45%)18 (44%)']",
        "Doc_id":"ASCO_44085-74",
        "Doc_title":" A randomized phase II study of paclitaxel (P) and carboplatin (C)  bevacizumab (B)  dulanermin (D) in non-small cell lung cancer (NSCLC).",
        "_version_":1606188979398377472},
      {
        "Meeting_name":" PD-L1 expression and its relationship with other driver genes in non-small cell lung cancer (NSCLC)",
        "Background":"['Aims', ' In order to understand the potential patient population who could benefit from anti PD-1/PD-L1 mono or combinational therapies, this study aimed to profile a panel of immune-mediated therapy for cancer (IMT-C) related biomarkers (CD8, PD-1, PD-L1 and CTLA-4) and molecular targeted therapy biomarkers (EGFRmut, KRASmut, ALK, ROS1 and MET) in NSCLC patients.Methods', ' Tumor samples from 356 Chinese NSCLC patients including 191 adenocarcinomas (AD) and 142 squamous carcinomas (SCC) were analyzed in this study. There were 221 early stage (I to IIIa) and 113 late stage (IIIb and IV) patients.PD-L1, PD-1, CTLA-4 and MET expression were detected using immunohistochemical (IHC) staining on formalin fixed paraffin embedded (FFPE) tissues. PD-L1 and CD8 expression were also simultaneously observed using a dual-color immunofluorescence (IF) assay. EGFR and KRAS mutations were detected by sequencing analysis. ALK and ROS1 gene rearrangements were defined by break-apart FISH assays, and MET gene amplification was also detected using a FISH assay.Results', ' Among 356 NSCLC patient samples, 145 (40.7%) had PD-L1 positive staining on 5% tumor cells (TC). The PD-L1 positive rate on TC was significantly higher in SCC than in AD (47.9% vs 34.0%, p = 0.011). In AD patients, PD-L1 expression was significantly elevated in males (p = 0.0059), smokers (p = 0.0003), higher tumor grade (p<0.00001) and late stage (p = 0.0009) patients. In addition, we found that 53.1% (113/213) patient samples had PD-L1 expression on tumor infiltrating immune cells (IC). Again, the PD-L1 positive rate on IC was higher in SCC than in AD (66.0% vs 36.6%, p<0.0001). Comparing the two cell types, 70% of the total cases had consistent PD-L1 staining status (positive or negative) on TC and tumor infiltrating IC (p<0.0001). Among 117 cases detected using dual-color IF, all had CD8 positive lymphocytes in the tumor samples while 54 cases were PD-L1 TC positive. The most interesting finding was CD8 and PD-L1 double stained lymphocytes were mainly located in the tumor center in 37 out of 42 cases. Furthermore, combined analysis of the eight biomarkers studied in this cohort of NSCLC samples showed that tumor PD-L1 positive staining (on 5% tumor cells) had overlaps with the other NSCLC driver genes alterations in 28% of SCC and 69% of AD samples.Conclusion', ' This study showed almost half of NSCLC patients have PD-L1 positive expression on TC, which to some extent overlaps with EGFR/KRAS mut, ALK/ROS1 rearrangement and MET alteration. As a potential patient selection biomarker, the PD-L1 positive prevalence in NSCLC TC and/or tumor infiltrating IC provides a strong evidence for PD-1/PD-L1 immune therapy in single agent or in combination with the molecular targeted agents. Furthermore, CD8+ lymphocyte infiltration in the tumor center and its PD-L1 expression status might also be considered as part of patient selection biomarker strategy.']",
        "Doc_id":"AACR_2016-5140",
        "Doc_title":" PD-L1 expression and its relationship with other driver genes in non-small cell lung cancer (NSCLC)",
        "_version_":1606189020371484672},
      {
        "Meeting_name":" Quality of surgical resection for non-small cell lung cancer (NSCLC) in a U.S. metropolitan area.",
        "Background":"['Background', ' Curative treatment of early stage NSCLC requires good quality oncologic resection (GQR). For GQR, the National Comprehensive Cancer Network (NCCN) requires a minimum of segmentectomy, negative margins, lymph node (LN) sampling from stations 10-14 (level-1) and >2 mediastinal (level-2) stations. We reviewed details of consecutive resections for NSCLC to determine the proportion that met NCCN GQR criteria and the proportion who would have met eligibility for the RADIANT trial which requires >1 level-2 stations. Methods', \" Retrospective review of medical records of all patients who underwent curative- intent resection for NSCLC in the Memphis Metropolitan Area from 1/1/2004 to 12/31/2007. Resections for benign and metastatic disease were excluded. Death information was obtained from a national death index search. Categorical variables were compared by chi-square test or Fisher's exact test, survival curves by log-rank test. Results\", ' 746 patients were eligible (Table). Median age was 67.7 (range, 36.5 - 89.4). 61/746 (8.2%) met NCCN GQR criteria. Black patients were more likely than whites to have GQR (P=0.022). No other patient demographic factor was associated with GQR. Three year survival was 72% in those with GQR versus 63% in those without GQR (P=0.50). There was a difference in achievement of GQR between the 3 major institutions where surgery was done (P=0.001) although it was low across the board. 77.9% of patients would have been disqualified from the RADIANT trial. Conclusions', ' Majority of surgical resections for NSCLC did not achieve GQR standards per RADIANT and NCCN. The greatest deficit is in surgical sampling of level-2 LNs, but evaluation of level-1 LNs is also frequently sub-optimal. Intervention is needed to improve current surgical and pathology practices in collection and examination of surgical specimens in order to achieve minimum standards for accurate staging, prognostication, determination of candidacy for post-operative adjuvant therapy, and eligibility for clinical trials.']",
        "Doc_id":"ASCO_34296-65",
        "Doc_title":" Quality of surgical resection for non-small cell lung cancer (NSCLC) in a U.S. metropolitan area.",
        "_version_":1606189040753704960},
      {
        "Meeting_name":" S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation",
        "Background":"['Background', ' Aberrant activity of MET, FGFR1 and AXL has been associated with development of resistance to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) patients. S49076 is a potent ATP-competitive tyrosine kinase inhibitor (TKI) of MET, AXL/MER, FGFR1/2/3 currently in phase I clinical trials.Methods', \" We obtained six resistant lines by treating EGFR-mutated, TKI-sensitive PC9 cells with increasing concentrations of gefitinib (GR1-5) or erlotinib (ER). The six resistant cell lines conserved the exon 19 deletion but the T790M resistance mutation only emerged in two (GR1, GR4), which remained sensitive to AZD9291, a third generation EGFR TKI. Six new AZD9291-resistant cell lines were derived from GR1 and GR4 by exposure to increasing concentrations of the inhibitor. Three of the AZD9291 resistant cell lines lost the exon 19 and T790M mutations, one conserved only the sensitizing mutation and two kept both mutations but with the T790M dropping to very low allelic fractions (1% and 0.03%). All resistant cell lines were characterized for AXL, MET, MER, FGFR1 and FGFR2 expression by Q-RT-PCR, immunohistochemistry and Western blotting. The effects of S49076 on the parental and resistant cell lines were analyzed by MTT, colony formation, basal membrane invasion and migration assays. Western blotting of key signal transduction proteins was used to gain insight in the drug's mechanism of action.Results\", ' AXL overexpression was the most common event related to gefitinib/erlotinib resistance in the panel of cell lines, with T790M mutation, FGFR1 or BCL-2 overexpression and MET activation being less frequent events. Regarding AZD9291 resistance, AXL upregulation was again widespread, with loss of EGFR mutations as the second most frequent event. In proliferation assays, S49076 showed strong antitumor activity against all PC9-derived cell lines with acquired resistance to EGFR TKIs (erlotinib, gefitinib or AZD9291) and not carrying the T790M mutation, with IC50 of 0.2-1.2 M and less than 10% surviving cells at 1 M of drug in most cases. In contrast, S49076 was less active against the parental PC9 cells and the T790M positive resistant lines, with more than 50% of surviving cells at 50 M of drug. S49076 also inhibited the anchorage-independent growth and migration of the resistant cell lines. A correlation was found between mRNA and protein levels of AXL and sensitivity to S49076. Also, PARP cleavage and moderate but reproducible inhibition of AKT phosphorylation by S49076 were observed exclusively in the non-T790M resistant cell lines.Conclusions', ' S49076 shows strong activity in preclinical assays against EGFR mutated cell lines resistant to EGFR TKIs not harboring EGFR T790M mutation and overexpressing AXL. A clinical trial of S49076 in non-T790M patients progressing to EGFR TKI and overexpressing AXL or MET has been initiated.']",
        "Doc_id":"AACR_2016-336",
        "Doc_title":" S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation",
        "_version_":1606189014486876160},
      {
        "Meeting_name":" Onartuzumab (MetMAb) restores sensitivity to erlotinib in EGFR mutant NSCLC cells expressing HGF",
        "Background":"['Background', ' Onartuzumab (MetMAb) is a humanized monovalent monoclonal antibody that blocks binding of HGF to Met. The combination of onartuzumab + erlotinib is currently being evaluated in a Phase III clinical trial for 2nd/3rd line NSCLC (1). EGFR-activating mutations, including deletions of exon 19 and L858R point mutations, are associated with better response to erlotinib. However, EGFR mutant NSCLC tumors with high HGF expression are less responsive to EGFR small molecule inhibitors (2) (3). Since onartuzumab blocks HGF-induced Met activation, the addition of onartuzumab to erlotinib may be more beneficial than erlotinib alone in such patients. To test this hypothesis preclinically, we engineered the human NSCLC cell line PC9 (exon 19 deletion of EGFR and Met positive) to express hHGF endogenously, and evaluated combination effects of onartuzumab + erlotinib in vitro and in vivo. Methods', ' PC-9 cells were transfected with hHGF expression plasmids, and a stable clone was selected. For in vitro analyses, parental PC-9 cells and PC-9/hHGF cells were treated with various concentrations of erlotinib combined with 30g/mL of onartuzumab, and cytotoxicity was examined. Additionally, the phosphorylation status of Met, EGFR, ERK and AKT was examined by western blot analysis of whole cell lysates. For in vivo analyses, PC-9/hHGF cells were inoculated subcutaneously into nude mice. After tumors reached approximately 200 mm3 in volume, onartuzumab (30 mg/kg, IP, Q3W) was administered alone or in combination with erlotinib (50 mg/kg, PO, daily) and tumor volume was measured over time. Results', ' One stable clone with high expression of hHGF was selected by hHGF ELISA and western blotting. This PC-9/hHGF clone was less sensitive to erlotinib compared to the parental PC-9 in vitro. Adding onartuzumab to erlotinib suppressed proliferation of these PC9/hHGF cells. pERK and pAKT levels were significantly reduced when PC-9/hHGF cells were treated with onartuzumab + erlotinib. In PC-9/hHGF xenograft tumors, onartuzumab or erlotinib alone had modest effects on tumor growth. However, combining onartuzumab and erlotinib dramatically suppressed tumor growth. Conclusions', ' Overexpression of hHGF decreases response of PC9 cells to erlotinib. Onartuzumab + erlotinib was more efficacious than erlotinib alone on PC9/hHGF cells in vitro and in vivo. These data support the hypothesis that addition of onartuzumab to erlotinib may enhance efficacy of erlotinib in EGFR mutant NSCLC tumors. References', ' (1) NCT01456325 at www.clinicaltrials.gov (2) S. Yano et al. Cancer Res 68 (2008) (3) A. B. Turke et al. Cancer Cell 17 (2010)']",
        "Doc_id":"AACR_2012-2728",
        "Doc_title":" Onartuzumab (MetMAb) restores sensitivity to erlotinib in EGFR mutant NSCLC cells expressing HGF",
        "_version_":1606189041805426689},
      {
        "Meeting_name":" SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).",
        "Background":"['Background', ' NSCLCs harboring activating EGFR mutations often respond to EGFR TKIs, but drug resistance invariably occurs, usually after 9-12 months. Although two validated resistance mechanisms include T790M (50%) and MET amplification (10-15%), the mechanisms of drug resistance (MODR) in the remaining 35-40% of pts remain unknown. We recently implemented an innovative multiplexed PCR-based assay (SNaPshot) to genotype cancer pts more comprehensively. SNaPshot is performed in a CLIA-certified lab with tumor DNA from paraffin-embedded samples; it tests for common mutations in 13 key oncogenes such as EGFR, KRAS, PIK3CA, BRAF, and TP53. We examined SNaPshot results in EGFR mutant cancers with acquired TKI-resistance. Methods', ' We reviewed all NSCLC samples sent for prospective SNaPshot analysis from 03/09 to determine the range of tumor genotypes. A simultaneous chart review identified EGFR mutant pts undergoing repeat biopsy after the development of TKI-resistance in which a corresponding pre-treatment tumor sample was available for SNaPshot analysis and MET FISH testing. Results', ' A total of 271 patients with NSCLC underwent SNaPshot testing between 03/09 and 11/09; 164 (61%) were found to have at least one mutation. We identified 27 EGFR mutant pts who developed TKI-resistance and had paired samples available. SNaPshot results are summarized in the Table. Interestingly, 3 pts demonstrated a major histological change from NSCLC to SCLC in the TKI-resistant biopsy (confirmed by IHC), while maintaining the original EGFR mutation. Conclusions', ' Here we introduce SNaPshot as a comprehensive tumor genotyping assay that is valuable for examining MODR in the clinic. Among 27 EGFR mutant pts with TKI-resistance, T790M was found in 48% and MET amplification in 4%. Notably, 1 pt acquired a PIK3CA mutation, which has been described as a MODR in vitro. Three pts experienced a fundamental transformation from NSCLC to SCLC harboring the same EGFR mutation. Investigation into the significance of the SCLC evolution and the remaining pts without identified MODR is ongoing. Observed resistance mechanismsNumberTotal pts27T790M (2 T790M + TP53)13MET amplification1PIK3CA1No identified mutations12']",
        "Doc_id":"ASCO_43365-74",
        "Doc_title":" SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).",
        "_version_":1606188970069196800},
      {
        "Meeting_name":" Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.",
        "Background":"['Background', ' Radiogenomics is focused on defining the relationship between image and molecular phenotypes. Therefore, we assess the association between metastatic sites at baseline CT and molecular abnormalities (MA) in NSCLC patients (pts). Methods', ' One senior radiologist reviewed retrospective basal CT scans of metastatic NSCLC pts from Gustave Roussy included in the MSN cohort. Tissue biopsy samples of these pts were collected for detecting the molecular profile by NGS platform (Ion-torrent) and/or Sanger sequencing molecular test as daily clinical practice. Radiological characteristics regarding metastatic sites were correlated with the molecular profile. Results', ' From 06/2009 to 06/2015, 332 metastatic NSCLC pts treated with first-line platinum-based chemotherapy were included (median age 59 years, 63% males, 14% never smokers, 76% adenocarcinoma, 11% with squamous cell carcinoma). Number of metastatic sites by patient was', ' one for 49%, 2 for 28%, 3 for 14%, > 4 for 9%. After 32.4 months of median follow-up, the median overall survival was of 15.3 months (95%CI', ' 12.9-17.8). Overall, 60% of NSCLC pts had a MA', ' 28% KRAS mutation, 14% EGFR mutation, 6% ALK rearrangement, 5% MET amplification or mutation, and 7% other mutations (BRAF and PI3K mutation, and HER2 mutation or amplification). Among pts with KRAS (n = 93), EGFR (n = 47), ALK (n = 21) and MET(n = 16) abnormalities, the respective percentages of brain, adrenal, metastatic pleural effusion, bone and lung metastases were', ' 39%/28%/18%/40%/33%; 45%/6%/36%/47%/49%; 52%14%/19%/43%/48%; and 44%/25%/0%/44%/25%. Among the 12 pts with peritoneal carcinomatosis, 5 had a mutation (3 with KRAS, 1 NRAS and 1 BRAF). Conclusions', ' Bone is the most common site of metastases in NSCLC pts. Baseline metastatic sites in molecular selected NSCLC pts are different according to the molecular abnormality. Among KRAS mutant tumours there are a higher percentage of adrenal metastases and a trend toward association with peritoneal carcinomatosis, whereas among ALK tumors exists higher percentage of brain metastases than pleural effusion. MET tumors have a tropism for the brain similar to the other molecular abnormalities, whereas lung metastases are especially frequent in EGFR and ALK tumours.']",
        "Doc_id":"ASCO_169610-176",
        "Doc_title":" Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.",
        "_version_":1606189022723440640},
      {
        "Meeting_name":" Tyrosine kinase inhibitor resistance were decreased in spheroid culture platform.",
        "Background":"['Lung cancer is the leading cause of cancer related death in the world. Platinum-based combination regimen or molecular target drugs, such as EGFR tyrosine kinase inhibitors (EGFR-TKIs) are used for first line chemotherapy of non small cell lung cancer (NSCLC). Somatic mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified in NSCLC and those mutations confer sensitivity to the EGFR-TKIs such as gefitinib. Unfortunately, it is already known that the almost cases are developed to drug resistance after chemotherapy. Several EGFR-TKI resistant mechanisms have been reported, including T790M gefitinib/erlotinib resistance mutation, C797S osimertinib resistant mutation, c-MET amplification and ErbB3 activation. In the previous study, we revealed that the miRNA biosynthesis pathway was critical for maintain the cisplatin resistant phenotype. Further, it was reported that EGFR modulated miRNA maturation through the phosphorylation of AGO2. Protein phosphorylation is one of most important post transcriptional modification mechanisms and miRNA is also associated with fine tuning of mRNA expression. Thus, we focused on the relationship between miRNA expression and kinase signaling in gefitinib resistance.Generally, developed resistant cell lines and cell culture techniques were used in resistance research. However, some resistance mechanisms observed in cultured cells are not reflected the in vivo. Recently, some three-dimensional (3D) cell culture techniques are developed and expected to bridge the gap between normal cell culture and in vivo models. In this study, we attempted to analyze the resistant mechanism of gefitinib resistant cell lines in suspended spheroid culture using RPMI1640 medium containing suspension polymer, FP001. We screened differences of relative resistance to anticancer compounds in 3D culture and normal culture condition using chemical library and ATP assay. As results; we revealed that ErbB3 and Akt phosphorylation levels were significantly decreased in spheroid formed from resistant cell lines in 3D culture condition compared to these levels with normal culture condition. On the other hand, miR-205 levels remain high in all resistant cell lines. Furthermore, some anticancer agents, including kinase inhibitors showed higher sensitivity in resistant cell lines under 3D condition than that under normal cell culture. We speculate that the decreased resistance depends on normal culture in plastic dish and remaining resistant mechanism in 3D culture is important and similar to in vivo. In conclusion, this approach with 3D culture is more close to in vivo, such as xenograft model, and promising contribute to drug resistance research.']",
        "Doc_id":"AACR_2017-4098",
        "Doc_title":" Tyrosine kinase inhibitor resistance were decreased in spheroid culture platform.",
        "_version_":1606188998937542656},
      {
        "Meeting_name":" LYN is a new prognostic and therapeutic target in non-small cell lung cancer",
        "Background":"['SRC family kinases (SFKs) have a strong rationale as a clinical strategy in non-small cell lung cancer (NSCLC). Unfortunately, the reviewed study showed disappointing activity of SFK inhibitor dasatinib in molecularly unselected patient cohort. Therefore, the studies in NSCLC should be investigated to identify patients more likely to benefit from dasatinib either as monotherapy or in combination with other agents. Here, we considered that LYN may play specific roles in lung cancer and therefore analysed survival prognosis according to the expression of LYN and the effect of dasatinib on the inhibition of cell growth and LYN activity. We evaluated LYN expression by immunohistochemistry on 446 NSCLCs using paraffin-embedded tissues. Elevated LYN expression level of NSCLCs, especially in adenocarcinoma, female, and non-smoker, affected poor overall survival (OS, P=0.036). In lung adenocarcinoma cell lines, LYN expression impacted on cell proliferation, migration and invasion. Dasatinib treatment resulted in decreased cell viability in most of these cell lines. Also, we found that dasatinib suppressed active tyrosine phosphorylation of LYN. In the resistant cell lines, H23 and SK-LU-1, which showed elevated epidermal growth factor (EGFR) and MET activities, combined treatment of EGFR or MET inhibitor with dasatinib revealed the synergistic effects on decreased cell viability. Our findings highly suggest that LYN has potential as a new selected target molecule of SFKs in the treatment of NSCLCs.']",
        "Doc_id":"AACR_2014-2785",
        "Doc_title":" LYN is a new prognostic and therapeutic target in non-small cell lung cancer",
        "_version_":1606188991439175680},
      {
        "Meeting_name":" In vivo generation of EGFR-TKI resistance in a patient-derived xenograft (PDX) with an activating EGFR mutation (L858R), and molecular characterisation of resistance mechanisms..",
        "Background":"['BACKGROUND', ' Non-small cell lung cancer (NSCLC) patients that have activating mutations in the EGFR gene are treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) e.g. Erlotinib (Tarceva) and Gefitinib (Iressa). Most NSCLC patients with activating EGFR mutations will respond to EGFR-TKIs; however, in about 50% of these cases a secondary mutation in EGFR (T790M) subsequently occurs which results in resistance to treatment. Other mechanisms of clinical resistance can also occur such as amplification of MET kinase and EMT conversion; however, additional routes of resistance are poorly defined. Using a novel patient-derived NSCLC xenograft model, driven by the L858R EGFR mutation, we set out to recapitulate the reported clinical routes of resistance to EGFR inhibitors and to evaluate if additional mechanism could also be identified.METHODS', ' LION102 is a NSCLC adenocarcinoma patient-derived xenograft (PDX) model with an activating EGFR mutation (L858R) which is maintained subcutaneously in vivo admixed with a human stromal cell component. Resistant models were generated in vivo through repeated cycling of treatment for up to 10 weeks with EGFR-TKI alone or in combination with a MET inhibitor. Resistant tumour material was characterised for further mutations in the EGFR gene by direct sequencing as well as for MET, AXL and HER2 over-expression and genomic amplification by quantitative PCR; Epithelial-to-Mesenchymal transition (EMT) was assessed by immunohistochemistry (IHC).RESULTS', ' Nave LION102 PDX tumours exhibited exquisite sensitivity to EGFR-TKIs (100% reduction in pre-treatment tumour volume, p<0.0001). Following successive cycles of EGFR-TKI treatment in vivo several resistant subtypes were generated and characterized.CONCLUSIONS', ' EGFR-TKI resistant subtypes were generated in vivo from a proprietary patient-derived xenograft model (LION102) bearing an activating EGFR mutation (L858R) and characterised for their resistance mechanism. PDX models of resistance will be invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent or overcome resistance to EGFR-TKIs.']",
        "Doc_id":"AACR_2013-5651",
        "Doc_title":" In vivo generation of EGFR-TKI resistance in a patient-derived xenograft (PDX) with an activating EGFR mutation (L858R), and molecular characterisation of resistance mechanisms..",
        "_version_":1606188998858899456},
      {
        "Meeting_name":" Different receptor tyrosine kinases mediate EMT and erlotinib-resistance in NSCLC cell lines through bypass signalling",
        "Background":"['Introduction', ' Erlotinib is a potent drug in the treatment of EGFR-driven lung cancer. Many patients initially benefit from erlotinib treatment, but nearly all acquires resistance and die of the disease. Several mechanisms related to erlotinib-resistance have been described including epithelial to mesenchymal transition (EMT). Signalling by TGF, Wnt or through receptor tyrosine kinases can initiate EMT, but not much is known about the trigger in relation to erlotinib-resistance. In this study, we investigate how EMT is initiated in two erlotinib-sensitive NSCLC cell lines developing erlotinib-resistance.Methods', ' HCC827 (EGFR mutated) and Calu-3 (HER2 amplified) were treated with erlotinib in escalating concentrations (0.01 M - 5 M) over approximately 3 months, and erlotinib resistant (ER) sublines were established and investigated.Results', ' Both HCC827ER and Calu-3ER gained EMT features including upregulation of SLUG, SNAIL and ZEB1. These changes were accompanied by increased IGF1R signalling in Calu-3ER and HCC827ER gained a MET amplification. To detect the relevance of MET and IGF1R signalling in accordance to EMT, we treated the cells with the tyrosine kinase inhibitors crizotinib (MET) and linsitinib (IGF1R). In both cases, we saw a decrease in EMT-marker transcription after the treatment. In addition, HCC827ER showed growth inhibition when treated with the MET-inhibitor crizotinib, but linsitinib did not inhibit the growth of Calu-3ER. Conclusion', ' Our study demonstrates how different receptor tyrosine kinase signalling pathways can induce EMT during the development of erlotinib-resistance. Furthermore, we show that EMT can accompany well-know resistance mechanisms such as MET-amplification and hereby contribute to the phenotype of the resistant cells.']",
        "Doc_id":"AACR_2015-339",
        "Doc_title":" Different receptor tyrosine kinases mediate EMT and erlotinib-resistance in NSCLC cell lines through bypass signalling",
        "_version_":1606188997797740545},
      {
        "Meeting_name":" Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.",
        "Background":"['Growth factor receptors (GFRs) are amenable to therapeutic intervention in cancer and it is important to select patients appropriately.One of the mechanisms for activation of GFRs is gene amplification (GA) but discrepancies arising from the difficulties associated with data interpretation and the lack of agreed parameters confound the comparison of results from different laboratories. Here, we attempt to establish appropriate conditions for standardization of the determination of GA in a panel of GFRs. A NSCLC tissue microarray panel containing 302 samples was screened for alterations at ALK,FGFR1, FGFR2, FGFR3, ERBB2, IGF1R, KIT, MET and PDGFRA by FISH, immunostaining and/or real-time quantitative RT-PCR. Strong amplification was found for FGFR1, ERBB2, KIT/PDFGRA and MET, with frequencies ranging from 1 to6%. Thresholds for overexpression and GA were established. Strong immunostaining was found in most tumors with ERBB2, MET and KIT amplification, although some tumors underwent strong immunostaining in the absence of GA. KIT and PDFGRA were always co-amplified, but only one tumor showed PDGFRA overexpression, indicating that KIT is the main target.Amplification of FGFR1 predominated in squamous cell carcinomas, although the association with overexpression was inconclusive. Interestingly, alterations at ALK,MET, EGFR, ERBB2 and KRAS correlated with augmented levels of phospho-S6 protein, suggesting activation of the mTOR pathway, which may prove useful to pre-select tumors for testing.Overall, here, we provide with parameters for the determination of GA at ERBB2, MET, KIT, and PDGFRA which could be implemented in the clinic to stratify lung cancer patients for specific treatments.']",
        "Doc_id":"AACR_2013-3034",
        "Doc_title":" Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.",
        "_version_":1606189042072813568},
      {
        "Meeting_name":" Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.",
        "Background":"['Background', '   Activating mutations of the epidermal growth factor receptor (EGFR) were discovered over 10 years ago. EGFR mutations predict increased response rates and progression-free survival (PFS) when treated with EGFR tyrosine kinase inhibitors (TKIs) compared to combination chemotherapy in advanced NSCLC. However, long-term outcomes including 5-year survival among patients (pts) with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs remain heterogeneous. Herein, we define clinical factors associated with prolonged overall survival (OS) in this cohort.   Methods', '   A retrospective analysis was performed of pts with metastatic NSCLC harboring a sensitizing EGFR mutation and treated with EGFR-TKIs at Dana-Farber Cancer Institute between Jan 1, 2002 and Sept 31, 2009. Pts alive at time of analysis must have had at least a 5-year survival. OS was compared based on clinical features using log-rank test. Coxs proportional hazards models were used to estimate hazard ratios.   Results', '   Among 134 pts, median PFS and OS were 13.1 mos (95% CI, 10.8-14.6) and 30.9 mos (95% CI, 28.2-35.7), respectively. 19 pts (14.2%) were long-term survivors (OS  5 years), of whom 10 remained alive at the time of analysis with median follow-up of 89.8 mos (range, 60.1-91.6). Multivariate analysis adjusted for factors significant at the 0.10 level in univariate models revealed that sensitizing EGFR mutations in exons other than exon 19 (n = 55) (HR 1.53; 95% CI, 1.05-2.23; p = 0.03), extrathoracic mets (n = 77) (HR 1.58; 95% CI, 1.04-2.43; p = 0.03) or brain mets (n = 29) (HR 2.17; 95% CI, 1.34-3.51, p = 0.002) at the time of diagnosis, and current smoking status (n = 5) (HR 4.31; 95% CI, 1.64-11.32; p = 0.003) were independent predictors of shorter OS. Age, gender, disease stage at diagnosis, liver or adrenal mets at diagnosis, specific TKI (erlotinib vs gefitinib), or line of TKI treatment did not correlate with OS.   Conclusions', '   Our data estimate 5-year OS among EGFR-mutant metastatic NSCLC pts treated with EGFR-TKIs at 14%--vs less than 5% in historic results for an unselected population with distant-stage NSCLC. Planned studies will elucidate the genetic alterations that may co-occur with EGFR mutations and influence treatment outcomes.']",
        "Doc_id":"ASCO_146757-156",
        "Doc_title":" Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.",
        "_version_":1606189010650136576},
      {
        "Meeting_name":" Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy",
        "Background":"['Background', '  MET and VEGF are important in mediating NSCLC tumorigenesis and EGFR TKI resistance. We hypothesized that treatment with the dual MET-VEGF inhibitor cabozantinib plus erlotinib in EGFR mutation-positive NSCLC following PD on EGFR TKI therapy may allow for tumors to overcome this resistance or restore sensitivity to therapy.      Methods', '  Eligible pts were required to have known EGFR mutation and PD on an EGFR TKI immediately prior to enrollment without intervening therapy.  Pts received erlotinib 150 mg daily + cabozantinib 40 mg daily on a 28 day cycle.  This was a single-arm study to distinguish between a promising response rate of 20% and a discouraging response rate of 5% (requiring at least 4/37 responders). There was a pre-planned analysis of the percent of patients with at least a 30% increase in the tumor doubling time (DT), reflecting a reduction in the tumor growth rate with the addition of cabozantinib using each patients tumor growth rate during prior TKI treatment as their own control.  Secondary endpoints include the evaluation of specific EGFR mutations and MET amplification in pre-treatment tissue.    Results', '  37 patients were registered between 5/2013 and 1/2014 in 4 centers; 35 have been treated. Median age was 63 years, 63% female and 51% ECOG PS 0. 4 pts had a PR (2 confirmed, 2 unconfirmed), with 13 patients remaining on treatment. In addition, 20/23 demonstrated significant growth rate reduction corresponding to a greater than 30% increase in DT.  Diarrhea (10/35, 29%) was the most common grade 3 AE; 2 patients (6%) had a grade 3 maculopapular rash. Grade 4 AEs include vomiting (1), elevated lipase (2), elevated amylase (1). Ongoing correlative studies are to determine correlation of response with MET amplification and T790M mutation.  Conclusions', '  Combination erlotinib and cabozantinib demonstrates anti-tumor activity in pts with EGFR mutation and PD on EGFR TKI. Supported by NCI N01CM2011-00038 and U01CA062505. Clinical trial information', ' NCT01866410.']",
        "Doc_id":"ASCO_132255-144",
        "Doc_title":" Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy",
        "_version_":1606189014190129153},
      {
        "Meeting_name":" Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Most patients (pts) with anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) NSCLC develop resistance to tyrosine kinase inhibitor (TKI) therapy, with the central nervous system (CNS) as a common site of relapse. Lorlatinib is a selective brain-penetrant ALK/ROS1 TKI active against most known resistance mutations. Methods', ' In Ph. I of the ongoing Ph. I/II study NCT01970865, eligible pts had ALK+ or ROS1+ NSCLC with/without brain metastases (mets) and were treatment nave or had disease progression after 1 TKIs. Pts received lorlatinib on day 7 and daily from day 1. Primary objective was to identify the MTD and recommended Ph. II dose (RP2D). Other objectives were safety and efficacy by RECIST v1.1, including intracranial activity. Results', ' Of 54 pts treated in Ph. I as of Nov 30 2015, 41 were ALK+, 12 ROS1+; and 1 with mutation status not recorded at cut-off date. Pts were heavily pretreated', '27 had received >1 prior TKI, 20 1 prior TKI and 7 were TKI nave; 39 pts had CNS mets at baseline. Pts were treated across 10 dose levels (10200 mg). Response rates (RR) are shown in the Table. 29 pts remain on treatment. The most common treatment-related adverse events (AEs) were hypercholesterolemia (54%) and peripheral edema (37%). Hypercholesterolemia was the most common (9%) grade (G) 3 treatment-related AE and most frequent reason for dose delay/reduction. No pt discontinued due to a treatment-related AE. One DLT occurred in a pt who received <16/21 planned 200 mg daily doses due to G2 CNS AEs. CSF concentrations in steady-state samples from 3 pts with CNS mets showed excellent penetration of lorlatinib into the CNS. Conclusions', ' Lorlatinib was well tolerated and demonstrated durable clinical responses, including intracranial responses, in ALK+ (including G1202R+) pts and ROS1+ NSCLC pts, many of whom had CNS mets and 1 prior TKIs. The RP2D was identified as 100 mg once daily. Ph. II is enrolling. Clinical trial information', ' NCT01970865NCRuCRPRuPROverall RRn (%)Intracranial (IC) + extracranial522 (4)1 (2)22 (42)1 (2)26 (50)IC (target + nontarget lesions)368 (22)2 (6)4 (11)2 (6)16 (44)IC (target lesions)205 (25)1 (5)4 (20)2 (10)12 (60)Abbreviations', ' CR, complete response; PR, partial response; U, unconfirmed.']",
        "Doc_id":"ASCO_161846-176",
        "Doc_title":" Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).",
        "_version_":1606189006885748736},
      {
        "Meeting_name":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.",
        "Background":"['Background', ' NSCLC p with EGFR mutations initially respond to EGFR tyrosine kinase inhibitors (TKIs) but ultimately relapse. Sub-genomic molecular studies indicate that the EGFR T790M mutation and the activation of MET, PI3K, AXL, HER2 and MAPK can lead to acquired resistance to EGFR TKIs. To date, no integrated comprehensive genomic investigation of EGFR TKI resistance has been performed. Methods', ' FFPE biopsies of erlotinib-sensitive and erlotinib-resistant tumors were obtained from 11 EGFR mutant NSCLC p. DNA was extracted from all tumor and corresponding normal tissue samples and underwent whole exome sequencing using the Illumina HiSeq2500. RNA was extracted from all tumor samples and analyzed by whole transcriptome sequencing, also using the Illumina HiSeq2500. Results', ' Erlotinib resistant NSCLC specimens harbored upregulation of known resistance drivers including MET and AXL and novel alterations including upregulation of genes that are', ' 1) recurrently mutated in NSCLC, including ALK, STK11; 2) components of established embryonic stem cell signatures, including targets of Nanog, Oct4, Sox2, c-Myc, 3) neuronal lineage specific regulators, including NTRK3, NRCAM, ALK, LRP4. The analysis also revealed downregulation of several genes that are', ' 1) components of innate and acquired immunity, including HLA-A, -B, DQ, CD40; 2) phosphatases regulating survival signaling pathways, including PTEN, PTPRD, 3) proapoptotic components, including BNIP3L, IKIP. Conclusions', ' This study demonstrated the feasibility and utility of comprehensive genomic analysis in the clinical management of NSCLC p receiving targeted therapy. We identified known and novel molecular biomarkers of erlotinib acquired resistance in NSCLC p, and uncovered a previously unappreciated role for genetic events governing stem cell and neuronal phenotypes as well as immune evasion in erlotinib acquired resistance in NSCLC p. Together, our data provide unprecedented insight into the molecular pathogenesis of escape from EGFR oncogene inhibition in NSCLC. We are now conducting a prospective observational study in additional NSCLC p.']",
        "Doc_id":"ASCO_117711-132",
        "Doc_title":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.",
        "_version_":1606188995734142976},
      {
        "Meeting_name":" Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients",
        "Background":"['Intratumor heterogeneity can confound the results of mutation analyses in oncodriver genes using traditional methods thereby challenging the application of targeted cancer therapy strategies for patients. Ultradeep sequencing can detect low frequency and expanded clonal mutations in primary tumors to better inform treatment decisions. KRAS coding exons in 61 treatment-nave colorectal cancer (CRC) tumors and KRAS, EGFR, ALK, and MET in lung tumors from three Chinese non-small cell lung cancer (NSCLC) patients were sequenced using ultradeep sequencing methods. Forty-one percent of CRC patients (25/61) harbored mutations in the KRAS active domain, eight of which (13%) were not detected by Sanger sequencing. Three (of eight) had frequencies less than 10% and one patient harbored more than one mutation. Low frequency KRAS active (G12R) and EGFR kinase domain mutations (G719A) were identified in one NSCLC patient. A second NSCLC patient showed an EML4-ALK fusion with ALK, EGFR, and MET mutations. A third NSCLC patient harbored multiple low frequency mutations in KRAS, EGFR, and MET as well as ALK gene copy number increases. Within the same patient, multiple low frequency mutations occurred within a gene. A complex pattern of intrinsic low frequency driver mutations in well-known tumor oncogenes may exist prior to treatment, resulting in resistance to targeted therapies. Current targeted cancer therapies usually lack durability and demonstrate limited overall efficacy in patients. The types of low frequency concurrent mutations in candidate oncogenes presented here suggest necessary modifications both to methods for detection of these variants and to general treatment strategies. To date, Sanger sequencing has been effectively used for detection of treatment-relevant somatic mutations. However, in a heterogeneous mixture of cancerous and normal tissue, Sanger sequencing will likely fail to detect low frequency mutations. More sensitive and cost-effective sequencing methods are required to systematically assess the mutation status within cancer pathway genes or at the whole genome level. Furthermore, because patients often develop resistance to targeted therapy over time that is due to the preexistence of low frequency mutations in oncogenes, treatment strategies based on combination therapy might prove to be the most optimal treatment approach for cancer patients. Ultradeep sequencing can characterize intratumor heterogeneity and identify such mutations to ultimately affect treatment decisions.']",
        "Doc_id":"AACR_2014-2377",
        "Doc_title":" Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients",
        "_version_":1606189019472855040},
      {
        "Meeting_name":" Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.",
        "Background":"['Background', '  The majority of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations eventually acquire resistance to EGFR tyrosine kinase inhibitors (TKI). There are little data about genetic alterations in rebiopsy samples of NSCLC developing acquired resistance to EGFR-TKI in Asian patients.  Methods', \"  We retrospectively reviewed the medical records of patients with NSCLC harboring EGFR mutations, who had undergone rebiopsy after acquired resistance to EGFR-TKI. We analyzed 30 practicable samples using our tumor genotyping panel to assess 23 hot-spot sites of genetic alterations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), gene copy number of EGFR, MET, PIK3CA, FGFR1 and FGFR2, and ALK, ROS1 and RET fusions using pyrosequensing plus capillary electrophoresis, quantitative PCR, and reverse transcription PCR, respectively.  In addition, 23 samples were analyzed by commercially available EGFR mutation tests (Cycleave PCR or Scorpion Amplification Refractory Mutation System). Acquired resistance was defined according to Jackman's criteria.  Results\", '  A total of 43 patients had undergone rebiopsy and analysis of resistance mechanisms. Thirty rebiopsy samples were analyzed using our tumor genotyping panel, and 13 rebiopsy samples were analyzed for EGFR mutations only by commercial clinical laboratories. Anatomic sites of rebiopsy were 28 thoracic lesions, 10 central nervous system lesions, and 5 other lesions. Eleven patients (26%) had second-site EGFR T790M mutations, and 4 patients had no EGFR activating mutations in rebiopsy samples. No patients had small cell histologic transformation. In samples analyzed using our tumor genotyping panel, MET gene copy number gain was seen in 3 of 30 (10%). In addition, we detected PIK3CA mutation (E542K), PIK3CA gene copy number gain, BRAF mutation (G466V), and KRASmutation (G12D), in one sample each. Genetic alterations were identified in 36% of central nerve system samples, and 53% of other samples.  Conclusions', '  Althoughfrequency of T790M mutation was lower than earlier reports for western patients, that of MET gene copy number gain was comparable to previous reports.']",
        "Doc_id":"ASCO_131062-144",
        "Doc_title":" Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.",
        "_version_":1606188986697515008},
      {
        "Meeting_name":" ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene",
        "Background":"['Dramatic clinical responses to a first generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) crizotinib have been observed in patients with advanced non-small cell lung cancer (NSCLC) haboring ALK fusion gene. Alectinib (CH5424802) (Chugai Pharmaceutical Co., Ltd.) is a second generation ALK-TKI could partially overcome acquired resistance to crizotinib in vitro (Cancer Cell 19, 2011', ' 679-90), and showed promising result in phase I/II clinical trials with high response rate (93.5 %) and less toxicity than crizotinib. However, even this promising ALK-TKI, the problem of acquired resistance is inevitable.To elucidate resistant mechanisms, we established an alectinib-resistant cell line H2228/CHR from H2228 that have echinoderm microtubule associated protein like 4 (EML4)-ALK fusion gene, by continuous exposure to this agent. ALK fusion gene disappeared in H2228/CHR, which was confirmed Western blotting, IHC, qRT-PCR and FISH. H2228/CHR cells presented higher phosphorylated levels of epidermal growth factor receptor (EGFR) than the parental H2228 cells and became more sensitive to EGFR-TKI erlotinib.Next, we established alectinib-resistant ABC-11/CHR cells from ABC-11, a cell line established from pleural effusion of EML4-ALK positive ALK-TKI nave patient. In ABC-11/CHR cells, phosphorylated levels of ALK was markedly decreased and phosphorylated levels of MET was increased.In addition, autocrine of HGF was increased in ABC-11/CHR cells. ABC-11/CHR showed sensitivity to ALK/MET tyrosine kinase inhibitor, crizotinib in vitro and in vivo model.In conclusion, inactivation of ALK signaling induced acquired resistance to alectinib in NSCLC harboring ALK fusion gene. Signaling switch from ALK to EGFR or MET was observed in the alectinib-resistant cells. We revealed to overcome such acquired resistance using erlotinib or crizotinib.']",
        "Doc_id":"AACR_2014-3721",
        "Doc_title":" ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene",
        "_version_":1606189035972198400},
      {
        "Meeting_name":" Actigraphy as an objective measure of performance status in patients with advanced cancer.",
        "Background":"['Background', '    Treatment decisions are often based on performance status (PS), a subjective rating of patient functioning derived from observation and patient-report. Devices that monitor physical activity, such as wrist actigraphs, can accurately measure the percent of time a person is immobile while awake (awake immobile). Thus, actigraphy may have potential to better estimate true PS. We compared actigraphy to both Eastern Cooperative Oncology Group PS (ECOG PS) and patient-reported physical activity as predictors of survival in patients with stage IV non-small cell lung cancer (NSCLC).  Methods', '    Participants (n = 41) were ambulatory patients with stage IV NSCLC receiving care at MGH. Participants wore a watch-sized accelerometer device (ACTIWATCH 2) for three consecutive 24-hour periods (72 hours) and completed a self-report questionnaire about physical activity, scored as METS (metabolic equivalents) per week. Patients oncologists rated their ECOG PS (0-5) at the end of the 72-hour actigraphy period. Relationships among ECOG PS, awake immobile, and METs per week were tested with Pearson correlations. A ROC curve for 6-month survival was used to determine a meaningful cut-off for awake immobile. Unadjusted Cox regression models tested associations with survival from assessment times.  Results', '    Participants ECOG PS ratings were', ' 0 (22%), 1 (63%), 2 (12%), and 3 (2%). ECOG PS and awake immobile were correlated (r = .42, p < .01). METS per week was correlated only with ECOG PS (r = -.35, p = .03). At time of analysis, 15 patients had died with a minimum follow up of 9 months. Among all patients, survival was predicted by ECOG PS, HR = 3.77 (95% CI 1.70-8.35), p < .01; awake immobile as both as a continuous (percentage points) and categorical ( > 23%) variable, HR = 1.04 (95% CI 1.00-1.09), p = .05 and HR = 4.12 (95% CI 1.37-12.39), p = .01, respectively; but not METS per week. Among patients with good EGOC PS (0-1), only awake immobile ( > 23%) predicted survival, HR = 5.80 (95% CI 1.39-24.12), p = .02. Moreover, within the largest ECOG group (PS1), awake immobile ( > 23%) still predicted survival, HR = 5.53 (95% CI 1.18-25.94), p = .03.  Conclusions', '    Actigraphy, an objective measure of patient activity, may have utility in determining patient PS.']",
        "Doc_id":"ASCO_155141-165",
        "Doc_title":" Actigraphy as an objective measure of performance status in patients with advanced cancer.",
        "_version_":1606189040052207616},
      {
        "Meeting_name":" The effect of talactoferrin on overall survival in prognostically important NSCLC subsets in a randomized, placebo-controlled phase II trial.",
        "Background":"['Background', ' Talactoferrin alfa (TLF), a novel immunomodulatory agent, has demonstrated anti-tumor activity in two randomized, placebo-controlled phase II studies in NSCLC, including a 100-patient 2nd/3rd-line monotherapy study and a 110-patient study in 1st-line in combination with chemotherapy.  Both studies met their primary endpoints, with improved overall survival (OS) in the monotherapy study and improved response rate in the combination study (ASCO 2006 and 2007).  Here we report the OS data of TLF in prognostically important patient subsets for patients enrolled in the monotherapy study in 2nd/3rd-line. Methods', ' A total of 100 patients with Stage IIIB/IV NSCLC whose disease had failed 1st or 2nd line therapy were randomized to receive oral TLF (1.5 g bid) or placebo in addition to best supportive care at 11 leading cancer centers in India. TLF or placebo was administered for a maximum of three 14-week cycles with a dosing regimen of 12 consecutive weeks followed by 2 weeks off.  The primary endpoint was OS. Results', ' The trial met its primary endpoint with a 65% increase in OS for the TLF arm (3.7 mos for placebo, 6.1 mos for TLF; HR 0.68, 1-tailed pConclusions', ' The effect of TLF on OS in this 2nd/3rd line NSCLC study was consistently also seen in various prognostically important patient subsets.  These findings remain to be confirmed in the ongoing phase III FORTIS-M trial.']",
        "Doc_id":"ASCO_79095-102",
        "Doc_title":" The effect of talactoferrin on overall survival in prognostically important NSCLC subsets in a randomized, placebo-controlled phase II trial.",
        "_version_":1606189010069225472},
      {
        "Meeting_name":" Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ERBB3 antibody",
        "Background":"['ERBB3 is widely expressed in human carcinomas, and its over expression is associated with poor prognosis in patients with various carcinomas, (i.e., breast, ovarian, prostate, colorectal, pancreatic, gastric, and head and neck cancers). The presence of ERBB3 correlates with local to distal metastasis in lung, gastric, and colorectal cancers as well as bone invasion in prostate cancer. Activation of ERBB3 is also implicated in the development of resistance to current cancer treatments. Due to its lack of kinase activity, the activation of the ERBB3 receptor is dependent on heterodimerization with active receptor tyrosine kinases (RTKs). The recruitment of ERBB3 into active, heterodimer complexes is mediated by its ligand Neuregulin-1 (NRG-1) or by amplified, over expressed RTKs in a ligand independent manner. Therefore, ERBB3 can crosstalk with most major receptors involved in cancer development and maintenance such as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and c-MET. AV-203 is a potent, humanized anti-ERBB3 antibody that inhibits both ligand-dependent and independent activation of ERBB3 both in vitro and in vivo. Pharmacokinetics and pharmacodynamics of AV-203 were characterized in mice using the A549 non-small cell lung cancer xenograft model. AV-203 administered IV in mice exhibits acceptable pharmacokinetics supporting preclinical efficacy studies. AV-203 administered IV in A549 NSCLC xenograft tumor bearing mice had lower serum AUC than nave mice, demonstrating that the presence of human ErbB3 may alter the PK parameters of AV-203. In evaluating pharmacodynamics in vivo, AV-203 was able to down regulate total ERBB3 and ERBB3 signaling in A549 tumors in a time-dependent manner. Inhibition of ERBB3 signaling correlated with significant dose-dependent tumor growth inhibition in the A549 xenograft model. Dose scheduling studies with the constant AV-203 dose of 2.5 mg/kg revealed that the most efficacious schedule is the more frequent dosing at Q3D. In comparing the total dose of 10 mg/kg per 14 day cycle, at varying dose per injection and frequency, AV-203 resulted in significant tumor growth inhibition at all dose schedules. These data conclude that the efficacy of AV-203 is driven by total drug exposure and that AV-203 is not dependent on Cmax for its antitumor activity.']",
        "Doc_id":"AACR_2012-3787",
        "Doc_title":" Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ERBB3 antibody",
        "_version_":1606189012806008832},
      {
        "Meeting_name":" Building comprehensive and fully annotated patient tumor derived xenogragft (PDX) library mirroring cancer patient population",
        "Background":"['Patient derived xenografts (PDXs) mirrors patients pathology and genetic profiles, thus valued as predictive experimental models for studying oncogenesis and personalized treatments. Cancer is not a single disease but diseases of complex genetic components and oncogenic processes. Limited number of PDX models with minimal genetic characterization is insufficient to meet current research needs. For this, we have built the largest and most comprehensive PDX library with full genetic profiles. By far, our PDX library contains over 1,100 models derived from patients of both Asian and Western origins, covering over 20 major cancer types, including large panels (over 100 models each) of NSLCL(1), CRC(2), gastric(3), HCC(4), and pancreatic, and smaller panels (<100) of esophageal, H&N, ovarian, cholangiocarcinoma, breast, brain, etc. Our PDX models come with original patient and pathology diagnosis information, and verified at the level of histopathology and genetic fingerprints. These models have tumor growth and standard of care (SOC) treatment information. They are fully profiled using GeneChip based technology (U219, SNP6.0, miRNA), NGS (RNAseq and WES), and hotspot mutation, etc (HuPrime 1.0), with HLA typing readily available to enable immuno-oncology research. Comparing our PDXs genomic profiles with published patient genomic profiles in literature (4) and TCGA data source (Guo et al., 2015 AACR Annual) revealed high degree of similarity. Subsets of models have been comprehensively characterized for special relevance to specific clinical characteristics and specific drug targeting mechanisms (HuPrime 2.0). These subsets include all clinically observed EGFR mutated NSCLC(1, 5, 6); c-MET activation diseases(7); FGFR driven diseases; RET-fusion driven CRC(8); FLT3-LTD driven AML (9), IDH mutated AML(9) and CRC; RSPO-fusion driven CRC; BCL-ABL fusion disease, HER driven gastric and breast cancers, and ALK fusion NSCLC, etc. We have also established numeric drug resistant models to various SOCs of both chemotherapy and target therapies. The resistance could be de novo (1) or induced (10). These resistant models can be great tools to investigate drug resistant mechanisms and approaches to overcome them. Many PDXs can also been tested orthotopically, including liver, brain, colon, pancreatic, ovarian, and breast etc. Models have great metastatic potential have also been identified, enabling study metastatic mechanism and identifying agents to block the metastasis. A number of PDXs can grow in humanized mice (HuPrime 3.0), where human immunity has been reconstituted in the immune-compromised mouse background (11) to facilitate immune-oncology research.Our large library of different disease panels are particularly useful in conducting mouse clinical trial (MCT of HuTrialTM) (2, 5, 12), which can be used to discover predictive biomarker (2, 5, 13) and guide clinical study design.']",
        "Doc_id":"AACR_2015-1472",
        "Doc_title":" Building comprehensive and fully annotated patient tumor derived xenogragft (PDX) library mirroring cancer patient population",
        "_version_":1606188990260576256},
      {
        "Meeting_name":" The effect of CYP2C19 polymorphism on the tolerability of ARQ 197",
        "Background":"['Background', \" ARQ 197 is a selective, non-ATP competitive inhibitor of c-MET, a receptor tyrosine kinase implicated in tumor cell migration, invasion and proliferation. ARQ 197 is mainly metabolized by CYP2C19. The ratio of the poor metabolizer (PM) of CYP2C19 in Asians is reported to be around 20 % while it is very low in Caucasians. Recommended phase II dose (RP2D) of ARQ 197 in western countries was determined to be 360 mg bid.In this monotherapy phase I study in Japanese patients (pts) with metastatic solid tumors, we examined the drug's safety profile, pharmacokinetics and preliminary antitumor activity and determined RP2D in PM pts as well as extensive metabolizer (EM) pts. Methods\", ' ARQ 197 was administered orally at 8 dose levels from 70 to 360 mg bid in a standard 3+3 dose escalation design. We enrolled PM and EM pts separately from 120 mg bid. Results', ' Forty-seven pts consisted of 33 EM pts (median age', ' 61.0 yrs; ECOG PS 0/1', ' 15/18; median prior therapies', ' 4) and 14 PM pts (median age', ' 59.5 yrs; ECOG PS 0/1', ' 6/8; median prior therapies', ' 4) were treated. The most common drug-related adverse events were fatigue, leukopenia, anemia, neutropenia and anorexia. Gr.4 neutropenia occurred in 1 of 6 EM pts at 360 mg bid and 3 of 7 PM pts at 240 mg bid, which identified each dosage as RP2D for EM and PM respectively. Cmax and AUC0-12 increased in a dose-dependent manner up to 300 mg bid in the EM cohorts and up to 240 mg bid in the PM. At 240 mg bid, the ARQ 197 Cmax and AUC0-12 of PM pts were 1.5-fold and 1.9-fold higher than those of EM pts respectively. Pts who had a relatively high exposure of ARQ 197 such as Cmax > 4,000 ng/mL or AUC0-12 > 40,000 ng.h/mL on day 1 tended to experience Gr.4 neutropenia regardless of CYP2C19 genotype. Two NSCLC pts, both of whom were PM at 240 mg bid, achieved partial response and 16 pts (34.0%) had stable disease (SD) for >= 16 weeks, especially 6 of 25 pts (24.0 %) in NSCLC had SD for >= 28 weeks. Conclusions', ' ARQ 197 was well tolerated in PM pts as well as EM pts. CYP2C19 genotype clearly affected the exposure to ARQ 197 which led different RP2Ds, 360 mg bid for EM pts and 240 mg bid for PM pts. ARQ 197 monotherapy showed a clear sign of activity. Further study is warranted.']",
        "Doc_id":"ASCO_77142-102",
        "Doc_title":" The effect of CYP2C19 polymorphism on the tolerability of ARQ 197",
        "_version_":1606189031116242944},
      {
        "Meeting_name":" Preoperative erlotinib in clinical stage I and II non-small cell lung cancer.",
        "Background":"['Background', ' Epidermal growth factor TKI inhibitors have demonstrable efficacy in the treatment of advanced non- small cell lung cancer (NSCLC). Little is known about their role in early-stage disease. The purpose of this study was to determine the response rate and treatment toxicity to preoperative erlotinib in stage I/II NSCLC. Methods', ' Patients with biopsy proven clinical stages I/II NSCLC were administered erlotinib 150 mg/day for 21 days in this single-arm open-label phase II trial. The study population was not enriched using clinical or molecular criteria. CT imaging was obtained at baseline and within 1 week after completion of erlotinib treatment. Surgical resection was performed after a one week washout period. Target accrual was 30 patients. Results', ' Twenty-two patients were enrolled between 10/06 and 11/08, 72% of whom had stage 1 NSCLC. Median age was 71 and the majority (77%) had adenocarcinoma. All patients completed preoperative erlotinib therapy. One patient had grade 3 rash and none had grade 4 toxicity. There were no treatment-related deaths. A partial response by RECIST was observed in one patient (5%), a never-smoking African American woman with adenocarcinoma. Seven patients had 25% reduction in tumor volume including four patients with > 40%, one of whom had a 75% reduction in volume and met RECIST criteria for partial response. Conclusions', ' Erlotinib can be delivered safely in patients with early stage NSCLC. In this study 32% experienced a reduction in tumor volume despite the fact that only one patient met RECIST criteria of response. Tumor volume measurements may allow for determination more subtle, but potentially important, responses to short-term targeted therapy. VariableMedian age71GenderMale11Female11EthnicityCaucasian20African American2Cell typeAdenocarcinoma15Squamous4Mixed1Adenocarcinoma/BAC2Clinical stageIA9IB7IIA1IIB5Smoking statusFormer16Current4Never2']",
        "Doc_id":"ASCO_52935-74",
        "Doc_title":" Preoperative erlotinib in clinical stage I and II non-small cell lung cancer.",
        "_version_":1606188991944589312},
      {
        "Meeting_name":" Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.",
        "Background":"['Background', ' The third generation EGFR tyrosine kinase inhibitor (TKI) rociletinib has demonstrated activity in non-small cell lung cancer (NSCLC) patients (pts) who progressed on prior EGFR TKIs due to an acquired T790M resistance mutation. Additional work is needed to understand the mechanisms of resistance to rociletinib and other third generation EGFR TKIs. Methods', ' We employed circulating tumor DNA analysis using Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) to study putative mechanisms of innate and acquired resistance to rociletinib. CAPP-Seq was applied to a total of 115 serial plasma samples from T790M-positive NSCLC pts (n = 43) enrolled in the TIGER-X (n = 42) (NCT01526928) and TIGER-2 (n = 1) (NCT02147990) clinical trials. Results', ' Rociletinib resistance was diverse, with mutations and/or copy number gains affecting 9 genes involved in bypass pathway activation and tumor suppressor pathways. Multiple resistance mechanisms were observed in 23% of pts. Examples of emergent alterations included activating KRAS mutations in three pts, a novel tertiary mutation in EGFR (L798I) in one patient, and an EGFRC797S mutation in one patient. Increased MET copy number was the most frequently observed mechanism of resistance, occurring in 26% of cases. Pts with heterogeneity of resistance mechanisms at baseline (both T790M and increased MET copy number) displayed inferior responses and significantly shorter progression free survival (P< 0.05). In agreement with these clinical findings, erlotinib-resistant xenografts treated with rociletinib reproducibly developed MET amplification. Importantly, sensitivity to rociletinib could be reinstated by combined therapy with the METinhibitor crizotinib. Conclusions', ' We observed diverse and heterogeneous resistance mechanisms to rociletinib. The association of inferior outcomes with multiple resistance mechanisms at baseline emphasizes the clinical importance of tumor heterogeneity in these pts. Our results demonstrate that non-invasive profiling using ctDNA analysis can define patterns of resistance to targeted therapies and potentially allows for personalization of combination therapies to overcome resistance.']",
        "Doc_id":"ASCO_165226-176",
        "Doc_title":" Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.",
        "_version_":1606189006664499200},
      {
        "Meeting_name":" CARD8/BCL-2 cascade in early adaptive drug resistant tumor escape against targeted inhibitors in NSCLC.",
        "Background":"['Background', '  Lung cancer targeted therapy is largely limited by inevitable recurrent resistant disease after initial response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), typically accompanied with divergent late acquired resistance mechanisms. We now focused on studying the emergence of early adaptive resistance to uncover attractive therapeutic targets to overcome drug resistance.    Methods', '  HCC827 cells were treated with EGFR-TKI (0-9 days) with apoptosis pathway-specific QPCR array and TLVM analysis performed.  MTS and crystal violet assays were performed. Western blot analysis was performed to examine prosurvival signaling developed against erlotinib, alone or in combination with MET inhibitor SU11274. IHC was performed on lung cancer tumor microarray (TMA) using BCL-2 and caspase-recruitment domain-containing protein 8 (CARD8) antibodies and graded (4 tier scoring system). NSCLC cell lines and murine xenograft models (HCC827, H1975) were developed for resistance biomarkers expression analysis in pre-/post-TKI treatment using anti-human CARD8, p-STAT3 and BCL-2 antibodies.        Results', '  We characterized the emergence of early resistant lung cancer cells in escape against targeted TKIs with 100-fold higher IC50 in adaptive drug resistance. The resistant cells that evaded EGFR-TKI based targeted inhibition exhibited MET-independent induction of CARD8 and STAT3/BCL-2 mitochondrial prosurvival signaling in cellular quiescence, and inhibited cytoskeletal functions. Expression analysis studies demonstrated common tumor-associated expression of CARD8 but relatively low BCL-2 level in NSCLC. In vitro cell line studies suggest that CARD8 induction was preceded by a resurgence of STAT3 activation. In vivo xenograft model (HCC827/erlotinib; H1975/erlotinib+ SU11274) also verified upregulated CARD8/BCL-2 activation within early resistant cells.   Conclusions', '  Resistant tumor cells that evaded EGFR inhibitors, alone or in combination with MET inhibitors, exhibited increased expression of CARD8-STAT3/BCL-2 prosurvival signaling cascade. Further studies to define the mechanism of CARD8 in promoting adaptive tumor drug resistance would be warranted.']",
        "Doc_id":"ASCO_112442-132",
        "Doc_title":" CARD8/BCL-2 cascade in early adaptive drug resistant tumor escape against targeted inhibitors in NSCLC.",
        "_version_":1606189009893064704},
      {
        "Meeting_name":" Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.",
        "Background":"['Background', ' Third generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has proven effective in Non-small cell lung cancer (NSCLC) patients who have developed EGFR T790M-mediated resistance to other EGFR TKIs. Unfortunately, a majority of patients still undergo progressed disease after receiving osimertinib treatment. Acquired EGFR C797S mutation has been identified as one major mechanism; however, resistance mechanisms of remaining cases are still largely unknown. Methods', ' Using next generation sequencing (NGS) targeting 416 cancer-relevant genes, we analyzed the mutation profiles of 99 NSCLC patients that were clinically resistant to osimertinib. Results', ' In addition to the notable EGFR C797 variants (22%), L792 mutations were identified in 10% of patients, and a further 7% cases carry L718 mutations. Further analysis of 14 patients with paired pre-treatment samples confirmed that these EGFR mutations were acquired during treatment. Interestingly, all L792 mutations are in cis with T790M and in trans with C797 mutations (when present in the same patient). 2 out of 10 L792-positive patients and 6 out of 7 L718-positive patients did not have co-existing C797 mutations, suggesting C797-, L792- and L718-mutated cells may represent different resistant clones. In vitro experiments demonstrated that L792 and L718 mutants also increase osimertinib IC50, and therefore confer their resistance. Besides secondary EGFR mutations, alterations in other key genes such as MET, KRAS, ERBB2 and PIK3CA may also contribute to osimertinib resistance. Notably, MET and KRAS amplifications are present only in patients without above EGFR secondary mutations. Conclusions', ' In this study, we identified secondary mutations on C797, L792 or L718 residues of EGFR in 29% of osimertinib-resistant patients. Combined with in vitro study, our data strongly suggest that L792 and L718 mutations are likely to alternatively cause osimertinib resistance. Furthermore, MET and KRAS amplification may serve as bypass resistance mechanisms in patients who are EGFR C797-, L792- and L718-wild type.']",
        "Doc_id":"ASCO_192596-199",
        "Doc_title":" Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.",
        "_version_":1606189021620338688},
      {
        "Meeting_name":" A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.",
        "Background":"['Background', '  MGCD516, is an orally-available, potent small molecule inhibitor of a closely related family of RTKs including RET, TRK family, DDR2, MET, Axl family, KIT,  as well as VEGFR and PDGFR family members. RTKs inhibited by MGCD516 are genetically altered in a variety of cancers, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC),  functioning  as oncogenic drivers promoting cancer development and progression. Alterations in these RTKs have also been implicated in tumor resistance mechanisms. MGCD516 has demonstrated broad antitumor activity including demonstration of tumor regression in preclinical models harboring genetic dysregulation of MGCD516 targets including MET amplification, METex14del, RET rearrangement and CHR4q12 amplification.  Methods', '  This first-in-human, open label Phase 1/1b study is designed to evaluate the safety, pharmacokinetics, metabolism, pharmacodynamics and clinical activity of MGCD516 in patients with advanced solid tumors. Phase 1 is the dose escalation phase and uses the modified toxicity probability interval (mTPI) method to determine the MTD /Recommended Phase 1b Dose. Phase 1b is the expansion phase in which MGCD516 will be evaluated in patients with NSCLC, HNSCC, or any other solid tumor type harboring specific MGCD516 RTK target mutations of interest. Phase 1 and 1b are each anticipated to enroll 60 patients. Phase 1 enrollment started in September 2014, with patients receiving continuous daily dosing (QD) of 10mg MGCD516 in cycles of 21 days. Cohort 1 and Cohort 2 (QD 20mg) have been completed without  DLTs and enrollment to Cohort 3 (QD 40mg) started in January 2015. Pharmacokinetics is evaluated after single and repeated administration. Pharmacodynamic biomarkers, including soluble (s)MET, sVEGFR2 and VEGFA will be explored in plasma samples for prognostic potential and possible relationship with clinical outcome. Clinical trial information', ' NCT02219711']",
        "Doc_id":"ASCO_146823-156",
        "Doc_title":" A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.",
        "_version_":1606189023501484032},
      {
        "Meeting_name":" A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.",
        "Background":"['Background', '  15-20% of all patients (pts) diagnosed with colorectal cancer (crc) develop metastases (mets) surgical resection remains the only potentially curative treatment available. Current 5-year survival rate following R0 resection of liver mets lies between 28-39%, recurrence occurs in up to 70% of pts. To date, adjuvant chemotherapy has not significantly improved clinical outcomes. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active MUC1-specific cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in crc pts following R0/R1 resection of liver mets known to highly express MUC1 glycoprotein.  Phase III data from L-BLP25 in NSCLC will be reported at this meeting.  Methods', '  This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 pts from 20 centers in 3 countries. Pts must have stage IV cr adenocarcinoma limited to liver mets. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous mets, eligible pts are randomized 2', '1 to receive either L-BLP25 or placebo. L-BLP25 arm receives a single dose of 300 mg/m2 cyclophosphamide (CPA) 3 d before 1st L-BLP25 dose, then primary treatment with sc L-BLP25 930 g weekly for 8 weeks, followed by sc L-BLP25 930 g maintenance doses at 6-week (year 1 and 2) and 12-week (year 3) intervals until recurrence. Control arm', ' CPA is replaced by saline solution and L-BLP25 by placebo. Primary endpoint (PE) is RFS time. Secondary endpoints', ' Overall survival (OS), safety, tolerance, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. Study start was in Q3 2011. 19 centers were initialized and 36 patients recruited, no SUSARs occurred. Study recruitment will end Q3 2013', ' follow-up until Q3 2017. PE assessment is in Q3 2016. Interim analyses are not planned.No major practical issues were identified during setup and early conduct of the study. Clinical trial information', ' 2011-000218-20.']",
        "Doc_id":"ASCO_112729-132",
        "Doc_title":" A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.",
        "_version_":1606189039031943168},
      {
        "Meeting_name":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib",
        "Background":"['Background', ' NSCLC p with EGFR mutations initially respond to EGFR tyrosine kinase inhibitors (TKIs) but ultimately relapse. Sub-genomic molecular studies indicate that the EGFR T790M mutation and the activation of MET, PI3K, AXL, HER2 and MAPK can lead to acquired resistance to EGFR TKIs. To date, no integrated comprehensive genomic investigation of EGFR TKI resistance has been reported.Methods', ' FFPE biopsies of erlotinib-sensitive and erlotinib-resistant tumors were obtained from 16 EGFR mutant NSCLC patients. The samples were analyzed by whole exome sequencing and whole transcriptome sequencing utilizing the Illumina HiSeq2500 platform. In addition, targeted gene sequencing was performed with the Illumina TruSeq Amplicon-Cancer Panel and run on the MiSeq system.Results', ' Erlotinib resistant NSCLC specimens harbored known resistance drivers, including EGFR T790M mutations (6/16; 38%), MET amplification (2/16; 13%), and AXL upregulation (3/16; 19%). Differential expression analysis between resistant and pre-treatment states revealed enrichment in the post-resistant tumors of ERBB2, and FGFR signaling pathways. Biopsies from patients that developed an EGFR T790M mutation post resistance exhibited enrichment in pathways associated with cell cycle, meiosis, telomere maintenance and transcriptional regulation. Copy number analysis demonstrated amplifications in the post-resistance setting that correlated significantly with progression free survival, including regions containing NFKBIA, NKX2-1, and TSC-1. There was also strong correlation between the copy number changes observed and the expression mRNA levels of specific genes. Of note, each resistant tumor exhibited greater copy number similarity to the corresponding matched pre-treatment sample compared to other tumors within the resistance cohort.Conclusions', ' We conducted the first ever comprehensive integrated genomic analysis of EGFR TKI resistant NSCLC patients, and identified both known and potentially novel drivers of EGFR TKI resistance. This study demonstrated the feasibility and utility of comprehensive genomic analysis in the clinical management of NSCLC receiving targeted therapy. Together, our data provide unprecedented insight into the molecular pathogenesis of escape from EGFR oncogene inhibition in NSCLC. We are now conducting a prospective observational study in additional NSCLC patients on targeted therapy.']",
        "Doc_id":"AACR_2014-954",
        "Doc_title":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib",
        "_version_":1606189013879750656},
      {
        "Meeting_name":" Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer",
        "Background":"['Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). However, almost all of the patients eventually develop resistance to EGFR-TKIs within approximately one year. The resistance mechanisms of EGFR-TKIs have not been fully elucidated. We previously established an erlotinib-resistant NSCLC cell line named PC-9/ER3 after continuously exposing PC-9 cells, which harbor an in-frame deletion in EGFR exon 19, to erlotinib. PC-9/ER3 cells were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 cells did not carry the T790M mutation or MET amplification and had similar levels of pSTAT3, pJAK2 increased in the resistant cells (Cancer Sci 103, 1795-802; 2012). Meanwhile, pacritinib is a novel macrocyclic pyrimidine-based JAK2/FLT3 inhibitor with clinical activity in patients with myelofibrosis and lymphoma, which will be used as a standard therapy for myelofibrosis. In this study, we evaluated the synergistic effect of pacritinib combined with erlotinib on JAK2-medatited EGFR-TKI resistant NSCLC.Drug sensitivity was determined using an MTT assay and the combination index was calculated according to the methods based on the median-effect analysis. The combination of pacritinib with erlotinib showed synergistic effects on JAK2-medated EGFR TKI-resistant PC-9/ER3 cells in some cases. Western blotting showed that the combination treatment markedly suppressed pAKT and pERK although pSTAT3 was equivalent regardless of treatment with the pacritinib, erlotinib, pacritinib plus erlotinib, or control in PC-9/ER3 cells. Receptor tyrosine kinase array profiling demonstrated that pacritinib suppressed MET in the PC-9/ER3 cells. The combined treatment of pacritinib and erlotinib in PC-9/ER3 xenografts showed more tumor shrinkage compared with each drug as monotherapy. Western blotting revealed that pMET in the tumor samples was inhibited. These results suggest MET suppression by pacritinib may play a role in overcoming the EGFR-TKI resistance mediated by JAK2 in the PC-9/ER3 cells.In conclusion, pacritinib combined with EGFR-TKI might be a potent strategy against JAK2-mediated EGFR-TKI resistance.']",
        "Doc_id":"AACR_2016-4675",
        "Doc_title":" Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer",
        "_version_":1606189023955517440},
      {
        "Meeting_name":" Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).",
        "Background":"['Background', ' A nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) was established in 2013. The objective of this project is to contribute to the development of precision medicine through the genomic biomarker screening, leading to improvement of patient prognoses. Methods', ' Advanced non-squamous non-small cell lung cancer (non-sq NSCLC) without EGFR mutations were eligible for inclusion. The tumors were analyzed for ALK/ROS1/RET fusions using RT-PCR and FISH. Since March 2015, the samples were further subjected to a next-generation sequencing (NGS) system, Oncomine Comprehensive Assay. Since April 2016, MET exon 14 skipping (MET skip) was also analyzed by RT-PCR. The clinical course and prognosis of patients were monitored every 6 month. Results', 'As of December, 2016, 3206 patients from 242 institutions across Japan had been enrolled. The success rates for RT-PCR and NGS were 94% (3020/3206) and 91% (1523/1666), respectively. ALK/ROS1/RET fusions were detected in 65 (2%)/116 (4%)/84 (3%), respectively. The NGS assay showed that 753 tumors (49%) had actionable gene alterations, including 184 KRAS (12%), 92 ERBB2 (6%), 73 BRAF (5%), 42 PIK3CA (3%), 11 NRAS (0.7%), 7 MAP2K1 mutations (0.5%) and 5 FGFR2/3 fusions (0.3%). ERBB2/MET/FGFR1 amplifications were also detected in 36 (3%)/28 (2%)/11 (1%) cases, respectively. The frequency of MET skip was 4% (26/597). Through this screening, a total of 576 genotype-matched patients to clinical trials of targeted agents were identified, and 111 of them (19%) were enrolled into the trials. Of the 1523 patients analyzed by NGS, the monitoring data were available in 870 (57%). The patients with actionable gene alterations who received targeted agents (n = 100) showed significantly longer survivals than those who did not receive targeted agents (n = 358) or the patients without actionable gene alterations (n = 412) (median survival [95%CI], 5.1 [3.0-N.R.] vs. 3.3 [2.1-5.9] vs. 2.3 [1.9-2.9] years, respectively; p < 0.01). Conclusions', ' Our nationwide screening contributes to the development of precision medicine for non-sq NSCLC and could improve patient prognoses.']",
        "Doc_id":"ASCO_190182-199",
        "Doc_title":" Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).",
        "_version_":1606189033696788480},
      {
        "Meeting_name":" Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Molecular profiling is limited by tumour heterogeneity and access to sufficient tissue for comprehensive analysis. Circulating tumour DNA (ctDNA) can be used as a minimally-invasive liquid biopsy for mutation detection, quantification and monitoring for personalised treatment strategies. Methods', ' We recruited 110 patients into a prospectively-designed study for Stage III/IV NSCLC patients intended to initiate 1stline platinum-based chemotherapy. Blood collections (10ml K2-EDTA) were performed prior to treatment and analysed by InVision (enhanced tagged-amplicon sequencing) using a 34-gene panel. Tissue biopsies, when available, were analysed by NGS (Ion-Torrent, Sanger) for concordance analysis. To evaluate correlation with outcome, repeat blood collections were performed in selected patients. Results', ' 110 NSCLC pts were included (61% male, 14% never-smoker, and 70% adenocarcinoma). ctDNA profiling detected mutations in 83 pts (79%). TP53 (44%), KRAS (17%), STK11 (18%; 11/19 with KRAS/STK11) and EGFR (10%) were the commonest abnormalities detected. Additionally, MET (6%), ERBB2 (6%), PIKC3A (6%) and BRAF (4%) mutations and EGFR, MET, ERBB2 amplifications were detected in 2% of patients, respectively. 20% of the mutations detected in ctDNA were observed at < 0.5% allele fraction, with 6% between 0.03%-0.25% AF. Tissue was available in 44 pts; somatic mutations were detected in 73%. Tissue & liquid concordance was 92.3%. 10 pts (23%) reported as tissue negative had a positive liquid biopsy. 33 advanced NSCLC patients were evaluated for longitudinal serial ctDNA monitoring up to cycle 4 of chemotherapy; the ratio of mutated molecules between D1 and D42 was significantly correlated with change in RECIST 1.1 measurement at D42 (p-value = 0.002625 CI 95% 0.298, 0.875). Conclusions', ' ctDNA can be used as a liquid biopsy for molecular profiling of NSCLC patients to detect clinically relevant and actionable mutations when tissue biopsy is unavailable. Liquid biopsies can be used longitudinally and may provide an early surrogate for response evaluation by radiographic RECIST.']",
        "Doc_id":"ASCO_193196-199",
        "Doc_title":" Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).",
        "_version_":1606189007791718401},
      {
        "Meeting_name":" Prolonged survival and time to disease progression with zoledronic acid in patients with bone metastases from non-small cell lung cancer.",
        "Background":"['Background', ' We previously reported that patients (pts) with bone metastases (mets) from non-small cell lung cancer (NSCLC) treated with zoledronic acid (ZOL) in addition to chemotherapy (CHT) had prolonged overall survival (OS) and time to disease progression (TTP) versus CHT alone (p < 0.01 for both; Zarogoulidis K, et al. Int J Cancer. 2009). However, the ZOL benefits reported were not adjusted for baseline covariates, and response rates at bone and primary sites were not separated. Methods', ' Pts with NSCLC and bone mets were assigned to treatment with CHT (docetaxel 100 mg/m2 + carboplatin AUC 6 q mo) alone if asymptomatic or CHT + ZOL (4 mg q mo) for bone pain. Disease responses (complete, partial, stable, or progressive) were assessed at bone and primary sites. The effects of treatment on OS and TTP were assessed by Cox regression in multivariate (MV) models controlling for type of bone lesions, sex, radiotherapy, and line of chemotherapy. Results', ' Of 144 enrolled pts, 57 received CHT alone, and 87 received CHT + ZOL. After completion of first-line CHT by all pts, the estimated rate of partial response in the primary tumor site was 2-fold higher for ZOL (32% vs 16% of pts for CHT alone), and the rate of progressive disease in bone was a relative 38% lower for ZOL (23% vs 37% of pts for CHT alone). The MV model confirmed the significantly increased median OS for CHT + ZOL vs CHT-alone pts that was detected in Kaplan-Meier (KM) analyses (median OS of 578 vs 384 d, respectively; p < 0.001). The ZOL-treated pts had a significant 39% reduced risk of death vs the CHT-alone pts (HR = 0.607; p = 0.015). Similarly, the MV model confirmed the significantly increased TTP in the CHT + ZOL vs CHT-alone pts that was detected in KM analyses (median TTP of 265 vs 150 d, respectively, p < 0.001). The ZOL-treated pts had a profound 61% reduced risk of disease progression vs the CHT-alone pts (HR = 0.392; p < 0.001). Conclusions', ' These analyses confirm previous results that pts with bone pain who received ZOL had superior disease progression and survival outcomes vs CHT alone in pts with asymptomatic bone mets from NSCLC. Moreover, the higher response rates in the primary tumor site with CHT + ZOL vs CHT alone suggest direct ZOL anticancer activity.']",
        "Doc_id":"ASCO_53329-74",
        "Doc_title":" Prolonged survival and time to disease progression with zoledronic acid in patients with bone metastases from non-small cell lung cancer.",
        "_version_":1606189035124948992},
      {
        "Meeting_name":" Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.",
        "Background":"['Background', ' Adjuvant chemotherapy (ACT) after radical surgery is known to improve the survival of patients with non-small cell lung cancer (NSCLC). However, there are few studies reporting the impact of age on the efficacy of ACT in NSCLC patients. Methods', ' All patients who received postoperative ACT in the Cancer Hospital of the Chinese Academy of Medical Sciences between 2001 and 2013 with complete records in the database of the hospital and met the inclusion criteria were enrolled in this study for analysis. The primary end point was disease-free survival (DFS) in terms of age. Survival analysis was performed using KaplanMeier estimates, log-rank tests and Coxs proportional hazards regression analysis. Propensity score matching (PSM) was used, and survival analysis of the match data was carried out. Results', ' Of 1,129 patients with stage IB to stage III NSCLC who underwent radical resection, 929 who met the inclusion criteria were analyzed. Of them, 166 (17.7%) patients were older than 65 years, and the remaining 763 (82.3%) patients were younger than 65 years as the control group. There was no significant difference in DFS between the two age groups before propensity score was matched (665 days [95%CI 579.46, 759.51] vs. 697 days [95%CI 581.55, 812.45], P = 0.807). Furthermore, no significant impact of age on DFS was observed between the PS-matched groups (653 days [95%CI 550.91, 755.09] vs. 706 days [95%CI 585.68, 826.32], P = 0.778). Surprisingly, the result of subgroup study showed that the risk of recurrence was increased in older patients who received postoperative radiotherapy after ACT as compared with younger patients (HR = 2.317, 95%CI 1.101-4.873, P = 0.027). Conclusions', ' The results suggest that DFS was similar regardless of age of NSCLC patients. Besides, postoperative radiotherapy could probably decrease the survival benefit from postoperative ACT in older patients. ACT should not be withheld from elderly patients. However, post-ACT radiotherapy might be not advised to the elderly NSCLC patients.']",
        "Doc_id":"ASCO_162932-176",
        "Doc_title":" Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.",
        "_version_":1606188976038739968},
      {
        "Meeting_name":" Inhibition of epidermal growth factor receptor pathway by epidermal growth factor antibodies in non-small cell lung cancer",
        "Background":"['Introduction', ' The Epidermal Growth Factor Receptor (EGFR) signaling system is frequently unbalanced in non-small-cell lung cancer (NSCLC). Epidermal Growth Factor (EGF) could be an attractive target in these tumors. We used a cancer vaccine composed of human recombinant EGF conjugated to a carrier protein P64K. The vaccine is intended to induce antibodies against patients own EGF that would block EGF-EGFR interaction.Objectives', ' In NSCLC cell lines we assessed whether anti-EGF antibodies can inhibit the pathway activated by EGF-EGFR binding and whether sera from immunized patients can block downstream key signal transduction proteins. NSCLC cell lines were selected to determine whethergenetic alterations in EGFR, KRAS, ALK, BRAF or MET can have an impact on inhibition of EGFR pathway by anti-EGF antibodies.Experimental Procedures', ' Western blotting was used to evaluate the capacity of antibodies and sera from patients to inhibit EGFR activation pathway. MTT assays were performed to evaluate the effects on tumor cell proliferation.Results', ' The anti-EGF antibodies showed a dose-dependent inhibitory effect on EGF-induced activation of EGFR and downstream pathway molecules such as Akt and ERK 1/2. This inhibition was observed in all cell lines tested, including KRAS, EGFR and BRAF mutated cells as well as cells with ALK translocations or MET amplification. Sera from 10 patients immunized with the P64K-EGF vaccine were then tested. All sera reversed EGF-induced activation of EGFR and ERK 1/2, but some sera were significantly more potent than others. By contrast, two control sera from non-vaccinated patients failed to inhibit EGF-induced phosphorylation of EGFR and ERK 1/2. Finally, anti-EGF antibodies were also able to block the stimulatory effects of EGF on the growth of some NSCLC cell lines.Conclusions', ' Anti EGF antibodies and sera from patients immunized with an EGF vaccine, called otherwise EGF Pathway Targeted Immunization inhibits EGFR signaling in NSCLC cell line models. This effect is independent of cells genetic background.']",
        "Doc_id":"AACR_2016-2368",
        "Doc_title":" Inhibition of epidermal growth factor receptor pathway by epidermal growth factor antibodies in non-small cell lung cancer",
        "_version_":1606189009420156928},
      {
        "Meeting_name":" Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in non-small cell lung cancer (NSCLC) patients (pts).",
        "Background":"['Background', ' Non-synonymous SNPs (nsSNPs) in RTKs can alter kinase activity and are not exclusive to the tyrosine kinase domain (TKD). In NSCLC, EGFR lesions were previously identified using TKD-limited tests; however, next-generation sequencing (NGS) enables the entire protein sequence of many RTKs to be interrogated. Methods', ' We analyzed all nsSNPs in 28 RTKs in lung cancer pts who received tumor profiling with Caris NGS from 2013-2015. Mutations were classified by location including the TKD, extracellular domain (ECD), transmembrane domain (TM), juxtamembrane domain (JM), and carboxy-terminal (CT) regions. nsSNPs underwent in silico analysis using PolyPhen-2 (Harvard) to predict pathogenicity. Results', ' 167 pts (156 NSCLC, 11 SC) were identified with a median age 65 (range 26-85); 51% male; 65% white, 31% black; 77% 20 pack-years (py), 11% non-smokers; 52% samples tested were metastases. NSCLC pts were 63% adenocarcinoma, 22%, squamous, 8% large-cell; 81% stage IV, 14% III; 17 were EGFR+, 6 BRAF+, 3 HER2+, 3 ROS1 rearranged and 1 MET exon 14. A total 300 nsSNPs (286 NSCLC, 14 SC) were found in 28 RTKs, excluding EGFR. 123/156 NSCLC pts (79%) and 9/11 SC (82%) had 1 RTK lesion with median 2 (range 0-8); 143/300 (48%) nsSNPs were predicted-damaging (pnsSNP) by in silico and 89 pts (53%) had 1 pnsSNP (median 1; range 0-5). 28/28 RTKs had 3 mutations, with median 11 (range 3-23), and 26/28 contained 1 pnsSNP (median 5; range 0-14). RTKs in NSCLC with the most frequent nsSNPs were EPHA3 (14/23 variants were pnsSNP), EPHA5 (11/17), EPHB1 (10/11), RET (9/11), ERBB4 (8/12), ALK (7/16), NTRK3 (7/15), ROS1 (6/22) and FLT1 (6/15). 6/14 lesions in SC pts were pnsSNPs in ERBB3, ERBB4, FGFR1, FLT1, RET and ROS1. nsSNPs were found along RTKs', ' 57% were ECD (72/172 pnsSNP), 26% TKD (47/77), 10% CT (14/29), 6% JM (8/18) and 1% TM (2/4). 6/6 SC pnsSNPs were ECD. 67% BRAF+ and ROS1-rearranged, 59% EGFR+, 33% HER2+ and 0/1 MET exon 14 pts had 1 pnsSNP. Conclusions', ' Nearly 80% NSCLC and SC pts had 1 nsSNP in 28 RTKs, excluding EGFR, with 48% pnsSNPs by in silico analysis. As > 70% nsSNPs were extra-TKD lesions, further characterization is needed to identify kinase-effecting variants and their potential clinical significance.']",
        "Doc_id":"ASCO_185154-199",
        "Doc_title":" Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in non-small cell lung cancer (NSCLC) patients (pts).",
        "_version_":1606188975055175680},
      {
        "Meeting_name":" Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients",
        "Background":"['Background', ' Therapy with immune checkpoint inhibitors (ICI) changed the paradigm of treatment in many solid tumors including NSCLC. Recently several ICI were approved for NSCLC second and first line. By now data on Nivo benefits/risks in NSCLC is quite limited. The aim of this study was to evaluate clinical and patient-reported outcomes on Nivo in second plus line within the expanded access program in NSCLC. We report interim analysis on response rates, safety and QoL. Methods', ' Adult pts with advanced refractory NSCLC received Nivo 3 mg/kg q2w. Tumor response was assessed using RECIST v. 1.1., adverse events (AEs) with NCI CTCAE v3.0. and QoL by RAND SF-36. Group comparisons were made using Wilcoxon test. Results', ' From July of 2015 to January of 2017, 157 pts were enrolled in 7 centers in RF. Median follow-up time was 14 weeks. Clinical characteristics', ' 66%  males; median age  62 (2980); ECOG PS 0-1/2-3  81%/19%; former/current smokers  73%; non squamous NSCLC  64%; 2 lines of previous systemic treatment  51%. We observed 1.5 increase of Integral QoL index in 53% of pts at 4 weeks; significant improvement was observed for emotional functioning (33.3 vs 50.0; p < 0.05). Efficacy was evaluated in 56 pts', ' PR  6/56, SD  35/56, PD  15/56. Clinical improvement was noticed in 36 pts. Early deaths from cancer occurred in 9 pts; early deaths not related to cancer  2 pts. 18 pts discontinued Nivo prematurely ( < 8 weeks) because of rapid clinical worsening. 72 pts were not evaluated for response on cut-off. More pts with quick worsening as compared with responders were with non squamous NSCLC (75% vs 50%) and had brain mets (20% vs 0%). Among responders 33% were with PS > 1 and were > 65 y.o; pts in this group had no brain mets. AEs were registered in 40 pts (median of Nivo treatment  6 weeks); among them 11 with grade 3-4 AEs. Conclusions', ' Early data from this study supports thata large number of pts benefits fromNivo treatment. Nivo is well tolerated by this population, with 7% of grade 3 or 4 toxicities. Nivo treatment is accompanied with significant QoL improvement in 53% pts.']",
        "Doc_id":"ASCO_191845-199",
        "Doc_title":" Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients",
        "_version_":1606189018135920641},
      {
        "Meeting_name":" Establishment and molecular characteristics of PC-9 derived erlotinib resistant cell lines.",
        "Background":"['Background', ' EGFR mutation is closely associated with tumor responsiveness to EGFR tyrosine kinase inhibitors (TKIs), gefitinib or erlotinib. However, many non-small cell lung cancer (NSCLC) cases with EGFR mutation that had responded to EGFR-TKIs finally acquire resistance to EGFR-TKIs. It has been reported that T790M mutation and MET amplification caused resistance to EGFR-TKIs . Recent study suggested that overexpression of HGF was also related to resistance to EGFR-TKIs. However, the whole mechanism of acquired resistance to TKIs is still not fully known. Methods', ' We established 5 clones of elrotinib resistant PC-9 cell line (harboring EGFR exon 19 deletion) (designated as PC-9ER1-5) by exposing PC-9 to low-dose erlotinib. The protein expression of EGFR-related molecules was examined by Western blotting. Array comparative genomic hybridization (aCGH) or real time quantitative PCR (qPCR) assay was performed to examine copy numbers of EGFR-related genes. Results', ' In MTS assay, the IC50 value for the parental PC-9 cells was 0.02 mol/L. By contrast, those for PC-9ER1-5 were more than 33mol/L. All 5 resistant cell lines retained exon19 deletions and did not obtain T790M mutation. The qPCR assay and aCGH showed no MET amplification in PC-9 or PC-9ER1-5. HGF protein was not overexpressed in PC-9ER1-5 by ELISA. The protein expressions of several molecules in the EGFR-Akt signaling pathway were examined by western blotting after erlotinib treatment. Although phospho-EGFR was suppressed in both PC-9 and PC-9ER1-5 with 2-mol/L erlotinib, phospho-Akt was not suppressed in PC-9ER1-5. PTEN expression was not down-regulated in PC-9ER1-5. The combination of erlotinib and PHA-665752, MET tyrosine kinase inhibitor, did not suppress phospho-Akt or cell proliferation in PC-9ER1-5. Conclusions', ' As common molecular features of our EGFR-TKI resistant cell lines, phospho-Akt was not suppressed with exposure to erlotinib. These cell lines did not show previously reported features of resistant cell lines including T790M mutation, MET amplification or HGF overexpression. Our results indicated that other mechanisms leading to Akt activation caused resistance to EGFR-TKIs.']",
        "Doc_id":"ASCO_34032-65",
        "Doc_title":" Establishment and molecular characteristics of PC-9 derived erlotinib resistant cell lines.",
        "_version_":1606188996768038913},
      {
        "Meeting_name":" Clinical trial risk reduction in non-small cell lung cancer though the use of biomarkers and receptor-targeted therapies.",
        "Background":"['Background', '  We analyzed the risk of clinical trial failure duringnon-small cell lung cancer (NSCLC) drug development between 1998 and 2012.  Methods', '  NSCLC drug development was investigated using trial disclosures from publically available resources. Compounds were excluded from the analysis if they began phase I clinical testing before 1998 and if they did not use treatment relevant endpoints. Analysis was conducted in regards to treatment indication, compound classification and mechanism of action. Costs of clinical drug development for advanced NSCLC were calculated using industry data and assumptions, a 9% yearly discount rate and assuming a clinical trial length of 2.5 years for phase I trials, 4 years for phase II trials, 5 years for phase III trials and an average of 5 phase I trials, 7 phase II trials, and 4 phase III trials per approved drug. All funding costs are in US dollars (USD).  Results', '  2,407 clinical trials met search criteria. 676 trials and 199 unique compounds met our inclusion criteria. The likelihood, or cumulative clinical trial success rate, that a new drug would pass all phases of clinical testing and be approved was found to be 11%, which is less than the expected industry aggregate rates (16.5%). The success of phase III trials was found to be the biggest obstacle for drug approval with a success rate of only 28%. Biomarker-guided targeted therapies (with a success rate of 62%) and receptor targeted therapies (with a success rate of 31%) were found to have the highest likelihood of success in clinical trials. The risk-adjusted cost for NSCLC clinical drug development was calculated to be 1.89 billion US dollars. Use of biomarkers decreased drug development cost by 26% to 1.4 billion US dollars. Potential savings may be even higher if fewer clinical trials are required for successful development.   Conclusions', '  Physicians that enroll patients in NSCLC trials should prioritize their participation in clinical trial programs that involve either a biomarker or receptor targeted therapy, which appear to carry the best chances for a successful treatment response. Given the high adjusted cost of clinical testing alone in NSCLC, efforts to mitigate the risk of trial failure need to explore these factors more fully.']",
        "Doc_id":"ASCO_109752-132",
        "Doc_title":" Clinical trial risk reduction in non-small cell lung cancer though the use of biomarkers and receptor-targeted therapies.",
        "_version_":1606189002309763073},
      {
        "Meeting_name":" Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.",
        "Background":"['Background', '  EGFR-TKI is now one of the standard therapies in advanced NSCLC in the first-line setting. It yields an excellent PFS, but most of pts recur. Although they should receive subsequently the standard cytotoxic chemotherapy, about 15-30% of pts could not possibly because of poor PS at the time of recurrence in our cohort [Kato Y, ASCO 2012]. We here investigated the pattern of relapse and potential factors affecting disease progression with PS deterioration during the first-line EGFR-TKI therapy.  Methods', '  Consecutive 48 pts with advanced EGFR-mutant NSCLC who had had PS of 0-2 and then recurred after the initiation of EGFR-TKI therapy in the first-line setting between 2003 and 2012 were retrospectively assessed.  Results', '  Eighteen (38%) had CNS mets at the time of diagnosis, 13 of whom received local therapy before initiating EGFR-TKI, whereas 11 and 5 pts had bone mets with or without the prior local therapy. Median time to progression was 14.7 months (95%CI; 8.1-16.5). The relapse sites included CNS (n=15), intrapulmonary (n=14), primary (n=11), and bone (n=9). At the time of relapse, PS deteriorated to 3 or worse in 8 (17%) most commonly due to symptomatic CNS relapse. Preexisting CNS involvement was a significant predictor for the development of PS 3 or worse, irrespective of the local therapy for the involvement prior the EGFR-TKI therapy; the adjusted odds ratios for PS deterioration were 12.1 (1.0-143.5; p=0.05) and 47.3 (1.5-1502.7, p=0,03) in pts with or without the previous CNS therapy, respectively. Pts with PS deterioration at the time of relapse received the subsequent standard cytotoxic chemotherapy less frequently (1/7; 14% vs. 31/37; 84%, p<0.01) and had a worse post-progression survival than those without (median', ' 3.2 vs. 28.8 months, p<0.01).  Conclusions', '  Pts with prior CNS mets had a high risk of PS deterioration possibly through CNS failure when they recurred in the first-line EGFR-TKI therapy, whichever they received CNS therapy before initiating EGFR-TKI therapy. They had less chance to receive the subsequent cytotoxic therapy, so further research is needed to clarify the benefit of concurrent EGFR-TKI and cytotoxic chemotherapy especially in such population.']",
        "Doc_id":"ASCO_131376-144",
        "Doc_title":" Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.",
        "_version_":1606189029259214848},
      {
        "Meeting_name":" Noninvasive analysis of acquired resistance to EGFR-TKI",
        "Background":"['BACKGROUNDEpidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance in non-small cell lung cancer (NSCLC). However, the tissue availability limits the genotyping of EGFR T790M mutation in the clinical setting. The aims of this study are to develop a blood-based, non-invasive approach to detect the EGFRT790M mutation in advanced NSCLC patients. Additionally, plasma concentrations of HGF, MET and amphiregulin which are also resistant factors of EGFR-TKIsEXPERIMENTAL DESIGNPlasma sample were collected from NSCLC patients with activating EGFR mutations, who had resistant to EGFR-TKIs treatment. EGFR T790M mutations were detected using droplet-digital PCR (ddPCR) system from plasma DNA at resistance to EGFR-TKI. Plasma concentrations of HGF, soluble MET (sMET) and amphiregulin were determined using enzyme-linked immunosorbent assay. The relationships between the EGFR T790M mutation status and the plasma concentrations, progression-free survival (PFS) overall survival (OS) were analyzed.RESULTSTwenty-one (35%) of the patients had EGFR T790M mutation in plasma DNA using ddPCR system. The levels amphiregulin tended to be increased at the resistance in the patients with EGFR T790M mutation. The PFS and OS of the patients with EGFR T790M mutation was significantly shorter than that of the patients without EGFR T790M mutation (P =0.03 and 0.04). The PFS of the patients who had high amphiregulin at the resistance and the OS of the patients who had high amphiregulin at pre-treatment were shorter than these of t low amphiregulin (P = 0.05 and 0.05)CONCLUSIONSThe ddPCR system is a detectable method for determining the plasma EGFR T790M mutation status. The combination of EGFR T790M mutation status by ddPCR and the amphiregulin levels may aid in monitoring drug resistance and in predicting a prognosis.']",
        "Doc_id":"AACR_2014-557",
        "Doc_title":" Noninvasive analysis of acquired resistance to EGFR-TKI",
        "_version_":1606188983072587776},
      {
        "Meeting_name":" Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors",
        "Background":"['Background', 'Patients with non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable mutations conferring drug-resistance can be helpful for guiding the subsequent treatment decision. Currently, the known mechanisms of acquired resistance includes', ' the secondary gatekeeper EGFR-T790M mutation, activation of members of downstream signaling pathways such as PI3K/AKT/mTOR pathway, activation of bypass signaling such as MET, and changes in tumor histology. However, the mechanisms in the remaining patients are still unknown. Methods', 'In this prospective study, thirty-one advanced NSCLC patients initially carrying sensitive EGFR mutations and subsequently developing acquired resistance to the first-generation EGFR-TKIs were enrolled. Pre-treatment tumor samples as well as re-biopsies of tumor and plasma when the patients were diagnosed with EGFR-TKI resistance were acquired, followed by mutation profiling using targeted next generation sequencing (NGS) on 416 cancer-related genes. Results', ' In total, 55% of patients were identified to carry acquired secondary EGFR-T790M mutation. Three patients (~10%) harbor EGFR-T854A mutation, which has been reported as another TKI resistant mutation. 26% and 19% of cases accumulated TP53 and RB1 mutations, respectively. In T790M/T854A-negative cases, 30% of patients acquired MET amplification. Other potential acquired resistance mechanisms includes single nucleotide variants (SNVs) in genes such as SMAD4, DNMT3A, GNAS, ATM, KRAS, PIK3CA and TET2, and copy number variations (CNVs) in genes such as CDK4, MDM2, MYC, RICTOR and ERBB2. Conclusions', 'The study depicted the genetic landscapes comprehensively in matched pre- and post-EGFR-TKIs samples of NSCLC population resistant to first generation TKI treatments. Our analysis demonstrates new perspectives for further study of resistance and putting forward corresponding relevant tactics against the challenge of disease progression. Clinical trial information', ' NCT02804217']",
        "Doc_id":"ASCO_187490-199",
        "Doc_title":" Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors",
        "_version_":1606189038801256448},
      {
        "Meeting_name":" Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib",
        "Background":"['Background', '  The ALK inhibitor crizotinib is approved for patients (pts) with ALK-rearranged (ALK+) NSCLC, but most pts progress within a year and CNS progression is common. The NP28673 study (NCT01801111) investigated the efficacy and safety of alectinib, a highly selective, CNS-active ALK inhibitor, in ALK+ NSCLC pts who had progressed on crizotinib.  Methods', '  Eligible pts (  18 yrs; locally advanced or metastatic ALK+ NSCLC [by FDA-approved FISH test]; failed on/intolerant to crizotinib) received alectinib 600mg p.o. BID until progression, death or withdrawal. Crizotinib was the only prior ALK inhibitor permitted. Primary endpoint was objective response rate (ORR) by independent review committee (IRC) using RECIST v1.1. Secondary endpoints included ORR by investigator; duration of response (DOR); CNS ORR and DOR; progression-free survival (PFS); disease control rate (DCR), CNS progression rate, overall survival, and safety.  Results', '  138 pts from 16 countries were enrolled by the 18 Aug 2014 cut-off. Median age 52 yrs; 80% had prior chemo; 60% had baseline CNS mets (60/83 treated). Median follow-up was 30 wks. In the response-evaluable population assessed by IRC (122 pts with measurable disease at baseline), ORR was 49.2% (95% CI 40.058.4; all PRs); DCR was 79.5% (95% CI 71.386.3). For patients with prior chemo and crizotinib (n = 96), ORR was 43.8% (95% CI 33.654.3); DCR was 78.1% (95% CI 68.585.9). For patients with baseline measurable CNS disease (n = 34), IRC-assessed CNS ORR was 55.9% (95% CI 37.972.8), including five CRs. Updated ORR, DOR and PFS data will be presented. Overall, 27.5% of pts had grade 35 adverse events (AEs), most commonly dyspnea (3.6%) and pulmonary embolism (2.2%); low rates of dose interruptions (19.6%), reductions (8.7%), and withdrawals (8.0%) due to AEs were seen.  Conclusions', '  Alectinib was well tolerated and achieved a robust treatment response, including excellent intracranial activity, in ALK+ NSCLC pts who had progressed on crizotinib; most had also failed prior chemo and had CNS mets. A phase 3 trial of first-line alectinib vs crizotinib and an expanded access program are ongoing. Clinical trial information', ' NCT01801111']",
        "Doc_id":"ASCO_149578-156",
        "Doc_title":" Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib",
        "_version_":1606189028186521600},
      {
        "Meeting_name":" Phase II study of carboplatin and pemetrexed followed by gefitinib for patients with advanced non-small cell lung cancer harboring sensitive EGFR mutation.",
        "Background":"['Background', ' To evaluate the efficacy, safety and survival of carboplatin and pemetrexed (Cb/Pem) as induction therapy followed by gefitinib (Gef) maintenance in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC). Methods', ' Eligible patients received 4 courses of Cb (AUC 6 mg/mLmin) /Pem (500 mg/m2), followed by sequential Gef (250 mg once daily). The primary endpoint was the 2-year survival rate. Secondary endpoints were progression-free survival (PFS), overall survival (OS), tumor responses, and the rate of adverse events. Based on an expected rate of 60% and a threshold rate of 40% at 2 years, 54 cases were required with < 0.1 and < 0.1. This study was to be effective if 28/54 patients survived for > 2 years. If fewer than 12 of the first 29 patients survived beyond 2 years then the trial was to be stopped. Results', \" 29 patients were enrolled between June 2010 - January 2015 and we performed an interim analysis The median age was 64 years, 27 patients had stage IV, and 2 patients were postoperative recurrence. There were 6 males and 23 females, performance status was 0 and 1 in 17 and 12 patients, and EGFR gene variations were Ex18, Ex19, and Ex21 in 1, 14, and 14 patients. 1 patient wasn't met starting criteria; therefore, 28 patients were analyzed. The median follow-up time was 30.2 months (range 765). 16 patients (57.1%) had partial response for Cb/Pem therapy and all of the patients were switched to Gef. The reasons for switching Gef were completion of Cb/Pem in 21 patients, toxicity in 5 patients, and the doctors judgment in 2 patients. There were no febrile neutropenia or treatment-related deaths. The overall response rate was 85.2%. The 2-year survival rate was 62.9%, PFS was 16.0 months and OS was not met. According to the EGFR gene variants, the PFS was 17.0 and 15.0 months for patients with Ex19 and Ex21. The OS was not met for patients with Ex19 and was 26.0 months for patients with Ex21. Conclusions\", ' Cb and Pem followed by Gef maintenance therapy might be an initial treatment option for advanced EGFR-positive NSCLC patients. This study was decided to stop after the first stage of enrollment because of the slow enrollment and a phase III study had been started. Clinical trial information', ' UMIN000003354.']",
        "Doc_id":"ASCO_166998-176",
        "Doc_title":" Phase II study of carboplatin and pemetrexed followed by gefitinib for patients with advanced non-small cell lung cancer harboring sensitive EGFR mutation.",
        "_version_":1606189035375558656},
      {
        "Meeting_name":" High content clonogenic survival assay for drug library screening identifies potent radiation sensitizers for non-small cell lung cancer",
        "Background":"['Radiotherapy is a critical component in the definitive treatment of locally-advanced non-small cell lung cancer (LA-NSCLC), and while concurrent platinum-based chemoradiation is the standard approach, improvements have been minimal. Molecularly-targeted therapy to further enhance radiation effects beyond platinum-sensitization is needed to further improve radiotherapy efficacy. A systematic approach needs to be developed that can rapidly identify novel drugs that can be combined to enhance radiation effects. However, current approaches using traditional clonogenic survival assay (tCSA) and colorimetric assays are inadequate for high throughput drug screens to identify novel radiation sensitizers. To enable screens adapted for radiation drug screening, we have developed a method which we coin the High Throughput Clonogenic Survival Assay (HCSA) that allows rapid screening of drug libraries to identify potent radiation sensitizers. As a proof-of-principle, we used the Kras mutated lung cancer cell line H460, and validated the hits using traditional assays. Drugs at various concentrations or vehicle were added to cells seeded overnight in 96 well plates at low densities, and after 6 hours, plates were irradiated at various doses. After incubation, colonies were stained and imaged on the INCell 6000 (GE Health), and colony count determined using the INCell Developer image analysis software. Drug screens were done using a Custom Clinical Collection of 150 compounds. We compared the HCSA method to tCSA and found that HCSA recapitulates a similar cell survival curve and survival fraction at 2 Gy (SF2) values for several cancer cell types. Drug screens identified several compounds that were cytotoxic to the KRAS mutant H460 cells alone at 1 M (inhibitors to Src/Abl, IGF1R, ROCK1, AKT, PI3K, c-MET) and at low nM concentrations (HSP90 and HDAC inhibitors). Multiple drugs of the same class were found to be radiation sensitizers and levels of potency seemed to reflect the clinical relevance of these drugs. For instance, several late generation PARP inhibitors were found to be good sensitizers in the HCSA, but the ones that have not made it into clinical development, or in the case of BSI-201, was proven to not even be a PARP inhibitor, do not come out in the screen. We also discovered that several inhibitors of pathways downstream of activated mutant KRAS (PI3K, AKT, mTOR, and MEK1/2) sensitized H460 cells to radiation, which is biologically relevant for this Kras mutant cell line. We believe these results demonstrate the promise of HCSA as a high throughput drug screening platform to identify novel radiation sensitizers. This will greatly expedite the discovery of novel targets and drugs for clinical translation to enhance the effects of radiotherapy in lung cancer.']",
        "Doc_id":"AACR_2014-4898",
        "Doc_title":" High content clonogenic survival assay for drug library screening identifies potent radiation sensitizers for non-small cell lung cancer",
        "_version_":1606189026535014400},
      {
        "Meeting_name":" Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for 1st salvage therapy (Tx) after response to 1st-line crizotinib (CRZ) in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  Crizotinib is standard 1st line Tx for ALK-positive NSCLC. 2nd line Tx after progression on CRZ is less well defined. Shaw, et al (N Engl J Med 2013; 368', '2385-2394) showed that ALK-positive NSCLC patients have higher response rates and improved PFS with pemetrexed (PEM) relative to docetaxel in the 2nd line setting.  Prior to the FDA approval of ceritinib (CER) on April 29, 2014, no salvage Tx specifically targeting ALK was available.  Methods', '  Prescribing preferences (PPrefs) of 364 U.S.-based medical oncologists (MOs) were studied using a validated, proprietary, live, case-based market research tool (Challenging Cases). Data were acquired using blinded, audience-response iPad technology and acquisition events took place in April, May, August and November 2014. A core case was constructed and PPrefs for three different patterns of treatment failure were assessed. Core case', ' 57-year-old man has a new diagnosis of stage IV adenocarcinoma of the lung. Pathology showed ALK positive NSCLC. You began the patient on daily CRZ. He had a clear RECIST PR after 8 weeks.  He tolerated the Tx well and he has been on Tx continuously for 8 months.  Results', '  See table.  PPrefs for CER increased in each scenario post FDA approval. A single site of failure, managed definitively with local Tx, triggers a move away from CRZ less than half the time. PPrefs for CER increased most as the number of sites of progression increased.  Conclusions', '    These data indicate that patterns of failure strongly influence prescribing preferences after 1st line Tx with CRZ for patients with ALK positive NSCLC.   PPrefs by pre- and post-FDA approval of CER by pattern of failure.*N = 360N = 364N = 360Pattern of FailureSingle brain met (resected)Brain met (resected) and liver metBrain, bone, lung, intrathoracic, and adrenal metsFDA ApprovalPrePostPrePostPrePostContinue CRZ78% 58%14%7%NONORadiate   liver site and continue CRZNONO36%24%NONOPEM-based CT7%10%12%12%37%28%Other CT1%4%6%2%11%4%CER10%26%30%51%44%61%Other-including   other ALK inhibitors3%3%2%4%7%5%NO - not offered; *May not equal 100% due to rounding']",
        "Doc_id":"ASCO_147967-156",
        "Doc_title":" Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for 1st salvage therapy (Tx) after response to 1st-line crizotinib (CRZ) in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).",
        "_version_":1606188984615043072},
      {
        "Meeting_name":" Weekly vinorelbine and paclitaxel in elderly patients with advanced non-small cell lung cancer",
        "Background":"['Background', '  Platinum-based doublet chemotherapy is the standard of care for advanced NSCLC for which the median age at diagnosis is 70 years. Despite a demonstrated benefit, the majority of patients over 65 years do not receive chemotherapy due to toxicity concerns. Vinorelbine and paclitaxel have single agent response rates of 20% in advanced NSCLC and preclinical studies show synergism between the two. Our phase II study evaluates the safety and efficacy of this combination in patients over 70 with advanced NSCLC.   Methods', '  Patients with metastatic NSCLC were administered one cycle that comprised of 6 weekly doses of vinorelbine (22.5 mg/m2) and paclitaxel (40 mg/m2). Patients with radiographic progression noted on imaging two weeks after completion of the first cycle came off study; others received a second cycle. Toxicity was assessed after 10 patients enrolled and again after a total of 19 patients. The study was powered to detect a disease control rate (complete response + partial response + stable disease) of 30% with stable or improved quality of life score (n = 29). Other outcomes measured were safety and efficacy, progression free and overall survival and quality of life. Kaplan-Meier method was used for statistical analysis.  Results', '  Mean age of the 19 enrolled patients was 76.9 years (range', ' 71-82 years). Enrollment was closed after the second interim analysis as it met the toxicity threshold with 6/19 patients developing grade 4 non-hematologic toxicities. Of the 16 evaluable patients, 7 completed the study. Causes of discontinuation were disease progression (n = 5), death (n = 3), infection (n = 3) and infusion reaction to paclitaxel (n = 1). The partial response rate was 26% (n = 5); another 21% (n = 4) had stable disease, while 37% (n = 7) had progressive disease. The median progression free survival was 3.48 months (95% CI', ' 1.4, 5.5 months) and the median overall survival was 7.8 months (95% CI', ' 1.9, 13.6 months).  Conclusions', '  Although the combination met its response end points, increased toxicity makes this combination unsuitable for older patients. Quality of life data are being analyzed and will be reported at the time of the meeting. Clinical trial information', ' NCT00602797']",
        "Doc_id":"ASCO_145414-156",
        "Doc_title":" Weekly vinorelbine and paclitaxel in elderly patients with advanced non-small cell lung cancer",
        "_version_":1606188991971852288},
      {
        "Meeting_name":" Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.",
        "Background":"['Background', '  Tivantinib (T) is a selective non-ATP competitive oral inhibitor of MET receptor. Preclinical data showed that MET inhibition blocks Malignant Pleural Mesothelioma (MPM) and Non Small Cell Lung Cancer (NSCLC) cell growth and migration. Adding T to standard first-line chemotherapy may improve efficacy.  Methods', '  Patients (pts) with advanced MPM or non-squamous NSCLC were eligible to receive escalating doses of T combined with carboplatin (C) AUC 5 i.v. d1-q21 and pemetrexed (P) 500 mg/m2 i.v. d1-q21 as first-line treatment. After 6 cycles of CP, T is continued as maintenance therapy until progression. Pts must be chemo-nave with ECOG Performance Status (PS) < 2 and adequate bone marrow, liver, and kidney functions. A standard 3+3 dose-escalation design was employed starting from dose level 0 (T 240 mg BID). The primary endpoint of the phase I study was to assess the maximum tolerated dose (MTD), defined as the highest dose level at which no more than 1 of 6 pts experiences a dose limiting toxicity (DLT) during the first cycle. To evaluate the anti-tumor activity (MPM pts', ' 3-month PFS%; NSCLC pts', ' 5-month PFS%) and the pharmacokinetics of the combination, a phase Ib trial is still ongoing.  Results', '  From April 2013 to September 2014, 12 pts were enrolled in the phase I study; mean age was 69 years (range, 37-73 years), M/F', ' 9/3, ECOG PS 0/1', ' 5/7, MPM/NSCLC', ' 6/6. The MTD was reached at dose level 0 (T 240 mg BID). DLTs (2 neutropenia G4, 1 thrombocytopenia G4) were observed in 2 pts, both at dose level 1 (T 360 mg BID). The most common all-grade toxicities were nausea/vomit (67%), anemia (58%), neutropenia (50%), and asthenia (50%). G3/4 treatment-related AEs were reported in 6 pts (50%) and all were hematological (neutropenia, thrombocytopenia, anemia). All pts received 6 cycles of CT. Among 12 evaluable pts, 1 had CR, 4 PR, and 7 SD as best response.  Conclusions', '  Adding T to CP is safe with preliminary evidence of antitumor activity. T 240 mg BID in combination with C AUC 5 i.v. d1-q21 and P 500 mg/m2 i.v. d1-q21 represents the recommended dose for phase II trials. Clinical trial information', ' NCT02049060']",
        "Doc_id":"ASCO_150233-156",
        "Doc_title":" Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.",
        "_version_":1606189010315640832},
      {
        "Meeting_name":" Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling. Addition of vandetanib to docetaxel (doc) prolonged progression-free survival (PFS) in a randomized phase II study in patients (pts) with previously treated NSCLC (Heymach et al, JCO, 2007). Methods', ' The primary objective was to determine whether vandetanib 100 mg/day + doc 75 mg/m2 every 21 days (max 6 cycles) prolonged PFS vs placebo + doc. Secondary endpoints included overall survival, objective response rate (ORR), time to deterioration of symptoms (TDS) and safety. Efficacy and safety in females were assessed as a co-primary analysis population. Eligibility criteria included stage IIIB/IV NSCLC, PS 0-1, and previous first-line chemotherapy. Results', ' Between May 2006 and April 2008, 1,391 pts (mean age, 58 years; 30% female; 25% squamous; 10% brain mets) were randomized to vandetanib + doc (n=694) or placebo + doc (n=697). Baseline characteristics were similar in both arms. Median duration of follow-up was 12.8 months, with 87% patients progressed and 59% dead. Addition of vandetanib to doc showed a statistically significant improvement in PFS vs doc (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; P<0.001), and a similar advantage in females (HR 0.79; P=0.024). Significant advantages for vandetanib + doc were also seen for ORR (17% vs 10%, P<0.001) and TDS (HR 0.78, P=0.002; FACT-L Lung Cancer Subscale). Overall survival showed a positive trend for vandetanib + doc that was not statistically significant (HR 0.91, 97.52% CI 0.78-1.07; P=0.196). The adverse event (AE) profile was consistent with that previously observed for vandetanib in NSCLC. Common AEs occurring more frequently in the vandetanib arm included diarrhea (42% vs 33%), rash (42% vs 24%) and neutropenia (32% vs 27%). Nausea (23% vs 32%), vomiting (16% vs 21%) and anemia (10% vs 15%) were less frequent in the vandetanib arm. The incidence of protocol-defined QTc prolongation was <2% in pts receiving vandetanib. Conclusions', ' The study met its primary objective of PFS prolongation with vandetanib + doc vs doc. Vandetanib is the first oral targeted therapy in phase III trials to show significant evidence of clinical benefit when added to standard chemotherapy in NSCLC.']",
        "Doc_id":"ASCO_31495-65",
        "Doc_title":" Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC)",
        "_version_":1606189031385726976},
      {
        "Meeting_name":" Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study",
        "Background":"['Background', ' Phase III trials have shown that bevacizumab (Avastin, BV), an anti-VEGF monoclonal antibody, prolongs progression-free and overall survival in advanced NSCLC pts. To further define clinical outcomes associated with BV treatment among a broader population of NSCLC pts in a real-world setting, the ARIES OCS was initiated. Pt populations in OCSs are often more reflective of pts encountered in practice, permitting examination of treatment benefit and toxicity in subgroups that might be too small for study in traditional randomized controlled trials (RCTs). The NSCLC cohort in ARIES will assess clinical outcomes in the overall cohort as well as subpopulations such as the elderly, pts with poor PS or pts on concurrent anticoagulants (AC). Methods', ' Pts with advanced NSCLC whose 1st-line therapy includes BV may enroll. 257 sites are enrolling pts; total accrual of 2000 pts is expected. There are no protocol-specified treatments or assessments. Data is collected at baseline (BL) then quarterly, including targeted adverse events (AEs) and BV-related serious AEs. Clinical outcomes will be descriptively summarized by baseline characteristics. Multivariate analyses will be conducted if cohort size is sufficient. Results', ' As of 9/15/08, 1518 NSCLC pts have enrolled. Median F/U is 7.5 mos. Key BL characteristics', ' 20% >75 yrs; 67% adenocarcinoma; 10% ECOG >2; 8% brain metastasis; 5% therapeutic AC. The most common 1st-line chemotherapy regimen was carboplatin/paclitaxel (64%). Key safety outcomes and cohort size of subpopulations are in the Table. Conclusions', ' The safety of BV in subpopulations of pts in ARIES (elderly pts, pts with ECOG PS >2, with brain mets at BL, or on therapeutic AC) is generally consistent with safety results from RCTs. Updated outcomes analyses will be presented at the meeting for >1600 pts and subpopulations. Patients experiencing targeted AEs (n, %) Adverse eventAll pts (n=1518)75 yrs or older (n=300)ECOG PS 2 (n=150)Brain mets (n=101)Therapeutic anticoagulants (n=77) Bleeding events (Gr 3 -5),45 (3.0)4 (1.3)5 (3.3)6 (5.9)a1 (1.3) CNS hemorrhage1 (0.1)0001 (1.3) GI hemorrhage17 (1.1)2 (0.7)3 (2.0)2 (2.0)0 Severe pulmonary hemorrhage11 (0.7)b1 (0.3)2 (1.3)1 (1.0)0 Serious arterial thromboembolic events21 (1.4)8 (2.7)4 (2.7)1 (1.0)2 (2.6) Hypertension requiring medical management57 (3.8)9 (3.0)4 (2.7)1 (1.0)0a Two bleeding events were reported as nonserious. b One patient experienced two sPH events.']",
        "Doc_id":"ASCO_30542-65",
        "Doc_title":" Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study",
        "_version_":1606188971077926912},
      {
        "Meeting_name":" Poor predictive power of BIM deletion polymorphism for EGFR tyrosine kinase inhibitor outcome in non-small cell lung cancer patients harboring EGFR mutation.",
        "Background":"['Background. Recently, a germline deletion polymorphism of BIM was reported to predict tyrosine kinase inhibitor (TKI) outcome in patients with chronic myelogenous leukemia or advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation. In this study, we examined the predictive role of BIM deletion in a Korean NSCLC cohort. Also, we explored genetic alteration profile of patients exhibiting primary resistance to EGFR TKI treatment despite EGFR mutation. Methods. Data from 197 consecutive patients who had stage IIIB/IV NSCLC with TKI-sensitive EGFR mutation were collected from the NSCLC database of Seoul National University Hospital between 2006 and 2011. BIM deletion polymorphism was genotyped with polymerase-chain reaction (PCR) and visualized with 2% agarose gel electrophoresis. Additionally, we also examined putative clinical predictors of EGFR TKI outcome, including line of treatment, EGFR genotype, and smoking status. For patients who exhibited primary resistance to EGFR TKI treatment, we performed additional molecular analysis including fluorescence in situ hybridization for MET amplification and ALK fusion, and targeted deep sequencing of 46 cancer-related genes to explore the mechanism of primary resistance. Results. In this cohort, the median progression-free survival (PFS) for patients receiving EGFR TKIs was 11.9 months, and the objective response rate was 78.8%. Patients with wild-type BIM (n = 172; 89.1%) and BIM deletion (n = 21; 10.9%) exhibited no difference in median PFS after EGFR TKI treatment (11.3 months for wild-type BIM, 11.9 months for BIM deletion; P = 0.791). Also, the line of treatment, the genotype of the EGFR-activating mutation, and smoking were not predictive of PFS for EGFR TKIs. However, patients with recurrent disease after curative surgical resection had a longer PFS than patients with initial stage IV disease (16.0 months for recurrent disease, 10.0 months for stage IV disease at initial presentation; P = 0.007). From the examination of pretreatment tissue of 11 patients exhibiting primary resistance, de novo EGFR T790M mutation was identified in one patient. We also found a patient with de novo MET amplification and another patient with ALK fusion. Targeted deep sequencing identified no recurrent, coexistent drivers of NSCLC. Conclusion. BIM deletion polymorphism showed poor predictive role in EGFR-mutant NSCLC patient cohort, although their initial report indicated remarkable predictive power. In a small portion of cases with primary resistance, we identified coexistent genetic alterations of cancer-related genes that could explain primary resistance. Our result suggests that the mechanism of primary resistance might be heterogeneous.']",
        "Doc_id":"AACR_2013-4461",
        "Doc_title":" Poor predictive power of BIM deletion polymorphism for EGFR tyrosine kinase inhibitor outcome in non-small cell lung cancer patients harboring EGFR mutation.",
        "_version_":1606189023039062016},
      {
        "Meeting_name":" Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC.",
        "Background":"['Background', '  MET is frequently overexpressed in NSCLC. Amplification of MET and its ligand (HGF), are mechanisms of resistance to EGFR inhibitors. R is an IgG2 human mAb that targets HGF. This phase I/II trial evaluated the safety and recommended phase 2 dose (RP2D) of R combined with E for pts with metastatic previously treated NSCLC (Phase I) and whether efficacy is high enough to warrant further interest (Phase II).  Methods', '  Phase I adopted a dose de-escalation design with R starting at 15 mg/kg IV every 3 weeks and E 150 mg orally daily (dose level 0). If dose de-escalation was needed it would proceed according to Narayana k-in-a-row design where a selected dose was estimated by isotonic regression. RP2D was the maximum below the dose associated with a 25% DLT rate. Phase II intended to test whether disease control rate (stable disease or response, DCR) of 50% for E could be improved by adding R. A Simon 2 stage design was used to select the optimal sample size for type I and II error of .10. Twenty-seven of 45 pts were required to have disease control for evidence of a statistically significant improvement over E alone. Response was assessed by RECIST every 6 weeks.  Results', '  In the absence of need for de-escalation among the first 8 pts, the RP2D was defined as dose level 0. Overall, 45 response-evaluable pts with stage IV were enrolled (13 squamous and 32 adenocarcinoma; 2 EGFR and 7 KRAS mutant). Median age was 65 years. A median of 4 cycles (range 1-18+) were administered. Four pts had partial response (one with EGFR and one KRAS mutation), 23 had SD, and 18 had progression, for a response rate of 8.9% (90% CI, 3.9 - 18.1) and DCR of 60% (90% CI, 47.1 - 71.3). Median PFS 2.6 months (90% CI 1.4- 2.7). At a median follow up of 15 months, median OS was 6.6 months (90% CI, 5.6 - 8.9). Probability of surviving one year was .33 (90% CI, .23 - .47). Among grade 3/4 AEs that were considered at least possibly related were rash (3), oral mucositis (1), elevated alkaline phosphatase (3) and bilirubin (1), thromboembolic event (3), diarrhea (5).   Conclusions', '  The combination of R and E in this study was found to have an acceptable safety profile and the DCR rate met the studys pre-specified criteria for success. Further investigation of this regimen is warranted. Clinical trial information', ' NCT01233687']",
        "Doc_id":"ASCO_152637-156",
        "Doc_title":" Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC.",
        "_version_":1606188986063126528},
      {
        "Meeting_name":" Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer",
        "Background":"['Detection and chemoprevention of non-small cell lung cancer (NSCLC) have been unsuccessful in part due to our limited knowledge of the pathogenesis of the disease. It has been suggested that normal airway epithelia share molecular abnormalities with tumors and may serve as progenitors for lung malignancies. We sought to analyze molecular profiles of lung adenocarcinomas and squamous cell carcinomas (SCCs), two major subtypes of NSCLC, and matched normal airways to elucidate aberrant expression patterns in early phases of lung tumorigenesis. All specimens were obtained from primary early stage NSCLC consented patients who did not receive neoadjuvant therapy (n=20). We profiled RNA isolated from tumors and normal lung as well as from brushings of multiple matched airways that were histologically confirmed to lack neoplastic or preneoplastic cells (n=194). Expression signatures signifying genes significantly and concurrently differentially expressed between both tumors and airways compared to normal lung tissue (tumor-airway-normal/TAN signatures) were then derived independently for SCC and smoker adenocarcinoma cases and were comprised of 1,803 and 1,938 genes, respectively. The TAN signatures effectively clustered tumor and airways from normal lung samples (p<0.001). Further analysis showed that a subset of the genes separated SCC- and adenocarcinoma-adjacent airways. Moreover, pathways and gene-network analysis using Ingenuity pathways software highlighted similarities and differences in pathway modulation between airway epithelial fields of SCCs and adenocarcinomas. Embryonic stem cell and eicosanoid signaling pathways were most significantly modulated among those common to both TAN signatures (p<0.001). Retinoic acid receptor and stem cell signaling pathways mediated by NANOG and lineage oncogene SOX2 were most significantly modulated in the SCC TAN signature, whereas NF-kB and PTEN signaling pathways were most prevalent in the adenocarcinoma TAN airway signature (all p<0.001). Gene networks mediated by lineage oncogene NKX2-1/TITF-1 down-regulation and TP63 up-regulation, and networks mediated by increased expression of the MET and ERBB2 oncogenes were predominantly functionally modulated in the SCC and adenocarcinoma TAN signatures, respectively. Quantitative PCR analysis confirmed up-regulation of MET in adenocarcinomas and normal airways compared to normal lung. These findings highlight expression patterns and pathways that are deregulated differentially in the pathogenesis of lung adenocarcinomas and SCCs and thus offer detection markers as well as therapeutic targets to guide personalized chemoprevention in early stage NSCLC patients. Supported by DoD grant W81XWH-10-1-1007.']",
        "Doc_id":"AACR_2012-1721",
        "Doc_title":" Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer",
        "_version_":1606189015776624640},
      {
        "Meeting_name":" Inhibition of tumor cell growth, invasion, and metastasis by SIM-89, a novel inhibitor of HGF receptor tyrosine kinases.",
        "Background":"['Background', '     The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies. SIM-89, developed by Simcere Bio-Pharmaceutical Co, Ltd, is a small-molecule kinase inhibitor that targets members of the HGF receptor tyrosine kinase families.  Methods', '     Kinase inhibition was investigated using Z-lyte detection technique(Invitrogen), LanthaScreen Tb-activity technique and LanthaScreen Binding technique. Inhibition of p-Met and Met is validated through Westernblot. IC50 of the compound is determined by CCK-8. HGF level in culture medium is determined by ELISA.Migration and invasion assayare done with Transwell system.  A549 and H460(2106)are implanted subcutaneous in right upper extremity of nude mice.Once daily oral administration of SIM-89/ placebo are given to nude mice for 35d.Tumor growth curve is calculated. B16F10 tumor cells (2  105) were implanted via i.v. tail vein injection into mice on day 0. SIM-89/ placebo administration was initiated 3 days after implantation for 10 days followed by assessment of lung tumor burden. Lung nodule diameters were morphometrically measured on digitally captured images. The results for each treatment group (n = 10 animals) were averaged, and statistical t test analysis was done comparing each treatment group to the placebo treated control.  Results', '     SIM-89 is a small-molecule kinase inhibitor that targets members of the HGF receptor tyrosine kinase families,with additional inhibitory activity toward AMPK (A1/B1/G1) and TRKA. SIM-89 significantly decreases HGF level in culture medium of nsclc cell lines at the IC50 of 625nmol/l. In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an experimental model of lung metastasis.  Once daily oral gavage administration of SIM-89 resulted in a dose-dependent reduction in tumor burden,  as determined by a reduction in lung wet weights. Conclusions', '    These data indicate that SIM-89 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion mediated by HGF receptors.']",
        "Doc_id":"ASCO_96331-114",
        "Doc_title":" Inhibition of tumor cell growth, invasion, and metastasis by SIM-89, a novel inhibitor of HGF receptor tyrosine kinases.",
        "_version_":1606188977949245440},
      {
        "Meeting_name":" Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACS phase II trial.",
        "Background":"['Background', '  Molecular alterations of crizotinib (crz) targets (ALK, MET, ROS1) are found in a wide range of malignancies. To avoid uncontrolled off-label use and allow for a nationwide safe access to crz for patients (pts) with an ALK, MET or ROS1 positive (+) tumor, the French National Cancer Institute (INCa) launched the AcS program, funding both access to tumor molecular diagnosis and an exploratory multi-tumor 2-stage design phase II trial. We report the preliminary results of the ROS1+ NSCLC cohort.  Methods', '  ROS1 status was determined in 28 regional INCa molecular genetic centers by break-apart FISH assays. Patients with ROS1 rearrangements, progressing after at least one standard treatment (including a platinum-based doublet, unless pts were considered as unfit for chemotherapy) were proposed to receive crz 250 mg BID. Responses were centrally assessed using RECIST v1.1. The objective response rate (ORR) and disease control rate (DCR) were assessed every 8 weeks.  Results', '  From Aug. 5, 2013 to Dec. 12, 2014, 34 pts with ROS1+ NSCLC were enrolled out of 37 expected pts. 32 pts had received crz, including 3 recently enrolled pts, leading to 29 pts with clinical information. Median age', ' 62 years (range 3381), 69% females, 93% non-squamous histology, and 93% metastatic disease at study entry. Median number of prior treatments', ' 2 (range 1 12). Twenty one pts were still on treatment at the cut-off date, 8 have stopped crz (5 PD, 2 adverse events (AEs), 1 death). Among the 24 pts evaluable for response at 8 weeks, we observed 1 CR, 14 PR, 6 SD and 3 PD, leading to ORR = 63% [95% CI', '41-81], and DCR = 88% [68-97]. DCR at 6 months was 53% and disease control was achieved in 8/15 evaluable pts. Crz was well tolerated with only 9 grade  3 AEs or SAE. Most common AEs, mainly grade 1, were visual disorders (62% of pts), peripheral edema (55%), diarrhea (51%), nausea (41%), and elevated transaminases (51%).  Conclusions', '  Crz was well tolerated and achieved a robust treatment response rate in ROS1+ NSCLC. These results underline the interest of integrating ROS1 in biomarkers routine screening. Survival data and duration of response will be presented. Clinical trial information', ' NCT02034981']",
        "Doc_id":"ASCO_151264-156",
        "Doc_title":" Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACS phase II trial.",
        "_version_":1606188978689540097},
      {
        "Meeting_name":" Co-treatment of statins and erlotinib to induce growth arrest and apoptosis in primary TKI-resistant non-small cell lung cancer (NSCLC)-cell lines.",
        "Background":"['Background', '  K-Ras mutations and amplification of MET lead to resistance to tyrosine kinase-inhibitor (TKI) treatment in NSCLC cell lines. HMG-CoA reductase inhibitors are widely prescribed and well tolerated drugs. However, the majority of statins are metabolized in the liver by Cyp3A4, which may lead to interactions with Erlotinib. Therefore we tested the efficacy of Erlotinib with either Fluvastatin or Pitavastatin (Statins), which are both not metabolized by Cyp3A4, for the treatment of primary TKI-resistant NSCLC celllines.  Methods', '  Experiments were carried out with human NSCLC celllines A549 (K-RAS mutation), Calu-6 (K-RAS mutation, P53 mutation), HCC 827 (EGFR mutation, Erlotinib sensitive) and H1993 (MET amplification). Apoptosis was measured by the activity of caspase 3 by cleavage of specific fluorescent caspase substrates, by binding of AnnexinV by FACS analysis or by the cleavage of PARP by Western blot. Inhibition of growth was assessed by MTS assays. The effect of either drug alone or in combination on phosphorylation of AKT and ERK1/2 was evaluated by Western blot.  Results', '  Erlotinib inhibited the growth of HCC 827 cells but had no effect on A549, Calu6 and H1993. Statins led to growth inhibition in all 4 cell lines investigated in a dose dependant manner. However, the combination of statins and Erlotinib was significantly more effective than either drug alone.  Erlotinib and Statins failed to induce apoptosis when used as single drugs in A549, Calu6 or H1993. However when a combination of TKI and Statin was used, a significant increase in caspase 3 activity and in the ratio of annexin V positive cells was seen. Moreover an increased cleavage of PARP was shown in the combination treatment.  Importantly the activation of survival pathways mediated by phosphorylation of AKT was markedly decreased, by the combined treatment of Erlotinib with either Statin in A549, Calu6 and H1993 cells. ERK 1/2 phosphorylation was reduced in H1993 and Calu6 cells upon combined treatment.  Conclusions', '  Our data indicate, that the treatment of primary EGFR-TKI resistant cells (A549, Calu6 and H1993) with Erlotinib in combination with each Statin leads to growth arrest and apoptosis.']",
        "Doc_id":"ASCO_152731-156",
        "Doc_title":" Co-treatment of statins and erlotinib to induce growth arrest and apoptosis in primary TKI-resistant non-small cell lung cancer (NSCLC)-cell lines.",
        "_version_":1606189034592272384},
      {
        "Meeting_name":" Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    The role of anti-VEGF therapy in recurrent NSCLC is unclear. We are currently conducting a phase II trial evaluating cediranib, an oral inhibitor of VEGFR 1, 2 and 3, and pemetrexed in recurrent NSCLC pts who may or may not have previously received bevacizumab.  Methods', '    Pts with progressive NSCLC following 1 or 2 prior regimens and with any histologic sub-type were eligible.  Pts on anti-coagulants and with treated brain mets were allowed. Pts received cediranib 30mg daily. 1 week after starting cediranib, pts received pemetrexed 500 mg/m2 every 21 days. The study consists of two cohorts- A (no prior bevacizumab) and B (prior bevacizumab). Planned accrual is 37 pts each cohort. Accrual to cohort A is completed. Consenting pts underwent blood draw for circulating tumor cells (CTCs) and circulating endothelial cells (CECs) before therapy, 1 week after cediranib was commenced, and after 1 cycle of the combination.  Results', '    38 pts were enrolled in cohort A.  Median age- 62, males- 50%, ever smokers- 92%, squamous- 18% (7 patients), brain mets- 34%, 2 prior regimens- 42%. Median cycles- 4 (range', ' 0-26). Grade 3/4 toxicities- neutropenia- 14%, febrile neutropenia- 5%, fatigue-22%, diarrhea- 14%, infection- 8%. One patient each developed pulmonary hemorrhage, cardiac ischemia and cerebrovascular event. Three deaths were deemed related to drug related toxicities. Response rate is 29% (95% CI', ' 17%-45%) and disease control rate (response+stable disease) is 74% (58%-85%). Median PFS is 5.6 (4.4-6.8) months and median survival is 11 (5.8-16.6) months. Efficacy parameters for squamous versus non-squamous were- Response rate- 0% vs. 35%, PFS- 3.7 vs. 5.7 months, survival 5.2 vs. 11.5 months. Among 18 pts with available data, 60% had decrease in CTCs and 31% of the patients had declines in CECs. There was no significant association between declines in CTCs or CECs and PFS.     Conclusions', '    1.The combination of cediranib and pemetrexed is tolerable. 2. The response rate of 29% (35%-non-squamous) and the median PFS of 5.6 (5.7-non-squamous) months are very promising. 3. Though the numbers are small, this combination is ineffective in recurrent squamous cell patients. 4. Enrollment to cohort B is ongoing.']",
        "Doc_id":"ASCO_77915-102",
        "Doc_title":" Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).",
        "_version_":1606189036537380865},
      {
        "Meeting_name":" The combination of polo-like kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistance in vitro and in vivo in non-small cell lung cancer",
        "Background":"['Introduction', ' Activation of epidermal growth factor receptor (EGFR) leads to the development and progression of human epithelial cancers, including non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (EGFR-TKI) are effective therapy for NSCLC with activating EGFR mutations. However, acquired resistance to EGFR-TKIs is unavoidable and occurs through various molecular mechanisms including the development of T790M secondary EGFR mutations, MET amplification, epithelial-mesenchymal transition (EMT) and other mechanisms. One of potential strategy to overcome EGFR-TKIs is through inhibition of polo-like kinase 1 (PLK1). PLK1 is one of the key regulators of mitotic progression and a DNA damage recovery checkpoint. PLK1 inhibitors are at various stages of clinical development. Our previous studies showed that mesenchymal NSCLC cell lines are more sensitive to PLK1 inhibitor than epithelial ones. This study examines the efficacy of PLK1 inhibition in NSCLC cell lines with acquired resistance to the EGFR-TKI erlotinib.Methods', ' Erlotinib resistant cell lines were developed in EGFR mutant, erlotinib sensitive cell lines PC9, HCC4006 and HCC827 by chronic exposure to stepwise increased concentrations of erlotinib. The effects of the PLK1 inhibitor volasertib alone or combined with erlotinib on proliferation, apoptosis, cell cycle, EGFR-dependent signaling, DNA damage and DNA damage response signaling were evaluated using CellTiter-Glo assay, TUNEL assay, BrDU incorporation assay, comet assay, western blot and immunofluorescence. Sensitivity of volasertib alone or in combination with erlotinib was also detected in the human tumor xenograft model. The combination index (CI) was calculated by Calcusyn software.Results', ' Acquired erlotinib resistant NSCLC cell lines with endogenous EGFR mutations (PC9, HCC4006 and HCC827) showed diverse resistance mechanisms', ' T790M EGFR mutation, MET amplification and EMT. Four of the 6 ER clones that underwent EMT became more sensitive to volasertib. Volasertib and erlotinib demonstrated synergistic effects only in cells bearing T790M EGFR mutations where we observed more pronounced G2M arrest and increased apoptosis. Volasertib alone or in combination showed enhanced DNA damage, activation of CHK1/ATR and CHK2/ATM pathways and an increase in H2AX foci but only a modest effect on canonical signaling downstream of EGFR. The combination treatment exhibited a pronounced reduction in the size of tumor compared to single agent treatment in subcutaneous xenograft model generated with T790M mutant EGFR TKI-resistant PC9 cell line.Conclusions', ' These data demonstrate that PLK1 inhibition alone induces apoptosis and DNA damage in EGFR-TKI resistant cell lines with EMT. The combination of volasertib and erlotinib overcomes T790M-mediated drug resistance in vitro and in vivo.']",
        "Doc_id":"AACR_2016-4665",
        "Doc_title":" The combination of polo-like kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistance in vitro and in vivo in non-small cell lung cancer",
        "_version_":1606189022892261376},
      {
        "Meeting_name":" CPI-based Crizotinib systemic study on discovery of phenotypic off-target",
        "Background":"['Crizotinib, a first ever ALK/MET multi-targeted receptor tyrosine kinase inhibitor for the treatment of ALK-rearranged NSCLC patients. We hypothesize that crizotinib acts on other molecular targets in addition to tyrosine kinases ALK/MET and may play critical role given that there is a complex network of kinases that work together to regulate a number of important cellular processes and different disease signature. Approaching with a comprehensive docking method with our established chemical-protein interactome (CPI) and crizotinib, we have discovered 301 PDB-deposited proteins corresponding to 353 ligand binding pockets among a total of 1,780 PDB-deposited human protein entries. Systemic pharmacology approach also applied including validation the molecular target(s) of TKIs in vitro. Especially multiple human cellular models (including NSCLC and melanoma) and signaling study, luc-reporter, autophagy/apoptosis, proteomics study and NGS analysis applied. Interestingly, crizotinib besides had a high CPI binding score (ZZ_score) of -2.2778 against tyrosine kinase Lck, also had -1.4672, -1.1242, -0.7033 and -1.5384 against MAPK3, S6K, GSK-3 and HDAC 7A, respectively, which indicated crizotinib had potential broad range interaction with both TK and ser/thr kinases. Our data have showed that the crizotinib induced autophagy by activated LC3 in vitro and inhibited oncogenic Akt/mTOR signaling in human multiple melanoma cells resulting in G2/M cell cycle arrest. Furthermore, crizotinib increased p21Waf1/cip1 and Foxo3A expression and tumor suppressor miR-146a in human melanoma cells. Taken together, crizotinib induces miR-146a, autophagy and p21waf1/cip1 may potentially treat other type of human cancer by concurrently targeting tyrosine kinase, Akt/mTOR/Foxo axis and nuclear receptor, shedding a light for future both anti-cancer and anti-metabolic disorder drug discovery and development. This is the first CPI-based systemic study on leading discovery of crizotinib off-target phenotypic importance. These findings suggest that non-tyrosine kinase target of crizotinib may play critical role(s) for drug repositioning may represent a new and effective approach to expanding the application of existing drugs.']",
        "Doc_id":"AACR_2015-698",
        "Doc_title":" CPI-based Crizotinib systemic study on discovery of phenotypic off-target",
        "_version_":1606188985610141696},
      {
        "Meeting_name":" Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma.",
        "Background":"['Background', '  An estimated 70,000 diagnoses of brain metastases (BM) occur each year in the U.S., with an incidence of 5-7% in breast and melanoma and 20% in lung cancer.  Despite its prominence, the biology of BM remains poorly understood.  Several theories of BM development exist, including the linear progression model, which suggests that the metastatic capabilities of tumor cells develop at primary sites following the accumulation of alterations. The parallel progression model argues that tumor cells disseminate early and accumulate changes independently at the secondary site.  We compare the tumor profiles of BM from common cancers to understand the biology and to identify differential treatment strategies.  Methods', ' Tumor samples were profiled using a multiplatform service (Caris Life Sciences, Phoenix, AZ), including sequencing (Sanger, NGS), protein expression (IHC) and amplification (ISH).  Results', '  5,391 NSCLC (293 BM, 5,098 lung), 3,595 breast cancer (99 BM, 3496 breast) and 761 melanoma (101 BM, 660 skin) unpaired samples were included. No significant differences were found in 48 genes between BM and the primary tumor sites, with the exception of PIK3CA in breast cancer, which was mutated less in BM vs. the breast samples (10% vs. 26%, p=0.02). In contrast,  expression of TOP2A, TOPO1 and TS, and amplification of EGFR, were more prevalent in BM as compared to the primary sites (Table).  Conclusions', '  A similar genetic landscape with limited differences was seen in BM of NSCLC, melanoma and breast cancer compared to primary tumors.  The limited differences are more consistent with a linear progression model of cancer metastasis. Additionally ,this suggests that both primary tumor and BM would respond to similar chemotherapeutics with the consideration of effective blood-brain barrier-penetrant drugs. Small molecule inhibitors of EGFR could be considered due to increased EGFR amplification and the higher TOP2A, TOPO1 expression prompts consideration of topoisomerase inhibitors like etoposide or irinotecan.  Brain met %Primary met%PNSCLCTOPO2A7555<0.01TOPO164550.02TS3522<0.01EGFR FISH3628nsBreastTOPO2A7850<0.01TOPO17863<0.01TS39280.04EGFR FISH3114<0.01MelanomaTOPO2A7646<0.01TOPO16157nsTS5645nsEGFR FISH506<0.01']",
        "Doc_id":"ASCO_151096-156",
        "Doc_title":" Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma.",
        "_version_":1606188991768428545},
      {
        "Meeting_name":" Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI.",
        "Background":"['Background', ' EGFR mutant(EGFRm) NSCLC patients develop adquired resistance after 12 months on EGFR TKI. Acquired T790mutation(T790M) is the most common mechanism of resistance in around 60% of patients, followed by MET amplification in 20% of cases. Inclusion in a clinical trials at progression may have an impact in patients outcome. Methods', ' We retrospectively assessed the overall survival in EGFRm patients according to post-progression treatment on 1st/2nd generation EGFR TKI', ' standard vs. experimental (clinical trial). Also, we assessed the survival in the cohort of acquired T790M NSCLC patients(p). X2 test and long rank test P values are described. OS was defined since progression 1st/2nd generation EGFR TKI to death or last follow up Results', ' 42p EGFRm were enrolled. According to EGFRm subtype (24 p EGFR del19, 14p EGFR L858R, 1p EGFR exon18, 1 EGFR exon20,2p unknown). Median age was 58 (33-83) and 27 (64%) females. First-line EGFR TKI was 30% gefitinib / 58 % erlotinib /10 % afatinib/2% dacotinib At PD, in 51 biopsies (b) were performed,11p were biopsy twice.Tumor tissue for molecular determinations was available in in 86% of cases. Druggable molecular alterations were detected in 57% of cases', ' 20 acquired T790M and 4 MET amplification. According to these results all 24 p were enrolled in a clinical trial (NCT02108964,NCT01802632,NCT02147990,NCT02335944, NCT02151981), and 18p were screening failure; 8p (45%) of them due to abscense of adquired resistance mechanisms. 10 received platinum-based chemotherapy and 6 only received best supportive care. OS metastatic disease was 51 months for patients included in a clinical trial vs 22 months for those on standard treatment (p < 0.001; 95%CI', ' 14.4-47). OS was', ' 34 months vs 10 months for those included in a clinical trial vs standard, respectively (p < 0.001; 95%CI', ' 8.88-25). For T790M tumours, OS post-progression was 25 months Conclusions', ' Enrolling patients in clinical trials may allow personalised treatment according to mechanisms of resistance improving survival after 1st/2nd generation EGFR TK progression disease.']",
        "Doc_id":"ASCO_193021-199",
        "Doc_title":" Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI.",
        "_version_":1606189012407549952},
      {
        "Meeting_name":" A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR)",
        "Background":"['Background', '  Erlotinib and gefitinib have been shown to have similar activity for EGFR mutation-positive (EGFRm+) NSCLC. Since the steady-state plasma trough concentration of erlotinib is approximately 3.5 times higher than that of gefitinib when administered at the respective approved dose, treatment with low-dose erlotinib may be as effective as full-dose therapy, with less toxicity and cost. Methods', '  Eligible patients had advanced EGFRm+ NSCLC with 1 to 3 prior chemotherapy treatments. Erlotinib with the initial daily dosage of 50 mg was administered. Dose was escalated to 150 mg in case of not achieving CR or PR by RECIST criteria at the evaluation after the first 4 weeks of treatment. Erlotinib was continued until disease progression or unacceptable toxicities. The primary endpoint was independent committee-determined objective response rate (ORR) to the low-dose erlotinib, with target ORR of 70% and threshold of 50%. The sample size was calculated to be 40, and the primary endpoint was met if 26 or more patients responded. Results', '  Thirty-four patients were enrolled between Apr. 2010 and Nov. 2012. Males/females 20/14; median age 67 (range 38-81); PS 0/1 16/18; Ad/Sq 33/1. One patient was excluded from evaluation due to absence of active tumor. The study was closed early according to the protocol definition when 15 of 33 evaluable patients failed to achieve CR/PR, making it impossible to meet the primary endpoint. ORR was 54.5% (95% C.I.', ' 36.4% to 71.9%), with disease control rate of 84.8%. Median progression free survival and overall survival were 9.5 months and 28.5 months, respectively. Grade 3 toxicities were 2 cases with transient neutropenia, and 1 with reversible AST/ALT elevation. No grade 4 toxicity or treatment-related death was observed.   Conclusions', '  This trial is the first prospective study evaluating low-dose erlotinib. Although it appeared to have a certain efficacy, the primary endpoint was not met. Because of its low toxicity, it may be worth further evaluation in elderly and/or frail patients. Trial registry UMIN #000003313.']",
        "Doc_id":"ASCO_127064-144",
        "Doc_title":" A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR)",
        "_version_":1606189026611560448},
      {
        "Meeting_name":" Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M",
        "Background":"['Activating EGFR mutations in non-small lung cancer (NSCLC) confer sensitivity to reversible EGFR tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib. Despite promising initial response acquired resistance develops mediated by the emergence of the secondary T790M mutation or by focal amplification of MET. An epithelial-to-mesenchymal transition (EMT) is clinically linked to NSCLCs with acquired EGFR TKI resistance. The exact mechanisms of EGFR TKI resistance with EMT phenotype remain elusive; therefore, we attempted to develop a strategy to prevent the emergence of EGFR TKI resistance with EMT phenotype. In order to mimic the development of acquired EGFR TKI resistance in NSCLC patients, TKI-sensitive HCC4006 cells harboring mutated-EGFR were exposed to increasing concentrations of gefitinib to generate resistant cells with mesenchymal phenotype. After 6 months, the cells became resistant to gefitinib (HCC4006GeR) with no MET copy number increase and with no apparent gain of secondary T790M mutation. Subsequent genomics and proteomics analyses of HCC4006GeR confirmed enrichment of genes distinctive to mesenchymal cells. Multiplex Luminex growth factor assays identified increased secretion of TGF1 from HCC4006Ge-R cells. We discovered that the depletion of EGFR by shRNA or inactivation of mutated EGFR activity by EGFR TKI promoted TGF1 secretion and subsequent induction of EMT, which modulate signaling and apoptosis pathways contributing to the development of the resistance. Consequently, we hypothesized that concurrent inhibition of EGFR and TGF receptor in HCC4006 cells should prevent the emergence of gefitinib resistance with mesenchymal phenotype. After culturing HCC4006 cells in EGFR (gefitinib) and TGF receptor (SB431542) inhibitors, we successfully prevented EMT, although those cells were still resistant to gefitinib (HCC4006GeSB-R). Interestingly, the cells remain sensitive to irreversible EGFR TKI AZD9291 and CO-1686, suggesting the presence of T790M mutation. DNA sequencing of EGFR expressed in HCC4006GeSB-R detected secondary T790M mutation. Droplet digital PCR analysis detected that the frequencies of EGFR allele coding for T790M in HCC4006Ge-R and HCC4006GeSB-R cells are 1.2% and 18.3%, respectively, which were increased from 0.015% in HCC4006 cells harboring heterozygous Del L747-E749+A750P/T790M mutation. The frequency of T790M allele in HCC4006 was higher than the frequency in PC9 cells (0.001%) which reproducibly develop EGFR T790M as a mechanism of EGFR TKI resistance. Taken together, we discovered that suppression of gefitinib-induced EMT in EGFR mutant HCC4006 NSCLC cells preferentially selects for the previously unreported and rare subpopulation of HCC4006 harboring T790M. These results also underscore heterogeneity within HCC4006 cells that give rise to the divergent resistance mechanisms according to treatment.']",
        "Doc_id":"AACR_2015-766",
        "Doc_title":" Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M",
        "_version_":1606188973939490816},
      {
        "Meeting_name":" Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance",
        "Background":"['Background', '    Modulation of the MET and VEGFR signaling pathways are associated with resistance to EGFR TKI therapy in addition to acquired T790M mutation (mt).  Cabozantinib is a TKI that targets MET and VEGFR2, and RET, AXL, IT and TIE-2. Third generation EGFR inhibitors are effective in T790M mt-pos tumors, although treatment of T790M-neg disease remains an area of unmet need.  Cabozantinib and erlotinib in EGFRmt-positive NSCLC following PD on EGFR TKI showed benefit, and we evaluated potential mechanisms of resistance to therapy.      Methods', '  Pts with EGFR mt and PD on an EGFR TKI immediately prior to enrollment were eligible. Erlotinib 150 mg daily + cabozantinib 40 mg daily were given on a 28 day cycle and ORR was the primary objective.  Pts were required to have archival tissue available, and a subset had biopsy samples post-progression on EGFR TKI.  MET amplification was determined by FISH and EGFRmt, including T790M, was analyzed by next-generation sequencing.   Results', '    37 pts were enrolled and baseline EGFR mt was del19 in 68%, L858R in 30%, and 1 patient had an exon 18 mt.  57% received two or more prior therapies. Fifteen (41%) had post-EGFR TKI biopsies available, with 8 T790M-pos.  METgene amplification was not found in any of those with post-progression biopsies.  ORR was 12.5% in pts with T790M-pos tumors, but DCR and PFS was increased in pts with T790M-neg tumors (see Table). OS was longer in pts with T790M-pos mt, which may reflect post-study therapy or biologic differences.   Conclusions', '    Cabozantinib and erlotinib had clinical benefit in heavily treated patients with EGFR mt and EGFR TKI resistance.  Further investigation in pts with T790M-neg tumors is warranted, and remains an unmet need.  Additional biomarkers will be evaluated in plasma.  Supported by NCI N01CM2011-00038 and U01CA062505.  Clinical trial information', ' NCT01866410All (n = 37)T790M-neg (n = 7)T790M-pos (n = 8)T790M n/a (n = 22)ORR (%)8012.59.1DCR at 8 weeks (%)68865064PFS, mo (95% CI)3.7 (2.4, 5.6)3.6 (1.7, 5.8)2.7 (1.6, 9.9)3.8 (1.7, 7.2)OS, mo (95% CI)9.1 (6.0, NR)7.7 (2.4, 13.3)NR (2.8, NR)12.2 (5.6, NR)']",
        "Doc_id":"ASCO_147467-156",
        "Doc_title":" Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance",
        "_version_":1606188984392744961},
      {
        "Meeting_name":" Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors.",
        "Background":"['Background', ' MGCD265 is an ATP-competitive inhibitor of MET and Axl RTKs and has demonstrated anti-tumor activity in xenograft cancer models of MET or Axl dysregulation and in Phase 1 clinical trial pts selected for these alterations. Methods', ' Study objectives were to evaluate the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), safety, PK, PD, and clinical activity of MGCD265. Eligible pts received MGCD265 on Cycle 1 Day 1 and initiated continuous dosing on Cycle 1 Day 3 in 21-day cycles. PK/PD were evaluated after single and repeated dose administration. Results', ' 18 pts received MGCD265  12 in softgel capsules and 6 in SDD tablets. With softgel capsules the MTD was established at 1050 mg BID; treatment-related AEs ( > 20% all grades) included diarrhea, nausea, vomiting, fatigue, AST increase, ALT increase and lipase increase. With 500 mg SDD, exposures partially overlapped those observed with 1050 mg softgel capsules. 1 of 6 SDD pts experienced a dose-limiting toxicity (DLT) of Gr 3 transaminase increase without clinical symptoms. Treatment-related AEs reported in > 20% of pts included Gr 1-2 diarrhea and Gr 2 fatigue, with fewer patients treated for diarrhea. Dose escalation of SDD is ongoing at 1000 mg BID. The rates of absorption and elimination of the two formulations were comparable with a median tmax of 8 hrs and an average t1/2 of 40  17 hrs for SDD versus 35  12 hrs for softgel capsules. The extent of absorption was 1.8 times greater with SDD tablets. The observed Cave,ss and AUC0-12,ss were 480 ng/mL and 5757 ngh/mL with 500 mg BID of SDD tablets and 561 ng/mL and 6731 ngh/mL with 1050 mg BID of softgel capsules, respectively. Conclusions', ' The SDD tablet formulation of MGCD265 shows similar PK characteristics as the softgel capsule formulation but with greater bioavailability, thus reducing the pill burden, and a more favorable safety profile to date. Expansion cohorts of softgel capsules demonstrating antitumor activity in pts with NSCLC with genetic alterations for MET and AXL are ongoing and may include evaluation of the SDD formulation as emerging data confirm similar or greater exposure and a better safety profile. Clinical trial information', ' NCT00697632']",
        "Doc_id":"ASCO_171184-176",
        "Doc_title":" Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors.",
        "_version_":1606189007440445440},
      {
        "Meeting_name":" A static diagnostic biopsy in patients with mutated EGFR lung adenocarcinom to guide therapeutic decisions.",
        "Background":"['Background', ' Approximately 70% of the pts. whose lung cancers harbor EGFR mutations acquire drug resistence  after a response to EGFR tyrosine kinase inhibitors (TKIs) treatment; this acquired resistance is mainly due to a  secondary mutation in EGFR (T790 M) in about 50% of patients,  amplification of  MET in 15%, PIK3CA mutations in 5%, an unknown mechanism in almost 30%, and SCLC transformation in some patients. Furthermore, clinical experience revealed that cancers with acquired resistance can respond again to  TKIs, after a drug-free interval. To aid in identification and treatment  of these patients we examined a cohort of patients whose cancers were assessed with tumor biopsies at multiple times  before and after their treatment with TKIs. Methods', ' 21 lung adenocarcinomas pts. (10 male, 11 female, median age 53 years) with EGFR mutations at 19 or 21 exons received TKIs, as first line of treatment. All showed a clinical response and all relapsed ( mTTP 10 months). At the time of relapse a new biopsy was performed, histologic samples were reviewed to re-confirm the diagnosis, EGFR and MET amplification were identified by FISH, while EGFR mutations have been tested by DNA sequencing.   Results', ' At the time that drug resistence was acquired all pts. retained their original activating EGFR mutations, 9 pts. developed EGFR T790M resistance mutation with pronunced EGFR amplification in 3, 2 pts. developed MET amplification,  8  biopsies did not reveal any new mutations, two pts. were found to have a diagnosis of small cell lung cancer in their drug resistant tumor biopsies and responded well to conventional chemotherapy regimen.15 of 19 confirmed lung adenocarcinoma patient underwent to a cisplatin - pemetrexed  chemotherapy regimen and at the time of progression 10 of them accepted to undergo a new biopsy.  Three pts. ( after 4,  5 and 6 months break from treatment with TKIs ) lost T790M mutation and their disease responded to a second-line course of erlotinib.  Conclusions', ' In our cohort of pts. with acquired EGFR resistence some patients lost acquired T790M mutation and become sensitive to EGFR inhibitor, in addition, two pts. underwent the histologic transformation from NSCLC to SCLC at the time of TKI resistence.']",
        "Doc_id":"ASCO_96130-114",
        "Doc_title":" A static diagnostic biopsy in patients with mutated EGFR lung adenocarcinom to guide therapeutic decisions.",
        "_version_":1606189020718563328},
      {
        "Meeting_name":" A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).",
        "Background":"['Background', '  Patients with HER2+ breast cancer (BC) have a high incidence of brain metastases (mets). Tesevatinib (formerly KD019) is a TKI with potent activity against EGFR, HER2, and SRC. In contrast to all of the approved anti-HER2 agents in BC, tesevatinib crosses the intact BBB in mouse and rat models and achieves levels in the brain similar to plasma levels. Single-agent trials of tesevatinib in NSCLC defined the maximum tolerated dose as 300 mg daily due to QTc prolongation.   Methods', '  This study was designed tofind the Recommended Phase 2 Dose for tesevatinib given daily combined with trastuzumab 6 mg/kg IV every 3 weeks. Secondary endpoints include pharmacokinetic evaluation of the combination. Eligible patients have HER2+ MBC with disease progression with or without brain mets. Three cohorts (tesevatinib 150 mg, 250 mg, and 300 mg/day) were planned. A 3 + 3 design was utilized for evaluating safety during the 21 days of Cycle (C) 1 to determine dose escalation.  Results', '  7 patients were enrolled into 2 dosing cohorts (median age 47). In Cohort 1 (150 mg) there was 1 patient with Gr 3 asymptomatic increased amylase, which resolved to Gr 1; not a DLT by protocol. There was 1 occurrence each of the following Gr 2 adverse events (AEs), all of which resolved', '  Gr 2 mouth sensitivity, acneiform rash, nausea, & vomiting. One patient in Cohort 1 missed doses of tesevatinib for 7/21 days (not due to AEs), and thus was not evaluable for dose escalation (but all AEs for this patient are included). The only Grade 2 or higher AE during C1 in Cohort 2 (250 mg) was a Gr 2 diarrhea that resolved to Gr 1 after 2 days with anti-diarrheal medications. Enrollment in the final dose cohort (300 mg) is ongoing.   Conclusions', '  The combination of tesevatinib and trastuzumab appears to be well tolerated with no QTc prolongation so far and enrollment into the final dose cohort in Phase 1b is proceeding. Tesevatinib is a TKI with anti-HER2 activity that freely crosses the BBB and therefore has promise in the treatment of brain mets in patients with HER2+ MBC. Clinical trial information', ' NCT02154529']",
        "Doc_id":"ASCO_150396-156",
        "Doc_title":" A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).",
        "_version_":1606189035640848384},
      {
        "Meeting_name":" Retrospective evaluation, of the randomized Phase 3 MARQUEE trial of tivantinib (T) + erlotinib (E) versus placebo (P) + erlotinib (E) using VeriStrat in patients with previously treated nonsquamous NSCLC",
        "Background":"['Background', ' MET, the high-affinity receptor for hepatocyte growth factor, is frequently deregulated in human cancer and is thought to be involved in resistance to EGFR TKIs. Tivantinib is an orally administered MET inhibitor currently under development as a cancer therapy. The Phase 3 MARQUEE trial enrolled 1048 subjects with locally-advanced or metastatic non-squamous NSCLC who had received one or two lines of prior systemic therapy. Patients were randomized 1', '1 to T+E (N = 526) or P+E (N = 522) until disease progression. In the ITT population, addition of tivantinib to erlotinib significantly improved PFS and ORR but did not improve OS, the primary endpoint. VeriStrat (VS) is a multivariate serum protein test that utilizes MALDI-TOF mass spectrometry to assign a GOOD (VS-G) or POOR (VS-P) classification and has demonstrated broad prognostic and predictive utility for EGFR TKI treatment regimens.Methods', ' Pre-treatment serum samples from the MARQUEE study were blinded to clinical outcome and analyzed by VeriStrat. Clinical benefit of T+E vs. P+E was analyzed as a function of VS status, in the ITT population as well as in pre-defined subgroups.Results', ' A total of 996 subjects were classified', ' 718 as VS-G and 278 as VS-P. Subjects testing VS-G had superior outcomes to those testing VS-P in both the T+E arm (OS HR = 0.32, CI', ' 0.26-0.41, p<0.0001; PFS HR = 0.55, CI', ' 0.44-0.69, p<0.0001) and P+E arm (OS HR = 0.43, CI', ' 0.34-0.55, p<0.0001; PFS HR = 0.70, CI', ' 0.55-0.88, p<0.028). VeriStrat status was a significant, independent predictor of OS, in these erlotinib treated patients, after adjustment for EGFR mutation, KRAS mutation, or MET IHC status. However, VeriStrat did not predict OS or PFS benefit for T+E vs. P+E (treatment * VS interaction p-value for OS of p = 0.09 and PFS of p = 0.19). VS was neither predictive nor prognostic for tivantinib effect in any molecular subgroup.Conclusion', ' These data support the previously demonstrated ability of VS to be both prognostic and predictive for survival in erlotinib treated patients, but not for tivantinib treated patients.']",
        "Doc_id":"AACR_2015-560",
        "Doc_title":" Retrospective evaluation, of the randomized Phase 3 MARQUEE trial of tivantinib (T) + erlotinib (E) versus placebo (P) + erlotinib (E) using VeriStrat in patients with previously treated nonsquamous NSCLC",
        "_version_":1606189041178378240},
      {
        "Meeting_name":" Transcriptome and metabolome reprogramming in EGFR-mutant NSCLC early adaptive drug-escape against erlotinib",
        "Background":"['Background. Advanced NSCLC with sensitizing EGFR mutation is being treated with EGFR inhibitor first-line. Despite initial tumor response, targeted therapy invariably fails due to acquired resistance. Classical studies of acquired drug resistance focusing on late clinical events in rebiopsy studies have identified some resistance mechanisms including T790M-EGFR, MET amplification and AXL upregulation.Methods. HCC827 and PC-9 NSCLC cells (sensitizing EGFR exon 19-del) were used in vitro and in vivo drug-sensitive models. MTS viability assay, TLVM cell mobility assay, immunoblot and immunofluorescence and in vivo xenograft IHC analysis were performed. Transcriptome analysis of HCC827 cells under erlotinib inhibition time-course was performed using Affymetrix microarray gene expression profiling (Human GeneChip 1.0 ST arrays) in triplicate at 0 hr, 8 hr, 9 days of erlotinib-treatment, and 9 days pretreatment with erlotinib followed by 7 days drug-washout. Data analysis was performed using PCA, heatmap, BAMarray and PathwayStudio 6.0 analysis. We also performed mass-spectrometry-based global profiling analysis of cellular metabolome in 5 replicate.Results. We analyzed drug-sensitive HCC827 and PC-9 cells under erlotinib inhibition to characterize the adaptive response that engenders drug resistance. We identified an early adaptive drug-escape that emerged after 9 days of erlotinib, characterized with MET-independent mitochondrial BCL-2/BCL-xL prosurvival priming to result in 100-fold IC50 increase towards resistance. These cells displayed a quiescence state associated with retarded cell proliferation/cytoskeletal functions. Transcriptome profiling analysis of the early adaptive resistant HCC827 cells revealed a remarkable genome-wide adaptive reprogramming of gene expression signature, involving pathways of cell adhesion, cell cycle regulation, cell division/mitosis, glycolysis and gluconeogenesis, response to DNA damage stimulus, and DNA repair. Metabolomic profiling revealed a global adaptive metabolic reprogramming also, with resultant suppression of glucose and TCA cycle metabolism, and lipid bioenergetics. Our studies also identified autocrine TGF2 signaling pathway in mediating the early adaptive resistance in the mutated-EGFR lung cancer cells that escaped erlotinib inhibition through a combination of quiescence-state and EMT, cellular metabolic reprogramming and STAT3/BCL-2/BCL-xL mitochondrial prosurvival priming.Conclusion. Early adaptive drug-escape emerges within a subpopulation of EGFR-mutant NSCLC under erlotinib inhibition. This constitutes an early-stage minimal residual disease leading to eventual resistant tumor relapse. These early drug-escaping tumor cells undergo global cellular reprogramming with upregulated mitochondrial prosurvival priming, representing attractive therapeutic targets to eradicate drug resistance.']",
        "Doc_id":"AACR_2014-1835",
        "Doc_title":" Transcriptome and metabolome reprogramming in EGFR-mutant NSCLC early adaptive drug-escape against erlotinib",
        "_version_":1606188973751795712},
      {
        "Meeting_name":" Genomic profiling of non-small cell lung cancer in the community setting.",
        "Background":"['Background', ' Genotyping in patients (pts) with advanced NSCLC may identify mutations (mut) amenable to targeted therapy (TT). We identified in a 2010-2014 community series a 60% testing rate for EGFR/ALK among stage IV pts (Gutierrez ASCO 2015; e19113). 2014 guidelines added 5 additional targets for testing. Methods', ' Retrospective review advanced non-squamous NSCLC treated by 89 community oncologists (16 sites) throughout NJ and MD (Jan 2013  Dec 2015). Results', ' 634 pts with NSCLC (566 stage IV and 68 stage IIIB) in the COTA database (89% adenocarcinoma, 7% NOS, 3% large cell, 1% sarcomatoid); median age 68 yrs; 52% female. 477 pts (75%) underwent any genotyping. Testing rates for EGFR were 67% in 2013, 80% 2014 and 69% 2015 (similar pattern with other mut). In never/passive smokers EGFR testing rate was 84% (47% pos for mut); 70% former smokers tested (13% pos); current 64% tested (5% pos) (p < 0.001 testing by smoking). KRAS testing performed in 32% with 31% pos, but did not triage genotyping (97% KRAS pos pts were tested for EGFR). Comprehensive NGS testing was performed in 15%, with additional 18% undergoing limited genotyping beyond EGFR/ALK. Rates of comprehensive NGS increased (2013', ' 10%, 2015', ' 23%; p < 0.001). Similar rates of NGS testing were observed among oncologists caring for > 10 pts or < 10 pts (15% vs 16%). 31 pts (5%) underwent second biopsy to obtain tissue for genotyping. Insufficient tissue was cited by 8%, with other documentation for non-testing lacking. Actionable EGFR/ALK findings were identified in 107 pts (22% tested); 73% of these received TT; 6% started chemo prior to test results (median 26 days vs 22 days who received TT; p = 0.36); 10% no treatment (7% early deaths). Genotyping identified actionable mut in 17 pts (2.6% overall population); (9 MET Amp/ 88 tested, 2 BRAF/98 tested, 2 ERBB2/ 52 tested, 2 RET/ 82 tested, 1 ROS1/ 85 tested, 1 MET Exon 14/ 46 tested). Among these 17 pts only 1 received TT (herceptin). Conclusions', ' Genotyping for EGFR/ALK remain below guidelines; most patients are undergenotyped for all 7 treatable mut. NGS testing rates are slowly increasing, which may reduce insufficient tissue exclusions. We plan to explore whether non-invasive comprehensive genotyping with cell-free DNA NGS may increase utilization of TT.']",
        "Doc_id":"ASCO_168560-176",
        "Doc_title":" Genomic profiling of non-small cell lung cancer in the community setting.",
        "_version_":1606189023327420417},
      {
        "Meeting_name":" A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models",
        "Background":"['Background', ' Mutations in the EGFR kinase are common in NSCLC. Patients with first-line EGFR mutations (exon 19 deletions, L858R mutations, exon 20 variants, codon 719 variants) initially respond to the reversible EGFR inhibitors erlotinib and gefitinib, but then relapse as additional mutations emerge. EGFR T790M is the most common of these mutations and is found in > 50% of refractory tumors. We assessed the in vitro and in vivo activity of CPD 24, a newly developed, covalent, small-molecule inhibitor of both first-line and T790M mutant EGFR, but not WT EGFR. Inhibition of WT EGFR in normal tissues can be a source of dose-limiting toxicities.Methods', ' The effects of CPD 24 were evaluated on H1975 (EGFR T790M/L858R), HCC827 (EGFR exon 19 deletion), and A431 (WT) cell lines. Inhibition of EGFR phosphorylation was measured in serum-starved cells using an MSD assay. Viability was assessed by measuring ATP in cells using a CellTiter-Glo assay. Dose- and time-dependent pharmacodynamic effects were evaluated by treating mice bearing matrigel plugs containing H1975 cells. Drug levels were measured in plasma samples by LC-MS. CPD 24 was administered to athymic nude mice bearing H1975, HCC827, or A431 xenografts (3, 10, and 30 mg/kg, QD, PO) and tumor growth was measured twice per week with digital calipers. CPD 24 was also formulated in PLGA microspheres and administered subcutaneously (SC) as a sustained release formulation to mice bearing H1975 or A431 xenografts (30 and 100 mg/kg, Q3D, SC). Proliferation of H1975 and HCC827 cells in the presence of CPD 24, growth factors, and a MET inhibitor was measured with an IncuCyte live-cell imaging system.Results', ' The IC50 of CPD 24 for p-EGFR inhibition was 4 nM on L858R/T790M mutant EGFR (H1975 cells), 17 nM on the exon 19 deletion EGFR (HCC827 cells), and 510 nM on WT EGFR (A431 cells). CPD 24 inhibited the growth of tumor cells in vitro and led to both dose- and time-dependent p-EGFR inhibition in vivo. Phosphorylation of EGFR in H1975 cells growing in matrigel plugs was inhibited by > 75% for 12 hours by a single 30 mg/kg dose. Tumor growth inhibition (TGI) was observed in two EGFR mutant NSCLC xenograft models (H1975, 89% TGI; HCC827, 139% TGI) but not in a WT EGFR model (A431). CPD 24 formulated in PLGA microspheres achieved drug levels above the IC50 for 72 hours after a single SC dose. Tumor regression was observed with this formulation in H1975 xenografts but not in WT tumors. HGF was able to confer resistance to CPD 24 inhibition in both H1975 and HCC827 cells in vitro. This resistance was prevented by the addition of a selective MET inhibitor.Conclusion', ' CPD 24 is a covalent inhibitor of both first-line and T790M mutant EGFR while maintaining > 100-fold selectivity over WT EGFR. The antiproliferative effects of CPD 24 can be reversed by HGF, and this resistance can be prevented by treatment with a MET inhibitor.']",
        "Doc_id":"AACR_2015-2587",
        "Doc_title":" A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models",
        "_version_":1606189030476611584},
      {
        "Meeting_name":" Efficacy and safety results from AvaALL",
        "Background":"['Background', ' The role of treatment with Bev beyond PD is unclear in the multiline treatment strategy of advanced NSCLC.AvaALL(NCT01351415), a multinational, open-label, randomized phase III trial, assessed continuous Bev and SOC beyond first PD (PD1) in pts with NSCLC following first-line treatment with platinum-based chemo plus Bev. Here we present efficacy and safety data from AvaALL. Methods', ' Pts with NSCLC who received 46 cycles of chemo + Bev and 2 cycles of maintenance Bev were randomized after PD1 to second-line SOC therapy (docetaxel, pemetrexed or erlotinib)  Bev. After second PD (PD2) and third PD (PD3), pts received third-line or fourth-line SOC  Bev treatment, respectively. Primary endpoint was overall survival (OS). Secondary endpoints were OS rates (6, 12, and 18-months [mos]), progression-free survival (PFS) from PD1 to PD2/from PD2 to PD3, overall response rate (ORR), disease control rate (DCR), and safety. Data cut-off', ' 24 Jun 2016. Results', ' Overall, 485 pts were randomized (n = 475 treated). Pt characteristics were well balanced between the two arms. Bev plus chemo resulted in a median OS of 11.9 mos versus 10.2 mos for SOC alone (HR 0.84, 90% CI 0.711.00; p = 0.1016; 387 OS events). The primary endpoint was not met (416 OS events were required, at 10% two-sided significance level). OS rates were 10% higher in the Bev arm vs SOC alone at 6-, 12- and 18-mos. Median PFS2 was 4.9 mos with Bev vs 3.8 mos with SOC (HR 0.85, 90% CI 0.721.00; p = 0.0907). PFS3 was significantly improved (3.5 mos for Bev, 2.4 mos for SOC; HR 0.65, 90% CI 0.510.84; p = 0.0047). ORR and DCR were slightly higher in the Bev arm versus the SOC arm (ORR 9.7% vs 6.7%; DCR 86.2% vs 79.3%, respectively). No new safety signals were identified. Grade 3 adverse events were reported in 78.2% of Bev pts and 61.6% of SOC pts. Conclusions', ' Although the primary endpoint was not met, efficacy data suggest a positive trend for continued Bev plus SOC after PD1 compared with SOC alone. No cumulative safety signals were identified. Clinical trial information', ' NCT01351415']",
        "Doc_id":"ASCO_185847-199",
        "Doc_title":" Efficacy and safety results from AvaALL",
        "_version_":1606188985078513664},
      {
        "Meeting_name":" Crizotinib induces tumor suppressor miR-146a, autophagy and p21 waf1/cip1 by alternative targeting non-TK target Akt-mTOR-Foxo axis",
        "Background":"['Crizotinib, a first ever ALK /MET multi-targeted receptor tyrosine kinase inhibitor developed by Pfizer and fast approved by FDA in 2011 for the treatment of ALK-rearranged NSCLC patients. We hypothesize that crizotinib acts on other molecular targets in addition to tyrosine kinases ALK/MET and may play critical role given that there is a complex network of kinases that work together to regulate a number of important cellular processes and different disease signature. Approaching with a comprehensive docking method with our established chemical-protein interactome (CPI) and crizotinib, we have discovered 301 PDB-deposited proteins corresponding to 353 ligand binding pockets among a total of 1,780 PDB-deposited human protein entries. Systemic pharmacology approach also applied including validation the molecular target(s) of TKIs in vitro. Especially multiple human cellular models (including NSCLC and melanoma) and signaling study, luc-reporter, autophagy, apoptosis assay, FACS and NGS analysis applied. Interestingly, crizotinib besides had a high CPI binding score (ZZ_score) of -2.2778 against tyrosine kinase Lck, also had -1.4672, -1.1242, -0.7033 and -1.5384 against MAPK3, S6K, GSK-3 and HDAC 7A, respectively, which indicated crizotinib had potential broad range interaction with both TK and ser/thr kinases. In addition, those crizotinib achieved high ZZ scores against PPAR- (-1.6145) and VitD3R (0.9479), suggesting a high binding affinity of crizotinib with these nuclear proteins. Our preliminary studies have showed that the crizotinib induced autophagy by activated LC3 in vitro and inhibited oncogenic Akt/mTOR signaling in human multiple melanoma cells resulting in G2/M cell cycle arrest. Furthermore, crizotinib increased p21Waf1/cip1 and Foxo3A expression and tumor suppressor miR-146a in human melanoma cells. Taken together, crizotinib induces miR-146a, autophagy and p21 waf1/cip1 may potentially treat other type of human cancer by concurrently targeting tyrosine kinase, Akt/mTOR/Foxo axis and nuclear receptor, shedding a light for future both anti-cancer and anti-metabolic disorder drug discovery and development. This is the first CPI-based systemic study on leading discovery of crizotinib off-target phenotypic importance. These findings suggest that non-tyrosine kinase target of crizotinib may play critical role(s) for drug repositioning may represent a new and effective approach to expanding the application of existing drugs.']",
        "Doc_id":"AACR_2014-3738",
        "Doc_title":" Crizotinib induces tumor suppressor miR-146a, autophagy and p21 waf1/cip1 by alternative targeting non-TK target Akt-mTOR-Foxo axis",
        "_version_":1606189004299960320},
      {
        "Meeting_name":" Switching oncogene signaling in a highly selective ALK tyrosine kinase inhibitor CH5424802 resistant cells.",
        "Background":"['We experienced dramatic responses to crizotinib, a multitargeted tyrosine kinase inhibitor including anaplastic lymphoma kinase (ALK), MET, and ROS1 in patients with non-small cell lung cancer (NSCLC) harboring ALK fusion gene; however, majority of the patients relapsed until around 10 months. The emergence of resistance to crizotinib is reportedly conferred by genetic alterations, such as ALK kinase domain mutation, ALK copy number gain or activation of the bypass pathways. CH5424802 (Chugai Pharmaceutical Co., Ltd.) is a new, highly selective ALK tyrosine kinase inhibitor that partially overcome acquired resistance to crizotinib, thereby inhibiting crizotinib resistant mutations of ALK in a preclinical experiment (Cancer Cell 19, 2011', ' 679-90) A phase II study of CH5424802 demonstrated 93.5% response rate (JLCS 2012); however, we also encountered acquired resistance phenomenon.To elucidate the acquired resistant mechanisms, we established CH5424802-resistant H2228 cells harboring EML4-ALK fusion gene under the step-wise continuous exposures of CH5424802. Six sublines that could grow in the presence of 1 mol/L of CH5424802 (designated H2228CHR clones -1, -2, -3, -5, -6, and -9) were obtained. All sublines revealed more than 30-fold resistance to CH5424802 (50% inhibitory concentration [IC50]', ' 1.0-4.8 mol/L) compared with the parental H2228 cells (IC50', ' 0.03 mol/L). In addition, the sublines similarly indicated resistance to Crizotinib. H2228CHR clones showed the constitutive phosphorylation of Akt and Erk1/2 even in the presence of CH5424802, whereas phosphorylation of Akt and Erk1/2 was markedly decreased in the parental H2228 cells. Surprisingly, ALK fusion gene disappeared in all H2228 CHR clones, which were confirmed immunostaining, reverse transcription PCR, FISH and Western blotting. H2228 CHR clones -1 and -2 presented higher phosphorylated levels of epidermal growth factor receptor (EGFR) than the parental H2228 cells and showed sensitivity to EGFR tyrosine kinase inhibitors, gefitinib and erlotinib.Furthermore, we also established CH5424802-resistant ABC-11CHR cells derived from ABC-11 cells from pleural effusion of an ALK inhibitor nave patient. In ABC-11CHR cells, phosphorylated ALK was markedly decreased and phosphorylated MET was increased.In conclusion, signal switching from ALK to other tyrosine kinase receptors induced resistance to a highly selective ALK tyrosine kinase inhibitor CH5424802 in NSCLC cell lines harboring ALK fusion gene.']",
        "Doc_id":"AACR_2013-4444",
        "Doc_title":" Switching oncogene signaling in a highly selective ALK tyrosine kinase inhibitor CH5424802 resistant cells.",
        "_version_":1606189010718294017},
      {
        "Meeting_name":" Studies of early adaptive resistance in mutant-EGFR and EML4-ALK addicted non-small cell lung cancer in escape against small molecule inhibitors.",
        "Background":"['Lung cancer is the second most common malignancy in the United States with the highest cancer-mortality rate. Molecular targeted therapy in oncogene addicted non-small cell lung cancer (NSCLC) has gain landmark proof-of-principle success in clinical utility in recent years. Prime examples are EGFR targeted therapy against mutated EGFR tumors using tyrosine kinase inhibitors (TKIs) such as erlotinib/gefitinib, and also ALK targeted therapy against EML4-ALK tumors using ALK inhibitor crizotinib. Superior response rates and progression free survival outcomes were observed with the use of targeted therapeutics even in first line setting. Nonetheless, targeted therapeutics against mutant-EGFR and EML4-ALK tumors invariably develop an acquired tumor resistance to the TKIs. Mutational resistant mechanism has been well-established. Alternative signal pathway activation such as MET/HGF in both EGFR and ALK TKI resistance, or HER family signaling activation in EML4-ALK resistance have also been reported. We have recently begun studies focusing on the non-mutational mechanisms of tumor resistance under early time window of TKI treatment. Using HCC827 and PC9 cells as mutant EGFR addiction model, as well as H3122 and H2228 NSCLC cells as EML4-ALK addicted model, we have uncovered a novel early adaptive TKI resistance that can be evident as early as 7-14 days under initial TKI treatment. The early adaptive tumor cells displayed remarkable tumor resistance against the TKIs with 100-fold higher IC50. In mutant-EGFR against erlotinib, there was an upregulated mitochondrial antiapoptotic/prosurvival BCL-2/BCL-xL signaling dependence that is MET-independent. The early resistant cells were adaptive, highly reversible and adopted a quiescent state during TKI-induced resistance. On the other hand, our studies of early TKI resistance in EML4-ALK fusion cells revealed that while the adaptive resistance to TAE684 was also reversible, it appears to be not dependent on BCL-2/BCL-xL upregulation. We found that in both targeted TKI early resistance, the tumor survivor cells exhibited epithelial-mesenchymal transition (EMT) markers changes with decreased E-cadherin expression and increased vimentin expression. Our studies also provided in vitro and in vivo evidence that these early adaptive TKI resistant tumor cells can be targetable for prevention or eradication of tumor resistance emergence, such as utilizing BCL-2/BCL-xL pathway inhibitors, such as ABT-737, in combination with EGFR TKI in mutant-EGFR addicted NSCLC. Further preclinical model studies will focus on investigating the molecular and genomic changes and gene network regulation in the early adaptive resistant tumor cells, to enable a new paradigm of novel therapeutic targets discovery to overcome early tumor resistance emergence and improve long term outcome of targeted therapy in lung cancer.']",
        "Doc_id":"AACR_2013-4455",
        "Doc_title":" Studies of early adaptive resistance in mutant-EGFR and EML4-ALK addicted non-small cell lung cancer in escape against small molecule inhibitors.",
        "_version_":1606189004885065728},
      {
        "Meeting_name":" Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers",
        "Background":"['Introduction', ' Noninvasive genotyping using plasma cfDNA from cancer patients has the potential to obviate the need for some biopsies while also characterizing disease heterogeneity. This study was undertaken to develop an ultra-deep plasma NGS panel for patients with non-small cell lung cancers (NSCLC).Methods / Results', ' Plasma was prospectively collected from 51 patients with advanced, progressive NSCLC and a known oncogenic driver from prior tumor genotyping. We performed ultra-deep NGS on extracted cfDNA using a customized Illumina library preparation, hybrid capture panel covering 37 lung cancer related genes (complete exons and partial introns), and ultra-deep sequencing (HiSeq4000). Mean sequencing depth was 50,000X (150 million, 150bp reads per sample). After specialized consensus-based error correction for low allele frequency (AF) genomic alterations, the median unique DNA molecules per position were 3,500. The mean sequence error rate was reduced by 20-fold to 0.002%, enabling the confident call of a driver mutation as low as 0.03%. In a subset of cases, paired plasma droplet digital PCR (ddPCR) was performed for common EGFR and KRAS mutations using a validated assay.Blinded to tumor genotype, plasma NGS detected SNVs (EGFR, KRAS, BRAF), indels (EGFR, ERBB2), and fusions (ALK, ROS1) as well as significant copy number gains (CNG) (ERBB2, MET). Sensitivity of cfDNA for the detection of known oncogenic drivers was 88% (45/51). A single false positive driver mutation was identified in a case with a known EGFR mutation in tumor; plasma NGS found both EGFR exon 19 del (0.88% AF) and KRAS G12D (2.65% AF), and plasma ddPCR confirmed the presence of both mutations (2.2% and 2.0% AF). Evaluation for an occult second primary is ongoing. In 22 EGFR, ALK, or ROS1 cases with acquired resistance to targeted therapy, plasma genotyping detected a range of potential resistance mechanisms', ' EGFR T790M and C797S, ALK F1174C, ERBB2 CNG, MET CNG. In 16 cases with paired resistance biopsies, concordance for EGFR T790M status was 94% (15/16).18 cases with known EGFR or KRAS mutations underwent paired ddPCR. In 14 cases the driver mutation was detected using both assays with high concordance of the%AF (r = 0.91). The remaining 4 cases were negative with ddPCR but 3 were positive with NGS at low AF (0.04%, 0.08%, and 0.29%), and the specificity for each driver was 100%.Conclusions', ' Ultra-deep plasma NGS can detect a wide range of oncogenic drivers in NSCLC and may be more sensitive than established ddPCR assays. In the setting of acquired resistance to targeted therapy, plasma NGS reliably captured EGFR T790M and additional somatic alterations as potential resistance mechanisms.']",
        "Doc_id":"AACR_2016-4342",
        "Doc_title":" Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers",
        "_version_":1606189006484144128},
      {
        "Meeting_name":" Retrospective study comparing cisplatin to carboplatin-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.",
        "Background":"['Background', ' It remains controversial whether cisplatin has the superior efficacy compared to that of carboplatin for advanced non-small cell lung cancer (NSCLC). Retrospective analysis was conducted to compare cisplatin-based chemotherapy with carboplatin-based chemotherapy. Methods', ' In a retrospective trial we evaluated the clinical efficacy and toxicity profile of cisplatin- and carboplatin-based chemotherapy given to advanced NSCLC patients with Eastern Cooperative Oncology Group performance status score(PS) of 0-1, whose survival times were over 90 days. The primary end points were overall survival (OS) and safety. Potential predictive factors of efficacy were also analysed. Results', ' From January 2002 to December 2008, 1014 patients met the inclusion criteria and were evaluable. 788 patients received at least 2 cycles of cisplatin-based doublet regimen and 226 carboplatin. All clinical characters at baseline were well balanced. The cisplatin-based regimen yield significant better OS with a median survival time of 10 months compared to that of the carboplatin-based regimen at 8.9 months, attributable to the survival benefit of patients with stage III B, or age less than 70. No significant differences were observed when grade 3 or 4 adverse events were compared. Conclusions', ' We found that the cisplatin-based chemotherapy produced substantial survival advantage compared to the carboplatin-based chemotherapy in NSCLC patients with stage IIIB or age less than 70. Prospective randomized trials recruiting NSCLC patients to study subgroup characteristics that would most likely receive the optimal therapy from each double regimen are needed.']",
        "Doc_id":"ASCO_49618-74",
        "Doc_title":" Retrospective study comparing cisplatin to carboplatin-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.",
        "_version_":1606189013062909952},
      {
        "Meeting_name":" Circulating tumor DNA profiling to reveal heterogeneity of EGFR-TKI resistance mechanisms in lung adenocarcinoma patients.",
        "Background":"['Background', ' EGFR-TKI therapy has significantly improved prognosis of NSCLC patients with EGFR sensitive mutation. However, almost all patients ultimately develop PD while receiving TKI treatment. Circulating tumor DNA (ctDNA) is promising as a minimally-invasive liquid biopsy for comprehensive analysis of molecular abnormalities. Methods', ' A total of 254 advanced lung adenocarcinoma patients with signs of EGFR-TKI resistance were enrolled in the study. ctDNA was analyzed using next-generation sequencing based ER-Seq method, which enables simultaneously assess single-nucleotide variants, insertions/deletions, rearrangements, and somatic copy-number alterations across 59 genes. Results', ' ctDNA profiling was possible for all patients, 172 patients had  1 ctDNA alteration(s). Median number of plasma somatic mutations was 2, predominantly located in EGFR and TP53, with MET, ERBB2 and PIK3CA followed. Of that, 30.6% of mutations detected in ctDNA were at a frequency below 1%. In exploring the mechanisms of TKI-resistance, we found TKI-sensitizing mutations were not detected in plasma of 138 patients (54.3%). Known mechanisms such as EGFR T790M/C797S mutation, activating mutations of PI3K-AKT-mTOR signaling, amplification of MET, activating mutation / amplification of ERBB2, activating mutation of KRAS, BRAF or mutations in EGFR EX20 other than T790M/C797S were identified in 59, 16, 8, 7, 3, 2, and 2 patients respectively. T790M/C797S was detected in 50.8% of patients with plasma positive for TKI-sensitizing mutations. Of note, C797S was only detected in patients treated with AZD9291. EGFR amplification were identified in 15 patients, though whether it would result in TKI-resistance was still controversial. Co-occurrence of resistance mechanisms were observed in 22 patients including 13 patients without TKI-sensitizing mutations. Conclusions', ' There was a high frequency of inter and intra-patient heterogeneity of resistance mechanisms after EGFR TKI therapy. ctDNA can be used as a liquid biopsy to facilitate the broad exploration of potential resistance mechanisms.']",
        "Doc_id":"ASCO_192168-199",
        "Doc_title":" Circulating tumor DNA profiling to reveal heterogeneity of EGFR-TKI resistance mechanisms in lung adenocarcinoma patients.",
        "_version_":1606189025312374784},
      {
        "Meeting_name":" Tolerability and toxicity of adjuvant cisplatin and gemcitabine for non-small cell lung cancer.",
        "Background":"['Background', '  The combination of cisplatin and vinorelbine is the evidence supported regimen for adjuvant chemotherapy of non-small cell lung cancer (NSCLC). But this doublet has considerable toxicity and unfavorable tolerability, and resulted in poor compliance. Cisplatin and gemcitabine regimen is one of the most active and well tolerated regimens against advanced NSCLC, but its toxicity and tolerability have not been adequately evaluated in the adjuvant setting.  Methods', '  From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m2) and gemcitabine (1250 mg/m2) between January 2005 and December 2011. Postoperative demographics, compliance to adjuvant therapy and toxicity were retrieved from medical records.  Results', '  A total of 132 patients met the criteria and included in the study, 96 were males (72.7%)and 36 females (27.3%). Median age was 60.5 years (range, 29-75 years), and 41.7% patients were 65 years old. Overall, 68.2% received all four planned cycles, and cumulative dose delivered for gemcitabine was 8333 mg (83.3% planned) and cisplatin 248 mg (82.7% planned). There were no treatment-related deaths. Grade 3/4 neutropenia developed in 47 (35.6%) patients and was the predominant hematologic toxicity. Common grade 3/4 non-hematologic toxicities were nausea/vomiting (22.0%), infection (12.3%), and febrile neutropenia (11.4%).  Conclusions', '  Cisplatin and gemcitabine are feasible in the adjuvant setting with favorable toxicity profile and superior tolerability compared with published data of cisplatin and vinorelbine.']",
        "Doc_id":"ASCO_98502-114",
        "Doc_title":" Tolerability and toxicity of adjuvant cisplatin and gemcitabine for non-small cell lung cancer.",
        "_version_":1606189010605047808},
      {
        "Meeting_name":" Diagnostic yield of targeted next-generation sequencing for personalized cancer therapeutics.",
        "Background":"['We have implemented a clinical assay to perform next-generation sequencing (NGS) of twenty-five genes relevant to multiple cancer types. We report findings from 210 consecutive malignancies submitted to Genomics and Pathology Services at Washington University in St. Louis (GPS@WUSTL). DNA was extracted from formalin-fixed, paraffin-embedded tumor selected by histopathologic review. Up to 1 g of DNA (minimum, 0.2 g) was used for library preparation using liquid-phase cRNA capture probes targeting all exons of BRAF, CTNNB1, CHIC2, CSF1R, DNMT3A, EGFR, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MAPK1, MAP2K2, MET, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RET, RUNX1, TP53, and WT1 (302 kb). Libraries were sequenced by Illumina technology to obtain 101bp or 150bp paired-end reads. Mean coverage was 1596; 50x depth was achieved at >95% of positions. The analysis pipeline was validated for variant allele frequency >10%. Variants were called and interpreted using the Clinical Genomicist Workstation. A list of clinically actionable variants (hot spots) was curated by literature review. Of 210 cases, 94 (45%) were non-small cell lung cancer (NSCLC), 20 (9.5%) were pancreatic cancer (PCA), and 17 (8.1%) were colorectal cancer (CRC), the balance representing 38 diverse other malignancies. FFPE tissue cores yielded a median of 2.4 g DNA (interquartile range 1.0-4.9 g). Sequencing identified a mean of 5.4 non-synonymous coding and/or splice site variants per case (single-nucleotide variants and indels). Of these, a mean of 2.8/case were not known polymorphisms and likely represented somatic mutations. Somatic variants most commonly occurred in TP53 (233 variants in 107 cases), KRAS (52 variants in 51 cases), and EGFR (40 variants in 33 cases). Sequencing identified 74 clinically actionable (i.e., predictive or prognostic) mutations in 61/210 = 29% of cases. In NSCLC, actionable mutations were present in KRAS codon 12 (29/94 cases), EGFR exons 19 (5 cases), 20 (1 case) and 21 (5 cases), and the PIK3CA helical domain (4 cases). In PCA, there were no variants currently recognized as actionable, but one potentially targetable MET T1010I variant was found. In CRC, actionable mutations were present in KRAS codon 12 or 13 (6/17 cases), PIK3CA (3 cases) and KIT (1 case). Average turnaround time was 29 days. In conclusion, NGS-based diagnostics can provide clinically relevant information using readily available FFPE tissue. Actionable variants were identified in 29% of cases. The existence of targeted therapies suggests that such diagnostics have the potential to improve patient outcomes.']",
        "Doc_id":"AACR_2013-813",
        "Doc_title":" Diagnostic yield of targeted next-generation sequencing for personalized cancer therapeutics.",
        "_version_":1606188994830270464},
      {
        "Meeting_name":" Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI)",
        "Background":"['Background', ' Lorlatinib is a selective, potent, brain-penetrant, next generation ALK/ROS1 TKI active against most known resistance mutations. In Ph I of this Ph I/II study, lorlatinib showed robust clinical activity in ALK+ or ROS1+ advanced NSCLC pts, most of whom had CNS metastases (mets) and were heavily pre-treated. In Ph II of this study, efficacy was explored based on prior ALK TKI tx as well as safety across all patients treated at the recommended Ph II dose. Methods', ' In this ongoing Ph II study (NCT01970865), pts with ALK+ or ROS1+ NSCLC,  asymptomatic untreated or treated CNS mets, were enrolled into 6 expansion cohorts (EXP) based on prior tx (EXP 1-5, ALK+) and rearrangement status (EXP 6, ROS1+). Pts received lorlatinib 100mg QD. Primary objective was ORR and intracranial ORR (IC-ORR) by independent central review (ICR). Results', ' Efficacy (ALK+ pts with prior tx)', ' At data cut-off (15 Aug 2016), 82 ALK+ pts were enrolled in cohorts EXP 2-5, received C1 no later than 31 Mar 2016 and were evaluated for ORR (ITT population); 52 were evaluated for IC-ORR and 35 were evaluated for IC-ORR response based on target lesions only (5mm; no prior radiotherapy or progression post prior radiotherapy). Confirmed response rates by ICR are reported in the table below. Safety (all pts)', ' 116 ALK/ROS1+ pts were evaluated for safety at data cut-off. Most common tx-related AEs (TRAEs) and grade 3/4 TRAEs were hypercholesterolemia (90%, 17%) and hypertriglyceridemia (72%, 17%). Dose interruptions and reductions due to TRAEs were reported in 29% and 20% of pts, respectively. 14% of pts had tx-related SAEs. 5 pts (4%) discontinued tx due to TRAEs and there were no tx-related deaths. 74/116 pts (64%) remain on tx. Conclusions', ' Lorlatinib showed compelling clinical activity, with substantial IC activity, in ALK+ pts who received 1 prior ALK TKI, many of whom were heavily pre-treated. Clinical trial information', ' NCT01970865ALK+ cohortsORRn(%)IC ORRn(%)IC ORRn(%)Target lesions onlyNNNEXP2 (prior Crizotinib only)74(57)53(60)22(100)EXP3 (prior Crizotinib + CT or any 1 other ALK TKI  CT)188(44)95(56)96(67)EXP4 (2 prior ALK TKI  CT)4411(25)3013(43)17(7(41)EXP5 (3 prior ALK TKI  CT)134(31)304(50)74(57)CT, chemotherapy']",
        "Doc_id":"ASCO_191846-199",
        "Doc_title":" Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI)",
        "_version_":1606189041168941057},
      {
        "Meeting_name":" Targeting wildtype and L858R/T790M mutant EGFR by isoliquiritigenin induces apoptosis and Inhibits tumor growth of NSCLC",
        "Background":"[\"Genetic alteration of epidermal growth factor receptor (EGFR) is a high risk factor of non-small-cell lung cancer (NSCLC). Isoliquiritigenin (ILQ), a chalcone derivative, reported anti-cancer activities. In this study, we investigated the effects of ILQ on the growth of tyrosine kinase inhibitor -sensitive and -resistant NSCLC cells and elucidated its molecular mechanisms. Treatment with ILQ inhibited growth and induced apoptosis in both tyrosine kinase inhibitor-sensitive (HCC827, H1650; delE746-A750 EGFR) and -resistant (H1975; L858R/T790M EGFR) NSCLC cells. However, ILQ didn't showed the inhibitory effects of cell growth and induction of apoptosis in Met amplified-HCC827GR or K-ras mutated-A549 cells. ILQ induced apoptotic markers, the cleavage of caspase-3 and poly-(ADP ribose)-polymerase, increased expression of Bim and reduced expression of Bcl-2. ILQ inhibited the catalytic activity of both wildtype and double mutant (L858R/T790M) EGFR by kinase assay. Treatment with ILQ inhibited the anchorage-independent growth of NIH3T3 cells stably transfected with either wildtype or double-mutant EGFR with or without EGF stimulation. ILQ also reduced the phosphorylation of Akt and ERK1/2 in both TKI-sensitive and -resistant NSCLC cells in the western blotting analysis. ILQ directly bound both wildtype and double-mutant EGFR by ATP-competitive manner. Computational docking model expected that ILQ interacted with Glu762 and Met793 sites of wildtype EGFR and Lys745, Met793 and Asp855 of mutant EGFR. ILQ attenuated the tumor growth of H1975 cell xenografted athymic mice in vivo, which was caused by decreased expression of Ki-67 and diminished phosphorylation of Akt and ERK1/2. Taken together, ILQ suppresses NSCLC cell growth by directly targeting wildtype or mutant EGFR.\"]",
        "Doc_id":"AACR_2015-1917",
        "Doc_title":" Targeting wildtype and L858R/T790M mutant EGFR by isoliquiritigenin induces apoptosis and Inhibits tumor growth of NSCLC",
        "_version_":1606188977480531968},
      {
        "Meeting_name":" Concordance and disease type variables between adjuvant chemotherapy (AC) recommended and received as assessed by the Quality Oncology Practice Initiative (QOPI).",
        "Background":"['Background', '  AC is indicated following curative-intent surgery for common solid tumors to reduce the chances of recurrence. Limited data are available to assess discrepancies between potential eligibility for chemotherapy, treatment recommendation and actual administration. For patients with completely resected early stage breast (BC), colorectal (CRC), and nonsmall lung cancer (NSCLC), QOPI assesses patient eligibility for AC, measures the rates of chemotherapy recommendation and administration. This analysis seeks to assess concordance between these measures and to explain differences.  Methods', '  QOPI data are submitted by practices into a web-based system and stored as a relational database.  For all categorical variables, frequency, and percent are presented. Concordance is shown as a ratepercent of charts eligible divided by those that met criteria. 2tests were used to compare rates of recommended/received chemotherapy across cancer types.  Results', ' Data were merged for 30,126 patients from the Fall 2011 and Spring 2012 QOPI collection periods. The analysis was limited to BC, CRC, and NSCLC patients for whom AC was clinically indicated by disease type and stage (eligible patients).  Conclusions', ' Oncologists recommend AC with a high degree of predictability for eligible patients with BC and CRC, but at a lower rate for patients with NSCLC. Eligible NSCLC patients receive AC at a rate far lower than BC and CRC patients; these lower rates are due to patient refusal and medical contraindications. Patient factors such as consent and comorbidity must be considered in establishing quality measure benchmarks as they vary significantly among disease type.   Summary of chemotherapy recommended and received in eligible patients.']",
        "Doc_id":"ASCO_104514-126",
        "Doc_title":" Concordance and disease type variables between adjuvant chemotherapy (AC) recommended and received as assessed by the Quality Oncology Practice Initiative (QOPI).",
        "_version_":1606189000105656320},
      {
        "Meeting_name":" Genetic and molecular biomarker characterization of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors.",
        "Background":"['Background', '  Preclinical studies demonstrated Brahma related gene 1 (BRG1) mutations or loss of expression, and mutations of LKB1 may be associated with lack of sensitivity for MEK inhibitor trametinib in a subset of KRAS mutant NSCLC lines. This study aimed to evaluate the frequency of KRAS, LKB1 and BRG1 mutations in NSCLC tumors; and determine whether KRAS mutations in corresponding plasma samples could be detected by evaluating circulating cell-free DNA (cfDNA).  Methods', '  Human NSCLC FFPE tumor tissue and matched plasma samples were procured from Indivumed GmbH.  KRAS mutation status of 101 NSCLC tumors and matched plasma were determined by direct sequencing of genomic DNA (gDNA) from tissue and/or BEAMing on tissue gDNA or plasma cfDNA. Genetic mutations of LKB1 and BRG1 were determined by direct sequencing. Additional mutations were determined using the Ion Torrent AmpliSeq Cancer Panel. BRG1 protein expression was evaluated by IHC.  Results', '  By direct sequencing and BEAMing we found 27/101 (28.4%) NSCLC tissue and/or plasma samples harbored KRAS mutations', ' G12V (37.0%), G12C (29.6%), G12D (18.5%), G12S, G13C, G13D and Q61H (3.7% each). The KRAS mutation status concordance (mutant or wild-type) between tumor gDNA and plasma cfDNA was 79-81%. Among the KRAS mutant tumors, LKB1 and BRG1 mutations were detected in 10/26 (38%) and 1/26 (3.8%) tumors respectively by direct sequencing. By IHC, loss of BRG1 expression was detected in 1/21 KRAS mutant tumors. The mutation frequency and variants for KRAS and LKB1 in patient samples were comparable with KRAS mutant NSCLC cell lines and COSMIC database. However the frequency of BRG1 mutation and protein loss were much lower in patient tumors. In a subset of 15 KRAS mutant tumors, Ion Torrent confirmed KRAS and LKB1 mutations and provided additional mutations found in TP53, FGFR2, FGFR3, GNAS, KDR, KIT and MET.  Conclusions', '  This study demonstrates that KRAS mutant NSCLC tissues have high frequency of LKB1 mutations along with other mutations. It also supports the feasibility of detection of KRAS mutations in cfDNA from blood of NSCLC patients using BEAMing technology, providing an alternative to invasive biopsy.']",
        "Doc_id":"ASCO_114742-132",
        "Doc_title":" Genetic and molecular biomarker characterization of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors.",
        "_version_":1606189040287088640},
      {
        "Meeting_name":" A targeted intervention to improve awareness to molecular testing in NSCLC.",
        "Background":"['Background', '  Molecular testing is now standard of care to guide treatment selection in advanced NSCLC. Population-based implementation of testing remains a challenge in Ontariospublic healthcare system, with ~37% of eligible samples undergoing testing and~12% insufficient for testing. We developed an intervention to improve understanding among Ontario specialists of the importance of molecular testing and appropriate diagnostic sampling in NSCLC.  Methods', '  Based on IASLC guidelines for molecular testing in NSCLC, leaders in lung pathology, respirology, interventional radiology and thoracic surgery identified key messages for each specialty regarding molecular testing and diagnostic sampling in lung cancer. Specialty-specific educational programs (delivered by a multidisciplinary team) were developed and administered at provincial and national specialty meetings. Participants were assessed on their knowledge of targeted therapy, molecular testing and sample requirements  Results', '  Ten educational programs were administered across the country targeting pathologists, thoracic surgeons, respirologists, interventional radiologists, medical and radiation oncologists. 210 pre- and 188 post-intervention surveys were completed.Baseline results demonstrated significant uncertainty', ' 30% were unsure regarding tissue handling techniques to ensure successful molecular testing, 20% chose an incorrect technique. Half were unfamiliar with how to initiate EGFR and ALKtesting, and 17% were uncertain of whom to test. After the intervention, specialist knowledge increased regardingtissue handling techniques (OR=3.01, p<0.0001), appropriate fixation (OR=2.48,p<0.0001), and the level of uncertainty decreased from 30% to 3% (p<0.0001). Participants understood the importance of initiating testing as soon as possible rather than deferring to the medical oncologist (p<0.0001), and to send samples even if unsure they met technicalrequirements (OR=4.63,p<0.0001).  Conclusions', '  Significant knowledge gaps existabout molecular testing in NSCLC among specialists that diagnose the disease. Specialist education significantly improves knowledge and awareness about molecular testing and its importance in NSCLC.']",
        "Doc_id":"ASCO_132268-144",
        "Doc_title":" A targeted intervention to improve awareness to molecular testing in NSCLC.",
        "_version_":1606189018348781568},
      {
        "Meeting_name":" Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' The immune checkpoint receptor programmed death-1 (PD-1) negatively regulates T-cell activation. Nivolumab, a PD-1 receptor blocking antibody, was evaluated in a phase 1 study in pts with various tumors including NSCLC (Topalian et al, NEJM 2012;366', '2443).  Methods', '  Pts with 1 prior chemotherapy regimen received nivolumab (1-10 mg/kg IV Q2W) for 12 cycles (4 doses/8W cycle) or until discontinuation criteria were met.  We report initial overall survival (OS) and updated safety and response data for NSCLC pts.   Results', '  127 pts evaluable for safety received nivolumab at 1, 3, or 10 mg/kg as of July 2012. Common drug-related AEs were decreased appetite (9%), anemia (8%), diarrhea, nausea, and pruritus (7% each). The most common G3/4 AEs were fatigue, pneumonitis, and elevated AST (2% each). Two drug-related deaths from pneumonitis occurred early in the trial and led to increased monitoring  without further deaths from pneumonitis. Median OS (mOS) across all dose cohorts was 9.2 mo and 9.6 mo for squamous (sq) and non-sq NSCLC, respectively.  mOS was not reached at the 3 mg/kg dose (phase 3 dose) for either histology. Sustained OS was observed, with 44%/ 41% and 44%/ 17% of pts (sq/non-sq) alive at 1 and 2 years, respectively (Table).  Prolonged ORs occurred in both histologies (Table).  Conclusions', '  In this long-term follow-up of a phase I trial, nivolumab had an acceptable safety profile and showed an encouraging sustained OS benefit across histologies in previously treated advanced NSCLC.  Follow-up through a Feb 2013 data cut (1 yr follow-up for all pts) will be provided at presentation.   Clinical trial information', ' NCT00730639.']",
        "Doc_id":"ASCO_114003-132",
        "Doc_title":" Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606189003257675776},
      {
        "Meeting_name":" Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT)",
        "Background":"['Background', '  Erlotinib has demonstrated major activity in EGFR mutation positive NSCLC, but may also benefit those with wild-type tumours. We conducted a single-arm trial of pre-operative erlotinib in early stage NSCLC to assess radiologic and functional response as well as correlation with known and investigational biomarkers.  Methods', '  Patients with clinical stage IA-IIB NSCLC received erlotinib 150 mg daily for 4 weeks followed by surgical resection. Tumor response was assessed using pre- and post-treatment CT and PET imaging. Pharmacodynamic changes were assessed through comparison of pre- and post-treatment tumour samples (including Sequenom MassARRAY analysis) and measurement of circulating markers/ligands for EGFR activation (TGF-, amphiregulin, epiregulin, EGFR SNP, EGFR ECD). Secondary endpoints included pathological response, toxicity and progression-free survival.  Results', '  Twenty-five patients were enrolled; 22 received erlotinib treatment with a median follow up of 4.4 years (range 2.2 to 6.4 years). Histology was predominantly adenocarcinoma (14) with smaller numbers of squamous carcinoma (7) and large cell carcinoma (1). PET response (25% SUV reduction) was observed in 2 patients (9%), both with confirmed squamous carcinoma histology. All patients met criteria for stable disease by RECIST and several experienced minor radiographic regression with histologic findings of fibrosis/necrosis, including 2 with squamous histology. The presence of an EGFR exon 19 deletion was detected in one adenocarcinoma case; the patient experienced a minor radiographic response to treatment. Genotyping, functional protein assays and ligand analysis are ongoing.  Conclusions', '  Erlotinib appears to demonstrate some activity in patients with squamous histology. While EGFR mutations have been infrequently demonstrated in squamous NSCLC, the potential exists for other biomarkers predictive of benefit. Clinical trial information', ' NCT00462995.']",
        "Doc_id":"ASCO_113303-132",
        "Doc_title":" Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT)",
        "_version_":1606189010674253824},
      {
        "Meeting_name":" ROR1 sustains caveolae and RTK-mediated survival signaling as a scaffold of cavin-1 and CAV1 in lung cancer",
        "Background":"[\"TTF-1/NKX2-1, a homeobox-containing transcription factor indispensable for lung morphogenesis, was previously identified by four independent groups including us, as a lineage-survival oncogene involved in the pathogenesis of lung adenocarcinoma. We have further shown that TTF-1/NKX2-1 induces expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which in turn plays a sustainer role for EGFR-mediated signaling. Interestingly, ROR1 knockdown effectively overcame EGFR-TKI resistance-conferring, HGF-mediated bypass signaling through MET, suggesting that ROR1 sustains not only EGFR but also additional RTK signaling. However, the underlying mechanism remained rather elusive.We report here an unanticipated function of this receptor tyrosine kinase (RTK) as a scaffold of cavin-1 and caveolin-1 (CAV1), two essential structural components of caveolae. Caveolae are 50-100 nm invaginations of the plasma membrane that play various physiological roles, including function as a platform for insulin-induced signaling in adipose tissue. We found that ROR1 facilitates the interactions of cavin-1 and CAV1 at the plasma membrane in a kinase-independent manner, thereby preventing the lysosomal degradation of CAV1, as well as consequential caveolae formation. Caveolae structures and prosurvival signaling towards AKT through multiple RTKs such as MET and IGF-IR are consequently sustained. The present findings thus provide mechanistic insight into how ROR1 inhibition can overcome EGFR-TKI resistance due to bypass signaling via diverse RTKs, which is currently a major clinical obstacle.Inhibition of prosurvival signaling and proliferation of lung cancer cells could be recapitulated by knocking down cavin-1 or CAV1, but they are unlikely to be suitable molecular targets for NSCLC treatment due to their crucial physiological functions in various organs even at low expression levels. In this regard, it should be noted that ROR1 is considered to be an onco-embryonic antigen with tumor-specific expression in adults. Taken together, development of novel therapeutic means to inhibit the scaffold function of ROR1 and thereby attack the cancer's Achilles heel is thus anticipated to be an attractive approach for improved treatment of this devastating cancer.\"]",
        "Doc_id":"AACR_2016-4585",
        "Doc_title":" ROR1 sustains caveolae and RTK-mediated survival signaling as a scaffold of cavin-1 and CAV1 in lung cancer",
        "_version_":1606188976345972737},
      {
        "Meeting_name":" Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.",
        "Background":"['Background', ' To better understand genetic determinants of response to ceritinib, tumor biopsies from NSCLC pts treated with ceritinib in ASCEND-1 (NCT01283516) were analyzed by next-generation sequencing (NGS). Methods', ' Biopsies were assayed by NGS using a Foundation Medicine panel targeting 295 genes. Somatic alterations were correlated with clinical outcome (cut-off 14 Apr 2014). Results', ' NGS data were generated for 85 pts (ALK inhibitor [ALKi]-pretreated [n=54]; ALKi-nave [n=31]). Baseline (BL) biopsy collection times differed among pts. The most frequent ALK rearrangements detected were EML4-ALK variant 1 (26/85) and variant 3 (23/85); 6 pts did not carry an EML4-ALK fusion but had an ALK rearrangement with another gene (HIP1 [n=2]; CLTC, CRIM1, STRN and TFG [n=1 each]). Comprehensive analysis correlating genetic landscape with ceritinib efficacy will be presented, including for 2 pts with ceritinib BL and post-progression biopsies. Of 28 pts with biopsies collected during or after prior ALKi treatment (Tx), 10 harbored an ALK tyrosine kinase domain mutation. Among these 10 pts, 8 had BL biopsies collected after (or less than 7 days before) the last day of prior ALKi Tx. All but one of these 8 pts benefited from ceritinib Tx (Table 1). One pt ALKi-nave had a MET amplification in a ceritinib post-progression biopsy (among other somatic mutations) but not in BL biopsy. Conclusions', ' This analysis increases our knowledge of the mechanisms of resistance to ALK inhibition and their impact on ceritinib Tx, including the potential role of MET amplification. It also illustrates that ceritinib is active against almost all ALK resistance mutations found in ALKi-pretreated pts. Ceritinib efficacy in pts with ALK mutations in biopsies collected after (or close to) last day of prior ALKi Tx.PtALK mutation(s)BORPFS, days1E1129VPR3372L1196MPR2673I1171T, F1174VPR2504bC1156YSD246+5L1196MPR2136cC1156YPR1747L1196MPR1638G1202RUnknown26aEfficacy per blinded independent review committee. bBiopsy 5 days before end of crizotinib Tx; + pt ongoing without event cBiopsy on last day of crizotinib Tx. BOR, best overall response; PFS, progression-free survival; PR, partial response; SD, stable disease.']",
        "Doc_id":"ASCO_167368-176",
        "Doc_title":" Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.",
        "_version_":1606188980453244928},
      {
        "Meeting_name":" Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations",
        "Background":"['Background', '  EGFR-TKI (E) therapy yielded a better PFS than standard cytotoxic chemotherapy (C) therapy and a comparable OS in untreated pts with EGFR-mt tumors, suggesting each of the treatments is now crucial for such subpopulation. But, it has not been fully evaluated yet which of each should be initiated first, and to what degree both of two are actually administered in early line setting in the treatment course. We here investigated a potential difference in incidence and pattern of delivery of subsequent crossover therapy after failure to each of the treatments in pts with EGFR-mt tumors.  Methods', '  Consecutive 79 pts with advanced EGFR-mt NSCLC were retrospectively assessed who underwent E therapy (n = 39) or standard C therapy (n = 40) in the 1st-line setting between 2007 and 2011.  Results', '  In E group 16 (41%) of 39 pts were still on 1st-line E therapy. Nine (39%) of the remaining 23 could not receive standard C therapy after failure to E therapy due to symptomatic CNS metastasis(mets) in 6, skeletal events in 2, and patient refusal in 1, whilst in C group only one (3%) of 40 failed to receive subsequent E therapy because of relapse (carcinomatous lymphangitis) (2-test; p < .001). Also, at the time of relapse to the 1-st line therapy, PS deteriorated more frequently in E group (8/23 vs. 7/40; p = .042) and, relapse with symptomatic CNS mets seemed frequently observed in E group (6/23 vs. 4/40; p = .093). Multivariate analysis revealed type of regimens undergone in the 1st-line setting (E vs. C) correlated with failure of administration of subsequent crossover therapy (odd ratio', ' 3.224, 95%CI', ' .1.032  5,417, p = .004).  Conclusions', '  It seems that pts with EGFR-mt tumors who were treated with 1st-line C had better opportunity to receive post-progression E therapy than those treated with 1st-line E had chance to receive subsequent C therapy, possibly due to difference in PS deterioration rate and relapse pattern.']",
        "Doc_id":"ASCO_99944-114",
        "Doc_title":" Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations",
        "_version_":1606189007392210944},
      {
        "Meeting_name":" Characteristics of NSCLCs harboring NRAS mutations.",
        "Background":"['Background', '  We sought to determine the frequency and clinical characteristics of patients with non-small cell lung cancers (NSCLCs) harboring NRAS mutations.  We used preclinical models to identify targeted therapies likely to be of benefit against NRAS mutant lung cancer cells.  Methods', '  We reviewed data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and clinical history from patients with NSCLC whose tumors underwent systematic screening for driver mutations including NRAS.  Patient characteristics examined included age, gender, race, smoking history, disease stage, treatment history, and overall survival (OS).  6 NSCLC cell lines with NRAS mutations were screened for sensitivity against multiple targeted agents.  Gene expression was profiled using Affymetrix U133A arrays in 5 NRAS mutant NSCLC cell lines, 8 with EGFR mutations and 17 with KRAS mutations.  Results', '  Among 4524 patients with NSCLC tested, NRAS mutations were present in 29 (0.64%).  The types of substitutions found were Q61H/K/L/R and G12A/C/D/R/S, with NRAS Q61L the most common (n=14; 48%). One tumor had a concurrent KRAS mutation.  83% had adenocarcinoma histology, with no significant differences in gender. While 90% of patients were former or current smokers, smoking-related G', 'C>T', 'A transversions were significantly less frequent in NRAS than in KRAS-mutant NSCLC (KRAS', ' 66%, NRAS', ' 13%, p<0.05).  Systemic chemotherapy showed limited efficacy in 7 patients with metastatic disease (median OS 7 mos). 5 of 6 NRAS mutant lung cancer cell lines were sensitive to the MEK inhibitors, AZD6244 and GSK1120212, while other targeted agents (against EGFR, ALK, MET, IGF-1R, PIK3CA, BRAF) were minimally effective.  Gene expression profiles of NRAS mutant cell lines were distinct from those with KRAS or EGFR mutations.  Conclusions', '  NRAS mutations define a distinct subset of NSCLCs (~1%) with potential sensitivity to MEK inhibitors. While NRAS gene mutations are more common in current/former smokers, the types of mutations are not those classically associated with smoking.']",
        "Doc_id":"ASCO_93761-114",
        "Doc_title":" Characteristics of NSCLCs harboring NRAS mutations.",
        "_version_":1606189000883699712},
      {
        "Meeting_name":" Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations.",
        "Background":"['Background', ' MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive with known driver mutations. Activation of the MEK1-cascade might play a pivotal role in resistance to targeted inhibition of BRAF V600E, EML4-ALK and EGFR T790M. So far, however, only MAP2K1 K57N could be identified and linked functionally to resistance in preclinical models. Clinical trials combining specific inhibitors for predefined NSCLC subgroups with MEK inhibitors are ongoing. We sought to characterize frequency and type of MAP2K1-mutated NSCLC regarding curated targetable aberrations. Methods', ' Tumor tissue collected consecutively from 4590 NSCLC patients within the German Network Genomic Medicine (NGM) between 07/2014 and 07/2015 was analyzed for MAP2K1 mutations using next-generation sequencing (NGS) with a set of 102 amplicons in 14 genes. Clinical and molecular characteristics of these patients were determined and compared with an internal control group of NSCLC patients and an independent control group of The Cancer Genome Atlas (TCGA). Results', ' We identified 21 (0.5%) patients with MAP2K1 mutations. They were frequently found in adenocarcinomas (n = 20) and were significantly associated with smoking. The most common MAP2K1 mutation was K57N. Most of the patients (n = 16) had additional oncogenic driver aberrations, including mutations in ALK, EGFR orBRAF, ROS1 rearrangements and MET amplification. TP53 mutations were found in 11 patients. In only five patients (23.8%) MAP2K1 occurred exclusively. TCGA analysis revealed additional 10 patients with MAP2K1 mutations, whereof 9 had additional TP53 mutations and one had BRAF mutation. Whereof most patients in our cohort had stage IV NSCLC, all patients in TCGA were systemic treatment naive. Compared with local stages in TCGA, our findings strongly suggest that targetable co-occurring mutations might occur more frequently in advanced stage NSCLC patients. Conclusions', 'MAP2K1 mutations co-occur frequently with targetable aberrations in smoking stage IV patients. Combination of targeted therapy against known driver aberrations with MEK inhibitors might be a promising therapeutic approach for such patients.']",
        "Doc_id":"ASCO_189139-199",
        "Doc_title":" Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations.",
        "_version_":1606189039733440512},
      {
        "Meeting_name":" ROS1 rearrangement in non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '    Rearrangements of the ROS1 oncogene occur in about 1-2% of non-small cell lung cancer (NSCLC) patients. While data suggest that the EML4-ALK/MET/ROS1 inhibitor crizotinib is highly effective in these patients, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients.   Methods', '    1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients.   Results', ' ROS1 status was analyzed in 1035 (91.0%) patients, whereof 19 (1.8%) had ROS1-rearrangement. The median OS of the patients has not been reached yet. Stage IV patients with ROS1-rearrangement had the best OS of all analyzed subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response under chemotherapy. Pemetrexed-containing regimens showed higher response rates than paclitaxel-containing ones (80% vs 17%). Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years (median not reached). Ten patients with ROS1-rearrangement (52.6%) harbored additional genetic aberrations in BRAF, MET, EGFR, MAP2K1, and TP53.   Conclusions', ' ROS1-rearangement is not only a strong predictive marker for response to crizotinib, but also seems to be the best prognostic molecular marker in NSCLC reported so far. In stage IV ROS1-positive patients, response to chemotherapy was remarkable high and overall survival regardless of systemic therapy significantly better compared to other genetically defined subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.']",
        "Doc_id":"ASCO_151873-156",
        "Doc_title":" ROS1 rearrangement in non-small cell lung cancer (NSCLC)",
        "_version_":1606188994453831680},
      {
        "Meeting_name":" Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' cMET dysregulation occurs in 310% of NSCLC and is a negative prognostic factor. INC280 is a highly selective cMET inhibitor with preclinical and clinical antitumor activity. The dose-escalation part of this ongoing Ph I study (NCT01324479) included a cMET-dysregulated NSCLC expansion group. Preliminary efficacy was seen in NSCLC pts with high cMET expression, prompting the addition of a second expansion group of pts with EGFRwt, high cMET-expressing NSCLC. We report here on both NSCLC groups. Methods', ' The primary objective of this Ph I study was met; INC280 RP2D was established at 400 mg BID in a tablet formulation. Secondary objectives included exploring the antitumor activity of INC280 at the RP2D in the original and additional NSCLC groups. Eligible pts (aged  18 years; ECOG PS  2) in the original group had documented cMET+ (H-score  150 or cMET/centromere ratio  2.0 or gene copy number [GCN]  5 or IHC 2+ or 3+) NSCLC. In the additional NSCLC group, pts had documented EGFRwt and centrally assessed cMET IHC 3+. Results', ' As of Sep 28 2015, 43 pts were enrolled in the NSCLC expansion groups', ' 26 and 17 pts in the original and additional groups, respectively (median age 60 years; 74% Caucasian; 2 median prior therapies; 86% PS 0/1). 27/43 (63%) pts discontinued treatment, mainly due to disease progression (44%). The most common AEs (all grades, regardless of causality) were nausea (47%), vomiting (37%), peripheral edema (35%), decreased appetite (33%), and fatigue (33%). The most common Grade 3/4 AEs (regardless of causality) were anemia, hypokalemia, and pneumonia (all 7%). Response by expansion group and cMET status was assessed in evaluable pts. In the original group, 5/26 pts had partial responses (PR; ORR 19%); 2 pts in the original group also had cMET exon 14 mutations and both had PRs. In pts with cMET IHC 3+, 5/17 had PRs (2 unconfirmed/ongoing; ORR 29%). In pts with cMET GCN  5, 5/8 had PRs (2 unconfirmed/ongoing; ORR 63%). Conclusions', ' Oral INC280 at the RP2D was well-tolerated with a manageable safety profile. Strong preliminary activity was observed in pretreated pts with NSCLC and high cMET GCN or cMET overexpression. Clinical trial information', ' NCT01324479']",
        "Doc_id":"ASCO_165406-176",
        "Doc_title":" Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
        "_version_":1606189038281162752},
      {
        "Meeting_name":" Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '  While potentially targetable genomic alterations have been identified in squamous NSCLC, none have yet been translated into effective therapy. The NCI LungMAP study was designed to match patients (pts) with advanced squamous NSCLC to genotype selected treatment using targeted NGS. We studied a large cohort of consecutive pts with squamous NSCLC to gauge the feasibility of NGS for clinical trial arm allocation.  Methods', '  All patients presenting to the Dana-Farber Cancer Institute are offered targeted NGS of existing biopsy samples under an institutional protocol (#11-104). This internally developed NGS assay sequences over 300 genomic targets of interest with a mean overall target coverage of 200x. All squamous NSCLC pts seen at our institution during the study period were identified from an institutional database. The rate of test utilization, assay failure, and detected genomic alterations were studied.  Results', '  174 pts with squamous NSCLC presented to our institution from 7/1/2013-11/18/2014. Of these, 100 consented to targeted NGS. Median age was 65, 89% and 11% were heavy versus light/never smokers, 66% were stage IIIB/IV. The majority of patients underwent core biopsy (52 core, 30 resection, 14 FNA, 3 cytology) Targeted NGS was successful in 74 patients, pending in 12 patients and failed in 13 patients due to insufficient tissue (5 FNA/cytology, 8 core). The mutational rates for each target of the LungMAP study were as follows', ' PIK3CA mutation 12% (9), CCND1-2 amplification 16% (12), CDK4 amplification 3% (2), FGFR1-4 amplification 24% (18), FGFR1-4 mutation 7% (5) and MET amplification 3% (2). Of these, 12% (9) pts had multiple targets detected. 18% (6/33) of these amplification events were high level (ploidy estimate > 5 copies).  Conclusions', '  NGS in a real-world squamous NSCLC cohort is feasible and yields a high rate (51% pts) of potentially targetable genetic alterations. The majority of amplification events are low-level (2-5 copies) which may be challenging to therapeutically target. Our findings support the use of targeted NGS as a tool to facilitate trial enrollment in studies such as the NCI LungMap and Match studies.']",
        "Doc_id":"ASCO_150970-156",
        "Doc_title":" Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC)",
        "_version_":1606188981663301632},
      {
        "Meeting_name":" Clinical characteristics and molecular profile in patients with non-small cell lung cancer harboring CRKL amplification.",
        "Background":"['Background', '  It has been reported that CRKL amplification, associated with overexpression, has induced cell transformation as well as resistance to EGFR inhibitors. We analyzed CRKLamplification in archived genomic DNA samples from the Shizuoka Lung Cancer Mutation Study.  Methods', '  To identify CRKL amplification, we performed copy number analysis using the real-time PCR system. The standard curve was generated by PCR of serially diluted plasmid clones of CRKL and a reference gene. Triplicate reactions were performed using 2 ng of genomic DNA extracted from surgically resected tissues and tumor biopsies from non-small cell lung cancer (NSCLC) patients. Biopsy samples were obtained from NSCLC patients with EGFR mutations. In surgically resected tissues, TruSeq amplicon cancer panel was used for the detection of somatic mutations in 48 cancer related genes followed by ultra-deep sequencing (Illumina) at an average coverage of approximately 3,400x. ALK, ROS1 and RET translocations and EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications were also detected by multiplex RT-PCR and quantitative PCR, respectively.  Results', '  Between July 2011 and March 2013, 268 NSCLC patients treated with surgical resection, and 40 NSCLC patients with EGFR mutations, were enrolled in this study. Patient characteristics (treated with surgical resection) were as follows', ' median age (range) 69 (38-92) years; female 35%; never-smoker 27%; histology adenocarcinoma/squamous cell carcinoma/others 74/23/3 %; and differentiation well/moderate/poor 21/53/23 %. We detected CRKL amplification in 7.5% of 268 NSCLC patients treated with surgical resection. Frequencies of CRKL amplification in patients with gene alterations were as follows', ' 7.5 % of 93 EGFR; none of 38 KRAS, 8.7% of 23 PIK3CA; 8.8% of 91 TP53, none of 4 EML4-ALK, and 50% of 4 KIF5B-RET. 18% of 40 patients with EGFR mutations  showed CRKL amplification before EGFR-TKI treatment.  Conclusions', '  CRKL amplification was identified in 7.5% of NSCLC patients. These results suggest that CRKL amplification may be mutually exclusive with mutations in KRAS, and frequently observed in those with KIF5B-RET.']",
        "Doc_id":"ASCO_133258-144",
        "Doc_title":" Clinical characteristics and molecular profile in patients with non-small cell lung cancer harboring CRKL amplification.",
        "_version_":1606189018308935680},
      {
        "Meeting_name":" Multiplex testing of driver mutations in non-small cell lung cancer (NSCLCs) of African-American (AA) patients.",
        "Background":"['Background', '    Recently driver genetic alterations have been identified in NSCLC that can be targeted for therapeutic interventions. Previous reports have suggested that rates of certain mutations may vary according to ethnic background. We conducted multiplex testing of NSCLCs of AA and white patients to assess variability in the mutation rates by race.      Methods', '    We identified tumor tissues of 136 AA and 320 white NSCLC patients collected as part of three different institutional review board approved studies. Using the Sequenom MassArray system and a multiplexed panel, we analyzed tumor DNA for 214 oncogenic mutations in 26 genes previously identified in NSCLC.  Estimated risk (Odds Ratios (OR)) of any mutation and  specific gene mutations among AA patients compared to white patients were calculated after adjusting for age, sex, smoking status and histology (adenocarcinoma versus non-adenocarcinoma). Information on smoking status was unavailable on 46 patients and was not included in calculations of ORs for some genes (OR).  Results', '     The median age at diagnosis was 60 vs 66 years in AA vs white patients; 43% of AA patients and 66% of white patients were males; 69% of AA patients and 52% of white patients had adenocarcinoma; 66% of AA patients and 85% of white patients had stage I/II NSCLC and 10% of AA patients and 6% of white patients were never smokers. 43% of the AA patients and 47% of white patients had at least one mutation detected (OR = 0.78; 0.5-1.2). 19% of AA patients and 6% of white patients had more than 1 mutation detected (OR 2.3; 1.1-4.9). AA patients were more likely to harbor mutations in STK11 (LKB1) (OR=8.4; 3.2-21.8) and NOTCH1 (OR=8.1; 2.2-30.8), and they were less likely to have MET mutations (OR= 0.12; 0.02-0.9) then white patients.  While not statistically significant, AA had lower prevalence of Kras mutations (OR=0.64, 0.3-1.4) and p53 mutations (OR= 0.82; 0.4-1.6).  Conclusions', '    Our analysis of NSCLCs shows that AAs were more likely to have multiple genetic mutations than whites and the mutation profile differs by race.']",
        "Doc_id":"ASCO_115860-132",
        "Doc_title":" Multiplex testing of driver mutations in non-small cell lung cancer (NSCLCs) of African-American (AA) patients.",
        "_version_":1606189039561474048},
      {
        "Meeting_name":" Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC",
        "Background":"['Background', ' Small cell lung cancer (SCLC) is a highly lethal malignancy characterized by rapid growth, early metastasis and poor prognosis. SCLC shows distinct molecular and clinical features when compared to other lung cancer subtypes. Previous analyses by us and others have identified genomic and proteomic differences between SCLC and Non-Small Cell Lung Cancer (NSCLC). Epigenetic alterations are some of the earliest events that could also lead to oncogenic changes and thus play an essential role in tumor initiation and progression. However, epigenetic differences between SCLC and NSCLC contributing to the alterations in gene and protein expression patterns, distinct biological features and therapeutic response have not been well characterized. Here, we investigate the differences in the methylation patterns of SCLC and NSCLC to provide novel insights into epigenetic associated gene alterations to identify potential therapeutic targets in SCLC.Material and Methods', ' A genome-wide DNA methylation profiling of SCLC and NSCLC cell lines was used for this investigation. We correlated DNA methylation status with gene expression and protein expression levels in 31 SCLC and 73 NSCLC lines to identify the relationship of epigenetic with genomic and proteomic features distinguishing SCLC from NSCLC.Results', ' SCLC and NSCLC lines exhibited different methylation profiles and we identified 484 genes that had a significant inverse correlation between methylation status and mRNA expression levels (Rho  -0.5 and FDR = 0.01), (genes regulated by methylation, GRM) that distinguished SCLC from NSCLC. Ingenuity pathway analysis of the 484 genes identified significant associations with neuregulin signaling, immune trafficking, integrin signaling, glioma invasiveness canonical pathways. Proteomic profiling by Reverse Phase Protein Array (RPPA) validated the different expression of some of the 484 genes identifying nine that were hypermethylated and downregulated at protein levels in SCLC compared to NSCLC lines (PTEN, CyclinD1, Caveolin, Notch3, TAZ, HSP27, STAT6 and both total and phosphorylated levels of receptor tyrosine kinases such Her2 and, MET).Conclusions', ' Genome wide methylation, mRNA expression, and detailed proteomic analyses have identified specific epigenic differences between SCLC and NSCLC that impact on important signaling pathways including widespread loss of PTEN function and receptor tyrosine kinase (RTK) expression in SCLCs which need to be considered in developing new rationale therapies for SCLC.']",
        "Doc_id":"AACR_2015-2961",
        "Doc_title":" Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC",
        "_version_":1606188974895792128},
      {
        "Meeting_name":" Phase II trial of personalized chemotherapy in stage IV NSCLC",
        "Background":"['Background', ' Personalized chemotherapy is an important advance for NSCLC pts. While genomic platforms have identified prognostic and predictive factors e.g., ERCC1 and RRM1/2, proteomic platforms are now identifying novel phosphoprotein targets. To address the complexity and redundancy of cell-death pathways, we applied Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) (Nagourney, R. Curr Treat Opt Oncol. 2006) to select therapy for chemo-nave pts with stage IV NSCLC. Methods', ' Using morphologic and metabolic endpoints EVA/PCD gauges cellular response to drugs and signal transduction inhibitors in human tumor micro-spheroids isolated from surgical biopsies. Modified Z-scores and synergy analyses (median-effect) then select ex vivo best regimens (EVBR) from FDA-approved NSCLC drugs. Trial powered to improve ORR by 2-fold and median TTP by 50% (p=.05). All pts sign informed consent. Results', ' 26/32 (81%) pts are evaluable with CR = 3/26 (11.5%); PR = 15/26 (57.6%); SD = 6/26 (23%) and PD = 2/26 (7.6%) for an ORR = 18/26 (69%) and CBR = 24/26 (92.3%). Selected EVBR were CDDP/gemcitabine 12/26 (46%); CDDP/taxane 7/26 (27%); erlotinib 5/26 (19%); CDDP/vinorelbine 1/26 (4%); CDDP/pemetrexed1/25 (4%). Nine of 26 (36.6%) pts were converted to surgical/radiation candidates. All first-line erlotinib pts responded (100%). Conclusions', ' At ORR = 69%, the trial has met response criteria and with current TTP up to 46 months and OS up to 60 months, accrual will be completed to allow formal TTP and OS analyses. The EVA/PCD platform, by examining drug-induced events in native-state micro-spheroids, has shown the unique capacity to capture stromal, vascular and inflammatory cell interactions with tumor cells, known crucial for clinical response prediction. Results support applications of personalized NSCLC therapy and warrant further evaluation. Supported by Memorial Medical Center Foundation, Long Beach.']",
        "Doc_id":"ASCO_51611-74",
        "Doc_title":" Phase II trial of personalized chemotherapy in stage IV NSCLC",
        "_version_":1606188978885623808},
      {
        "Meeting_name":" Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' PF-02341066 (PF-1066) is a selective, ATP-competitive, small molecule, orally bioavailable inhibitor of the ALK and MET/HGF receptor tyrosine kinases. EML4-ALK fusion oncogenes have been reported in approximately 4% of NSCLC. Patients with NSCLC harboring an ALK fusion were recruited into an expanded cohort at the recommended phase II dose within the first-in-patient monotherapy trial of PF-1066. Methods', ' Patients with ALK fusions, as determined by FISH using a break-apart probe to ALK, were enrolled into the expanded cohort irrespective of prior therapy. Treated brain metastases were allowed. PF-1066 was given orally at a dose of 250 mg BID. Responses were determined using RECIST with radiographic studies repeated every 8 weeks. The disease control rate (DCR) was determined based on the frequency of patients with RECIST CR, PR and stable disease at 8 weeks. Results', ' To date, 76 ALK+ NSCLC patients have been treated. The median number of prior treatments was 3 (range, 0-7). Most patients had adenocarcinoma histology and were never or former smokers. Mean plasma Ctrough was 292 ng/mL, which was above the predicted efficacious concentration from preclinical models (120 ng/mL). The median t1/2 was ~53 hours. To date, 50 patients are evaluable for response; ORR is 64% and DCR 90%. The median progression-free survival is not yet mature. The median duration of treatment is 25.5+ weeks. Radiological responses typically were observed at the first or second restaging CT scan. Gastrointestinal toxicities, including nausea (55%) and vomiting (39%), were the most frequent adverse events. Conclusions', ' The oral ALK inhibitor, PF-1066, demonstrated a high response rate in patients selected for ALK fusions and was associated with a good safety profile. A phase III study has been initiated. This study supports the concept of molecular selection of NSCLC patients for appropriately designed treatment.']",
        "Doc_id":"ASCO_50854-74",
        "Doc_title":" Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).",
        "_version_":1606188995054665728},
      {
        "Meeting_name":" The long-term impact of surgical complications after resection of stage I non-small cell lung cancer",
        "Background":"['Background', ' Surgical morbidity may play an important role in long-term cancer survival. Because surgical resection of early stage non-small cell lung cancer (NSCLC) is primary therapy, we sought to determine the long-term impact of surgical complications for patients undergoing resection of stage I NSCLC. Methods', ' Using the Surveillance, Epidemiology, and End-Results-Medicare linked database (2000- 2005), we identified patients who underwent wedge resection, segmentectomy, or lobectomy for stage I NSCLC. We identified in-hospital, postoperative complications (pulmonary, cardiac, and systemic) from ICD-9 diagnosis codes. We constructed a logistic regression model to determine patient, tumor, and treatment characteristics associated with in-hospital postoperative complications. To assess the association between in-hospital complications and long-term cancer-specific survival (CSS) for those patients surviving the initial 30 days after surgical resection, we performed unadjusted survival analyses using the Kaplan Meier method ( = 0.05). Results', ' 5,856 patients met initial inclusion criteria. The overall in-hospital, postoperative complication rate exceeded 40%; arrhythmia was the most common complication, followed by respiratory failure. Complications were predicted by older age, gender, larger tumor size, and surgical procedure. Patients undergoing > 1 resection were significantly more likely to experience a complication. The 30-day mortality rate was 3.9% (n = 230). For the 5,626 remaining patients who survived their initial 30 days postoperatively, the 5-year CSS was significantly poorer for those who had an in-hospital, postoperative complication (82.2%) compared to those who did not (86.5%, p < 0.001). Overall survival was also significantly worse (p < 0.001). Conclusions', ' In-hospital, postoperative complications have a negative impact on 5-year CSS after surgical resection of stage I NSCLC. Importantly, our study suggests that surgical complications may impact survival well after the initial perioperative event. These findings may have important implications for best practice guidelines.']",
        "Doc_id":"ASCO_53808-74",
        "Doc_title":" The long-term impact of surgical complications after resection of stage I non-small cell lung cancer",
        "_version_":1606188999417790465},
      {
        "Meeting_name":" Third-line treatment",
        "Background":"['Background', ' Anlotinib hydrochloride, an oral TKI targeting VEGFR, FGFR, PDGFR and c-Kit, showed promising efficacy in Phasestudy. Here, we evaluated the efficacy and safety of anlotinib as third-line treatment for advanced NSCLC, a randomized, double-blind, placebo-controlled Phase trial (ALTER-0303). Methods', ' Eligible B/ NSCLC pts who progressed after at least 2 lines of prior therapies were randomized 2', '1 to receive anlotinib or placebo (12 mg QD from day 1 to 14 of a 21-day cycle) till progression or intolerable toxicity. Enrolled pts harboring EGFR or ALK mutations must had failed in previous match-targeted therapies. The primary endpoint is OS; secondary endpoint includes PFS, DCR and ORR. Results', ' As of Aug 2016, total of 437 pts from 31 sites were randomized. The baseline characteristics of Anlotinib arm (N=294) and placebo arm (N=143) were well balanced in the age, gender, ECOG PS and gene states. With 292 OS events (66.82%), significant superiorities in OS, PFS, DCR and ORR were observed in Anlotinib arm according to investigator-assessed results. Grade  3 treatment-related AEs were hypertension, dermal toxicity and hypertriglyceridemia. There was no treatmentrelated death in either arm. (Data presented in the Table.) Conclusions', ' ALTER-0303 trial met its primary endpoint. Anlotinib significantly improved OS and PFS in advanced NSCLC with a manageable safety profile. The results strongly suggest that anlotinib should be considered as a candidate for the third-line treatment or beyond in advanced NSCLC. Clinical trial information', ' NCT02388919Anlotinib arm N = 294Placebo arm N = 143p-valueEfficacyOS, median, months9.63 (95% CI', ' 8.17, 10.60)6.30 (95% CI', ' 5.00, 8.10)0.0018HR', ' 0.68 (95% CI', ' 0.54, 0.87)PFS, median, months5.37 (95% CI', ' 4.40, 5.63)1.40 (95% CI', ' 1.07, 1.50)<0.0001HR', ' 0.25 (95% CI', ' 0.19, 0.31)ORR (CR+PR), %9.180.7<0.0001DCR (CR+PR+SD), %80.9537.06<0.0001Treatment-related AEs (  3 grade), %Hypertension13.610.00<0.0001Dermal toxicity3.740.000.019Hypertriglyceridemia3.060.000.034']",
        "Doc_id":"ASCO_182187-199",
        "Doc_title":" Third-line treatment",
        "_version_":1606189007873507328},
      {
        "Meeting_name":" Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib",
        "Background":"['Background', '  Preclinical modeling in NSCLC cell lines shows that in some E-sensitive cells (whether epidermal growth factor receptor [EGFR] mutated or wild type), stimulation with HGF reverses the cytostatic and cytotoxic effects of E. Inhibitors of AKT signaling mitigated this HGF-mediated resistance, partially restoring E activity. We conducted a phase II trial of E plus MK2206, a highly selective inhibitor of AKT, in NSCLC pts previously benefiting from E.  Methods', '  Eligible pts must have had progression (PD) following prior benefit from E [response or stable disease > 12 weeks].  Treatment consisted of E 150 mg po QD + MK-2206 45 mg po QOD on a 28-day cycle. Pts were accrued into 2 strata', ' 1) presence of EGFR activating mutation; and 2) EGFR wild type. Primary endpoints', ' RECIST response rate (RR)  > 30% (stratum 1) and disease control rate (DCR) > 20% at 12 weeks (stratum 2). Up to 41 pts per stratum were planned in a two-stage design.  Results', '  Eighty pts were enrolled with median age 64 years (range 40-86); tumor EGFR status', ' mutant  46, wild type-34; females - 51 (64%); performance status 90-100% - 53 (66%); and median time from diagnosis  2.3 years (range 0.2-11.1). Most common attributable adverse events (all grade 3) were rash (12), diarrhea (11), fatigue (7), and mucositis (5). There was one treatment-related death (pneumonia). Efficacy results are shown in the Table. Conclusions', '  Combination MK2206 and E met its primary endpoint (DCR 47%) in E-pretreated pts with EGFR wild type NSCLC while its activity in EGFR mutants appears modest (RR 9%). Treatment was generally tolerable and toxicities manageable. AKT pathway inhibition merits further clinical evaluation in pts with E-refractory EGFR wild type NSCLC (N01-00038).  Clinical trial information', ' NCT01294306.']",
        "Doc_id":"ASCO_127481-144",
        "Doc_title":" Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib",
        "_version_":1606189021011116032},
      {
        "Meeting_name":" Combined EGFR and MEK inhibition prevents the emergence of drug resistance in EGFR mutant non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' EGFR inhibitors are effective clinical therapies for EGFR mutant NSCLC, but efficacy is limited by the development of acquired drug resistance. The mechanisms of resistance include secondary mutations in EGFR (T790M) and activation of compensatory signaling pathways (MET, IGFR and AXL). Mutant selective EGFR inhibitors (WZ4002, CO-1686 and AZD9291) are effective in preclinical and clinical models of EGFR T790M. Our lab has demonstrated that reactivation of ERK signaling is a mechanism of resistance to WZ4002 (WZ) which could be reversed or prevented by using a combination of WZ and MEK inhibitors. Given the broad array of possible EGFR inhibitor resistance mechanisms, we evaluated whether WZ combined with the MEK inhibitor trametinib (TRA) can prevent the emergence of resistance in vitro and in vivo.Methods and Results', ' We developed a plate based resistance assay in which 350 cells/well are plated in 96 well plates and treated weekly. This system allows for evaluation of drug efficacy over weeks of treatment and can be used to measure both time to development and frequency of drug resistance. Given that ERK reactivation can cause resistance to WZ, we evaluated WZ, TRA or the combination thereof (WZ/TRA) using PC9 cells. Single agents led to 100% resistance in 2-3 weeks, versus 5% with WZ/TRA in 24 weeks. We then tested WZ/TRA in 5 additional EGFR TKI sensitive cell lines, including several known to develop acquired resistance to gefitinib (HCC827, MET amplification; HCC4006, EMT or FGFR activation; HCC2279; FGFR activation; H3255, T790M; HCC2935). In all cases, WZ/TRA significantly reduced the emergence of drug resistant clones compared to each single agent. In models with established drug resistance mechanisms, WZ/TRA was effective in 3/3 models with T790M mutations, but not (0/5) in models with established non-T790M resistance mechanisms. In models where WZ/TRA was effective, the combination led to increased apoptosis compared to single agents and effective inhibition of ERK signaling. We also evaluated the effectiveness of the WZ/TRA combination in vivo using EGFR L858R/T790M genetically engineered mouse model and PC9GR4 (T790M+) xenografts. Combination WZ/TRA treatment prevented tumor outgrowth for 24 weeks in 5 EGFR L858R/T790M GEMM mice whereas individual treatments did not. Additionally, we found that WZ/TRA combination treatment, but not single agents, could cure 7/15 xenograft tumors as assessed by lack of tumor regrowth after treatment cessation.Conclusion', ' Our studies suggest that the combination of a mutant selective EGFR inhibitor and a MEK inhibitor can prevent the emergence of both T790M and non-T790M mediated drug resistance mechanisms. This strategy is more effective at preventing (6/6) than treating (3/8) cancers with established drug resistance mechanisms and should be evaluated in clinical trials in EGFR TKI nave EGFR mutant NSCLC patients.']",
        "Doc_id":"AACR_2014-1832",
        "Doc_title":" Combined EGFR and MEK inhibition prevents the emergence of drug resistance in EGFR mutant non-small cell lung cancer (NSCLC)",
        "_version_":1606188976418324481},
      {
        "Meeting_name":" eXalt3",
        "Background":"['Background', ' Ensartinib is a novel, potent anaplastic lymphoma kinase (ALK) small molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1 and SLK. Ensartinib has demonstrated activity in ALK treatment nave and previously treated patients and has a generally well tolerated safety profile. Methods', ' eXalt3 (NCT02767804) is a global, randomized, open-label phase III study comparing the efficacy and safety of ensartinib to crizotinib in ALK- positive TKI nave non-small cell lung cancer (NSCLC) patients. It is being conducted in > 100 sites in North America, South America, Europe, and the Asia/Pacific region. Enrollment began in 2016. The primary efficacy endpoint is progression free survival (PFS) assessed by independent radiology review. Secondary efficacy endpoints include overall survival, response rates (overall and central nervous system [CNS]), PFS by investigator assessment, time to response, duration of response, and time to CNS progression. Approximately 270 patients with ALK+ NSCLC who have received no prior ALK TKI and up to one prior chemotherapy regimen will be randomized 1', '1 to ensartinib 225 mg QD, or crizotinib 250 mg BID, with stratification based on prior chemotherapy, ECOG performance status (PS), CNS metastases and geographic region. Eligibility includes patients  18 years of age, stage IIIB or IV ALK+ NSCLC. Patients are required to have measurable disease per RECIST 1.1, adequate organ function, and an ECOG PS of 2. Adequate tumor tissue (archival or fresh biopsy) must be available for central testing. The study has > 80% power to detect a superior effect of ensartinib over crizotinib in PFS at a 2-sided alpha level of 0.05. Clinical trial information', ' NCT02767804']",
        "Doc_id":"ASCO_189311-199",
        "Doc_title":" eXalt3",
        "_version_":1606189032057864192},
      {
        "Meeting_name":" Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients",
        "Background":"['Background', ' There is a growing need for accurate molecular diagnostics for proper targeted therapeutics selection in NSCLC patients (pts). We assess whether next generation techniques increase the identification of alterations in a prospective cohort of NSCLC pts, and evaluate prognostic value of different molecular alterations. Methods', ' Next generation sequencing (Amplicon-seq, 60 genes) and NanoString Gene fusion (20 genes) testing were conducted in NSCLC pts treated in a single center from November 2014 to May 2016. Overall survival (OS) according to the molecular profile was analysed by Kaplan-Meier method and Cox models. Results', ' Molecular tests were performed in 73advanced NSCLC pts.Median age was 54 year, 50% were women. Histology', ' 73% adenocarcinoma; 7% squamous, 20% others (Neuroendocrine, NOS). Tests were performed in biopsies from metastatic sites in 55% of pts.These techniques identified molecular alterations in 89% of cases', ' TP53 mutation (mut) 37/73 (51%); KRASmut 21/73 (29%); EGFRmut 11/73 (15%); CDKN2mut 7/73 (9%); BRAFmut (pG469R), ERBB2mut and METexon14mut in (1/73) 1.3%, respectively; ALKfusion (fus) 2/73 (2.7%); ROS1fus 1/73 (1.3%), and RETfus 3/73 (4%). Concomitant mutations were identified in 32% of pts mainly with TP53 (TP53/EGFR', ' (5/11) 45% and TP53/KRAS', ' (7/21) 33%). Matched targeted treatment was offered in 17/73 (23%), mostly tyrosine kinase inhibitors (TKI); anti-EGFR in 11/17 (65%) and ALK/ROS TKI in 3/17 (17.5%). Three pts (17.5%) received anti-MET or anti-HER2 TKI. OS in this whole population treated with target therapies (n = 17) was 45.7 months (m) (CI95% 26.8-NA). The KRASmut group had median OS of 10 m (CI95% 7.5-NA), while the remaining population with wild type (WT) for all driver alterations had median OS of 23 m (CI95% 20-NA), (HR 1.71 for KRASmut vs WT pts, p = 0.18). The presence of coexisting TP53mut did not negatively impact on OS in the cohorts with EGFRmut and KRASmut (p > 0.1) in a multivariate model. Conclusions', ' Combined next generation techniques for molecular profile in NSCLC pts identifies molecular alterations that have clinically relevant impact in survival. Coexisting TP53mut alteration shows no detrimental effect in OS.']",
        "Doc_id":"ASCO_185875-199",
        "Doc_title":" Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients",
        "_version_":1606188983252942849},
      {
        "Meeting_name":" Uptake and disparities of neoadjuvant therapy for stage III non-small cell lung cancer.",
        "Background":"['Background', '  The optimal use and sequence of radiation therapy (RT), chemotherapy, and surgery for patients with stage III non-small cell lung cancer (NSCLC) is unknown. We conducted a cross-sectional study using the Surveillance Epidemiology and End Results (SEER) population-based cancer registry to examine the relationship between year of diagnosis and receipt of neoadjuvant RT for patients with stage III NSCLC diagnosed in the United States from 2000 to 2008, with additional focus on the role of race and treatment location.   Methods', '  Thirteen SEER registries were used for data analysis. Patients diagnosed with stage III NSCLC treated with both surgery and RT between the years 2000 and 2008 were included. We used multiple logistic regression to describe the relationship between type of therapy for lung cancer and year of diagnosis. Covariates identified for analysis included age, grade, sex, race, ethnicity, and SEER registry.   Results', '  The total sample size was 393,711 of which 5,949 patients met our inclusion criteria. The cohort had a mean age of 64, was predominantly white (85.8%) and had predominantly high grade tumors (50.9%).  Use of neoadjuvant RT for stage III NSCLC was lowest in 2000 and higher in every year from 2002 to 2008  (OR 1.325 in 2002, p= 0.035; 1.921 in 2007, p<0.0001). Substantial heterogeneity among registries existed, with more neoadjuvant RT use in Seattle and San Francisco-Oakland (OR 1.83, 1.698 p<0.0001 and 0.0002 respectively) and less use in Metropolitan Detroit, New Jersey and Louisiana (OR 0.754, 0.570, 0.493, p=0.25, <0.0001, and <0.0001 respectively).  Black race was significantly associated with lack of neoadjuvant therapy without controlling for registry, but the association weakened after controlling for registry (OR 0.81, p=0.072). Conclusions', '  The use of neoadjuvant RT for stage III NSCLC substantially increased from 2000 to 2008.  Location of treatment was strongly associated with receipt of neoadjuvant therapy and outweighed the association of race and therapy. The effort to equitably distribute care should focus additional study on the important role of regional and local medical culture in determination of medical care.']",
        "Doc_id":"ASCO_117821-132",
        "Doc_title":" Uptake and disparities of neoadjuvant therapy for stage III non-small cell lung cancer.",
        "_version_":1606188997958172672},
      {
        "Meeting_name":" Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.",
        "Background":"['Background', '  A high quality PD-L1 companion diagnostic may help predict which patients are more likely to respond to PD-1/PD-L1 antibody-based therapy. Here we describe a PD-L1 immunohistochemical (IHC) diagnostic test developed by Ventana Medical Systems for use with MEDI4736.  Methods', '  An anti-human PD-L1 rabbit monoclonal antibody (SP263) was optimized for use with Ventana OptiView DAB IHC Detection Kit on the automated BenchMark ULTRA platform. The PD-L1 IHC assay was validated for use in formalin-fixed, paraffin-embedded samples of NSCLC and SCCHN in a series of studies addressing sensitivity, specificity, robustness, and precision. MEDI4736 is a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity. A subset of clinical trial samples from a Phase 1/2 study of MEDI4736 (NCT01693562) was analyzed to determine optimal cut-off for enriching response to MEDI4736. Inter-reader precision was established by 3 pathologists who evaluated 81 NSCLC and 100 SCCHN samples across the range of expression levels. Results', '  The Ventana PD-L1 IHC (SP263) assay met all pre-defined acceptance criteria. The scoring algorithm was defined using statistical analysis of clinical response data and PD-L1 staining parameters observed in a set of NCT01693562 clinical trial samples. Samples of both cancer types are considered test positive when the membrane of   25% of tumor cells stain for PD-L1 at any intensity. Inter-reader precision in determining PD-L1 status resulted in an overall percentage agreement of 97% and 92% for NSCLC and SCCHN, respectively. For both NSCLC and SCCHN, PD-L1+ patients identified by the scoring algorithm had a higher response rate than PD-L1- patients. Conclusions', '  These results highlight the robustness and reproducibility of the PD-L1 IHC (SP263) assay in a clinical setting. In NSCLC and SCCHN patients treated with MEDI4736, PD-L1+ patients identified by the scoring algorithm had a higher response rate than PD-L1- patients. The clinical utility of the PD-L1 diagnostic assay will be further validated in a prospective manner using additional patients in this study and in other MEDI4736 studies. Clinical trial information', ' NCT01693562']",
        "Doc_id":"ASCO_146980-156",
        "Doc_title":" Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.",
        "_version_":1606189000330051585},
      {
        "Meeting_name":" Use of FDA-approved vs. lab-developed tests in advanced non-small cell lung cancer.",
        "Background":"['Background', ' Molecular testing is central to the management of many cancers. We measured the extent to which FDA-approved and lab-developed tests (LDTs) are used in stage IV adenocarcinoma non-small cell lung cancer (NSCLC) patients, with a focus on EGFR mutations and ALKrearrangements. Methods', ' A retrospective chart review of NSCLC patients was conducted between April and September of 2015. A representative sample of US oncologists was asked to complete an online form containing fields for anonymized patient information, including year of diagnosis, whether molecular testing was performed, and if so, which markers were tested, type of test used, and test location. 8,129 NSCLC-treating oncologists in the US were invited to participate in the study. Oncologists were eligible to participate if they personally managed at least 5 NSCLC patients per month, and diagnosed at least one NSCLC patients in the past 12 months Results', ' Information on 765 patient records was obtained from the 153 physicians who met eligibility criteria. Histological subtype split was as follows', ' 76% of patients had adenocarcinoma, 19% had squamous cell carcinoma and 5% had other types. Among the 579 patients with adenocarcinoma, 95% and 84% were tested for EGFR mutations and ALK-rearrangements, respectively. Sample was further reduced to only include patients for which the type of test was known, and whose diagnostic was performed after FDA approval of the relevant test (May 14, 2013 for EGFR and August 26, 2011 for ALK), resulting in 424 patients for EGFR, and 399 for ALK. 87% of adenocarcinoma patients were tested with non-FDA-approved tests for EGFR, and 49% for ALK. Conclusions', ' This study highlights the prevalence of non-FDA-approved testing in the treatment of lung cancer. Further evaluation of the comparability of approved and unapproved tests currently being used interchangeably is needed to mitigate uncharacterized variability between tests. Type of test performed.FDA-ApprovedLDTEGFR55 (13%)369 (87%)ALK204 (51%)195 (49%)']",
        "Doc_id":"ASCO_163709-176",
        "Doc_title":" Use of FDA-approved vs. lab-developed tests in advanced non-small cell lung cancer.",
        "_version_":1606189007717269504},
      {
        "Meeting_name":" The relationship of delay in time to deterioration of chest pain, cough and dyspnea with radiographic response with targeted therapies (TT) and chemotherapy (CT) in NSCLC.",
        "Background":"['Background', '  In non-small cell lung cancer (NSCLC), TT in molecularly defined patient populations have yielded high Objective Response Rates (ORR). Whether ORR is related to improvement or delay in NSCLC symptoms as reflected by patient reported outcomes (PRO) is unknown. Therefore, we conducted an exploratory responder analysis to evaluate the relationship of ORR and time to deterioration of patient-reported chest pain, dyspnea, and cough (TTD).  Methods', '  A retrospective analysis of crizotinib study 1007, a second-line, open-label, ALK positive NSCLC study, was conducted to evaluate the effect of ORR on TTD. Patients (n = 374) were randomly assigned to receive either chemotherapy (pemetrexed or docetaxel) or crizotinib and the primary endpoint of improved PFS was met. PRO measures were collected (QLQ-C30 and LC13) and exploratory analysis suggested improved TTD in the crizotinib arm, see Shaw et al. (NEJM 2013). We conducted a responder analysis (CR or PR versus SD or PD) to assess TTD by response (yes vs no), irrespective of treatment.  Results', '  In the exploratory analysis population, 313 were considered PRO-evaluable. The exploratory retrospective Kaplan-Meier analysis indicated improvement in TTD for responders. The HR was 0.56 (95%CI', ' 0.42,0.74) with a  median TTD of 5.6 months (95%CI', '2.9,11.0) versus 1.5 months (95%CI', '1.2,2.0) for responders vs. non-responders, respectively. Analysis of the three symptoms individually also demonstrated improvement for responders.  Conclusions', '  This exploratory retrospective responder analysis supports that radiographic response may be associated with a delayed TTD in three NSCLC-related symptoms, irrespective of whether a TT or CT is administered. Limitations of this analysis include an open-label design leading to potential bias and the need for further validation of a lung cancer symptom score and definition of symptom progression. Drugs with large magnitude of durable ORR may lead to delay in disease symptoms by decreasing and/or delaying tumor burden. Fit-for-purpose PRO instruments describing NSCLC symptoms should continue to be investigated.']",
        "Doc_id":"ASCO_152467-156",
        "Doc_title":" The relationship of delay in time to deterioration of chest pain, cough and dyspnea with radiographic response with targeted therapies (TT) and chemotherapy (CT) in NSCLC.",
        "_version_":1606189011112558592},
      {
        "Meeting_name":" Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling.",
        "Background":"['Background', '  NSCLC p with EGFR mutations respond initially to EGFR tyrosine kinase inhibitors (TKIs) but invariably develop acquired EGFR TKI resistance.  Prior studies identified the EGFR T790M mutation and activation of MET, PI3K, AXL, HER2 and the MAPK pathway as drivers of acquired EGFR TKI resistance. To date, comprehensive molecular profiling to identify actionable modifiers of EGFR TKI response has not been conducted in NSCLC p on therapy.    Methods', '  We performed next generation sequencing (NGS) using a 263-gene Nimblegen custom cancer panel on DNA isolated from primary patient lung adenocarcinoma FFPE specimens prior to initiating standard erlotinib treatment and upon the development of acquired erlotinib resistance after only 3 months of therapy.   Results', '  In the pretreatment sample, we confirmed the presence of the EGFRL858R mutation in 95% of the sequencing reads and discovered a concurrent BRAF V600E mutation with a frequency of ~ 6%. NGS performed on the acquired erlotinib resistance sample revealed acquisition of the EGFR T790M mutation with a frequency of ~ 14%. Notably, the frequency of the BRAF V600E mutation increased 10-fold upon acquired erlotinib resistance from ~ 6% in the pretreatment tumor to ~ 60% in the recurrent tumor.  We found that overexpression of BRAF V600E in H3255 human NSCLC, which harbor EGFR L858R (but not BRAF V600E) and are erlotinib sensitive, caused resistance to erlotinib treatment (10-fold increase in erlotinib IC50).  BRAF V600E-mediated erlotinib resistance was reversed by treatment with the BRAF inhibitor vemurafenib. Additional functional studies are ongoing and the complete dataset will be presented.  Conclusions', '  These results indicate that EGFR-mutant NSCLC can harbor additional oncogenic driver mutations in BRAF at low frequencies prior to therapy.  EGFR TKI treatment can lead to expansion of BRAF V600E expressing tumor cells, resulting in acquired EGFR TKI resistance that can be reversed by BRAF inhibitor treatment. The data demonstrate the utility of routine molecular profiling of NSCLC p on targeted therapy and offer unprecedented insight into the genetic basis of therapeutic resistance.']",
        "Doc_id":"ASCO_118069-132",
        "Doc_title":" Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling.",
        "_version_":1606189024149504000},
      {
        "Meeting_name":" Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.",
        "Background":"['Background', '  Ultimately, the majority of anaplastic lymphoma kinase (ALK) rearranged (+) non-small cell lung cancers (NSCLC) are either unresponsive to crizotinib or develop resistance mutations. Similarly, gene rearrangements in NTRK1 have been identified as a potentially actionable oncogenic aberration. TSR-011 inhibits ALK and tropomyosin-related kinase (TRK) A, B, and C receptor activity with IC50 values < 3 nM and exhibits inhibition of oncogenic echinoderm microtubule associated protein like 4 (EML4)-ALK and tropomyosin (TPM)-TRKA dependent tumor growth in mice.  Methods', '  A Ph 1-2a dose escalation and cohort expansion study is underway to evaluate safety, tolerability, PK, and preliminary efficacy of TSR-011.  Ph 1 is evaluating unselected patients with advanced solid tumors and lymphomas. The recommended Ph 2 dose will be evaluated in Ph 2a in patients with ALK+ or TRK ligand/receptor + tumors (defined by immunohistochemistry or fluorescent in-situ hybridization) including those with NSCLC progressing on, or nave to, ALK inhibitor therapy.  Results', '  Twenty-three patients with advanced cancer have been enrolled at oral total daily doses between 30 and 480 mg, including NSCLC (n=10, including 5 ALK+), pancreatic (3), ovarian (2), salivary gland (2) and 1 each with papillary thyroid, cholangiocarcinoma, bladder, carcinoid, colon & leiomyosarcoma. Bi-exponential PK was observed, with dose proportional Cmax and AUC and t1/2 of 12-24 h. Dose-limiting toxicities included dysaesthesia and QTc prolongation; MTD has been defined. PK modeling revealed that a fractionated dose of 60 mg daily (dose expansion cohort) minimizes peak exposure and achieves sustained trough concentrations well above the IC50 for ALK inhibition. Of 5 patients with ALK+ NSCLC, 3 (all crizotinib-resistant) achieved PR (1 met RECIST criteria and 2 had non-measurable disease, so not formally RECIST-classified) 1 is early (not imaged yet), and 1 discontinued for DLT.  Stable disease was observed in ALK- papillary thyroid, pancreatic and colorectal patients.  Conclusions', '  TSR-011 is a well-tolerated promising second-generation agent for ALK-dependent and crizotinib resistant NSCLC, and is being explored in ALK+ and TRK+ tumors. Clinical trial information', ' NCT02048488.']",
        "Doc_id":"ASCO_134653-144",
        "Doc_title":" Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.",
        "_version_":1606189028669915136},
      {
        "Meeting_name":" Trimodality therapy for locally advanced non-small cell lung cancer.",
        "Background":"['Background', ' Management of locally advanced non-small cell lung cancer (LA-NSCLC) lacks consensus. Trimodality therapy is promising, but concerns about its safety and deliverability persist. A retrospective analysis of patients treated with trimodality therapy for LA-NSCLC at our institution to determine outcomes was conducted. Methods', ' All patients with LA-NSCLC treated with neoadjuvant chemoradiation (2-3 cycles of a platinum-based doublet with 45 Gy concurrent thoracic radiation) followed by resection performed by one of two thoracic surgeons (RL, KT). Two cycles of the same chemotherapy regimen were planned post-resection. Age at diagnosis, gender, smoking history, disease stage, treatment received, surgical complications and overall survival were collected. Outcomes were compared using log- rank test. Results', ' This analysis includes 35 patients who met the inclusion criteria. Median age of the patients was 63 years (range', ' 39-84 years). Clinical stage at diagnosis was IB - 1; IIB - 1; IIIA - 23; IIIB - 9; IV - 1 (resected brain metastasis). Carboplatin/paclitaxel was administered to 27 patients. Of these 23 received standard doses (AUC 5 and 175 mg/m2 respectively), while 4 received low-dose weekly therapy. Other regimens were carboplatin/gemcitabine (n=1), cisplatin/vinblastine (n=1), cisplatin/etoposide (n=3), carboplatin/etoposide (n=1), cisplatin/VP16 (n=1). Data on 1 patient was unavailable. Resection included pneumonectomy (n=5), bilobectomy (n=3) and lobectomy (n=27). Post-operative complications were atrial fibrillation (11), pneumonia (4), ARDS (4), air leak and recurrent laryngeal nerve injury (3 each). Surgical mortality at 28 days was 8.6% (n=3). Survival ranged from 4-54.6 months (median', ' 15.6 months). Median survival of 27 patients (77%) receiving postoperative chemotherapy was 31.9 months. Survival at 1, 2 and 3 years was 60%, 29% and 17% respectively. Conclusions', ' Trimodality therapy is feasible in locally advanced NSCLC. Patients who received their entire planned treatment had a prolonged median survival. Studies evaluating proper patient selection for trimodality therapy for LA-NSCLC are needed.']",
        "Doc_id":"ASCO_54602-74",
        "Doc_title":" Trimodality therapy for locally advanced non-small cell lung cancer.",
        "_version_":1606189041359781888},
      {
        "Meeting_name":" Trends in use of PET imaging in surveillance of lung and colorectal cancer.",
        "Background":"['Background', \"  Surveillance PET imaging following curative intent treatment of non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) is not supported by available evidence. ASCO and ABIM's joint Choosing Wisely campaign recommends against surveillance PET, yet the frequency with which PET imaging is performed during surveillance care is unknown.  Methods\", '  65,748 patients age 66+, diagnosed with stage I-IIIA NSCLC or Stage I-III CRC in 2001-2009, who underwent surgical resection were identified in SEER-Medicare data. Eligibility for surveillance started 180 days post-operatively. Use of imaging was assessed during the first year of surveillance and classified as 1) Any PET', ' receipt of PET or PET/CT regardless of other imaging, or 2) PET-only', ' receipt of PET or integrated PET/CT only, in patients who did not undergo separate dedicated CT imaging. Unadjusted proportions of patients receiving each category of surveillance were calculated by cancer type, diagnosis year, and stage. Equality of proportions was assessed between diagnosis years with ANOVA tests.  Results', '  7,393 NSCLC patients and 35,050 CRC patients met inclusion criteria. PET use more than doubled over the study period in both cohorts. 11% of all NSCLC patients diagnosed in 2001 received any PET vs. 25% diagnosed in 2009 (P < 0.001). Similarly, 4% of all CRC patients diagnosed in 2001 received any PET vs. 12% diagnosed in 2009 (P < 0.001). PET utilization was more common in higher stage NSCLC and CRC patients, and increased significantly between 2001 and 2009. In Stage IIIA NSCLC patients diagnosed in 2001, 15% received any PET compared to 42% diagnosed in 2009 (P = 0.015). In this same group of patients, 1.5% diagnosed in 2001 received PET-only, compared to 15% diagnosed in 2009. Among Stage III CRC patients any PET use increased from 9% for those diagnosed in 2001 to 27% for those diagnosed in 2009 (P < 0.001), while use of PET-only increased from 1% to 8% over the same period (P < 0.001).   Conclusions', '  Although not indicated in surveillance, PET utilization has more than doubled among NSCLC and CRC survivors over the study period. While surveillance rates may be increasing generally, increased rates of PET-only imaging suggest PET is inappropriately replacing existing surveillance protocols.']",
        "Doc_id":"ASCO_144314-156",
        "Doc_title":" Trends in use of PET imaging in surveillance of lung and colorectal cancer.",
        "_version_":1606189035344101376},
      {
        "Meeting_name":" Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).",
        "Background":"['Background', '    To compare the efficacy of gefitinib versus pemetrexed as second-line therapy in never-smokers with advanced pulmonary adenocarcinoma previously treated with platinum-based chemotherapy.  Methods', '    Eligible patients had a performance status 0 to 2, previous treatment with one prior platinum-based regimen, pulmonary adenocarcinoma, and never-smoking state. Epidermal growth factor receptor (EGFR) mutation status was not considered for the enrollment. Randomized patients received either gefitinib 250 mg per oral every day or pemetrexed 500 mg/m2 iv day 1 with vitamin B12 and folic acid supplement every 21 days. The primary end point was progress-free survival (PFS).  Results', '    One hundred thirty-five patients were randomly assigned with being stratified with performance status (0-1 vs. 2) and gender. Overall response rates were 30.1% and 14.9% (P < 0.001) for gefitinib and pemetrexed, respectively. The primary endpoint of PFS was met with 9.4 months for gefitinib versus 2.9 months for pemetrexed, which was significantly different (P = 0.010). The median overall survival has not been reached yet in both groups. The 1-year survival rate for gefitinib and pemetrexed arm was 73.6% and 70.5% (P = 0.89), respectively. The further analyses of EGFR mutation status, post-study treatment and adverse events will be presented on the ground.  Conclusions', '    Gefitinib showed superior efficacy to pemetrexed as second-line therapy in clinically selected NSCLC patients in Korea. Considering sequence of salvage therapy, gefitinib would be preferable to pemetrexed in enriched NSCLC patients.']",
        "Doc_id":"ASCO_80152-102",
        "Doc_title":" Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).",
        "_version_":1606188978209292288},
      {
        "Meeting_name":" Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations.",
        "Background":"['Background', '  Although somatic mutations of CTNNB1 in lung cancer have been described, there is still lack of information about prevalence, genetic variability, occurrence of additional aberrations and influence on outcome. This study was performed to analyze CTNNB1mutations in NSCLC genetically and clinically.  Methods', '  Tumor tissue collected from 3885 patients within a regional screening network was analyzed for CTNNB1 mutations using next generation sequencing (NGS). Clinical, pathological and genetic characteristics of these patients are described and compared with a control group of patients without CTNNB1 mutation.  Results', '  We have identified 58 (1.5%) CTNNB1-mutated patients, whereof 51 have been analyzed so far. This cohort consisted of 32 female and 19 male patients. Adenocarcinoma histology was found in 42 patients (82.4%), but CTNNB1 mutations were also found in squamous cell and neuroendocrine carcinomas. 21 different CTNNB1 mutations were detected on exon 3, of which most are miss-sense mutations (49) besides 2 deletions. The most frequent mutations were S37F and S37C substitutions which each occurred in nine patients. Exclusive CTNNB1 mutations were only detected in five patients. In all remaining patients an additional driver mutation was found including mutations in KRAS, EGFR, BRAF, AKT, PIK3CA and ERBB2 as well as MET amplification, RET-KIF5b-Inversion, ROS1-fusion and mutations and polymorphisms of TP53.  Conclusions', ' CTNNB1 mutations occur alone or in combination with other known oncogenic aberrations in NSCLC. Results of the ongoing clinical characterization of the patients as well as the prognostic and predictive impact of CTNNB1 mutations will be presented.']",
        "Doc_id":"ASCO_149516-156",
        "Doc_title":" Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations.",
        "_version_":1606189007961587712},
      {
        "Meeting_name":" Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC)",
        "Background":"['Background', '    The incidence of LC in patients (pts) with LTx is higher than general population. Treatment (trmt) remains controversial given the immunosuppressive state and comorbidities. The goal of this study is to evaluate trmt outcome among LTx pts.  Methods', '    Pts with LC diagnosed at the time of or after LTx were identified using the CC database. LTx-, LC-, and oncologic trmt specifics were collected.  Results', '    Among 847 LTx pts between 2005-2013, 17 (2%) were diagnosed with LC and included in the study', ' median age at LTx was 61 (range 48-70). LC was found in explanted (ex-)(n=8), native (na-)(n=5), and transplanted (tx-) (n=3) lungs. 1 pt had LC as distant metastasis (mets) only. LC in the na- and tx- lung was detected at a median of 26.7 months (m) (7.9 m -5.4 years) after LTx. Majority were early stage (I/II, n=11), 1 had stage IIIA and 5 were stage IV. NSCLC histology (adeno, squamous, pleomorphic) was more common than SCLC (n=2).  Curative trmt was performed as lobectomy in na-LC (n=1) and radiation in tx-LC (n=2).  Chemotherapy (CT) was given in 10 pts, primarily carboplatin-based doublets (n=8), along with docetaxel, pemetrexed, or etoposide. Best response in pts who received CT for metastatic disease was progressive disease during trmt in all three (3/3).  Upfront adjuvant and palliative CT was given in stage I-II (n=5/11), and stage IV (n= 3/5). In general, pts who received CT had a median survival (MS) of 7.5m ( 95% C.I. 0.3-20.6m) from the start of CT. Anemia was the most common toxicity (30%), and sepsis was most severe (grade 5 in 20%). MS from diagnosis of LC was better in ex-LC than na-/tx- LC', ' 24m (C.I. 12.9-29m) vs 4.8m (C.I.1.3-13.3m), and more favorable in stage I-IIIA (23.2m) [C.I. 9.4-27.8m] compared to IV ( 2.5m ) [C.I. 1.3-9.7m].  Conclusions', '    LC detected at the time or after LTx carries various clinical courses. Pts with mets have poor survival and significant toxicities, but variability in outcome still remains. Early stage pts and those with LC in ex-lung should be considered for trmt with modified regimens to decrease the chance of severe adverse events.']",
        "Doc_id":"ASCO_134418-144",
        "Doc_title":" Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC)",
        "_version_":1606188994043838464},
      {
        "Meeting_name":" Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '    Mechanisms of resistance are responsible for the progression of the disease both in patients (pts) with lung cancer treated with cytotoxic drugs and in those receiving targeted therapies. Histological and genetic analyses on tissue samples performed after treatments could be relevant to define subsequent strategies. Methods', '    NSCLC pts with adequate archival tissue samples before and after at least one treatment have been evaluated from July 2006 to December 2013 in a single institution. All had ECOG Performance Status of 0 and IIA-IV stage at diagnosis, median age of 51 years. After histological examination, mutational analyses for EGFR, K-RAS, PIK3CA, B-RAF and HER2 genes were performed using pyrosequencing and Real time PCR was used to detect EGFR resistance mutation. ALK and MET genomic rearrangements were tested by FISH. Results', '   33 cases were analysed. Diagnoses were re-confirmed in all but one case (3%) in which morphological and immunophenotypical features of small cell lung cancer were detected. At the first biopsy, EGFR activating mutations were identified in 15/33 (45%) pts and 12/15 (80%) of them maintained activating mutations at the second biopsy with 5/12 (42%) having also a pT790M mutation (4/5 (80%) de novo and 1/5 (20%) already detected at baseline). ALK rearrangement was identified in 6/33 (18%) pts and it was mutually exclusive with EGFR mutations, both at the first and the second biopsy. MET amplification was evidenced at the first biopsy in 5/33 (15%) pts (3/5(60%) of these were also EGFR mutated) and in 11/33 (33%) pts at the second one. K-RAS mutations were found in 5/33 (15%) and in 6/33 pts (4 maintained and 2 de novo) at the first and second biopsy, respectively. PIK3CA mutations were present in 2/33 (6%) pts at the first and only one was maintained at the second biopsy. BRAF mutation was detected at the second biopsy in 2/33 (6%) pts. No HER2 mutations were found. Conclusions', '    This study confirms a relevant percentage of molecular profile changes (up to 61%) after therapy and underlines the value of repeated evaluations for molecular diagnostic purposes, in order to design appropriate tailored therapies, even after acquisition of various resistance mechanisms.']",
        "Doc_id":"ASCO_129646-144",
        "Doc_title":" Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC)",
        "_version_":1606188996485971968},
      {
        "Meeting_name":" A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.",
        "Background":"['Background', ' MGCD516 is an oral, potent small molecule inhibitor of a closely related spectrum of RTKs including RET, TRK family, DDR2, MET, AXL and split RTKs (VEGFR, PDGFR and KIT). MGCD516 has demonstrated antitumor activity in nonclinical cancer models harboring genetic alterations of MGCD516 targets including rearrangement of RET or NTRK or CHR4q12 amplification. Methods', ' Study objectives include evaluation for safety, pharmacokinetics (PK), pharmacodynamics (PD), the maximum tolerated dose (MTD) and clinical activity of MGCD516 in patients (pts) with advanced solid tumors. Eligible pts received a single dose for PK profiling followed by continuous daily dosing (QD) in 21 day cycles. Results', ' 32 unselected pts (14 men/18 women; median age 62 years; range 27-85) with advanced solid tumors were treated in escalating dose cohorts of 10, 20, 40, 80, 110, 150 or 200mg MGCD516. At 80mg, 1 of 6 evaluable pts experienced a DLT (Grade 3 palmar plantar erythrodysesthesia). At 200mg, 3 DLTs were observed among 3 evaluable pts (intolerable Grade 2 neuropathy, fatigue and stomatitis in 1 pt each), demonstrating 200mg exceeded the MTD. Treatment-related AEs ( > 15% of pts; Grade1-3) included hypertension, fatigue, diarrhea, nausea and decreased appetite. One treatment-related Grade 4 AE (febrile neutropenia) was reported. Prolonged stable disease (SD) has been observed in multiple pts including 3 pts with at least 17 weeks SD and 1 pt with 35 weeks SD. Preliminary PK data show that exposure increased dose proportionally with doses up to 200mg. At 150mg, the Cavg and AUC0-24 values at steady state (90.7 ng/mL and 2.18 gh/mL, resp.) exceed plasma exposure projections required for inhibition of key RTK targets and antitumor efficacy in nonclinical tumor models. Preliminary clinical PD data indicate dose dependent inhibition of the VEGF and MET pathways. Conclusions', ' The Phase 1b dose for MGCD516 was established at 150mg QD. MGCD516 shows favorable PK characteristics, on-target PD effects and is associated primarily with constitutional or GI-related AEs. Phase 1b enrollment began November 2015. Pts with NSCLC or other solid tumors with specific genetic alterations in MGCD516 target RTK genes are being enrolled. Clinical trial information', ' NCT02219711']",
        "Doc_id":"ASCO_165199-176",
        "Doc_title":" A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.",
        "_version_":1606189010275794945},
      {
        "Meeting_name":" Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.",
        "Background":"['Background', '  AR typically develops after 9-12 mos of EGFR TKI therapy among EGFR-mutant patients (pts). Here we report a unique series of 42 EGFR mutants who had >1 post-resistant biopsy (bx) that illustrates the heterogeneity of AR within individual pts.  Methods', '  We analyzed prospective data from 126 EGFR mutants with advanced NSCLC who had 1 bx after AR developed on EGFR TKI therapy.  All biopsies underwent multiplexed CLIA-certified SNaPshot genotyping. Some pts consented to provide tissue for patient-derived cell-line (PDCL) establishment. 42 pts had >1 post-AR bx.  We collected data on EGFR TKI therapy, mechanisms of AR observed over multiple biopsies, bx safety and correlations between clinical and PDCL data.  Results', '  Among 42 pts with multiple post-AR biopsies, median age= 57 (range 39-88), 73% were female, 62% had EGFR exon 19 deletion and 31% had L858R. The median number of post-AR biopsies was 2 (range 2-5). While the original EGFR mutation was uniformly maintained, we observed variation in AR mechanisms among 20/42 pts, with changes in T790M status over time in 10 pts. Notably, both gain and loss of T790M were observed on serial biopsies, without a clear correlation to the timing of EGFR TKI therapy or bx site. Changes in histology (8), development of EMT (1) and EGFR amp (1) were also seen.  22/42 pts had no variations in detected mechanisms of AR on serial biopsies, including T790M (n=11), MET amp (2), EGFR amp (1), both MET and EGFR amp (1), SCLC transformation (1), BRAF mutation (1), and no AR mechanism identified (5). Repeat biopsies were safe, with 2.4% bx-related complications and no serious complications.  Conclusions', '  We observed frequent and unexpected changes in the mechanism of AR, particularly T790M status, in pts undergoing serial biopsies, suggesting heterogeneity of resistant clones in these pts. Among pts with T790M, 48% gained or lost the mutation over time. Relationship of AR mechanisms to therapy at the time of bx, bx location and correlations with PDCL data to understand their biologic implications will be presented. Our data suggest serial biopsies in EGFR pts are informative and safe, and may become increasingly important as T790M-specific TKIs become available.']",
        "Doc_id":"ASCO_126123-144",
        "Doc_title":" Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.",
        "_version_":1606189025593393152},
      {
        "Meeting_name":" ALK oncogene regulates epithelial-mesenchymal transition (EMT) in ALK-rearranged non-small cell lung carcinoma through repression of the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2)",
        "Background":"['A subset of Non-Small Cell Lung Carcinoma (NSCLC) carries chromosomal rearrangements involving the Anaplastic Lymphoma Kinase (ALK) gene. More frequently ALK is juxtaposed to the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2 and generates a constitutively active EML4-ALK fusion protein that triggers downstream oncogenic signals leading to increased cell proliferation and survival. The majority of ALK-rearranged NSCLC presents a peculiar histology characterized by a solid signet-ring cell and a mucinous cribriform pattern that is frequently associated with a metastatic phenotype. As the signet ring phenotype and metastasis are associated with epithelial-mesenchymal transition (EMT), a cellular reprogramming often activated in cancer cells during invasion and metastasis, we investigated whether ALK induces EMT in NSCLC. We performed RNA sequencing analysis on human ALK-rearranged NSCLC cell lines treated with ALK inhibitors or where EML4-ALK was knocked-down by shRNA. We found that EML-ALK regulated several genes related to EMT. In particular, the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2), key regulators of a splicing switch during EMT, were repressed in ALK-rearranged NSCLC cells and their repression was dependent on ALK activity. In keeping with these observations, H2228 and DFCI032 cells displayed a mesenchymal phenotype with almost complete suppression of the epithelial marker, E-cadherin, and a strong expression of the mesenchymal markers, vimentin and N-cadherin. In H2228 and DFCI032 cells, both E-cadherin suppression and vimentin up-regulation were dependent upon EML-ALK kinase activity because treatment with ALK inhibitors (TAE684 and crizotinib) or ALK knock-down reverted the phenotype of H2228 and DFCI032 from mesenchymal to epithelial and decreased their invasive potential. We excluded the involvement in EMT of ALK-rearranged NSCLC of other RTKs, such as EGFR or MET, because their inhibition did not have any effect on E-cadherin and vimentin expression. In ALK-rearranged NSCLC, the regulation of E-cadherin suppression was mainly transcriptional whereas vimentin regulation was post-transcriptional for both cell lines. Overexpression of ESRP1 led to up-regulation of E-cadherin, whereas ESRP1 knock-down impaired the reversion to an epithelial phenotype associated to inhibition of ALK activity. In conclusion, we showed that oncogenic ALK regulates EMT in NSCLC through ESRP repression. These findings could have implications for the biology of ALK-rearranged NSCLC in terms of metastatic potential and resistance to therapy.']",
        "Doc_id":"AACR_2015-131",
        "Doc_title":" ALK oncogene regulates epithelial-mesenchymal transition (EMT) in ALK-rearranged non-small cell lung carcinoma through repression of the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2)",
        "_version_":1606188985944637440},
      {
        "Meeting_name":" Reconstructing targetable pathways in KRAS dependent lung cancer by integrating transcriptome, proteome and phosphoproteome.",
        "Background":"['Activating mutations in the Ras oncogenes characterize 20-40% of all non-small cell lung cancer (NSCLC), the leading cause of cancer mortality in the United States, which establishes Ras genes as the most commonly mutated oncogenes in this malignancy. Mutations in the KRAS oncogene characterize more than 20% of all NSCLC malignancies and recent studies suggest that those tumors can be divided into KRAS dependent (KRAS-Dep) and KRAS independent (KRAS-Ind), according to their dependency on KRAS mutant for cell survival and proliferation. Although, the KRAS signaling pathway has been considerably studied using high throughput transcriptomic or proteomic technologies in isolation, the specific network of effector genes and proteins that drives carcinogenesis in NSCLC is still far from being understood.Integrative profiling with different omics technologies harbors the potential for characterizing the specific network of effector proteins associated with specific oncogenes. We developed a bioinformatics approach to reconstruct active and targetable networks associated with KRAS dependency in non-small cell lung cancer (NSCLC). By integrating matched global transcriptomics, proteomics and phosphoproteomics datasets, we stratified NSCLCs into those dependent on, or independent of, KRAS signaling by defining the S score that combines transcript, protein and phosphoprotein abundance in order to identify differential expressed proteins. We demonstrate that the S score outperforms nave integration methods and improves the functional specificity of the proteins identified as differential expressed. Next, we reconstruct targetable network modules associated with KRAS dependency by employing the Prize Collecting Steiner Tree (PCST) algorithm to formulate the module reconstruction. This reconstruction identified three conspicuous modules centered on KRAS and MET, LCK and PAK1, and B-Catenin. We validated activation of those proteins in KRAS dependent cell lines and performed functional studies defining LCK as a critical gene to the cell proliferation in KRAS-dependent, but not KRAS-independent, NSCLCs. We further define a functional module of LCK signaling in NSCLC, in which LCK activates downstream proteins such as PAK1 in order to regulate cell death. Finally, we find evidence of LCK signaling in human NSCLCs tissues. These results are the first evidence that suggest LCK as potential targetable protein in the context of KRAS dependency. In summary, our integrative analysis establishes a novel mechanistic basis for KRAS dependency in NSCLC and nominates KRAS-LCK-PAK1 network module as a potentially druggable pathway in KRAS-dependent lung cancers.']",
        "Doc_id":"AACR_2013-5214",
        "Doc_title":" Reconstructing targetable pathways in KRAS dependent lung cancer by integrating transcriptome, proteome and phosphoproteome.",
        "_version_":1606188986080952320},
      {
        "Meeting_name":" Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Approximately 12% of NSCLCs harbor a rearrangement of the ROS1 gene, an oncogene for which screening is difficult due to its low incidence. Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and MET, showed marked antitumor activity in ROS1-positive advanced NSCLC (Shaw, N Engl J Med 2014). In the present study, we assessed the antitumor activity and safety of crizotinib in East Asian pts with ROS1-positive advanced NSCLC. Methods', ' In this ongoing open-label, single-arm phase II study (NCT01945021), pts with ROS1-positive, ALK-negative advanced NSCLC who had received  3 lines of prior systemic therapy were administered crizotinib at a starting dose of 250 mg BID. Treatment was continued until RECIST-defined progression (determined by independent radiology review [IRR]), unacceptable toxicity, or withdrawal of consent, or at the investigators discretion for ongoing clinical benefit. The primary endpoint was ORR by IRR. Results', ' Between September 2013 and January 2015, 129 pts were enrolled at 37 sites in China, Japan, Korea, and Taiwan, making this the largest study of ROS1-positive NSCLC to date. Crizotinib was administered to 127 pts (all were included in the antitumor and safety analyses), and 63% were ongoing at data cutoff (6 months after the last pt enrolled). ORR by IRR was 69% (95% CI', ' 6177) and was similar (6380%) irrespective of the number of prior lines of therapy. For most pts, responses were observed within the first 2 months. Disease control rates were 84% at week 8 and 76% at week 16. At data cutoff, responses were durable (median duration of response', ' not reached [NR]; 95% CI', ' 8.5 months  NR). The median duration of crizotinib treatment was 7.8 months. The most frequently reported all-causality AEs (any grade) were elevated transaminases (58%), vision disorder (47%), diarrhea (46%), and nausea (44%). Of 18 deaths on study (15 due to PD, 2 to pneumonia, and 1 to respiratory failure), none were attributed to crizotinib. Conclusions', ' This study supports the clinical benefit of crizotinib in East Asian pts with ROS1-positive advanced NSCLC. Crizotinib was generally well tolerated, with a safety profile consistent with that previously reported. Clinical trial information', ' NCT01945021']",
        "Doc_id":"ASCO_168126-176",
        "Doc_title":" Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188970736091136},
      {
        "Meeting_name":" Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.",
        "Background":"['Background', '  Chromosomal rearrangements of the ROS1 receptor tyrosine kinase gene define a new molecular subset of NSCLC. In cell lines, ROS1 rearrangements lead to expression of oncogenic ROS1 fusion kinases and sensitivity to ROS kinase inhibition. We examined the efficacy and safety of crizotinib, a small molecule tyrosine kinase inhibitor of MET, ALK and ROS, in patients with advanced, ROS1-rearranged NSCLC.  Methods', '  Patients with advanced NSCLC harboring ROS1 rearrangement, as determined using a break-apart FISH assay, were recruited into an expansion cohort of a phase 1 study of crizotinib. Patients were treated with crizotinib at the standard oral dose of 250 mg BID. The objective response rate (ORR) was determined based on RECIST 1.0. The disease control rate (DCR; stable disease [SD] + partial response [PR] + complete response [CR]) was evaluated at 8 weeks.  Results', '  Thirteen patients within the ROS expansion cohort received crizotinib and all were evaluable for response. The median age was 47 yrs (range 3172), and all but one of the patients were never-smokers. All patients had adenocarcinoma histology.  12/13 patients were tested for ALK rearrangement and all were negative. The median number of prior treatments was 1 (range 03). To date, the ORR is 54% (7/13), with 6 PRs and 1 CR, with 6 responses achieved by the first restaging scan at 78 wks. There was 1 additional unconfirmed PR at the time of data cut-off. The DCR at 8 wks was 85% (11/13). Median duration of treatment was 20 wks (range 4+59+). All responses are ongoing, and 12 patients continue on study. One patient had disease progression at first restaging and was discontinued from the study. The pharmacokinetics and safety profile of crizotinib in this group of patients were similar to that observed in patients with ALK-positive NSCLC.  Conclusions', '  Crizotinib demonstrates marked antitumor activity in patients with advanced NSCLC harboring ROS1 rearrangements. Like ALK, ROS defines a distinct subpopulation of NSCLC patients for whom crizotinib therapy may be highly effective. This study represents the first clinical validation of ROS as a therapeutic target in cancer.']",
        "Doc_id":"ASCO_100153-114",
        "Doc_title":" Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.",
        "_version_":1606188973094338560},
      {
        "Meeting_name":" The role of adjuvant chemotherapy in stage IB non-small cell lung cancer",
        "Background":"['Background', ' Despite complete surgical resection (SR), half of stage I non-small cell lung cancer (NSCLC) patients die from systemic relapse. An independent risk factor for systemic progression is pathologic stage IB subtype (T2aN0M0, AJCC 7). The role of adjuvant chemotherapy (AC) in stage IB NSCLC is controversial. We studied the effectiveness and cost-effectiveness of AC after SR in stage IB NSCLC. Methods', ' Propensity score matching was performed on the National Cancer Database (2004-2011). The Kaplan-Meier method generated conditional probabilistic incremental 1- to 5-year survival after SR stratified by receipt of AC. Medicare allowable charges for SR, AC, and their respective complications were used. Decision analysis modeling and microsimulation were performed to account for proportions of chemotherapeutic agents administered in real-world settings. The incremental cost-effectiveness ratio (ICER) was calculated over a 5-year horizon. Probabilistic and two-way sensitivity analyses were performed. Results', ' 3662 of 18709 patient (19.6%) who met inclusion criteria received AC for SR stage IB NSCLC, with usage ranging from 15-27% annually. After propensity score matching, an overall survival benefit of AC was conferred over SR alone (at 5 years', ' 68.9% vs 60.4%, p < 0.001). The incremental cost of AC over SR alone was $11,541. The incremental effectiveness of AC was 0.28 life-years, with an ICER of $41,218. In two-way sensitivity analysis, AC plus SR dominated for the entire range of cost and survival estimates. In probabilistic sensitivity analysis, AC plus SR dominated the model above a willing-to-pay threshold of $16,000. AC costs could nearly double and the ICER remained under conventional thresholds. However, only 3 of the 4 common AC regimens were cost effective. Conclusions', ' In stage IB NSCLC, surgery is insufficient to render a cure. The addition of AC to SR extends life-expectancy and is cost-effective compared to SR alone. These conclusions are valid over a range of clinically meaningful variations in cost and treatment outcomes, though a cost-conscious approach is needed when selecting an AC regimen. This represents a novel change in the treatment of stage IB NSCLC.']",
        "Doc_id":"ASCO_181268-199",
        "Doc_title":" The role of adjuvant chemotherapy in stage IB non-small cell lung cancer",
        "_version_":1606188985178128384},
      {
        "Meeting_name":" Drug development for breast (BC), colorectal (CRC), and non-small cell lung cancers (NSCLC) over the past 34 years.",
        "Background":"['Background', '   The purpose of this study was to delineate the drug development timeline and attrition rate of different drug classes for common cancer disease sites.  Methods', '   A pharmaceutical business intelligence database (Citeline Pharmaprojects) was used to identify drugs entering clinical trials specifically for BC, CRC, and NSCLC from 1980 to 2014. Data regarding drug characteristics, clinical trials and approval dates were obtained from the database, clinical trial registries, PubMed and FDA website. Comparisons were made using Chi-squared and Fishers exact tests.  Results', '   A total of 411 drugs met our inclusion criteria for BC, 246 for CRC and 315 for NSCLC (see table).  A larger percentage of drugs reached phase II (P2) trials for NSCLC compared to BC (p = 0.02). Phase transition probabilities did not differ for the three tumor sites. Immuno-modulators/cancer vaccines were less likely to transition between phase I (P1) and P2 than other drug classes for BC (p < 0.001). Tyrosine kinase inhibitors were more likely to transition between P1 and P2 for BC (p = 0.001), but not for CRC or NSCLC. Cytotoxic chemotherapy and tyrosine kinase inhibitors were more likely to transition between P2 and phase III (P3) in NSCLC (p = 0.001).  Conclusions', '   Specific drug classes have higher success rates in different cancer types. More research is required to determine whether this is due to differences in drug efficacy or limitations in preclinical models and trial design.   BC(n = 411)CRC(n = 246)NSCLC(n = 315)Number of Drugs in Each Class (%)ChemotherapyTargeted antibodyTyrosine kinase inhibitorImmuno-modulator/VaccineOther100 (24%) 55 (13%) 86 (21%) 45 (11%) 125 (30%)65 (26%) 49 (20%) 48 (20%) 34 (14%) 50 (20%)80 (25%) 51 (16%) 74 (24%) 31 (10%) 79 (25%)Number of Drugs Reaching Each Phase of Development (%)P1P2P3FDA Approval411 (100%) 350 (85%) 92 (22%) 25 (6%)246 (100%) 212 (86%) 43 (18%) 10 (4%)315 (100%) 289 (92%) 80 (25%) 10 (3%)Phase Transition Probability (%)P1 - P2P2 - P3P3 - FDA ApprovalP1 - FDA Approval91% 36% 38% 10%92% 30% 33% 7%94% 39% 19% 5%Mean Development Duration (Years)P1P2P32.8 2.6 3.62.8 3.2 4.42.8 2.7 3.0Mean Time From P1 Start to P3 End (Years)8.67.27.9']",
        "Doc_id":"ASCO_148224-156",
        "Doc_title":" Drug development for breast (BC), colorectal (CRC), and non-small cell lung cancers (NSCLC) over the past 34 years.",
        "_version_":1606188994351071232},
      {
        "Meeting_name":" Expanded molecular routine testing for targetable mutations in non-small cell lung cancer to reveal frequent co-occuring mutations.",
        "Background":"['Background', ' Using next-gen sequencing of predefined gene panels in routine clinical diagnostics of lung cancer allows, in contrast to single-gene assays, assessment of co-occuring mutations, which might underly heterogeneity of response to targeted drugs and survival. The Network Genomic Medicine (NGM) performs high sensitive next generation sequencing (NGS) based routine molecular diagnostics on a central platform for about 5000 inoperable lung cancer patients (pts) annually in Germany. Methods', ' NGS panel used in NGM consists of 17 genes to cover potentially targetable aberrations. Mutation analyses were run on an Illumina (MySeq) platform, while FISH analyses were performed separately. In 2016, we have started the evaluation of all NGM pts with available clinical data who had received NGS-based molecular diagnostics. In particular, we have focused on non-squamous (non-sq) and squamous (sq) NSCLC pts with co-occurring mutations', ' their frequency, significance and impact on overall survival. Results', ' From 2014 molecular genotyping was performed for 7,893 NGM pts (n = 7,246 NSCLC (5,667 non-sq and 1,487 sq pts) and n = 489 SCLC) with eligible clinical data. Genetic alterations in transformation-associated pathways were found in 79 % of all NSCLC pts. Furthermore, co-occurring mutations were detected in 39 % of these pts', ' 40 % in non-sq and 37 % in sq NSCLC. 11 % of pts had more than 2 co-occurring mutations. 1 % of all pts had 5 co-occurring mutations. The most frequent paired mutations were KRAS, EGFR and MET each with TP53 in non-sq and FRGF1 and TP53 in sq NSCLC. The incidences and significance of 3, 4 and 5 co-mutations as well as the impact of these co-occurring mutations on overall survival will be presented. Conclusions', ' Frequent occurrence of co-occuring mutations in transformation  associated pathways underlines the genetic heterogeneity also of lung cancer with classical driver mutation and the impact of co-occurring mutations on survival. This work confirms the use of molecular multiplex testing in routine molecular diagnostics of NSCLC. Assessment of co-occuring mutations will help to further specify genetically defined subgroups of lung cancer with therapeutic relevance.']",
        "Doc_id":"ASCO_193683-199",
        "Doc_title":" Expanded molecular routine testing for targetable mutations in non-small cell lung cancer to reveal frequent co-occuring mutations.",
        "_version_":1606189041161601024},
      {
        "Meeting_name":" Multimodality therapy in IIIA-N2 NSCLC",
        "Background":"['Background', ' Multimodality therapy is recommended in the management of clinical stage IIIA-N2 non-small cell lung cancer (NSCLC). However, the optimal combination and sequence of treatments and their relative outcomes is not clear. We examined patterns of care, outcomes of different treatment regimens, and associated socieconomic and clinicopathologic factors. Methods', ' Patients with clinical stage IIIA-N2 NSCLC were identified in the National Cancer Database from 2004-2013 and stratified based on treatment regimens. Four treatment cohorts were evaluated', ' definitive chemoradiation (CR), neoadjuvant chemoradiation followed by surgery (CRS), neoadjuvant chemotherapy followed by surgery (CS), and surgery followed by adjuvant therapy (SA). The impact of clinicopathologic factors and treatment sequencing on overall survival (OS) was analyzed using Cox regression and multivariate analysis. Results', ' A total of 28,147 patients met inclusion criteria. The frequency of treatment courses was', ' 71% CR, 8.8% CRS, 3.9% CS and 16.5% SA. Median OS was 21 months with a median follow-up of 19.3 months (0-131 months). The 2-year OS rate for each treatment cohort was', ' 38.6% CR, 66.7% CRS, 68.7% CS, and 60.3% SA. Multivariate analysis showed OS was associated with age, race, gender, Charlson-Deyo comorbidity index (CD), laterality, grade, clinical T stage, and treatment cohort. Improved OS was associated with patients that received CRS or CS (HR 0.8 p < .0001). Receipt of surgery was associated with age, race, gender, CD, insurance status, facility type and region, laterality, grade, clinical T stage and histology. Conclusions', ' The majority of patients with IIIA-N2 NSCLC were treated with CR. Patients who received neoadjuvant therapy followed by surgery had improved OS including when controlling for age and comorbidity index. Further randomized prospective trials in this population are needed to evaluate sequencing of multimodality therapy and the contribution of surgery to OS.']",
        "Doc_id":"ASCO_171268-176",
        "Doc_title":" Multimodality therapy in IIIA-N2 NSCLC",
        "_version_":1606188978434736128},
      {
        "Meeting_name":" Adaptive cell plasticity in autocrine TGF2 coordinated transcriptome-metabolome reprogramming of EGFR-mutant lung cancer in precision therapy escape.",
        "Background":"['Background', '  Precision therapy for advanced NSCLC with EGFR mutations is the current standard-of-care. Emergence of acquired resistance to therapy invariably occurs despite effective initial response. Classical rebiopsy studies of EGFR-mutant pts at progression have identified diverse resistance mechanisms involving T790M-EGFR, METactivation and AXL upregulation. Our studies focus on tumor cells adaptation early during therapy to map the initial course of therapeutic resistance evolution.  Methods', '  Drug-sensitive model studies were performed usingHCC827 and PC-9 NSCLC cells under erlotinib, and H1975 cells under CL-387,785 inhibition. Affymetrix microarray profiling was performed at 0h, 8h, 9d and 9d TKI followed by 7d drug-washout. Both in vitro and in vivo xenograft analyses were conducted. Mass-spectrometry based metabolomics profiling was also conducted.  Results', '  We identified an early adaptive drug escape in EGFR-mutant cells that emerged as early as 9 days on therapy. The prosurvival cell state was MET-independent with a TKI cytotoxicity escape at 100x higher IC50. Transcriptome profiling revealed a remarkable genome-wide signature adaptive reprogramming, centered on the autocrine TGF2 cascade, involving pathways of cell adhesion, cell cycle regulation, cell division, glycolysis, and gluconeogenesis. Corroborating the transcriptome profiling results, metabolomic profiling also revealed an adaptive metabolic reprogramming with suppression of glycolysis, TCA cycle, amino acids metabolism, and lipid bioenergetics during drug escape. Our studies identified a direct link of TGF2 within the early adaptive drug escaping cells, with the metabolic-bioenergetics quiescence and mitochondrial BCL-2/BCL-xL priming. Furthermore, this state of cellular plasticity displayed an increased EMT and cancer stem cell signaling as adaptation to the drug treatment and that could be overcome by dual BCL2/BCL-xL BH3 mimetics.  Conclusions', '   We have identified and characterized a cellular plasticity state in early adaptivedrug escaping EGFR-mutant NSCLC cells undergoing remarkable cellular reprogramming, with therapeutic implications.']",
        "Doc_id":"ASCO_133716-144",
        "Doc_title":" Adaptive cell plasticity in autocrine TGF2 coordinated transcriptome-metabolome reprogramming of EGFR-mutant lung cancer in precision therapy escape.",
        "_version_":1606188992981630976},
      {
        "Meeting_name":" Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations",
        "Background":"['Background', ' EGFR tyrosine kinase activating mutations are present in 10-26% of NSCLC tumors and are associated with increased response to gefitinib and erlotinib. However, little is known about how the efficacy and safety profile of erlotinib compares with CT in EGFR-mutant Caucasian p. We have performed a prospective, randomized phase III study comparing erlotinib with platinum-based CT in chemonaive advanced NSCLC p with EGFR mutations. Methods', ' From February 2007 to January 2011, we screened 1,227 p for EGFR mutations, and 174 patients were randomly assigned to receive erlotinib or platinum-based CT. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response, overall survival and toxicity profiles. Results', ' 153 p (76 CT, 77 erlotinib) are evaluable for the interim analysis. p characteristics CT arm', ' 16 males; median age, 64; never smokers, 56; PS 0, 26; PS 1, 41; adenocarcinoma, 67.  p characteristics erlotinib arm', ' 25 males; median age, 65; never smokers, 54; PS 0, 23; PS 1, 44; adenocarcinoma, 73. Preliminary results of the interim analysis are now available. Response rate was 10.5% to CT vs 54.5% to erlotinib (P<0.0001). PFS in the CT arm was 5.2 months (m) (95%CI, 4.4-5.8 m) compared to 9.4 m (95%CI, 7.9-12.3) in the erlotinib arm (HR, 0.42; P<0.0001). Median survival was 18.8 m in the CT arm and 22.9 m in the erlotinib arm (HR, 0.80; P=0.42). Most common toxicities were asthenia (68.9%), anemia (45.9%), nausea (40.5%) and neutropenia (36.5%) in the CT arm, and diarrhea (57.3%), asthenia (53.3%), and rash (49.3%) in the erlotinib arm. Final results of the interim analysis will be presented. Conclusions', ' The EURTAC study met its primary endpoint at the interim analysis. Erlotinib as first-line treatment for advanced NSCLC p with EGFR mutations improves PFS, with acceptable toxicity, compared to platinum-based chemotherapy.']",
        "Doc_id":"ASCO_78285-102",
        "Doc_title":" Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations",
        "_version_":1606188995474096128},
      {
        "Meeting_name":" Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive stage IV non-small cell lung cancer.",
        "Background":"['Background', ' Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting ALK, MET, and ROS1 tyrosine kinases. It was first approved by the Food and Drug Administration (FDA) in 2011 for treatment of patients in late-stage (locally advanced or metastatic) non-small cell lung cancer (NSCLC) with abnormal anaplastic lymphoma kinase (ALK) gene as detected by an FDA-approved test, as it confers improved progression-free survival comparison with chemotherapy. Methods', ' This is a retrospective chart review study of patients with stage IV ALK-positive NSCLC who attended the medical oncology department of Kuwait Cancer Control Centre (Kuwait) and King Fahad Specialist Hospital (Saudi Arabia) between January 2013 and May 2016. The efficacy and safety of crizotinib (250 mg orally, twice daily, with or without food.) were evaluated based on overall survival (OS), progression-free survival (PFS), Objective response rate (ORR), time to objective response, duration of response, and dose reduction or cessation because of crizotinib toxicity. Results', ' Twenty-three patients were involved in this study with a median age of 55.5 years and male-to-female ratio of 2.4', '1 The median OS from initiation of crizotinib has not been reached; 1-year overall survival was 71.2%. Crizotinib treatment demonstrated median PFS of 9.6 months (95% CI, 3.0-24.1 months). The ORR was 70.9%. Complete response was achieved in 4.2% of patients, and partial response was achieved in 66.7% of patients. The most frequently reported adverse effects of crizotinib (Grade 1 / 2) were muscle ache, fatigue, nausea, vomiting, diarrhea, constipation, edema, elevated transaminases, bradycardia, and vision disorders. Grade 3 / 4 diarrhea was reported in 12.5% of patients. The proportion of patients who required dose reduction because of Crizotinib-induced bradycardia was 8.3% of patients. Conclusions', ' Crizotinib appears to be a very favorable option for treating patients with stage IV ALK-positive NSCLC. Crizotinib showed a very tolerable toxicity profile.']",
        "Doc_id":"ASCO_193638-199",
        "Doc_title":" Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive stage IV non-small cell lung cancer.",
        "_version_":1606188998514966529},
      {
        "Meeting_name":" Survival following stereotactic body radiation therapy or conventionally fractionated radiation for definitive non-operative treatment of stage I non-small cell lung cancer",
        "Background":"['Background', '  Despite a dramatic increase in utilization of stereotactic body radiation therapy (SBRT) for non-operative treatment of clinical stage I NSCLC over the last decade, there are no reported clinical trials or large scale comparisons with standard conventionally fractionated radiation (CFRT). We sought to compare overall survival (OS) between these modalities using the National Cancer Data Base (NCDB).  Methods', '  Patients with clinical stage I (AJCC 6th edition T1-T2N0M0) NSCLC who underwent definitive non-operative treatment with either SBRT or CFRT from 1998 to 2010 were identified from the NCDB. Cox regression was used to assess the impact of patient and treatment variables on OS. Inverse probability adjusted Kaplan-Meier survival curves were calculated to assess differences in OS while adjusting for baseline imbalances between the treatment groups.  Results', '  A total of 19373 patients met inclusion criteria (5944 SBRT, 13429 CFRT). Median follow-up was 18.7 months. On multivariable analysis, improved OS was independently correlated with younger age, female gender, non-Caucasian race, lower Charlson comorbidity score, smaller tumor size, use of chemotherapy, treatment at an academic facility, and was most strongly associated with use of SBRT (HR .775, 95% CI, .737 to .817). Chemotherapy was delivered in 32.9% of CFRT patients and 4.2% of SBRT patients. Chemotherapy was correlated with improved OS on multivariable analysis for CFRT but not SBRT. In an adjusted Kaplan-Meier comparison, SBRT was associated with a significant increase in median (29.8 v 26.2 months) and 3-year (42.3% v 36.4%) OS compared with CFRT (P < .0001).   Conclusions', '  In a large population-based analysis of outcomes in a modern cohort of patients with clinical stage I NSCLC treated with definitive non-operative therapy, SBRT was associated with a significant improvement in OS compared with CFRT.']",
        "Doc_id":"ASCO_144312-156",
        "Doc_title":" Survival following stereotactic body radiation therapy or conventionally fractionated radiation for definitive non-operative treatment of stage I non-small cell lung cancer",
        "_version_":1606189002635870208},
      {
        "Meeting_name":" Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC).",
        "Background":"['Background', \" Cet, a monoclonal antibody (mAb) that specifically targets epidermal growth factor receptor (EGFR) and Bev (anti-VEGF mAb) combined with chemotherapy has resulted in superior survival compared to chemotherapy alone in some stage IV NSCLC trials. Combining both mAb's with chemotherapy might increase survival in stage IV NSCLC pts. Methods\", ' Chemotherapy nave advanced NSCLC patients with ECOG status <1, adequate hematologic, hepatic, and renal function received Cet (400 mg/m2 on Day 1 as initial dose and weekly thereafter at 250 mg/m2) plus Bev (15 mg/kg on Day 8 of each 3-week cycle) for 6 cycles in combination with either 6 cycles (Arm A) or 3 cycles (Arm B) of P (200 m/kg) and C (AUC=6) on Day 1 of each 3-week cycle. Patients without progressive disease (PD) after 6 cycles continued Cet until PD or other withdrawal criteria were met. Comparison of progression-free survival (PFS) for arm A vs B is the primary objective. Results', ' Accrual is completed. Data are available for 85 pts', ' 47% women, median age 65 yrs, and 88% Caucasian. Median PFS for arm A was 6.0 vs 4.2 months for arm B, hazard ratio of 0.57 for arm A relative to arm B. Objective response was Arm A=31% and B=30%. Most frequent AEs Grade 3 in pts were neutropenia [9 (10.6%), A=8, B=1], fatigue [8 (9.4%), A=4, B=4], dermatitis acneiform [6 (7.1%), A=3, B=3].13 pts withdrew due to AEs (A=4, B=9), 4 were related to Cet (2 per arm). Two pts discontinued due to death (A=2, B=0) unrelated to Cet. Conclusions', \" Adding both mAb's to PC resulted in acceptable toxicity. The trend for superior PFS with 6 courses of PC suggests that 3 courses of PC are not optimal.\"]",
        "Doc_id":"ASCO_34196-65",
        "Doc_title":" Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC).",
        "_version_":1606189011243630592},
      {
        "Meeting_name":" Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.",
        "Background":"['Background', ' Treatment options for bronchoalveolar carcinoma (BAC) include conventional chemotherapy and erlotinib in tumors that harbor activating EGFR mutations. The chaperone Hsp90 regulates the folding, stability and activity of many signal transduction proteins important in NSCLC, including EGFR, KRAS, MET and HER2. STA-9090 is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation ansamycin class of Hsp90 inhibitors, such as 17-AAG and IPI-504, and has shown superior activity and an improved safety profile relative to these agents in preclinical studies. Methods', ' We report the case of a 66-year-old white male with metastatic BAC, treated with STA-9090 on a phase I study. Results', ' The patient was diagnosed with BAC in 2006. Molecular profiling showed wild type KRAS and EGFR, and EGFR was not amplified on FISH testing. Prior treatment included erlotinib, bevacizumab, carboplatin, paclitaxel, pemetrexed, and topotecan with progression of disease on each, and an investigational rexinoid with a three month stabilization of disease. He enrolled in a phase I solid tumor study of STA-9090, and began weekly infusions at 150 mg/m2 for 3 weeks (followed by a rest week). The treatment was well tolerated, with adverse events of mild diarrhea and moderate hypophosphatemia. Target lesions were reduced by 25% after cycle 4 (SD per RECIST), and that response was maintained. The dose of STA-9090 was increased to 180 mg/m2 starting at Cycle 8 and continues to be well-tolerated through Cycle 11. The 11 month treatment duration compares favorably with the average 2-3 month duration of prior regimens. Conclusions', ' Reduction in tumor size and prolonged stabilization, and a well-tolerated AE profile are encouraging and support the evaluation of STA-9090 in patients with NSCLC, including BAC. A phase II study of STA-9090 in patients with advanced NSCLC is ongoing.']",
        "Doc_id":"ASCO_53656-74",
        "Doc_title":" Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.",
        "_version_":1606189015157964800},
      {
        "Meeting_name":" A phase II trial of zoledronic acid in combination with cisplatin and docetaxel in non-small cell lung cancer patients with bone metastases.",
        "Background":"['Background', ' Recent studies suggest that zoledronic acid (ZOL) may act by directly affecting tumor progression, possibly in synergy with chemotherapy. However, combination of ZOL and cisplatin may have the potential for deterioration in renal function. This study was conducted to evaluate the safety and efficacy of combined ZOL, cisplatin and docetaxel in patients with non- small cell lung cancer (NSCLC) with bone metastases. Methods', ' Cisplatin 80 mg/m2 and docetaxel 60 mg/m2 (CD) with ZOL 4mg were given intravenously on day 1 every 3-4 weeks for up to 4cycles. Main eligibility criteria included advanced NSCLC with bone metastases, no prior chemotherapy, and performance status of 0 or 1. The primary endpoint was feasibility defined by the number of patients receiving two cycles or more of CD with ZOL without severe toxicity. Data was also assessed prospectively on development of skeletal-related events (SRE), pain score, and urinary N-telopeptide (NTX) and bone-specific alkaline phosphatase as bone marker. Results', ' Between July 2007 and November 2009, 35 patients were enrolled in the study. The primary endpoint was met', ' Two or more cycles of CD with ZOL were administered in 29 (83%) patients. Within the first cycle, only 2 patients had an increase in serum creatinine levels of > 0.5 mg/dL from a baseline level. No grade 3 or 4 renal toxicity including serum creatinine increase was observed. To date, 7 PR, 16 SD, and 7 PD were observed among the 30 patients assessed for efficacy. After 6 weeks, the majority of patients experienced improvement in pain score and decrease of NTX level from baseline. Conclusions', ' Combination of CD with ZOL is well tolerated with acceptable renal toxicity as treatment of advanced NSCLC patients with bone metastases.']",
        "Doc_id":"ASCO_42368-74",
        "Doc_title":" A phase II trial of zoledronic acid in combination with cisplatin and docetaxel in non-small cell lung cancer patients with bone metastases.",
        "_version_":1606189019099561985},
      {
        "Meeting_name":" Prognostic significance of tumor size in patients with stage III non-small cell lung cancer",
        "Background":"['Background', ' Although tumor size is a known predictor of stage I and II non-small cell lung cancer (NSCLC) treated with surgery or radiotherapy, there is limited information regarding its prognostic significance in patients with mediastinal lymph node involvement. Methods', ' The Surveillance Epidemiology and End Results (SEER) registry was queried for patients with unresected NSCLC stage III, without malignant pleural effusion, aged 21 or older, and diagnosed between 1998 and 2003. Tumor size was defined as S1 (0.1-3 cm), S2 (3.1-5 cm), S3 (5.1-7 cm) and S4 (7.1-20 cm). Demographic variables included age, gender, race and histology. The Kaplan-Meier method was used to estimate the overall survival (OS) and disease-specific survival (DSS), and the Cox proportional hazard model to evaluate whether tumor size remained an independent risk factor after adjusting for stage and other demographic variables. Results', ' A total of 12,205 patients met the eligibility criteria. Median age at diagnosis was 70 years and most patients were male (58.8%) and white (81.3%). Tumor size was a statistically significant predictor for both overall survival (p<0.0001) and disease-specific survival (p<0.0001) on multivariate analysis. Selected groups of patients with smaller stage IIIB disease had better OS compared to patients with stage IIIA, including; IIIBS1 vs. IIIAS3 (p=0.0005) or IIIA S4 (p<0.0001) and IIIBS2 vs. IIIAS4 (p=0.0001). Conclusions', ' Tumor size is an independent predictor for OS and DSS in patients with unresected stage III NSCLC and should be considered in the stratification of patients treated in this setting. Tumor size and overall survival (OS) StageTumor size1-y OS (%)2-y OS (%)3-y OS (%)4-y OS (%)5-y OS (%) III A0.1-3 cm50.227.717.111.68.5 III A3.1-5 cm43.922.413.29.37.2 III A5.1-7 cm39.016.611.48.35.6 III A7.1-20 cm34.914.49.04.43.6 III B0.1-3 cm43.922.513.410.08.3 III B3.1-5 cm40.218.810.07.25.0 III B5.1-7 cm35.115.49.37.45.7 III B7.1-20 cm31.613.68.66.35.4']",
        "Doc_id":"ASCO_32506-65",
        "Doc_title":" Prognostic significance of tumor size in patients with stage III non-small cell lung cancer",
        "_version_":1606189032217247745},
      {
        "Meeting_name":" Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.",
        "Background":"['Background', '  CUSTOM is the first completed prospective clinical trial using molecular selection for treatment assignments into multiple targeted therapy arms and in multiple cancer histological subtypes concurrently.  Methods', '  All patients with advanced NSCLC, SCLC or TM were eligible to participate in the study. Oncogenic mutations, amplifications or translocations in 12 genes detected in CLIA-certified laboratories were used to assign patients to 1 of 5 biomarker/treatment groups per histological subtype', ' EGFR mutations/erlotinib; KRAS, NRAS, HRAS or BRAF mutations/AZD6244; PIK3CA, AKT or PTEN mutations/MK2206; ERBB2 mutations or amplifications/lapatinib; and KIT or PDGFRA mutations/sunitinib; or to standard-of-care therapy. For each arm, the study was conducted as an optimal two-stage phase II trial in favor of a response rate of 40% or more.  Results', '  668 patients were enrolled at two academic institutions. The most frequent genetic alterations in NSCLC were KRAS and EGFR mutations (25.2 and 19.7% respectively), ALK rearrangements 7.8%, HER2 amplifications 2.7% and mutations in PIK3CA 2.5%, BRAF 1.9%, HRAS 1.5%, ERBB2 1.7%, AKT1 0.4%, and NRAS 0.7%. PTEN mutation analysis was only feasible in 13 patients with NSCLC of which 3 were positive (23%). The most frequent genetic alterations in SCLC were mutations in PIK3CA 6.5%, ERBB2 amplifications 5.3% and mutations in HRAS 3.4%, AKT1 2.2%, BRAF 2% and KRAS 2%. The most frequent genetic alterations in TMs were HER2 amplifications 7.7% and mutations in HRAS 4.7%, PIK3CA 1.4% and EGFR 1.4%. Only 6.2% (n=42) of patients met criteria for enrollment into the treatment arms of the study. Efficacy analyses including response rates will be presented.  Conclusions', '  CUSTOM is the first completed prospective clinical trial demonstrating the feasibility of conducting efficacy analyses of multiple biomarker-matched therapies in multiple cancer histological subtypes concurrently. CUSTOM is also the largest prospective molecular profiling study of patients with SCLC and TMs. Clinical trial information', ' NCT01306045.']",
        "Doc_id":"ASCO_108629-132",
        "Doc_title":" Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.",
        "_version_":1606189037647822848},
      {
        "Meeting_name":" REVEL",
        "Background":"['Background', '  RAM is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. The REVEL study evaluated the efficacy and safety of RAM+DOC vs. PL+DOC (DOC) in patients (pts) with stage IV nonsquamous (NSQ) and squamous (SQ) NSCLC after platinum-based therapy.  Methods', '  Pts with NSQ and SQ stage IV NSCLC were randomized 1', '1 (stratified by sex, region, ECOG PS, and prior maintenance therapy) to receive DOC 75 mg/m2 in combination with either RAM 10 mg/kg or PL on day 1 of a 21-day cycle until disease progression, unacceptable toxicity, or death. The primary endpoint was overall survival (OS). Secondary efficacy endpoints included progression-free survival (PFS), and objective response rate (ORR).  Results', ' Between Dec 2010 and Feb 2013, 1,253 pts (26.2% SQ) were randomized (RAM+DOC', ' 628; DOC', ' 625). Pt characteristics were balanced between arms. ORR was 22.9% for RAM+DOC and 13.6% for DOC (P<0.001). The hazard ratio (HR) for PFS was 0.762 (P<0.0001); median PFS was 4.5 months (m) for RAM+DOC vs. 3.0m for DOC. REVEL met its primary endpoint; the OS HR was 0.857 (95% CI 0.751, 0.98; P=0.0235); median OS was 10.5m for RAM+DOC vs. 9.1m for DOC. OS was longer for RAM+DOC in most pt subgroups, including SQ and NSQ histology. Grade 3 adverse events (AEs) occurring in >5% of pts on RAM+DOC were neutropenia (34.9% vs. 28.0%), febrile neutropenia (15.9% vs. 10.0%), fatigue (11.3% vs. 8.1%), leukopenia (8.5% vs. 7.6%), hypertension (5.4% vs. 1.9%), and pneumonia (5.1% vs. 5.8%). Grade 5 AEs were comparable between arms (5.4% vs. 5.8%), as was pulmonary hemorrhage (any grade; all pts', ' 2.1% vs. 1.6%; SQ pts', ' 3.8% vs. 2.4%).  Conclusions', ' REVEL demonstrated a statistically significant improvement in ORR, PFS, and OS for RAM+DOC vs DOC in NSCLC pts with stage IV NSCLC as second-line treatment after platinum-based therapy.  Benefits were similar in NSQ and SQ pts, and no unexpected AEs were identified.  Clinical trial information', ' NCT01168973.']",
        "Doc_id":"ASCO_126433-144",
        "Doc_title":" REVEL",
        "_version_":1606188972574244864},
      {
        "Meeting_name":" Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous nonsmall cell lung cancer (WJOG 5910L)",
        "Background":"['Background', '  Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous nonsmall cell lung cancer (NSCLC). However, there have been no evidence-based studies to support the use of bevacizumab beyond disease progression in NSCLC patients receiving such treatment.  Methods', '  WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial of docetaxel (60 mg/m2) versus docetaxel (60 mg/m2) plus bevacizumab (15 mg/kg) every 3 weeks in patients with recurrent or metastatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. The primary end point was progression-free survival (PFS). Results', '   One hundred patients were randomly assigned to receive docetaxel (Doc, n = 50) or docetaxel plus bevacizumab (Doc+Bev n = 50). The median PFS was 4.4 months for the Doc+Bev group and 3.4 months for the Doc group, with a hazard ratio (HR) of 0.71 (95% confidence interval [CI], 0.471.09) and stratified log-rank P value of 0.058, which met the predefined value for statistical significance (P < 0.2). The median overall survival also tended to be longer in the Doc+Bev group (13.1 months; 95% CI, 10.621.4) than in the Doc group (11.0 months; 95% CI, 7.616.1), with a HR of 0.74 (95% CI, 0.461.19; stratified log-rank P = 0.11). Frequent adverse events of grade  3 included neutropenia (90% in the Doc+Bev group vs. 82% in the Doc group), leukopenia (64% vs. 52%, respectively), and febrile neutropenia (26% in both groups). There were two treatment-related deaths (one in each group).  Conclusions', '  The addition of bevacizumab to docetaxel in the second-line setting shows promising efficacy with regard to PFS for patients with nonsquamous NSCLC whose disease has progressed while receiving bevacizumab plus a platinum-based doublet. The addition of bevacizumab was associated with a slight increase in toxicity, although the combination regimen was tolerable. Phase III studies of this combination are warranted. Clinical trial information', ' 000004715.']",
        "Doc_id":"ASCO_146939-156",
        "Doc_title":" Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous nonsmall cell lung cancer (WJOG 5910L)",
        "_version_":1606188984650694656},
      {
        "Meeting_name":" Adjuvant chemotherapy with cisplatin and gemcitabine in resected non-small cell lung cancer",
        "Background":"['Background', '  Adjuvant chemotherapy in operable non small cell lung cancer (NSCLC) has been shown to improve overall survival in many meta-analysis. The use of cisplatin and gemcitabine combination is considered one of the standard regimens for first-line treatment of advanced NSCLC, with mild side effects. The aim of the study was to evaluate the clinical feasibility and toxicity of the cisplatin-gemcitabine combination in adjuvant setting.  Methods', '  Resected NSCLC patients who met criteria for recommending adjuvant chemotherapy received treatment with cisplatin 75 mg/m2 on day 1 and gemcitabine 1.200 mg/m2 on days 1 and 8 of each 21 days cycle. A maximum of four cycles were delivered. Main objectives were clinical feasibility, drug delivery, and efficacy.  Results', '  From November-2004 to July-2011 a total of 89 patients (73 male/16 female, median age 57) were included. Surgery', ' lobectomy 62.9%, pneumonectomy 29.2%, bilobectomy 5.6%, wedge resection 2.2%. Tumor stages', ' 19.1% IB, 55.1% II, 23.6% III, 2.2% IV; histology', ' 48.3% squamous, 43.8 % adenocarcinoma, 3.4 % large cell carcinoma and 4.5% NSCLC not otherwise specified. ECOG 0', ' 62.9%, ECOG 1', ' 37.1%. Toxicity', ' grade 3/4 neutropenia 19.1%/6.7 %; grade 3 febrile neutropenia 3.4%; grade 3/4 anaemia 6.7%/1.1%; grade 3/4 thrombocytopenia 6.7%/4.5%; grade 3 ototoxicity 1.1%; no grade 3/4 nephrotoxicity was reported. There was one toxic death. Compliance', ' 85.4% of the patients received 4 cycles of the combination chemotherapy. Cisplatin dose intensity was 24.6 mg/m2/wk and gemcitabine dose intensity was 773.6 mg/m2/wk. Median overall survival and progression free survival has not yet been reached. With a median follow up of 36 months, 77.5% of the patients are still alive and 61.8% without documented relapse. Reported 3 year overall survival in patients with ECOG 0 was 82%, and in patients with ECOG 1 54%, being this difference statistically significant.  Conclusions', '  Combination chemotherapy with cisplatin and gemcitabine in adjuvant setting is safe and feasible with a good toxicity profile. Those patients with ECOG 0 benefit most. Our data are similar to those obtained in previously reported trials.']",
        "Doc_id":"ASCO_96692-114",
        "Doc_title":" Adjuvant chemotherapy with cisplatin and gemcitabine in resected non-small cell lung cancer",
        "_version_":1606188985019793408},
      {
        "Meeting_name":" Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).",
        "Background":"['Background', '  Various driver gene alterations have emerged as critical targets for molecular therapies in non-small cell lung cancer (NSCLC), but these alterations other than EGFR mutations occur in rare populations. A nationwide genomic screening network in Japan (LC-SCRUM-Japan) was established in February 2013 for the development of novel targeted therapies against advanced NSCLCs harboring these rare alterations. Methods', '  Advanced non-squamous NSCLCs without EGFR mutations were eligible for inclusion in LC-SCRUM-Japan. The tumors were analyzed for ALK/RET/ROS1 fusions using RT-PCR, and detected fusions were confirmed by FISH. Between November 2013 and March 2014, fusion-negative tumors were further examined for other driver gene mutations using a next-generation sequencing (NGS) system (Ion PGM with Ion Torrent AmpliSeq Cancer Hotspot Panel, version 2), enabling the simultaneous analysis of 50 cancer-related genes. Results', '  As of December 26, 2014, a total of 188 institutions across Japan were participating and 1347 patients had been enrolled in LC-SCRUM-Japan. Among 1271 available samples, ALK/RET/ROS1 fusions were detected in 24 (2%)/31 (3%)/55 (4%) cases, respectively. The NGS analysis was performed in 201 cases without the fusions, and 82 cases (41%) had driver mutations, including 45 KRAS mutations (22%), 10 BRAF mutations (5%), 9 ERBB2 mutations (4%), 2 PIK3CA mutations (1%), and 1 NRAS mutation (0.5%). MET and ERBB2 amplifications were also detected by the NGS in 4 (2%) and 2 (1%) cases, respectively. Among a total of 198 cases harboring targetable gene alterations, 16 with RET fusions, 26 with ROS1 fusions, and 2 with BRAF mutations were enrolled in clinical trials for vandetanib (LURET study, Japan), crizotinib (OO12-01, East Asia), and dabrafenib (BRF113928), respectively. Conclusions', '  This nationwide and population enrichment screening system enabled various rare driver gene alterations to be efficiently detected in advanced NSCLC, thereby contributing to the rapid accrual of matched patients in clinical trials for targeted therapies.']",
        "Doc_id":"ASCO_148248-156",
        "Doc_title":" Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).",
        "_version_":1606188999705100288},
      {
        "Meeting_name":" Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt)",
        "Background":"['Background', ' BV prolongs progression free and overall survival in advanced NSCLC pts. ARIES, a prospective OCS, evaluates BV clinical outcomes in a real world setting. Post hoc analyses from randomized controlled trials suggest location and cavitation as potential risk factors for SPH, a serious and often fatal adverse event (AE). ARIES presents a unique opportunity to independently evaluate BL tumor characteristics and correlate with SPH. Methods', ' Pts with advanced nonsquamous NSCLC on first-line chemotherapy and BV enrolled. No doses, regimens or assessments were prespecified. Data were collected electronically at BL and quarterly. SPH were reported expeditiously. BL CT scans were requested for all pts and reviewed by an independent review facility (IRF). Results', ' NSCLC enrollment completed 06/2009. As of 09/2009, 1,970 pts had median follow-up of 9.6 mo. The IRF reviewed BL scans of 1,881 pts; 1,470 (78%) had  1 BL measurable (meas) tumor ( 0.5cm) and 49% (718) were central; 67% had largest tumor size  3 cm; 14% had cavities and 10% had > 1 cavity. BL tumor characteristics were generally similar across subpopulations (age  70, PS  2, pts with CNS mets). Pts with a history (Hx) of hemoptysis (n = 105) had more centrally located tumors, fewer numbers of meas tumor, and larger cavity size. There are 15 (0.8%) reported SPH events to date; 2 pts had no BL CT scan submitted and 2 pts with BL scans had no meas tumor (1 had Hx of hemoptysis). Of the remaining 11 pts with SPH', ' 8 had central tumors; 1 had cavitation (1.2 cm); 0 were on anticoagulants at BL; largest tumor size ranged from 1.8-11.6cm. There was 1 SPH in pts with  1 cavity (0.5%) and 8 in pts with central tumors (1.1%). Conclusions', ' ARIES has the largest series of independently reviewed BL scans from advanced NSCLC pts, providing an opportunity to correlate radiographic factors with outcomes in BV treated pts. Although limited by small numbers, the data suggest that cavitation is not predictive of SPH. Correlation of BL radiographic characteristics with outcomes and risk factor analysis will be presented.']",
        "Doc_id":"ASCO_51314-74",
        "Doc_title":" Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt)",
        "_version_":1606189000306982913},
      {
        "Meeting_name":" The influence of medical comorbidities on the presentation and outcome of stage I-III non-small cell lung cancer.",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) outcomes vary widely among patients. We previously reported the associations between several clinical characteristics and outcomes among patients with stage I-III NSCLC at a medical center providing care to a diverse patient population [Yorio et al. J Clin Oncol 27', '15s, 2009 (suppl; abstr 7534)]. To determine potential reasons for these associations, we incorporated a validated medical comorbidity index into the analysis. Methods', ' We performed a retrospective analysis of consecutive patients diagnosed with NSCLC stages I-III from 2000 to 2005 at the University of Texas Southwestern Medical Center. Demographic, tumor, and comorbidity data were obtained from hospital tumor registries, administrative databases, and individual patient records. The association between these variables was assessed using univariate analysis, multivariate logistic regression, and survival analysis. Results', ' A total of 478 patients met criteria for analysis. Median age was 64 years, and 52% were men. A higher Charlson Comorbidity Index (CCI) was associated with a lower likelihood of presentation with locally advanced (stage III) disease (OR 0.58; 95% CI, 0.38 to 0.88; p=0.01). In univariate analysis, overall survival was associated with age, gender, race, insurance type, stage, histology, and CCI. In multivariate logistic regression, overall survival remained associated with all variables', ' age (p=0.0001), gender (p=0.001), race (p=0.01), insurance type (p=0.01), stage (p<0.0001), histology (p=0.003), and CCI (p=0.0007). The CCI was associated with survival for patients with both early stage (I-II) and locally advanced (stage III) disease (p=0.02 and p=0.01, respectively). Conclusions', ' In this cohort of patients with stage I-III NSCLC, the presence of comorbidities was associated with diagnosis at an earlier disease stage. Although comorbidities were significantly associated with outcome in both early stage and locally advanced disease, they did not fully account for survival differences based on age, gender, race, insurance type, stage, and histology. These findings warrant further study.']",
        "Doc_id":"ASCO_41752-74",
        "Doc_title":" The influence of medical comorbidities on the presentation and outcome of stage I-III non-small cell lung cancer.",
        "_version_":1606189002232168449},
      {
        "Meeting_name":" Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863).",
        "Background":"['Background', ' Vorinostat, a HDAC inhibitor, enhances paclitaxel and platinum-mediated anti-cancer activity in preclinical studies by enhanced tubulin acetylation and DNA fragmentation respectively. Promising activity with carboplatin (C), paclitaxel (P), and vorinostat in patients with advanced NSCLC in the phase I study (Ramalingam et al, Clin Cancer Res, 2007) prompted this placebo-controlled, randomized phase II study. Methods', ' Pts. with stage IIIB (wet) or IV NSCLC, performance status (PS) 0/1, no prior therapy and adequate bone marrow, renal and hepatic function were randomized (2', '1) for therapy with PC with either vorinostat or placebo. Treatment consisted of C', ' AUC=6 mg/ml.min; and P 200 mg/m2 both given on day 3 along with either vorinostat (400 mg PO QD) or placebo on days 1-14 of each 3 wk cycle to a maximum of 6 cycles. The estimated sample size to demonstrate a 50% improvement in response rate for vorinostat over placebo was 93 pts. (one-sided P, type I error 10%). Results', ' Ninety-four pts. were enrolled (vorinostat-64; placebo-32). Pts. baseline characteristics were similar between the two arms (median age 64, male 60%, PS 0 40%, brain mets 16%). Median # cycles', ' vorinostat-3.5; placebo - 4. The confirmed response rate was superior with vorinostat over placebo (34% vs. 12.5%, P = 0.02). At the time of analysis, the preliminary median PFS for vorinostat and placebo were 5.75 and 4.1 m respectively (ITT). Follow up for survival is ongoing. Common grade 3/4 toxicities (vorinostat vs. placebo)', ' neutropenia (44% vs. 47%); thrombocytopenia (33% vs. 16%); fatigue (13% vs. 3%); hyponatremia (21% vs. 6%); diarrhea (5% vs. 0). Discontinuation from study after cycle 1 was higher with vorinostat (27% vs. 16%). Biomarker studies on baseline tumor tissue and peripheral blood cells are ongoing. Conclusions', ' Administration of vorinostat with carboplatin and paclitaxel resulted in a significantly superior response rate for pts.with advanced NSCLC. HDAC inhibition is a novel therapeutic strategy for treatment of NSCLC. Supported by ASCO Career Development Award to S.S.Ramalingam, and NCI NO1-CM-62209, NO1-CM-62201, NO1-CM-62208.']",
        "Doc_id":"ASCO_31511-65",
        "Doc_title":" Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863).",
        "_version_":1606189003234607105},
      {
        "Meeting_name":" Use of chemotherapy for advanced non-small cell lung cancer in a contemporary and diverse patient population.",
        "Background":"['Background', ' Despite evidence that chemotherapy prolongs survival, without substantially impairing quality of life, for patients with advanced non-small cell lung cancer (NSCLC), population-based studies have shown that only 20-30% of these patients receive systemic therapy. However, these studies have relied on Medicare-based datahence including only patients aged  65 years. We therefore determined the use of chemotherapy in a contemporary NSCLC population encompassing all patient ages. Methods', ' We performed a retrospective analysis of consecutive patients diagnosed with stage IV NSCLC from 2000 to 2007 at the University of Texas Southwestern Medical Center. Demographic, tumor, and treatment data were obtained from hospital tumor registries and individual patient records. The association between these variables was assessed using univariate analysis, multivariate logistic regression, and survival analysis. Results', ' A total of 718 patients met criteria for analysis. Mean age was 64 years, 42% were female, and 45% were non-Hispanic white. 353 patients (49%) received chemotherapy. In univariate analysis, receipt of chemotherapy was associated with age (53% for age < 65 years vs. 41% for age  65 years; p = 0.003) and insurance type (40% for no insurance vs 60% for private insurance; p = 0.0002), but was not associated with gender, race, or year of diagnosis. In a multivariate model, age (OR [< 65 years vs  65 years] 1.96; 95% CI, 1.26- 3.06; p = 0.003) and insurance type (OR [no insurance vs private insurance] 0.44; 95% CI 0.30-0.64; p < 0.0001) remained associated with receipt of chemotherapy. In multivariate analysis, gender (HR [female vs male] 0.85, 95% CI, 0.72-0.99; p = 0.04) and receipt of chemotherapy (HR [no chemo vs. chemo] 2.81; 95% CI, 2.38-3.31; p < 0.0001) were associated with overall survival. Conclusions', ' In a contemporary population representing the full age range of patients with stage IV NSCLC, chemotherapy was administered to nearly half of all patientssubstantially more than in previous studies. Younger patients and insured patients were more likely to receive chemotherapy. Receipt of chemotherapy was associated with longer survival. These findings warrant further investigation.']",
        "Doc_id":"ASCO_41403-74",
        "Doc_title":" Use of chemotherapy for advanced non-small cell lung cancer in a contemporary and diverse patient population.",
        "_version_":1606189007197175809},
      {
        "Meeting_name":" Presentation of early-stage non-small cell lung cancer (NSCLC) without radiographic screening",
        "Background":"['Background', '  In contrast to other common malignancies, screening for lung cancer is currently not recommended.  However, recent evidence suggests that computed tomography (CT)-based screening of select populations may decrease lung cancer mortality.  We determined how screening would impact current presentation patterns of early stage disease.  Methods', '  Retrospective analysis of patients diagnosed with stage 1-2 NSCLC from 2000-2009 at the University of Texas Southwestern Medical Center.  Data were obtained from tumor registries and medical records.  Associations between baseline characteristics and the reason for and type of imaging were assessed using univariate analysis and multivariate logistic regression.  Results', '  A total of 412 patients were included in the analysis.  Mean age was 67 years, 49% were men, 70% were white, and 79% had stage I disease.  Only 52% were age 55-74 years and had 30+ pack-year smoking history and would therefore have met criteria for the National Lung Screening Trial (NLST).  Reason for initial imaging was symptoms in 51%, follow-up of other medical conditions in 43%, and lung cancer screening in 6%.  Dominant symptoms were cough/hemoptysis (36%), dyspnea (29%), and chest pain (15%).  Chest x-ray was the initial imaging modality in 57%, with CT scans accounting for almost all other cases.  Reason for imaging was significantly associated with race (P<0.001), socioeconomic status (P=0.005), and stage (P<0.001), with non-white patients, indigent patients, and those diagnosed with stage 2 disease more likely to present with symptoms.  Type of imaging was associated with reason for imaging (P<0.001), year of diagnosis (CXR 67% 2000-2004 vs. 49% 2005-2009; P<0.001), and disease stage (P=0.005).  Conclusions', '  Symptoms remain the dominant reason for initial detection of early stage NSCLC, particularly among underrepresented populations.  The proportion of early stage NSCLC initially detected by CT scan, principally for follow-up of other medical conditions, has increased markedly in recent years.  If widespread lung cancer screening is implemented, these patterns may persist, as only half of patients currently diagnosed with early stage NSCLC meet NLST eligibility criteria.']",
        "Doc_id":"ASCO_79370-102",
        "Doc_title":" Presentation of early-stage non-small cell lung cancer (NSCLC) without radiographic screening",
        "_version_":1606189016295669760},
      {
        "Meeting_name":" Exosomes isolation and characterization in non small cell lung carcinoma patients",
        "Background":"['Background', '  The liquid biopsy is a noninvasive tool that could change the vision of diagnostic, prognostic and predictive analysis in oncology. In the liquid biopsy potential blood-based biomarkers such as exosomes could be determinate. These biological nanovescicles (40-100 nm) are involved in regulation of tumor progression and it was demonstrated that they transport miRNAs. miRNAs are shown to be key regulators of many biological processes and promising disease biomarkers. The main aim of this study is to investigate whether exosomes isolation from clinical samples (fresh plasma from NSCLC pts) is feasible. Furthermore we have investigated selected exosome miRNAs known to be related with NSCLC.  Methods', '  A total of 12 patients with NSCLC (adenocarcinoma) were included in this pilot project, after obtaining the informed consent. Exosomes were isolated from fresh plasma by means of both Density-Gradient centrifugation and commercial isolation kit and characterized through Western-Blot (WB), NanoSight and Trasmission Electron Microscopy (TEM) analysis. The expression of selected miRNAs was performed through Real-Time PCR; miR-1228 was used as endogenous control and the fold change was calculated according the formula 2-Cq.  Results', '  Exosomesof all samples are characterized through WB analysis for ALIX and TSG-101, known as exosome markers, and by NanoSight and TEM analysis where all samples contains particles of size between 40-100nm. Interestingly, miR-30b and -30c are up-regulated in all samples, except for one patient (adenosquamous carcinoma with a predominance of squamous cell carcinoma) in which miR-30c is down-regulated. This result might indicate that miR-30c could be related to squamous histology. In our series we have one EGFR-positive sample (exon19 deletion) that show the highest expression of miR30b, -30c, -103, -195, -221, -222. This is partially in concordance with the results from Garofalo et al., which mir-30b, -30c, -221 and -222 are regulated by EGFR and MET receptor.  Conclusions', '    With this pilot study we have demonstrated that exosome analysis and exosomal miRNAs profiling is feasible in NSCLC this might be a noninvasive test for follow up, response and resistance to therapy.']",
        "Doc_id":"ASCO_147899-156",
        "Doc_title":" Exosomes isolation and characterization in non small cell lung carcinoma patients",
        "_version_":1606189030235439105},
      {
        "Meeting_name":" First-line crizotinib versus pemetrexedcisplatin or pemetrexedcarboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '  The efficacy of the oral ALK inhibitor crizotinib as 1st-line treatment for advanced ALK-positive NSCLC compared with standard chemotherapy is unknown. A multicenter, randomized open-label phase III study was conducted to compare the efficacy and safety of crizotinib vs. pemetrexedplatinum chemotherapy (PPC) in this setting.  Methods', '  Between Jan 2011 and Jul 2013, 343 pts with previously untreated advanced non-squamous ALK-positive NSCLC were randomized 1', '1 to receive crizotinib 250 mg PO BID (n=172) or PPC (pemetrexed 500 mg/m2 + either cisplatin 75 mg/m2 or carboplatin AUC 56; all IV q3w for 6 cycles; n=171). Continuation of/crossover to crizotinib after PD (per independent radiologic review) was allowed for pts randomized to crizotinib or PPC, respectively. The primary endpoint was PFS. Secondary endpoints included ORR, OS, safety, and pt-reported outcomes.  Results', ' Proportions of pts in the crizotinib and PPC treatment groups with each stratification factor were 45% and 47% Asians, 94% and 95% with ECOG PS 0/1, and 26% and 28% with previously treated brain metastases, respectively. The study met its primary objective, demonstrating superiority of crizotinib over PPC in prolonging PFS (median 10.9 vs. 7.0 mo; HR', ' 0.454; 95% CI', ' 0.3460.596; P<0.0001). The ORR was significantly higher with crizotinib (74% vs. 45%; P<0.0001). With 68% of pts still in follow-up, a statistically significant improvement in OS was not demonstrated (HR', ' 0.821; 95% CI', ' 0.5361.255; P=0.1804). At time of data cut-off 109 pts on PPC had crossed over to crizotinib. AEs with crizotinib and PPC were consistent with those previously reported in patients with advanced ALK-positive or unselected NSCLC, respectively. The most common all-causality AEs with crizotinib were vision disorder and GI symptoms.  Conclusions', ' First-line crizotinib treatment showed significant improvements in PFS and ORR compared with standard chemotherapy and had an acceptable safety profile. These findings establish crizotinib as the standard of care for pts with previously untreated advanced ALK-positive non-squamous NSCLC. Clinical trial information', ' 2010-021336-33.']",
        "Doc_id":"ASCO_129938-144",
        "Doc_title":" First-line crizotinib versus pemetrexedcisplatin or pemetrexedcarboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC)",
        "_version_":1606189040139239424},
      {
        "Meeting_name":" Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.",
        "Background":"['Background', '  The nanoparticle albumin-bound formulation of paclitaxel, nab-paclitaxel, reaches the tumor microenvironment more efficiently than conventional formulations via caveolae-mediated transcytosis, and is preferentially taken up by cancer cells. In clinical and preclinical studies, nab-paclitaxel was efficacious and safe in metastatic breast cancer and in various other solid tumor types, including non-small cell lung cancer (NSCLC). This phase III trial compared the efficacy and safety of nab-paclitaxel plus carboplatin (nab-PC) vs paclitaxel plus carboplatin (PC) in advanced NSCLC.  Methods', '  First-line stage IIIB or IV NSCLC patients (ECOG 0/1) were randomized to receive carboplatin AUC6 q3w and either nab-paclitaxel 100 mg/m2 qw w/o premedication (n = 521) or paclitaxel 200 mg/m2 q3w with premedication (n = 531). Primary endpoint was overall response rate (ORR) by independent radiologic review. The main secondary endpoints included progression-free survival (PFS), overall survival, and safety.  Results', '  Baseline and histologic characteristics were well balanced between arms. nab-PC produced higher ORR compared with PC (33 vs 25%, P = 0.005). Age (75 vs <75 years old), smoking status, and geographic location did not effect primary efficacy outcome. Particularly, ORR was 34 vs 26% in Russia/Ukraine, 35 vs 27% in Asia/Pacific, and 25 vs 20% in North America/Australia, respectively. nab-PC was well tolerated, with significantly improved safety profile vs PC despite 30% higher mean total paclitaxel dose delivered (1514 vs 1169 mg/m2). Of the statistically significant grade 3 adverse events, neutropenia, neuropathy, myalgia, and arthralgia were lower in the nab-PC arm, and thrombocytopenia and anemia were lower in the PC arm. Interim PFS analysis with 47% events revealed no significant differences between the 2 arms. Final survival data with 70% patients with an event will be presented at ASCO.  Conclusions', '  The primary endpoint was met, with significantly improved ORR. Interim PFS did not show a difference between the arms. nab-PC is efficacious and safe as first-line therapy for advanced NSCLC.']",
        "Doc_id":"ASCO_83839-102",
        "Doc_title":" Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.",
        "_version_":1606189040517775360},
      {
        "Meeting_name":" Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC).",
        "Background":"['Background', ' MEK inhibitors have limited success in cancer treatment because tumors circumvent their action. Here, we report broad proteomic analysis of NSCLC cell lines after treatment with the allosteric MEK1/2 inhibitor BAY86-9766. Methods', ' We treated 109 NSCLC cell lines with BAY86-9766. Proteomic analysis for total and phospho-proteins was performed by reverse phase protein array. Results', ' BAY86-9766 was effective at reducing pERK ( < 0.001) but this modulation was not significantly different between sensitive and resistant cell lines (P = 0.64). MEK inhibition induced expression and activation of receptor tyrosine kinases (RTK) including pEGFR, pHER2, pMET, pAXL, EGFR, VEGFR2, MET, KIT, IGF1R, and AXL (all < 0.001). This suggests a dominant negative feedback effect of the MAPK pathway on RTKs that is relieved upon MEK inhibition. MEK-ERK signaling is known to enhance stability of c-MYC. Moreover, c-MYC has been shown to be a negative regulator of RTKs transcription. Indeed, BAY86-9766 caused a decrease in c-MYC ( < 0.001) and phospho-c-MYC ( < 0.001) providing a potential explanation for the observed activation of RTKs in MEK-inhibitor treated NSCLC cells. The PI3K pathway was also activated in response to MEK inhibition with increased levels of pAKT(S473), pAKT(T308), AKT, and PI3K P110 as well as the AKT target GSK3 (all P < 0.02). In line with this, PTEN knockdown promoted MEKi resistance while overexpression increased MEKi sensitivity in vitro. MEK inhibition resulted in a dramatic increase in the expression of DNA damage response proteins; pATM(S1981), pATR(S428), pCHK1(s345), ATM, RAD50, RAD25, PARP, ERCC1, XRCC, BRCA1, MSH2, and KU80 (all P < 0.01). MEK inhibition led to decreased pLKB1(S428) ( < 0.001), increased total LKB1 ( < 0.001), pAMPK(T172) (P = 0.017), and AMPK ( < 0.001) indicating activation of LKB1-AMPK pathway in response to MEK inhibition. Conclusions', ' Our data uncovers a burst of signaling in several oncogenic pathways upon MEK inhibition. Taken together, this preclinical data help defining mechanisms of MEK inhibition resistance allowing rational design of combination therapies for NSCLC.']",
        "Doc_id":"ASCO_171488-176",
        "Doc_title":" Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC).",
        "_version_":1606189042167185408},
      {
        "Meeting_name":" Cytokine signaling through the JAK2/STAT3 pathway is a viable therapeutic target in non-small cell lung cancer",
        "Background":"['The emergence of molecular methods for classifying solid tumors based upon specific driver mutations has made rationally-designed chemotherapy possible in a variety of cancers. Non-small cell lung carcinoma (NSCLC) is a prototypical example of these clinical advances, and is routinely treated with targeted kinase inhibitors including erlotinib and gefitinib. Despite the success of this approach, drug resistance continues to be a significant problem in patients with advanced NSCLC. Constitutive activation of STAT3 is a common feature in non-small cell lung carcinoma (NSCLC), and has been proposed to play an important role in tumor cell resistance to conventional and targeted small-molecule therapies. Previous studies have suggested that STAT3 can be activated in NSCLC by hyperactive growth factor receptors or cytokine signaling, though the interplay between STAT3 activation and other well-characterized oncogenic driver mutations in NSCLC has not been fully characterized. We analyzed the activation status of key growth factor signaling pathways in seven NSCLC lines with four distinct classes of driver mutations, including activating mutations to KRAS and several receptor tyrosine kinases (EGFR, MET, PDGFRA). Targeted pharmacologic inhibitors were used to evaluate the relative contribution of each oncogene to signaling pathway activation. While common downstream effectors such as ERK, AKT, mTOR were repressed by these drugs, we observed that STAT3 remained activated in all seven cell lines independent of mutational subtype. However, pharmacologic or genetic inhibition of the gp130/Janus kinase (JAK2) signaling pathway uniformly disrupted STAT3 activation. Interestingly, only 3/7 lines produced significant levels of the cytokine interleukin-6 (IL-6), which was previously suggested to be the key mediator of gp130/JAK2 signaling in NSCLC. Gene expression and ELISA analysis of other IL-6 family ligands suggests that cardiotrophin-like cytokine factor-1 (CLCF1) may be responsible for pathway activation in the other four cell lines lacking IL-6. At the functional level, treatment of cells with the JAK1/2 inhibitor ruxolitinib had little effect on proliferation and viability in two-dimensional culture, though it inhibited anchorage-independent growth of NSCLC cells in soft agar. Ruxolitinib also slowed growth of xenografted NSCLC cells, indicating that JAK2 activity is required for optimal growth of lung tumors in vivo. Together these results demonstrate that JAK2/STAT3 signaling operates independent of known driver mutations in NSCLC and may play a key role in growth and/or progression of lung tumors. We suggest that addition of a JAK2 inhibitor to therapies which target commonly altered oncogenes such as KRAS or EGFR will improve clinical outcomes for NSCLC patients.']",
        "Doc_id":"AACR_2012-168",
        "Doc_title":" Cytokine signaling through the JAK2/STAT3 pathway is a viable therapeutic target in non-small cell lung cancer",
        "_version_":1606189019667890176},
      {
        "Meeting_name":" A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' B when added to chemotherapy, and E alone, each lead to improved survival in the treatment of patients (pts) with NSCLC (Sandler et al, NEJM 2006, 355', '2542-2550; Shepherd et al, NEJM 2005, 353', '123-132). Pre-clinical and clinical data (Herbst, J Clin Oncol 2007, 25', ' 4743-4750) suggest that the combination of B and E may improve the efficacy of NSCLC treatment. This potential was demonstrated in the BETA (B in combination with E compared with E alone for treatment of advanced NSCLC after failure of standard first-line chemotherapy) trial, a phase III trial in which progression free survival (PFS) was improved for patients treated with B + E (Hainsworth, Thoracic Oncol 2008, 3(11) Supp. 4', 'S302). Methods', ' The ATLAS study was designed to evaluate B + E (150 mg daily) versus B alone, following B + platin-containing doublet chemotherapy, in pts with stage IIIb/IV NSCLC. Enrolled pts were B-eligible, including pts with treated brain metastases, and pts anticoagulated with low molecular weight heparin(s). Pts with peripheral and/or extra-thoracic squamous tumors were also eligible. Pts received 4 cycles of B (15 mg/kg every 3 weeks) with chemotherapy. Pts who had not experienced disease progression (DP) or significant toxicity were then randomized to receive B + E or B + placebo (P). The primary objective of ATLAS was to compare PFS in pts receiving B + E versus B + placebo. Secondary objectives included the assessment of safety, and overall survival. A data safety monitoring committee (DSMC) monitored safety and efficacy. Results', ' 1,160 patients were enrolled and 768 randomized from May 2005 to May 2008. The DSMC recommended stopping the trial at the second planned interim efficacy analysis, because it met the primary endpoint. The median PFS after randomization was 4.8 mos for (B + E) vs. 3.7 mos for (B + P), HR= 0.722 (95% CI', ' 0.592-0.881), p = 0.0012. The safety profile for B + E was consistent with known profiles for B and E. Conclusions', ' E added to B treatment after chemotherapy with B significantly improves the PFS of patients treated in the first-line setting for locally advanced, recurrent, or metastatic NSCLC.']",
        "Doc_id":"ASCO_30819-65",
        "Doc_title":" A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).",
        "_version_":1606188971146084352},
      {
        "Meeting_name":" Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Platinum-based doublet therapy in NSCLC, regardless of the combination used, reached a therapeutic plateau. PC produced 15-25% overall response (ORR, Kelly 2001; Sandler 2006; Schiller 2002). Albumin-bound paclitaxel, nab-P, utilizes the albumin receptor (gp60)/caveolin-1 (CAV1) pathway achieving high intratumoral paclitaxel accumulation (Desai 2006), which may have contributed to a 48% ORR observed with nab-PC in NSCLC (Stroyakovsky, 2009). This phase III trial studied the efficacy of nab-PC vs. PC in advanced NSCLC of all histologic types. Methods', ' First-line stage IIIB or IV NSCLC pts (ECOG 0/1) were randomized to C AUC6 q3w and either nab-P 100 mg/m2 qw w/o premed (n = 521) or P 200 mg/m2 q3w with premed (n = 531). Primary endpoint', ' ORR by independent radiologic review (IRR). Results', ' Baseline and histologic characteristics were well balanced. Dose intensity of paclitaxel was higher in nab-PC vs. PC (82 vs. 65 mg/m2/wk). nab-PC was superior to PC both by IRR (33 vs. 25%, p=0.005), a 31% improvement (1.31 response ratio [RR], 95% CI', ' 1.08, 1.59), and by investigator review (37 vs. 30%, p=0.008), a 26% improvement (1.26 RR, CI', ' 1.06, 1.50). Histologic analysis showed significantly improved ORR for nab-PC (n = 228) vs. PC (n = 221) in squamous cell carcinoma (SQC) pts (41 vs. 24%, p<0.001, IRR), a 67% improvement (1.67 RR, CI', ' 1.26, 2.21). nab-PC was as effective as PC in nonSQC pts (ORR 26 vs. 25%). nab-PC was well tolerated, with significantly improved safety profile vs. PC despite higher paclitaxel dose delivered (1,338 vs. 1,100 mg/m2). Conclusions', ' The primary endpoint was met, with significantly improved ORR and safety profile of nab-PC vs. PC as first-line therapy for advanced NSCLC. nab-PC was highly active in the SQC subset, which may in part be attributed to the aberrant CAV1 overexpression in SQC (Yoo 2003) and the high intratumoral accumulation of nab-P via the gp60-CAV1 pathway. Statistically significant eventsnab-PCn = 514PCn = 524P valueG 3 Nonhemat, n (%)Neuropathy MyalgiaArthralgia15 (3)1 (<1)056 (11)10 (2)8 (2)<0.0010.0110.008G 4 Hemat, n (%) Neutropenia Thrombocytopenia Anemia49 (11)23 (5)21 (5)98 (22)5 (1)4 (1)<0.0010.0010.001']",
        "Doc_id":"ASCO_52889-74",
        "Doc_title":" Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188975529132032},
      {
        "Meeting_name":" Early detection of lung-cancer in a community screening program using low-dose computer tomographic scanning.",
        "Background":"['Background', ' Lung cancers high mortality rate and often advanced staging at diagnosis has motivated the field of medicine to devise an appropriate screening tool to help combat its aggressive nature. The landmark National Lung Screening Trial (NLST) found using Low-Dose CT (LDCT) as a screening tool reduces mortality in lung cancer patients (N Engl J Med 2011;365', '395-409). Northwest Arkansass Lung Cancer Screening Program (LCSP) initiated LDCT screenings based on the findings of the NLST. Methods', ' From March of 2013 to January 2016, the LCSP screened 1,791 individuals. Their primary care physicians referred patients to the program. If they met certain high-risk criteria they underwent LDCT and multidisciplinary evaluation. High-risk category 1 (CAT1) were at least 55 years old, had at least a 30 pack-year smoking history. If they had quit smoking, it was within the last 15 years. High risk category 2 (CAT2) patients were greater than 50 years old with a more than 20 pack-year smoking history and one of the following risk factors', ' second hand smoke exposure, radon exposure, occupational exposure, cancer history, family history of lung cancer, or lung disease history, and not in CAT1. Results', ' The adherence rate of screening was above 99%. Of 1,791 participants screened, cancers were diagnosed in 46 patients, 2 of which had 2 cancers. There were 25 patients who had stage Ia non-small cell lung cancer (NSCLC). CAT1 patients comprised the majority of the cancer diagnoses finding 46 cancers in 44 patients while only 2 cancers were diagnosed in CAT2 patients. Of these 48 cancers, 11 were cancers other than NSCLCs. Overall, stage Ia cancers comprised 67.6% of the NSCLCs diagnosed (37 NSCLC total). The NSCLC incidence rate along with similar data from the NLST can be seen in table 1. Conclusions', ' Screening with LDCT resulted in earlier detection of lung cancer at diagnosis and the LCSP provides a template for screening in a community setting using a multidisciplinary approach. Incidence rates in the LCSP exceeded the NLST for CAT 1 patients. CAT2 had a low rate of positive screening. Incidence rate for lung cancer detection (per 100,000 person-years).LCSPNLST (using LDCT)Overall730645CAT1914645CAT289N/A']",
        "Doc_id":"ASCO_167238-176",
        "Doc_title":" Early detection of lung-cancer in a community screening program using low-dose computer tomographic scanning.",
        "_version_":1606188982729703424},
      {
        "Meeting_name":" DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.",
        "Background":"['Background', ' Carcinoma of unknown primary (CUP) has a poor prognosis and accounts for diagnoses in > 30,000 patients annually in the United States. Current tissue of origin (TOO) methods use protein or RNA-based expression signatures, are costly, and often provide little clinically relevant information. We previously showed that use of comprehensive genomic profiling (CGP) identifies a clinically relevant genomic alteration in 96% of CUPs. We hypothesized that CGP could also potentially identify a TOO for some CUP patients, further refining potential targeted therapeutic options. Methods', ' DNA alterations from 44,065 samples that underwent CGP as part of standard clinical care were classified using logistic regression based on mutational profiles and select clinical features. Results', ' We first trained a logistic regression classifier to identify non-small cell lung cancers (NSCLC) with alterations in EGFR, ERBB2, BRAF, MET, KRAS, ALK, RET, or ROS1 (lung gene set). In cross-validation, the classifier correctly identified 79% of NSCLCs (92% of EGFR mutant samples) and 93% of non-NSCLCs. When applied to a set of 1352 CUPs with an alteration in the lung gene set, 425 (31%) were predicted to be NSCLC. We next trained a classifier to distinguish BRAF V600-mutant colorectal cancers (CRCs) from other BRAF V600-mutant cancers. The classifier correctly identified 90% of CRCs and 93% of non-CRC. Use of this classifier with a BRAF-mutant CUP data set predicted 32/87 (37%) of BRAF-mutant CUP tumors to be CRC. Conclusions', ' In a large series of CUP patients with alterations in the lung gene set, one-third were likely NSCLC, and could potentially benefit from approved targeted therapies in this disease. When applied to BRAF V600-mutant CUPs, 37% were predicted to be CRC, and therefore single agent vemurafenib therapy is unlikely to be effective and combination therapy indicated. This approach is useful for identifying targeted therapeutics likely to be effective based on molecular match and TOO. We plan to extend this DNA-based tool to 4 additional tumor types. Application of this classifier to CUPs may help identify therapeutic strategies from CGP without the need for additional material or testing.']",
        "Doc_id":"ASCO_168528-176",
        "Doc_title":" DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.",
        "_version_":1606188993074954240},
      {
        "Meeting_name":" Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Tissue biopsy is the gold standard for detection of genomic alterations (GA) and selection of matched targeted therapies in NSCLC, but ctDNA assay provides a possible complementary approach for some pts. Methods', ' Hybrid-capture based genomic profiling of 62 genes using a ctDNA assay (FoundationACT) was performed on blood samples from 1,019 consecutive NSCLC pts. The fraction of ctDNA in the blood was estimated using the maximum somatic allele frequency (MSAF) for each sample. Results', ' Pt characteristics', ' Median age 69 years (range 8-94); 54% were female. Histologies included adenocarcinoma (n = 720), NSCLC not otherwise specified (NSCLC NOS; n = 179), squamous cell (n = 57), LC NOS (n = 51), large cell (n = 6), and sarcomatoid (n = 6). 1 reportable GA was detected in 71% of all cases and in 83% of cases with evidence of ctDNA in the blood (MSAF > 0). For 22 pts with paired blood and tissue samples collected within 30 days and MSAF > 0, 33/64 (52%) GA detected in tissue were also detected in ctDNA. In 55 pts for whom tissue was insufficient for analysis, 1 GA was detected in ctDNA in 43 (78%) cases. For 856 cases with MSAF > 0, an average of 1.8 GA/sample were reported. GA were most frequently detected in TP53 (57%), EGFR (23%) and KRAS (17%). Comparative analysis with the tissue-based FoundationCORE database (n = 19,264) showed similar frequencies of GA per gene, although KRAS mutation was more frequent in tissue than ctDNA (27% vs 17%, P < 0.0001), and EGFR T790M was more frequent in ctDNA than tissue (7% vs 2%, P < 0.0001), likely reflecting use of liquid versus tissue biopsy after relapse on targeted therapy.Kinase fusions (ALK, ROS1, RET, FGFR3, PDGFRA) were identified in 5% (39/856) of cases. Diverse and novel mechanisms of acquired resistance (AR) were detected in ctDNA including MET Y1230C and EGFR amplification post-crizotinib, FGFR3-TACC3 fusion post-EGFR inhibitor, and multiple EGFRAR mutations post-osimertinib. Conclusions', ' In this series, use of a rigorously validated capture-based assay revealed evidence of ctDNA in the blood in 84% of cases. Our results provide clinical support for use of this assay as a complementary technology to tissue-based genomic testing in a subset of pts with NSCLC.']",
        "Doc_id":"ASCO_187245-199",
        "Doc_title":" Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188994219999232},
      {
        "Meeting_name":" Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases",
        "Background":"['Background', ' Brain metastases (BrMs) occur in  25% of patients (pts) with NSCLC. Sunitinib (SU) is an oral, multitargeted inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and RET that has single-agent antitumor activity in refractory NSCLC. Final data are presented from this phase II study that assessed the efficacy and safety of SU in NSCLC pts with previously irradiated BrMs. Methods', ' Pts with NSCLC  18 years of age who had received whole brain radiation therapy for BrMs and  2 prior systemic therapies received SU at a starting dose of 37.5 mg with continuous daily dosing (CDD) in 4-week cycles. The primary endpoint was PFS. Antitumor efficacy was based on overall (RECIST) and intracranial (WHO criteria) tumor assessments. Intracranial disease was assessed by MRI. Safety was assessed by monitoring AEs and focused on neurologic status. Results', ' Sixty-four pts received SU for a median of 2 cycles (range', ' 1-13). Pts (male/female', ' 61%/39%; median age 61 yrs, range', ' 35-77) had a good performance status (ECOG 0/1, n = 63; ECOG 2, n = 1), and most had adenocarcinoma (n = 40, 63%) or squamous cell carcinoma (n = 12, 19%). Most received prior systemic therapy (n = 53, 83%). Stable disease was reported in 16 (27%) of 60 pts via RECIST and in 6 (26%) of 23 pts with measurable BrMs via WHO; one pt (4%) had an intracranial PR. Median PFS was 9.4 weeks (95% CI', ' 7.5, 13.4). Median OS was 26.0 weeks (95% CI', ' 13.4, 38.1). Dose reductions to 25 mg occurred in 25% pts. Most frequent grade (G) 3/4 AEs were dyspnea (n = 6, 9%) and fatigue (n = 5, 8%). Serious neurologic AEs occurred in 6 pts (9%)', ' epilepsy (n = 2) and convulsion, cerebral ischemia, intentional self injury and tremor (all n = 1). Six pts had peripheral neuropathy (G1/2 n = 4; G3 n = 2) and one pt had G4 mental impairment. ICH was not reported. G3/4 hematologic abnormalities included lymphopenia (n = 12) and neutropenia (n = 8). Conclusions', ' This phase II study reveals that treatment with SU on a CDD schedule is manageable in NSCLC pts with BrMs. No cases of ICH were reported. Preliminary efficacy assessments of the complete data set indicate that the primary endpoint (PFS > 10 weeks) was not met in these heavily pretreated pts.']",
        "Doc_id":"ASCO_43394-74",
        "Doc_title":" Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases",
        "_version_":1606189023752093696},
      {
        "Meeting_name":" Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' There are only limited data regarding the use of anti-VEGF therapy in recurrent NSCLC and no data in NSCLC pts previously treated with bevacizumab. We are currently conducting a phase II trial evaluating cediranib, an oral inhibitor of VEGFR 1,2 and 3, and pemetrexed in recurrent NSCLC pts who may or may not have previously received bevacizumab. Methods', ' Pts with progressive and measurable NSCLC, 1 or 2 prior regimens, PS0-2, all histologic sub-types, BP  140/90, treated brain metastases are eligible. Pts on anti-coagulants are allowed. Pts with hemorrhage within 4 weeks are excluded. Pts start on cediranib 30mg daily followed 7 days later by pemetrexed at 500 mg/m2 every 21 days and cediranib daily. The study consists of two cohorts- cohort A (no prior bevacizumab) and cohort B (prior bevacizumab). Planned accrual is 37 pts each cohort. Consenting pts will undergo FLT PET scans and blood draw for circulating tumor cells before therapy, 1 week after cediranib, and after 1 cycle of the combination. Results', ' 33 pts have started therapy, (Cohort A- 20, Cohort B- 13), median age- 60, males- 56%, ever smokers- 88%, adenocarcinoma- 64%, squamous- 12%, brain mets- 27%, 1 prior regimen- 52%, PS0-1- 88%. Median cycles- 4 (range- 0-15). Grade 3/4 toxicities- neutropenia- 7pts, febrile neutropenia- 1pt, fatigue-7pts, diarrhea- 3pts, hypertension- 1pt, anorexia- 2pts, cardiac ischemia- 1pt, bronchopleural fistula- 1pt, esophagitis- 1pt. No major hemorrhage. Of the 17 pts who received cediranib for  4 cycles, 71% required dose reduction and of the 18 pts who received pemetrexed for  4 cycles, 22% required dose reduction. 31 pts (Cohort A- 19, Cohort B- 12) are response evaluable. Confirmed response rate is 16%(90% CI- 0.08-0.30) (Cohort A- 10%, Cohort B- 25%) and disease control rate (response+stable disease) is 71% (90% CI-0.56-0.82) (Cohort A- 74%, Cohort B- 67%). 8 of 9 pts who had FLT PET scans had a 20% or greater decline in standard uptake value after 1 week of cediranib alone. Conclusions', ' Cediranib and pemetrexed combination is tolerable. Efficacy has been observed with the combination in recurrent NSCLC pts, including those previously treated with bevacizumab. Accrual to this trial is ongoing.']",
        "Doc_id":"ASCO_30831-65",
        "Doc_title":" Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).",
        "_version_":1606189024757678080},
      {
        "Meeting_name":" First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  KRAS WT colorectal cancer (CRC) is responsive to the EGFR inhibitors panitumumab (P) and cetuximab. Phase III data suggest a small, but statistically significant overall survival (OS) advantage with cetuximab + chemotherapy in KRAS unselected NSCLC (Pirker, Lancet 2009); and phase I data suggest P alone has activity in non-CRC tumors including NSCLC (Weiner, Clin Ca Res. 2008). This single-arm phase II trial examined the safety and efficacy of P in combination with carboplatin (C) and pemetrexed (Pem) in patients (pts) with advanced non-squamous KRAS WT NSCLC. The addition of P was hypothesized to improve the median time-to-progression (TTP) from 3.6 months (mos) (historical) to 5.4 mos (1-sided  .10, 80% power).  Methods', '  Pts with previously untreated, unresectable stage IIIB/IV non squamous KRAS WT NSCLC received P 9 mg/kg, Pem 500 mg/m2, and C AUC=6 IV day 1 every 21 days for 6 cycles, followed by P and Pem maintenance every 21 days until progressive disease or unacceptable toxicity. Responses were evaluated every 2 cycles per RECIST 1.1. KRAS mutation testing was performed centrally (DxS kit). Tissue was also collected for EGFR FISH testing.  Results', '  60 pts were enrolled; median age, 65 years; 58% female, ECOG PS 0-1 (98%), and prior adjuvant chemotherapy (10%). Median number of cycles was 5 (range 1-22). At a median follow-up of 8.7 mos, the median TTP was 6.2 mos (95% CI', ' 3.7, 9.5), PFS 6.2 mos (95% CI 3.0, 9.0), 1 year OS 65.5% (95% CI 44.8%, 80%). 23 pts (38%) had partial responses (PR); the disease control rate (PR + proportion with stable disease) was 68%. Treatment-related toxicity (TRT) included (all grades) nausea (38%), fatigue (30%), rash (30%), and mucositis (23%). Severe (grade 3/4) TRT in > 2 pts included', ' thrombocytopenia (11%), neutropenia (7%), and dehydration (5%). There were no treatment-related deaths. EGFR mutation and FISH analyses will be presented.  Conclusions', '  The addition of panitumumab to carboplatin and pemetrexed in the first-line treatment of advanced KRAS WT NSCLC was safe and well-tolerated; the median TTP of 6.2 mos met the primary endpoint. Definitive assessment of the value of panitumumab in this setting requires a randomized trial. Clinical trial information', ' NCT01042288.']",
        "Doc_id":"ASCO_112375-132",
        "Doc_title":" First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC).",
        "_version_":1606189040579641344},
      {
        "Meeting_name":" IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.",
        "Background":"['NSCLC accounts for approximately 85% of all lung cancers. Based on tumor histology, NSCLC can be subdivided into adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC), which account for 40%, 25-30% and 10-15% of NSCLC cases, respectively. In a fraction of AC cases, driver oncogenes have been identified that enable effective treatment with targeted therapies. For most NSCLC cases, however, etiology is still unknown and effective targeted therapies have yet to be achieved. Additionally, even cancers that initially respond to targeted therapies eventually develop resistance, creating the need for other therapeutic approaches.EGFR is one of the best characterized driver oncogenes in NSCLC and also is frequently expressed at high levels in this indication. In house immunohistochemical analysis found EGFR to be highly expressed in 23.8% of AC (n = 21), 60% of SCC (n = 10) and 50% of LCC (n = 8), confirming published data that EGFR represents an attractive therapeutic target for NSCLC. As a novel approach to targeting EGFR-expressing tumors, we have developed IMGN289, an antibody-drug conjugate (ADC) consisting of the J2898A antibody (Ab), which selectively binds to EGFR and inhibits EGFR-driven tumor cell growth, conjugated to the maytansinoid DM1, a potent anti-microtubule agent, via the SMCC thioether linker. IMGN289 showed significantly enhanced cytotoxic activity, relative to cetuximab or unconjugated J2898A, against a panel of NSCLC cell lines dependent on EGFR signaling. In vitro, anti-EGFR Abs typically inhibit less than 70% of tumor cell growth at 30 nM concentration, whereas IMGN289 exposure approached 100% inhibition at a significantly lower concentration. Enhanced potency of IMGN289 against EGFR-dependent tumors was demonstrated in vivo in the H292 xenograft tumor model, where the minimally effective doses of IMGN289 and its J2898A Ab were 1 and 3 mg/kg, respectively. In addition, IMGN289 was effective against EGFR-expressing NSCLC cells that are not dependent on EGFR signaling and therefore resistant to anti-EGFR Abs. For example, IMGN289 was active against H226 and H1703 mesenchymal cell lines in vitro and H1703 xenograft tumor in vivo, while neither cetuximab nor J2898A alone was active. IMGN289 was also active against EGFR mutant HCC827 cell lines that have acquired resistance to EGFR tyrosine kinase inhibitors through T790M EGFR mutation or MET gene amplification. Thus, EGFR-targeting IMGN289 achieves a distinct anti-tumor mechanism that is independent of EGFR pathway inhibition.In summary, IMGN289 is highly active against EGFR-positive NSCLC cells regardless of dependency on the EGFR pathway and represents a promising therapeutic candidate for NSCLC.']",
        "Doc_id":"AACR_2013-5467",
        "Doc_title":" IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.",
        "_version_":1606189018683277312},
      {
        "Meeting_name":" Inhibition of non small-cell lung cancer by stress reduction",
        "Background":"['Non small-cell lung cancer (NSCLC) is the leading type of lung cancer with a poor prognosis. Smoking is a risk factor but NSCLC develops in a significant number of nonsmokers. We have reported that social stress significantly promoted the growth of NSCLC xenografts, a response mediated by multiple cAMP-driven signaling cascades downstream of Gi-coupled beta-adrenergic receptors activated by the stress neurotransmitters norepinephrine and epinephrine and reversed by -aminobutyric acid (GABA) via Gi-coupled GABA-B-receptor signaling. In addition, improved clinical outcomes in NSCLC patients with incidental beta-blocker therapy have been reported. These findings suggest that psychological stress with the associated increase in systemic stress neurotransmitter levels and suppression of physiological agonists for Gi-coupled receptors may significantly contribute to the high incidence and poor therapeutic response of NSCLC. On the other hand, these findings suggest that stress reduction may have significant inhibitory effects on NSCLC. To test this hypothesis, we achieved stress reduction in athymic nude mice by maintaining the animals in larger cages and by providing them with several enrichment items, resulting in reduced systemic levels of corticosterone, norepinephrine and epinephrine while the levels of GABA and the physiological agonists for Gi-coupled opioid receptors, dynorphin A and B and met-enkephalin increased. We found that stress reduction significantly inhibited the establishment of xenografts and significantly reduced xenograft sizes. Xenografts in the stress reduction group expressed lower levels of cAMP, VEGF and sonic hedgehog (SHH) accompanied by reduced protein expression of p-ERK, p-AKT, p-CREB, p-SRc and Gli1 while cleaved caspase-3 and p53 proteins were induced. Based on the observed reduction of the cancer stem cell markers SHH and Gli1 in xenograft tissues, we conducted additional mechanistic experiments with cancer stem cells enriched from three NSCLC cell lines under selective sphere formation conditions over 21 days with subcultures every seven days. We found that epinephrine significantly increased stem cell self renewal associated with increased intracellular cAMP, increased levels of the stem cell markers SHH and aldehyde dehydrogenase-1 and increased expression of Gli1. Simultaneous treatment of the enriched cancer stem cells with GABA or dynorphin B completely reversed all of these effects. We conclude that stress reduction can act as a powerful inhibitor of NSCLC by restoring cAMP homeostasis and should be incorporated as important component into existing NSCLC prevention and therapy protocols to improve clinical outcomes.Supported in part by 5RC1CA144640 and State of Tennessee Center of Excellence for Human and Livestock Disease']",
        "Doc_id":"AACR_2015-3729",
        "Doc_title":" Inhibition of non small-cell lung cancer by stress reduction",
        "_version_":1606189032484634624},
      {
        "Meeting_name":" Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutationpositive non-small cell lung cancer (NSCLC) patients.",
        "Background":"['Background', '    Activating BRAF V600E mutations in NSCLC are present in < 2% of tumors, primarily adenocarcinoma. The BRAF inhibitor dabrafenib has demonstrated clinical activity in BRAF V600 mutationpositive melanoma. Here we report interim efficacy and safety data obtained in 17 BRAF V600Emutant NSCLC patients enrolled in dabrafenib phase II study BRF113928.   Methods', '    Single-arm, 2-stage, phase II study in stage IV BRAF V600E mutationpositive NSCLC pts who failed at least 1 line of chemotherapy. Dabrafenib dosed at 150 mg orally twice daily. The primary endpoint was investigator-assessed overall response rate (ORR) per RECIST 1.1 criteria.  Results', '    The median age of the 17 pts was 69 years (range, 51-77 years). Most pts (12/17) were male, all were white with adenocarcinoma, and 13 were former smokers. All pts had failed at least 1 line of prior anticancer therapy, and 5 subjects had failed  2. At the time of reporting, 11 pts remain on therapy, and 6 have stopped therapy (5 with PD and 1 due to an AE). Thirteen pts were evaluable for efficacy. The best response for these pts included 7 PRs (5 confirmed PRs), 1 SD, and 4 PD; 1 pt discontinued due to an SAE (hypersensitivity reaction) prior to response assessment (ORR, 54%). The median duration of treatment for all 17 pts is approximately 9 weeks (range, 1-69 weeks). Among the 5 pts with confirmed PRs, duration of response was 29 and 49 weeks for the 2 pts who progressed, while the remaining 3 pts were responding for 6+ to 24+ weeks. The safety of dabrafenib in NSCLC pts appears to be generally consistent with what has been previously observed. The most common AEs were decreased appetite, fatigue, asthenia, dyspnea, and nausea, mostly grade 1 or 2. Five pts (29%) had a grade 3 AE, and 1 pt (6%) had a grade 4 SAE (hemorrhage).  Conclusions', '    Dabrafenib shows early antitumor activity in BRAF V600E mutationpositive pretreated NSCLC pts, with an ORR of 54% and with the longest duration of response of 49 weeks thus far. Dabrafenib is generally well tolerated, and the study has met the minimum response rate ( 3 of first 20 pts) to continue into the second stage. This study represents the first clinical evidence of BRAF as a therapeutic target in NSCLC. Clinical trial information', ' NCT01336634.']",
        "Doc_id":"ASCO_112427-132",
        "Doc_title":" Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutationpositive non-small cell lung cancer (NSCLC) patients.",
        "_version_":1606188999656865792},
      {
        "Meeting_name":" Phase 2 trial of chemotherapy followed by consolidative radiation therapy for initial treatment of oligometastatic NSCLC.",
        "Background":"['Background', ' Unselected patients with stage 4 lung cancer who receive front line platinum based chemotherapy and maintenance chemotherapy have demonstrated a PFS less than 6 months with very few patients alive at 5 years. Patients with a small number of metastatic lesions may have a different biology, and aggressive local treatment of oligometastases is an active area of investigation. Methods', ' Patients were required to have stable disease or response after 3-6 cycles of platinum based chemotherapy and PS 0-2. Oligometastatic disease was defined as a maximum number of 5 metastatic lesions for all disease sites including no more than 3 active extracranial metastatic lesions. Limited mediastinal lymph node involvement was allowed. Results', ' 29 patients were enrolled between 10/2010 and 10/2015. 3 patients were excluded from analysis due to concerns regarding eligibility/treatment response. Despite closing early due to slow accrual, the study met its primary endpoint for success which was PFS greater than 6 months. The median PFS (95% CI) was 11.0 months (7.4-15.9 months) and the median OS was 22.2 months (13.3-45.7 months). The 1-year, 3-year, and 5-year OS were 73%, 35%, and 29%. Conclusions', ' Patients with oligometastatic NSCLC who received platinum based chemotherapy followed by oligometastatic consolidative radiation without maintenance chemotherapy demonstrated prolonged disease control and overall survival. Clinical trial information', ' nct01185639']",
        "Doc_id":"ASCO_193905-199",
        "Doc_title":" Phase 2 trial of chemotherapy followed by consolidative radiation therapy for initial treatment of oligometastatic NSCLC.",
        "_version_":1606188993924300800},
      {
        "Meeting_name":" Stability and stemness of the hybrid epithelial-mesenchymal phenotype.",
        "Background":"[\"Transitions between epithelial and mesenchymal phenotypes  EMT and MET  are hallmarks of cellular plasticity during embryonic development and cancer metastasis. During these transitions, cells can also adopt a hybrid epithelial/mesenchymal (hybrid E/M) phenotype enabling them to migrate collectively as observed during gastrulation, wound healing, and clusters of Circulating Tumor Cells (CTCs). The hybrid E/M phenotype has largely been tacitly assumed to be 'metastable', i.e. transient state. Here, we integrate mathematical modeling with in vitro experiments to identify certain 'phenotypic stability factors' (PSFs) - GRHL2, OVOL2 and NP63 that can stabilize a hybrid E/M phenotype. We show that H1975 (NSCLC cell line) cells can display a hybrid E/M phenotype stably and migrate collectively, a behavior that is impaired by knockdown of GRHL2 or OVOL2. Further, our computational model predicts that these PSFs can also associate hybrid E/M phenotype with high tumor-initiating potential, a prediction strengthened by the observation that the higher levels of one or more of these PSFs may predict poor patient outcome. Overall, our results suggest that a hybrid E/M phenotype need not be 'metastable', and bolster the notion that a hybrid E/M phenotype, but not necessarily full EMT, associates with aggressive tumor progression.\"]",
        "Doc_id":"AACR_2017-3053",
        "Doc_title":" Stability and stemness of the hybrid epithelial-mesenchymal phenotype.",
        "_version_":1606189021817470977},
      {
        "Meeting_name":" An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation ansamycin class of Hsp90 inhibitors and has shown superior activity to these agents in preclinical studies.  Ganetespib has been well tolerated and has shown promising antitumor activity in early trials in multiple cancers.   Methods', '  Patients (pts) with advanced NSCLC who failed prior treatments received 200 mg/m2 ganetespib as a 1-hr infusion once weekly for 3 of a 4-wk cycle in a Simon two-stage study design assessing primary endpoint of PFS rate at 16 wks.  Initial cohorts were defined by mutation status', ' A) EGFR B) KRAS C) EGFR and KRAS wild type (WT). If 2/14 pts in A, B or C were progression-free at 16 wks, enrollment increased to 23 pts for that cohort.  Tumor response was assessed every 8 wks. Cohort D was added to include 35 additional EGFR and KRAS WT pts with adenocarcinoma histology.  Additional mutational analysis of BRAF, PIK3CA, ERBB2 and MET, as well as FISH analysis for ALK translocation, were performed for Cohorts C and D.  Results', '  73 pts (31 M, 42 F; median age 62 yrs, range 28-82; ECOG 0-1; prior therapies range 1-10) received a median of 2 cycles (range 1-12) of ganetespib in cohorts A (14), B (17), and C+D (42).  AEs reported in 20% of pts included diarrhea, fatigue, nausea, anorexia, constipation, and dyspnea and were generally grade 1-2.  Expansion criteria were achieved for cohort C, including a durable partial response (PR) and seven pts with prolonged stable disease (16 wks).  Cohort D continues recruitment.  Mutational analyses of Cohort C and D samples will be presented.  Conclusions', '  Ganetespib administered as a single-agent is well-tolerated in pts with NSCLC at 200 mg/m2 once weekly without severe liver, ocular, cardiovascular or renal toxicity.  Clinical activity has been observed in pts with advanced NSCLC tumors harboring wild-type EGFR and KRAS.']",
        "Doc_id":"ASCO_82185-102",
        "Doc_title":" An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188971408228353},
      {
        "Meeting_name":" Outcomes of patients with stage III (clinical N2) NSCLC",
        "Background":"['Background', ' Management of locally advanced non-small cell lung cancer (NSCLC) lacks consensus. Also, it is unclear if outcome disparities exist according to race. We conducted a retrospective analysis of patients included in the Veterans Affairs Central Cancer Registry (VACCR) to evaluate if these disparities exist. Methods', ' Patients with clinical N2 disease and stage 3 NSCLC diagnosed between 1995 and 2003 were included. Data abstracted included age at diagnosis, gender, race, smoking history, disease stage, tumor grade, treatment received and overall survival. Outcomes were compared using multivariate Cox proportional hazards regression analysis. Results', ' Of the 7,469 patients who met the inclusion criteria, analyses were limited to 7,238 Caucasians and African-American (AA) patients. Median age of the patients was 68 years (range', ' 27-93 years). Of these, 7,218 (98.5%) were male, 6,061 (82.7%) were Caucasian and 321 (4.4%) were never smokers. Median follow-up of survivors was 9 months (range', ' <1 - 154 months). Treatment received included', ' none-1,746 (23.8%), chemotherapy-1,045 (14.3%), radiation-1,689 (23%); chemotherapy and radiation (sequential or concurrent)-2,300 (31.4%), while 548 patients (7.5%) had a surgical resection (either alone or as part of multimodality therapy). Median survival (months) of the different treatments were', ' surgery-19.3; chemotherapy and radiation-13; chemotherapy alone-9.2; radiation alone-7.3; no treatment-4 (p<0.0001). On multivariate analysis, AA had a significantly decreased risk of mortality compared to Caucasians (HR 0.92; 95% CI, 0.87-0.98, p=0.01) while adjusting for age, disease stage and treatment type. When this was further analyzed according to type of treatment, AA had decreased mortality compared to Caucasians when chemotherapy alone was given (HR 0.81; 95% CI, 0.69- 0.96, p=0.02) and a trend towards decreased mortality when no treatment was given (HR 0.88; 95% CI 0.78-1.01, p=0.06). Conclusions', ' AA had a significantly better outcome when compared to Caucasians, especially when treated with chemotherapy, suggesting possibly a better tumor biology or pharmacogenomics. Surgery should be considered in conjunction with other modalities in patients with clinical N2 NSCLC.']",
        "Doc_id":"ASCO_41145-74",
        "Doc_title":" Outcomes of patients with stage III (clinical N2) NSCLC",
        "_version_":1606188972946489344},
      {
        "Meeting_name":" Survival analysis of induction cisplatin (CDDP)-docetaxel (DOC)-bevacizumab (BEV) chemotherapy followed by maintenance BEV-pemetrexed (PEM) therapy in advanced nonsquamous non-small cell lung cancer (NonSq NSCLC)",
        "Background":"['Background', '  BEV maintenance therapy and PEM maintenance therapy in platinum-based chemotherapy yield a significant survival advantage in CALGB and PARAMUNT trials, respectively, but each agent gave only modest impact on survival. We conducted a phase II trial of CDDP-DOC-BEV therapy followed by maintenance BEV-PEM therapy inchemo-nave advanced NonSq NSCLC.  Methods', '  Forty-one patients (pts) participated in the induction phase, specified as four cycles of induction CDDP (80 mg/m2), DOC (60 mg/m2) and BEV (15 mg/kg) on day 1 of a 21-day cycle. Pts who had not progressed during CDDP-DOC-BEV received maintenance BEV (15 mg/kg) and PEM (500 mg/m2) on day 1 of a 21-day cycle until disease progression. The primary endpoint was PFS, and the secondary endpoints included OS, toxicity, and response. Survival time was calculated from the date of registration.  Results', '  Pt characteristics were as follows', ' median age', ' 62 yrs; 76% male; 32% PS 0; 73% stage IV; 93% Ad; 5% EGFR-mutant and 2% ALK-mutant. At the time of this analysis, 34 pts (83%) discontinued the treatment, mainly due to progressive disease (53%). The principal toxicity was myelosuppression (gr. 4 hematological', ' 21 pts [51%]), and grs. 3/4 febrile neutropenia was observed in 10 (24%) despite no treatment-related deaths. The objective response rate and disease control rate (DCR, % pts with CR/PR/SD) was 82.9% and 97.6%, respectively. Median follow-up time was 15.6 months, and 1-yr PFS rate was 34.2% with 95% confidence interval (CI) of 20.3-48.5%, which met the primary endpoint. Also, 1-yr OS rate was 75.6% (95%CI', ' 59.4-86.1%). Exploratory analysis for pts with both EGFR- and ALK-wild-typed NonSq NSCLC (n = 16) demonstrated 1-yr PFS and OS rates of 50.0% (24.5-71.1%) and 87.5% (58.6-96.7%), respectively. Also, pts with maintenance therapy (n = 34) had 1-yr PFS and OS rates of 41.2% (24.8-56.9%) and 82.4% (64.9-91.7%), respectively.  Conclusions', '  CDDP-DOC-BEV followed by BEV-PEM maintenance seems highly effective despite moderately toxic profiles in chemo-nave pts with advanced NonSq NSCLC. Clinical trial information', ' UMIN000004127.']",
        "Doc_id":"ASCO_114147-132",
        "Doc_title":" Survival analysis of induction cisplatin (CDDP)-docetaxel (DOC)-bevacizumab (BEV) chemotherapy followed by maintenance BEV-pemetrexed (PEM) therapy in advanced nonsquamous non-small cell lung cancer (NonSq NSCLC)",
        "_version_":1606188983262380032},
      {
        "Meeting_name":" Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Metastasis to lymph nodes (LN) connotes poor prognosis in NSCLC. Sufficient LN must be examined to accurately determine LN negativity. Patients with no LN examined (pNx) may be incompletely staged and erroneously assigned to a low risk group. To evaluate this possibility, we compared the survival of patients with node negative disease and at least 1 LN examined (pN0) to those with pNx. Methods', ' Retrospective analysis of all resections for NSCLC from January 1, 2004 to December 31, 2007 identified through a search of pathology databases at hospitals in the Memphis Metropolitan Area. Benign and metastatic disease, pre-operative chemo/radio therapy, bronchoalveolar cell, small cell lung, carcinoid tumors and repeat lung resection were excluded. Date of death was obtained from a National Death Index search. Variables were compared by chi-squared test, survival estimates calculated by Kaplan Meier analysis, survival estimates compared by log-rank test. Results', ' 746 of 809 resections met inclusion criteria. 86 (11.5%) were pNx and 510 (68.4%) pN0. Demographic and histologic characteristics were similar (Table). 55.8% of the pNx group had sublobar resection, compared to 5.7% of pN0 (p<0.0001). 179 pN0 patients (35.1%) had only hilar-intrapulmonary LN (stations 10-14), median 3 (range 1-18) examined. 46 patients (9.02%) had only mediastinal LN (stations 1-9), median 2 (1-13); 281 patients (55.1%) had both stations 10-14 and 1-9, median 7 (2-45). 85% of pN0 patients had <10 LNs examined. 3-year survival estimate for the T1NxM0 vs T1N0M0 patients was 69% vs 70% (p= 0.14); for T2NxM0 vs T2N0M0 it was 25% vs 65% (p <0.01). Conclusions', ' A high percentage of patients (11.5%) undergoing surgical resection for NSCLC had pNx. These patients were more likely to have sublobar resections. Most (85%) patients with pN0 had <10 nodes examined and a large proportion (35.1%) had no mediastinal LNs, raising the possibility of understaging. Patients with pT2NxM0 did significantly worse than those with pT2N0M0.']",
        "Doc_id":"ASCO_33123-65",
        "Doc_title":" Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC).",
        "_version_":1606188995068297216},
      {
        "Meeting_name":" Association of self-reported physical activity with survival among patients with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Patient assessment strategies are needed to individualize treatment planning for adults receiving palliative chemotherapy for NSCLC. We evaluated the utility of a cancer-specific geriatric assessment (GA) and Fried Frailty Index (FFI) to predict overall survival (OS). Methods', ' We conducted a multi-site pilot study of 50 patients (2010-14) with newly diagnosed metastatic NSCLC, age  18 years with no prior palliative chemotherapy. All subjects received carboplatin AUC 6, paclitaxel 200mg/m2every 3 weeks as initial therapy. GA and FFI were administered prior to chemotherapy. The GA includes', ' functional status (activities of daily living [ADLs], instrumental ADLs, Karnofsky performance status (KPS), Timed Up and Go (TUG), falls), self-reported comorbidity, Blessed-Orientation-Memory-Cognition (BOMC) test, social functioning and support, nutrition (weight loss, body mass index[BMI]), and polypharmacy. The FFI includes', ' weight loss, self-reported exhaustion, reported physical activity (frailty < 383Kcals/week men; < 270 Kcals/week women), walking speed, and grip strength. OS was measured from chemotherapy initiation using the Kaplan-Meier method. Cox proportional hazards models were fit to estimate the association between baseline patient characteristics and OS. Results', ' 48 subjects received chemotherapy and evaluable. The mean age was 68.5 y (range 42-86), 79% male, 85% KPS  80, mean hemoglobin 13.11.6. The median OS was 8 months. GA detected heterogeneity of baseline characteristics in multiple measures [mean (range)] including', ' IADL score 13.2 (7-14), TUG 11.4 seconds (5-22), comorbidities 2.4 (0-7), BOMC 3.6 (0-25), medications 5.9 (0-14), and BMI 26 (17-37.6). 27% met FFI criteria for frailty with  3 impairments. In multivariate analyses KPS  80 (Hazard ratio[HR] 3.6, 95% Confidence Interval [CI] 1.4, 9.3), hemoglobin (HR 1.3, 95% CI 1.1, 1.6) and low physical activity (HR 2.2, CI 95% 1.2, 4.3) were independently associated with shorter survival. Conclusions', ' Self-reported physical activity is associated with poor survival in this cohort and warrants further study as a marker of frailty among adults with advanced stage NSCLC. Clinical trial information', ' NCT01026467']",
        "Doc_id":"ASCO_171568-176",
        "Doc_title":" Association of self-reported physical activity with survival among patients with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188996211245057},
      {
        "Meeting_name":" Detection of ROS1 translocations in triple-negative lung adenocarcinomas.",
        "Background":"['Background', '  After ALK (anaplastic lymphoma kinase) rearrangements, ROS1 (c-ros oncogene 1, located at 6q22) translocations were recently shown to define a new molecular subgroup in non-small cell lung cancers (NSCLC). These translocations, activating a proto-oncogene with a tyrosine kinase domain, are also targeted by the MET and ALK crizotinib. ROS1 rearrangements are found in only 1.2-1.7% NSCLCs, but seemingly only in triple negative (EGFR and KRAS non-mutated and ALK non-rearranged) adenocarcinomas and preferentially in non- or light smokers.  Methods', '  60 triple negative non- or light-smoking patients with lung adenocarcinoma were screened for ROS1 rearrangements by fluorescent in situ hybridization (FISH). Two commercially available break-apart FISH probe kits containing a mixture of two probes hybridizing on each side of the ROS1 locus, one located in a centromeric (3) position, and the other one in a telomeric (5) position relative to the ROS1 gene were used. ROS1 fusions were therefore detected without any preconception on the fusion partner, as multiple fusion partners have been described. At least 100 nuclei were screened, and a tumor was considered positive if it contained more than 15% rearranged nuclei.  Results', '  Forty-nine of the 60 tumors were interpretable. Four (8.2%) of theses 49 tumors were ROS1 rearranged by FISH. Only one of the positive cases showed a classical split rearrangement pattern (one fusion, one green and one red signal in more than 15% of nuclei), whereas the three other tumors showed a variant pattern, with a deletion of the telomeric probe, located in a 5 position relative to the ROS1 gene locus, indicating the presence of a fusion partner upstream of the ROS1 gene. The four positive cases were all at an advanced stage (3 or 4), but did not display any common architectural feature.  Conclusions', '  The prevalence of ROS1 positivity in our selected population was far superior (8.2%) to that of a non-selected NSCLC population, suggesting that this type of screening may be more effective (faster and more cost-worthy) to detect ROS1 positive tumors.']",
        "Doc_id":"ASCO_116245-132",
        "Doc_title":" Detection of ROS1 translocations in triple-negative lung adenocarcinomas.",
        "_version_":1606188997653037056},
      {
        "Meeting_name":" Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes.",
        "Background":"['Background', ' Historically, survival in patients (pts) with NSCLC brain metastases (BM) is poor, however, improved systemic therapies are now available including targeted therapies and immunotherapy. We sought to evaluate the prevalence of genetic alterations in pts with BM from non-squamous (NS) lung cancer, and to determine clinical outcomes in the modern era. Methods', ' With IRB approval, pts with BM from NS-NSCLC from 1/2010-1/2016 with genetic testing were captured and retrospectively reviewed. Snapshot genotyping was performed prior to 1/2014, after which Next Generation Sequencing was utilized, along with FISH lung cancer panel. Genes examined included', ' EGFR, ALK, RET, ROS1, TP53, KRAS, NRAS, MET, PTEN, BRAF, FBXW7, MAP2K1, APC, PIK3CA, CTNNB1, and SMAD4. Univariable and multivariable analysis (MVA) were utilized to assess factors associated with overall survival (OS). Results', ' 92 pts were included. Median number of BM was 4 (range 1-45). Median age was 64 (32-90 years). 59.8% were male. 38% received targeted therapy, 11% received immunotherapy, and 70% received conventional chemotherapy. 52.2% and 47.8% received whole brain radiotherapy and stereotactic radiosurgery, respectively. Median OS from first brain radiotherapy (RT) was 10.7 months (0.1-56.4). EGFR mutation, ALK fusion, ROS1 rearrangement, and RET rearrangement occurred in 27.5%, 5.2%, 1.7%, and 0% of pts. EGFR L858 and EGFR T790 mutations occurred in 19.2% and 2.7% of all pts. TP53, KRAS, and NRAS mutations occurred in 63.9%, 28.8% and 7% of pts. All other mutations had an incidence of less than 3%. On MVA, targeted therapy (HR 0.43 95% CI 0.22-0.86), immunotherapy (HR 0.04 95% CI 0.01-0.3), surgical resection (HR 0.38 95% CI 0.18-0.81), and ECOG performance status (0.23 95% CI 0.1-0.54) were associated with improved OS. No specific genetic aberration, RT modality, or number of BM was associated with OS. Conclusions', ' In pts with BM from NS-NSCLC, the most common molecular aberrations include TP53, EGFR, and KRAS mutations. Treatment with brain RT and modern systemic therapies yields a median survival greater than ten months. The use of targeted therapy or immunotherapy was associated with increased OS.']",
        "Doc_id":"ASCO_190952-199",
        "Doc_title":" Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes.",
        "_version_":1606188997833392128},
      {
        "Meeting_name":" Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma.",
        "Background":"['Background', ' Liquid biopsies were used to assess genomic alterations in plasma circulating tumor DNA (ctDNA) from patients with non-small cell lung adenocarcinoma (NSCLC), and therapeutic outcomes analyzed. Methods', ' ctDNA testing (digital next-generation sequencing (NGS)) was performed in 88 patients with advanced NSCLC; (54 or 68 gene panel; 40 and 48 patients, respectively (Guardant Health, Inc. (Guardant360 test))) (Clinical Laboratory Improvement Amendment (CLIA) laboratory). Fifty-five patients (62.5%) also had some tissue molecular testing, 37 of whom had a consistent tissue NGS panel (  182-genes). Results', ' Eighty-two percent of patients (72/88) had  1 ctDNA alteration(s) (median = 2 alterations), most frequently TP53 (44.3% of patients), EGFR (27.3%), MET (14.8%), KRAS (13.6%), and ALK (6.8%). Retrospective analysis showed that 25 of 88 patients (28.4%) had received a therapy matching at least one ctDNA alteration(s) (most frequently an inhibitor of EGFR (N = 18), ALK, BRAF, other). Sixty-five percent of evaluable (N = 5 patients, too early) matched patients (N = 13/20) achieved stable disease (SD)  6 months or partial response (PR). The median progression-free survival for the 25 matched patients was 13.9 months. For the 37 patients who had both the tissue NGS panel and the ctDNA test (median 1.3 months (range, 0.1 to 20.9) between tissue biopsy and blood draw), the concordance rate for EGFR ctDNA alterations with tissue NGS was 70.3% (k = 0.361), with higher concordance when time interval between tissue and blood tests was  1.3 months. When we only considered patients in whom ctDNA confirmed present (N = 27), the EGFR concordance was 77.8% (k = 0.526). Fifty-one patients (58%) did not have the tissue NGS test performed, including 33 (37.5%) who had no other tissue molecular testing, usually because of inadequate tissue or potential morbidity for repeat biopsy. Conclusions', ' ctDNA frequently revealed genomic alterations in NSCLC adenocarcinoma, including in difficult-to-biopsy patients. Patients who received cognate therapies demonstrated a high rate of SD  6months/PR, suggesting clinical utility.']",
        "Doc_id":"ASCO_162939-176",
        "Doc_title":" Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma.",
        "_version_":1606189001997287424},
      {
        "Meeting_name":" A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-nave patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation.",
        "Background":"['Background', '    EGFR-TKI is the recommended treatment for patients with advanced NSCLC who have an EGFR-TKI-sensitizing mutation (EGFRm). However, most patients develop resistance, and in ~60% of cases the EGFR T790M mutation is the cause. AZD9291 is an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M mutations. Preliminary data from a Phase I/II study demonstrated clinical activity and a manageable tolerability profile for AZD9291 as first-line treatment of patients with EGFRm advanced NSCLC.  Methods', '    This Phase III, double-blind, randomized study (FLAURA, NCT02296125) is designed to assess the efficacy and safety of AZD9291 (80 mg qd, orally) versus standard of care (SoC) EGFR-TKI (gefitinib [250 mg qd, orally] or erlotinib [150 mg qd, orally]) in treatment-nave patients with locally advanced or metastatic EGFRm NSCLC.  Eligible patients must have pathologically confirmed adenocarcinoma harboring an EGFR Ex19del or L858R mutation, alone or in combination with another EGFRm, determined by local (accredited laboratory) or central testing. Patients  18 years of age (  20 in Japan), WHO performance status 01, will be randomized 1', '1 to receive either AZD9291 or SoC EGFR-TKI, stratified by mutation status (Ex19del or L858R) and race (Asian versus non-Asian), until RECIST v1.1 defined progression or a discontinuation criterion is met. Patients may continue randomized treatment beyond RECIST defined progression if they continue to show clinical benefit, as judged by the Investigator.  The primary objective is to compare progression-free survival (PFS) for AZD9291 to SoC EGFR-TKI. PFS in patients with tumors harboring T790M is a key secondary objective. Additional secondary objectives include PFS by Ex19del or L858R detectable in circulating tumor DNA, objective response rate, duration of response, disease control rate, depth of response, overall survival, PK, health-related quality of life, patient satisfaction with treatment, and the safety and tolerability profile of AZD9291 compared with SoC EGFR-TKI. The study was opened to accrual in November 2014. Clinical trial information', ' NCT02296125']",
        "Doc_id":"ASCO_144153-156",
        "Doc_title":" A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-nave patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation.",
        "_version_":1606189006175862784},
      {
        "Meeting_name":" Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Overall response rates (ORR) to 2nd-line SACTx in NSCLC have consistently not exceeded 15%. Exploratory analysis of clinical trials in various tumor types have demonstrated potential improvements in ORR to CTx after exposure to vaccine-based immunotherapy. The objective of this retrospective study was to determine if SACTx (3rd-line or beyond) would yield improved ORR when given after exposure to programmed-death-(ligand)1 inhibitors (PD1i) in metastatic NSCLC. Methods', ' Eligibility criteria - patients registered in the Thoracic GEMINI database of MD Anderson treated between 06/12 and 11/16 who received at least one SACTx as 3rd-line or beyond, following progression after platinum-based CTx and PD1i. We computed efficacy outcomes to each therapy, including ORR by RECIST v1.1, progression-free survival (PFS) and overall survival (OS). Results', ' Of 306 PD1i-treated patients registered in the database, 28 met eligibility criteria - 54% were male, median age 66 years, 82% adenocarcinoma, 29% never smokers. The PD1i and SACTx most commonly used were nivolumab (82%) and docetaxel (54%). ORR to SACTx after exposure to PD1i was 39% (11/28 patients, 8 confirmed). In contrast, ORR to 1st-line CTx in this cohort was 30% (Table). Liver metastasis and pembrolizumab as the PD1i of choice were the only factors associated with response to SACTx on univariate analysis (p < 0.05). Conclusions', ' In NSCLC patients, ORR to SACTx after immunotherapy exposure was higher compared to historical data from the pre-PD1i era, and approached ORR to 1st-line platinum-based CTx. Further investigation of a possible chemosensitization effect by immunotherapy is warranted. 1st Line CTx n = 27*At least 2ndLine PD1i n = 28At least 3rdLine SACTx n = 28Complete response001 (3.6%)Partial response10 (37%)010 (35.7%)**Stable disease15 (55.6%)14 (50%)10 (35.8%)Progressive disease2 (7.4%)14 (50%)7 (25%)Median duration of response, months7.84.1**Median PFS, months (95% CI)7.3 (4.9-8.4)2.6 (1.9-3.7)4.6 (2.8-6.3)Median OS from start of therapy, months (95% CI)37.8 (25.9-47.8)13.9 (10.2-2836)8.9 (7.7-24.2)*1 patient inevaluable for response, 3 patients received chemoradiation; **3 unconfirmed']",
        "Doc_id":"ASCO_185475-199",
        "Doc_title":" Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).",
        "_version_":1606189006388723713},
      {
        "Meeting_name":" Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' Resistance to small molecule EGFR tyrosine kinase inhibitors (TKIs) is seen in some NSCLC patients with activating EGFR mutations. We evaluated in vivo PDX models for their utility in studying EGFR-targeted drug resistance mechanisms.Methods', ' Surgically resected early stage NSCLC tumors were implanted into non-obese diabetic severe combined immune deficient (NOD-SCID) mice. Tumors were passaged and expanded in new mouse hosts once the humane endpoint of 1.5 cm maximum diameter was reached. EGFR TKI treatment was initiated at an average tumor volume of 150mm3. Treatments included daily oral gavage with first and second generation EGFR TKIs, and with weekly intraperitoneally administered cetuximab.Results', \" Of the 55 NSCLC tumors with EGFR activating mutations, only 6 engrafted (11%) and could be propagated beyond the first passage, and 4 have been studied for their responsiveness to EGFR-targeted agents. Model 148, developed from a patient who received pre-operative erlotinib, showed intrinsic pan-resistance to all EGFR-targeted therapies despite having an L858R mutation. The corresponding patient did not respond to erlotinib, relapsed after surgery and did not receive additional TKI therapy. Model 137, with an exon19 E746-A750 deletion, recapitulated the patient's response to gefitinib at relapse; this model was sensitive to first and second generation EGFR TKIs. Model 192 also has the exon19 E746-A750 deletion, however it did not recapitulate the patient's observed sensitivity to erlotinib. Selection for a MET amplified population during engraftment may be the cause for the disparate drug sensitivities. Model 164 has a double exon19 L747-T751 deletion and T790M EGFR mutation. Neither patient nor xenograft responded to erlotinib; the xenograft responded to cetuximab. Resistance developed over time to a second generation EGFR TKI; this resistant phenotype was not stable as each subsequent passage of the resistant tumor exhibited the same initial response pattern. Two potential mechanisms for this transient sensitivity are currently being investigated\", ' epigenetic mechanisms and intratumoural mutational heterogeneity.Conclusions', ' PDX models may provide important insight into biomarkers and mechanisms of resistance to targeted therapies, and provide a means to test novel treatment strategies to improve future treatment efficacies.']",
        "Doc_id":"AACR_2014-1184",
        "Doc_title":" Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC)",
        "_version_":1606189012258652160},
      {
        "Meeting_name":" Discovery of potent and selective Ros1 inhibitors with a unique DFG-out binding mode",
        "Background":"['Chromosomal rearrangements resulting in oncogenic fusion proteins containing the ROS1 receptor tyrosine kinase have been described in subsets of a variety of human malignancies including non-small-cell lung cancer (NSCLC), cholangiocarcinoma, and glioblastoma multiforme. Promising clinical responses have been observed in patients bearing tumors with ROS1 fusions treated with Xalkori, an ALK/MET kinase inhibitor that also inhibits Ros1. However, resistance has been observed and a ROS1 kinase domain mutation, G2032R, was identified in a ROS1 fusion positive NSCLC patient who developed resistance to Xalkori treatment. Clinical experience with other receptor tyrosine kinase inhibitors suggests that additional resistance mutations are likely to arise, highlighting the need for therapeutic agents that can overcome this type of resistance.We identified a novel chemical series of potent and selective Ros1 inhibitors with a unique DFG-out binding mode. The structure of human Ros1 in a complex with a ligand from this chemical class was confirmed by X-ray crystallography. Here we describe the structure-activity relationships and synthesis route for this chemical series. A representative compound from this series inhibited isolated recombinant Ros1 kinase activity with an IC50 of approximately 30 nM. This compound inhibited less than 6% of kinases in a panel of 400 at 1 M concentration. Growth of Ba/F3 cells engineered to express Ros1 autophosphorylation in HCC78 NSCLC cells that harbor a SLC34A2-ROS1 fusion were inhibited at similar concentrations as the isolated protein. This activity translated into potent Ba/F3-Ros1 tumor growth inhibition in mice. This compound was also active on Ba/F3 cells containing Ros1 with a mutation in the gatekeeper residue, L2026M, in cell growth assays in vitro and tumor growth in vivo. Furthermore, this unique binding mode provides scope for activity on additional Ros1 mutations that confer resistance to Xalkori, such as the clinically relevant G2032R mutation. The results shown here describe a novel chemical series with a unique binding mode that has potential for activity in Ros1 driven tumors with mutations that confer resistance to Xalkori.']",
        "Doc_id":"AACR_2014-4745",
        "Doc_title":" Discovery of potent and selective Ros1 inhibitors with a unique DFG-out binding mode",
        "_version_":1606189014920986624},
      {
        "Meeting_name":" Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.",
        "Background":"['Background', ' Most of targetable gene alterations are found only in 1-5% of non-small cell lung cancer (NSCLC) cases. Large scale screening systems for these rare populations are necessary for the development of molecular targeted therapies. Thus, a nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) has been operated since February 2013. Methods', ' Non-squamous NSCLCs without EGFR mutations were eligible for inclusion in this study. The tumors were analyzed for ALK/RET/ROS1 fusions using RT-PCR, and detected fusions were confirmed by FISH. Since March 2015, this nationwide project has been amended to an academic-industrial collaboration project with 14 pharmaceutical companies, and the samples were further subjected to a next-generation sequencing (NGS) system, Oncomine Comprehensive Assay, enabling the simultaneous analysis of 143 cancer-related genes. Results', ' As of December 31, 2015, 195 institutions across Japan were participating and 2161 patients had been enrolled. Among 1988 available samples, including 497 for the NGS analysis, ALK/RET/ROS1 fusions were detected in 37 (2%)/51 (3%)/86 (4%), respectively. The NGS analysis also showed that 269 cases (54%) had targetable gene alterations, including 82 KRAS mutations (17%), 36 ERBB2 mutations (7%), 28 BRAF mutations (6%), 22 PIK3CA mutations (4%), 6 NRAS mutations (1%), 6 MAP2K1 mutations (1%) and 2 FGFR2 fusions (0.4%). MET/ERBB2/FGFR1 amplifications were also detected by the NGS in 13 (3%)/11 (2%)/3 (1%) cases, respectively. Through this screening, the preplanned numbers of patient with RET and ROS1 fusions (n = 19 and 26, respectively) were successfully enrolled in clinical trials of vandetanib (LURET study in Japan) and of crizotinib (OO12-01 study in East Asia), respectively. Three patients with ERBB2 alterations and 2 with MET amplifications were also enrolled in genotype-matched ongoing trials. Conclusions', ' This nationwide screening system enables efficiently and successfully detecting various targetable gene alterations in NSCLC, thereby contributing to promote cancer precision medicine through the development of targeted therapies.']",
        "Doc_id":"ASCO_166878-176",
        "Doc_title":" Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.",
        "_version_":1606189016056594432},
      {
        "Meeting_name":" Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '     Approximately 35% of NSCLC harbors ALK gene rearrangements. Crizotinib is a first-in-class, oral, small-molecule competitive ALK inhibitor with anti-MET activity.  Methods', '     PROFILE 1005 is an ongoing global, multicenter, open-label, single-arm, phase II study evaluating the safety and efficacy of crizotinib (250 mg BID in 3-week cycles) in patients with advanced ALK-positive NSCLC who progressed after 1 chemotherapy for recurrent/advanced/metastatic disease. Tumor response was evaluated by RECIST 1.1 every 6 weeks. Patient-reported symptoms and global quality of life (QOL) were assessed using the EORTC QLQ-C30 and LC-13 at baseline, day 1 each cycle and at end of treatment.  Results', '      As of June 2011, 439 patients were evaluable for safety and 255 patients for tumor response. Median age was 53 years. The majority of patients were female (53%), never smokers (65%), and had adenocarcinoma (92%), ECOG PS 01 (83%) and 2 prior chemotherapy regimens (85%). Among patients evaluable for efficacy, median treatment duration was 25 weeks (77% of patients still ongoing). ORR was 53% (95% CI', ' 4760), disease control rate at 12 weeks was 85% (95% CI', ' 8089), median duration of response was 43 weeks (96% CI 3650) and median PFS was 8.5 months (95% CI', ' 6.29.9).  The most frequent treatment-related AEs were visual effects (50%), nausea (46%), vomiting (39%), and diarrhea (35%), mostly grade 12. 29 patients (6.6%) had treatment-related SAEs, including dyspnea and pneumonitis (4 patients each; 0.9%), and febrile neutropenia and renal cyst (2 patients each; 0.5%). A statistically significant (p<0.05) and clinically meaningful ( 10 points) improvement from baseline was observed for patient-reported overall pain, pain in chest, cough, dyspnea, insomnia, fatigue and global QOL.  Conclusions', '      Crizotinib demonstrated a high response rate and PFS, favorable tolerability profile and improvement in patient-reported symptoms. These results provide strong evidence for crizotinib as a standard of care for advanced ALK-positive NSCLC.']",
        "Doc_id":"ASCO_96607-114",
        "Doc_title":" Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).",
        "_version_":1606189028729683969},
      {
        "Meeting_name":" Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients previously treated for advanced wild-type EGFR non-small-cell lung cancer.",
        "Background":"['Background', '  A personalized peptide vaccination (PPV) strategy has been developed as a new immune-system-based therapy. In this method, vaccine antigens are selected and administered based on pre-existing host immunity prior to vaccination. Previous clinical studies on PPV showed promising results for treating various types of advanced cancers, including lung cancer. However, the clinical efficacy of PPV in combination with standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains unclear. We therefore conducted this multicenter, randomized, phase II trial.  Methods', '  Fifty previously treated PS0-1 patients with stage IIIB/IV EGFR wild-type NSCLC were randomly assigned to the docetaxel (60 mg/m2on day 1) plus PPV arm based on pre-existing host immunity (n = 24) or to the docetaxel plus placebo arm (n = 26). Docetaxel administration was repeated every 3 weeks until disease progression. Personalized peptides or placebo was injected subcutaneously weekly during the first 8 weeks and biweekly during the subsequent 16 weeks. The first PPV or placebo injection was performed within 3 days of docetaxel administration. The primary efficacy endpoint was progression free survival.  Results', ' The toxicity profile of docetaxel plus PPV was very similar to that previously reported for docetaxel alone. PPV-related toxicity was grade 1 or 2 skin reaction. The median PFS was 53 days in the placebo arm and 59 days in the PPV arm. There was no significant difference between the arms by the log-rank test (p = 0.42). Interestingly, PFS and overall survival in humoral immunological responders were significantly longer than in non-responders, with hazard ratio 0.28 and 0.27 (both p < 0.01), respectively.   Conclusions', ' The primary endpoint was not met in this clinical trial and PPV did not improve survival when combined with docetaxel for previously treated advanced EGFR wild-type NSCLC. However, PPV may be efficacious for humoral immunological responders. Further clinical investigation is needed to identify which patients will benefit from cancer vaccination. Clinical trial information', ' 000003521.']",
        "Doc_id":"ASCO_148722-156",
        "Doc_title":" Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients previously treated for advanced wild-type EGFR non-small-cell lung cancer.",
        "_version_":1606189034978148352},
      {
        "Meeting_name":" Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project.",
        "Background":"['Background', ' In recent years, adjuvant chemotherapy has become the standard of care for completely resected (R0) stage II and IIIA NSCLC patients, while the use of adjuvant therapy in stage IB remains controversial. We evaluated the use of adjuvant therapy among R0 stage IA-IIIA NSCLC patients in the NCCN Outcomes Database Project. Methods', ' Completely resected stage I-IIIA NSCLC patients who did not receive preoperative therapy were selected for analysis. Eligible patients received adjuvant treatment at 8 participating NCCN institutions between 01/2007 and 06/2009 and were at least 90 days postsurgery. Adjuvant therapy was defined as therapy initiated within 3 months of surgery. Analyses were done on 12/11/09. Results', ' A total of 498 patients met the inclusion criteria. Patient characteristics were', ' male 42%; median age 67 yrs; stage IA 39%, IB 35%, II 16%, IIIA 10%; lobectomy (uni or bi) 84% (N=416); adenocarcinoma 58% (N=289); performance status (PS) 0-1 54% (N=271), PS 2 3% (N=16), and undocumented PS 42% (N=211). Adjuvant treatment category is presented by stage in the Table. Of patients receiving adjuvant therapy, 5 (4%) did so on a clinical trial. The most common reason for not receiving adjuvant systemic therapy in stage II-IIIA was patient refusal (26%). Conclusions', ' Adjuvant therapy was commonly administered to stage II and IIIA patients. Radiation was most common among stage IIIA patients. While the majority of R0 NSCLC patients received treatment that follows NCCN guidelines, relatively few patients at these NCCN centers are participating in clinical trials. Adjuvant treatment category by stageStageTreatment category IA (N=193) IB (N=174) II (N=79)IIIA (N=52)No treatment190 (98%)126 (72%)25 (32%)14 (27%)Chemotherapy2 (1%)43 (25%)43 (54%)20 (38%)Cisplatin-based2 (100%)25 (58%)25 (58%)10 (50%)Carboplatin-based0 (0%)14 (33%)17 (40%)8 (40%)Other0 (0%)4 (9%)1 (2%)2 (10%)Chemotherapy + targeted therapy0 (0%)2 (1%)0 (0%)0 (0%)Targeted therapy alone0 (0%)2 (1%)2 (3%)1 (2%)Sequential chemo/RT1 (<1%)0 (0%)6 (8%)13 (25%)Concurrent chemo/RT0 (0%)0 (0%)1 (1%)3 (6%)RT alone0 (0%)1 (<1%)2 (3%)1 (2%)']",
        "Doc_id":"ASCO_53578-74",
        "Doc_title":" Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project.",
        "_version_":1606188990816321537},
      {
        "Meeting_name":" Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  In 78 BRAF V600E mut NSCLC pts, single agent D induced an overall response rate (ORR) of 32%. The combination of D and T (DT) has demonstrated significant improvements in efficacy compared with BRAFi monotherapy in BRAFV600 mut metastatic melanoma. Here, we report interim safety (33 pts) and efficacy (24 pts) data for NSCLC pts enrolled in this phase II DT study.  Methods', '  This single-arm, 2-stage, phase II study was in advanced BRAFV600E mut NSCLC pts who failed at least 1 line of chemotherapy. D was dosed at 150 mg orally twice daily and T at 2 mg once daily. The primary endpoint was investigator-assessed ORR per RECIST 1.1 criteria. A minimum response rate (  6 out of first 20 pts) was required to continue into the second stage.  Results', '    Median age of 33 pts was 66 yrs (range 4988 yrs). Most pts were female (64%), White (82%), former smokers (73%), and had adenocarcinoma (88%). Twenty-seven pts (82%) remain on therapy, and 6 have stopped (4 with disease progression, 2 due to adverse events [AEs]). Twenty-four pts were evaluable for efficacy (confirmed response). ORR was 63% (n = 15, partial responses; 95%CI 40.6%81.2%), with responses being observed by the first scan (6 weeks) and disease control rate (DCR) for > 12 weeks was 88% (95% CI 67.6%97.3%). Independent review response rates were consistent with investigator-assessed response. Most common ( > 20%) AEs were pyrexia, diarrhea, nausea, vomiting, decreased appetite, asthenia, cough, peripheral edema, and rash, mostly grade 1 or 2. Grade 3 AEs occurred in 39% of pts; most frequent were hyponatremia (6%), neutropenia (6%), and dehydration (6%). One pt (3%) had a grade 4 AE (hyponatremia) and 1 pt (3%) had a fatal serious AE of pleural effusion. AEs leading to a dose reduction were reported in 9 pts (27%). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 2 pts (6%). Conclusions', '  DT in BRAF V600E mut advanced NSCLC pts shows early antitumor activity with an ORR of 63% and a manageable safety profile. The study met the criteria for progression to the second stage. Clinical trial information', ' NCT01336634']",
        "Doc_id":"ASCO_147124-156",
        "Doc_title":" Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).",
        "_version_":1606188993502773249},
      {
        "Meeting_name":" Early palliative care, depression, and survival in metastatic NSCLC.",
        "Background":"['Background', '  We observed that early palliative care (EPC) for metastatic non-small cell lung cancer (NSCLC) improves survival. Because depression is associated with worse survival in this population, we hypothesized that the survival benefit may be the result of treating depression. As a secondary analysis of our randomized trial of EPC, we examined the effect of EPC on depression and its relationship with survival.  Methods', '  151 patients with metastatic NSCLC were enrolled within 8 weeks of diagnosis in a randomized trial of EPC (n=76) versus standard care (n=75). Depression was assessed at baseline and week 12 with the Patient Health Questionnaire-9 (PHQ-9), scored diagnostically using DSM-IV criteria for major depression syndrome (MDS) and with less stringent criteria of PHQ-9 scores  10 for probable depression (PD). Depressed patients with  50% reduction in PHQ-9 scores at 12 weeks were considered responders. Differences in rates were tested with Chi square. Survival was calculated from time of enrollment and differences were tested with Cox proportional hazards models.  Results', '  Over a quarter (41/151) had PD at baseline, but only 21 met diagnostic criteria for MDS. Depression rates were balanced between trial arms. Among those with depression, EPC was associated with greater rates of response at 12 weeks (PD 37.5% vs. 9.5%, p=.05; MDS 42.9% vs. 0%, p=.04). However, EPC was not significantly associated with increased survival among those with depression (compared to standard care, EPC median survival was 33 days shorter for PD and 10 days longer for MDS). Among those without depression, the difference in median survival between arms was twice that of the sample as a whole. Controlling for ECOG performance status, sex, age, smoking, and marital status, depression was only associated with survival in the EPC arm (PD HR=1.78, p=.05; MDS HR=3.27, p=.006).  Conclusions', '  EPC for metastatic NSCLC improved survival only in patients without depression. Although EPC improves depression in patients with metastatic NSCLC, it is not associated with longer survival among those with depressive syndromes. These findings result in an association of depression with survival only in the EPC arm. Depression appears to moderate the observed survival benefit from EPC.']",
        "Doc_id":"ASCO_76702-102",
        "Doc_title":" Early palliative care, depression, and survival in metastatic NSCLC.",
        "_version_":1606188996272062464},
      {
        "Meeting_name":" Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Immunotherapy (IO) has brought dramatic clinical benefit to patients with NSCLC. Most patients tolerate IO, but serious irAE have been reported. In melanoma, a correlation between development of irAE and clinical benefit has been suggested. For NSCLC, the risk of irAE including pneumonitis has been described in clinical trials but not for the wider population. Risk factors for irAE and the impact of irAE on OS are unknown. Methods', ' A retrospective review of patients with NSCLC treated with single-agent IO between September 2014 and June 2016 was carried out at The Ohio State University. Patients had confirmed pathologic disease and received IO either on clinical trial or as standard of care. IrAE were assessed based on the treating physician diagnosis. OS was calculated from the date of initiation of IO to death from any cause or date or last follow-up. Results', ' A total of 90 patients met criteria. Median age was 67. Histology was nonsquamous in 58 (64%) and squamous in 32 (35%). Most patients received nivolumab (n = 87). Median months of IO was 2.6 (95% CI 1.9  4.2). IrAE occurred in 24 patients (26.67%). The most common irAE were pneumonitis (n = 8), thyroid dysfunction (n = 6), and rash/pruritus (n = 5). Other irAE included colitis in 2 patients and new onset diabetes and autoimmune hepatitis in 1 patient each. Development of pneumonitis did not have a statistically significant impact on overall survival (median OS 5.8 vs 8.1 months, p = 0.11). Prior thoracic radiation (TR) was not associated with pneumonitis (11.54% vs 8.33%, p = 0.69), but was associated with shorter survival (median OS 3.9 vs 8.7 months, p = 0.018). Development of irAE was not associated with histology (p = 1.00), KRAS mutation (p = 0.10), TP53 mutation (p = 0.09), or recent flu vaccination (p = 1.00). Patients with irAE had longer median OS (13.2 vs 5.8 months, p = 0.018). Conclusions', ' The incidence of irAE and pneumonitis match that seen in published clinical trials. The development of irAE was associated with better prognosis, whereas patients with prior TR had worse outcomes. Further prospective research is warranted to investigate the correlation of irAE with clinical benefit from IO in patients with NSCLC.']",
        "Doc_id":"ASCO_190090-199",
        "Doc_title":" Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).",
        "_version_":1606188996467097600},
      {
        "Meeting_name":" Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    Technologies to isolate and study circulating tumor cells (CTCs) became available in recent years.  To date, the most widely employed techniques to detect CTCs use EpCAM based enrichment protocols. However, those assays are only able to find CTCs in a minority of patients with NSCLC, thus limiting its potential applicability. We are reporting performance of a new enrichment-free HD-CTC assay in patients with NSCLC.  Methods', '    This multi-institutional study recruited patients with all stages of NSCLC. Blood was collected at the time of the study entry, 3 weeks, 3m, 6m, 9m, and 12 m. CTCs were identified with enrichment free fluorescent labeling followed by automated digital microscopy. CTCs were physically and morphologically characterized by cytokeratin (CK) intensity, nuclear size, apoptotic changes, and aggregate formation. Cells were classified as HD-CTCs if they met strict morphologic and immunofluorescence characteristics.  This assay has been previously validated in 15 normal controls.  Results', '    106 patients were recruited (I-10, II-3, III-34, IV-59), 78 were chemotherapy nave. 85%, 79%, and 53% of patients with stages, I+II, III, and IV had detectable HD-CTCs. The chemotherapy nave cohort had median HD-CTCs of 4.4/mL (range 0515.6) and a mean of 44.1 (95.2)/mL. No significant differences were detected in median HD-CTC count between tumor stages (p = 0.32). CK intensity, nuclear size, frequency of apoptosis and aggregate formation was also similar across stages. 28 patients with stage IV disease were analyzed with multiple draws over time. Mean CTC counts were averaged over multiple draws. In each individual patient there was a trend for increased CTC prevalence with advancement of the disease. Median survival was 244 days for patients with 5 CTC/mL vs. 304 days for patients with < 5 CTC/mL. HR 4.0, (p=0.0084).  Conclusions', '   The HD-CTC assay can detect CTCs in a high percentage of patients with early and advanced NSCLC. Small subset analysis demonstrated the prognostic value for the enumeration of HD-CTCs. The high prevalence of HD-CTCs across stages could make this assay an ideal candidate for larger scale investigation into prognostic and predictive features of HD-CTCs.']",
        "Doc_id":"ASCO_101512-114",
        "Doc_title":" Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).",
        "_version_":1606188997202149376},
      {
        "Meeting_name":" Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer.",
        "Background":"['Background', ' The epothilones represent a new class of cytotoxic agents which are active in several solid tumor settings, including non-small-cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the objective response rate (ORR) of a novel combination of ixabepilone (I) and carboplatin (C) ( bevacizumab) in advanced NSCLC. A prior phase I trial of I and C established the doses for this study (Plummer, CCR 2008). Methods', \" Eligible patients (pts) were aged  18 years, treatment nave, with stage IIIB/IV NSCLC, ECOG PS 0-1, and adequate organ function. Pts received either I/C (Arm A) or I/C/bevacizumab (Arm B) per the treating physician's decision, following lead-in safety phases for both arms. Pts must have met standard bevacizumab eligibility criteria for enrollment on Arm B. Treatment\", ' I 30 mg/m2 and C AUC = 6, both IV q21 days (Arms A and B); and bevacizumab 15 mg/kg IV q21 days (Arm B only). After 6 cycles, pts on Arm B could continue bevacizumab until progression. Results', ' 82 pts were enrolled from11/08-9/09. 66 pts (Arm A = 40; B = 26) are included in this analysis. Baseline characteristics were similar in each arm; except only nonsquamous histology was permitted on Arm B. The median age was 63 yrs (range 43-85); male, 50%; ECOG 0 = 45%; adenocarcinoma (A = 30%, B = 82%). The median follow-up was 7 months (range 3.6-12.5); and the median number of cycles for arms A and B were 2 and 3, respectively. 88% of pts are alive. The ORRs for arms A and B were', ' 28% (95% CI 15%-44%) and 46% (CI 27%-67%), respectively. 40% of pts (Arm A) and 28% (Arm B) had stable disease. Median PFS and OS have not been reached. Grade 3/4 toxicity', ' anemia (A-8%/B-8%), neutropenia (A-33%/B-27%), thrombocytopenia (A-17%/ B-3%), hypersensitivity reaction (A-2%/B-14%), diarrhea (A-8%/B-5%), dyspnea (A-10%/B-12%), and neuropathy (A-2%/B-0). Bevacizumab-specific toxicities included', ' G1/2 hypertension (17%) and proteinuria (17%), and G3 gastrointestinal perforation (appendiceal, diverticular, 1pt each). Conclusions', ' These ixabepilone-based regimens appear to be active in the first-line NSCLC treatment setting with expected and manageable toxicities. PFS and OS results will be presented.']",
        "Doc_id":"ASCO_52825-74",
        "Doc_title":" Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer.",
        "_version_":1606188998637649920},
      {
        "Meeting_name":" Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).",
        "Background":"['Background', ' Although molecularly targeted therapy improves outcome of selected patients with advanced non-small-cell lung cancer (NSCLC), most of the patients ultimately become candidates of cytotoxic chemotherapy, which is the cornerstone of patient management. S-1 plus cisplatin (SP) has shown activity and good tolerability in phase II settings. Docetaxel plus cisplatin (DP) is the only third-generation regimen that demonstrated statistically significant improvement of overall survival and quality of life by head to head comparison with a second-generation regimen, vindesine plus cisplatin, in patients with advanced NSCLC. Methods', ' Patients with previously untreated stage IIIB or IV NSCLC, an ECOG PS of 0-1 and adequate organ functions were randomized to receive either oral S-1 80 mg/m2/day (40 mg/m2 b.i.d.) on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 every 5 weeks or docetaxel 60mg/m2 on day 1 plus cisplatin 80 mg/m2 on day 1 every 3 weeks, both up to 6 cycles. The primary endpoint is overall survival (OS). Non-inferiority study design was employed as upper confidence interval (CI) limit for HR<1.322. Secondary endpoints include progression-free survival (PFS), response, safety, and quality of life (QOL). Results', ' From April 2007 to December 2008, 608 patients from 66 sites in Japan were randomized to SP (n=303) or DP (n=305). Patient demographics were well balanced between the two groups.   Two interim analyses were preplanned. At the final analysis, total of 480 death events were observed. The primary endpoint was met. OS for SP was non inferior to DP (median survival, 16.1 v 17.1 months, respectively; HR=1.013; 96.4% CI, 0.837-1.227). PFS was 4.9 months in the SP arm and 5.2 months in the DP arm. Statistically significantly lower rate of febrile neutropenia (7.4% v 1.0%), grade 3/4 neutropenia (73.4% v 22.9%), grade 3/4 infection (14.5% v 5.3%), grade 1/2 alopecia (59.3% v 12.3%) were observed in the SP arm than in the DP arm. QOL data investigated by EORTC QLQ-C30 and LC-13 favored for the SP arm. Conclusions', ' S-1 plus cisplatin is a standard first-line chemotherapy regimen for advanced NSCLC.']",
        "Doc_id":"ASCO_94574-114",
        "Doc_title":" Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).",
        "_version_":1606188999269941248},
      {
        "Meeting_name":" Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors.",
        "Background":"['Background', '  Epitinib is an oral small molecule compound selectively inhibits epidermal growth factor receptor (EGFR). It has demonstrated potent inhibitory effects on multiple human tumor xenografts with a large safety window and broad tissue distribution including high drug contribution in brain. This first-in-human study is being conducted to assess the safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of Epitinib.  Methods', '  This phase I study uses a 3+3 design for dose-escalation of Epitinib given once daily (QD) in 28-day treatment cycles in patients with solid tumors who failed or have no access to standard therapies. Safety and tumor response are assessed according to NCI CTCAE 4.0 and RECIST 1.1, respectively.  Results', '  By Dec 31, 2012, 19 pts aged 40-66 yr old (ECOG PS 1) with NSCLC (n=16) or breast cancer (n=3) were enrolled in 5 dose cohorts of 20-160 mg. Six NSCLC pts had EGFR mutations (3 with T790M). All pts had 2 lines of prior systemic treatments (7 pts with gefitinib or elotinib). Most AEs were mild (Gr1). Treatment-related AEs included skin rash (36.8%), abnormal liver function tests (42.1%), diarrhea (10.5%), vomiting (5.3%), paronychia (5.3%), decreased neutrophil count (5.3%) and increased creatinine (5.3%). Three SAEs were reported as possibly unrelated to the study drug. No DLT was observed and MTD has not been reached yet. PK analysis showed that the mean elimination half-life of Epitinib was approximately 40 hours and Tmax was around 2 h. Both Cmaxand AUC exhibited good dose proportionality over the studied dose range with low inter-patient variability following single and multiple doses. Among 15 evaluable pts, 1 EGFR mutation+ NSCLC pt achieved confirmed partial response (66.7% tumor reduction) for more than 6 months and the treatment is ongoing; 8 pts had stable disease, including 1 with T790M for 6 months and 1 with brain metastasis for 12 months who is still on treatment.  Conclusions', '  Epitinib was well tolerated at doses up to 160mg QD to date with manageable adverse events and excellent pharmacokinetic properties. Encouraging clinical activity was observed, including durable SD in NSCLC patients with T790M or brain mets.']",
        "Doc_id":"ASCO_114269-132",
        "Doc_title":" Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors.",
        "_version_":1606189000568078337},
      {
        "Meeting_name":" The association between clinical characteristics, treatment modality, and outcomes of non-small cell lung cancer.",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death in the United States. NSCLC outcomes vary widely among patients. The degree to which these disparate outcomes reflect differences in treatment modality remains unclear. We therefore examined these associations at a medical center providing care to a diverse patient population. Methods', ' We performed a retrospective analysis of consecutive patients diagnosed with NSCLC stages I-III from 2000 to 2005 at the University of Texas Southwestern Medical Center. We recorded patient, disease, and treatment characteristics. The association between these characteristics and outcome was assessed using univariate analysis, multivariate logistic regression, and survival analysis. Results', ' A total of 482 patients met criteria for analysis. Mean age was 64 y, and 52 percent were men. For stage I/II disease, median survival was 6.7 y for patients aged < 65 y vs 4.4 y for age  65 y (P=0.01); 3.1 y for men vs >5.8 y for women (P=0.0002); 5.6 y for patients with household income below the national median ($41,995) vs 5.6 y for above-median income (P not significant). For stage III, median survival was 1.1 y for age < 65 y vs 0.7 y for age  65 y (P=0.02); 0.8 y for men vs 1.2 y for women (P=0.02); 0.7 y for below-median income vs 1.2 y for above-median income (P=0.02). Race and hospital setting (public versus private) were not associated with survival. For stage I/II, patients treated with surgery had a median survival of 5.8 y, vs 1.7 y for non-surgical treatment (P<0.0001). For stage III, patients who received surgery and/or radiation had a median survival of 1.2 y vs 0.5 y for other patients (P<0.0001). For stage I/II, treatment modality was associated with hospital setting, race, and income. For stage III, treatment modality was associated with age, gender, hospital setting, race, and income. In multivariate analysis, age (for stage I/II), gender (for stage I/II), and treatment modality (for all stages) were associated with survival. Conclusions', ' For stages I-III NSCLC, a number of clinical characteristics are associated with outcomes. Differences in treatment modality may account in part for these disparities. These findings warrant further study.']",
        "Doc_id":"ASCO_32226-65",
        "Doc_title":" The association between clinical characteristics, treatment modality, and outcomes of non-small cell lung cancer.",
        "_version_":1606189001434202112},
      {
        "Meeting_name":" Risk stratification of lung cancer patients at initial presentation",
        "Background":"['Background', ' Early detection and treatment of non-small cell lung cancer (NSCLC) has been shown to improve survival. Current screening guidelines focus on at-risk populations, overlooking a significant proportion of patients (pts) who will develop NSCLC. There is a need for further risk stratification in this group. Methods', ' A retrospective cohort analysis was conducted on pts referred to the BC Cancer Agency  Vancouver Centre for NSCLC. Records were reviewed for the date of first abnormal imaging and 6 clinical factors (CF) noted by the referring clinician at initial presentation. CFs were', ' ECOG PS > 2, new-onset dyspnea > MRC 3, chest pain, hemoptysis, weight loss > 10% and systemic symptoms (seizure, bone pain, or paraneoplastic syndrome). Individuals meeting current low-dose CT screening criteria (age 55-74, 30 pack-year smoking history within the last 15 years) were also identified. Results', ' 435 cases were identified from Jan 1 to Dec 31, 2013; 308 had sufficient information to be included for analysis. Median age', ' 69; smoking history', ' 69%; stage', ' I = 5%, II = 9%, III = 26%, IV = 60%. Multivariate analysis identified 4 of 6 CF were associated with worse overall survival (OS, p < 0.05); hemoptysis and weight loss were not significant predictors and were not retained for analysis. Cases were stratified based by the number of CFs. Pts with no CF had significantly improved OS (median 30.5 mo) compared to those with 1 (12.1 mo), 2 (8.1 mo) or 3-4 (2.5 mo; p < 0.001 for all comparisons) CF. Screening criteria were met for 94 pts (31%). For the other 214 pts (69%), number of CF was 0 = 29%, 1 = 29%, 2 = 33%, 3-4 = 9%. OS was similar whether or not pts were eligible for screening. In the subset of ineligible pts, CFs retained their predictive value (p < 0.05). Conclusions', ' Four clinical factors predict poor outcomes in pts presenting with abnormal imaging suspicious for NSCLC. In this population, 31% of patients would have been eligible for low-dose CT screening. An additional 49% of patients with abnormal imaging had at least one CF identifiable upon initial contact with a healthcare provider. Determination of key clinical factors may assist in risk stratification of pts ineligible for screening who warrant further investigation for lung cancer.']",
        "Doc_id":"ASCO_187112-199",
        "Doc_title":" Risk stratification of lung cancer patients at initial presentation",
        "_version_":1606189009063641088},
      {
        "Meeting_name":" A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).",
        "Background":"['Background', '  Crizotinib is an approved treatment for patients (pts) with ALK-rearranged (ALK+) NSCLC. However, progression on crizotinib, particularly in the CNS, frequently occurs within a year. Alectinib is a highly selective ALK inhibitor; preclinical data show high CNS exposure and limited efflux. The NP28761 study (NCT01871805) investigated the efficacy/safety of alectinib in ALK+ NSCLC pts in the US and Canada who had progressed on crizotinib.  Methods', '  Pts  18 yrs with locally advanced/metastatic ALK+ NSCLC (by FDA-approved FISH test) who progressed on crizotinib, with or without prior chemo, were enrolled; alectinib 600mg BID was given until progression, death or withdrawal. The primary endpoint was objective response rate (ORR) by an independent review committee (IRC) based on RECIST v1.1. Secondary endpoints included disease control rate (DCR = ORR plus stable disease); ORR and DCR in the CNS; progression-free survival; CNS progression rate; duration of response; overall survival; safety and quality of life.  Results', '  By 24 Oct 2014, 87 pts were enrolled. Median age 54 yrs; 74% had prior chemo; 55% had baseline CNS mets (21/48 treated). Median follow-up was 21 wks. In the response-evaluable population assessed by IRC (69 pts with baseline measurable disease) ORR was 47.8% (95% CI 35.660.2); DCR was 79.7%. In pts with baseline measurable CNS disease (n = 16), IRC CNS ORR was 68.8% (95% CI 41.389.0), including 2 CRs; CNS DCR was 100%. When pts with baseline measurable and non-measurable CNS disease were both included (n = 48), CNS DCR was 87.5%, with 9 CNS CRs. 31% of pts had gr35 adverse events (AEs), most commonly increased blood CPK (8%), increased ALT (6%) and increased AST (5%); one gr5 AE (hemorrhage) occurred. Low rates of dose interruptions (29%), reductions (14%), and withdrawals (2%) due to AEs were noted. Conclusions', '  Alectinib was well tolerated and achieved a strong treatment response in ALK+ NSCLC pts who had progressed on crizotinib, with notable CNS activity, a common site of first progression on crizotinib. A global ph3 head-to-head trial of first-line alectinib vs crizotinib and an expanded access program are ongoing. Clinical trial information', ' NCT01871805']",
        "Doc_id":"ASCO_151415-156",
        "Doc_title":" A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).",
        "_version_":1606189010238046209},
      {
        "Meeting_name":" Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC",
        "Background":"['Background', ' Crizotinib (C) was the first approved ALK inhibitor for use in in ALK positive (pos) NSCLC, but resistance ultimately develops through both ALK-related and other signaling pathways. Onalespib (AT13387; O) is an HSP90 inhibitor which can interfere with the maturation of many client proteins, including ALK. In ALK-driven preclinical models, O when combined with C, delays the emergence of resistance, providing the rationale for this phase 2 study. Previously, Besse, et al (Ann Onc[2014]25[suppl_4]iv426-iv470), noted that C + O can be safely combined at effective doses of each and some activity was seen. Here we report the results of a randomized study comparing C+ O to C-alone in ALK-pos NSCLC patients (pts). Methods', ' This was an open-label, randomized, controlled study in which pts with ALK-pos NSCLC receiving C without progression, ECOG PS 0-2 and adequate organ function were randomized 1', '1 to continuing C (250 mg BID) vs. adding O (220 mg/m2 D1,8,and 15 Q28 D) to the treatment regimen. C-only pts were allowed to crossover to C+O at progression. The primary endpoint was Progression-free survival (PFS) and secondary endpoints included Overall Survival (OS), Safety, and Objective Response Rate (ORR). Results', ' Pts (68 C/68 C+O) were generally balanced for age (50.4/55.8), Sex (50%M/34%M), ECOG 0-1 (93% /95%), Brain mets (48%/43%), and prior systemic therapy (68%/66%), respectively. PFS analysis showed no difference between the groups (median PFS C', ' 266 days/C+O', ' 269 days, HR 1.025). ORR slightly favored the C+O group (55.4% vs. 45.3%), and OS was not mature. The C+O treatment produced more  Gr.3 AEs (51% vs. 29%, most common diarrhea, nausea, and vomiting), however there was no increase in the percent of pts discontinuing due to AE (4% vs. 5%). Conclusions', ' This is the first randomized study to clinically test the hypothesis that early dual inhibition of an HSP90 client protein by a kinase inhibitor combined with an HSP90 inhibitor may delay the emergence of resistance and prolong PFS. Despite previous promising non-clinical studies, while O + C could be safely combined, the combination did not delay the emergence of clinical resistance in ALK-pos NSCLC. Clinical trial information', ' NCT01712217']",
        "Doc_id":"ASCO_171030-176",
        "Doc_title":" Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC",
        "_version_":1606189011708149760},
      {
        "Meeting_name":" A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib.",
        "Background":"['Background', '   Genotype directed therapy is now standard of care for advanced NSCLC pts. However, adequate tumor tissue for comprehensive genotyping remains a challenge. Recent research suggests that CTC capture or cfDNA analysis allows for non-invasive diagnosis and monitoring of treatment. This prospective trial was designed to quantify the predictive value of CTC and cfDNA analyses of EGFR-mutant NSCLC pts treated with first-line erlotinib.  Methods', '  TKI nave EGFR mutant NSCLC pts were enrolled in a phase II trial of erlotinib treatment. Paired blood for cfDNA and CTC analysis was collected at baseline prior to therapy and every 2 months during follow ups. Plasma genotyping was performed by ddPCR for EGFR19del, L858R, T790M while CTCs were isolated by CellSearch and analyzed by IF and MET-FISH. Repeat biopsies at progression were performed when feasible.   Results', '   Between 2/10 and 1/15, 60 EGFRmutant pts (L858R', '17, 19del', '38, other', '5) were enrolled. As of 1/15, 44 patients have discontinued therapy (39 for RECIST progression; 5 for adverse events). Blood was available for cfDNA analysis on 53 and 33 pts at baseline and progression respectively, and EGFR mutations were detected in 25/53 pts (47.1 %, median', ' 57 copies/mL plasma, range', ' 2-1649) and 10/33 pts (30.3% median, 71 copies/mL plasma, range', ' 5-2530). Blood was available for CTC analysis on 47 and 33 pts and CTCs were detected in 17/47 pts (36.1%, median', ' 3 CTCs/7.5 mL blood, range', ' 1-1145) at baseline and 15/33 pts (45.4%, median', ' 6 CTC/7.5 mL blood, range', ' 1-328) at progression. METamplification was identified in CTCs of 2 pts. For 18 pts with detectable cfDNA at baseline and >  = 3 follow up blood draws, treatment reduced cfDNA levels to non-detectable for >  = 4 months in 83.3 % (15/18). In contrast, for 17 pts with detectable CTCs at baseline, CTCs continued to be intermittently detected on treatment in 58.9% (10/17) of pts.  Conclusions', '   cfDNA and CTCs are complementary non-invasive assays for EGFRmut NSCLC although the low yield of CTCs may preclude genotyping. Serial cfDNA monitoring may be a better predictor of treatment efficacy than CTCs.  Funding', ' R01-CA135257, P50-CA090578, Conquer Cancer Foundation, Genentech']",
        "Doc_id":"ASCO_149949-156",
        "Doc_title":" A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib.",
        "_version_":1606189014312812544},
      {
        "Meeting_name":" DETERRED",
        "Background":"['Background', ' Immune checkpoint blockade in non-small cell lung cancer (NSCLC) may be enhanced when combined with radiation therapy. Atezolizumab (atezo) is a humanized and Fc receptor modified monoclonal antibody that blocks programmed death-ligand-1 (PD-L1) interacting with PD-1 or B7.1 sparing PD-L2, which may result in less pulmonary toxicity. We report the early safety data of combining atezo added sequentially after standard concomitant chemoradiation (CRT) for locally advanced NSCLC (LA-NSCLC). Methods', ' This is a phase II study in LA-NSCLC assessing the safety and feasibility of adding atezo to CRT in two parts', ' I) sequentially (N = 10) with CP after completing CRT, or II) concurrently (N = 30) with CRT followed by consolidation atezo with CP. We report on the early toxicity results from part I of the trial. Atezo was given at 1200 mg IV Q3 weeks with consolidation CP for 2 cycles after CRT followed by atezo monotherapy for up to one year. Radiation dose at 60-66 Gy in 30-33 fractions was combined with weekly low dose CP, followed by 2 cycles of full dose CP. Dose limiting toxicities were defined as any adverse events (AEs)  grade 3 within 15 weeks of start of therapy or any immune-related AEs during atezo treatment. Results', ' From January to December 2016, 10 evaluable patients were enrolled. Seven patients have received consolidation atezo ranging from 1 to 14 doses, with 3 yet to receive atezo after completing CRT. Three patients reported potential immune-related AEs. One patient developed grade 3 arthralgia, and another developed grade 2 radiation-induced pneumonitis, which resolved with steroids. A third patient who experienced grade 3 dyspnea due to COPD exacerbation after 1 dose of atezo discontinued additional therapy. Of the 7 patients who have received atezo, 2 patients developed progression of disease after 6 and 8 doses of atezo. Conclusions', ' Atezo consolidation with 2 cycles of CP after CRT appears to be feasible and well tolerated with manageable toxicities. Additional data from part I will be reported. Conditions for proceeding after part I are met and part II of the study which adds atezo to CRT followed by atezo-CP consolidation is open for accrual. Clinical trial information', ' NCT02525757']",
        "Doc_id":"ASCO_187891-199",
        "Doc_title":" DETERRED",
        "_version_":1606189020122972160},
      {
        "Meeting_name":" Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutationpositive non-small cell lung cancer.",
        "Background":"['Background', ' EGFR-activating mutations (eg, exon 19 deletions [ex19del], L858R) occur in ~50% of East Asian patients with non-small cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitor (TKI) treatment. ASP8273, an orally administered EGFR TKI that inhibits EGFR-activating mutations, has demonstrated clinical activity in subjects with EGFR mutation-positive (EGFRmut+) NSCLC. Methods', ' EGFR TKI-nave adult subjects (20 yr) with EGFRmut+ NSCLC were enrolled in this single arm Phase 2 study conducted in Japan (NCT02500927). Subjects received open-label ASP8273 300 mg once daily until discontinuation criteria were met. Primary endpoint was tolerability; secondary endpoint was antitumor activity defined by RECIST v1.1. Results', ' A total of 31 Japanese subjects (12 M/19 F; median age 64 years [range', ' 3182]) were enrolled. Based on local testing, 27 subjects had an ex19del (n = 13, 42%) or a L858R (n = 14, 45%) EGFR activating mutation; 4 subjects (13%) had other EGFR activating mutations (L861Q [n = 2], G719X [n = 2]). ASP8273 300 mg had tolerable adverse events with diarrhea and peripheral neuropathy being most common; no interstitial lung disease events were reported (Table). Across all 31 subjects, based on investigator assessment, treatment with 300 mg ASP8273 was associated with an overall response rate (ORR) of 52%, disease control rate (DCR) of 94%, and a median duration of progression-free survival (PFS) of 11.3 months (95% CI', ' 7.2, 15.5). In subjects with ex19del, ASP8273 300 mg was associated with an ORR of 46% and DCR of 85%; median PFS was 8.3 months (95% CI', ' 2.9, -). In subjects with the L858R, ASP8273 300 mg was associated with an ORR of 57% and DCR of 100%; median PFS was 15.5 months (95% CI', ' 7.2, 15.5). Conclusions', ' Once-daily ASP8273 300 mg was tolerable in TKI-nave Japanese subjects with EGFRmut+ NSCLC and demonstrated antitumor activity. Clinical trial information', ' NCT02500927TEAE occurring in 30% of the study population, n (%)Total (N = 31)DiarrheaAny Grade24 (77)Grade 32 (6)Peripheral neuropathyAny Grade18 (58)Grade 30NauseaAny Grade12 (39)Grade 30Increased ALTAny Grade11 (35)Grade 32 (6)HyponatremiaAny Grade10 (32)Grade 37 (23)Decreased appetiteAny Grade10 (32)Grade 31 (3)']",
        "Doc_id":"ASCO_182445-199",
        "Doc_title":" Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutationpositive non-small cell lung cancer.",
        "_version_":1606189028654186496},
      {
        "Meeting_name":" Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.",
        "Background":"['Background', '  EGFR mutated advanced NSCLC treated with EGFR TKIs typically progresses after initial response due to acquired resistance. TKI therapy is often continued beyond RECIST progression (PD). We investigated the frequency of this practice and patterns of RECIST PD via imaging findings, as well as the association between patient characteristics and discontinuation of TKI among patients (pts) who progressed while on TKI.  Methods', '  Among a cohort of 101 advanced NSCLC pts with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib at DFCI, 70 pts treated between 2002 and 2010 had at least two CT scans for retrospective radiographic assessments using RECIST1.1; 56 pts had experienced PD by the data closure date of June 2011.   Results', '  Among 56 pts experiencing PD, 46 (82%) were female, median age was 63 (range 35-79), 28 (50%) were never-smokers, 32 (57%) had distant mets, 32(57%) had exon 19 deletion, and 50 (89%) received erlotinib. 49 pts (88%) continued TKI therapy for at least 2 mos beyond retrospectively assessed PD. 31/32 (97%) pts who progressed by increase of target lesions continued TKI. 13/16 (81%) pts who progressed by new lesion remained on TKI. Two pts with PD in non-target lesions discontinued therapy at PD. 5/6 (83%) pts with both increase of target lesions and new lesion at PD continued TKI.  In 49 continuing pts, the median time from RECIST PD to termination of TKI was 10.1 mos (range', ' 2.2-64.2 mos). 15/49 (31%) pts who continued TKI received additional chemo compared to 0/7 pts who discontinued (Fishers p=0.17).  Pts who discontinued therapy (n=7) were significantly younger (median 48 yrs) than those who continued TKI at PD (median 64 yrs, Wilcoxon p=0.003). Median OS beyond RECIST PD among those who continued TKI was 31.8 mos (95% CI 15.9- not reached) and though underpowered, this did not appear to be impacted by TTP when adjusted in a Cox model (p=0.84).  Conclusions', '  88% of EFGR-mutant NSCLC pts who progressed on first-line TKI continued therapy beyond RECIST PD, which is not the single determining factor for terminating TKI in EGFR-mutant NSCLC pts. Additional progression criteria specific to this population are needed to better guide therapeutic decision making.']",
        "Doc_id":"ASCO_91580-114",
        "Doc_title":" Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.",
        "_version_":1606189035322081280},
      {
        "Meeting_name":" A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  Treatment options are limited for patients (pts) with advanced SQ NSCLC who fail platinum-based doublet chemotherapy (PT-DC). We report results of a randomized, open-label, global phase III study of NIVO, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, vs DOC in pts with SQ NSCLC and with disease progression (PD) during/after one prior PT-DC regimen.  Methods', '  Pts (N = 272) were randomized 1', '1 to receive NIVO 3 mg/kg (n = 135) Q2W or DOC 75 mg/m2(n = 137) Q3W until PD, discontinuation due to toxicity, or other reasons. The primary objective was overall survival (OS). Secondary objectives included investigator-assessed objective response rate (ORR; RECIST v1.1), progression-free survival (PFS), efficacy by PD-L1 expression (PD-L1 testing not required for enrollment), quality of life, and safety.  Results', ' Superior OS was observed with NIVO vs DOC (HR = 0.59; 95% CI', ' 0.44, 0.79; p = 0.00025). NIVO improved PFS vs DOC (HR = 0.62; 95% CI', ' 0.47, 0.81; p = 0.0004). ORR was 20% (27/135) for NIVO and 9% (12/137) for DOC (p = 0.0083). OS HRs favored NIVO regardless of PD-L1 expression (Table). Grade 34 drug-related AEs occurred in 7% (9/131) of NIVO and 55% (71/129) of DOC pts. No deaths were related to NIVO vs 3 DOC-related deaths.  Conclusions', ' CheckMate 017 met its primary objective, demonstrating superior OS of NIVO vs DOC in pts with advanced, previously treated SQ NSCLC and demonstrated PFS and ORR superiority. Tumor PD-L1 status was neither prognostic nor predictive for efficacy endpoints. The safety profile of NIVO 3 mg/kg Q2W is acceptable and favorable vs DOC. NIVO represents a significant improvement in second-line therapy for SQ NSCLC.  Clinical trial information', ' NCT01642004NIVO (n = 135)DOC (n = 137)mOS, mo (95% CI)9.2 (7.3, 13.3)6.0 (5.1, 7.3)1-yr OS, % (95% CI)42 (34, 50)24 (17, 31)Median duration of response, mo (range)Not Reached (2.920.5+)8.4 (1.4+15.2+)mPFS, mo (95% CI)3.5 (2.1, 4.9)2.8 (2.1, 3.5)1-yr PFS, % (95% CI)21 (14, 28)6 (3, 12)PD-1 expressionNIVO (n)DOC (n)OS HR (95% CI) 1%63560.69 (0.45, 1.05)< 1%54520.58 (0.37, 0.92) 5%42390.53 (0.31, 0.89)< 5%75690.70 (0.47, 1.02) 10%36330.50 (0.28, 0.89)< 10%81750.70 (0.48, 1.01)']",
        "Doc_id":"ASCO_144815-156",
        "Doc_title":" A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).",
        "_version_":1606189038394408960},
      {
        "Meeting_name":" Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '    Bevacizumab (B) was FDA-approved in 2004 in combination with carboplatin and paclitaxel (CP) for treatment of first-line metastatic NSCLC after a phase III trial was conducted showing a median improvement in overall survival (OS) of 2 months with addition of B (10.3 vs. 12.3, HR for death, 0.79; p=0.003).  The CPB regimen was added to US Oncologys (USON) Level I NSCLC Pathway shortly thereafter; however, widespread adoption of CPB has not occurred.  In this study, we analyzed OS between patients who received CP vs. CPB from the USON network.  Methods', '    Data from USONs electronic medical record, iKnowMed (iKM) was used to evaluate stage IV NSCLC patients from July 1, 2007  June 30, 2009, receiving >/=1 cycle of first-line CP or CPB.  Patients were excluded if they received any other B-based regimen, were enrolled in a clinical trial, or had insufficient data.  Patients were followed for a minimum of 12 months.  OS was calculated from first chemotherapy administration date until date of death or censored for last date of contact with documented vital signs.  Patients were stratified by age, sex, and KPS. Results', '    During the study timeframe, 9783 NSCLC patients were identified who received any chemotherapy regimen for any line of therapy. Of these, 1572 met defined inclusion/exclusion criteria, 1057 CP (67%), 515 CPB (33%).  Sex distribution was similar between the groups (M/F 57%/43% vs. 56%/44%, CP vs. CPB, respectively).  More subjects in the CP arm were >65 yo or had a KPS <80 (>65 yo', ' 60% vs. 52%; KPS <80', ' 34% vs. 24%, CP vs. CPB, respectively).  Overall survival for the total population was 11.4 months (CP) vs. 16 months (CPB), p<0.0001.  Estimated 1- and 2-yr OS in the CP arm was 49% and 23% vs. 61% and 35% for the CPB arm.  Those most likely to benefit from the addition of B, were patients <65 yo (HR 0.52, p<0.0001) or with KPS >80 (HR 0.67, p<0.0001).  Conclusions', '    Published study results evaluating the impact of B on OS for NSCLC demonstrate a 2-month improvement.  Our results support the finding that B improves OS but that this benefit is limited to certain subgroups (<65yo and KPS >80).  Further study is warranted to verify these results.']",
        "Doc_id":"ASCO_78050-102",
        "Doc_title":" Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC)",
        "_version_":1606189023003410432},
      {
        "Meeting_name":" Intra-tumor heterogeneity in non-small-cell lung cancer (NSCLC) carrying EGFR mutations",
        "Background":"['Introduction. Driver mutations of the epidermal growth factor receptor (EGFR) are usually detected in 10% to 15% of Caucasian non-small cell lung cancer (NSCLC) patients. Evidence suggests that a fraction of EGFR mutant NSCLC might have intra-tumor heterogeneity which could potentially affect response to EGFR tyrosine kinase inhibitors (TKIs). We performed next generation sequencing (NGS)-based analysis of a large cohort of Italian EGFR mutant NSCLC to assess the level of intra-tumor heterogeneity.Materials and methods. Genomic DNA from EGFR mutant NSCLC samples as assessed with routine diagnostic methods (N. 181; 141 tissue specimens and 40 cytology samples), was retrospectively analyzed with the Ion AmpliSeq Colon and Lung Cancer Panel using Ion Torrent semiconductor sequencing. The panel assesses over 500 somatic mutations in 22 genes at a sensitivity of 2%. Variants with allelic frequency >2% and <5% were confirmed by droplet digital PCR (ddPCR), if material was available.Results. Analysis of EGFR mutant samples with NGS revealed the presence of two different hotspot EGFR mutations in 17/181 cases (9.4%). In 11 cases a EGFR sensitizing mutation and the p.T790M resistance mutation were detected; 6 tumors carried two different EGFR activating mutations at different allelic frequency. In addition, the presence of at least one variant in genes other than the EGFR was observed in 84/181 cases (46.4%), with TP53 being the most frequent mutant gene in EGFR mutant NSCLC (32/181; 17.7%). In 42 samples (23.2%) hotspot mutations were found in genes other than the EGFR, such as KRAS, NRAS, BRAF, ERBB2, PIK3CA or MET, which might cause primary resistance to EGFR targeting drugs. In 29 samples the additional mutations were at an allelic frequency >5%, and in 13 at a frequency >2% and <5%. All mutations at low allelic frequency for which material was available were confirmed by ddPCR (N.5). The allele frequency of the driver EGFR mutation and of the additional mutations were usually different, suggesting the sub-clonal origin of some driver mutations. In particular, in 15/42 cases the EGFR mutant allele frequency was lower as compared with the additional driver mutation.Conclusion. These preliminary data suggest that a subgroup of EGFR mutant tumors have intra-tumor heterogeneity and are likely to carry tumor clones with different molecular profile. Follow-up data are being collected to assess whether this phenomenon might affect the activity of first line EGFR TKIs.']",
        "Doc_id":"AACR_2016-2251",
        "Doc_title":" Intra-tumor heterogeneity in non-small-cell lung cancer (NSCLC) carrying EGFR mutations",
        "_version_":1606189023908331520},
      {
        "Meeting_name":" Structure-function analysis of twist1-e2a transcriptional activity in kras-driven non-small cell lung cancer",
        "Background":"['Lung cancer is the leading cause of cancer death in the United States and in the world. Although a large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations, little progress has been made in the treatment of patients with the most common driver mutation, mutant KRAS. We previously demonstrated that inhibition of the basic helix-loop-helix transcription factor, TWIST1, in KRAS mutant, EGFR mutant, and MET amplified/mutant NSCLC can induce either oncogene induced senescence or apoptosis. However, the key functions of TWIST1 that are required for its transcriptional activity in cancer are unknown.In the current study, we engineered domain-specific mutations in TWIST1 to determine the impact of altered DNA binding, dimerization and post-translational modifications on its transcriptional activity by luciferase reporter assays. Testing the promoter activity at three TWIST1-regulated loci involved in tumorigenesis, YBX1, SNAI2, and FLIP, we found that DNA binding and nuclear localization were uniformly required for TWIST1 transcriptional function. However, phosphorylation, TWIST1 box function, and ability to form homo- versus hetero- dimers impacted TWIST1 activity in a locus-specific manner. Previous studies have demonstrated that TWIST1 dimerizes with the E2A proteins, E12 and E47. We have shown that silencing of E2A phenocopies loss of TWIST1 in NSCLC and that formation of the TWIST1-E2A heterodimer results in a reciprocal stabilization of the binding partner. Therefore, we sought to determine how differential dimerization by TWIST1 might modulate tumorigenic gene expression. We utilized tethered TWIST1 dimers with either TWIST1 or the E2A proteins to form TWIST1-TWIST1 (homodimer), TWIST1-E12 or -E47 (heterodimers), and tested their transcriptional activities at several TWIST1-regulated promoters. We found that TWIST1-E2A heterodimers could enhance TWIST1 transcriptional activity compared to that of the TWIST-TWIST homodimer. In addition, we determined that the TWIST-E2A heterodimer is degraded by harmine, a harmala alkaloid that we have shown degrades TWIST1, whereas the TWIST-TWIST homodimer is resistant to harmine degradation. This suggests that the TWIST1-E2A heterodimer is the key target of harmine. Furthermore, we have found that overexpression of the TWIST1, E2A proteins, or the TWIST1-E2A heterodimer is able to partially rescue harmine induced cytotoxicity in KRAS mutant NSCLC. Taken together, these data suggest that E2A is essential for TWIST1 mediated tumorigenesis and that targeting of the TWIST1-E2A axis may be an effective therapeutic strategy against oncogene-driven NSCLC.']",
        "Doc_id":"AACR_2016-2020",
        "Doc_title":" Structure-function analysis of twist1-e2a transcriptional activity in kras-driven non-small cell lung cancer",
        "_version_":1606189041657577472},
      {
        "Meeting_name":" Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC.",
        "Background":"['Background', ' ABP 215 is a biosimilar candidate highly similar to BEV, a VEGF inhibitor, in analytical and functional comparisons. Pharmacokinetic similarity between ABP 215 and BEV has been demonstrated in a phase 1 study. Here we present primary efficacy and safety results from a phase 3 study in non-small cell lung cancer (NSCLC). Methods', ' In this double-blind, active-controlled trial, subjects with non-squamous NSCLC on first-line chemotherapy with carboplatin and paclitaxel were randomized (1', '1) to ABP 215 or BEV (15 mg/kg IV infusion Q3W for 6 cycles). Patients (Pts) remained on treatment until 21 days after the last dose of investigational product (IP) or study specified chemotherapy. Clinical equivalence of the primary endpoint was evaluated by comparing the 2-sided 90% confidence interval (CI) of the risk ratio (RR) of objective response rate (ORR) between study arms with the prespecified margin (0.67, 1.5). Results', ' Baseline characteristics were balanced between groups (ABP 215', ' n = 328; BEV', ' n = 314). ORR (ITT population) was 39.0% (n = 128) for ABP 215 and 41.7% (n = 131) for BEV; the RR for ORR was 0.93 (90% CI', ' 0.80, 1.09). Pts with grade  3 treatment-emergent adverse events (TEAEs) were 42.9% in ABP 215 group vs 44.3% in BEV group; TEAEs leading to IP discontinuation affected 18.8% and 17.2% subjects in the two groups. Pts reporting at least one serious TEAE were 26.2% in ABP 215 group vs 23.0% in BEV group. TEAEs with > 10% incidence included alopecia, nausea, neutropenia, peripheral neuropathy, and hypertension. Patients developing binding antibodies were 1.4% in the ABP 215 group vs 2.5% in the BEV group; no subject tested positive for neutralizing antibodies. Conclusions', ' The study met its primary endpoint demonstrating that ABP 215 is clinically similar to BEV. TEAEs were comparable between ABP 215 and BEV. Clinical trial information', ' NCT01966003']",
        "Doc_id":"ASCO_166241-176",
        "Doc_title":" Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC.",
        "_version_":1606188980375650304},
      {
        "Meeting_name":" Predicting significance of EGFR mutation existing in tissues and plasma concuurrently or alone to EGFRtyrosine kinase inhibitors (EGFR-TKIs) for advanced non-small cell lung cancer.",
        "Background":"['Background', '  To investigate predicting significance of EGFR mutations existing in tissues couples with plasma or either sample alone to EGFRtyrosine kinase inhibitors (EGFR-TKIs) treatment for advanced nonsmall-cell lung cancer (A-NSCLC).  Methods', '  Two hundred-eighty-seven A-NSCLC patients met following criteria were included into this study', ' 1) had received EGFR-TKIs as first- or second-line therapy; 2) had sufficient tissue and plasma samples for EGFR mutation analysis. All patients were divided into four subgroups which were wild-type EGFR in both of specimens (B-/T-), mutated in both of specimens (B+/T+), mutated only in one specimen (B+/T- and B-/T+). EGFR mutation was screened by denaturing high performance liquid chromatograph (DHPLC) and confirmed by ARMS. Objective response rate (ORR) and progression-free survival (PFS) were compared among four subgroups.  Results', '  Of all 287 patients, 101 patients carried EGFR mutation both in tissue and plasma, 103 patients carried mutation only in tissue (65 cases) or plasma (38 cases). Median PFS was 9.2 months (95% CI, 6.3 to 12.1) and 2.0 months (95% CI, 1.3 to 2.7) in B+/T+ and B-/T- group, respectively. For single mutated group,  mPFS were 7.87 month for B-/T+ group (95% CI, 5.1 to 10.6) and 11.87 months for B+/T- group (95% CI, 3.3 to 20.5) (P=0.001). For ORR, 53.0% for B+/T+ group, 15.8% for B-/T- group, 40.0% for B-/T+ group and 28.9% for B+/T- group (P=0.000). EGFR-TKIs therapeutic line could not change trend which B+/T- or B+/T+ group had better PFS than B-/T+ group.  Conclusions', '  Detection of EGFR mutation in tissue and plasma may have different significance in predicting response of EGFR-TKIs.']",
        "Doc_id":"ASCO_116609-132",
        "Doc_title":" Predicting significance of EGFR mutation existing in tissues and plasma concuurrently or alone to EGFRtyrosine kinase inhibitors (EGFR-TKIs) for advanced non-small cell lung cancer.",
        "_version_":1606188984704172032},
      {
        "Meeting_name":" Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung to reveal association between immune activation and a lower risk of recurrence.",
        "Background":"['Background', ' The sarcomatoid carcinoma of the lung (SCL) is a rare subtype of non-small cell lung cancers (NSCLC). The prognosis of SCL is poor with 5-year survival of ~20%. There have been only a few studies on genomic landscape of SCL. Comprehensive genomic and transcriptomic profiles of SCL have not been systematically studied. Methods', ' In this study, we performed whole-exome sequencing and ultra-deep targeted sequencing of 400 cancer genes on 21 resected localized SCLs and matched normal lung tissues. RNA sequencing (RNA-seq) was also performed to 17 SCLs and matched normal lung tissues for those with materials available. Results', ' On average, 688 mutations including 503 non-synonymous mutations were identified per tumor. Canonical cancer gene analysis demonstrated that the most frequently mutated gene in this cohort was TP53 (detected in 11 out of the 21 tumors) followed by KRAS (detected in 6 out of the 21 patients). The recently discovered potentially targetable MET exon 14-skipping mutation was also detected in 3 patients in our cohort. For the 17 tumors, for, whom RNA-seq was conducted, unsupervised clustering analysis using non-negative matrix factorization (NMF) led to two stable clusters of patients in our cohort. Of particular interest, all patients (7/7) in Cluster 1 have relapsed, while only 3 of 10 patients in Cluster 2 relapsed (p-value < 0.01). Further pathway analyses demonstrated that immune activation pathways are significantly up regulated in tumors from Cluster 2 compared to Cluster 1. Conclusions', ' SCLs seem to have similar genomic landscape and canonical cancer gene mutations compared to other types of NSCLCs such as squamous cell carcinoma and adenocarcinomas. Immune pathway activation may be associated with lower risk of postsurgical recurrence in patients with localized SCL.']",
        "Doc_id":"ASCO_189415-199",
        "Doc_title":" Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung to reveal association between immune activation and a lower risk of recurrence.",
        "_version_":1606188993626505216},
      {
        "Meeting_name":" Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Molecular profiling is often limited by access to sufficient tumour tissue for comprehensive analysis and due to tumour heterogeneity, the complete range of tumor DNA abnormalities may not be represented nor accurately reflect the clinical evolution of disease. Circulating tumour DNA (ctDNA) can be used as a liquid biopsy for molecular abnormalities detection, quantification and monitoring for personalised treatment strategies. Methods', ' Plasma was collected at baseline (BL) and during study therapy from advanced NSCLC patients (pts) enrolled in a placebo controlled phase III trial of a novel irrerversible EGFR inhibitor; all patients had received standard therapy with chemotherapy and gefitinib or erlotinib. Archival tissue was collected when available but biopsy was not required prior to enrolment. BL Plasma ( < 3ml), stored for ~8 years was used to extract DNA and analysed using InVision (enhanced tagged-amplicon sequencing). Results', ' BL plasma from 387 pts was tested; 289 pts had available tissue results (from archival tissue collected at diagnosis) for EGFR (174WT/115Mut) and 243 for KRAS (205WT/38Mut). Despite age of plasma samples, ctDNA analysis detected cancer mutations in 310 pts (82%)', ' TP53 (45%),KRAS (15%), and EGFR (43%; 56% were EGFR del19 and 29% L858R); T790M was detected in 80 patients. EGFR mutations were identified in 29 patients and KRAS in 10 patients with unknown tissue status. Also of note, STK11 (32 pts, 12 with KRAS), BRAF (5pts, 3 with V600E), MET(7 pts, 4 with METamp), ERBB2 (16pts, 10 with ERBB2amp) were identified in ctDNA analysis. Median time and median number of lines of systemic therapy between tissue biopsy and blood was 714 days and 3 lines respectively. Further analyses of ctDNA analyses in context of patient and trial outcomes are in progress. Conclusions', ' Liquid biopsies provide opportunity to evaluate molecular mutation profile in NSCLC patients. We demonstrate a highly sensitive method for ctDNA analysis which is complementary to tissue molecular analysis.']",
        "Doc_id":"ASCO_193212-199",
        "Doc_title":" Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).",
        "_version_":1606189008424009728},
      {
        "Meeting_name":" FDG-PET and CT as early predictors of outcome in NSCLC patients treated with erlotinib.",
        "Background":"['Background', '  Tumor metabolism as assessed by FDG-PET is an early biomarker for clinical benefit in oncology. This multi-national study evaluated associations of changes in mean standardized uptake values (SUVmean) of FDG and tumor burden with disease control rates (DCR', ' CR+PR+SD), PFS and OS in 48 NSCLC patients (EGFR mutants or favorable clinical/demographic characteristics) treated with erlotinib. The primary hypothesis was that changes in SUVmean at day 8 predicted DCR.     Methods', '  Patients were scanned by FDG-PET (twice pre-therapy, 1 and 3 weeks post-therapy) and CT (same as FDG-PET and every 6 weeks post-therapy until progression or death). Early response biomarkers included the decrease in SUVmean (DiSUV), sum of diameters (DiSOD) and sum of volumes (DiSOV). For the primary hypothesis, metabolic response (MR) was defined as a decrease of >2SD the variability between baseline PET scans (30%). Exploratory analyses of the biomarkers at various thresholds were performed.    Results', '  The primary hypothesis was met', ' DCR was 34.6% (80% CI', ' 17.5%, 48.2%) higher in patients with a MR at day 8 (p = 0.033); the association was stronger for day 22. The table compares hazard ratios derived from the \"optimal\" % decrease (smallest upper 80% confidence limit) over the 10% to 50% (by 10%) range for all biomarkers and time points, by PFS and OS.    Conclusions', '  FDG-PET was predictive for clinical responses after 8 days of treatment. Comparing all biomarkers, DiSOV had stronger associations than both DiSUV and DiSOD with PFS or OS. For NSCLC treated with erlotinib in this clinical context, the decrease in CT-based tumor volume may be a better early predictor of clinical outcome than FDG-based SUVmean.   Hazard ratio and the 80% confidence interval by change in biomarker and time.']",
        "Doc_id":"ASCO_92928-114",
        "Doc_title":" FDG-PET and CT as early predictors of outcome in NSCLC patients treated with erlotinib.",
        "_version_":1606189011392528384},
      {
        "Meeting_name":" Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.",
        "Background":"['Background', ' Immune checkpoint inhibitors are active for patients with stage IV NSCLC who have progressed following platinum-based chemotherapy. We evaluated responses to chemotherapy in patients who had progressed on a checkpoint inhibitor. Methods', ' Eligible patients were adults with NSCLC who received salvage chemotherapy following PD-1/PD-L1 inhibitors (cases) versus no PD-1/PD-L1 inhibitors (controls). CT-imaging was done within 4 weeks of initiation of salvage chemotherapy and every 6 weeks thereafter. Revised RECIST guidelines were used to define response. Clinical and imaging data were abstracted from review of electronic medical records. Multivariate logistic regression analysis was used to calculate probability of response. Results', ' Three-hundred and fifty patients charts were reviewed and 82 patients met eligibility criteria. Among evaluable patients, 46 were males. Sixty-seven patients were cases versus 15 controls. Fifty-six patients received nivolumab, 7 pembrolizumab and 4 atezolizumab. Sixty-three (77%) had adenocarcinoma, 18 (22%) squamous cell carcinoma and 1 (1%) large cell carcinoma. The mean number of chemotherapy regimens prior to salvage chemotherapy was 2.37 (95% C.I. 2.10-2.64)) in cases versus 1.93 (95% C.I', ' 1.32-2.54) in controls. Salvage drugs included docetaxel (62%), pemetrexed (20%), gemcitabine (12%), paclitaxel (6%). Eighteen (27%) cases had partial response to chemotherapy versus 1(7%) controls. Fifteen (22%) cases had progressive disease versus 6 (40%) controls. Thirty-four (51%) cases had stable disease versus 8 (53%) controls. The odd ratio for achieving a partial response was 0.30 (95% CI', ' 0.18 to 0.50, P = 0.000). In multiple logistic regression model, age, gender, number of prior chemotherapy regimens, tumor histology, smoking status, different salvage chemotherapy regimens were not associated with the likelihood of achieving a partial response. Conclusions', ' The odds of achieving a partial response to salvage chemotherapy were more than 3 times higher inpatients with prior exposure to PD-1/PD-L1 inhibitors. Ongoing investigations include the duration of response as well as evaluation of toxicity.']",
        "Doc_id":"ASCO_190933-199",
        "Doc_title":" Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.",
        "_version_":1606189017865388032},
      {
        "Meeting_name":" KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    Mutations in genes of the KEAP1-NFE2L2 pathway of patients with NSCLC are associated with an increased tumor growth, resistence towards cytostatic drugs and reduced survival rates. KEAP1 suppresses NFE2L2 under physiological conditions. Oxidative stress or electrophiles cause NFE2L2 to stabilize and translocate to the nucleus, resulting in the transcription of various cytoprotective genes. Mutations in KEAP1 are described for diverse tumor entities with a relatively high frequency causing an increased level of NFE2L2. This leads to resistance of cancer cells against anti-cancer drugs and irradation. This study was performed to characterize KEAP1-mutated NSCLC clinically and genetically.  Methods', '    Tumor tissue collected from 446 patients within a regional screening network was analysed for KEAP1 mutations using next-generation sequencing (NGS). Clinical, pathological and genetic characteristics of these patients are described and compared with a control group of patients without KEAP1 mutation.  Results', '    So far, we identified 33 patients with KEAP1 mutations. Among these we found 34 different mutations, of which the majority was not previously described. KEAP1 mutations were not restricted to a special exon. In 30 patients (90.9%), additional driver aberrations in KRAS, EGFR,FGFR1, FGFR3, STK11, ALK, DDR2, HRAS, BRAF, PIK3CA, PTEN, NFE2L2, EP300, TSC1, CREBBP, NRAS, MET and Her2 could be detected, as well as mutations and polymorphisms in TP53. KEAP1 mutations occurred in both genders (male/female ratio 3/1), in squamous-cell carcinoma (36.4%) and adenocarcinoma (60.6%) and were significantly associated with smoking. The prognostic and predictive impact of KEAP1 mutations in a prospective cohort will be presented.  Conclusions', '    Our data suggest a role of KEAP1-mutations as a cofactor in addition to classical driver mutations underlying the malignant phenotype of lung cancer cells. So far, this is the largest cohort of patients with KEAP1-mutations analysed and described. Further survival and treatment analyses will reveal the role of these mutations for the outcome of these patients.']",
        "Doc_id":"ASCO_149401-156",
        "Doc_title":" KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).",
        "_version_":1606189028646846464},
      {
        "Meeting_name":" A single institution's experience in the use of bevacizumab in advanced non-small cell lung cancer.",
        "Background":"['Background', ' Bevacizumab, a humanized monoclonal anti-VEGF antibody, has demonstrated significant clinical benefit in the first-line treatment of advanced nonsquamous non-small cell lung cancer. However, numerous exclusion factors limit the proportion of patients eligible for bevacizumab. We sought to evaluate the exact proportion of patients eligible or ineligible for bevacizumab in a consecutive series of advanced NSCLC patients in a large academic/private practice, and to characterize the reasons for exclusion or inappropriate usage of bevacizumab. Methods', ' A retrospective review of all new patients with stage IIIB (wet)/IV lung cancer at UTCI from January 2007 through October 2009 was conducted. Data were abstracted from the EMR. Bevacizumab eligibility criteria were those of ECOG 4599 (Sandler, 2006). University of Tennessee IRB approved. Results', ' 212 patients were identified of whom 199 were fit for systemic treatment (see Table). 75 patients were bevacizumab eligible, 55 of whom received bevacizumab (73.3%). Of the 20 eligible patients who did not receive bevacizumab, all received either a platinum doublet (16) or erlotinib (4). Only 13 patients (9.5%) met exclusion criteria and received bevacizumab. There was no statistically significant difference in the above groups on the basis of any demographic variables including gender, race, and age. Conclusions', ' In our cohort, the proportion of patients eligible for bevacizumab was low (35%). Overall, only 68/212 (32%) patients received bevacizumab. The majority of patients at our institution remain either bevacizumab ineligible or were treated with alternative regimens. Despite the survival advantage seen with bevacizumab in ECOG 4599, the majority of NSCLC patients are ineligible and future studies should target this population, either by expanding the eligibility criteria or by using novel agents. DemographicsTotal (N = 212)Age<651176595Sex Male130Female82RaceAA103Ca83Other/NOS26HistologyAdenocarcinoma111Squamous75Large5NOS21StageIIIB (wet)18IV194Bevacizumab eligibilityEligible75Ineligible137Reasons for ineligibilitySquamous histology75CNS mets40Uncontrolled HTN1Significant CV disease7Hemoptysis6Other8']",
        "Doc_id":"ASCO_53243-74",
        "Doc_title":" A single institution's experience in the use of bevacizumab in advanced non-small cell lung cancer.",
        "_version_":1606189040329031680},
      {
        "Meeting_name":" CT413 is a novel dual Axl/Mer inhibitor that potently inhibited the growth of Axl overexpressed tumors",
        "Background":"['Receptor tyrosine kinases (RTKs), which play an important role in cell signal transduction, are proven therapeutic targets for the treatment of human cancers. Axl and Mer are members of the TAM family which also includes Tyro-3. Axl has been established as a strong drug target candidate for therapeutic inhibition of cancer invasion and dissemination. As metastatic disease is the most frequent cause of cancer patient mortality, therapeutics specifically aimed at inhibiting metastatic dissemination and colonization would be important additions to the arsenal of drugs in clinical use. Some FDA-approved or in clinical trial molecules block Axl and Mer activity, however, there is no inhibitor clearly designed to inhibit Axl and Mer on the market. As a potential new therapy against malignant tumor, the development of Axl and Mer dual inhibitors is of great significance.CT413 is a novel, orally bioavailable Axl/Mer inhibitor that is currently in our preclinical development pipeline. In biochemical assay, CT413 potently inhibit Axl and Mer with respective IC50 values of 4 and < 1 nM. Among 97 kinase screened, CT413 inhibited Met and Ron receptor tyrosine kinases with IC50 values of 3 and 9 nM, respectively. Furthermore, CT413 blocked the Axl, Met and Ron autophosphorylation in cells with IC50 values of 13, 34 and 540 nM, respectively, demonstrating high kinase selectivity in both biochemical and cell-based assays. CT413 potently suppressed tumor growth in BALB/cA-nu/nu mice bearing subcutaneous human tumor xenografts. For example, in A549 (NSCLC), SK-OV-3 (ovarian) and K562 (CML) tumor models, CT413 inhibited tumor growth with TGIs of 84%, 110% and 66% dosed orally at 30 mg/kg QD, as compared to the vehicle-treated group. CT413 did not inhibit CYP450 subtype 3A4, 2D6, 1A2, 2C9 and 2C19 (IC50 > 10 M) and showed no induction effect on CYP450 subtype 1A2, 2B6 and 3A4. Furthermore, the IC50 of CT413 at hERG sodium ion channel was determined to be greater than 30 M, indicating its minimal cardio-liability. CT413 exhibited good metabolic stability when incubated with human or rat microsome. Pharmacokinetic studies performed in rodents and large animals showed that CT413 had low clearance and high oral exposures across animal species. The oral bioavailability for mice, rats, dogs and monkeys are 133%, 85%, 83% and 68% respectively. The non-GLP 28-day toxicity studies in rats and dogs indicated that CT413 has an excellent therapeutic window. Based on these promising results, CT413 is advanced in our project pipeline as a clinical candidate for cancer therapy.']",
        "Doc_id":"AACR_2015-789",
        "Doc_title":" CT413 is a novel dual Axl/Mer inhibitor that potently inhibited the growth of Axl overexpressed tumors",
        "_version_":1606188976517939200},
      {
        "Meeting_name":" Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer.",
        "Background":"['Background', '  Although C and D both demonstrate activity resistance can develop. Preclinical studies demonstrated that activation of MET requires c-SRC. We hypothesized that a c-SRC inhibitor (D), in combination with a MET inhibitor (C), may overcome resistance and demonstrate activity. This study is the first in-human attempt to combine C and D.   Methods', '   This is a 2 arm concurrent phase I study (3+3) to determine the safety of oral C and D (Table). Arm A', ' C fixed at 250mg BID with escalation of D. Arm B', ' D was fixed at 140mg QD with escalation of C. Endpoints included MTD, DLT, RP2D at least 10 evaluable pts at MTD of each arm and response (RECIST 1.1).  Results', '  47 pts were enrolled. Median age was 59 yrs (16- 76), 3 median prior therapies (1 - 11). Most common cancers were prostate (21%) and sarcoma (19%).  27 pts in Arm A were enrolled. 10 pts were not evaluable', ' consent withdrawal (n=3) primarily for G2 AEs, missed doses <15% (n=7) primarily for early progression. Among 17 pts evaluable for DLT/AE (dose level [DL] 1 [n=13], DL2 [n=4]), 7 pts (41%) had at least one G3 drug-related AE with diarrhea (n=3) the most common AE. 2/4 pts had DLTs at DL2 (all G3; dehydration, infection, nausea, vomiting [n=1 each]). We expanded Arm A DL1 to determine the MTD with 1/13 pts with DLT (G3 esophageal pain).  Arm B, 20 pts were enrolled. 6 pts were not evaluable', ' consent withdrawal (n=1), missed doses (n=5). Among 14 pts evaluable for DLT/AE (DL1 [n=10], DL2 [n=4]), 5 pts (36%) had at least one G3 drug-related AE with fatigue (n=3) being the most common. 2/4 pts had DLT at DL2 (G3 renal failure, G3 fatigue, G3 anorexia [n=1 each]). We expanded Arm B DL1 to determine the MTD with 2/10 pts with DLT (G3 fatigue [n=2]).  Based on number of DLTs in the MTDs of each arm, our preliminary RP2D is DL1 on Arm A.  2 pts had PR (prostate [-34%] and uterine carcinosarcoma [-27%]) and 2 pts had SD  6 months (NSCLC [10.1] and melanoma [(+)14.4]).  Conclusions', '  Preliminary RP2D for the combination is C (250mg PO BID) + D (50 mg QD). Responses have been observed and specific tumor and molecular expansions are ongoing.    Clinical trial information', ' NCT01744652Arm A Crizotinib 250 mg BIDDasatinib (mg)DL 150 QDDL 270 QDDL 3100 QDDL 4120 QDDL 5140 QDClinical trial information', ' NCT01744652Arm B  Dasatinib 140 mg QDCrizotinib (mg)DL 1250 QODDL 2200 QDDL 3250 QDDL 4200 BIDDL 5250 BID']",
        "Doc_id":"ASCO_151549-156",
        "Doc_title":" Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer.",
        "_version_":1606189008813031424},
      {
        "Meeting_name":" SNAI2 expression by cancer-associated fibroblasts is a negative prognostic factor in non-small cell lung cancer",
        "Background":"['The tumor microenvironment is increasingly recognized as a contributor to cancer development and progression since several stromal components, including fibroblasts, interact with cancer cells regulating their behavior and ultimately affecting tumor phenotype. Using primary cultures of human fibroblasts isolated from resected lung cancers we previously demonstrated that co-injection with cancer cells results in increased tumorigenicity and altered expression of ECM related genes in heterotypic tumors. To identify factors involved in the cross-talk between fibroblasts and lung cancer cells, microarray gene expression profiling was performed on 60 fibroblast lines from cancerous and normal lung tissue from primary lung cancer patients, including 25 pairs of normal (NF) and cancer-associated fibroblasts (CAF) from the same patients. Lines were also characterized for presence of the activation marker alpha-SMA and for in vivo pro-tumorigenic activity by co-injection with A549 adenocarcinoma cells. Class comparison analyses identified', ' (i) Factors highly expressed in cancer-associated fibroblasts (CAF) compared to normal fibroblasts (NF)', ' RHOB, SNAI2, EDIL3, LRRN3, CHN1, CTSC, NOPE and DOCK10; (ii) Genes highly expressed in activated fibroblasts', ' POSTN, TNFAIP6, CLEC2B and (iii) Genes associated with an in vivo pro-tumorigenic phenotype', ' CNTN3, ELOVL6, MET, XPO1.To explore the potential prognostic value of these microenvironment related markers, we selected antibodies against 20 proteins differentially expressed in lung fibroblasts and evaluated their performance in immunohistochemistry on FFPE sections of 74 cases of NSCLC. Selection criteria to prioritize candidates for IHC were based on results from molecular analyses (both microarray hybridization and Real-Time PCR validation) and involvement in biological pathways identified as potentially relevant by Gene Set Enrichment Analysis (GSEA). The frequency of positive cells was evaluated on', ' cancer cells, cancer-associated fibroblasts (CAF) and fibroblasts in normal tissue adjacent (AF) or distant (NF) from the surgical margin. This in-depth analysis revealed heterogeneous expression of different proteins with factors predominantly expressed by cancer cells (LRRN3) and others by the stromal component (CLEC2B). Among factors expressed by fibroblasts, positivity for NOPE, MET, CTSC and CLEC2B was detected in the majority of cases (60-70%) and they were generally expressed at higher frequency by CAF compared to NF. In univariate Cox models, SNAI2 expression by CAF was shown to correlate with worst overall survival (p=0.0288) and we further identified association of CNTN3 expression by CAF with shorter disease free survival (p=0.0125).These findings strengthen the hypothesis that identification of factors responsible for proficient tumor-stroma cross-talk could be instrumental in innovative strategies for risk assessment.']",
        "Doc_id":"AACR_2014-2852",
        "Doc_title":" SNAI2 expression by cancer-associated fibroblasts is a negative prognostic factor in non-small cell lung cancer",
        "_version_":1606189020481585152},
      {
        "Meeting_name":" TWIST1 is required for suppression of apoptosis in oncogene driven non-small cell lung carcinoma",
        "Background":"['A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. The most common oncogene driver mutation is mutant KRAS for which no effective therapies exist. In addition, acquired resistance to currently available targeted therapies for oncogene driver dependent disease is inevitable. Our lab has demonstrated that inhibition of the basic helix-loop-helix transcription factor, TWIST1 in KRAS mutant, EGFR mutant, and MET amplified NSCLC can induce either oncogene induced senescence or apoptosis. The fact that a subset of oncogene dependent NSCLC undergo apoptosis following TWIST1 inhibition suggests that these cells are potentially addicted to TWIST1 and might be more vulnerable to TWIST1 inhibitors. Importantly, we have identified the harmala alkaloid, harmine, as a novel TWIST1 inhibitor which could inhibit growth in several oncogene driver defined NSCLC cell lines and decrease TWIST1 levels via degradation. Given that TWIST1 is rarely expressed post-natally, therapies targeting TWIST1 may have minimal toxicities.In the current study, we examine the key TWIST1 functions, target genes and apoptotic pathways that are required for suppression of apoptosis. We found that genetic or pharmacological (harmine) inhibition of TWIST1 resulted in apoptosis in several oncogenic driver dependent cell lines. TWIST1 inhibition resulted in cleavage of caspase 3, 8, 9, and PARP. TWIST1 inhibition resulted in increased levels of Bid, Bim, and TNFRSF10B, as well as, reduced c-FLIP and Bcl-2 levels. Conversely, we demonstrated that TWIST1 overexpression leads to increased levels of c-FLIP and anti-apoptotic Bcl-2 family members as well as decreased levels of Bid. Overexpression of Bcl-2 or c-FLIP resulted in partial abrogation of apoptosis following TWIST1 silencing. These findings suggest that the intrinsic and extrinsic pathways are important for TWIST1 mediated suppression of apoptosis. Preliminary gene expression analysis of NSCLC cells following TWIST1 silencing has identified multiple candidate target genes in these apoptotic pathways. In addition, structure/functional analysis of TWIST1 suggests that nuclear localization, homo- and heterodimerization and proper phosphorylation of TWIST1 are necessary for suppression of apoptosis. Remarkably, TWIST inhibition with harmine treatment decreased tumor growth in our mouse model of KrasG12D/Twist1 NSCLC as well as decreased TWIST1 expression and induced apoptosis.In summary, we found that TWIST1 was required for suppression of apoptosis in several oncogenic driver dependent cell lines. Furthermore, the apoptosis observed after TWIST1 inhibition is dependent on the intrinsic and extrinsic pathways possibly mediated through c-FLIP and Bim. Our studies will establish the molecular pathways that are required for suppression of apoptosis with the ultimate goal of identifying predictive biomarkers of response to TWIST1 inhibitors.']",
        "Doc_id":"AACR_2015-21",
        "Doc_title":" TWIST1 is required for suppression of apoptosis in oncogene driven non-small cell lung carcinoma",
        "_version_":1606189004086050817},
      {
        "Meeting_name":" EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC",
        "Background":"['Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond to EGFR tyrosine kinase inhibitors (TKI) but ultimately develop resistance to these therapies. The most common mechanism of resistance is a second site gate-keeper mutation within exon 20 of EGFR (T790M), followed by MET and other receptor tyrosine kinase amplification/activation. We developed a covalent mutant-selective EGFR inhibitor, EGF816 that potently inhibits both activating EGFR mutations as well as the T790M resistance mutation while sparing wild-type EGFR. EGF816 demonstrated strong tumor regressions in several EGFR activating and resistant tumor models in vivo. These include H1975 (L858R; T790M), HCC827 (exon 19 del) and H3255 (L858R) that are representative of the relevant clinical settings. In all of the models EGF816 inhibited tumor growth in a dose dependent manner and achieved regressions of established tumors at well tolerated doses. In single dose studies, EGF816 showed sustained inhibition of pEGFR, consistent with the irreversible binding mechanism of EGF816. EGF816 also performs exceptionally well in long term dosing studies providing durable responses in the preclinical models. Together, this data indicates that EGF816 exhibits excellent anti-tumor activity in the relevant patient derived tumor cell lines at well tolerated doses and is expected to provide long term duration of responses compared to current EGFR TKI therapy in the clinic.']",
        "Doc_id":"AACR_2014-1733",
        "Doc_title":" EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC",
        "_version_":1606188971099947008},
      {
        "Meeting_name":" Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' X-396 is a novel, potent anaplastic lymphoma kinase (ALK) small molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1 and SLK. We report data on ALK TKI-naive and crizotinib (C)-resistant NSCLC pts treated with X-396. Methods', ' In this multicenter expansion study, pts with ALK+ NSCLC were treated with X-396 225 mg daily on a 28-day schedule. Pts had measurable disease, ECOG PS 0-1, untreated brain metastases (CNS) and leptomeningeal disease were allowed. NGS on plasma samples was performed at baseline and on study and compared with central tissue results (FISH/IHC). All pts were assessed for response to therapy using RECIST 1.1, adverse events (AEs) using CTCAE version 4.03 were recorded. Results', ' 60 pts (53% female) have been enrolled. Median age 56 (20-79) years, 67% ECOG PS 1. Of 30 ALK+ NSCLC pts evaluable for response; partial response (PR) was achieved in 19 pts (60%) and stable disease (SD) in 2 pts (7%). In the C-nave pts (n = 8), PRs were observed in 7 pts (88%). In the 12 pts with prior C but no other ALK TKI, 10 pts (83%) achieved PR and 1 (8%) SD. Median duration of response was 24 - 128 wks. In the 8 pts who had received two or more prior ALK TKIs, there was 1 PR, 3 SD (50% DCR) with response duration of 8-32 wks. CNS responses have been observed in both C nave and C resistant pts. Plasma and tissue genotyping are available on 27 pts (26 ALK + and 1 ALK -) ALK was detected in plasma in 16 pts all had a response to therapy, two pts were tissue +ve and -ve on plasma testing and had PD, 9 plasma samples were inevaluable. Serial sequencing demonstrated a decrease in ALK in pts responding and an increase at the time of progression. The most common drug-related AEs (  20% of pt s) included rash (48%), nausea (26%), vomiting (23%), and fatigue (21%). Most AEs were Grade (G) 1-2. The G3 treatment-related AEs were rash (8 pts), fatigue (1 pt), decreased appetite (1 pt), pruritus (1 pt), and face edema (1 pt). Conclusions', ' X-396 is well-tolerated and induces response in both C-naive and C-resistant ALK+ NSCLC pts, as well as pts with CNS disease. Plasma sequencing may be used to select pts for therapy and monitor for response and development of acquired resistance. Clinical trial information', ' NCT01625234']",
        "Doc_id":"ASCO_169016-176",
        "Doc_title":" Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).",
        "_version_":1606188974879014912},
      {
        "Meeting_name":" Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Induction of PD-L1 expression due to constitutive oncogenic signaling has been reported in NSCLC models harboring EML4ALK rearrangements. Here we explore whether the combination of ALKi (ceritinib) and PD1-inhibitor (NIVO) will provide sustained clinical benefit to pts with ALK+ NSCLC. Methods', ' This phase 1 dose escalation study enrolled previously treated (ALK inhibitor [ALKi] or chemotherapy) or tx-naive pts with stage IIIB/IV ALK+ NSCLC; who received NIVO 3 mg/kg IV Q2W + ceritinib with low-fat meal, at 450 mg/day (group 1) or 300 mg/day (group 2) until progression/unacceptable toxicity. Primary objective', ' MTD/recommended dose for expansion. Dose escalation was guided by Bayesian logistic regression model with overdose control. Results', ' Median follow-up', ' group 1 (n = 14) 13 mos (10-15); group 2 (n = 22) 6 mos (2-10). As of 9 Sep 2016, 16/36 (44%) pts discontinued tx', ' disease progression (11 [31%] pts), AEs (3 [8%] pts), and death (2 [6%] pts). In group 1, 4 pts experienced DLT', ' pancreatitis (n = 2), lipase and transaminase increase (n = 1), and autoimmune hepatitis (n = 1). In group 2, 2 pts experienced DLT', ' G3 ALT increase. Both dose levels met Bayesian criteria for dose expansion. Overall most frequent (40%) AEs (n = 36), were diarrhea (64%), ALT increase (56%), AST increase (44%) and vomiting (42%). Most frequent ( > 10%) grade 3 AEs were increases in ALT (22%), GGT (17%), amylase (11%), and lipase (11%), and maculopapular rash (11%). Incidence of rash (grouped term) was 61%; similar in both groups. Grade 3 rash was reported in 29% pts in group 1 and 14% pts in group 2. Preliminary ceritinib steady state PK (AUC0-24 and Cmax) suggested that 300 mg/day exposure was ~ 70-75% of 450 mg/day. Confirmed (c)/unconfirmed (u) ORR', ' ALKi-pretreated pts (group 1 [n = 8], group 2 [n = 12]) was 63% (4 cPR,1 uPR; 95% CI', ' 25%, 92%), and 33% (4 uPR) 95% CI', ' 10%, 65%) respectively; ALKi-nave pts, (group 1 [n = 6], group 2 [n = 10]) was 83% (5 cPR; 95% CI', ' 36%, 100%), and 70% (1 cCR, 3 cPR 3uPR; 95% CI', ' 35%, 93%) respectively. Conclusions', ' Ceritinib + NIVO is an active combination in ALK+ NSCLC. However, the protocol will be amended to address observed toxicities. Data will be updated for presentation. Clinical trial information', ' NCT02393625']",
        "Doc_id":"ASCO_185625-199",
        "Doc_title":" Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188986071515136},
      {
        "Meeting_name":" Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.",
        "Background":"['Background', ' ALK represents one of the newest tyrosine kinase targets in lung cancer.  In a seminal phase I trial, the ALK tyrosine kinase inhibitor crizotinib showed marked antitumor activity in patients with advanced, ALK+ NSCLC.  However, in the absence of randomized data, the impact of crizotinib on overall survival (OS) of these patients is not known. Methods', ' We examined survival of 82 ALK+ patients who enrolled in the expansion cohort of the phase I trial of crizotinib (Kwak et al., NEJM, 2010).  For comparators, we identified 37 ALK+ patients from phase I sites who were not treated with crizotinib (ALK+ controls), as well as 253 ALK-/EGFR- patients from one site (ALK- controls).  All ALK+ and ALK- controls had advanced NSCLC. Results', ' In 82 ALK+ patients treated with crizotinib, 1-yr OS was 77% and 2-yr OS was 64%; median (med) OS has not been reached (NR).  OS did not differ based on sex (p=0.35), ethnicity (Asian vs non-Asian, p=0.46), smoking history (never vs any smoking, p=0.82) or age (< or  > 60 yrs, p=0.93).  Among the 37 ALK+ controls, 1- and 2-yr OS was 73% and 33%, respectively, and med OS was 20 mos.  As ALK+ controls were identified at sites outside of Korea, we compared controls with the non-Korean cohort of crizotinib-treated patients (n=56).  Both groups were similar in age (median 51 vs 51, p=0.97), sex (57% vs 46% F, p=0.40), smoking history (68% vs 79% neversmokers, p=0.33), presence of brain mets at any time (49% vs 48%, p=1.00), number of prior therapies (mean 2.05 vs 2.09, p=0.17), and types of prior chemotherapy.  We examined subsets of ALK+ patients by line of therapy.  Survival of 32 patients treated with 2nd /3rd line crizotinib was significantly longer than that of 24 ALK+ controls (p=0.004)', ' 1-yr OS was 71% vs 46%, 2-yr OS was 61% vs 9%, and med OS was NR vs 11 mos for the subset of crizotinib-treated patients vs the subset of ALK+ controls, respectively.  For 123 ALK- controls in the 2nd line setting, the 1- and 2-yr OS was 49% and 33%, respectively, and the med OS was 11 mos. Conclusions', ' In patients with ALK+ NSCLC, crizotinib therapy is associated with a higher OS than that of historical, crizotinib-nave controls.  We propose that crizotinib represents a new standard of care for patients with ALK+ NSCLC.']",
        "Doc_id":"ASCO_76959-102",
        "Doc_title":" Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.",
        "_version_":1606188990597169152},
      {
        "Meeting_name":" Phase 3 study of first-line crizotinib vs pemetrexedcisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' The phase 3 study PROFILE 1014 showed a superior outcome of crizotinib over PCC in ALK+ NSCLC. A phase 3 study of similar design (ongoing; NCT01639001) was conducted in an East Asian population in China, Hong Kong, Malaysia, Taiwan, and Thailand. Methods', ' The study was designed to detect an improvement in median PFS from 6.4 to 10 mo with 80% power and 1-sided type I error of 0.025. Between Sep 2012 and Jul 2014, 207 pts with previously untreated ALK+ advanced NSCLC were randomized 1', '1 (stratification', ' ECOG PS 0/1 vs 2) to receive crizotinib 250 mg PO BID (n = 104) or pemetrexed 500 mg/m2 with either cisplatin 75 mg/m2 or carboplatin AUC 56, IV q3w for  6 cycles (n = 103). Continuation of/crossover to crizotinib after PD (per independent radiological review) was allowed. The primary endpoint was PFS; key secondary endpoints were ORR, OS, safety, and PROs. Results', ' In the crizotinib and PCC arms, respectively, 91% and 93% were Han Chinese, 95% and 95% had ECOG PS 0/1, and 20% and 31% had brain metastases. The study met its primary objective', ' crizotinib significantly prolonged PFS vs PCC (HR', ' 0.40; 95% CI', ' 0.290.57; 1-sided P < 0.0001; median 11.1 and 6.8 mo). The ORR was significantly higher with crizotinib (87.5% vs 45.6%; 2-sided P < 0.0001). At data cutoff, 82 pts (80%) on PCC had crossed over to crizotinib and 59% of pts (122/207) remained in follow-up. With only 35% of OS events, there was a numerical (not statistically significant) improvement in OS with crizotinib (HR', ' 0.90; 95% CI', ' 0.561.45; 1-sided P = 0.33). Crizotinib and PCC safety profiles were consistent with those previously published. The most common all-causality AEs with crizotinib were elevated transaminases (69%), diarrhea (59%), and vision disorder (56%); the most common grade 3/4 AEs were neutropenia (16%) and elevated transaminases (12%). Two grade 5 AEs (death of unknown cause, interstitial lung disease) were considered crizotinib-related. Conclusions', ' These results confirm the findings from PROFILE 1014 and demonstrate that first-line crizotinib significantly improves PFS and ORR vs PCC in an East Asian population with ALK+ advanced NSCLC with an acceptable safety profile. Clinical trial information', ' NCT01639001']",
        "Doc_id":"ASCO_165546-176",
        "Doc_title":" Phase 3 study of first-line crizotinib vs pemetrexedcisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).",
        "_version_":1606188979028230144},
      {
        "Meeting_name":" Retrospective review of concurrent chest radiation and chemotherapy (CRT) in newly diagnosed stage IV non-small cell lung cancer (NSCLC) with oligometastatic disease (OM) treated with stereotactic radiation.",
        "Background":"['Background', 'The primary treatment for patients (pts)with stage IV NSCLC is palliative chemotherapy (CT), with a median OS of approximately 10-12 months, and 5-year survival of ~2%. Several studies have demonstrated that pts with a lung nodule with a solitary brain or adrenal metastasis can achieve relatively high 5-year survival rates with resection of the metastasis and the lung nodule. Studies have also demonstrated that OM can be effectively treated with stereotactic body radiation (SBRT) or stereotactic radiosurgery (SRS) to the brain. We hypothesize that treatment of OM with SBRT and/or SRS and treatment of the thoracic disease with CRT will improve survival over palliative chemotherapy alone. Methods', 'A retrospective review of charts in the RADTRACS database at the Univ of Florida was conducted between 1/1/2010 - 6/30/2015 to identify pts with newly diagnosed stage IV NSCLC with 5 or less OM at diagnosis that were treated with concurrent CT and definitive RT (60-66 Gy) to the primary lung mass in addition to SRS and/or SBRT to the OM. Date and site of first progression, and date of death/last follow-up were noted. Endpoints included median progression free survival (PFS) and median overall survival (OS). Results', '26 pts met these criteria. 20 pts (77%) had recurrence of disease after treatment with CRT + SRS/SBRT. Median PFS was 6 months, and median OS was 14.4 months. Of the 20 recurrences, 10 (50%) were in the brain, while 10 (50%) were in non-CNS sites. One year OS was 60% and 3-year survival was 33% in our patients. When pts with CNS OM at diagnosis were compared to non-CNS OM, PFS (5.5 vs 5.8 months, respectively, p > 0.05) and OS (16.6 vs 13.8 months, respectively, p > 0.05) were similar. 8/12 CNS OM pts progressed in the brain while only 3/9 non-CNS OM progressed in the brain. Of the 5 patients with no progression, 4/5 had non-CNS OM at diagnosis. Conclusions', 'When compared to standard palliative CT where median OS 10-12 months, median OS was 14.4 months in our pts treated with CRT + SBRT/SRS. This data suggests a possible role for more aggressive treatment of stage IV NSCLC pts with SBRT/SRS to OM and definitive chest CRT.']",
        "Doc_id":"ASCO_184630-199",
        "Doc_title":" Retrospective review of concurrent chest radiation and chemotherapy (CRT) in newly diagnosed stage IV non-small cell lung cancer (NSCLC) with oligometastatic disease (OM) treated with stereotactic radiation.",
        "_version_":1606188985119408128},
      {
        "Meeting_name":" Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.",
        "Background":"['Background', ' BRG is a potent and selective ALK inhibitor with preclinical and clinical activity against wild-type ALK and a broad range of mutants associated with clinical CRZ resistance, including G1202R. Herein we examine the association between BRG efficacy and ALK mutation status using plasma specimens from the initiation of BRG treatment (baseline [BL]) and the end of BRG treatment (EOT) in CRZ-resistant ALK+ NSCLC pts enrolled in the BRG Ph1/2 or pivotal Ph2 (ALTA) trials. Methods', ' Plasma samples were analyzed using the Resolution Bioscience ctDx Lung Panel v3.0. BRG activity was described using the confirmed objective response rate (cORR) (RECIST v1.1). Data are reported as of May 31, 2016 for the Ph1/2 (NCT01449461) and ALTA (NCT02094573) trials. Results', ' Of 291 CRZ-resistant ALK+ NSCLC pts enrolled in the Ph1/2 (N = 69) and ALTA (N = 222) trials, evaluable plasma samples were obtained from 67 pts at BL. cORR to BRG in these pts was 49% (33/67). An ALK fusion was detected in plasma in 45% (30/67) of these pts (cORR 57% [17/30]), of whom 33% (10/30) had secondary ALK mutations (cORR 50% [5/10]) and 67% (20/30) did not (cORR 60% [12/20]). Best responses in pts with secondary ALK mutations were', ' 2 CR (ALK amplification [Amp] copy number [CN] = 10; T1151M); 3 PR (L1196M; E1408V; Amp CN = 6); 4 SD (L1196M; E1419K; F1174C; C1156Y+S1206F+G1269A); 1 PD (T1151R+C1156Y+E1161D+F1174L). Of 67 pts with evaluable plasma at BL, 35 discontinued BRG therapy, of whom 20 had evaluable samples collected at EOT. No new mutations were detected at EOT in 75% (15/20) of pts. Complex mutation patterns were associated with resistance in the remaining 25% (5/20)', ' High-level ALK-Amp (CN = 58); ALK-Amp (CN = 14)+MET-Amp (CN = 6); ALK-S1206F+S1206C+Amp (CN = 6); ALK-G1202R+L1196M+L1198Q; ALK-G1202R+BRAF-V600E+KRAS-G12D. Conclusions', ' ALK fusions were detected in plasma in < 50% of CRZ-resistant ALK+ NSCLC pts. BRG had substantial activity in ALK fusionpositive pts with a range of CRZ-resistance mutations. Neither primary nor secondary resistance to BRG was associated with any single plasma ALK mutation. The therapeutic implications of complex secondary resistance patterns associated with BRG require further exploration. Clinical trial information', ' NCT01449461, NCT02094573']",
        "Doc_id":"ASCO_183510-199",
        "Doc_title":" Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.",
        "_version_":1606188985743310848},
      {
        "Meeting_name":" Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714).",
        "Background":"['Background', '  Vandetanib (V) is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling. Single-agent gemcitabine (G) is a standard of care option for unselected patients (pts) unfit for doublet platinum based chemotherapy. This study assessed the progression-free survival (PFS) benefit of G+V compared to G plus placebo (P) in pts with advanced NSCLC aged  70 years.  Methods', '  Eligible pts (stage IIIB/IV NSCLC; WHO PS 0-2; all histologies; chemonave, aged 70) were randomized 1', '1 to receive G 1200 mg/m2 i.v. day 1 and 8 of each 21-day cycle, up to 6 cycles plus V 100 mg/day or plus P until progression/toxicity. The primary objective was PFS (80% power to detect a hazard ratio [HR]  0.667). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Results', '  Between Oct 2008-May 2010, 124 pts (median age 75 yrs (70-84); 72.6% male; 57.2% WHO PS 0-1; 74.2% past/never-smoker; 58.1% adenocarcinoma; 89.5% stage IV) were randomized to G+V (n = 61) or G+P (n = 63). Baseline characteristics were similar in both arms. At data cut-off (Apr11), 87.9% pts progressed and 73.4% pts had died. PFS was significantly prolonged for G+V (HR=0.729; 95% CI 0.484-1.096; p=0.0417), median PFS G+V=6.0 months, G+P=5.5 months. No differences were seen in ORR (14.8% and 12.7%; p = 0.74), DCR (72.1% and 66.7%; p =0.51), OS (HR=1.024 [95% CI 0.667-1.571] p=0.8960), proportion of pts alive at 1-year G+V=31.1% and G+P=30.2% (p=0.90). Adverse events (AEs) observed for V 100 mg were generally consistent with previous NSCLC studies of V 100 mg. Common AEs (any grade) occurring with a greater frequency in the G+V arm included skin toxicity (34.4% vs 15.9%) and hypertension (9.8% vs 3.2%). Diarrhea and neutropenia were similar in both arms (14.8% and 14.3%; 19.7% and 19.0%). Conclusions', '  Despite a marginally statistically significant improvement in PFS the study did not met the primary and secondary end points. The combination G+V was well tolerated in this clinical setting.']",
        "Doc_id":"ASCO_96537-114",
        "Doc_title":" Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714).",
        "_version_":1606188994390917120},
      {
        "Meeting_name":" Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' Adding bevacizumab to weekly paclitaxel (wPB) has shown synergistic effect and increased activity in various tumor types. The ULTIMATE study evaluated wPB vs. docetaxel (DOC) as 2nd or 3rd-line treatment in patients with advanced non-squamous NSCLC. Methods', ' Patients with non-squamous NSCLC progressing after 1 or 2 lines of treatment including platinum-based chemotherapy were randomized 2', '1 (stratified by PS, previous lines, prior exposure to bevacizumab) to wPB (paclitaxel 90 mg/m D1, 8, 15 and bevacizumab 10 mg/kg D1, 15, q28d) or DOC (75 mg/m q21d) until progression. Patients were allowed to cross-over to the other arm following progression. The primary endpoint was progression-free survival (PFS). Results', ' From 05/2013 to 08/2014, 166 patients were randomized (wPB', ' 111, DOC', ' 55). Clinical characteristics were balanced between both arms. 31% had received previous bevacizumab and 69% had received 1 previous line of treatment. Median follow-up was 28.9 months. The adjusted hazard ratio (HR) for PFS was 0.62 (IC95%', ' 0.44-0.86, p=0.005). Median PFS was 5.4 months for wPB vs. 3.9 months for DOC. Efficacy was observed regardless of number of previous lines (1 line', ' HR 0.56, IC95% [0.39-0.89], p=0.01; 2 lines', ' HR 0.56, IC95% [0.30-1.04], p=0.07). ORR was 22.5% with wPB and 5.5% with DOC (p=0.006). 21 out of 55 pts treated with DOC crossed over to wPB. No difference in OS was observed (median wPB 9.9 months, DOC 10.8 months, adjusted HR 1.15, p=0.49). Grade 3-4 adverse events (AE) occurring during the first sequence of treatment were comparable between wPB and DOC (45.9% and 54.5%) and included neutropenia (19.3% vs. 45.4%), asthenia (8.3% vs 5.5%), neuropathy (8.3% vs. 0.0%) and hypertension (7.3% vs. 0.0%). Grade 3-4 bleeding AEs upon wPB occurred in 0.9% of patients. 3 patients had grade 5 drug-related AEs (1.8% in each arm). Conclusions', ' ULTIMATE trial mets its primary endpoint. wPB significantly improved PFS and ORR vs. DOC in advanced non-squamous NSCLC patients as second or third-line treatment, with a manageable safety profile. wPB should be considered as a treatment option in this setting. Clinical trial information', ' NCT01763671']",
        "Doc_id":"ASCO_167643-176",
        "Doc_title":" Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC)",
        "_version_":1606188999528939520},
      {
        "Meeting_name":" A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).",
        "Background":"['Background', '  Pemetrexed or gefitinib is one of the standard second-line treatments for advanced non-squamousNSCLC in East Asia. The CTONG 0806 a multi-center, randomized, controlled, open-label phase II trial was designed to explore the efficacy of pemetrexed versus gefitinib as the second-line treatment in advanced NSCLC patients without EGFR mutation.  Methods', '  The patients with locally advanced or metastatic, non-squamous NSCLC previously treated with platinum-based chemotherapy and no EGFR mutation in exons 18-21 were enrolled. Patients were 1', '1 randomized to receive either gefitinib 250 mg per oral every day (G arm) or pemetrexed 500 mg/m2 iv day 1 with vitamin B12 and folic acid supplement every 21 days (P arm) until disease progression, unacceptable toxicity, or discontinuation of treatment due to other reason. The primary endpoint was progression-free survival (PFS). The secondary endpoints were 4-month and 6-month progression-free survival rate, overall survival (OS), objective response rate (ORR), quality of life using the FACT-L questionnaire and safety, EGFR and K-ras mutation status were evaluated and correlated with outcomes.  Results', '  From Feb. 2009 to Aug. 2012, 157 evaluable patients were randomized (81 cases in G arm and 76 in P arm). Baseline age, gender, and ECOG performance status were balanced between arms. The primary endpoint of PFS was met with 1.6 months for G arm versus 4.8 months for P arm, the HR is 0.51 (95% CI 0.36~0.73, P<0.001). Overall response rates were 14.7 % and 13.3 % (P=0.814) and DCR were 32.0% and 61.3% (P<0.001) for G arm and P arm, respectively. OS data were not yet mature. More skin rash and diarrhoea were seen in G arm, but more fatigue and ALT increased in P arm. CTCAE grade 3 or 4 of AEs was 12.3% in G arm and 32.9% in P arm (p=0.002). The further analyses of efficacy evaluated by IRR and biomarkers analysis will be presented on the ground.  Conclusions', '  CTONG0806 is the first trial to show significant improvements in PFS and DCR with pemetrexed compared with gefitinib in second-line setting for advanced NSCLC with EGFR wild type. Patients with EGFR wild type did not benefit from EGFR TKI gefitinb in second-line setting. Clinical trial information', ' NCT00891579.']",
        "Doc_id":"ASCO_109906-132",
        "Doc_title":" A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).",
        "_version_":1606189023482609664},
      {
        "Meeting_name":" SWOG 0709",
        "Background":"['Background', '  Advanced NSCLC pts with Zubrod PS2 are often excluded from clinical trials and platinum-based therapy. In SWOG 0341, ERL in PS 2 pts yielded progression-free (PFS) and overall survival (OS) of 2.1 and 5 months respectively. In a trial of ERL versus C/T in PS2 pts (Lilenbaum, JCO 2008), PFS for ERL and C/T were 1.9 and 3.5 months. Early reports suggested a potential role for serum proteomics in predicting ERL benefit beyond that of EGFR mutational status. We conducted a trial in PS2 pts enriched by serum proteomics (Veristrat-good).  Methods', '  NSCLC pts with PS2 and Veristrat-good status were randomized to either Arm A (ERL 150 mg po QD) or Arm B (ERL 150 mg po QD d2-16 + carbo AUC 5 IV day 1, paclitaxel 200 mg/m2 IV d1 x 4 cycles, then ERL 150 mg QD).  Cycles were q3 weeks. Arm B agents were pharmacodynamically separated to mitigate potential antagonism. The arm with superior observed median PFS would be selected for further evaluation, but only if  3 months. A sample size of 98 pts was based on a variety of assumed PFS probabilities for each arm. The trial prematurely closed after the FDA determined an IDE application was required for VeriStrat; however SWOG had limited resources available for such filing.  Results', '  Of 156 pts screened, 83 (59%) were Veristrat-good, of which 59 (60%) met trial eligibility & were randomized. Treatment-related grade 4 adverse events were seen in 2 pts in Arm A (DVT, hypoMg+); 5 pts in Arm B (neutropenia 5, febrile neutropenia 1, leukopenia 1). Conclusions', '  In PS2 pts with advanced NSCLC and Veristrat-good status, ERL + C/T (vs. ERL alone) had better observed median PFS/OS and surpassed the protocol-specified benchmark of PFS >= 3 months required for further study.  Clinical trial information', ' NCT00661193Arm A', ' ERL (N=33)Arm B', ' ERL + C/T (N=26)p-valueCharacteristics (n,%)Median age (years)7571Male sex14 (42%)10 (38%)Adenocarcinoma27 (82%)23(88%)Never smoker6 (18%)6 (23%)EfficacyResponse rate* (n, %)2/32 (6%)6/26 (23%)0.06DCR* (n, %)13/32 (41%)20/26 (77%)0.0046PFS (median, months)1.64.60.06OS (median, months)6110.27*Subset w/ measurable disease at baseline.']",
        "Doc_id":"ASCO_143014-156",
        "Doc_title":" SWOG 0709",
        "_version_":1606189033483927552},
      {
        "Meeting_name":" A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).",
        "Background":"['Background', '    An unmet medical need exists in NSCLC pts after failure of E or G [reversible EGFR tyrosine kinase inhibitors (TKIs)], particularly in pts with T790M EGFR mutations, the most common mechanism of acquired resistance. Afatinib (A), an irreversible erbB family blocker, has preclinical activity against T790M. A was tested in this phase II study in pts enriched for acquired resistance to E or G.  Methods', '   Pts in Japan with Stage IIIB/IV NSCLC (ECOG PS 01) who had progressed according to RECIST after 12 lines of chemotherapy and 12 wks of E or G received 50 mg A orally qd. The primary endpoint was objective tumor response.   Results', '  Of 62 pts (F', '48; M', '14), 11.3%, 79% and 9.7% had received prior erlotinib, gefitinib or both, respectively. 65% of pts had achieved a prior response with E/G. Median duration between end of prior treatment with E/G and the start of A was 3 wks.  73% of pts were EGFR mutation-positive in their primary tumors.  82% of pts met the definition of acquired resistance to E/G by (1) EGFR mutation positive or (2) CR/PR to E/G or (3) SD for at least 6 months to E/G and (4) less than 4 wks off E/G.  By investigator assessment, 13% of pts treated with A had a PR and the disease control rate (DCR >8 wks) was 72%; these values were 8.2% and 67%, respectively, by independent review.  Median PFS was 4.6 months.  Similar efficacy was seen in those pts meeting acquired resistance criteria (5.9% PR; 69% DCR; median PFS of 4.4 months, by independent review).  Two pts had T790M mutations in their primary tumors; one, harbouring L858R+T790M, had a long SD (308 days).  At data cut-off, the 25th percentile of OS was 10.6 months.  Common adverse events included diarrhea, rash/acne, stomatitis, nail effects and decreased appetite.  Conclusions', '   Pts in this study largely meet criteria for acquired resistance to first generation EGFR TKIs in NSCLC.  Afatinib has demonstrated clinically meaningful efficacy (including 69% DCR >8 wks and 4.4 month median PFS) in these pts.']",
        "Doc_id":"ASCO_83135-102",
        "Doc_title":" A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).",
        "_version_":1606189033791160320},
      {
        "Meeting_name":" S0536",
        "Background":"['Background', ' Cetuximab (CX) plus platinum-based chemotherapy improves overall survival (OS) in advanced NSCLC (FLEX). SWOG previously showed that EGFR FISH is associated with efficacy outcomes in patients (pts) receiving CB/P/CX (S0342). Bevacizumab (B) plus chemotherapy also increases survival (E4599) in eligible pts. Given the biologic rationale for combining EGFR and VEGFR targeted agents, S0536 investigated the safety and efficacy of carboplatin (CB), paclitaxel (P) and CX plus B. Methods', ' Eligibility', ' treatment-nave advanced stage non-squamous cell NSCLC, no requirement for EGFR positivity, PS 0-1, no brain metastases or hemoptysis. Treatment', ' CB AUC 6, P 200 mg/m2, B 15 mg/kg IV day 1 every 3 weeks, CX 400 mg/m2 day 1 then 250 mg/m2 weekly for up to 6 cycles; then B 15 mg/kg every 3 weeks and CX 250 mg/m2 weekly until progression. Primary endpoint', ' feasibility defined by the frequency and severity of grade 4 hemorrhagic toxicities. Secondary endpoints', ' response rate, progression-free survival (PFS), OS and toxicity. Results', ' 110 pts enrolled from August 2006 to September 2007; 104 assessable. Pt characteristics', ' median age 64 years (42-78), Male/Female 52/52, PS 0/1 43/61, stage IIIB/IV 9/95, adenocarcinoma', ' 81, current/former smoker', ' 82. Overall toxicities were acceptable and comparable to S0342 and E4599. Primary endpoint was met', ' grade 4 hemorrhage', ' 2% (95% CI', ' 0-7%). There were 4 treatment-related deaths', ' lung hemorrhage (2), infection (1), unknown (1). Partial response (PR)', ' 51/95 assessable (54%; 43%-64%); Stable disease (SD)', ' 22/95 (23%). Disease control rate (PR+SD)', ' 77%. With median follow up of 15 months (mos), PFS is 7 mos (18 pts remain progression-free) and OS is 14 mos. 1 year survival is 57% (47-67%). EGFR IHC by H score (>0 vs 0) showed a nonsignificant trend toward improved survival', ' 15 vs 11 mos (p=0.14). Conclusions', ' CB/P, CX plus B demonstrates safety, tolerability and efficacy in advanced NSCLC and is the most active regimen studied to date in SWOG. Additional S0536 biomarker studies including EGFR FISH will be presented. S0819, a Phase III trial of CB/P  CX (plus B in eligible pts) is under development and is designed to validate EGFR FISH as a predictive biomarker.']",
        "Doc_id":"ASCO_31259-65",
        "Doc_title":" S0536",
        "_version_":1606189034209542144},
      {
        "Meeting_name":" Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST)",
        "Background":"['Background', ' We performed a randomized study to assess the effect of aggressive LCT in patients with oligometastatic NSCLC who did not progress after IST. Methods', ' This study was performed at MD Anderson, U. Colorado, and London HSC, Canada. Eligibility', ' 1) histologically confirmed NSCLC, 2) Stage IV disease, 3)  3 metastases, and 4) no RECIST progression after IST. Appropriate IST was defined as either  4 cycles of platinum doublet therapy or  3 months of erlotinib/crizotinib for patients with EGFR mutations/ALK fusions, respectively. Patients were randomized to either LCT ([chemo]radiation or surgical resection of all sites) +/- systemic therapy (ST) vs. ST alone. The ST regimen was physician choice from predefined standard-of-care regimens. The primary endpoint was PFS, with the hypothesis that immediate LCT would improve PFS time from 4 months to 7 months (HR = 0.57) using ITT analysis. The planned study size was 94 randomized patients. Randomization was balanced dynamically by number of metastases, IST response, CNS metastases, nodal status, and EGFR/ALK status. Results', ' Based on the DSMC recommendation, the study was closed early due to significant efficacy benefit observed in the study arm. 49 patients were randomized from 2/2013-1/2016 (25 in LCT arm), 7 of which had EGFR/ALK alterations. At a median follow-up time of 16.2 months, the median PFS time in the LCT arm was 14.4 months (95% CI 5.2 months-NR), compared to 3.9 months (95% CI 2.2-6.6 months) in the no-LCT arm (HR = 0.36, p = 0.013). Seventeen patients in the no-LCT arm crossed over, 14 due to progression. No grade 3-5 toxicity was observed in the LCT group. Of the 28 patients that progressed (12 in LCT, 16 in no-LCT), 7 had progression in the primary site, 3 in a known metastasis, 7 in a different metastasis, and 11 in a combination of sites. The median overall survival time has not yet been reached and patients continue to be followed for this endpoint. Conclusions', ' In oligometastatic NSCLC patients (  3 mets) without progression after IST, immediate LCT +/- ST improved PFS compared to ST alone. Clinical trial information', ' NCT01725165']",
        "Doc_id":"ASCO_169928-176",
        "Doc_title":" Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST)",
        "_version_":1606189034639458304},
      {
        "Meeting_name":" Hypofractionated radiotherapy for oligometastatic non-small cell lung carcinoma.",
        "Background":"['Background', ' Outcomes data on treatment of oligometastatic (OM) non-small cell lung carcinoma (NSCLC) with hypofractionated image guided radiotherapy (HIGRT) are limited. Methods', ' Consecutive OM NSCLC patients were reviewed. Treatment of all active disease was required. Lesions receiving prior radiation or with radiographic/metabolic resolution after chemotherapy were inactive, and did not receive HIGRT. Time to progression (TTP) was defined as time from the start of HIGRT to any failure. Local failure was defined as 20% increase in size on single dimensional axial measurement. Lesion control (LC), TTP, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Multivariate analysis (MVA) was performed using Cox proportional hazards regression. Results', ' Of 26 patients screened, 24 met the inclusion criteria. Median follow-up was 12.4 months. Median age was 66 yrs. Ten patients had adenocarcinoma, 14 had newly diagnosed stage IV disease, and 11 received HIGRT for progressive disease (PD) after chemo. Eighteen patients received systemic therapy prior to HIGRT, having received an average of 1.3 regimens. Seventeen patients received HIGRT to all disease and 7 received treatment to active disease only. A median of 2 (range 1-5) OM lesions were treated per patient. Median OS and TTP were 16.7, and 8.1 months, respectively. The 1 yr OS and PFS were 76.7% and 48.1%, respectively. On MVA, newly diagnosed stage IV disease independently predicted TTP (HR 0.22, p = 0.04). Fifty-eight individual lesions were treated, with a median size of 2.65cm (range 0.6 to 9.6 cm). Median total and fraction dose were 42 (range 18-70) and 8 Gy (range 3.5-18), respectively. The 1 yr LC was 84%. The calculated median standard equivalent dose (SED) in 2 Gy fractions was 64.6 Gy for extracranial lesions. SED  64.6 Gy was associated with a trend towards increased control (18 mo LC 89 vs 52%, p = 0.06). Two patients experienced grade 3 toxicity. Conclusions', ' Treatment of OM NSCLC with HIGRT is safe and provides durable LC when sufficient doses are used. Future studies should be aimed at optimizing patient selection for HIGRT and integration with systemic therapy.']",
        "Doc_id":"ASCO_50791-74",
        "Doc_title":" Hypofractionated radiotherapy for oligometastatic non-small cell lung carcinoma.",
        "_version_":1606189041154260992},
      {
        "Meeting_name":" Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' Optimal chemotherapy for older patients with advanced NSCLC is still undetermined. Both single agent D and the combination of D&G are active and well-tolerated. The aim of this study was to compare the efficacy of single-agent weekly D with weekly D&G in elderly patients with advanced NSCLC. Methods', ' This multicenter, one-stage, randomized phase II trial aimed to identify the most promising of the two regimens; 49 patients per arm were planned, with  8 objective responses required for the \"winner\" to warrant further study. Chemotherapy-naive patients with stage wet-IIIB/IV NSCLC aged  70 years, with ECOG performance status  2 were randomized to receive D (35 mg/m2) on days 1, 8, and 15 (arm A) or D (35 mg/m2) plus G (800 mg/m2) on days 1, 8, and 15 (arm B). In both arms, treatment was repeated every 4 weeks for a maximum of 4 cycles. The primary end point was response rate (RECIST); secondary endpoints were', ' toxicity, time-to-progression (TTP), survival. Results', ' between July 2002 and November 2009, 75 patients were randomized; 69 were evaluable (intention to treat). Enrollment was closed early due to slow accrual. Median age was 75 years (range 70-82). There was 1 (3%) CR in arm B, with 5 (14%) and 10 (28%) PRs in arms A and B, respectively. Disease control (CR+PR+SD) was achieved in 56% and 73% of patients in arms A and B, respectively. Median survival was 7.2 months in arm A and 7.9 months in arm B (p = 0.58; HR = 1.15, 95% CI 0.69-1.9). Median TTP was longer in arm B (7.4 months and 3.9 months; p = 0.099, HR = 1.57, 95% CI 0.91-2.7). Grade 3-4 neutropenia was more common with D&G than D (3% and 25%, respectively; p = 0.013), as was anemia (3% and 9%, respectively). No case of neutropenic fever was observed. Nonhematological toxicity was mild with all grades fatigue occurring in 58% and 78% of patients receiving D and D&G, respectively. Conclusions', ' treatment with D&G resulted in higher response rate and modest improvement in TTP but not survival when compared with single-agent D. The combination of D&G has met the statistical endpoint of  8 responses and is worthy of further investigation.']",
        "Doc_id":"ASCO_52918-74",
        "Doc_title":" Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC)",
        "_version_":1606189041836883968},
      {
        "Meeting_name":" Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.",
        "Background":"['Many of the patients with non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR)-mutation who initially responded well to EGFR-tyrosine kinase inhibitors (TKIs) eventually relapse. In spite of many studies over the last few years to elucidate this mechanism of acquired resistance to EGFR-TKIs, approximately 30% of the mechanisms of acquired resistance are still unknown. Recently autocrine signaling of fibroblast growth factors (FGFs) and their receptors (FGFRs) has been demonstrated in NSCLC cell lines. And several studies suggest that the FGF-FGFR autocrine growth pathway could be an important mechanism for intrinsic resistance to EGFR-TKIs in NSCLC cell lines with wild-type EGFR. But until now, no report has clarified the role of FGF-FGFR pathway in acquired resistance to EGFR-TKIs in NSCLC cell lines with sensitive EGFR mutations. We have established a gefitinib-resistant cell line (PC9 GR), by serial exposure of gefitinib to PC9, an originally gefitinib-sensitive lung cancer cell line (PC9 na). We confirmed that these cell lines did not harbor two well-known EGFR-TKI resistance mechanisms, the second mutation in the EGFR gene itself, EGFR T790 and the amplification of the MET oncogene. We collected total RNA from both PC9 na and PC9 GR and examined mRNA expression profile, by using cDNA microarray analysis. We found the expressions of FGFR1 and FGF2 were increased in PC9 GR compared to in PC9 na. The growth of PC9 GR cells was inhibited either by PD173074 (inhibitors of FGFRs) or knocking down of FGFR1 or FGF2 by siRNA in combination with gefitinib. FACS analysis revealed that the combination treatment with PD173074 and gefitinib induced apoptosis more efficiently in PC9 GR cells compared to gefitinib alone. PC9 na cells and PC9 GR cells did not show any change in the proportion of apoptotic cells after treatment with PD173074 alone. To further investigate how FGF2-FGFR1 pathway affects resistance to gefitinib in these cell lines, the downstream targets of EGFR signaling including the MEK-ERK and PI3K-AKT pathways were examined. In PC9 na cells, the phosphorylation of EGFR, ERK, and AKT was efficiently inhibited by gefitinib alone. On the other hand, in PC9 GR cells, the phosphorylation of ERK and AKT was not efficiently inhibited by gefitinib alone. However, the inhibition of phosphorylation of ERK was completely and AKT was less efficiently rescued by gefitinib and PD173074 combination therapy. In conclusion, these data suggest the activation of FGF2-FGFR1 signaling pathway contributes to the gefitinib resistance in PC9 GR. FGF2-FGFR1 pathway will be a therapeutic target for a subset of NSCLC that acquires EGFR-TKI resistance.']",
        "Doc_id":"AACR_2013-5652",
        "Doc_title":" Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.",
        "_version_":1606188990165155840},
      {
        "Meeting_name":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "Background":"['Targeted deep massive parallel sequencing (MPS) has been implemented in routine molecular diagnostics for high-throughput genetic profiling of formalin-fixed paraffin-embedded cancer samples. This approach is now widely used to interrogate simple somatic mutations but experience with the analysis of copy number variations (CNV) is still limited. Here, we retrospectively analyzed CNVs in 822 cancer cases (n = 135 melanoma, n = 468 non-small cell lung cancers (NSCLC), n = 219 colorectal cancers (CRC)) that were sent to our institution for routine molecular profiling using a semiconductor based sequencing platform. Amplifications and deletions inferred by MPS coverage data were independently validated by a qPCR assay. We observed a decreasing frequency of CNV in clinically actionable genes from melanoma to NSCLC to colorectal cancer.Of 56 melanomas with genetic aberrations in BRAF, 31 showed co-occurring CNV in other genes, mainly affecting CDKN2A. Some tumors (5 cases each) revealed clustered deletions affecting either ABL1, NOTCH1, and RET or STK11, GNA11, and JAK3. 8.1% of the cases had amplifications in clinically actionable genes. In the group of NRAS mutant tumors (n = 39), 26 showed co-occurring CNVs in other genes, such as CDKN2A and FGFR3, and 9 NRAS mutant cases were additionally mutated in BRAF. 19.1% had amplifications in clinically actionable genes. In contrast to BRAF mutant tumors, we did not see any specific CNV clusters. In the group of BRAF/NRASwt tumors (n = 11), we observed 5 cases with co-amplification of KDR, KIT, PDGFRA and another 6 cases with KIT mutations. While co-amplified cases had many gene deletions, KIT mutated tumors harbored only very few genetic aberrations in other genes.Across both NSCLC data sets, we identified 14 cases with amplified EGFR (10 of them harboring co-occurring EGFR mutations) and detected 8 NSCLC with KRAS amplifications (of which 7 had co-occurring mutations of KRAS). KRAS mutated tumors displayed frequent amplifications in MYC (n = 10) and MDM2 (n = 5). Of the 22 BRAF mutant tumors, two harbored mutated KRAS. In contrast to melanoma, we observed no clustering of CNVs in BRAFmut NSCLCs. Within the group of KRAS/EGFR/BRAFwt tumors, we identified 15 cases harboring genetic aberrations in MET (n = 8 mutations, n = 7 amplifications).Compared to melanoma and NSCLC, the number of CNV in CRC was rather low. IGF2 amplifications were most prevalent (n = 13) followed by MYC (n = 9). Two cases showed amplified wild-type alleles of KRAS. Two KRAS mutant tumors showed concomitant amplification of NRAS and three cases harbored amplified EGFR.In conclusion we demonstrate that i) detection of CNVs by targeted MPS data obtained from FFPE material is feasible and ii) could be validated independently, iii) this approach enables detection of known CNV patterns, and iv) uncovers new CNV patterns in clinically actionable targets across cancers.']",
        "Doc_id":"AACR_2016-3167",
        "Doc_title":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "_version_":1606188994698149888},
      {
        "Meeting_name":" PARAMOUNT",
        "Background":"['Background', ' The PARAMOUNT trial investigated whether pem continuation maintenance therapy improves progression-free survival (PFS) after pem-cisplatin induction therapy in patients (pts) with advanced nonsquamous NSCLC. Methods', ' In this double-blind, placebo-controlled trial, 939 pts participated in the induction phase, specified as four cycles of induction pem (500 mg/m2) and cisplatin (75 mg/m2) on day 1 of a 21-day cycle. Pts who had not progressed during pem-cisplatin induction and had an Eastern Cooperative Oncology Group performance status (PS) of 0/1 (n=539; 57.4%) were randomized (2', '1, stratified for disease stage, PS, and induction response) to maintenance pem (500 mg/m2 on day 1 of a 21-day cycle) plus BSC (n=359) or placebo plus BSC (n=180) until disease progression. All pts received vitamin B12, folic acid, and dexamethasone. The primary endpoint was PFS (target', ' HR=0.65, two-sided alpha=0.05; 90% power with minimum of 238 events). Results', ' Pt characteristics were balanced between arms', ' median age=61 years; 58% male; 95% Caucasian; 32% PS 0; 91% stage IV; 87% adenocarcinoma; and 45% induction complete/partial response. Pem continuation maintenance resulted in a 36% reduction in the risk of progression (HR=0.64, 95% CI', ' 0.51-0.81; P=0.00025). The median independently reviewed PFS (472 pts, 297 events), measured from randomization, was 3.9 months (95% CI', ' 3.0-4.2) on the pem arm, and 2.6 months (95% CI', ' 2.2-2.9) on the placebo arm. The disease control rate (% pts with response/stable disease) was 71.8% on the pem arm, and 59.6% on the placebo arm (P=0.009). The drug-related serious adverse event (AE) rate was 8.9% on the pem arm, and 9.2% of pts had grade 3/4 laboratory Common Toxicity Criteria AEs. On the placebo arm, the rates were 2.8% and 0.6%, respectively. Discontinuations due to AEs were 5.3% on the pem arm, 3.3% on the placebo arm. Conclusions', ' PARAMOUNT met its primary endpoint and showed that pem continuation maintenance following pem-cisplatin induction is an effective and well tolerated treatment for pts with advanced nonsquamous NSCLC.']",
        "Doc_id":"ASCO_78420-102",
        "Doc_title":" PARAMOUNT",
        "_version_":1606188973339705344},
      {
        "Meeting_name":" Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC.",
        "Background":"['Background', ' Third generation (3rd gen) epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to treat EGFR T790M-mediated resistance to EGFR TKIs by inhibiting EGFR T790M, as well as EGFR L858R and EGFR exon 19 deletions. The mechanisms of resistance to third-generation EGFR TKIs are largely unknown and clinical cross-resistance among 3rd gen EGFR TKIs has not been routinely evaluated. Osimertinib is an FDA-approved irreversible 3rd gen EGFR TKI. In patients with EGFR T790M mutant NSCLC, the response rate (ORR) to osimertinib is 61%. EGF816 is a covalent, irreversible, 3rd gen EGFR TKI in clinical development. In early phase data of EGF816, the ORR was 47% and disease control rate was 87% in patients with EGFR T790M mutant NSCLC. To assess clinical cross-resistance between EGF816 and osimertinib, we evaluated the clinical outcomes of patients treated with osimertinib in patients previously treated with EGF816 during the phase I/II trial. Methods', ' Patients with metastatic EGFR mutant lung adenocarcinoma were identified who were previously treated with EGF816 and received osimertinib after progression of disease on EGF816 (NCT02108964). All patients had documented T790M mutation prior to treatment with EGF816. The best overall response to osimertinib was determined by RECIST 1.1 criteria. Duration of clinical benefit was defined as duration of osimertinib therapy. Results', ' Fourteen (3 men, 11 women, median age 58 [range 33-77]) patients met eligibility criteria at our centers. The ORR to subsequent osimertinib therapy was 14% (1 CR, 1 PR, 8 SD, 4 POD). Patients continued treatment with osimertinib for a median of 9 months (95% CI 3.8-10.1, [median follow up 11 months, range 1-13 months]). 5 patients are still on osimertinib to date (one patient each 3+, 6+, 8+, 11+, and 12+ months). Conclusions', ' This series suggests a potentially meaningful clinical benefit for patients with sequential therapy with two different third-generation EGFR inhibitors, emphasizing the importance of understanding resistance mechanisms (genetic alteration of target, bypass signaling, pharmacology, etc.) and raising the possibility of the need for multiple third generation EGFR TKIs in clinical practice.']",
        "Doc_id":"ASCO_186066-199",
        "Doc_title":" Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC.",
        "_version_":1606188973791641600},
      {
        "Meeting_name":" Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing.",
        "Background":"['Background', '  Detection of tumor genetic alterations is critically needed for lung cancer clinic as well as for the development of molecular targeted therapeutics. Here we report the results of a broad spectrum of genetic alterations identified in Japanese non-small cell lung cancer (NSCLC) patients by ultra-deep targeted sequencing.  Methods', '  Highly multiplexed amplicon sequencing was performed using genomic DNA extracted from snap-frozen tumor specimens. TruSeq amplicon cancer panel was used for the detection of somatic mutations in 48 cancer related genes followed by ultra-deep sequencing (Illumina) at an average coverage of approximately 2800x. ALK, ROS1 and RET traslocations and EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications were also detected by multiplex RT-PCR and quantitative PCR, respectively.  Results', '  The demographics of 204 consecutive patients enrolled in this prospective study at Shizuoka Cancer Center between July 2011 and November 2012', ' median age 69 years (range', ' 38-92); male 66%; never smoker 25.5%; histology', ' adenocarcinoma 68.6%, squamous cell carcinoma (SQ) 27.0%, others 4.4%; tumor stage', ' I 53.9%, II 28.4%, III 12.7%, IV 4.9%. TP53 mutation was most frequently detected (44.4%) in all patients, particularly in SQ (67.9%). Mutations in genes such as MLH1 (4.9%), STK11 (6.3%), CTNNB1 (5.6%), SMAD4 (1.4%), VHL1 (1.4%), PTPN11 (0.7%) and GNAS (0.7%) were detected besides major mutations in genes such as EGFR (43.0%), KRAS (17.6%) and PIK3CA (14.1%) in adenocarcinoma. PIK3CA (21.4%), MLH1 (5.4%), APC (3.6%), STK11 (3.6%), FGFR2 (1.8%) and VHL (1.8%) mutations were identified in SQ and notably, 48.2% of SQ patients harbored simultaneous gene mutations, suggesting the genetic complexity of this histology. FGFR1 amplification was found in 8.9 % of SQ, suggesting lower frequency in Asian population than in Caucasian population.  Conclusions', '  We managed to detect a wide range of genetic alterations and identified additional actionable mutations besides popular driver mutations. This approach may facilitate elucidation of detailed molecular characteristics of NSCLC, thereby implementing personalized cancer medicine.']",
        "Doc_id":"ASCO_117390-132",
        "Doc_title":" Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing.",
        "_version_":1606188975214559232},
      {
        "Meeting_name":" Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel",
        "Background":"['Background', ' E4599 was a randomized phase III study which demonstrated a survival advantage in advanced NSCLC pts treated with bevacizumab (bev) + carboplatin/paclitaxel (BPC) versus carboplatin/paclitaxel alone (PC). Recent studies have shown certain germline polymorphisms (SNPs) are associated with clinical outcome in advanced breast cancer pts treated with paclitaxel plus bev and in advanced colorectal cancer pts treated with first line 5-FU or capecitabine in combination with oxaliplatin and bev. A study also found 2 SNPs in WNK1 gene were associated with bev-induced hypertension. We tested the hypothesis that SNPs involved in angiogenesis pathway (VEGF, EGF, EGFR, IL-8, KDR, ICAM1, FGFR4), DNA repair pathway (ERCC1, XPD, XRCC1, GSTP1) and WNK1 may predict clinical outcome in a subset of pts enrolled on E4599. Methods', ' Of 878 pts enrolled, samples from 146 pts were available for the current pharmacogenetic study and only 133 of the samples (67 PC, 66 BPC) came from eligible pts. PCR-RFLP assays were performed on genomic DNA extracted from sera of pts. The Kaplan-Meier method was used to estimate time-to-event distributions. Multivariable Cox models adjusted for gender, PS, stage, adrenal, liver and bone mets were separately fitted for each SNP to obtain estimates of hazard ratios. Results', \" Median OS for the 133 patients was 10.3 mos (8.2-15.6) for PC and 13.0 mos (10.2-16.6) for BPC. Median PFS was 4.6 mos (3.6-5.6) for PC & 6.5 mos (5.4-8.3) for BPC. Pts with mutant homozygote CC genotype for ICAM1 T469C had significantly higher tumor response rate (39%) than heterozygote CT (13%) and homozygote TT (20%) genotype (Fisher's test, p=0.04). Tests for whether treatment effect differs by genotype via interaction terms in the Cox models were statistically significant (p<0.05) for VEGF G-634C, ICAM1 T469C and WNK1-rs11064560 for OS, and for ICAM1 T469C, EGF A-61G and CXCR2 C785T for PFS. Conclusions\", ' Although exploratory, our preliminary results suggest germline SNPs in angiogenesis pathway may predict response, PFS and OS in NSCLC pts treated with BPC. Prospective trials based on these correlative studies are warranted.']",
        "Doc_id":"ASCO_33186-65",
        "Doc_title":" Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel",
        "_version_":1606188983401840640},
      {
        "Meeting_name":" NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung cancer patients with leptomeningeal carcinomatosis.",
        "Background":"['Background', ' In current clinical setting, NSCLC patients harboring specific driver mutation were usually treated guiding by prior profiling of the primary tumor when developed to brain metastasis. Some studies have shown that circulating tumor DNA (ctDNA) derived from cerebrospinal fluid (CSF) can reveal unique genomic alterations present in brain malignancies. We assessed CSF as a liquid biopsy media and compared to matched plasma. Methods', ' We performed capture-based ultra deep sequencing on ctDNA derived from matched CSF, plasma of 40 non-small cell lung cancer (NSCLC) patients with suspected leptomeningeal carcinomatosis (LC) using a panel consisting of 168 genes. Results', ' Among the 40 suspected LC cases, 35 were confirmed to have LC, ctDNA in CSF from the 5 non-LC cases are all undetectable. Circulating tumor DNA was detected in 93.8% of CSF and 66.7% of plasma. We compared mutation profiles and identified 86 and 46 SNVs from CSF and plasma, respectively, with 42 SNVs overlapping. Furthermore, ctDNA from CSF revealed many copy number variations (CNVs) that were not detected from plasma (189 CNVs vs. 3 CNVs). The average maximum allelic fraction (AF) of CSF ctDNA is significantly higher than in plasma (56.7% vs. 4.4% p < 10^-6). Twenty-eight patients were pre-treated with EGFR-TKIs and developed subsequent resistance. EGFR T790M and MET amplification were detected in 21% and 39% in CSF, respectively, showing a unique resistance profile among leptomeningeal metastases patients compared to the general population. Interestingly, 60% of CSF samples harbor TP53 loss of heterozygosity, only 11% of which were detected in the matched plasma samples. Such heterogeneity may reflect unique biological themes for brain metastatic tumor sub-clones. Furthermore, 26 patients received molecular targeted therapy based on the results from CSF, and 23 reported alleviation of symptoms at subsequent evaluations. Conclusions', ' Collectively, our data reveal that ctDNA derived from CSF provides a unique and more comprehensive characterization of genomic alterations of leptomeningeal carcinomatosis than plasma, supporting the importance of CSF as a liquid biopsy media.']",
        "Doc_id":"ASCO_193122-199",
        "Doc_title":" NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung cancer patients with leptomeningeal carcinomatosis.",
        "_version_":1606188988255698944},
      {
        "Meeting_name":" LungMATCH",
        "Background":"['Background', ' For metastatic non-small cell lung cancer (NSCLC), guidelines include molecular testing for actionable biomarkers and recommend broad profile testing. Yet previous studies indicate that not all patients with NSCLC receive testing, even for actionable mutations in EGFR, ALK, and ROS. We hypothesized low testing rates for patients calling a community HelpLine and that we could increase rates with one-on-one caller education and free precision medicine services. Methods', ' Caller statistics were collected on the toll-free Lung Cancer Alliance (LCA) HelpLine from Sept 1, 2016  Jan 31, 2017. Recruitment to the LungMATCH molecular testing program began Nov 10, 2017. Patients are recruited through conversations on the LCA HelpLine, then consented into Perthera Cancer Analysis (PCA) through an IRB-approved registry protocol. PCA includes tissue acquisition, multi-omic molecular profiling, and medical review of testing results and clinical and treatment history. PCA reports are returned to both treating physicians and patients. Data is being collected longitudinally on treatment decisions, patient outcomes including progression-free and overall survival, and patient experience. Results', ' Data from the LCA Helpline identified a gap in molecular testing. 50% (57/115) of patients asked if they received any kind of molecular testing replied \"No\". Of 32 patients who were tested and knew the results, patients indicated potentially actionable changes in EGFR(15), ALK(8), PD-L1(3), RET, MET, BRAF, and HER2, along with KRAS (4). Since LungMATCH launch, 23 interested patients were referred for PCA. Six patients consented and are undergoing PCA with seven more in the consent process. Reasons for non-consent include', ' doctor refusal, initiation of testing at the treating institution, concern about financial implications, and one death. Updated results will be presented. Conclusions', ' Our data indicate that patients with lung cancer are not receiving molecular testing in accordance to guidelines. To address this, we created a program through nonprofit-corporate partnership that navigates patients and their physicians through comprehensive precision therapy. This type of program is feasible and there is patient interest.']",
        "Doc_id":"ASCO_186095-199",
        "Doc_title":" LungMATCH",
        "_version_":1606188991565004801},
      {
        "Meeting_name":" Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.",
        "Background":"['Background', ' Molecular profiling is limited by access to sufficient tumor tissue for comprehensive analysis and due to tumor heterogeneity, the complete range of tumor DNA abnormalities may not be represented nor accurately reflect the clinical evolution of disease. Circulating tumor DNA (ctDNA) can be used as a minimally-invasive liquid biopsy for the detection, quantification and monitoring of molecular abnormalities for personalized treatment strategies. Methods', ' In a prospectively designed program, to date, we have recruited 227 advanced NSCLC patients having received prior therapy, with unknown molecular profile at time of blood collection. Blood collections (10ml K2-EDTA) were performed to assess molecular profile prior to or at time of relapse. Repeat samples were performed on patients initiated on treatment and followed for up to 18months. Patient samples were analyzed with InVision (enhanced tagged-amplicon sequencing) using a 34 gene panel. Interim analysis performed with full descriptive summary statistical analyses to be presented at conference. Results', ' ctDNA profiling detected somatic mutations in 182pts (80.2%), predominantly located in TP53 (46%), EGFR (28%), KRAS (11%) and STK11 (7%, half of which had concurrent KRAS). Of note, clinically actionable mutations were detected', ' T790M (25pts, median 1.4% AF), ERBB2 (8 pts), MET (8pts) and BRAF (4pts) providing eligibility for new therapy options. 20pts including 12 EGFR/T790M+ve were evaluated for ctDNA monitoring up to 18 months (median 10m); correlation between dynamic change in mutation allele fraction and clinical response was observed, especially predictive of relapse to treatment. 10 patients demonstrated SD/PR response to osimertinib treatment with T790M detection at low allele fraction (7/10 < 1% AF with 1pt at 0.08% AF). Conclusions', ' ctDNA can be used as a non-invasive liquid biopsy for molecular profiling of NSCLC patients to detect clinically relevant and actionable mutations when tissue biopsy is unavailable. Liquid biopsies can be repeated as needed where tissue is not feasible, providing real-time information to support personalised treatment.']",
        "Doc_id":"ASCO_194012-199",
        "Doc_title":" Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.",
        "_version_":1606188997841780736},
      {
        "Meeting_name":" Lymphovascular invasion as a prognostic indicator in stage I non small cell lung cancer",
        "Background":"['Background', '  Identification of pathologic features able to predict outcomes in resected stage I non-small cell lung cancer (NSCLC) may help to further stratify patients into risk groups, allowing for further refinement of adjuvant treatment recommendations.  We performed a systematic review and meta-analysis to evaluate whether the presence of lymphovacular invasion (LVI) is associated with disease outcome in stage I NSCLC patients.  Methods', '  A systematic search of the literature was performed (1990 to December 2012; Medline/Embase) using search terms related to lymphovascular invasion, lung cancer and prognosis. Studies were considered eligible if they reported the outcome of lung cancer in patients with LVI compared to those without. Pooled Hazard Ratios (HR) were estimated with a random effects model.  Two different endpoints were independently analyzed', ' recurrence-free survival (RFS) and overall survival (OS).  We analyzed both unadjusted and adjusted effect estimates, for a total of four separate meta-analyses.  Several studies presented multiple results (i.e. adjusted and unadjusted and/or recurrence-free and overall survival) and were therefore included in more than one pooled analysis.  Results', '  Of 2,878 titles identified, 20 articles met the inclusion criteria. Of these, 5 studies were excluded from the analysis due to duplication of results (n=4) and lack of data to calculate HR (n=1). The unadjusted models consisted of 808 (RFS) and 1675 (OS) patients, while the adjusted models consisted of 1,545 (RFS) and 2,601 (OS).  The unadjusted pooled effect of LVI was significantly associated with worse both RFS (HR', ' 4.71, 95% Confidence Interval (CI)', ' 3.08-7.21), and OS (HR', ' 3.05, 95% CI', ' 2.34-3.98).  Adjusting for potential confounders yielded the same results with both RFS (HR', ' 2.49, 95% CI', ' 1.6-3.89), and OS (HR', ' 1.80, 95% CI', ' 1.44-2.25) being significantly worse for patients exhibiting LVI in their pathologic specimens.  Conclusions', '  The present study indicates that LVI is an adverse prognostic factor in patients with surgically managed stage I lung cancer. Based on these results, the use of LVI as a stratifying factor in future prospective lung cancer trials seems to be justifiable.']",
        "Doc_id":"ASCO_113873-132",
        "Doc_title":" Lymphovascular invasion as a prognostic indicator in stage I non small cell lung cancer",
        "_version_":1606188998004310016},
      {
        "Meeting_name":" Coexistence of driver aberrations in NSCLC patients including ALK/RET/ROS1 rearrangements.",
        "Background":"['Background', ' Major driver mutations of lung cancer are largely considered to be mutually exclusive. Although a few exceptions of coexisting driver mutations have been noted, it is thought that the coexistence of ALK, RET, and ROS1 rearrangements with other major driver mutations is also rare. However, NGS has allowed us to revisit this assumption given the amount of clinical data that are generated. We report findings of the frequency of driver mutations and their coexistence in a cohort of 181 lung cancer patients tested in our laboratory. Methods', ' A comprehensive molecular- and histopathology-based strategy was conducted on FFPE samples of 181 lung cancer patients. NGS molecular profiling was performed using Molecular Healths Engineus Profile+ 613-targeted gene panel. For patients diagnosed with adenocarcinoma; ALK, RET, and ROS1 rearrangements were evaluated using FISH method (Personalized Dx, CA). Results', ' Including both NGS and FISH analysis, major driver aberrations were detected as follows', ' KRAS codon 12/13 (50, 28%), EGFR exon 19/21 (26, 14%), BRAF V600E (7, 4%), BRAF non-V600E (4, 2%), PIK3CA (5, 3%), ERBB2 amplification (4, 2%), MET amplification (4, 2%), ALK rearrangement (7, 4%), RET rearrangement (3, 2%), and ROS1 rearrangement (2, 1%). The majority (101 out of 109, 93%) of these specimens harbored only one major driver mutation. Coexistence of two major drivers were identified in 8 patients (8 out of 109, 7%), including KRAS/PIK3CA (3), KRAS codon 12/13/BRAF non-V600E (1), ALK fusion/KRAS p.G12V (1), ALK fusion/EGFR p.L858R (1), RET fusion/KRAS p.G12C (1), and RET fusion/EGFR exon 19 del (1). Among tumors with ALK, RET or ROS1 rearrangements, 30% (4/12) harbored another driver mutation. Conclusions', ' Our results illustrate the coexistence of multiple driver mutations in a small but significant number of NSCLC patients, including ALK, RET, or ROS1 rearrangements. Concomitant testing of both ALK, RET, and ROS1 rearrangements and comprehensive molecular profiling of other driver genes may be necessary for better clinical management of NSCLC patients.']",
        "Doc_id":"ASCO_168777-176",
        "Doc_title":" Coexistence of driver aberrations in NSCLC patients including ALK/RET/ROS1 rearrangements.",
        "_version_":1606189002140942336},
      {
        "Meeting_name":" Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.",
        "Background":"['Background', ' Identification of oncogenic drivers is critical in selecting appropriate targeted therapy. Using next-generation sequencing (NGS), we performed comprehensive genomic profiling (CGP) of lung adenocarcinoma tumors. Methods', ' Formalin-fixed paraffin-embedded tumors from 51 lung adenocarcinoma patients whose tumors previously tested negative for EGFR/KRAS/ALK by conventional methods in an ongoing trial (NCT01964157) were collected, and CGP was performed via hybridization capture of 4,557 exons from 287 cancer-related genes and 47 introns from 19 genes frequently rearranged in cancer and next generation sequencing. Results', ' Genomic profiles of all 51 cases were obtained, with a median coverage of 564x and a total of 190 individual genomic alterations (GA). GA per specimen was a mean of 3.7 (range 0-10).Cancer genomes are characterized by 50% (80/190) non-synonymous base substitutions, 15% (29/190) insertions or deletion, and 3% (5/190) splice site mutation. TP53 was the most commonly mutated gene (30%, n = 24/80) among non-synonymous base substitutions, followed by KRAS (10%, n = 8/80) and EGFR (9%, 7/80). Insertions or deletions commonly occurred TP53 (17%, 5/29) and ERBB2 (14%, 4/29), and splice site mutations occurred in TP53, INPP4B, ATR, and MAP2K4. Gene amplification comprised 20% (39/190) of genomic alterations, and MDM2 amplification was the most frequent (13%, 5/39). Homozygous loss comprised 5% (10/190) of all GA which were CDKN2A/B. GA found with NCCN guidelines for NSCLC were identified in 16 patients (31%) (BRAF mutation [n = 1], EGFR mutation [n = 8], ERBB2 mutation [n = 4], MET amplification [n = 1], KIF5B-RET rearrangement [n = 2], CCDC6-RET rearrangement [n = 1], CD74-ROS1 rearrangement [n = 1], EZR-ROS1 rearrangement [n = 5], and SLC34A2-ROS1rearrangement [n = 1]). Other genes that conferred the possibility of benefit from targeted therapy were found in another 14 patients (27%). Conclusions', ' Fifty eight percent of patients wild type by standard testing for KRAS/EGFR/ALK have GA identifiable by CGP that suggest benefit from target therapy. CGP used when standard molecular testing for NSCLC is negative is able to reveal additional avenues of benefit from targeted therapy.']",
        "Doc_id":"ASCO_166704-176",
        "Doc_title":" Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.",
        "_version_":1606189015779770368},
      {
        "Meeting_name":" Development and validation of a real-world clinicogenomic database.",
        "Background":"['Background', ' Genomic findings have diagnostic, prognostic, and predictive utility in clinical oncology. Population studies have been limited by reliance on trials, registries, or institutional chart review, which are costly and represent narrow populations. Integrating electronic health record (EHR) and genomic data collected as part of routine clinical practice may overcome these hurdles. Methods', ' Patients in the Flatiron Health Database with non-small cell lung cancer (NSCLC) who underwent comprehensive genomic profiling (CGP) by Foundation Medicine were included. EHR processing included structured data harmonization and abstraction of variables from unstructured documents. EHR and CGP data were de-identified and linked in a HIPAA-compliant process. Data included clinical characteristics, alterations across > 300 genes, tumor mutation burden (TMB), therapies and associated real-world responses, progression, and overall survival (OS). Results', ' The cohort (n = 1619) had expected clinical (mean age 66; 75% with smoking hx; 80% non-squamous) and genomic (18% EGFR; 4% ALK; 1% ROS1) properties of NSCLC. Presence of a driver mutation (EGFR, ALK, ROS1, MET, BRAF, RET, or ERBB2; n = 576) was associated with younger age, female gender, non-smoking, improved OS (35 vs 19 mo, LR p < 0.0001), and prolonged survival when treated with NCCN-recommended therapy (42 vs 28 mo, LR p = 0.001). CGP identified false negative results in up to 30% of single-biomarker tests for EGFR, ALK, and ROS1. CGP accuracy was supported by clinical outcomes. For example, 5 patients with prior negative ALK-fusion testing began ALK-directed therapy after positive CGP results. All 5 exhibited at least a partial response as recorded in the EHR by treating clinicians. Immunotherapy was used in 22% of patients (n = 353). TMB predicted response to nivolumab, including in PD-L1 negative populations. We recapitulated known associations with smoking, histology, and driver mutations. Conclusions', ' We present and validate a new paradigm for rapidly generating large, research-grade, longitudinal clinico-genomic databases by linking genomic data with EHR clinical annotation. This method offers a powerful tool for understanding cancer genomics and advancing precision medicine.']",
        "Doc_id":"ASCO_194753-199",
        "Doc_title":" Development and validation of a real-world clinicogenomic database.",
        "_version_":1606189018541719553},
      {
        "Meeting_name":" A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' Pemetrexed (Pem) + Cisplatine (Cis) + Bevacizumab (Bev) followed with maintenance therapy (Bev and/or Pem) is a therapeutic standard in advanced non-squamous NSCLC. Methods', ' A single arm phase II trial aimed to evaluate a stop and go strategy', ' Sequence 1', ' 3 cycles Pem 500 mg/m + Cis 75 mg/m + Bev 7.5 mg/kg q3 weeks, followed by maintenance Bev 7.5 mg/kg/3 week until progression ; sequence 2', ' reintroduction Pem + Cis + Bev, 3 cycles, Pem + Bev maintenance until progression. Primary endpoint', ' at least 75% of patients in the sequence 2 received the 3 cycles without cisplatin/carboplatin dose modification. Results', ' from Dec. 2012 to Aug. 2014, 120 patients (77 males) were included in 14 French hospitals', ' PS 0 (50%); median age 60.6 y (36.0  77.3). Of 113 eligible patients, 65 (57.5 %) were treated in sequence 2. 37 patients (56.9%, IC95% [45.1%-73.6%]) received the 3 cycles (sequence 2) at full dose; 86 % (n = 56) with or without dose reduction. At sequence 2, specific bev-induced grade 3  4 toxicity was reported in 7 (10.3%) patients (1 grade 5 haemoptysis). Median follow-up was 27.1m [24.7-29.6]. Secondary objectives showed a median Progression-Free Survival 1 (PFS1) (inclusion  progression 1) 5.8 m (IC95%', '5.0  6.3); median PFS2 (progression 1  progression 2) 6.6 m (IC95%', '5.7  8.4); median duration of disease control (PFS1 + PFS 2) (n = 65) 11.4 m (IC95', '10.1  13.4). Objective response rate after sequence 2 was 15.4% (IC95%', ' 6.6-24.2) with 60% of stable disease. The median overall survival for eligible population was 17.7 m (IC95% 13.1  21.6) and 20.5 m (16.9  NR) for patients who reached the sequence 2 (n = 65). Conclusions', ' Although the stringent primary endpoint was not met, this study highlighted that a stop and go strategy using a platinum-based chemotherapy with bevacizumab continuation beyond progression, compares favourably with standard schedule, deserving to be further studied in non-squamous advanced NSCLC. Clinical trial information', ' NCT01705184']",
        "Doc_id":"ASCO_170303-176",
        "Doc_title":" A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC)",
        "_version_":1606189021545889792},
      {
        "Meeting_name":" Delivery of meaningful cancer care",
        "Background":"['Background', ' ASCO and ESMO have developed frameworks to evaluate the benefit of cancer therapies. Here, we apply the frameworks to a cohort of contemporary randomized controlled trials (RCTs) to explore agreement and to evaluate the relationship between treatment benefit and cost. Methods', ' Characteristic and outcome data from RCTs evaluating systemic therapies in non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), and pancreatic cancer published and cited in PubMed between 2011-2015 were abstracted. Trial endpoints were evaluated using ASCO and ESMO frameworks. Cohens kappa statistic was calculated to determine agreement between the two frameworks, using the median ASCO score as a benefit threshold. Differences in monthly drug cost between RCT experimental and control arms were derived from 2016 average wholesale prices. Analyses included Pearson chi-square tests, Fishers Exact tests, independent samples t-tests, and Pearson correlation to assess the association between continuous variables. Results', ' Fifty percent (136/271) of published RCTs favoured the experimental arm; scoring rubrics were applicable to 109 RCTs (39% NSCLC, 33% breast, 23% CRC, 5% pancreas). ASCO scores ranged from 2 to 72; median score was 25. Thirty seven percent (40/109) of RCTs met benefit thresholds using the ESMO framework. Agreement between frameworks was fair at best ( = 0.28, p = 0.002). When stratified by treatment intent (19 curative, 90 palliative RCTs), agreement remained poor ( = 0.23, p = 0.115;  = 0.34, p < 0.001). Major differences leading to limited agreement includes the relative weights each framework places on HR, endpoints, and toxicity/QOL analysis. Smaller RCT sample size was the only trial characteristic associated with higher ASCO scores (p = 0.015). Among the 100 RCTs for whom drug costing data were available, there was no association between ASCO benefit score and monthly drug costs (r = -0.12, p = 0.22); those meeting ESMO thresholds had a lower mean drug cost than those who did not (p = 0.046). Conclusions', ' There is only fair correlation between ASCO and ESMO clinical benefit frameworks. Drug costs are not associated with ESMO/ASCO measures of magnitude of clinical benefit.']",
        "Doc_id":"ASCO_185086-199",
        "Doc_title":" Delivery of meaningful cancer care",
        "_version_":1606189021629775872},
      {
        "Meeting_name":" Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC)",
        "Background":"['Background', '   Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities of diarrhea and rash. Preclinical data and small clinical series suggest that lower doses of erlotinib are biologically active against EGFR mutations. However, this has not been systematically studied. We aimed to study whether reduced-dose erlotinib is as effective as full-dose erlotinib for EGFR-mutant NSCLC.  Methods', '    An institutional database was reviewed to identify patients (pts) who received erlotinib for advanced NSCLC carrying an EGFR exon 19 deletion or L858R mutation. Using a retrospective chart review, erlotinib dose was determined at treatment start and after 4 months of therapy. Progression free survival (PFS) was calculated from time of treatment start until date when the treating clinician documented clinical disease progression.  Results', '    206 eligible pts were identified', ' 118 exon 19 del, 88 L858R; 144 1st-line, 62 later-line. 34 pts (17%) initiated erlotinib at a reduced dose', ' 100mg (n = 29), 50 mg (n = 4),  25 mg (n = 1). Reduced-dose pts were older than full-dose pts (median age 70 vs. 64 yrs, p < 0.01), but otherwise clinically similar (Table). Reduced-dose pts had a median PFS of 8.8 months, not significantly different from those at full-dose (11.2 months, HR = 1.3, p= 0.14). Of 173 pts who had not progressed at 4 months, the 86 (50%) on reduced-dose erlotinib at that time had a significantly lower median PFS  (11.7 vs. 14.0 months, HR = 1.5, p< 0.05).  Conclusions', '    This is the largest series to date describing outcomes when initiating treatment for EGFR-mutant lung cancer with reduced-dose erlotinib. PFS was acceptable when treating at a reduced biologically active dose, though trends towards a lower PFS than with MTD dosing. A multivariate analysis controlling for baseline differences is underway. Full dose (n = 172)Reduced dose (n = 34)pMedian age (years)64700.004PS', ' 0-1, 2+113, 820, 30.383Brain mets at start57 (33%)9 (26%)0.548Line', ' 1, 2+120, 5224, 101.000Median PFS11.28.80.14 (HR 1.3)']",
        "Doc_id":"ASCO_152121-156",
        "Doc_title":" Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC)",
        "_version_":1606189027781771264},
      {
        "Meeting_name":" Circulating tumor DNA as a non-invasive tool to identify patients at risk for recurrence after chemoradiotherapy in stage III non-small cell lung cancer.",
        "Background":"['Background', ' Outcomes for curative-intent chemoradiotherapy of unresectable stage III non-small cell lung cancer (NSCLC) remains poor. Heterogeneity in tumors is correlated with therapeutic resistance and poor prognosis. We hypothesize that tumor-specific alterations (alts) in circulating tumor DNA (ctDNA) quantifies tumor heterogeneity and can serve as a non-invasive means to determine prognosis and recurrence. Methods', ' Between 2009-2013, 156 patients (pts) with unresectable NSCLC receiving definitive radiotherapy (XRT) or chemo-XRT were consented to have blood drawn pre-XRT, 1-2 times during XRT, and 1-2 times in follow up ( > 670 samples). We used a ctDNA NGS assay to detect SNVs in 70 genes, amplifications in 16, and select fusions and indels. Statistical analyses were performed for association between OS/PFS and ctDNA serial samples results. Here we report the initial interim analysis. Results', ' Of 44 pts, 32 (73%) recurred (PFS range 0-26.6 months) and 12(27%) had no evidence of recurrence as of last contact (1.9-43.5 months post-XRT). We found 4 main patterns of ctDNA changes', ' specific alts persistent throughout XRT (n = 9); no alts detected in the post-XRT sample (n = 14), increased levels from baseline (n = 10), or fluctuates throughout therapy (n = 11). Alleles which persisted throughout XRT were found in TP53, ARID1A, BRCA2, NF1, KRAS, APC, AR, ERRB2, PIK3CA, ATM, MET, BRAF, PDGFRA, CRCA1, NOTCH1, RAF1, GATA3, KIT. While the 4 patterns of cfDNA fluctuations were not found to be prognostic in this interim analysis, the presence of specific mutations appears to correlate with outcomes, with reappearance of the driver mutations post-tx associated with shorter PFS. Using FDR cutoff of 0.1, NF1 mutations were associated with shorter OS (p = 0.07), and APC/ARID1Amutations associated with shorter PFS (p = 0.09) after adjustment for tumor histology or stage. Conclusions', ' In this interim analysis, we found that specific mutant alleles in cfDNA are correlated with potentially treatment resistance and early metastatic recurrence. Final analysis of the larger cohort may be required to achieve significance for additional prognostic patterns.']",
        "Doc_id":"ASCO_171703-176",
        "Doc_title":" Circulating tumor DNA as a non-invasive tool to identify patients at risk for recurrence after chemoradiotherapy in stage III non-small cell lung cancer.",
        "_version_":1606189030688423936},
      {
        "Meeting_name":" Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC.",
        "Background":"['Background', ' The SATURN (BO18192) study investigated whether erlotinib maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had obtained clinical benefit from 1st-line chemotherapy. This study included a prospective analysis of the prognostic/predictive value of several molecular markers. Methods', ' 889 pts with advanced NSCLC whose disease had not progressed following 4 cycles of 1st-line platinum-doublet chemotherapy were randomized to erlotinib 150 mg/day or placebo. Mandatory tumor specimens were collected at baseline and tested for EGFR protein expression using immunohistochemistry (IHC), EGFR gene copy number using fluorescent in-situ hybridization (FISH), and EGFR and KRAS somatic mutations using DNA sequencing. Pts were stratified according to EGFR IHC status (any membranous staining in 10% tumor cells used as cut-off); the co-primary endpoint was PFS in EGFR IHC+ pts. Baseline whole blood samples were obtained for genotyping of EGFR (intron 1 CA-repeat polymorphisms). Results', ' In the overall population, erlotinib significantly prolonged PFS vs placebo (HR 0.71, p<.0001; primary endpoint). The co-primary endpoint was also met, with erlotinib significantly improving PFS in the EGFR IHC+ group (HR 0.69, p<.0001). Many tumor samples were assessable for molecular marker status (see table). Biomarker data suggest that patients derived a PFS benefit with erlotinib irrespective of EGFR FISH or EGFR intron 1 CA-repeat status. The magnitude of benefit with erlotinib was similar in both KRAS-mutant and KRAS wild-type pts. Conclusions', ' This is the largest biomarker analysis performed for erlotinib in a randomized, placebo-controlled setting, and answers key scientific questions regarding the prognostic and predictive value of potential biomarkers of efficacy. Full data will be presented. Biomarker analyses AnalysisNo. of pts with definitive results% of pts with positive biomarker status EGFR IHC (positive', ' 10% any membranous staining)74284 EGFR FISH (classified according to Cappuzzo et al. JNCI 2005)48848 EGFR mutations (exon 19 deletion/L858R)37711 KRAS mutations (codons 12, 13 and 61)49418 EGFR intron 1 CA-repeat polymorphism (long', ' sum of alleles >35 for Caucasian pts and >37 for Asian pts)78451 (long)']",
        "Doc_id":"ASCO_32849-65",
        "Doc_title":" Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC.",
        "_version_":1606189039520579584},
      {
        "Meeting_name":" Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.",
        "Background":"['Background', ' In pts with EGFR+ NSCLC, genotyping of plasma cell-free DNA (cfDNA) has become a routine option for non-invasive detection of EGFRT790M. We hypothesized that serial NGS of cfDNA would allow early detection of co-existent resistance mutations during osimertinib treatment. Methods', ' Serial plasma samples were collected from pts with advanced EGFR+ NSCLC and T790M+ acquired resistance treated with osimertinib. Up to 4 specimens were analyzed, blinded to tumor genotype', ' baseline, initial 2 follow-ups, and progression. Plasma NGS was performed using enhanced tagged amplicon sequencing of hotspots and coding regions from 36 genes. Diagnostic accuracy was compared to tumor genotype (including NGS when available) and droplet digital PCR (ddPCR) of cfDNA. Results', ' 94 specimens from 26 pts underwent plasma NGS. Studying 26 baseline specimens, plasma NGS was more sensitive than ddPCR for known EGFR driver mutations (100% vs 88.5%). In 8 pts with pretreatment tumor NGS, 5 of 6 TP53 mutations were detected; one plasma positive/tissue negative result was seen across 36 genes, a PIK3CA mutation (0.6% AF) which was confirmed using ddPCR (99.6% specificity). Quantitative concordance of AF compared to ddPCR was high (R = 0.94). 21 pts had detectable EGFR driver mutations at resistance. Among 6 pts with maintained T790M, 4 acquired C797S and 2 of these additionally acquired low level KRAS mutations (G13D, Q61K). Among 15 pts with loss of T790M, 7 had competing non-EGFR alterations identified', ' MET amp, PIK3CA E545K, BRAF V600E (n = 2), HER2 amp, KRAS G12S, and FGFR1 amp. Resistance mutations detected at AF > 0.3% were confirmed with ddPCR. In 3 pts, a competing resistance mutation (1 KRAS, 2 BRAF) could be detected in plasma NGS pretreatment and reemerged as putative drivers at time of resistance. Conclusions', ' In this retrospective blinded validation, tagged amplicon-based plasma NGS was more sensitive than ddPCR with high specificity and quantitative concordance. In a subset of cases, serial plasma NGS can detect emergence of competing resistance mutations, creating an opportunity for the study of osimertinib-based targeted therapy combinations.']",
        "Doc_id":"ASCO_187023-199",
        "Doc_title":" Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.",
        "_version_":1606189040012361729},
      {
        "Meeting_name":" cMET in non-small cell lung cancer",
        "Background":"['A rapidly growing domain in present-day oncology is the development of targeted therapies, including several cMET inhibitors against non-small cell lung cancer (NSCLC). Nowadays, cMET amplification is used as a standard biomarker for patient selection, however there is no clear cut-off value to determine amplification, nor is there a real consensus about the way to test this. More recently, splicing variants of cMET, which skip exon 14, are gaining importance since it has been shown that patients harboring this mutation can respond to cMET directed targeted therapy. In this study, we explored the occurrence of cMET aberrations and their correlation with cMET expression in a population of 155 primary EGFR-TKI naive NSCLC tumors. Since cMET is considered as important in metastatic behavior, we also investigated the correlation of cMET expression and amplification between the primary tumor and metastases. Finally, given the link between the EGFR and cMET pathways, the EGFR status was also studied.Samples were collected at the Antwerp University Hospital and the Onze-Lieve-Vrouw Hospital Aalst. The expression of EGFR and cMET was determined by immunohistochemistry (Ventana, clones 3C6 and SP66 respectively), while cMET amplification was examined by in situ hybridization (Ventana, MET DNP and CEN7 DIG probes). EGFR mutations and cMET splice site mutations were detected by Sanger sequencing. Significant correlations were tested using the Chi2 and kappa test (SPSS 23).In 146/155 tumors cMET expression could be determined; 73/146 samples showed high (2+ or 3+ score) cMET expression and 4/118 samples showed amplification (ratio  2). No significant correlations could be determined between cMET expression and histological subtype of NSCLC (p = 0.065), differentiation degree (p = 0.468) and cMET amplification (p = 0.214). However, a significant correlation was found between cMET expression, EGFR expression (p = 0.015) and EGFR mutations (p = 0.029). Splice site mutation regions were sequenced in 87/155 samples, all of which were wild-type. When comparing cMET amplification between the primary tumor and the corresponding metastases (n = 40), only one sample showed amplification in the metastases and not in the primary tumor. Hence, cMET expression showed a significant correlation between primary tumors and their metastases (kappa = 0.003).The overall results of our study are in agreement with earlier data. Moreover, we showed that overall expression levels of cMET in primary tumors and metastases are very similar despite large intratumor heterogeneity. In conclusion, this study shows that high cMET expression in most NSCLC samples does not originate from presently known genetic cMET aberrations. High cMET expression is likely to be caused by temporary changes in transcription and translation, influenced by EGFR-signaling, miRNAs or other regulatory mechanisms.']",
        "Doc_id":"AACR_2016-2242",
        "Doc_title":" cMET in non-small cell lung cancer",
        "_version_":1606188975297396736},
      {
        "Meeting_name":" TWIST1/E2A signaling axis suppresses apoptosis in oncogene driven non-small cell lung cancer",
        "Background":"['Although a large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations, little progress has been made in the treatment of patients with the most common driver mutation, mutant KRAS. In addition, acquired resistance to currently available targeted therapies is inevitable. We previously demonstrated that inhibition of the basic helix-loop-helix transcription factor, TWIST1 in KRAS mutant, EGFR mutant, and MET amplified/mutant NSCLC can induce apoptosis, which suggests that a subset of oncogene dependent NSCLC are potentially addicted to TWIST1. Importantly, we have identified the harmala alkaloid, harmine, as a novel TWIST1 inhibitor which could inhibit growth in several oncogene driver defined NSCLC cell lines and decrease levels of TWIST1 and its dimerization partners, the E2A proteins, via degradation.We examined the target genes and pathways required for suppression of apoptosis by TWIST1 and E2A. Genetic or pharmacological (harmine) inhibition of TWIST1 or E2A resulted in apoptosis in several oncogenic driver dependent cell lines. Additionally, treatment with a pan-caspase inhibitor resulted in rescue of growth inhibition following TWIST1 or E2A silencing or harmine treatment. This suggests that apoptosis is the mechanism of growth inhibition following TWIST1 inhibition. TWIST1 or E2A inhibition resulted in increased levels of Bid, Bim, and DR5, as well as, reduced c-FLIP and Bcl-2 levels. Conversely, we demonstrated that TWIST1 overexpression leads to increased levels of c-FLIP and anti-apoptotic Bcl-2 family members as well as decreased levels of Bim and Bid. c-FLIP appears to be a direct transcriptional target of TWIST1 as TWIST1 overexpression leads to transactivation of the c-FLIP promoter and is dependent on the ability of TWIST1 to bind DNA. Interestingly, the TWIST1-E2A heterodimer results in greater promoter transactivation when compared to the TWIST1 homodimer. Furthermore, knockdown of Bim, overexpression of Bcl-2, or overexpression of c-FLIPs resulted in partial rescue of growth inhibition and apoptosis following TWIST1 silencing. However, only knockdown of Bim or Bcl-2 overexpression was able to rescue apoptosis following harmine treatment. This suggests that apoptosis following harmine treatment only requires the intrinsic machinery, while specifically silencing TWIST1 also engages the extrinsic pathway.In summary, we found that the apoptosis observed after TWIST1/E2A inhibition is dependent on the intrinsic and extrinsic pathways possibly mediated through its novel target genes, c-FLIP and Bim. Our studies will establish the target genes of TWIST1 that are required for suppression of apoptosis with the ultimate goal of identifying biomarkers of response to TWIST1 inhibitors. We also aim to determine if TWIST1, through its apoptotic target genes, modulates response to targeted therapies or standard chemotherapies.']",
        "Doc_id":"AACR_2016-3573",
        "Doc_title":" TWIST1/E2A signaling axis suppresses apoptosis in oncogene driven non-small cell lung cancer",
        "_version_":1606188980827586560},
      {
        "Meeting_name":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "Background":"['Background', ' In-frame insertions between codons 775 and 881 in exon 20 of the ERBB2 gene, of which a 12 base pair YVMA insertion is the most common, are activating mutations in 2%-4% of non-small cell lung cancers (NSCLC), and have also been reported in exon 19 and 20 in breast cancer. These driver mutations are not captured with IHC or FISH staining because in the majority of cases, the ERBB2 gene is not amplified and HER2 protein is not overexpressed. Next generation sequencing (NGS) of circulating cell-free DNA (cfDNA) provides a non-invasive means of identifying these potential driver mutations.Method', ' Guardant360TM is a targeted cfDNA NGS panel using hybrid capture and complete exon sequencing for single nucleotide variant detection in 70 genes, copy number amplifications (CNA) in 16 genes, and fusions in six genes and indels in EGFR, ERBB2 and MET exon 14 skipping. De-identified pathology and genotyping reports were reviewed for consecutive patients in which ERBB2 indels were identified in clinical practice.Results', ' Guardant360 identified ERBB2 indels in 27 of 2,093 (1.3%) of non-squamous NSCLC cases, with a single concomitant ERBB2 gene amplification. For this ERBB2 indel series, pathology reports revealed no patients with HER2 amplification via IHC or FISH, nor ERBB2 point mutation via NGS, but were only available in 25% of cases. Eight of the ERBB2 indels were confirmed by tissue NGS reports with zero false positives (100% PPV). 80% of ERBB2 indels were the common p.Tyr772_Ala775dup (YVMA insertion) in exon 20 followed by other insertions in codons 772 through 814. A single ERBB2 exon 20 p.Leu755_Glu757delinsProLys net deletion at 3.9% mutant allele fration (MAF) was noted in one patient, for whom outcome data was available. Initial tissue was IHC negative for HER2 overexpression at the referring hospital where the archival tissue biopsy was exhausted and so could not be sequenced. Based on the cfDNA finding of ERBB2 indel, the patient was switched from cytotoxic chemotherapy to trastuzumab with objective response on PET/CT and a repeat Guardant360 showed the ERBB2 indel MAF had dropped below the test limit of detection. After four months the patient progressed and it was decided to switch to ado-emtansine trastuzumab (T-DM1) in late November.Results', ' ERBB2 indels can be identified without tissue in NSCLC patients with 100% PPV in this modest cfDNA series. In a patient whose tissue was not available for sequencing, an objective response with trastuzumab was obtained.']",
        "Doc_id":"AACR_2016-2240",
        "Doc_title":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "_version_":1606189013979365376},
      {
        "Meeting_name":" Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '    This study compared switch maintenance with S versus placebo (P) in patients (pts) with advanced NSCLC following four cycles of first-line chemotherapy. The primary endpoint was progression-free survival (PFS) after randomization. Overall survival (OS) was a secondary endpoint.  Methods', '    Stage IIIB/IV pts, PS 0-1 with stable/responding disease after 4 cycles of platinum-based therapy were randomized to S (37.5 mg po qd) vs P. Pts were assessed for progression every 6 weeks. PFS and OS were measured from the time of randomization. The trial was designed to have 90% power to detect a 6 week improvement in PFS using a log rank test at a 2-sided significance level of 0.05. Planned accrual was 244 pts. All p values are 2-sided.  Results', '    The trial crossed the superiority boundary on the primary endpoint at an interim analysis. 210 pts were randomized (106 S, 104 P). Median age 66 yrs (range 25-89), 55.7% male, 60.5% ECOG PS 1, 87.6% stage IV, 22.4% received bevacizumab  (which had to be discontinued at randomization), 91.7% current/past smokers. 45.9% had adenocarcinoma, 33.2% squamous, 13.7% undifferentiated NSCLC and 4.4% large cell. PFS was 4.3 mos on the S arm vs 2.8 mos on the P (HR 0.59, p=0.0008). PFS was improved for both squamous (4.3 S vs 2.4 P mos, HR=0.55, p=0.02) as well as non-squamous histology (4.3 S vs 2.8 P mos, HR=0.64, p=0.02). OS was not different (11.2 mos S vs 11.2 mos P, HR 1.05, p=0.77). Protocol treatment discontinuation was most commonly due to disease progression for P (90.6% for P vs 51.1% on S) and adverse event for S (28.7% for S vs 4.2% for P). Grade 3/4 toxicities (%) occurring in >5% of patients (S vs P) were anemia (6 vs 0), neutropenia (6 vs 1), thrombocytopenia (12 vs 0), hypertension (8 vs 0), fatigue (25 vs 4), rash (11 vs 0) and mucositis/stomatitis (11 vs 0). The rate of subsequent therapy was 74% on the P arm vs 61% on the S arm (p=0.049).  Conclusions', '    CALGB 30607 met its primary endpoint by demonstrating a significant improvement in PFS for S switch maintenance therapy in advanced NSCLC. No effect on the secondary endpoint of OS was seen. Clinical trial information', ' NCT00693992.']",
        "Doc_id":"ASCO_128285-144",
        "Doc_title":" Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC)",
        "_version_":1606189024104415232},
      {
        "Meeting_name":" Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '   Pathological complete response (pCR) with neoadjuvant chemotherapy is associated with improved survival in many solid tumors. We evaluated efficacy and tolerability of neoadjuvant plus adjuvant C+P in this phase II trial.    Methods', '   We recruited  patients (pts) with clinical stage IB-IIIA (TNM 7th ed) NSCLC, ECOG performance status (PS) 0-1 in this single-arm phase II trial using two-stage design with 90% power to detect pCR rate of >10% (vs null hypothesis of <2%). Pre-treatment mediastinal biopsy was required. Protocol was amended in 2009 to exclude squamous histology. Pts received 3 cycles of C 75mg/m2 + P 500mg/m2 (day 1 every 21 days) followed by surgical resection. Two cycles were delivered adjuvantly within 60-80 days after surgery. The primary end point was pCR. Secondary endpoints were objective response rate (ORR), overall survival (OS), disease-free survival (DFS), and adverse events (AEs).  Results', '   38 pts were enrolled with median age of 62 yrs, 19 males', ' 19 females. 74% (N=28) had ECOG PS 0. Preoperatively, 26% (N=10) had squamous histology, 29% (N=11) had biopsy-proven N2 involvement. Median of 4 cycles were administered. ORR was 29% (11 pts with PR). 4 pts did not undergo surgery (3 had disease progression; one became hypoxic during intubation in the OR). Resection status was R2 in 9% (3 of 34 pts), remaining pts had R0 resection. 6 pts had documented N2 clearance; median DFS (mDFS) and OS (mOS) of these pts have not reached (NR) vs 15 and 24 months respectively, in pts with persistent N2 disease. CTC grade 3+ nonhematologic AEs (<10%) include arterial thrombosis, bronchopleural fistula, empyema, hyperglycemia, fatigue and tinnitus. There was no pCR seen and thus accrual to 2nd stage was not pursued. There was no correlation between DFS or OS with ORR or pre-operative stage. There was statistically signification association between DFS with histology (favoring squamous, p=0.03) and post-op stage (p=0.024). The table shows mDFS and mOS in months according to pre-op stage.  Conclusions', '   While the primary endpoint was not met, this regimen is active and well-tolerated perioperatively in NSCLC pts.']",
        "Doc_id":"ASCO_99020-114",
        "Doc_title":" Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).",
        "_version_":1606188976182394880},
      {
        "Meeting_name":" SATURN",
        "Background":"['Background', ' Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated to evaluate E as maintenance therapy after standard 1st-line platinum-based chemotherapy (CT) in advanced NSCLC. Methods', ' Patients with no evidence of disease progression after 4 cycles of CT were randomized to receive either E 150 mg/day or P until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) in all patients and the co-primary endpoint was PFS in EGFR immunohistochemistry-positive (IHC+) patients. Results', ' A total of 1,949 patients entered the CT phase, of whom 889 were randomized to E (n=438) or P (n=451). Median age was 60 years for both arms. Baseline characteristics for E and P arms (%)', ' male/female', ' 73/27 and 75/25; adenocarcinoma + BAC/squamous-cell/other', ' 47/38/15 and 44/43/13; stage IIIB/IV', ' 26/74 and 24/76; Caucasian/Asian/other', ' 84/14/2 and 83/15/2; ECOG PS 0/1', ' 31/69 and 32/68; current/former/never smoker', ' 55/28/18 and 56/27/17. PFS (by investigator assessment; confirmed by independent review) was significantly prolonged with E versus P in all patients (HR 0.71 [95% CI 0.62-0.82]; p<.0001) and in EGFR IHC+ patients (HR 0.69 [95% CI 0.58-0.82]; p<.0001). Subgroup analyses will be reported. Response rate was 12% with E versus 5% with P. Disease control rate (complete response + partial response + stable disease >12 wks) was 40.8% with E versus 27.4% with P (p<.0001). OS data are not yet mature. E was well tolerated', ' the majority of treatment-related adverse events (AEs) were grade 1/2. AEs reported in 10% of all patients were rash (60% with E versus 9% with P) and diarrhea (20% with E versus 5% with P); again, most were grade 1/2. Only 2.3% of patients receiving E had a serious treatment-related AE and 2.8% withdrew due to a treatment-related AE. Conclusions', ' The SATURN study met its primary and co-primary endpoints with high statistical significance. Erlotinib in the 1st-line maintenance setting is well tolerated, and significantly improves disease control and delays progression versus placebo across patient subgroups.']",
        "Doc_id":"ASCO_32756-65",
        "Doc_title":" SATURN",
        "_version_":1606188979069124608},
      {
        "Meeting_name":" A comprehensive study comparing smokers and non-smokers with lung cancer in an urban minority population.",
        "Background":"['Background', ' Cigarette smoking is strongly associated with lung cancer; however, very few studies have been conducted in the urban minority population comparing various parameters between smokers and non-smokers with lung cancer. We investigated epidemiological profiles, histological subtypes, staging at diagnosis, survival after diagnosis and the quality of life. Methods', ' This retrospective study included urban minority population diagnosed with primary lung cancer at the Brooklyn Hospital Center between 2005-2016. The study population was divided into two groups based on smoking history and various parameters listed below were compared. The health care quality of life (HcQOL) was assessed using parameters of weight loss, cough/hemoptysis, shortness of breath, pain, opioid use and functional capacity. Results', ' Of the total 576 patients, 432 met inclusion criteria, who were divided into Group A (GA) - Smokers (n = 341 (78.9%)) and Group B (GB) - Non-Smokers (n = 91 (21.1%)). Majority of our study population were African American (GA 71.8%, GB 65.9%) followed by Hispanics. The prevalence of lung cancer was higher in females (GA 56%, GB 52.7%). Patients diagnosed with lung cancer before age 60 were 48.4% in GA versus 5.5% in GB. SCLC pathology was 20% in GA & 0% in GB; NSCLC pathology was 80% in GA & 100% in GB. At the time of diagnosis, 27% in GA had metastatic stage-4 (0% in GB), and 71.4% in GB had stage-1 (27% in GA) NSCLC. Less than 1 year survival was 15.5% in GA and 2.4% in GB; > 3 years survival was 32.3% in GA and 95.2% in GB. HcQOL measure of weight loss of > 10 pounds, hemoptysis, shortness of breath at rest, uncontrolled pain, opioid dependence and functional capacity < 1 block was 67.6%, 17%, 61.9%, 54.1%, 75.1% and 92.2% respectively in GA and 29.1%, 3.5%, 23.2%, 18.5%, 49.4% and 24.3% respectively in GB. A 6-minute walk test was abnormal in 77% of GA and 39.1% of GB. Conclusions', ' In comparison to non-smokers, smokers were diagnosed with lung cancer at a younger age, had advanced stages of cancer at the time of diagnosis, higher mortality and increased opioid dependence. Smokers had significantly poor HcQOL, which was supported by abnormal six-minute walk test results. Females had overall increased incidence of lung cancer.']",
        "Doc_id":"ASCO_181811-199",
        "Doc_title":" A comprehensive study comparing smokers and non-smokers with lung cancer in an urban minority population.",
        "_version_":1606188989752016896},
      {
        "Meeting_name":" Occurrence of PDL1/2 copy number gains detected by FISH in adeno and squamous cell carcinomas of the lung and association with PDL1 overexpression in adenocarcinomas.",
        "Background":"['Background', ' PDL1 expression measured by immunohistochemistry (IHC) is used as predictive biomarker for immune checkpoint inhibitors and is becoming clinical routine at least in pulmonary adenocarcinomas. We aimed to evaluate the presence of PDL1/2 gene cluster copy number gains in NSCLC by FISH and correlate these data to PDL1 IHC levels in adenocarcinomas (AC). Methods', ' We investigated 107 AC and 78 squamous cell carcinomas (SQCLC) for PDL1/2 FISH. Furthermore, AC were analyzed by IHC with the clone 28-8 stained on a DAKO platform. Cut-off level was 1% (  5% highly positive). FISH was carried out with the ZytoLight SPEC CD274,PDCD1LG2/CEN 9 Dual Color Probe. The FISH evaluation criteria included CD274,PDCD1LG2/CEN 9 ratio as well as average gene copy numbers, proportions of tumor cells with  4 PDL1/2 and  5 PDL1/2 signals as well as gene clusters. Results', ' 28/178 (16%) of NSCLC were FISH positive, 39% (11/28) thereof fulfilled the criteria for high level PDL1/2 amplification (PDL1,2/CEN9 ratio  2.0 or average gene copy number per cell  6.0 or  10% of tumor cells containing  15 gene signals), 4% (1/28) for intermediate level copy number gain (  50% of cells containing  5 gene signals) and 57% (16/28) for low level copy number gain (  40% of tumor cells with  4 PDL1/2 signals). Overall PDL1/2 amplifications occur at almost equal frequencies in AC and SQCLC, 18% and 13% respectively, but high level amplifications are more often seen in SQCLC (7/78 vs. 4/107 in AC). FISH results were independent of KRAS, EGFR,ALK, ROS1 or MET status. 35/107 AC (33%) were PDL1 IHC positive (28 high, 7 low positivity). The correlation between IHC and FISH was statistically significant (Chi square', ' p < 0.001). 15/18 of FISH positive AC were IHC positive (vs. 3/66 IHC negatives). 75% (3/4) high level amplified AC were highly IHC positive. Conclusions', 'PDL1/2 gene copy number gains occur in AC and SQCLC, but high level amplifications are more frequent in SQCLC. PDL1/2 gains seem to be associated with PDL1 overexpression in a subset of AC. PDL1/2 FISH could contribute to our understanding of PDL1 expression and could therefore be a valuable adjunct biomarker in upcoming trials with PD1/PDL1 inhibitors.']",
        "Doc_id":"ASCO_167588-176",
        "Doc_title":" Occurrence of PDL1/2 copy number gains detected by FISH in adeno and squamous cell carcinomas of the lung and association with PDL1 overexpression in adenocarcinomas.",
        "_version_":1606188995020062721},
      {
        "Meeting_name":" Effect of timing of vitamin B12 supplementation in patients receiving pemetrexed for treatment of advanced non-squamous non-small cell lung cancer or malignant pleural mesothelioma.",
        "Background":"['Background', ' Pemetrexed (Pem) is a folate analog inhibitor considered first line (1L) for advanced non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Before the routine use of folic acid and vitamin (vit) B12 supplementation prior to initiating Pem, there were high rates of cytopenias. These rates have been reduced with vit B12 supplementation, but the optimal timing of supplementation has not been thoroughly investigated. Methods', ' This was a single center, retrospective chart review investigating patients (pts) treated in the 1L setting with > 2 cycles (C) of Pem, with or without a platinum agent, from January 1, 2012 to June 30, 2015, who received same-day vit B12 supplementation versus those who received it > 1 day prior to Pem administration. The objective was to evaluate safety outcomes in pts who received vit B12 same-day (group A) versus vit B12 administration > 1 day (group B) prior to Pem. Results', ' A total of 281 pts met inclusion criteria', ' 137 pts in group A and 144 pts in group B (median time of vit B12 administration prior to Pem; 7 days, range 1-42 days). There were no clinically significant differences between groups at baseline. Mean change in hemoglobin (HGB), platelet count, and absolute neutrophil count (ANC) from C1 to C2 or C2 to C3 did not differ significantly between groups. There were no significant differences in clinical events (neutropenic fever, hospitalization, or anemia) between C 1 and C2 or C2 and C3 requiring supportive care (antibiotics or transfusions). There was no difference in treatment delay > 7 days in C2 but a significant difference was noted in C3 [28/114 (24.6%) group A vs 14/118 (11.9%) group B, p = 0.0164]. In group A, significant predictors of delay in C3 were baseline HGB (mean 13.3 g/dL vs 12.4 g/dL, p = 0.0137) and ANC (mean 6 x109/L vs 5 x109/L, p = 0.0003). There was a significant difference in percent change in ANC from C1 to C2 (group A -28.4% vs group B -8.2%, p = 0.0419), but this did not result in C2 delay. Conclusions', ' Same-day administration of vit B12 and Pem is a safe practice in pts with NSCLC and MPM as there were no clinically meaningful changes in hematologic indices.']",
        "Doc_id":"ASCO_162010-176",
        "Doc_title":" Effect of timing of vitamin B12 supplementation in patients receiving pemetrexed for treatment of advanced non-squamous non-small cell lung cancer or malignant pleural mesothelioma.",
        "_version_":1606188995781328897},
      {
        "Meeting_name":" Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer",
        "Background":"['Background', ' Cisplatin, etoposide and concurrent thoracic radiation has remained the standard treatment for locally advanced unresectable non small cell lung cancer (NSCLC) over the past two decades. The Cancer and Leukemia Group B (CALGB) conducted a phase II study using a novel chemotherapy regimen administered in systemically active doses with thoracic radiation (CALGB 30407). We previously reported the preliminary safety results (ASCO 2008, abstract 7518). Methods', ' Eligible patients with previously untreated stage III NSCLC received thoracic radiation (70 Gy) along with carboplatin (AUC 5) and pemetrexed 500 mg/m2 on day 1 administered intravenously every 21 days for 4 cycles (arm A) or the same chemotherapy regimen with weekly cetuximab for 6 weeks concurrent with radiation (arm B). All patients received four additional cycles of pemetrexed (500 mg/m2 every 21 days) as consolidation therapy. The primary endpoint was the percentage of patients who lived longer than 18 months after starting initial treatment. We planned to study the regimen (s) further if the 18 month survival rates equaled or exceeded 55%. Results', ' Characteristics of the 99 eligible pts (48 in arm A and 51 arm B) enrolled from 09/05 to 1/08', ' male 62%, 22% were 70 yrs or older. The most common histological type was adenocarcinoma (46% in Arm A and 41% in Arm B). Updated toxicity data (grade 3 or greater, %) by arms (arm A/arm B) for 106 pts', ' neutropenia 40/47; febrile neutropenia 8/6, thrombocytopenia 36/34, nausea/vomiting 8/10, esophagitis 32/24, skin rash 2/21 and fatigue 22/17. The median follow up time is 17 months. Preliminary efficacy data by arms (arm A/arm B) for 99 pts', ' complete or partial response 73% (95% CI 59-83)/71% (95% CI 57-81%), median failure free survival (months) 12.9 (95% CI 8.6-18.0)/10.3 (95% CI 8.7-18.9); 18 month survival 57% (95% CI 41-79)/47% (95% CI 33-67) and median survival (months) 22.3/18.7. Conclusions', ' The combination of pemetrexed, carboplatin and thoracic radiation has met the protocol-specified criteria for further study. Although it does not appear that the addition of cetuximab confers additional benefit in this setting, further follow-up is necessary.']",
        "Doc_id":"ASCO_34259-65",
        "Doc_title":" Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer",
        "_version_":1606188999330758656},
      {
        "Meeting_name":" Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1Positive NSCLC.",
        "Background":"['Background', ' In the phase III KEYNOTE-010 study (NCT01905657), pembrolizumab (pembro; MK-3475) provided superior OS over docetaxel (doce) in patients (pts) with previously treated, PD-L1positive advanced NSCLC (P = 0.0008 for 2 mg/kg and P< 0.0001 for 10 mg/kg in the total [tumor proportion score (TPS)  1%] population). We assessed outcomes in KEYNOTE-010 when PD-L1 was further categorized as a TPS of 1%-24%, 25%-49%, 50%-74%, and  75%. Methods', ' Pts with progression after  2 cycles of platinum-doublet chemotherapy and PD-L1 TPS  1% assessed by IHC (22C3 antibody) were randomized to pembro 2 or 10 mg/kg Q3W or doce 75 mg/m2 Q3W for 24 mo or until progression, intolerable toxicity, or other reason. PD-L1 TPS 1%-49% vs  50% was a randomization stratification factor. Response was assessed centrally per RECIST v1.1 every 9 wk. Survival was assessed every 2 mo. Primary end points were OS and PFS; ORR was secondary. Pembro doses were pooled for this analysis. Results', ' Of the 2222 pts screened for PD-L1, 33.6% had TPS < 1% and were ineligible. Of the 1034 pts who met all eligibility criteria and enrolled, PD-L1 TPS was 1%-24% in 45.6% of pts, 25%-49% in 11.6%, 50%-74% in 15.3%, and  75% in 27.5%. Doce outcomes were similar regardless of TPS (Table). For pembro, OS, PFS, and ORR generally increased along with TPS, with the longest OS and PFS and highest ORR in pts with TPS  75% (Table). Pembro provided longer OS than doce in all 4 TPS categories evaluated. Conclusions', ' Increasing PD-L1 expression was associated with more favorable outcomes with pembro, but not with doce, verifying PD-L1 as a predictive biomarker for pembro in NSCLC. Pembro improved OS over doce even at the lowest TPS category assessed. Clinical trial information', ' NCT01905657Pembro/DoceTPS 1%-24%n = 324/147TPS 25%-49%n = 76/44TPS 50%-74%n = 106/52TPS  75%n = 184/100OSMedian, mo9.7/8.59.8/9.915.8/8.216.6/8.2HR (95% CI)0.74(0.56-0.96)0.86(0.51-1.45)0.58(0.36-0.95)0.51(0.36-0.73)P*.01.29.01< .0001PFSMedian, mo2.6/4.02.9/3.84.3/4.36.2/4.0HR (95% CI)1.08(0.86-1.36)0.95(0.60-1.50)0.78(0.52-1.17)0.52(0.38-0.69)P*.74.42.12< .0001ORR, %8.6/10.915.8/9.122.6/9.633.7/7.0P*.76.14.01< .0001*P values are nominal.']",
        "Doc_id":"ASCO_170332-176",
        "Doc_title":" Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1Positive NSCLC.",
        "_version_":1606189002419863552},
      {
        "Meeting_name":" Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.",
        "Background":"['Background', '  TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A previous study showed that the baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) might be a predictive biomarker for TG4010 efficacy in NSCLC. Methods', '  TIME is a double blind, placebo-controlled phase IIb/III study. The phase IIb part compared first line chemotherapy combined with TG4010 or placebo and further assessed the predictive value of baseline level of TrPAL. Eligibility criteria included stage IV NSCLC not previously treated, MUC1+ tumor by immunohistochemistry (IHC), PS  1. TG4010 108pfu or placebo was given SC weekly for 6 weeks (w), then every 3w up to progression in immediate combination with chemotherapy. Primary endpoint was progression-free survival (PFS). Results', '  222 patients (pts) were randomized 1', '1. In pts with normal TrPAL the study met the primary endpoint of having a Bayesian probability for HR < 1 being > 95%. PFS was significantly improved in the TG4010 arm in pts with low TrPAL (152 pts HR = 0.66 [CI95% 0.46-0.95] p = 0.013) while it was not the case in pts with high TrPAL (70 pts HR = 0.97 [CI 95% 0.55-1.73] p = 0.463). In addition, PFS was also significantly improved in pts with non-squamous tumors (196 pts HR = 0.69 [CI95% 0.51-0.94] p = 0.009) as well as in pts with non-squamous tumors and low TrPAL (131 pts HR = 0.61 [CI95% 0.42-0.89] p = 0.005). In this last group PFS at 9 months was 37% with TG4010 versus 18% with placebo. Overall survival (OS) data show an improvement in line with that observed for PFS and will be presented at the time of the meeting. Preliminary data on the effect of PDL1 expression by IHC in the tumor support the activity of TG4010 whether the tumor is positive or negative for PDL1 expression. Frequency and severity of adverse events were similar in both treatment arms. Conclusions', '  These results provide additional data supporting the efficacy of TG4010, particularly in patients with non-squamous tumors and/or a low level of TrPAL at baseline. The phase III part of the TIME study will continue in patients with non-squamous tumors and with OS as primary endpoint. Clinical trial information', ' NCT01383148']",
        "Doc_id":"ASCO_144554-156",
        "Doc_title":" Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.",
        "_version_":1606189005451296768},
      {
        "Meeting_name":" Analysis of patients (pts) with pathological (p-) stage I (T1> 2 cm) non small cell lung cancer (NSCLC) who were excluded from clinical trial of adjuvant chemotherapy.",
        "Background":"['Background', ' From Nov. 2008 to Dec. 2013, JCOG0707, the phase III randomized study of adjuvant chemotherapy for the pts with completely resected, p-stage I (T1 > 2 cm) NSCLC, accrued 963 cases. The monitoring in Jun. 2013 showed the combined overall survival (OS) of the 2 arms far exceeded initial presumption, with 4-year OS of 91.6%. We undertook the survey of pts excluded from the clinical trial during the same period. Methods', ' Pts characteristics, tumor profiles, reasons for non-enrollment to a trial, actual post-surgical therapy, and outcomes of pts with completely resected, p-stage I (T1 > 2 cm) NSCLC were surveyed at each institution. Accrual rates to the trial, as well as the reasons for exclusion and patterns of care, were analyzed according to pts background and institutions. Results', ' Of the 48 institutions that took part in JCOG0707, 34 (enrolling 917 or 95.2% of JCOG0707 cases) participated in the survey, and 5006 pts were registered. Among them, 2617 pts (52.3%) fulfilled the eligibility criteria of JCOG0707, but were not enrolled mainly due to patients decline (69.2%), or decision by attending physicians (20.5%). Therefore, JCOG0707 enrolled 917/3534 (25.9%) of the eligible and 917/5923 (15.5%) of all pts. The other 2389 (47.7%) were ineligible for JCOG0707, due to concomitant malignancy (33.4%), attending physicians clinical judgment (22.2%), delay of recovery from surgery (16.2%) or age limitation (12.2%). Proportion of trial participation differed widely by institutions (4.1 to 46.1%), and was not correlated with total number of pts (r2= 0.003) or number of eligible cases (r2= 0.046) at each institution. It declined after the adverse events-associated temporary suspension of accrual from May to Jul. 2011 (20.1 to 12.6%). No adjuvant chemotherapy was given to 3338 pts (66.7%), and 1550 (31.0%) received standard UFT treatment. Conclusions', ' Only a minority of candidate pts, even when they met the eligibility criteria, were accrued to JCOG0707. The excluded cases were treated with observation only or standard therapy. Further analysis of the population, including OS, would be needed to define the external validity of the randomized trial. Clinical trial information', ' UMIN000015732.']",
        "Doc_id":"ASCO_166073-176",
        "Doc_title":" Analysis of patients (pts) with pathological (p-) stage I (T1> 2 cm) non small cell lung cancer (NSCLC) who were excluded from clinical trial of adjuvant chemotherapy.",
        "_version_":1606189006564884481},
      {
        "Meeting_name":" Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Many clinical trials in metastatic NSCLC patients who failed first-line chemotherapy have utilized pre-treatment, diagnostic tissues for marker assessment. BATTLE was a randomized, biopsy-driven clinical study in patients with metastatic NSCLC previously treated with systemic therapy. Fresh biopsies were obtained at the time of enrollment for biomarker evaluation. We hypothesized that molecular abnormalities found at the time of enrolment in BATTLE would differ from baseline, pre-chemotherapy, diagnostic tissue.    Methods', ' We isolated DNA (SPRI-TE-based DNA recovery and cleanup methodology) from 82 matched pre-chemotherapy and BATTLE formalin-fixed paraffin-embedded specimens. Mutations were assessed by MALDI-TOF MS (MassArray, Sequenom Inc) using a lung cancer panel of 16 genes/140 assays (AKT1, BRAF, CTNNB1, EGFR, ERBB2, FGFR3, HRAS, KRAS, MEK1, MEK2, MET, NRAS, PIK3CA, PIK3R1, PTEN, and STK11) and were compared between pre-chemotherapy versus BATTLE samples.  Results', ' Mutations were identified in 25 pre-chemotherapy samples (14 K-RAS, 5 EGFR, 3 PIK3CA, 1 STK11, 1 PTEN, 1 HRAS, 1 CTNNB1). Conversely, 29 BATTLE samples had at least one mutation (14 K-RAS, 7 EGFR, 5 PIK3CA, 2 STK11, 1 PTEN, 1 HRAS, 1 CTNNB1). For the matched pair analysis, 46 patients had wild-type tumors both in pre-chemotherapy and BATTLE samples. 11 patients had wild-type tumors in pre-chemotherapy samples, but had a mutation identified in BATTLE samples (4 K-RAS, 4 EGFR,  2 PIK3CA, 1 STK11). 7 patients had a mutation in pre-chemotherapy samples, but no mutations in BATTLE samples (4 K-RAS, 2 EGFR, 1 HRAS). The remaining 18 patients had mutations in both the pre-chemotherapy and BATTLE samples; of these, 2 had different mutations in the paired samples (both within the same genes, 1 KRAS, 1 PIK3CA). Overall, there was a 24% gene mutation discordance rate between pre-chemotherapy and BATTLE samples.  Conclusions', ' Profiling of fresh biopsies may more accurately reflect molecular abnormalities present in the tumor at the time of initiation of salvage therapy, underscoring the importance of real time tissue collection in biomarker-driven studies in this setting (V Foundation, DoD).']",
        "Doc_id":"ASCO_114230-132",
        "Doc_title":" Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC).",
        "_version_":1606189010774917120},
      {
        "Meeting_name":" Mechanisms of resistance to EGFR tyrosine kinase inhibitors involving HER-family ligands and receptors",
        "Background":"['Known mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI), including the second mutation of EGFR, T790M, MET amplification, and HGF overexpression, explain approximately 60% of cases, but the remaining mechanisms have not been clarified. To investigate novel mechanisms of acquired resistance to EGFR-TKI, we examined HER-family ligands and HER-family receptor status in non-small cell lung carcinoma (NSCLC) cell lines (n=13). Cell lines were divided into two groups with respect to EGFR-TKI sensitivity', ' highly sensitive (HCC827, PC-9, HCC2935, and HCC4006) and resistant (H1395, H1666, H596, H1437, A549, H226B, H1299, H460, H1792). We examined expression levels of eleven HER-family ligands_EGF, TGF, amphiregulin (AREG), betacellulin (BTC), HB-EGF, epigen (EPGN), epiregulin (EREG), and neuregulin (NRG) 1, NRG2, NRG3, and NRG4_in these cell lines. NRG2, NRG4, and EPGN were expressed at 39.5-, 31.4-, and 6.5-fold higher levels, respectively, in EGFR-TKI primary resistant NSCLC cell lines than in highly sensitive cell lines, whereas TGFA, EGF, and AREG were expressed at 0.22-, 0.3-, and 0.34-fold lower levels. Phosphorylation of EGFR was elevated in sensitive cell lines compared to resistant cell lines, but HER2-4 receptors did not evidence a difference in phsophorylation. These results suggest that the EGFR pathway is activated in sensitive cell lines, and HER2-4, which binds to EPGN, EREG, NRG2, and NRG4, might be activated in resistant cell lines. We prepared cell lines HCC827GR and HCC827ER, derived from HCC827, which acquired resistance to gefitinib or erlotinib, respectively. We analyzed HER-family ligands and receptors using these cell lines. Compared to parent cells, EPGN, EREG, HB-EGF, TGFA, NRG1, and AREG were up-regulated in HCC827GR. Phosphorylation status of EGFR, HER2, and HER3 was not altered, but that of HER4 was increased in HCC827GR. In HCC827ER, EGFR binding ligands AREG, BTC, and EGF were down-regulated, while phosphorylation of EGFR, HER2, and HRE3 was decreased. However, NRG2 was remarkably elevated and HER4 and its downstream STAT5 were phosphorylated. These results indicate that HER4 and its binding ligands may contribute to acquired resistance to EGFR-TKI. Considering these results, it is possible that the HER4-STAT5 pathway might be common to primary and acquired resistance to EGFR-TKI. We continue to investigate its significance.']",
        "Doc_id":"AACR_2012-1906",
        "Doc_title":" Mechanisms of resistance to EGFR tyrosine kinase inhibitors involving HER-family ligands and receptors",
        "_version_":1606189025913208832},
      {
        "Meeting_name":" Prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing",
        "Background":"['Background', ' Detection of tumor genetic alterations is critically needed for lung cancer clinic as well as for the development of molecular targeted therapeutics. Here we report the results of a broad spectrum of genetic alterations identified in Japanese patients with non-small cell lung cancer (NSCLC) by ultra-deep targeted sequencing.Material and Methods', ' Highly multiplexed amplicon sequencing was performed using genomic DNA extracted from snap-frozen tumor specimens. TruSeq amplicon cancer panel was used for the detection of somatic mutations in 48 cancer related genes followed by ultra-deep sequencing (Illumina) at an average coverage of approximately 3,400x. ALK, ROS1 and RET translocations and EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications were also detected by multiplex RT-PCR and quantitative PCR, respectively.Results', ' Between July 2011 and March 2013, 279 consecutive patients were enrolled in this prospective study at Shizuoka Cancer Center', ' median age 69 years (range', ' 38-92); male 66%; never smoker 25.8%; histology', ' adenocarcinoma 70.6%, squamous cell carcinoma (SQ) 25.1%, others 4.3%; pathological stage', ' I 58.1%, II 22.6%, III 15.4%, IV 3.9%. TP53 mutation was most frequently detected (35.9%) in all patients, particularly in SQ (59.2%). Mutations in genes such as CTNNB1 (4.0%), SMAD4 (1.5%), GNAS (1.0%), STK11 (1.0%), HRAS (0.5%) and PTPN11 (0.5%) were also detected in addition to major mutations in genes such as EGFR (44.8%), KRAS (18.4%) and PIK3CA (4.5%) in adenocarcinoma. PIK3CA (19.7%), HRAS (2.8%), APC (1.4%), FGFR2 (1.4%), FGFR3 (1.4%) and SMAD4 (1.4%) mutations were identified in SQ and notably, 40.9% of SQ patients harbored concurrent gene mutations, suggesting the genetic complexity of this histological subset. In EGFR mutation, deletion in exon 19 (42.6%) and L858R point mutation in exon 21 (41.5%) were frequently observed. As for PIK3CA mutation, the majority (92.8% of all PIK3CA mutant SQ cases) was detected in exon 9 (residues E542 and E545) in SQ but in contrast, mutations in exon 1 and 20 (residues G106 and H1047, respectively) were more frequently detected (33.3% combined of all PIK3CA mutant adenocarcinoma cases) in adenocarcinoma.Conclusions', ' We managed to detect a wide range of genetic alterations and to identify additional actionable mutations along with popular driver mutations in NSCLC by next-generation sequencing technology. These data should be incorporated into lung cancer clinic to implement personalized cancer medicine.']",
        "Doc_id":"AACR_2014-1537",
        "Doc_title":" Prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing",
        "_version_":1606189028165550080},
      {
        "Meeting_name":" Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' The proteasome inhibitor PS-341 sensitizes tumor cells to chemoinduced apoptosis. In preclinical NSCLC models, p53-dependent growth arrest after PS-341 treatment resulted in an antagonistic interaction if PS-341 preceded Doc. The reverse sequence (Doc -> PS- 341) was optimal, associated with reduced protein levels of Bcl-2 and increased apoptosis with cleavage of caspase-3 and PARP. To further evaluate these observations, we conducted a randomized phase II trial of concurrent vs. sequential Doc-PS-341. Methods', ' Platinum-pretreated metastatic NSCLC patients (pts) were randomized to concurrent (Arm 1) or sequential (Arm 2) Doc 75 mg/m2 IV followed by PS-341, every 3 weeks. In Arm 1, PS-341 (1.6 mg/m2 IV) was given on days 1 and 8. In Arm 2, PS-341 was on days 2 and 8. Pts must have performance status (PS) 0-1 and adequate end-organ function. Prior erlotinib (n=13) and treated/controlled brain mets were allowed. Primary endpoint was RECIST response (RR); progression-free (PFS) and overall survival (OS) were secondary endpoints. With 40 pts per arm, there was 90% probability to correctly \"pick the winner\" if the RR on the two arms were 0.05 vs. 0.13, or 0.10 vs. 0.20, or 0.15 vs. 0.27. Results', ' 81 pts were randomized', ' 40 in Arm 1, 41 in Arm 2. Pt characteristics and efficacy by arm and overall are summarized below. Grade (Gr) 3+ toxicities were mostly due to myelosuppression (Arm 1 vs. 2)', ' leukopenia (6 vs. 11), lymphopenia (10 vs. 2), neutropenia (8 vs. 15), and thrombocytopenia (0 vs. 3). One pt each had Gr 4 hyponatremia and syncope. One pt in Arm 2 died after experiencing Gr 4 heme toxicities, Gr 3 neuropathy and anorexia. Conclusions', ' The combination of Doc plus PS-341 concurrently given on day 1 has similar RR as sequential therapy, but results in OS exceeding prior published OS estimates for either agent alone or in combination. (NO1 CM-62209) Arm 1 (concurrent)Arm 2 (sequential)OverallMale sex23 (57%)20 (49%)43 (53%)PS=017 (42%)21 (51%)38 (47%)Median age, years616261Response rate (all partial)4 (10%)4 (10%)8 (10%)Disease control rate (partial + stable)20 (50%)20 (49%)40 (49%)PFS, 6 months (%)30%17%25%OS, median in months (95% CI)13.3 (7, 17)7.8 (6, 18)10.5 (7, 14)']",
        "Doc_id":"ASCO_43081-74",
        "Doc_title":" Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).",
        "_version_":1606189037086834689},
      {
        "Meeting_name":" Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' The ATLAS study (n=768) was designed to evaluate B (15 mg/kg q3w)+ E (150 mg qd) vs. B + placebo (PL) following B + platin-containing doublet chemo in patients (pts) with stage IIIb/IV NSCLC. The trial met its primary (1) endpoint of improving PFS. Median PFS was 4.8 mo for B + E vs. 3.7 mo for B + PL (HR=0.72, 95% CI', ' 0.59-0.88, p=0.0012). The safety profile for B + E was consistent with known profiles for B and E. Here we report on OS, a secondary endpoint. Methods', ' Enrolled pts were B-eligible (including pts with treated brain metastases and pts receiving low MW heparins); peripheral and/or extrathoracic squamous tumors allowed. Pts received 4 cycles of B (15 mg/kg q3w) + platinum-containing doublet chemo. Pts who did not progress after 4 cycles of B + chemo and had no significant toxicity were randomized to receive B + E or B + PL as maintenance therapy. OS was defined as time from randomization to death. The study was not powered to detect OS difference. The 1 OS analysis was prespecified to occur at the time of primary PFS analysis (July 18, 2009 cutoff). At the time of primary OS analysis, few death events had occurred (31% of pts had died). Two post-hoc analyses of OS, after more death events had occurred, were performed (data cutoffs, January 28 and June 19, 2009). Results', ' See Table. An equal percentage (39.7%) of patients in the B + E and B + PL arms received subsequent therapy with an EGFR tyrosine kinase inhibitor. Conclusions', ' For pts treated in the first-line setting for locally advanced, recurrent, or metastatic NSCLC, the addition of E to B after chemotherapy significantly improved PFS and may also provide OS benefit. Clinical and biomarker subset data will be presented. Data CutoffPatients with events n/N (%)Median OS (mo)B+E vs. BHR (95% CI)p value July 18, 2008 (prespecified)228/743 (31)14.4 vs. 13.30.92 (0.70-1.21)0.5604 January 28, 2009357/768* (46)14.4 vs. 13.60.90 (0.73-1.12)0.3574 June 19, 2009439/768* (57)15.9 vs. 13.90.90 (0.74-1.09)0.2686* 25 pts were randomized after cutoff for main analysis of PFS. ** HR and p value based on prespecified, stratified analysis.']",
        "Doc_id":"ASCO_54084-74",
        "Doc_title":" Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).",
        "_version_":1606189042186059776},
      {
        "Meeting_name":" Whole genome and transcriptome sequencing of lung cancer",
        "Background":"['Background', ' Targeted therapy against driver mutations has revolutionized lung cancer management. The Personalized OncoGenomics (POG) program uses whole genome and transcriptome derived information to build pathways and identify potential therapeutic targets. We examined the lung adenocarcinoma (LUAD) patients enrolled in POG in order to identify novel cancer drivers and correlate the findings with clinical characteristics. Methods', ' Patients with advanced LUAD and survival > 6 months were eligible. Blood, archival and fresh tumour specimens were subjected to comprehensive DNA and RNA sequencing. SNV data were compared to the TCGA-LUAD cohort using the cBioPortal platform. Whole tumor transcriptome data were compared to matched normal blood specimens. Clinical characteristics were collected by chart review. Results', ' 30 POG LUAD cases were analyzed. Baseline characteristics; 47% female, median age 60, 57% never/light smokers, biopsy site - 50% lung, 50% metastatic lesion. High mutations rates in TP53, KRAS, NF1 were comparable to the TCGA-LUAD cohort. Four genes (GOLGA6L2, FAM186A, ARMCX4 and RBMXL3), were mutated 17-27% of the time in POG patients, while the rate in TCGA-LUAD was < 1%. Driver mutations (KRAS and EGFR) and known fusions (ROS1 and RET) were present in 63%.Other potential drivers included ERBB3, ERBB2, SDC', 'NRG1 fusion were identified. Copy number alterations and expression data revealed variations in cell cycle, mTOR, androgen receptor,HSP90, MET and Wee1 proteins, all potential targets for therapy. PD-L1 over-expression and a strong smoking signature were not mutually exclusive to EGFR copy gain and FGFR3 overexpression. Conclusions', ' The molecular signature of NSCLC is complex and involves multiple key oncogenic drivers. Whole genome sequencing and transcriptome data should be used together to map out the pathways of carcinogenesis and reliably identify targets for therapy.']",
        "Doc_id":"ASCO_190111-199",
        "Doc_title":" Whole genome and transcriptome sequencing of lung cancer",
        "_version_":1606189000018624512},
      {
        "Meeting_name":" Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC).",
        "Background":"['Background', '  The PRONOUNCE trial was a phase III, randomized, open-label U.S. study comparing pemetrexed (PemC) with bevacizumab (PCB) in the treatment of advanced chemo-naive nonsquamous non-small cell lung cancer (NS-NSCLC). The primary endpoint of improved PFS without grade 4 toxicity for PemC over PCB was not met. There were no differences in PFS or OS. This analysis was conducted to estimate differences in costs of treatment and related patient care between the groups to inform evidence-based treatment decision making.  Methods', '  A cost-minimization analysis was performed using data from the PRONOUNCE trial and publically available U.S. unit costs. Drug costs modeled included induction, maintenance, and subsequent therapies. Other estimated medical costs were drug administration, concomitant medications, and treatment of grade 3/4 toxicities. A probabilistic sensitivity analysis (PSA) was conducted to model joint uncertainty associated with model parameters.  Results', '  The average cost of treatment with PemC was $4,689 less than PCB ($30,334 vs $35,024). Drug acquisition and administration costs were less in all modeled settings (induction, maintenance, and subsequent lines) for PemC. Costs associated with concomitant medications and grade 3/4 toxicities were similar ($13,286 vs $13,738). PemC was cost saving in 99% of 10,000 PSA iterations.  Conclusions', '  Based on the PRONOUNCE trial and model results, PemC may present a similarly effective but less costly treatment option for patients in the United States compared with PCB. While treatment decision making should consider the overall safety profile and patient preferences, this study provides estimates of the costs of treatment of these two therapeutic options. The analysis was based on clinical trial data; therefore, the results may not be generalizable to all patients.     Results.']",
        "Doc_id":"ASCO_120302-140",
        "Doc_title":" Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC).",
        "_version_":1606189019681521664},
      {
        "Meeting_name":" A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Addition of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab to first-line carboplatin (C) and paclitaxel (P) improved survival and objective response rate (ORR) of patients (pts) with advanced nonsquamous NSCLC and improved ORR and progression-free survival (PFS) when added to first-line cisplatin plus G. The addition of cediranib (CED), a potent oral VEGF receptor tyrosine kinase inhibitor, to C and P resulted in improved ORR and PFS, but was not tolerable at a 30-mg dose in the NCIC BR24 study. The safety and efficacy of CED, with C and G as first-line therapy for advanced NSCLC is reported here. Methods', ' A lead-in phase to determine the tolerability of CED 45 mg qd was followed by a 2', '1 randomization of treatment nave pts with stage IIIB/IV NSCLC to GC + CED (Arm A) vs GC alone (Arm B) to test the hypothesis that the confirmed objective ORR in A was at least p0+0.15, where p0 is the confirmed ORR in B. The trial had 86% power to test whether the 6-month progression-free survival rate (PFS6) in A was at most 25% versus at least 40% using a type I error rate of 0.09. Results', ' CED 45 mg qd was not tolerable in the lead-in phase and thus 30 mg qd was used in the randomized pts. 58 and 29 evaluable pts were accrued to (A) and (B), with comparable clinical characteristics in both arms except that proportionately more pts in arm B had squamous histology (28% vs. 16%, p = 0.25). Pts in (A) experienced more grade 3+ nonhematologic adverse events (AEs),71% vs 45%, p = 0.01. The most common grade 3+ AEs in A vs B were', ' neutropenia (60% vs 45%; p = 0.17), thrombocytopenia (57% vs 45%, p = 0.28), fatigue (14% vs 10%; p = 0.74), and anemia (10% vs. 28%; p = 0.06). Three deaths occurred (1 A, 2 B), none attributed to treatment. The ORR in A vs B was 20% vs. 18% (p = 1.0). PFS6 in A was 46% (26/56; 95% CI', ' 33%-60%), thus meeting the secondary endpoint. For A vs B, the median PFS was 6.3 vs 4.5 months (HR = 0.69; p = 0.15), and the median OS was 11.8 vs. 9.9 months (HR = 0.66; p = 0.16). Conclusions', ' CED 30mg qd with GC as first-line therapy is tolerable. While the trial did not meet its primary endpoint of ORR, the secondary endpoint of PFS6 was met with a trend towards improved OS and PFS when CED was added to GC.']",
        "Doc_id":"ASCO_41866-74",
        "Doc_title":" A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188981625552896},
      {
        "Meeting_name":" A phase II study of biweekly carboplatin (Cb) and gemcitabine (G) with bevacizumab (B) as first-line treatment in patients with advanced, inoperable stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Cb and G is an active platinum doublet used as first line therapy in advanced, inoperable lung cancer. The addition of B to a platinum doublet has shown improved efficacy. A combination of Cb and G is known to generate a high frequency of thrombocytopenia. Therefore, we developed a biweekly schedule that resulted in low thrombocytopenia rates and better tolerance. This study evaluated the efficacy and safety of Cb and G combined with B. Methods', ' This was a single arm phase II study in non- squamous NSCLC. A 14-day treatment cycle was given with a maximum of 6 cycles per patient.B was to continue until disease progression. G 2,000 mg/m2 and Cb with AUC = 3 was administered with B 10 mg/kg on day 1. The primary endpoint was progression-free survival (PFS) > 4 months with the power 85% at one-sided 0.05 significant level. Results', ' 36 patients were enrolled in this study from 3/2007 to 11/2009. A total of 301 cycles were administered, with a median number of cycles 6 (range 2 to 30). Grades 3-5 toxicities that occurred in at least 10 percent of patients included grade 3 hypertension (n = 7), and grade 4 PE (n = 4). There were no CR, 17 (47%) PR, 14 (39%) SD, 3 (8%) DP, and 2 (6%) unknown. Median PFS was 5.3 months (95% CI', ' 4.44, 7.71). Estimate of 6 month PFS was .404 (95% CI', ' 0.263, 0.620) and 12 month PFS was 0.197 (95% CI', ' 0.094, 0.410). Median overall survival (OS) was 15.2 months (95% CI', ' 11.6, Inf). Estimate of 6 month OS was 0.879 (95% CI', ' 0.775, 0.998) and 12 month OS was .594 (95% CI', ' 0.429, 0.821). Conclusions', ' Study met its primary endpoint. The regimen was well tolerated despite six patients having grade IV non-hematologic toxicities, resulting in early study termination.']",
        "Doc_id":"ASCO_54308-74",
        "Doc_title":" A phase II study of biweekly carboplatin (Cb) and gemcitabine (G) with bevacizumab (B) as first-line treatment in patients with advanced, inoperable stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC).",
        "_version_":1606188989480435712},
      {
        "Meeting_name":" Palbociclib enhances the antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating hypoxia in squamous cell lung cancer.",
        "Background":"['Lung cancer remains one of the leading causes of cancer-related mortality. Squamous cell lung cancer (SqCLC) is the second most common subtype of non-small cell lung cancer (NSCLC) and is responsible for ~100,000 deaths in the US and EU. Most SqCLC patients receive chemotherapy as 1st line treatments and have a high un-met medical need for new therapies. Therapeutic approaches that enhance the efficacy of chemotherapy would therefore improve clinical outcomes for this patient population. CDK inhibitors comprise a class of drugs that target the dysregulated cell cycle in malignant cells. Treatment of tumor cells with the CDK4/6 inhibitor palbociclib inhibits tumor growth by decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition. Based on promising clinical trial results, palbociclib in combination with letrozole was granted accelerated approval by the US FDA for the treatment of postmenopausal women with ER-positive, HER2-negative advanced breast cancer. Like hormone receptor positive breast cancer patients, the vast majority of SqCLC patients harbor wild type RB and thus may also benefit from palbociclib treatment. Previously, we reported robust cytotoxicity and antitumor effects of palbociclib plus taxanes, including nanoparticle albumin-bound paclitaxel (Nab-PTX) or docetaxel (DTX), in several preclinical models of SqCLC. In the present study, we extended our efficacy studies of this combination to additional RB+ SqCLC models with diverse molecular genetic backgrounds. In search of mechanisms of action underlying the observed combinatorial effects, we identified several novel mechanisms, including cell cycle checkpoint abrogation as well as reduction of hypoxia-inducible factor 1 alpha (HIF-1). Decrease in HIF-1 protein led to strong modulation of downstream genes involved in angiogenesis, resulting in reduced blood vessel size in tumor vasculature. Our results suggest that palbociclib enhances the antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating hypoxia in SqCLC.']",
        "Doc_id":"AACR_2017-2355",
        "Doc_title":" Palbociclib enhances the antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating hypoxia in squamous cell lung cancer.",
        "_version_":1606189003917230081},
      {
        "Meeting_name":" Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.",
        "Background":"['Background', '  Maintenance monotherapy has been associated with improved survival for NSCLC pts. AVAPERL was designed to evaluate the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment and demonstrated improved progression-free survival (PFS) (Barlesi, JCO in press).   Methods', '  Pts with advanced nsNSCLC received first-line Bev (7.5 mg/kg), cisplatin (75 mg/m2), and Pem (500 mg/m2) every 3 weeks (q3w) for 4 cycles. Those non progressing were randomized to maintenance Bev (7.5 mg/kg) +/-Pem (500 mg/m2) q3w until progressive disease or unacceptable toxicity. The primary end point (PFS) was met. An independent update analysis has been conducted to assess OS.  Results', '  A total of 376 pts receive induction treatment; 125 and 128 were randomized to the Bev-alone and Bev+Pem arms, respectively. Induction therapy resulted in confirmed disease control in 71.9% of pts. After a median follow-up of 14.8 months, PFS for the Bev+Pem arm was significantly improved both from induction (10.2 v 6.6 m, HR 0.58 [0.45-0.76], p<.0001) and randomization (7.4 v 3.7 m, HR 0.57 [0.44-0.75], p<.0001). With 58% of events, OS for the Bev+Pem arm was also improved both from induction (19.8 v 15.9 m, HR 0.88 [0.64-1.22], p=.32) and randomization (17.1 v 13.2 m, HR 0.87 [0.63-1.21], p=.29). The PFS and OS improvements were comparable across age, PS, smoking status, and response to induction (SD vPR/CR) subgroups. No new safety signal was observed during this updated analysis.  Conclusions', '   Continuation maintenance with Bev+Pem in an unselected population of nsNSCLC pts who had achieved disease control after induction was associated with an increase by almost 4 months in OS benefit over standard Bev alone. Clinical trial information', ' NCT00961415.']",
        "Doc_id":"ASCO_113046-132",
        "Doc_title":" Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.",
        "_version_":1606189004081856513},
      {
        "Meeting_name":" An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.",
        "Background":"['Background', ' Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are requisite for localization to the inner cell membrane. While all RAS isoforms (KRAS/NRAS/HRAS) are FT substrates, only HRAS is exclusively dependent upon farnesylation for membrane localization and signaling activation, making HRAS mutant tumors uniquely susceptible to tipifarnib mediated inhibition of FT. Tipifarnib has demonstrated robust activity in HRAS mutant head and neck squamous cell carcinoma (HNSCC) and HRAS mutant squamous non-small cell lung cancer (NSCLC) patient derived xenograft (PDX) models resistant to standard therapies. Methods', ' This is a multi-institutional, open-label Phase II trial evaluating the efficacy and safety of tipifarnib for pts with HRAS mutant solid tumors. Pts must have either unresectable, locally advanced or metastatic non-hematological malignancies that harbor a missense HRAS mutation. The primary endpoint of the study is overall response rate. Secondary endpoints include safety and tolerability, PFS, duration of response. Two cohorts (N = 18 each) are enrolling, each being evaluated with a Simon two-stage design. Cohort 1 is for patients with malignant thyroid tumors of any histology. Cohort 2 was originally designated for pts with any other solid tumor. The prespecified activity goal for the first stage of accrual in Cohort 2 was met. Based on data observed in the first stage of this group, enrollment to the second stage of Cohort 2 has been limited to HRAS mutant HNSCC since August 2016. Enrolled patients are treated with tipifarnib 900 mg administered orally twice daily on days 1-7 and 15-21 of 28-day treatment cycles until progression of disease or unacceptable toxicity. Clinical trial information', ' NCT02383927']",
        "Doc_id":"ASCO_189424-199",
        "Doc_title":" An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.",
        "_version_":1606189007180398592},
      {
        "Meeting_name":" Pathways impact on chemotherapy administration before death.",
        "Background":"['Background', '    Continuing IV chemotherapy (chemo) in patients (pts) with advanced cancer near death does not extend survival or improve quality, but does increase costs. Pathways (PW) programs have compared treatment (tx) costs but have not evaluated the impact on chemo given near death. The primary goal is to evaluate IV chemo administered in the last 14 and 30 days of life in pts treated On vs. Off-PW.  Methods', '  Eligibility', ' in US Oncologys (USO) iKnowMed (iKM) EHR 7/1/09-6/30/12; diagnosis (dx) of breast, colon, NSCLC, SCLC or pancreas cancer; >/=3 visits to a USO clinic; assessed for Level I PW compliance in the last 12 mths of life; and a date of death. IV chemo received in the last year of life was assessed. Pts were defined On-PW if all tx was On-PW or if pts did not receive IV chemo 12 mths before death (best supportive care). Pts were Off-PW if any tx received was Off-PW.  PW-status, age, sex, dx, and last line of therapy (LOT) received were assessed. Multivariate logistic regression analysis was used to assess if PW status predicted likelihood of chemo within 14 and 30 days of death.  Results', '  12,551 pts met inclusion criteria. PW status was independently associated with chemo 14 and 30 days before death. Pts treated Off-PW had 2-fold higher odds of receiving IV chemo within 14, 30 days of death vs. pts treated On-PW (OR', ' 2; 95% CI', ' 1.8-2.3, OR', ' 2.2, 95% CI', ' 2-2.4), see Table.  Findings were similar for each dx. Tx for pts On-PW vs Off-PW showed lower mean last LOT overall (1 vs. 2) and by dx.  Conclusions', '  Pts On-PW were less likely to receive IV chemo within 14 and 30 days of death and had fewer LOT. This suggests adherence to Level I PWs is associated with improved quality metrics.']",
        "Doc_id":"ASCO_120047-140",
        "Doc_title":" Pathways impact on chemotherapy administration before death.",
        "_version_":1606189008858120192},
      {
        "Meeting_name":" Erlotinib beyond progression study",
        "Background":"['Background', '     EGFR-driven NSCLCs are dependent on the EGFR pathway for proliferation which EGFR TKIs potently block. Progression occurs when resistance to erlotinib developsthrough the emergence of EGFRT790M or MET gene amplification. This event is likely specific to any given individual tumor clone and therefore on relapse only some tumor clones carry resistance mutations, others likely remain dormant while the EGFR pathway is inhibited providing rationale for maintenance therapy. This concept is supported by clinical observations demonstrating of tumor flares in patients taken off of EGFR TKI therapy on progression. Similar analogies exist in prostate cancer/maintenance of castrate state, breast cancer/maintenance trastuzumab. This study seeks preliminary evidence that such a strategy can lead to meaningful benefits in advanced non-small cell lung cancer. Methods', '     Randomized, phase II study of pemetrexed chemotherapy versus pemetrexed chemotherapy plus erlotinib in patients who derived a clinical benefit from erlotinib but now have evidence of progressive disease (NCT00660816).  Pemetrexed is given at standard dose of 500 mg/m2 every 3 weeks to a maximum of 8 cycles while erlotinib is given at 150 mg oral daily dose on days 2-19 of each cycle. Our main hypothesis is that maintenance erlotinib in this patient population could extend PFS by 50%, from 3 to 4.5 months and we seek to enroll 78 patients by randomized phase II screening design to allow 80% power to detect such a difference. Standard eligibility criteria include progression following at least twelve weeks of treatment with single-agent erlotinib during which time the patients experienced a clinical benefit. 23 of planned 78 patients have been enrolled and current enrollment averages 1-2 new patients per month. An amendment to allow either pemetrexed or docetaxel as the chemotherapy base is under review to further enhance accrual. Translational studies, including EGFR and other gene mutation analyses will also be performed.']",
        "Doc_id":"ASCO_79061-102",
        "Doc_title":" Erlotinib beyond progression study",
        "_version_":1606189014960832513},
      {
        "Meeting_name":" Activation of FGFR signaling as a mechanism of acquired resistance to erlotinib in EGFR-mutant lung cancer associated with an EMT.",
        "Background":"['Treatment of NSCLC patients harboring activating EGFR mutations with EGFR TKIs results in anti-tumor responses to therapy, however patients ultimately progress on therapy due to the acquisition of drug resistance. Known mechanisms of resistance include secondary mutations in the EGFR gene (EGFRT790M) or MET gene amplification, however the underlying mechanism of resistance remains to be elucidated in 40-45% of cases. Previous studies provide evidence for an epithelial-to-mesenchymal transition (EMT) in a subset of cases that is not associated with the known mechanisms of resistance. In this study, we identify 2 models of acquired resistance to erlotinib that are associated with an EMT phenotype and a dependence on autocrine FGF-FGFR signaling for resistance. Evidence for FGFR pathway activation in the erlotinib-resistant cell population included an increase in FGF2, FGFR1 and phospho-FRS2. Inhibition of FGFR signaling using a small molecule kinase inhibitor or FGFR1-Fc neutralization of FGFR1 ligands re-sensitized resistant cells to erlotinib. Re-sensitization was accompanied by an inhibition of downstream signaling. In contrast, inhibition of AXL, a kinase that has recently been identified as an EMT-associated driver of erlotinib resistance in some pre-clinical models, failed to re-sensitize erlotinib-resistant cells. Our findings are consistent with autocrine FGFR pathway activation, as FGF ligand neutralization in the absence of an exogenous source of ligand can re-sensitize cells to erlotinib. Finally, FGFR pathway inhibition suppressed the development of resistance to erlotinib in sensitive parental cells. These data indicate that FGFR activation could potentially serve as a mechanism of acquired resistance to erlotinib in cases associated with an EMT and suggest that combined inhibition of EGFR and FGFR signaling could be beneficial in treating such cases.']",
        "Doc_id":"AACR_2013-4463",
        "Doc_title":" Activation of FGFR signaling as a mechanism of acquired resistance to erlotinib in EGFR-mutant lung cancer associated with an EMT.",
        "_version_":1606189023694422016},
      {
        "Meeting_name":" Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup.",
        "Background":"['Background', '  Surgical resection followed by adjuvant platinum-based CT is the standard of care in stages II and III of NSCLC. ERCC1 is considered as a molecular determinant of benefit to platin-based CT and is an independent good prognostic marker in resected NSCLC. EGFR mutations predict for erlotinib efficacy. We included ERCC1 IHC status and EGFR mutational status in a prospective randomized multicentric phase II/III customized adjuvant CT trial.  Methods', '  Completely resected patients (pts) with non-squamous tumors, mediastinal lymph node dissection and pathological stage IIA, IIB or IIIA (N2 excluded) (6th TNM edition) were randomized either to a control arm (A) or a customized arm (B). Surgical blocks were centralized for biomarkers analyses. The control arm encompassed 4 cycles of standard dose cisplatin-pemetrexed (CP). In the experimental arm, EGFR mutated pts received erlotinib 150 mg for one year. ERCC1 negative pts received four cycles of CP. ERCC1 positive pts were closely monitored. The Flemings single stage phase II primary endpoint was feasibility (ie % of patients able to start therapy within 2 months of surgery and for which the biomarkers status was readily available) (H0 64%, H180%,  5% and  95%).  Results', '  150 pts were randomized between May 2009 and July 2012, 74 in arm A and 76 in arm B. Most pts were male (61%),  60 years (51%), and smokers (91%). Pathological stage was IIA in 69 pt, IIB in 48 pt and IIIA in 32 pt. ERCC1 was positive in 38 pts (19 in each arm), EGFR mutation was identified in 10 pts (3 in arm A, 7 in arm B). In arm A, all pts received CP. In arm B, 7 pts received erlotinib, 53 pts received CP and 16 were followed-up. The median exposure time to erlotinib was 276 days (10-365). Out of 127 pts allocated to CP, 82% received the expected 4 cycles with a very good tolerability profile (no febrile neutropenia). The success rate was 80% (120 out of 150 pts).  Conclusions', '  This adjuvant trial met its primary end point for its phase II component, demonstrating the feasibility of a national biology-driven trial in the adjuvant setting. Nevertheless the phase III was canceled due to the unexpected unreliability of the ERCC1 IHC read-out. Clinical trial information', ' NCT00775385.']",
        "Doc_id":"ASCO_110534-132",
        "Doc_title":" Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup.",
        "_version_":1606189019168768001},
      {
        "Meeting_name":" Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma",
        "Background":"['Background', ' EGFR kinase inhibitors are effective in never-smokers with NSCLC especially in those harboring EGFR mutations. In a prior phase III study (TRIBUTE) ECP was associated with improved RR, PFS, and OS compared to CP but only in never-smokers. CALGB 30406 prospectively evaluated E and ECP in never/light former smokers with chemotherapy-nave advanced lung adenoca and evaluated the impact of EGFR mutations on outcome. Methods', ' Chemotherapy-nave, never, or light former ( 10 pack years, > 1 yr since cessation) smokers, with advanced lung adenoca were randomized to E alone (150 mg/day) or ECP (E 150 mg/day given continuously; C [AUC = 6] and P (200 mg/m2) both q21 days) for 6 cycles followed by E. Primary endpoint was PFS in both arms. Collection of pretreatment tumor for assessment of EGFR mutations was mandatory. Results', ' Between 8/05 and 4/09 188 pts were accrued; 182 pts randomized (E=82; ECP=100) and treated. Baseline characteristics (E/ECP) were well balanced', ' Female', ' 61%/58%; Caucasian', ' 76%/84%; never smokers', ' 76%/77%; ECOG PS0', ' 61%/46%; adenoca', ' 87%/80%. Median number of cycles', ' E', '6; ECP', '7.Toxicity', ' Grade 3/4 hematologic toxicity', ' E', ' 1/0 (1%); ECP', ' 28/20 (48%). Grade 3/4 nonhematologic toxicity', ' E', ' 17/2 (23%); ECP', ' 39/11 (50%). EGFR genotyping possible in 172 pts (95%). EGFR mutant/wild type', ' 67 (39%)/105 (61%). Exon 19', '36; L858R', '31. Outcomes are shown in the Table. Median follow-up is 25 mos. 53% of pts have died in both arms. Primary endpoint was met in both arms. EGFR mut pts had a significantly better RR (p < 0.0001 both arms), PFS (p < 0.0001 both arms) and OS (p = 0.0027 E; p = 0.0009 ECP) than EGFR WT pts. Conclusions', ' E and ECP have similar efficacy, but E is less toxic, in predominantly Caucasian never smokers with advanced NSCLC. EGFR mutations identify patients most likely to benefit from E and ECP. E (n = 82)RRPFS months (80% CI)OS months (80% CI)All pts34%6.7 (4.7-8.2)24.0 (18.4-27.6)EGFR mutation (n = 32)66%16.4 (12.1-23.8)27.6 (24.0-42.8)EGFR WT (n = 48)8%2.8 (1.6-4.1)15.4 (11.2-19.9)ECP (n = 100)All pts47%6.0 (5.6-7.3)19.6 (14.7-24.6)EGFR mutation (n = 35)69%17.2 (11.1-27.6)39.0 (39.0-NR)EGFR WT (n = 57)31%4.8 (4.2-5.6)13.7 (10.0-18.0']",
        "Doc_id":"ASCO_42579-74",
        "Doc_title":" Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma",
        "_version_":1606189031259897856},
      {
        "Meeting_name":" Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples",
        "Background":"['Introduction', ' Approximately 30% of patients with an adenocarcinoma of the lung have an actionable driver mutation. Further understanding the molecular mechanisms of acquired resistance to targeted therapies provides key information for determining subsequent treatment options. Access to tumor tissue to perform either the initial molecular profile or at the point of acquired resistance, however, is often limited. Circulating tumor DNA (ctDNA) can be used as a minimally invasive method for the detection and quantification of molecular abnormalities. We performed a prospective study to assess molecular alterations in the ctDNA of NSCLC patients in whom the initial molecular profile or profile at acquired resistance was unknown due to lack of tumor tissue biopsy or insufficient cellularity in the biopsy.Methods', \" Plasma samples were collected from 52 pre-treated advanced NSCLC patients at the Gustave Roussy. DNA was extracted from < 5 ml of plasma and analysed using Inivata's enhanced TAm-SeqTM assay covering regions from 35 cancer-related genes. Sequences were generated using Illumina sequencing. We also analysed plasma taken following treatments prescribed after the original molecular profile detected using plasma ctDNA.Results\", ' From July 2015 to October 2015, 52 patients were included (63% female, 37% never-smoker, 95% diagnosed with an adenocarcinoma subtype, 95% with stage IV disease, and 54% had EGFR mutant tumors of which 68% had mutations in exon 19 and 32% had mutations in exon 21). ctDNA profiling was successfully performed for all patients, and mutations were detected in 38 of 52 patients. The median number of mutations detected in plasma samples was 1. Within the EGFR mutant subpopulation, T790M mutations were identified including 8 acquired cases (with a concomitant C797S mutation in 1 case) and 1 primary T790M mutation. Of these patients, 5 started personalised treatment with AZD9291 based on the results of ctDNA analysis. In the other 18 patients with EGFR mutant tumors, no acquired mutations associated with resistance were detected. Other results encompassed', ' 2 plasma samples with EGFR mutation exon 18 (G719A, G719C) leading to initiation of afatinib in one case, 1 case with EGFR mutation exon 21 (L861Q), 1 patients with ERBB2 exon 20 insertion, 3 KRAS mutant detected in plasma (G12C, G12S, G12F), 2 STK11 mutant samples, and 1 patient with a MET mutation (exon 14) who subsequently started crizotinib.Conclusions', \" ctDNA analysis with Inivata's enhanced TAm-Seq provides an alternative method of liquid biopsy for obtaining molecular profile of mutations present in NSCLC patients in the absence of an invasive tissue biopsy. Liquid biopsy identified cancer mutations in 73% of the study population, and 18% of those patients subsequently received treatment tailored to the plasma ctDNA detected mutations. An update on the analysis of 75 patients will be presented during the conference.\"]",
        "Doc_id":"AACR_2016-3192",
        "Doc_title":" Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples",
        "_version_":1606189021611950080},
      {
        "Meeting_name":" Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC.",
        "Background":"['Introduction', ' Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) which is highly active in EGFR-mutant NSCLC with resistance to prior EGFR TKI. Acquired resistance to osimertinib had been observed clinically; an improved understanding of the molecular mechanisms of resistance is needed. Methods/Results', ' We initially studied an institutional cohort of 86 patients (pts) treated with osimertinib for advanced T790M-positive NSCLC. 50 pts had progressed on therapy, of whom 25 underwent a resistance biopsy and 17 had NGS results available. 6 pts maintained the T790M mutation at resistance, of whom 3 also acquired an EGFR C797S mutation. The remaining 11 pts had loss of T790M, of whom 5 had evidence of a competing resistance mechanism', ' 2 with histologic transformation to SCLC, one with BRAF V600E, one with an FGFR3-TACC fusion, and one with KRAS Q61K. For the final case, we confirmed the acquired KRAS Q61K on therapy using serial plasma genotyping. Time to treatment failure (TTF) on osimertinib was 3 months median in pts with loss of T790M and 14 months median in pts with maintained T790M. To test the hypothesis that loss of T790M is a poor prognosis subtype of resistance, we analyzed 127 pts treated for T790M-positive NSCLC on the phase I AURA trial of osimertinib. Plasma drawn after progression was submitted for genotyping using droplet digital PCR. 88 pts had a detectable EGFR driver mutation and were eligible for resistance analysis. 45 pts (51%) had detectable T790M at resistance, 17 (19%) of whom also acquired a C797S mutation; the remaining 43 pts (49%) had loss of T790M and no C797S. Median TTF on osimertinib was 6 months in pts with loss of T790M and 11 months in pts with maintained T790M; among pts with TTF <5 months, 72% had loss of T790M. To study whether baseline plasma genotyping could predict the eventual pattern of resistance on osimertinib, we studied 30 pts from the AURA trial with pretreatment plasma genotyping positive for T790M and an EGFR driver. The relative allelic fraction (AF) of T790M was calculated as the ratio of the T790M AF to the driver AF. In 9 pts with eventual loss of T790M, the relative T790M AF trended lower (25% median) than in 21 pts with maintained T790M at resistance (38% median, P = 0.086). Conclusion', ' Different molecular mechanisms of acquired resistance to osimertinib have different clinical presentations, with early resistance being associated with loss of T790M and the potential for overgrowth of a competing resistance mutation. These findings have implications in steering pts towards suitable trials for overcoming resistance - pts with early resistance to osimertinib could favor trials targeting a competing resistance mechanisms (e.g. MET inhibition) while pts with late resistance could favor trials targeting EGFR C797S.']",
        "Doc_id":"AACR_2017-4112",
        "Doc_title":" Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC.",
        "_version_":1606189040113025024},
      {
        "Meeting_name":" Implications for cardiotoxicity with targeted therapies.",
        "Background":"['Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of multiple cancer types. However, unexpected cardiotoxicity has arisen that was not wholly predicted by current FDA mandated pre-clinical tests. Thus a more robust tool to predict the cardiotoxic potential of these compounds is warranted. For this purpose, we developed a panel of in vitro tests in a clinically relevant human cardiomyocyte model that assesses drug impact on overall cardiac health (cell viability, apoptosis, and morphology), mitochondria and metabolic intactness (reactive oxygen species (ROS) generation, AMPK activity, and lipid accumulation), and electrophysiological function (impedance (beat rate) and ion channel blockage). To demonstrate the utility of our panel, we examined the effect of 4 FDA-approved TKi with known clinical outcome on cardiac health. The 3 drugs with known cardiac adverse events (crizotinib, sunitinib, and nilotinib) all proved to be cardiotoxic by our panel although each showed distinct mechanisms of toxicity. However erlotinib, a cardiac-safe drug that targets EGFR and is used primarily in non-small cell lung cancer (NSCLC), did not show any indications of toxicity. Surprisingly, the most cardiotoxic drug by our panel was crizotinib, an ALK/ MET inhibitor that has revolutionized treatment for ALK+ NSCLC patients. Crizotinib potently impaired overall cardiac health by increasing ROS and apoptosis but also impeded electrophysiological function by inducing ion channel blockage and reducing cardiac beat rate. Interestingly crizotinib also induced lipid and cholesterol accumulation which was shown to be correlated with increased expression of the sterol-regulatory binding protein (SREBP) pathway by transcriptome analysis. The multi-targeted TKi sunitinib (used in renal cell carcinoma and gastrointestinal stromal tumors) and nilotinib (used in chronic myelogenous leukemia) also showed unique cardiotoxicity profiles. In conclusion, our studies showed a distinct cardiotoxicity profile for each TKi that correlates with clinical outcome. These results suggest that caution should be taken with these TKi especially when used long-term or in the adjuvant setting. Furthermore, these effects may be exacerbated in patients with adverse cardiac genetic predispositions and studies are ongoing in our lab on patient-derived cardiac cell lines to investigate this possibility. This multi-parameter screening approach allows for a more complete assessment of the potential for drug-induced cardiotoxicity and may allow for earlier detection in the drug development process. In addition, understanding the mechanisms of cardiac toxicities may lead to the discovery of novel mitigation strategies and combination therapies to improve cardiac cell health during treatment with oncology therapies.']",
        "Doc_id":"AACR_2013-4423",
        "Doc_title":" Implications for cardiotoxicity with targeted therapies.",
        "_version_":1606189022617534465},
      {
        "Meeting_name":" Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer.",
        "Background":"['BT1718 is a Bicycle Drug Conjugate (BDC) comprising a constrained bicyclic peptide (Bicycle) that binds with high affinity and specificity to membrane type 1-matrix metalloprotease (MT1-MMP; MMP14) covalently linked through a hindered disulfide linker to the potent anti-tubulin agent DM1. MT1-MMP is involved in normal tissue remodeling and is also expressed in tumor associated stromal cells. However, overexpression is linked to increased tumor aggression and metastasis. Specifically, over-expression of MT1-MMP is also associated with poor clinical prognosis and shorter survival times in patients with NSCLC and a range of other solid tumors. The Bicycle MT1-MMP binding element within BT1718 was identified using a proprietary phage display peptide technology consisting of highly diverse phage libraries of linear amino acid sequences constrained into two loops by a central tri-functional chemical scaffold. These MT1-MMP binding Bicycles exhibit a profound affinity and specificity, more often associated with monoclonal antibodies, whilst their low molecular weight (1.5-3 kDa), akin to that of a small molecule, aids in rapid extravasation and tumor penetration. Together these attributes make Bicycles an ideal format for the targeted delivery of cytotoxic payloads. We evaluated the ability of BT1718 to bind to and kill tumor cells in vitro and in vivo in a panel of tumor cells. BT1718 demonstrated MT1-MMP target-specific binding and MT1-MMP-dependent cell killing of lung tumor cells in vitro as well as efficacy across a panel of lung tumor xenograft mouse models. For example, in the Met-amplified squamous NSCLC lung EBC-1 model, complete regressions were observed in all mice at doses as low as 5 mg/kg (iv) twice weekly and across a range of other dosing schedules, from daily to weekly. MT1-MMP-dependent activity was demonstrated by blocking target specific interactions through co-administration of an excess of unconjugated Bicycle binder, which inhibited tumour regression, or a non-binding Bicycle, which had no effect. Further evaluation in patient-derived lung xenograft (PDX) models indicates a similar activity to that seen in cell-line derived xenografts, with efficacy seen from 3mg/kg twice weekly and rapid full regression of tumors at higher doses. The molecular attributes of these Bicycles', ' rapid tumor penetration and specific binding, makes them ideal therapeutics for targeted delivery of toxins as Bicycle drug conjugates (BDCs). The small size of the BDC may offer a significant advantage to other targeted cytotoxic approaches such as antibody-drug conjugates due to rapid extravasation and improved tumor penetration. BT1718, a Bicycle Drug Conjugate, shows potent anti-tumor activity in human lung tumor xenograft models and IND-enabling studies are underway.']",
        "Doc_id":"AACR_2017-1167",
        "Doc_title":" Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer.",
        "_version_":1606189036251119616},
      {
        "Meeting_name":" Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.",
        "Background":"['Background', '  PD-L1 has been reported to be expressed broadly in human cancer and can lead to inhibition of anti-tumor T-cell responses. MPDL3280A, a human monoclonal antibody containing an engineered Fc-domain designed to optimize efficacy and safety, targets PD-L1, blocking PD-L1 from binding its receptors, including PD-1 and B7.1. Pts with a broad range of tumors were examined in an expansion study with MPDL3280A. Methods', '  Pts with locally advanced or metastatic tumors received MPDL3280A administered IV q3w. Pts were treated for up to 1 y. Response was assessed by RECIST v1.1. Results', '  As of Jan 10, 2013, 20 pts with tumor types other than NSCLC, RCC and mM were evaluable for safety and treated at doses of 0.01-20 mg/kg (1 [n=3], 3 [n=1], 10 [n=3] and 20 mg/kg [n=13]). Median pt age was 67 y (range 26-80 y), 100% were PS 0-1, 90% had prior surgery and 45% had prior radiotherapy. 95% of pts received prior systemic therapy. Pts received MPDL3280A treatment for a median of 96 days (range 22-330). The incidence of all G3/4 AEs, regardless of attribution, was 50%. No G3-5 pneumonitis or diarrhea was reported. Confirmed RECIST responses were observed in several tumor types, including CRC, GC and SCCHN. Additionally, antitumor activity (tumor shrinkage that has not yet met criteria for a RECIST response) has been observed in sarcoma and lymphoma. Analysis of biomarker data from archival tumors revealed that all pts reported to have RECIST response had baseline tumors that were PD-L1 positive. Updated data will be presented. Conclusions', '  Treatment with MPDL3280A was well tolerated, with no pneumonitis-related deaths. Rapid responses were observed in pts with CRC, GC and SCCHN. PD-L1 tumor status appears to correlate with responses to MPDL3280A. These data suggest that PD-L1 is a conserved mechanism for mediating tumor immune escape across a range of tumor types. MPDL3280A may be broadly active as anti-cancer therapy in PD-L1expressing tumors, supporting further investigation. Clinical trial information', ' NCT01375842.']",
        "Doc_id":"ASCO_115915-132",
        "Doc_title":" Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.",
        "_version_":1606188983120822272},
      {
        "Meeting_name":" Recreational activity and sedentary behavior in relation to lung cancer incidence and mortality in the Womens Health Initiative.",
        "Background":"['Background', '  Studies have suggested that physical activity may decrease cancer incidence and mortality. Data fromthe Womens Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT) were used to investigate this relationship in a prospective cohort of postmenopausal women.  Methods', '  The WHI study enrolled women aged 50-79 years from 1993-1998 at 40 U.S. clinical centers. Among 134,058participants, Cox proportional hazards models were used to assess the association between lung cancer incidence/mortality and physical activity levels at study baseline [MET-minutes/week', ' inactive < 100 (reference), low 100- < 500, medium 500- < 1200, high 1200+] and sedentary behavior (sitting time/day in WHI-OS).  Results', '  Over 11.8 mean follow-up years, 2,229 total incident lung cancer cases and 1,427 lung cancer deaths were identified. Increased total physical activity at study entry was associated with significant decreases in both lung cancer incidence [p = 0.004; physical activity levels', ' low HR 0.86 (95% CI', ' 0.77-0.96), medium HR 0.81 (0.72-0.91), high HR 0.89 (0.78-1.01)] and mortality [p < 0.0001, low HR 0.80 (0.70-0.92), medium HR 0.68 (0.58-0.79), high HR 0.77 (0.65-0.91)]. BMI was found to be an effect modifier of the relationship between total physical activity and lung cancer incidence (p = 0.008), with reduced HRs found for increasing physical activity levels for BMI < 30. While smoking status was not a statistically significant effect modifier, former smokers  > 10 pack-years and current smokers were estimated to have reduced lung cancer incidence and mortality HRs for increasing physical activity levels, when compared to inactive women with the same smoking status. In the subtype analysis, decreased lung cancer mortality was associated with increased total physical activity levels for both overall NSCLC and adenocarcinoma. No association was found for sedentary behavior and lung cancer incidence or mortality.  Conclusions', '  In a cohort of postmenopausal women, physical activity prior to diagnosis may decrease lung cancer incidence and mortality. Physical activity may be particularly protective for women with BMIs under 30, and for current and heavy former smokers. Clinical trial information', ' NCT00000611']",
        "Doc_id":"ASCO_143533-156",
        "Doc_title":" Recreational activity and sedentary behavior in relation to lung cancer incidence and mortality in the Womens Health Initiative.",
        "_version_":1606188983706976256},
      {
        "Meeting_name":" Impact of pathways on chemotherapy administration before death.",
        "Background":"['Background', '  Continuing IV chemotherapy (chemo) in patients (pts) with advanced cancer near death neither extends survival nor improves quality, but does increase costs. Pathways (PW) programs have focused on comparing treatment (tx) costs but have not evaluated the impact on chemo given near death. The primary goal is to evaluate IV chemo administered in the last 14 days of life for pts treated On-PW vs. Off-PW.  Methods', '  Eligible pts', ' in US Oncologys (USO) iKnowMed (iKM) EHR; diagnosis (dx) of breast, colon, NSCLC, SCLC or pancreas cancer; >/=3 visits to a USO clinic; assessed for Level I PW compliance in the last 12 mths of life; and a documented date of death.  IV chemo received in the last year of life was assessed. Pts were defined On-PW if all tx was On-PW or if pts did not receive IV chemo 12 mths before death (best supportive care).  Pts were defined Off-PW if any tx received was Off-PW.  PW-status, age, sex, dx, and last line of therapy (LOT) received were assessed.  Multivariate logistic regression analysis was used to assess if PW status predicted likelihood of chemo within 14-days of death.  Results', '  From 7/1/09-6/30/12, 12,551 pts met inclusion criteria.   PW status was independently associated with chemo 14 days before death.  Pts treated Off-PW had a two-fold higher odds of receiving IV chemo within 14 days of death compared to pts treated On-PW (OR', ' 1.99; 95% CI', ' 1.77-2.26), see the Table.  Findings were similar for each dx.  Tx for pts On-PW vs Off-PW showed lower mean last LOT overall (1 vs. 2) and by dx.  Conclusions', '  Pts On-PW were less likely to receive IV chemo within 14 days of death and had fewer LOT. This suggests adherence to Level I PWs is associated with improved quality metrics.   Chemo 14 days before death, LOT.']",
        "Doc_id":"ASCO_110795-132",
        "Doc_title":" Impact of pathways on chemotherapy administration before death.",
        "_version_":1606189015974805504},
      {
        "Meeting_name":" Update of the EORTC questionnaire for assessing quality of life in patients with lung cancer",
        "Background":"['Background', ' The EORTC QLQ-LC13 was the first module developed to be used in conjunction with the core questionnaire C30. Since the publication of the LC13 in 1994, major advances have been made in the treatment of lung cancer as well as in assessing quality of life. Therefore, the EORTC decided to support a project to update the LC13. Methods', ' The study design followed the Phase I to III approach described in the EORTC Module Development Manual. Phase I generates relevant quality of life issues using a mix of sources, including patient involvement. Phase II transforms issues into questionnaire items. An international multi-center study investigated the feasibility of the provisional module (Phase III). Patients had to fill in the EORTC QLQ-C30 and a 78-item provisional lung cancer module generated in Phases I and II. Patients rated each of the items regarding perceived importance, comprehensibility, and acceptance. The 78 items were assessed against a set of pre-specified statistical criteria comprised of distribution properties of the items and patient ratings. Biometrical methods primarily included descriptive statistics and basic psychometric analyses (Cronbachs alpha). Results', ' A total of 12 centers from Cyprus, Germany, Italy, Israel, Spain, Norway, Poland, Taiwan, and UK participated in the Phase III study. 200 patients with histologically confirmed lung cancer were enrolled. Mean age was 64 years (range 3991). 59% of the patients were male, 82% had NSCLC, and 56% were treated with a palliative approach. 29 out of the 78 items met the pre-specified statistical. Initial psychometric analyses suggested a five multi-item scale structure (coughing, shortness of breath, side effects, tumor progression related to existential issues, surgery-related symptoms; all Cronbachs alphas > .70). Conclusions', ' The updated module retained 12 of the 13 original LC13 items and contains new items that assess therapy side effects of targeted therapy, radio-chemotherapy, and thoracic surgery. A large-scale international multi-center Phase IV study will be conducted to fully assess the psychometric properties of the updated lung cancer module. Clinical trial information', ' NCT01434784']",
        "Doc_id":"ASCO_164903-176",
        "Doc_title":" Update of the EORTC questionnaire for assessing quality of life in patients with lung cancer",
        "_version_":1606189017836027904},
      {
        "Meeting_name":" Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).",
        "Background":"['Background', '   WJTOG3405 met its primary endpoint of progression free survival (PFS) (9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence interval (CI)', ' 0.336-0.710). (Mitsudomi et al., Lancet Oncol., 2010). However, the impact on overall survival (OS) was not clear then because of relatively short follow-up period. Methods', '  Overall survival (OS) was re-evaluated using updated data (data cutoff, 31 July, 2011, median follow-up, 34 months) for 172 patients.  Results', '  Eighty-two events had occurred (48%). Median survival time (MST) for G arm was 36 mo. (95% CI', ' 26.3 -) which was not significantly different from 39 mo. (95% CI', ' 31.2 -) for CD arm (HR 1.185, 95% CI 0.767-1.829). Multivariate analysis using Cox proportional hazards model revealed that none of covariates (treatment arm, smoking status, sex, age, postoperative recurrence or IIIB/IV, and mutation type) significantly affected OS. In the G arm, MST of patients with exon 19 deletion (36 mo.) was comparable to that of patients with L858R (35 mo.). In the CD arm, 78 patients (91%) received EGFR-TKI as the 2nd or later line treatment, whereas in the G arm, 52 patients (61%) received platinum doublet. Accordingly, 130 patients received both platinum doublet and EGFR-tyrosine kinase inhibitor (TKI) and 34 patients received EGFR-TKI without platinum doublet in their whole courses of therapy. MST for the former and the latter group were 36 months (95% CI', ' 31.2-45.7) and 45 months (95% CI', ' 25.6-), without significant difference.  Conclusions', '  This update OS analysis revealed that G for advanced NSCLC with EGFR mutation offers distinct survival benefit of 3 years. There was no difference in OS whether the first-line treatment was G or CD, in accordance with the precedent studies. The reason why PFS difference was not translated into OS difference is probably due to high cross over rate to EGFR-TKI. However, it was noteworthy that 40% of patients in the G arm could be managed without platinum doublet and yet had similar outcome.']",
        "Doc_id":"ASCO_93530-114",
        "Doc_title":" Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).",
        "_version_":1606189020046426112},
      {
        "Meeting_name":" Resistance to selective kinase inhibitors upon epithelial to mesenchymal transition.",
        "Background":"['Epithelial to mesenchymal transition (EMT) is a pivotal mechanism contributing to cancer metastasis and has been associated with resistance to multiple cancer therapies including targeted kinase inhibitors (TKIs). EMT has been associated with an acquired resistance to the EGFR TKI erlotinib independent of known resistance mechanisms such as secondary mutations T790M or MET amplification. RTK-addicted cancer cell lines that are induced to undergo EMT with exogenous TGF- become resistant to their appropriate TKI. In vitro-based assays determined that the resistance is not due to exogenous TGF-, drug efflux, or autocrine/paracrine growth factor signaling. To identify potential therapeutic vulnerabilities specifically within the mesenchymal, TKI resistant cells, we performed a small molecule screen of approximately 200 agents using the EGFR mutant non-small cell lung cancer (NSCLC) HCC827 cell line and its corresponding TGF--induced mesenchymal derivative line. This screen revealed that the mesenchymal cells are cross-resistant to a variety of small molecules, including TKIs and chemotherapeutic agents. However, a small number of agents showed selective growth inhibitory activity against the mesenchymal cells, with the most potent being the dual Brc-Abl and Src inhibitor, dasatinib. Within the parental HCC827 cell line, we detected a non-proliferating vimentin positive sub-population of cells. Interestingly, when the parental cell line was co-treated with erlotinib and dasatinib the entire cell population was killed and drug-resistant clones failed to emerge after prolonged treatment. To determine the mechanism underlying the resistance observed within the mesenchymal cells a proteomic analysis was undertaken, which demonstrated that the focal adhesion kinase, FAK, is the most abundant differentially phosphorylated protein in the resistant mesenchymal cells that is specifically suppressed by dasatinib. However, specific gene knock-down of FAK was not sufficient to kill the mesenchymal cells or revert their sensitivity to Erlotinib suggesting that FAK alone is not required to maintain resistance upon EMT. These findings identify dasatinib as a potential therapeutic for treatment of erlotinib resistance associated with EMT.']",
        "Doc_id":"AACR_2013-4462",
        "Doc_title":" Resistance to selective kinase inhibitors upon epithelial to mesenchymal transition.",
        "_version_":1606189025663647744},
      {
        "Meeting_name":" A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  Advanced NSCLC management has evolved toward individual tumor subtyping based on targetable oncogenic drivers. Most molecularly characterized lung adenocarcinoma patients (pts) could thus potentially benefit from targeted treatment. This study investigates the innovative paradigm of allocating pts to specific treatment arms based on their genetic profile. The targeted therapies AUY922 (HSP90 inhibitor[i]), BYL719 (PI3Ki), LDK378 (ALKi), INC280 (METi), and MEK162 (MEKi) will be evaluated in different pt subgroups with appropriate confirmed molecular aberrations, in a single cluster study.  Methods', '  This Phase II, multiple arm, open-label study will enroll pts (aged 18 years, ECOG PS 2) with advanced (stage IIIB/IV) lung adenocarcinoma bearing different molecular alterations, who have failed prior treatment or are unsuitable for chemotherapy, and have received 2 prior lines of therapy. Pts must have locally obtained documentation of a relevant molecular alteration from either a new or the most recent archival tumor sample, using primary genetic profiling. Pts will be allocated to a specific treatment arm accordingly (AUY922, 70 mg/m2 QW', ' activating EGFR mutation and resistant to EGFR inhibitors; BYL719, 350 mg QD', ' PIK3CA mutation/amplification [other PI3K pathway alterations may be eligible]; INC280, 600 mg BID', ' MET-positive tumors [by IHC or FISH]; LDK378, 750 mg QD', ' ALK or ROS1 rearrangement; MEK162, 45 mg BID', ' KRAS, NRAS or BRAF mutation). Sample size was calculated based on a Bayesian approach using either a minimally informative prior (BYL719, INC280 and MEK162; N=20 for each) or an informative prior using relevant historical data (AUY922 [N=30] and LDK378 [N=25]). The sample size will allow detection with high likelihood, of statistically and clinically relevant antitumor activity. Each treatment arm is independent from one another and will be analyzed separately. Study treatment is given until disease progression or discontinuation. The primary endpoint is overall response rate; secondary endpoints are overall survival, progression-free survival, disease control rate, duration of response, safety, and pharmacokinetics.']",
        "Doc_id":"ASCO_129092-144",
        "Doc_title":" A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606189034904748032},
      {
        "Meeting_name":" NEOSCAN",
        "Background":"['Background', '  Perioperative chemotherapy improves survival in pts with resectable lung cancers.  Administering chemotherapy prior to surgery enables assessment of response and opportunity to switch non-responding pts to potentially more effective regimens.  Response measured by PET correlates better than CT with clinical outcomes.  This trial assessed PET-guided neoadjuvant chemotherapy, assigning pts with suboptimal PET response after 2 cycles of platinum-based therapy to alternative switch chemotherapy.  Methods', '  We enrolled pts with clinical stage IB-IIIA NSCLCs (primary tumor >2 cm and SUVmax4.5) deemed to be resectable by a thoracic surgeon.  All pts had a pretreatment PET.  Pts received 2 cycles of cisplatin (or carboplatin) + gemcitabine (squamous) or pemetrexed (adenocarcinoma/other), followed by repeat PET.   If PET showed 35% decrease in SUVmax, pts continued on platinum-based therapy.  Pts with suboptimal response (<35% decrease) were switched to vinorelbine + docetaxel q2 weeks (2 doses = 1 cycle).  The primary endpoint was partial metabolic response after 2 cycles of switch therapy as assessed by PERCIST (SUVmax decrease 30% using the pre-switch scan as new baseline).  We powered the study to detect a 30% response rate to switch chemotherapy (6 responses in 25 pts who received vinorelbine + docetaxel).  Results', '  32 pts were enrolled (7 gemcitabine, 25 pemetrexed).  21 (66%) had >35% decrease in SUVmax and continued platinum-based therapy.  11 (34%) had <35% decrease and switched therapy.  The study met its primary endpoint when 6 of 9 pts (66%, 95% CI 35-88%) who received vinorelbine + docetaxel had a PERCIST partial metabolic response.  27 pts have been surgically explored with 23 (85%) R0 resections, including 7 of 7 who switched chemotherapy and were explored.  There were no on-study deaths.   Conclusions', '  Pts with resectable lung cancers who have a suboptimal PET response to histology-selected, platinum-doublet neoadjuvant chemotherapy can be effectively treated with vinorelbine and docetaxel followed by surgery.  We now plan to correlate pathologic response in resected tumors with SUV change.  Clinical trial information', ' NCT01443078.']",
        "Doc_id":"ASCO_132441-144",
        "Doc_title":" NEOSCAN",
        "_version_":1606189040588029952},
      {
        "Meeting_name":" Molecular profiling in African American NSCLC patients to identify novel potential driver mutations",
        "Background":"['African Americans continue to have poorer 5 year survival after a lung cancer diagnosis than whites for reasons that remain to be fully characterized. This disparity remains even with advances in treatments targeting specific driver mutations that have improved outcomes for some patients. Although the relative frequency of these genetic alterations varies in subsets of individuals defined by sex, histologic subtype, smoking history and race, little is known about the occurrence of these mutations in African Americans. In this study, we characterize the spectrum of known driver mutations in 200 African American NSCLC patients and seek to identify novel somatic mutations in this population. Initially, the population was screened using the Sequenom LungCarta panel of 216 mutations in 24 genes known to contain alterations associated with lung cancer, RET and ROS1 fusion gene expression, and amplification of FGFR1. Whole-exome sequencing is being performed on tumors from those patients with no known somatic mutations. Paired normal and tumor DNA/RNA samples are being genotyped to distinguish germline from somatic mutations in both the screening and sequencing phases. Initial screening has been completed on 130 patients, with the remaining 70 underway. The mean age of the patients enrolled is 61.7 years, 58.5% are female, and 8.5% are never smokers. In profiling the first 130 African American patients, we find that only 28% of patients (N = 36) carry a known somatic mutation that is not present in the germline, far lower than the 41% reported in white patients in our previous studies. Of the identified mutations, approximately 23.8% are KRAS and 23.8% are PT53 alterations. The next most frequent somatic alterations are in EGFR (16.7%). The remaining alterations occurred in only 1 or 2 tumors and include EPHA3, ERBB2, FGFR1, MET, NOTCH1, NRAS, NTRK2, PIK3CA, PTEN, RET and STK11. Five percent of patients have tumors with two driver mutations. Half of the tumors carrying 2 driver mutations had concurrent alterations in KRAS and TP53. Patients with known genetic alterations were more likely to be female than patients with no known genetic alterations (p = 0.42), but did not differ in age, smoking status, pack-years, family history of lung cancer, history of COPD, stage at diagnosis or histology. Mutations in EGFR were responsible for the differences by sex. Exome sequencing is complete for the first 48 of the 92 patients with no known somatic mutations. Sequences are being aligned using Novoalign and GATK will be used for variant calling; results will be available soon. Genetic profiling of NSCLC in African Americans has the potential to both identify novel mutations, expanding the list of potential targets for tailored treatments, and aid clinical decision making in African American patients leading to improvements in outcomes.']",
        "Doc_id":"AACR_2016-5227",
        "Doc_title":" Molecular profiling in African American NSCLC patients to identify novel potential driver mutations",
        "_version_":1606188979986628608},
      {
        "Meeting_name":" The MVA viral platform for the treatment of cancer and chronic infectious diseases",
        "Background":"['The modified vaccinia strain Ankara (MVA) is attenuated and non-propagative but retains infectivity and immunogenicity, its large DNA genome allows the insertion of several full-length coding sequences for disease associated antigens or other transgenes of interest. MVA based targeted immunotherapeutics are designed to induce a cytolytic cellular immune response.TG4010 expresses the full-length sequences of MUC1 and IL2 and was tested in combination with first line platin-based chemotherapy in stage IV non-small cell lung cancer (NSCLC) versus chemotherapy alone (NCT00415818 and NCT01383148); 108 plaque forming units (pfu) was given S/C weekly for 6 weeks then every three weeks up to progression. TG4001 expressing E6 and E7 of HPV16, and IL2 was assessed versus placebo in women with cervical intra-epithelial neoplasia (CIN2/3) (NCT01022346) at the dose of 5.107 pfu, three S/C injections a week apart. TG4040 expresses the HCV antigens NS3, NS4 and NS5B and was evaluated in combination with peg-interferon- and ribavirin versus the same treatment alone in treatment-nave patients with chronic hepatitis C, (107 pfu). Two distinct schedules of administration were evaluated', ' with or without immunotherapy run-in phase (NCT01055821).A total of 729 patients were included and randomized in these four studies', ' 443 in active arms (185 NSCLC, 136 CIN2/3, 122 HCV) and 286 in control arms. In all studies the repeated S/C administration of the MVA vectors alone or in combination therapies appeared feasible and well tolerated, neither dose reduction nor modification of the schedules of administration have been necessary. Injection site reactions have been the most frequent adverse events associated with treatment, mild to moderate in the majority of cases. Despite lower doses they seemed more prevalent for vectors expressing xenoantigens (TG4001 99% pts, TG4040 42% pts) than for TG4010 (31%). The phase II studies with TG4010 met their primary endpoints based respectively on 6 month progression free survival (PFS) and overall PFS. The primary endpoint of improvedcomplete early viral response (cEVR) was also achieved in the study with TG4040. These studies had in common 1/ to combine the MVA from the beginning of standard of care and 2/ to use a schedule of administration with a run-in phase of 6 or more weekly injections followed by at least monthly injections. The study with TG4001 did not meet its threshold-based primary endpoint of complete response but significantly more women in the experimental arm had a clearance of their cervical lesions at a conization performed 6 months later.Three MVA-based immunotherapeutics have shown meaningful clinical activity in different settings. Their favorable safety profile allows the combination of these products with standard of care therapies and also with immune checkpoint inhibitors (ongoing).']",
        "Doc_id":"AACR_2015-2498",
        "Doc_title":" The MVA viral platform for the treatment of cancer and chronic infectious diseases",
        "_version_":1606188987752382465},
      {
        "Meeting_name":" Modeling patient-derived lung cancer in mice",
        "Background":"['Background', ' Genotype directed treatment is the standard of care for patients with advanced non-small cell lung cancer (NSCLC). However, acquired drug resistance invariably develops. There is a need to develop clinically relevant animal models from patients who have developed acquired resistance in order to study mechanisms of resistance and validate new therapeutic strategies. We have generated a portfolio of clinically relevant, early passage, patient-derived xenograft (PDX) models of lung cancer.Methods', ' Tumor biopsies (core biopsies (n = 8), pleural effusions (n = 28) and surgical samples (n = 11)) were implanted subcutaneously (n = 39) or into the sub-renal capsule (n = 8) of NSG mice under an IRB approved protocol. After implanting 35 specimens, mostly from pleural effusions, several mice exhibited weight and fur loss. Histopathology revealed infiltration of the liver, skin and lungs by human derived T-cells consistent with graft-versus-host disease (GVHD). Subsequent pleural effusions were then subjected to CD45 depletion using a human CD45 microbead separation kit which eliminated the incidence of GVHD. Tumors from all three sources were allowed to grow and subsequently passaged only as subcutaneous implants in NSG mice. Molecular characterization of PDX models was performed using targeted next generation sequencing and tumor histology confirmed by H&E staining. Some established tumor models have also been propagated as cell lines in vitro.Results', ' 47 specimens were implanted with an overall take rate of 30%. The initial take rate was 22% but increased to 66% following CD45 depletion. We have established 11 NSCLC adenocarcinoma and 3 small-cell lung cancer (SCLC) PDX models from patient samples. The models established thus far range from erlotinib resistant EGFR mutant models with T790M mutation (n = 3), MET amplification (n = 1), SCLC transformation (n = 2) or an unknown mechanism (n = 1); to models including SCLC with an NRAS Q61K mutation (n = 1); EML4-ALK resistant to crizotinib and ceritinib (n = 1); KRAS G12C mutation (n = 1); NUT-mid line carcinoma with BRD4 rearrangement (n = 1); pan wild-type (n = 2) and a PIK3CA mutation (n = 1). We have used these models to study therapeutic interventions. Treatment of the NRAS Q61K mutant SCLC with trametinib resulted in complete tumor regression. Pharmacodynamic analyses revealed inhibition of pERK 1/2 and induction of apoptosis. Data will be presented with further characterization and platform development of the lung PDX models. Notably, >50% of the models do show pulmonary metastases from the subcutaneous implant site.Conclusions', ' PDXs can be established from lung cancer patients undergoing routine clinical biopsies. Establishment of models from pleural effusions is also feasible following CD45 depletion to prevent GVHD. These models will provide unique information on mechanisms of drug resistance and can be used to evaluate pre-clinical therapeutic strategies.']",
        "Doc_id":"AACR_2015-1451",
        "Doc_title":" Modeling patient-derived lung cancer in mice",
        "_version_":1606189032763555840},
      {
        "Meeting_name":" Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599.",
        "Background":"['Background', ' B is a monoclonal antibody that targets VEGF with demonstrated efficacy in combination with PC for the TX of advanced NSCLC. Administration of B is thought to decrease nitrous oxide synthesis and lead to HTN, one of the known toxicities associated with PCB on E4599. This side effect may be a physiological sign that the VEGF pathway is more actively being blocked and indicate differential outcomes between hypertensive and non-hypertensive pts. Methods', ' Pts randomized to PCB constituted the cohort. Hypertensive pts (HTN of any grade or TX relation reported via a toxicity form, CTCAE v2) were compared to nonhypertensive pts with respect to baseline pt characteristics, overall survival (OS) and progression-free survival (PFS). Blood pressure (BP) data were also collected at each TX cycle; similar comparisons were made for high BP (>150/100). Results', ' In E4599, 33/417 (7.9%) eligible pts experienced HTN; 30/33 (90.9%) were grade 3 events. Baseline characteristics of the HTN cohort were similar to those in the non-HTN cohort except for a higher proportion of PS 0 pts (70% vs. 38%, p=0.001) and females (67% vs. 48%, p=0.05). Median follow-up was 54.8 mos. The 6-month cumulative incidence of HTN adjusting for death as a competing risk was 6.2% (95% CI', ' 3.9-8.6%). Landmark analyses measured from the median time to onset of HTN (1.9 mo) suggested higher OS for the HTN pts (14.0 vs. 11.3 mo) as well as higher PFS (8.0 vs. 4.5 mo) although these comparisons did not reach statistical significance. Proportional hazards models for OS and PFS adjusting for HTN as a time-varying covariate resulted in an OS HR=0.64 (0.43-0.96, p=0.03) and PFS HR=0.83 (0.57-1.20, p=0.32). The same modeling adjusting for high BP (>150/100) as a time-varying covariate resulted in OS HR=0.60 (0.44-0.82, p=0.002) and PFS HR=0.71 (0.54-0.95, p=0.02). Results for high BP remained statistically significant after adjusting for sex, PS, histology, adrenal, liver and bone mets. Conclusions', ' Data from E4599 suggest that onset of HTN during TX with PCB may be associated with improved OS and PFS. Further studies of the downstream effects of VEGF suppression and HTN are needed.']",
        "Doc_id":"ASCO_33539-65",
        "Doc_title":" Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599.",
        "_version_":1606188975018475520},
      {
        "Meeting_name":" A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.",
        "Background":"['Background', '  BBI608 is an oral first-in-class cancer stemness inhibitor which inhibits the Stat3, -catenin and Nanog pathways. Preclinically, potent, broad-spectrum anti-tumor and anti-metastatic activity was observed in vitro and in vivo, alone and in combination with other agents.  BBI608 with paclitaxel showed marked synergy in vivo. In a phase I study, BBI608 monotherapy was well tolerated with encouraging signs of anti-tumor activity and a RP2D of 500 mg BID.  Methods', '  A phase Ib dose-escalation study in patients with advanced cancer was undertaken to determine safety, tolerability, RP2D, and preliminary anti-cancer activity of BBI608 plus weekly paclitaxel.  BBI608 was administered in 3 escalating dose cohorts (200 mg BID, 400 mg BID, 500 mg BID) in combination with paclitaxel  (80 mg/m2 weekly; 3 of every 4 weeks) until progression of disease, unacceptable toxicity, or other discontinuation criteria was met.   Results', '  24 patients were enrolled. The BBI608 monotherapy RP2D could be given in combination with paclitaxel in full dose.  MTD was not determined.  No new adverse events were observed, and the safety profile was similar to that of each agent as monotherapy.  The most common adverse events included grade 1 and 2 diarrhea, abdominal cramps, nausea, vomiting.  Grade 3 events related to protocol therapy occurred in 4 patients and included diarrhea, dehydration, and weakness. No significant pharmacokinetic interactions were observed. Disease control (CR+PR+SD) was observed in 10 of 15 (67%) evaluable patients. Of 5 patients with refractory gastric/GEJ adenocarcinoma enrolled, 2 had PR (48% and 45% regressions), 1 had SD with 25% regression, and 2 (who failed prior taxane) had prolonged SD  24 wks. Tumor regression or SD  16 wks was also seen in patients with platinum-resistant ovarian cancer (1 of 2), melanoma (2 of 3), bladder CA (1 of 3) and NSCLC (1 of 1).     Conclusions', '  This phase Ib study demonstrated that BBI608 and weekly paclitaxel can be safely combined at full dose.  Encouraging anti-tumor activity was observed across several tumor types, particularly in patients with gastric and GEJ adenocarcinoma. Clinical trial information', ' NCT01325441.']",
        "Doc_id":"ASCO_135212-144",
        "Doc_title":" A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.",
        "_version_":1606188980974387200},
      {
        "Meeting_name":" A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer.",
        "Background":"['Background', '  In vitro and in vivo studies have demonstrated the antiproliferative effects of 1, 25 (OH)2D3 (calcitriol) as single agent and antitumor synergy with cisplatin. The goals of this Phase I/II study were to determine the maximum tolerated dose (MTD) of 1, 25 (OH)2 D3 in combination with cisplatin and docetaxel, and to evaluate the efficacy in patients (pts) with metastatic NSCLC.Methods', '  The study was a multicenter, open-label study in pts with metastatic NSCLC. Pts were adults 18 yrs., PS 0-1 with normal liver/kidney function. For the phase I study, pts (36 per cohort) received 1, 25 (OH)2 D3 I.V. every 21 days prior to docetaxel and cisplatin.  The starting dose of 1,25 (OH)2D3 was 15 mcg/m2 at sequential ascending dose levels (DL) (15, 30, 60 and 80 mcg/m2) using a 3+3 design targeting a dose-limiting toxicity (DLT) rate of <33%. Docetaxel was administered at 75 mg/m2 and cisplatin 75mg/m2 following 1, 25 (OH)2 D3 for 4 cycles.  We analyzed SNPs in the CYP24A1 gene.Results', '  37 pts were enrolled (16 in phase I and 21 in phase II) with a median age of 54 (range 3479) yrs.; M', ' F, 12', '17.  At the 80 mcg/m2 dose level, 2/4 pts had DLT of grade 4 neutropenia. There were no cases of hypercalcemia or azotemia.  The MTD and recommended Phase II dose was 60 mcg/m2.  Among 6 response-evaluable Phase I pts, and 21 phase II pts, there were', ' 2 confirmed partial responses (PR), 6 unconfirmed PRs and 10 pts with stable disease.  The median time to progression was 6.9 months (95% CI 4.4, 12.9) and the median overall survival was 8.3 months (95% CI 5.8, 14.9). Of the CYP24A1 SNPs, the IVS4-308C>G  was associated with progressive disease (Chi-Square=0.0062)Conclusions', '   The MTD of 1,25 (OH)2D3 in combination with docetaxel and cisplatin was 60 mcg/m2 IV every 21 days. Pre-specified endpoint of a 50% response rate was not met in the phase II study. However, disease control in 66% of patients argues for further study of 1,25 (OH)2D3 as maintenance therapy.  The CYP24A1 polymorphism IVS4-308C>G may be associated with resistance to a 1,25 (OH)2D3 based therapeutic regimen']",
        "Doc_id":"ASCO_101436-114",
        "Doc_title":" A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer.",
        "_version_":1606188981859385344},
      {
        "Meeting_name":" Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance.",
        "Background":"['Background', '  The UC Davis - Jackson Labs Consortium has established a PDX resource of over 50 NSCLC models (12 EGFR mutant)  for experimental therapeutics and personalized medicine, using the NSG mouse. Here we report on a unique PDX model, LG703, derived from a patient at time of acquired E resistance. This tumor harbors EGFR L858R with no T790M mutation, high MET and very high EGFR protein expression.  The patient is in remission following treatment with AFAT-CET.  In this model, we investigated the respective contribution of CET and AFAT relative to E on tumor growth and signal transduction.  Methods', '    Individual mice implanted with LG703 tumor fragments were randomized to E (50 mg/kg qd po), AFAT (20 mg/kg qd po), CET (10 mg/kg twice weekly iv), AFAT-CET, or vehicle control (n per arm = 12) for 3 weeks followed by a 75-day monitoring period. Changes in signal transduction mediators and RTKs were assessed after 6 and 24h treatment exposures using kinase arrays (R&D systems) and immunoblotting.   Results', '    AFAT, CET and AFAT-CET resulted in complete tumor response (CR) during the 21-day treatment period; whereas E resulted in temporary growth delay. After cessation of treatment, E-treated mice progressed rapidly and AFAT-treated mice progressed within 2 weeks. Mice treated with CET or AFAT-CET remained in complete remission. At 6h, E and AFAT significantly (>70%) reduced EGFR phosphorylation as well as that of AKT1, AKT2, ERK1, p38a, RSK1 and p70S6K. At 24h, E-treated tumors had returned to baseline-like states for all factors, AFAT showed an intermediate response, and CET, alone or with AFAT, achieved the greatest inhibition of pEGFR with sustained inhibition of all downstream effectors.  Conclusions', \"   In the LG703 PDX model, CET and AFAT+CET resulted in CRs, mirroring the patient's response to similar therapy, associated with sustained inhibition of pEGFR and multiple downstream signaling factors. In contrast, E exhibited only temporary growth delay associated with transient inhibition of EGFR pathway factors. These experiments demonstrate the potential of this PDX resource to assess new therapeutic strategies in models representing individual patients. Supported by BJALCF.\"]",
        "Doc_id":"ASCO_117570-132",
        "Doc_title":" Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance.",
        "_version_":1606188986992164864},
      {
        "Meeting_name":" Serum biomarker analysis of WJOG4107",
        "Background":"['Background', '  We conducted a randomized phase II trial for patients with resected stage II-IIIA NSCLC comparing postoperative long-term oral S-1 (80 mg/m2/day for consecutive 2 weeks q3w for 1 year) (S) (N=100) and cisplatin (CDDP) (60 mg/m2 day1) plus oral S-1, (80 mg/m2/day for 2 weeks) q3w for 4 cycles (CS) (N=100), and previously reported that the disease-free survival rate at 2 years (DFS@2yr), a primary endpoint, was 66 % (95%CI, 55-74%) for S and 58% (48-67%) for CS (Yoshioka et al., ESMO 2012). Here, we report the results of pre-planned serum biomarker analysis to identify biomarkers that are significantly associated with patient outcome.  Methods', '  Serum samples were obtained from the 197/200 patients. Concentrations of 16 growth factors and 27 cytokines were measured by Luminex. Concentration of each protein was dichotomized at its median.  Results', '  As is often the case with interaction test, a p-value of less than 0.10 was considered to be statistically significant and was used for this study. HGF, GCSF and leptin showed the moderate association with prognosis by multivariate Cox regression analysis considering treatment arm, age, sex, histology, smoking history, and stage with P for treatment-protein interaction <0.10 (HGF, P=0.0576; GCSF, P=0.0579; leptin, P=0.0741). Furthermore, patients with lower serum HGF level showed significantly favorable prognosis than those with higher serum HGF level in postoperative long-term S-1 therapy (P=0.0072 by the log-rank test). DFS@2yr for HGF low/S and HGF high/S were significantly different, 77% (95%confidence interval', ' 66-91%) and 56% (44-72%), respectively, while those of HGF low/CS and HGF high/CS were almost identical, 61% (48-77%) and 61 (48-78%), respectively.  Conclusions', '  Low serum HGF level may define patient subset that would benefit from postoperative long-term S-1 therapy. It is possible to hypothesize that low HGF may enhance S-1- induced apoptosis through inhibition of angiogenesis, because HGF is a potent angiogenetic factor and S-1 acts on tumor angiogenesis (Cancer Lett., 2008, 267, 26). Indeed, NK4 (HGF/MET antagonist) reportedly enhances 5FU-induced apoptosis.']",
        "Doc_id":"ASCO_129672-144",
        "Doc_title":" Serum biomarker analysis of WJOG4107",
        "_version_":1606188987769159680},
      {
        "Meeting_name":" A phase I study of PT-112 in advanced solid tumors.",
        "Background":"['Background', ' PT-112 is a novel platinum-pyrophosphate agent designed to avoid the toxicity and drug resistance mechanisms of conventional chemotherapy. Pre-clinical models show effects on multiple cell signaling components', ' p16 mediated G1/S cell cycle arrest; modulation of MDM2/p53 expression; extrinsic apoptosis initiation; and immunogenic cell death (ICD) induction. This Phase I first-in-human, multicenter, open label study assesses PT-112s safety and pharmacokinetic (PK) profile in advanced solid tumor patients (pts), to determine the RP2D and signals of activity. Methods', ' Pts with advanced solid tumors and acceptable marrow / organ function received PT-112 IV over 1-hr on days 1, 8, and 15 every 4 wks in a 3+3 dose escalation design. Intra-subject escalation was allowed. PK samples from cycles 1-2 were analyzed by ICP-MS and LC-MS/MS. Results', ' 44 pts have been treated across dose levels (DL) from 12-300mg/m2. Cumulative dosing ranged from 1 to 60 infusions, and cumulative exposure from 96 to 5,244 mg/m2. PK parameters were dose proportional. Target Cmax and AUC levels were achieved, with constant VD. DLTs were observed at 150mg/m2 (G3 pancytopenia); 250mg/m2 (G2 renal injury in a cervical ca pt with hydro-nephrosis); and 300mg/m2 (G3 rash). The most common treatment-related AEs were G1-2 fatigue (26% pts), nausea (23%), vomiting (14%), constipation (12%), and diarrhea (12%). Numerous signals of activity were observed at DLs  125mg/m2. These include a confirmed PR in a NSCLC pt with 6 prior lines of therapy and no response to TKI inhibition or PD-1 blockade; PFS > 6 months (7-18 months) in 3 pts; metabolic response via PET scan in bone and liver mets (basal cell and pancreatic ca.); biomarker responses in ovarian and prostate ca.; and nodal/metastatic volumetric reduction in 3 pts. Conclusions', ' PT-112 is a well-tolerated novel agent with a pleiotropic mode of action and feasibility for long-term and combination treatment. Numerous signals of anti-cancer efficacy in heavily pre-treated pts suggest lack of cross-resistance with conventional agents. MTD has not yet been reached. PT-112s profile makes it an attractive candidate for further development, including in combination with immunotherapy. Clinical trial information', ' NCT02266745']",
        "Doc_id":"ASCO_192840-199",
        "Doc_title":" A phase I study of PT-112 in advanced solid tumors.",
        "_version_":1606188997340561408},
      {
        "Meeting_name":" Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.",
        "Background":"['Background', ' Abemaciclib is an oral selective CDK4 and CDK6 inhibitor administered on a continuous dosing schedule, which has demonstrated clinical activity and an acceptable safety profile in patients (pts) with heavily pre-treated HR+ metastatic breast cancer (MBC). Abemaciclib has been shown preclinically to cross the blood-brain barrier, providing rationale for testing this agent in pts with BM. Furthermore, as previously presented, levels of abemaciclib similar to plasma were detected in resected BM in a subset of pts with HR+, HER2- MBC in this study. Methods', ' Study I3Y-MC-JPBO is an open-label, Phase 2, Simon 2-Stage trial evaluating the safety and efficacy of abemaciclib 200 mg BID in pts with new or progressive BM secondary to HR+ MBC, NSCLC, or melanoma. Eligible pts in Part B (the focus of this presentation) include pts with HR+, HER2- MBC who have 1 measurable brain lesion. The primary objective was objective intracranial (IC) response rate as defined by Response Assessment in Neuro-Oncology BM response criteria. Secondary objectives (IC related) include best overall response, duration of response, disease control rate, and clinical benefit rate. Exploratory objectives include assessment of drug concentrations in resected tumors. Safety, tolerability, and PK of abemaciclib were also assessed. Stage 1 includes 23 pts; if < 2 of the 23 pts respond to abemaciclib, futility is met. However, if 2 respond, 33 additional pts are to be enrolled to Stage 2. Results', ' This Stage 1 efficacy analysis included 23 pts; 32 pts were included in the safety analysis. Although 5 pts were considered nonevaluable, 2 pts (8.7%) had confirmed partial response (PR) (meeting the predefined threshold for advancement to Stage 2); enrollment is ongoing. At the time of the analysis, the 2 pts with PR had completed 14 and 15 cycles each (21d cycles) of therapy. The majority of adverse events were gastrointestinal in nature, consistent with previous studies of abemaciclib. Conclusions', ' This study has provided preliminary evidence that abemaciclib penetrated BM in pts with HR+, HER2- MBC and had antitumor activity in this population. Final results will be presented following Stage 2 analyses. Clinical trial information', ' NCT02308020']",
        "Doc_id":"ASCO_182896-199",
        "Doc_title":" Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.",
        "_version_":1606188997655134209},
      {
        "Meeting_name":" Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).",
        "Background":"['Background', ' Establishing an early diagnosis of LMST may be difficult, as MRI findings can be equivocal and CSF cytology has low sensitivity (50% on a first spinal tap, increasing to 90% with repeat samples). IMPT based on the anti-EpCAM antibody (Veridex LLC, Warren, NJ) is a widely available tool for capturing and quantifying circulating tumor cells (CTC) in the blood of pts with solid tumors. We hypothesize that IMPT can be used in the diagnosis of LMST through identification of CSF CTC. Methods', ' Pts undergoing a spinal tap for suspicion of LMST were eligible. All pts had an initial MRI evaluation. CSF was analyzed by conventional cytology, and additional 7.5 mL were used to capture and quantify CSF CTC using anti-EpCAM antibody covered ferroparticles, through a modification of previously described methods (CellTracks Autoprep, Immunicon). Positive CTC was defined as  1 cell/7.5 mL (0.13/mL). A definitive diagnosis of LMST was defined as any positive CSF cytology or unequivocal MRI findings (leptomeningeal enhancement with subarachnoid nodules, enhancement/clumping of nerve roots or enhancement in basal cisterns) observed within 1 month of the spinal tap. Results', ' Forty-eight pts were included', ' NSCLC (n = 19), breast (15), gliomas (4), carcinoid tumor (3), ovarian (2), other (5). Fifteen pts met criteria for LMST within one month of the tap. CSF cytology was positive in 10 pts, MRI was positive in 11, and CSF CTCs were found in 16 (median', ' 13.3 cells/mL, range 0.13 to 42.8). Thus, initial cytology achieved a sensitivity of 67% (95% CI 42, 85), initial MRI 73% (95% CI 48, 89), and CTC 100% (95% CI 80, 100). One pt with 0.27/mL CTCs had breast cancer brain metastases and hydrocephalus, but no evidence of LMD after a 2-m follow-up. This pt has been treated with bevacizumab, known to mask MRI leptomeningeal enhancement. Conclusions', ' IMPT allows for an earlier diagnosis of LMST, outperforming CSF cytology and MRI, and identifying 100% of pts developing overt LMST within one month of the tap. Additional follow- up is needed for evaluation of the one false-positive pt. Caution should be exerted in pts with primary tumors with low expression of EpCAM, and confirmatory studies in a population enriched for such histologies is needed.']",
        "Doc_id":"ASCO_51206-74",
        "Doc_title":" Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).",
        "_version_":1606189004543229952},
      {
        "Meeting_name":" Liquid biopsy in the clinic",
        "Background":"['Background', ' Liquid biopsy for plasma ctDNA NGS is a rapidly evolving science. Plasma ctDNA assays are commercially available and are increasingly adopted in the community with a paucity of evidence-based guidance. We set out to study the optimal timing and utility of plasma ctDNA NGS in clinic. Methods', ' Pts with advanced NSCLC who were driver unknown, defined as not having prior tissue NGS or clinical concern for tumor heterogeneity that may affect treatment decisions, were eligible. Peripheral blood was collected in a Streck tube (10mL), DNA extracted, and subjected to a bias-corrected hybrid-capture 21 gene targeted NGS assay in a CLIA lab with unique reads at 3000x and sensitive detection at variant allele frequency above 0.1% (ResolutionBio Bellevue, WA). Pts also had concurrent tissue NGS via MSK IMPACT. Clinical endpoints included detection of oncogenic drivers in plasma, ability to match pts to targeted therapy, concordance and turnaround time of plasma and tissue NGS. Results', ' Forty-one pts were prospectively accrued. Plasma ctDNA detected an oncogenic driver in 39% (16/41) of pts, of whom 17% (7/41) were matched to targeted therapy; including pts matched to clinical trials for HER2 exon 20 insertionYVMA, BRAF L597Q and MET exon14. Mean turnaround time for plasma was 7 days (4-12) and 28 days (20-43) for tissue. Plasma ctDNA was detected in 56% (23/41) of pts; detection was 40% (8/20) if blood was drawn on active therapy and 71% (15/21) if drawn off therapy, either at diagnosis or progression (Odds ratio 0.28, 95% CI 0.06 - 1.16; p = 0.06). All pts had concurrent tissue NGS; of the 10 samples resulted, there was 100% driver concordance between tissue and plasma in pts drawn off therapy. Conclusions', ' In pts who were driver unknown or who had clinical concern for tumor heterogeneity, plasma ctDNA NGS identified a variety of oncogenic drivers with a short turnaround time and matched them to targeted therapy. Plasma ctDNA detection was more frequent at diagnosis of metastatic disease or at progression. A positive finding of an oncogenic driver in plasma is highly specific, but a negative finding may still require tissue biopsy.']",
        "Doc_id":"ASCO_189219-199",
        "Doc_title":" Liquid biopsy in the clinic",
        "_version_":1606189007885041664},
      {
        "Meeting_name":" Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  We previously reported the adverse events and objective responses in a multicenter phase II study of high-dose chemoradiotherapy. This is a final analysis of the pattern of recurrences, progression free survival (PFS) and OS.  Methods', '  Patients with stage III NSCLC were eligible if they met the following key criteria', ' age between 20 and 74 years, PS 0-1 and V20 30%. Participants received 3-4 cycles of CDDP (80 mg/m2 day 1) and VNR (20 mg/m2days 1 and 8) every 4 weeks. The 3D-RT was administered at a total dose of 72 Gy divided into 36 fractions from day 1 chemotherapy. The primary endpoint was the 2-year survival rate and the planned sample size was 60 to reject the rate of 45% under the expectation of 65% with a power of 90% and an alpha error of 5%.  Results', '  Thirty-one patients were enrolled between 2009 and 2011. The median follow-up time (range) was 51.4 (28.8-65.6) months at the point of data cut-off. This trial was terminated early due to the slow accrual and appearance of grade 5 pulmonary toxicities in 2 patients. There were 25 men and 6 women with a median (range) age of 59 (32-72) years. Of the 25, 23 had adenocarcinoma and 21 had stage IIIA disease. The median (range) V20value was 20 (9-30). Among the 20 patients showing disease progression, in-field failures were observed in 5 (25%) patients as the first relapse and a further 4 patients (9 [45%] patients in total) during the follow-up period. The 2-, 3-, and 5-year PFS rates (95% CI) were 44.9% (27.1-61.2), 34.6% (18.5-51.2), and 34.6% (18.5-51.2), respectively. The 2-, 3-, and 5-year OS rates (95% CI) were 64.5% (45.2-78.5), 51.2% (32.6-67.1), and 43.8% (25.8-60.5), respectively. The median PFS and median survival time were 17.1 months and 41.2 months, respectively.  Conclusions', '  The higher TRT dose associated both with an unacceptable incidence of pulmonary toxicities and with relatively better long-term survival. Development of a better strategy is warranted to obtain both a better outcome and tolerable pulmonary toxicities. Clinical trial information', ' UMIN000001743.']",
        "Doc_id":"ASCO_143598-156",
        "Doc_title":" Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).",
        "_version_":1606189016059740160},
      {
        "Meeting_name":" KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy.",
        "Background":"['Background', '  KRAS mutations are the most common driver mutation indentified in NSCLC, occurring in 20 - 30% of adenocarcinomas. While several studies suggest KRAS predicts for lack of response to TKI therapy, few data exist regarding its association with outcomes for patients treated with cytotoxic chemotherapy. This study explores the association between KRAS mutations and outcomes (RR, PFS) in a cohort of patients treated with frontline platinum/pemetrexed (PPm) based therapy.  Methods', '  In this retrospective chart review, we evaluated RR and PFS for 16 KRAS + EGFR  pts  treated with carboplatin (AUC 5-6) or Cisplatin 75mg/m2 and (Pm)pemetrexed (500 mg/m2) +/- (B)bevacizumab 15mg/kg.  For comparators, we identified 19 KRAS - EGFR - patients treated with the same regimen. Maintenance therapy with Pm or Pm+B was given at the discretion of the treating physician.  KRAS and EGFR mutational status were assessed by RT-PCR on tumor tissue collected at first diagnosis.  RR was assessed using RECIST criteria.  Kaplan-Meier estimates for PFS were evaluating using log rank test. Fisher exact test was used to assess the association between KRAS mutation status and response rate.  Results', '  The groups were similar in age (KRAS + mean 61 vs. 60; p=0.87), gender (62% vs. 57% F; p= 0.9), ECOG 2 (0 vs. 10%,p=0.47), smoking hx (93% vs. 94% current/former smokers, p=0.7), brain mets (0% vs. 18% p=0.22), mean number induction cycles (4 in each, p=0.6), cisplatin and bevacizumab use (12% vs 10%, p > 0.1;10% vs. 40%, p=0.10). Pm maintenance was used in 31% KRAS+ (5/16) and 26% KRAS-(5/19) (p=0.79).  P+B maintenance was used in 12% (2/16) and 5% (1/19) (p=0.70). RR was 56% in the KRAS + (9/16) vs. 36% KRAS- (7/19) respectively  (p=0.3). There was a statistically significant improvement in PFS in the KRAS + group (10.3 mos vs. 5.7 mos, p =0.03).    Conclusions', '  In this small retrospective review, KRAS mutations appeared to be associated with a non-significant improvement in RR and significant improvement in PFS for patients treated with frontline PPm based therapy.  Future prospective studies should investigate and validate the predictive value of KRAS for this cytotoxic regimen.']",
        "Doc_id":"ASCO_93677-114",
        "Doc_title":" KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy.",
        "_version_":1606189025543061504},
      {
        "Meeting_name":" An orthotopic lung tumor model for image-guided microirradiation in rats",
        "Background":"['Introduction', 'Studies have confirmed that a new lung cancer treatment called stereotactic body radiation therapy (SBRT) can cure certain patients with early stage tumors situated peripherally in their lungs, using a non-invasive, outpatient procedure. While nearly curative for peripheral lung tumors, SBRT also may present life-threatening toxicity for patients with centrally located lung tumors. Moreover, large, hypoxic tumors are at a further risk of radiotherapy failure with SBRT. The efficacy of SBRT application can be improved through the addition of agents designed to sensitize the tumor and/or protect normal tissue. To investigate and validate the response to SBRT, alone or in combination with radiomodulating compounds, it is necessary to develop a tumor model for image-guided high-dose irradiation of rodent tumors and normal tissues in a manner that closely mimics delivery of SBRT in humans. Therefore, the purpose of this study was to develop a rat orthotopic lung tumor model with a solitary intrapulmonary nodule to study the effects of high-dose radiation.Methods', 'Adult female athymic nude rats were anesthetized, intubated and then placed on a ventilator (Inspira, Harvard Apparatus, Holliston, MA) prior to surgery. A small incision (1.0 cm) was made between ribs 5 and 6 on the right side. The right lung was captured using a forceps, clamped with a carotid clamp and H460-luc/A549-luc NSCLC cells (one million cells and matrigel in 20 l) were then injected into the right lung. The tumor growth was monitored by in vivo bioluminescent imaging (BLI) weekly. Other imaging modalities, including microCT, CBCT, and MRI, were also performed. At the end of study, the rats were sacrificed and lungs were harvested to confirm tumor location and size.Results', 'We achieved 100% survival from this surgical orthotopic implantation procedure. We also achieved >90% success in generating solitary lung tumors in the rats, whereas percutaneous orthotopic injection of tumor cells/chunks in our previous model met only 50 to 60% success in producing solitary tumors.Conclusion', 'This study presents a successful solitary lung tumor model in rodents which provides investigators a useful model to apply conformal radiation treatment, using a sophisticated treatment planning system and significantly preventing normal tissue damage.']",
        "Doc_id":"AACR_2015-5115",
        "Doc_title":" An orthotopic lung tumor model for image-guided microirradiation in rats",
        "_version_":1606189037534576640},
      {
        "Meeting_name":" hnRNP A2/B1 regulates S1PR3 expression in lung cancer",
        "Background":"['Several clinical trials have shown that elevated expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) in exfoliated bronchial epithelial cells correlates with eventual development of lung cancer. Cells with high levels of hnRNP A2/B1 expression have also been reported to manifest multiple molecular features of genetic injury. The hnRNPs are a complex group of RNA-binding proteins which play a key role in mRNA processing', ' stability, splicing, export and subcellular localization and participate also in telomere biogenesis. To elucidate the mechanism that links hnRNP A2/B1 overexpression with lung cancer progression we have knocked down hnRNPA2/B1 mRNA in non-small cell lung cancer (NSCLC) cell line A549 with a stable siRNA vector-based system. Silencing hnRNP A2/B1 increased proliferation and decreased migration in A549 and H1703 cell lines. These changes in migration and proliferation in A549 and H1703 hnRNPA2/B1-silenced cell lines correlated with an increase of E-Cadherin expression in both cell lines at mRNA and protein level. This increase in E-Cadherin expression was accompanied with a down-regulation of E-Cadherin inhibitors Twist1 and Snai1. We have proposed that hnRNP A2/B1 modulates epithelial-mesenchymal transition (EMT) in lung cancer cell lines that present a mesenchymal or intermediate phenotype such as H1703 and A549. It has been proposed that EMT may induce metastasis of cells with a mesenchymal phenotype. After metastatic seeding, EMT would be reversed trough mesenchymal-epithelial transition (MET) allowing tumor growth. However, mechanisms that regulate reversion of EMT are still poorly characterized. Interestingly, sphingosine 1-phospate (S1P) is an important angiogenic factor and regulator of vascular permeability. Microarray expression analysis revealed that silencing hnRNP A2/B1 decreases expression of the sphingosine 1-phosphate receptor 3 (S1PR3), a pro-migration RhoGTPAse activating S1P receptor, in A549 cells. Therefore, Moreover, S1P also stimulates motility of cancer cells through S1P receptors. It has been described that S1PR3 regulates migration and invasion in breast, prostate and gastric cancer. In A549 cells, S1PR3 is the most abundant receptor for S1P. Here we report that down regulation of hnRNP A2/B1, in lung cancer cells, decreases S1PR3 expression at the mRNA and protein level. We propose that further study of the mechanistic link between hnRNP A2/B1, S1P function and S1P receptors may allow a better understanding of the molecular mechanisms involved in invasion, metastasis. It may also provide new insights regarding the interaction between endothelial and epithelial cells and the regulation of EMT during tumor progression.']",
        "Doc_id":"AACR_2012-352",
        "Doc_title":" hnRNP A2/B1 regulates S1PR3 expression in lung cancer",
        "_version_":1606188975590998016},
      {
        "Meeting_name":" Clinical Survey of 19 actionable proteins in multiple indications using multiplex mass spectrometry",
        "Background":"['Many available oncology therapies are targeted to specific proteins, the most notable examples being therapies targeted to EGFR and Her2. For targeted therapies to have maximal efficacy, it is necessary to identify patients whose tumors express the target protein. As more pathways and proteins are identified as tumor drivers and therapies are developed that target those proteins, and more patient screening tools are needed to efficiently direct patients to correct therapeutic regimens.While chemotherapy regimens are not often considered targeted therapies, protein biomarkers for chemotherapy efficacy have been identified; for example amplification of TOPO2A is known to improve response to anthracycline-based therapy combinations. Though many chemotherapy biomarkers have been identified, screening is not routine, and chemotherapy regimens are not being adjusted for individual tumor biology.To address the growing need for efficient patient screening using minimal tissue, OncoPlex Diagnostics has built a comprehensive protein quantification panel that allows for the simultaneous quantitation of multiple actionable proteins from formalin-fixed, paraffin-embedded patient biopsies using multiplex mass spectrometry. This panel currently quantifies nine proteins that are markers of targeted therapy (including ALK, AR, EGFR, HER2, HER3, MET, MSLN, and PD-L1) and includes the ChemoPlex panel, which quantifies chemotherapy biomarkers (ERCC1, FRalpha, hENT1, RRM1, SPARC, TOPO1, TOPO2A). Since 2013, over 270 biopsies from multiple indications have been analyzed for protein expression in the OncoPlex Diagnostics CAP-qualified, CLIA-certified laboratory, revealing large ranges of expression for many drug targets that are not routinely assayed.Because of the importance of TOPO2A in anthracycline-based therapies, which are commonly prescribed in breast cancer patients, sixty-two breast cancer biopsies were retrospectively reviewed. Of the 62 samples, 41 were positive for TOPO2A expression; ranging from 233-1750amol/ug. Of the primary biopsies, 80% of them expressed TOPO2A; however only two of seven liver metastases were positive for TOPO2A. These data suggest that anthracycline-based therapy might not be as efficacious in metastatic sites due to the lack of TOPO2A.Also of interest, quantification of FRalpha, a biomarker for folate-targeted therapies, showed a 50-fold range of expression in NSCLC cases, and TOPO1, the target of irinotecan and topotecan, showed a 10-fold range of expression in various indications, with 4% of biopsies having no detectable TOPO1.These wide expression ranges of known biomarkers suggest that certain therapies might have vastly different response rates based on biomarker expression. To derive the best therapeutic response to both targeted and chemotherapy regimens, it is necessary to understand each patient tumor biology individually.']",
        "Doc_id":"AACR_2015-3395",
        "Doc_title":" Clinical Survey of 19 actionable proteins in multiple indications using multiplex mass spectrometry",
        "_version_":1606188975941222400},
      {
        "Meeting_name":" Circulating tumor cell (CTC) detection and 5T4 characterization in breast, ovarian, and lung cancer patients on active therapy",
        "Background":"['Introduction', 'Monitoring CTCs from a blood draw could enable a minimally invasive, longitudinal observation of an evolving disease. Antibody drug conjugates (ADC) are a promising approach to deliver highly potent chemotherapeutics to cells expressing target proteins. An ADC that targets 5T4, an oncofetal antigen expressed on tumor initiating cells, is currently in clinical development. Patients with tumors or CTCs expressing 5T4 may benefit from this therapeutic. We sought to develop a 5T4 CTC test and to evaluate the incidence of 5T4 expressing CTCs in breast, ovarian, and lung cancer patients.Experimental Procedures', 'Blood samples from breast (n = 10), ovarian (n = 10) and NSCLC (n = 25) patients on active therapy were collected and shipped to Epic Sciences. Upon receipt, nucleated blood cells were plated onto glass microscope slides and stored at -80C. Two slides per patient were thawed and stained for cytokeratins (CK), CD45, 5T4, and DAPI. CTCs were detected using a combination of CD45 exclusion, CK and 5T4 expression, and morphology parameters. CTC enumeration and 5T4 expression were analyzed alongside pathology, staging and treatment information.Results', 'Assay Development', ' A novel CTC assay utilizing an antibody against 5T4 was developed. Dilutions of high, medium and low/negative 5T4 expressing cell lines were spiked into normal whole blood to assess the linearity (R2 = 0.99) of CTC detection. These cell lines as well as 5T4 high and 5T4 low patient samples were used to assess intra- and inter-assay reproducibility of% 5T4(+) CTCs. All patient and calibration control samples met acceptance criteria of  30% CV and  20% CV, respectively.Breast Cancer', ' 7 of 10 patients had traditional CTCs (median', ' 6/mL range', ' 0-23/mL). 9 of 10 patients had additional subpopulations of CK(-) CTCs, apoptotic CTCs, and CTC clusters. Among non-apoptotic CTCs, 5T4 positivity was detected in 6 of 10 patient samples, with the highest% positivity seen in patients with corresponding ER(+) primary tumors.Ovarian Cancer', ' 3 of 10 patients had traditional CTCs (median', ' 0/mL, range', ' 0-41/mL). Additional subpopulations were identified in the same 3 of 10 patients.NSCLC', ' 14 of 25 patients had traditional CTCs (median', ' 1/mL, range', ' 0-45/mL). 20 of 25 patients had additional subpopulations.Conclusions', 'We have developed a robust, sensitive and specific assay to quantify 5T4 expression on CTCs and tested this assay on small cohorts of breast, ovarian and lung cancer patients on active therapy. CTCs expressing 5T4 were detected in a subset of patients from each indication.']",
        "Doc_id":"AACR_2015-565",
        "Doc_title":" Circulating tumor cell (CTC) detection and 5T4 characterization in breast, ovarian, and lung cancer patients on active therapy",
        "_version_":1606189003393990656},
      {
        "Meeting_name":" N0821",
        "Background":"['Background', '    In a retrospective exploratory analysis of E4599, patients (pts) > 70 yo had a higher frequency of and more severe toxicities without apparent survival benefit from the addition of B to C+paclitaxel. We hypothesized that in this pt population, B will have better safety and efficacy profile when used in combination with C+P.  Methods', '  Pts >/= 70 yo with previously untreated stage IIIB/IV (TNM 6th ed) nonsquamous NSCLC, ECOG PS 0-1, measurable disease and adequate organ function were eligible. C at AUC 6, P at 500 mg/m2 and B at 15 mg/kg were administered on day 1 of each 21-day cycle for up to 6 cycles followed by maintenance P+B in patients with CR, PR or SD. The primary endpoint was 6-month progression-free survival (PFS) rate.  The treatment would be considered promising based on a single arm one-stage binomial design if 34 or more successes out of 55 patients were observed.  This design had an exact significance level of 0.05 at 93% power to detect a true success rate of at least 70%.  Polymorphisms in VEGFA, FPGS, GGH, SLC19A1 and TYMS in germline DNA were correlated with treatment outcome.  Results', '  58 eligible pts were enrolled; 29 males/29 females. Median age was 75. Median treatment cycles received was 6. Grade 3 or higher adverse events (AE) were reported in 49 (85%) pts.   There were no treatment-related deaths. The most common grade 3/4 AEs(regardless of attribution) were hypertension (10%), fatigue (28%), dehydration (9%),  neutropenia (43%) and thrombocytopenia (21%). There were 3 (5%) grade 3/4 hemorrhagic events. 8 (14%) had grade 4 neutropenia and 3 (5%) had grade 4 thrombocytopenia. Grade 3/4 ischemic/thromboembolic events occurred in 6 pts (10%). Thirty-four out of the first 54 (63%, 95% CI', ' 48.7-75.7%) evaluable pts met the primary endpoint (4 pts were lost to follow-up prior to 6 months). The confirmed ORR was 37.9% (95% CI', ' 25.5-51.6%). Median time to treatment failure was 4.8 months (95% CI', ' 3.9-6.4). Median PFS was 7.1 months (95% CI', ' 5.9-11.7), median OS was 13.7 months (95% CI', ' 9.4-15.7). Results of SNP analysis will be presented.  Conclusions', '    C+P+B followed by maintenance P+B is an active and tolerable first-line regimen for elderly patients with good PS.']",
        "Doc_id":"ASCO_96883-114",
        "Doc_title":" N0821",
        "_version_":1606189006500921344},
      {
        "Meeting_name":" Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E).",
        "Background":"['Background', ' Assessing the efficacy of molecularly targeted agents, especially in the absence of tumor shrinkage, remains a challenge. The primary objective of this prospective international trial was to evaluate whether on-treatment 18F-deoxyglucose (FDG) and 18F-deoxythymidine (FLT) PET responses predict improved progression-free (PFS) and overall survival (OS) following treatment of 2nd/3rd line NSCLC with E, an epidermal growth factor receptor (EGFR) inhibitor. Methods', ' Study assessments included FDG- and FLT-PET/CT imaging at baseline (BL), d14 and d56, and diagnostic CT at BL and d56. Detailed uniform protocols were applied for image acquisition and analysis. PET and CT response were determined by central review. Up to 5 target lesions that met RECIST 1.0 and were FDG avid (SUVmax > 2.5) were identified in each pt at BL. Based on EORTC PET response guidelines, partial metabolic response (PMR) was defined as mean decrease >15% in SUVmax across all target lesions. PFS was investigator determined. Results', ' From October 2006-April 2009, 51 patients (pts) at 8 sites in Australia and United States were treated on study with E at 150 mg PO QD and completed all assessments through d56. Of these 51 pts, 4 showed partial responses (PR) by d56 CT; all 4 had PMR by d14 FDG-PET while 3 had PMR by d14 FLT-PET; 3 of these 4 CT PR pts had evaluable archival tumor tissue, showing all 3 had EGFR mutations. Among the 47 CT nonresponders, 9 had PMR by d14 FDG-PET; 6 of these 9 pts had evaluable archival tumor tissue showing all 6 were EGFR wildtype with 1 Kras mutation. Both early (d14) and late (d56) PMR by either FDG or FLT were positively associated with PFS. D14 FDG-PET PMR was the only measurement significantly associated with OS. Conclusions', ' Early (d14) FDG-PET PMR appears to predict improved PFS and OS, even in the absence of later RECIST response. Relationship between PR/PMR and PFS or OS (n=51)CT d56FDG d14FDG d56FLT d14FLT d56 PFSPR/PMR n (%)4 (7.8)13 (25.5)8 (15.7)9 (18.0)8 (16.0) Median (R vs. NR), wks32 vs. 1224 vs. 1128 vs. 1220 vs. 1226 vs. 12 HR for R/NR0.290.280.320.410.38 pn/a<0.0010.010.020.02 OSMedian (R vs. NR), mos18 vs. 812 vs. 812 vs. 89 vs. 910 vs. 9 HR for R/NR0.240.410.411.011.0 p0.130.040.130.980.99Abbreviations', ' R, responder; NR, nonresponder.']",
        "Doc_id":"ASCO_41166-74",
        "Doc_title":" Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E).",
        "_version_":1606189035328372737},
      {
        "Meeting_name":" Neoadjuvant chemotherapy is associated with increased expression of DNA repair proteins and epithelial to mesenchymal transition (EMT) in patients with non-small cell lung cancer (NSCLC)",
        "Background":"['Background', ' Proteomic profiling has elucidated several dysregulated pathways in NSCLC. We sought to identify patterns of protein expression that are enriched following neoadjuvant chemotherapy in patients with resected lung cancers.Methods', ' Tissue samples were selected from the PROSPECT trial at MD Anderson Cancer Center, the goal of which was to correlate molecular profiles with treatment response. Samples from 189 patients were analyzed, which included 26% squamous tumors; 27% with neoadjuvant chemotherapy (n = 49); and predominantly localized disease (distribution', ' I = 91, II = 35, III = 58, IV = 5). Reverse phase protein array (RPPA) analysis was utilized to quantify 127 total or phosphorylated proteins. Interactions between protein expression and the receipt of neoadjuvant chemotherapy were assessed by analysis of variance (ANOVA). Cox regression was performed to determine the relationship between protein expression and recurrence-free survival (RFS).Results', ' Twenty one of the 127 proteins (16%) were expressed at significantly different levels in patients receiving neoadjuvant chemotherapy. Specifically, patients receiving neoadjuvant chemotherapy had higher expression of multiple DNA repair proteins, including MSH2 (p<0.001), 53BP1 (p = 0.01), and p-CHK1 (p = 0.02), as was Rb (p = 0.01), which regulates the expression of several proteins involved in DNA repair. Thymidylate synthase (TS), a target of the chemotherapeutic agent pemetrexed, also showed increased expression (p = 0.02). In addition, there was lower expression of phosphorylated proteins in the PI3K pathway, including p-70S6K (p = 0.008), p-mTOR (p = 0.02), and p-PDK (p = 0.02). Finally, we observed an expression of proteins indicative of an epithelial to mesenchymal transition (EMT), with lower expression of E-cadherin (p = 0.007) and Met (p = 0.03). Notably, there was also lower expression of COL6A, an excreted extracellular protein involved in cellular adhesion (p<0.001), and a trend towards significance in increased expression of stathmin (p = 0.06), a microtubule destabilizer that has previously been implicated in EMT. Finally, we found that higher expression of multiple proteins involved in DNA repair were associated with a reduction in RFS after induction chemotherapy, including p-Rb (p = 0.015), CHK1 (p = 0.027), and p-CHK1 (p = 0.049).Conclusions', ' The receipt of neoadjuvant chemotherapy was associated with higher expression of DNA repair proteins, suppression of the PI3K pathway, and an EMT shift. Increased expression of DNA repair proteins was also associated with reduced RFS. These findings suggest that higher expression of DNA repair proteins may contribute to treatment resistance, and support the combination of standard chemotherapy with targeted agents such as Chk inhibitors or immunotherapy (to address EMT-mediated immune escape).']",
        "Doc_id":"AACR_2015-3623",
        "Doc_title":" Neoadjuvant chemotherapy is associated with increased expression of DNA repair proteins and epithelial to mesenchymal transition (EMT) in patients with non-small cell lung cancer (NSCLC)",
        "_version_":1606189002510041089},
      {
        "Meeting_name":" Hsp90-inhibitor drug conjugates (HDC)",
        "Background":"['Background', ' Various strategies have been used to make chemotherapeutic compounds more tumor selective in order to increase their safety and efficacy, but they were met with only limited success. Antibody Drug Conjugates (ADCs) and folate receptor mediated drug delivery (FRDC) are the emerging concepts in the drug delivery field, but they are limited to high potent toxins and narrow sets of indications. We established a novel tumor-directed drug delivery platform technology based on the unique property of Hsp90 inhibitors. One prominent feature of Hsp90 inhibitors is their ability to be retained selectively in tumor cells for a prolonged period of time. The difference in residency time in tumor against plasma and normal tissues is 10-25 fold. Moreover, the chaperone protein Hsp90 is overexpressed 2-3 fold in tumor compared to normal tissues. Combining the overexpression Hsp90 and longer residency of its inhibitors in tumor, a strategy to link anticancer drugs to an Hsp90 inhibitor, where the attached payload is released in the tumor selectively for prolonged periods, was conceived. Results', ' Though the HDC concept is applicable to most small molecule anticancer drugs, we chose a common topoisomerase-1 inhibitor (SN-38) for proof-of-concept studies. More than 100 Hsp90 inhibitor/SN38 conjugates were synthesized; we chose STA-12-8666 as our lead molecule based on its in vitro and in vivo pharmacokinetic properties. The conjugate binds strongly to Hsp90 as determined by client protein degradation assays and has good stability in plasma of several species (human>rat>mouse). In xenograft tumor tissue distribution studies, we demonstrate that mice dosed once weekly with 50 mg/kg STA-12-8666 clear the parental HDC and its cleavage products, SN-38 and the Hsp90 inhibitor, from plasma and normal tissue within 24 hr. However, we detected 0.6 M and 0.3 M SN-38 in tumor at 24h and 48h, respectively. SN-38 was not detected in tumor at 24h or 48h with an equivalent dose of the SN-38 prodrug, irinotecan. Xenograft studies using multiple cell lines demonstrated superior efficacy for STA-12-8666 compared to irinotecan. For example, in MCF-7 breast cancer xenografts, STA-12-8666 produced 70% regression in tumor volume compared to moderate tumor growth inhibition by irinotecan with no regression. Similar results were observed in in colon, SCLC, ovarian, bladder, NSCLC, melanoma models. Preliminary toxicological evaluation of STA-12-8666 resulted in better or comparable toxicities to that of irinotecan. Conclusion', ' We designed a novel tumor-directed drug delivery platform by conjugating previously validated small molecule chemotherapeutics to HSP90 inhibitors. Our lead candidate STA-12-8666, has great tissue distribution profile, superior in vivo antitumor activity and better safety profile than the active control irinotecan, warranting its clinical evaluation.']",
        "Doc_id":"AACR_2014-2509",
        "Doc_title":" Hsp90-inhibitor drug conjugates (HDC)",
        "_version_":1606189039209152512},
      {
        "Meeting_name":" Targeted sequencing for the assessment of intratumor heterogeneity",
        "Background":"['Adenocarcinoma, the most common subtype of lung cancer, is notorious for eluding early detection. Thus, understanding the early steps of lung tumorigenesis at the genetic level might facilitate the development of more effective strategies for the prevention, early diagnosis, and treatment of lung cancer. Nearly 10% of lungs resected for adenocarcinomas harbored minute discrete foci of cytologically atypical bronchiolalveolar cells that are designated as atypical adenomatous hyperplasia (AAH). It has been postulated that these lesions represent an early stage in glandular neoplasia, which is now viewed as a progression from AAH to adenocarcinoma in situ (AIS) to minimally invasive adenocarcinoma (MIA), although, the biological nature of AAH is poorly understood and very controversial. To delineate tumor clonal heterogeneity as a function of tumor progression in early NSCLC neoplasias, we isolated DNA from different zones of histologic progression within the same lesion and performed targeted next generation sequencing which targets a panel of 134 well-characterized cancer and pharmacogenomics genes. We found that mutational landscape varies significantly between the three groups of patients. The most mutated genes in MIA were EGFR and TP53. 4 out of 5 MIA cases harbored multiple alternations in EGFR catalytic domain and inactivating mutations in TP53 were found in 3 out of 5 patients. Furthermore, mutations in Wnt pathway genes were found in 4 out of 5 cases. Notably, mutations/amplification in Notch family was detected in 3 out of 5 cases (predominantly in the tumor invasive zone). In contrast to MIA, in AIS, only one case out of 5 harbors mutated TP53 or EGFR. Unlike in MIA, only one AIS patient carried mutated APC gene, suggesting that Wnt signaling plays insignificant role in AIS carcinogenesis. On the contrary, we found that AIS carcinogenesis heavily relies on alternations of AKT pathway, since aberrations in KIT, KRAS, HRAS, IGF1R, FGFR3, MET or TSC2 genes were found in 4 out of 5 patients. For AAH cohort we sequenced 25 independent lesions from 6 patients. Sequencing revealed that RAS and AKT/ERK pathways were most frequently affected in these lesions. In 3 cases we were able to track a possible cancer driving mutation from AAH to the primary tumor. This observation provides for the first time a direct link between AAH lesion and primary adenocarcinoma. Most of the patients in all groups carried mutations in genes associated with DNA repair and chromatin remodeling, suggesting that deregulation of the DNA repair machinery is an early onset event of adenocarcinoma tumorigenesis. In all groups our analysis revealed mutations in genes that have been never implicated in lung adenocarcinoma. Our study helps to understand the potential role of heterogeneous clonal events in the progression of early glandular neoplasms including the transition from non-invasive to invasive disease.']",
        "Doc_id":"AACR_2014-1505",
        "Doc_title":" Targeted sequencing for the assessment of intratumor heterogeneity",
        "_version_":1606189012335198209},
      {
        "Meeting_name":" c-Met activation mediates resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer.",
        "Background":"['Background', ' Inhibiting polo-like kinase 1 PLK1 may be an effective treatment for non-small cell lung cancer (NSCLC). PLK1 is a key regulator of mitosis and DNA damage checkpoints. PLK1 inhibitors are well tolerated, but only a few unselected patients with NSCLC respond to single-agent therapy. However, predictive biomarkers have not been used to select patients who are likely to experience a response to PLK1 inhibitors, and the mechanisms of resistance to PLK1 inhibitors have not been elucidated, making these unknowns a major gap in knowledge. To address this gap, we compared basal gene and protein expression in 63 NSCLC cell lines and discovered that mesenchymal NSCLC cell lines were more sensitive to PLK1 inhibitors than epithelial cell lines in vitro and in vivo. The induction of apoptosis in some NSCLC cell lines at very low drug concentrations and the need to find better therapy for mesenchymal NSCLC motivated us to further study PLK1 inhibition.']",
        "Doc_id":"AACR_2017-4095",
        "Doc_title":" c-Met activation mediates resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer.",
        "_version_":1606189019882848256},
      {
        "Meeting_name":" Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models.",
        "Background":"['Background. Third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib and ASP8273 demonstrated biologic activity in patients with non-small cell lung cancer (NSCLC) harboring the EGFR T790M mutation; however, acquired resistance inevitably develops and the mechanisms of have not been fully elucidated. This study evaluated potential mechanisms of resistance to ASP8273.']",
        "Doc_id":"AACR_2017-3152",
        "Doc_title":" Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models.",
        "_version_":1606189011511017472}]
  }}
